<SEC-DOCUMENT>0001213900-24-028859.txt : 20240401
<SEC-HEADER>0001213900-24-028859.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401170354
ACCESSION NUMBER:		0001213900-24-028859
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		24810684

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0202882-20f_scisparc.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 20:47:28 UTC 2024 -->
<html xmlns:sprcy="http://trpx.com/20231231" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-27538">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-27539">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION
12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-27540">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-27541"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-27542">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-27543">2023</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-27544">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-27545">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-27546">001-38041</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-71"><b>SCISPARC LTD.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Translation of registrant&#8217;s name into
English:</i> Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-27547">Israel</ix:nonNumeric>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Jurisdiction of incorporation or organization)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-93"><b>20 Raul Wallenberg St.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-97"><b>Tower A, 2<sup>nd</sup> Floor</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-27548">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-27549">6971916</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-27550">Israel</ix:nonNumeric>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-110"><b>Oz Adler</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-27551">+972</ix:nonNumeric>-<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-27552">3-7175777</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Email: <ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress" id="ixv-27553">oz@scisparc.com</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-123"><b>20 Raul Wallenberg St.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-127"><b>Tower A, 2<sup>nd</sup> Floor</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-27554">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-27555">6971916</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-27556">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Name, Telephone, E-mail and/or Facsimile number
and Address of Company Contact Person)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities to be registered or to be registered
pursuant to Section 12(b) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" name="dei:Security12gTitle" id="ixv-27557">Ordinary Shares, no par value</ix:nonNumeric>&#160;</span></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:TradingSymbol" id="ixv-165"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPRC</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c2" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-27558">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><ix:nonNumeric contextRef="c3" name="dei:Security12gTitle" id="ixv-172"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights to Purchase Ordinary Shares, no par value</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c3" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-27559">Nasdaq</ix:nonNumeric> Stock Market LLC</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-27560">706,683</ix:nonFraction> Ordinary Shares, no par value, as of December
31, 2023</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Yes &#9744; &#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-27561">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-27562">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-27563">Yes</ix:nonNumeric> &#9746;&#160;&#160;No
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months
(or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-27564">Yes</ix:nonNumeric> &#9746;&#160;&#160;No
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-27565">Non-accelerated filer</ix:nonNumeric>&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-260"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8224; The term &#8220;new or revised financial
accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-27566">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-27567">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. GAAP &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-27568">International Financial Reporting Standards</ix:nonNumeric> as issued by the International
Accounting Standards Board &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9744; Item 17&#160;&#9744; Item 18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-27569">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 80%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">INTRODUCTION</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">SUMMARY RISK FACTORS</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">PART I</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: right">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">OFFER STATISTICS AND EXPECTED TIMETABLE</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">KEY INFORMATION</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">[Reserved]</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Capitalization and Indebtedness</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Reasons for the Offer and Use of Proceeds</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Risk Factors</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plants and Equipment</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, patents and licenses, etc.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="text-align: center">107</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Action to Recover Erroneously Awarded Compensation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements and Other Financial Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="width: 80%"><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td><a href="#a_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td><a href="#a_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td><a href="#a_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td><a href="#a_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td><a href="#a_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants and rights</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Securities</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American Depositary Shares</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td><a href="#a_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="vertical-align: top"><a href="#a_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td><a href="#a_061"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><a href="#a_062"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved].</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td><a href="#a_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td><a href="#a_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td><a href="#a_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td><a href="#a_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I.</span></td>
    <td><a href="#a_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J.</span></td>
    <td><a href="#a_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSIDER TRADING POLICIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K.</span></td>
    <td><a href="#a_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CYBERSECURITY</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td><a href="#a_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td><a href="#a_077"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#a_078"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INTRODUCTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty clinical-stage
pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With
this focus, we are currently engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines and cannabinoids
such as Palmitoylethanolamide, or PEA, and/or &#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or
other cannabinoid receptor agonists, from which we have derived three main proprietary combinations: SCI-110 for the treatment of Tourette
syndrome and Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of Autism Spectrum
Disorder, or ASD, and Status Epilepticus, or SE. We hold a 50.86% controlling stake in our subsidiary SciSparc Nutraceuticals Inc., which
focuses on the sale of hemp-based products on the Amazon.com marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated under
the laws of the State of Israel on August 23, 2004. Our Ordinary Shares are listed on the Nasdaq under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us, &#8220;our&#8221; and &#8220;SciSparc&#8221; refer to SciSparc
Ltd. (formerly known as Therapix Biosciences Ltd.) and its subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 28, 2023, we completed a reverse split of our share capital in the ratio of 26:1, or the Reverse Split. Unless the context expressly
indicates otherwise, all references to share and per share amounts referred to in this Annual Report on Form 20-F reflect the amounts
after giving effect to the Reverse Split.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References to &#8220;U.S.
dollars&#8221; and &#8220;$&#8221; are to currency of the United States of America, and references to &#8220;NIS&#8221; are to New Israeli
Shekels. References to &#8220;Ordinary Shares&#8221; are to our Ordinary Shares, no par value. We report financial information under International
Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board and none of the financial statements
were prepared in accordance with generally accepted accounting principles in the United States. Unless derived from our financial statements
or otherwise indicated, U.S. dollar translations of NIS amounts presented in this Annual Report on Form 20-F, or the Annual Report, are
translated using a rate of NIS 3.627 to USD 1.00, the last exchange rate published by the Bank of Israel on December 29, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this Annual Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of
the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by
the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;project&#8221;
or other similar words, but are not the only way these statements are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
include, but are not limited to, statements about:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise capital through the issuance of additional securities and ability to continue as a going concern;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance the development of our pharmaceutical product candidates, including the anticipated starting and ending dates of our anticipated clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our assessment of the potential of our pharmaceutical product candidates to treat certain indications;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully receive approvals from the U.S. Food and Drug Administration, or FDA, or other regulatory bodies, including approval to conduct clinical trials, the scope of those trials and the prospects for regulatory approval of, or other regulatory action with respect to our product candidates, including the regulatory pathway to be designated to our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory environment and changes in the health policies and regimes in the countries in which we operate, including the impact of any changes in regulation and legislation that could affect the pharmaceutical industry;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize our existing product candidates and future sales of our existing product candidates or any other future potential product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
</table><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet our expectations regarding the commercial supply of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to integrate our new eCommerce operations business, which focuses on the sale of hemp-based products on the Amazon.com marketplace;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to pursue our intended restructuring plan which involves transferring our pharmaceutical activities to Jeffs&#8217; Brand Holding Inc., a wholly owned subsidiary of Jeff&#8217;s Brands, or NewCo, or the Restructuring Plan, and list NewCo on a leading stock exchange;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the overall global economic environment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition and new technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political and economic conditions in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel&#8217;s war against them and the military hostilities with the Hezbollah organization along the Northern border of Israel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">projected capital expenditures and liquidity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors referred to in &#8220;Item 3. Key Information - D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects,&#8221; as well as in this Annual Report.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements are only
current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#8217;s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. You should not rely upon forward-looking statements as predictions of future events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Readers are urged to carefully
review and consider the various disclosures made throughout this Annual Report which are designed to advise interested parties of the
risks and factors that may affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not put undue reliance
on any forward-looking statements. Any forward-looking statements in this Annual Report are made as of the date hereof, and we undertake
no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Risk Factors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk factors described
below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should
carefully consider these risk factors, together with the risk factors set forth in Item 3.D of this Annual Report and the other reports
and documents filed by us with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Financial Condition and Capital
Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a specialty clinical-stage pharmaceutical company and have a limited operating history on which to assess the prospects for our business, have incurred significant losses since the date of our inception, and anticipate that we will continue to incur significant losses until we are able to successfully commercialize our product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated any revenue from the sale of our current product candidates and may never be profitable.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that we will need to raise substantial additional funding before we can expect to become profitable from sales of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate development efforts or other operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The report of our independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to the Discovery and Development of
Our Pharmaceutical Product Candidates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are heavily dependent on the success of our pharmaceutical product candidates, which are in the late stages of pre-clinical development or early stages of clinical development. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results. We may also find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our pharmaceutical product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the FDA does not conclude that our pharmaceutical product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for our pharmaceutical product candidates under Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated and in either case may not be successful.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In respect of our pharmaceutical product candidates targeting rare indications, orphan drug exclusivity may afford limited protection, and if another party obtains orphan drug exclusivity for the drugs and indications we are targeting, we may be precluded from commercializing our pharmaceutical product candidates in those indications during that period of exclusivity. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Reliance on Third Parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our pharmaceutical product candidates and our business could be substantially harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will rely on third parties to manufacture our active pharmaceutical ingredient, or API, and formulations. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our needed supplies or fail to do so at acceptable quality levels or prices.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Commercialization of Our Pharmaceutical
Product Candidates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the market opportunities for our pharmaceutical product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face intense competition and rapid technological change and the possibility that our competitors may discover, develop or commercialize therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our pharmaceutical product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Intellectual Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively in our markets. Further, if we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to identify infringements of our patents and accordingly the enforcement of our intellectual property rights may be difficult.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Pharmaceutical Business Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements. There can be no assurance that we will enter into any such definitive agreements. Similarly, we may strategically invest in transactions from time to time, and there can be no assurance that the value of our investment will increase or that it will not fluctuate.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may strategically invest in transactions from time to time, and there can be no assurance that the value of our investment will increase or that it will not fluctuate or that we will be able to successfully integrate or operate any new business we acquire. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to our Intended Corporate Restructuring
Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Restructuring Plan may not be completed in accordance with the expected plans or anticipated timeline, or at all, and may not achieve the expected results.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Our Subsidiary&#8217;s eCommerce
Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to successfully integrate or execute our new subsidiary&#8217;s eCommerce operations business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our subsidiary&#8217;s eCommerce operations rely on the Amazon.com marketplace and fulfillment by Amazon.com and changes to the Amazon.com marketplace, Amazon&#8217;s services and their terms of use may harm our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to the Ownership of Our Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need additional capital in the future. Raising additional capital by issuing securities may cause dilution to existing shareholders. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not know whether a market for the Ordinary Shares will be sustained or what the trading price of the Ordinary Shares will be and as a result it may be difficult for you to sell your Ordinary Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Risks Related to Israeli Law and Our Operations in
Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law may make it easy for our shareholders to demand that we convene a shareholders meeting, and/or allow shareholders to convene a shareholder meeting without the consent of our management, which may disrupt our management&#8217;s ability to run our company.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal executive offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including (i) the recent attack by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region and Israel&#8217;s war against them as well as the war&#8217;s potential impact on our business and operations and (ii) the military hostilities with the Hezbollah organization along the Northern border of Israel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. KEY INFORMATION </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A.</b> [Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Capitalization and Indebtedness</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Reasons for the Offer and Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Risk Factors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully consider
the risks described below, together with all of the other information in this Annual Report. The risks described below are not the only
risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially
and adversely affect our business operations. If any of these risks actually occurs, our business and financial condition could suffer
and the price of our Ordinary Shares could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a specialty clinical</i></b>-<b><i>stage
pharmaceutical company and have incurred significant losses since the date of our inception, and anticipate that we will continue to incur
significant losses until we are able to successfully commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have historically incurred
substantial net losses; including net losses of approximately $5.9 million for the year ended December 31, 2023, $2.6 million for the
year ended December 31, 2022 and $5.8 million for the year ended December 31, 2021. As of December 31, 2023, we had an accumulated deficit
of approximately $69 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have devoted substantially
all of our financial resources to develop our product candidates, and more recently, to a lesser degree, we have been searching for strategic
transactions. We have financed our operations primarily through the issuance of equity securities. The amount of our future net losses
will depend, in part, on completing the development of our product candidates, the demand for our product candidates, the rate of our
future expenditures and our ability to obtain funding through the issuance of our securities, strategic collaborations or grants. Pharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We are in the late stages of preclinical
and at the early stages of clinical development for our product candidates, we have not yet commenced pivotal clinical studies for any
product candidate. Although we have begun early commercialization efforts for our proprietary Palmitoylethanolamide, or PEA, oral tablets
formulation, CannAmide&#8482;, which we expect will be marketed to pharmacies and other retail outlets across Canada following our entering
into a distribution agreement(s), it may be several years, if ever, before we complete pivotal clinical studies and have our lead product
candidate approved for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenue will
depend upon the size of the markets for which our product candidates may receive approval and our ability to achieve sufficient market
acceptance, pricing, reimbursement from third-party payors and adequate market share for our product candidates in those markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant losses until we are able to commercialize our main pharmaceutical product candidates, which we may not be successful in achieving.
We anticipate that our expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the research and development of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand the scope of our current clinical studies for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing approvals for our product candidates that successfully complete clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing and distribution infrastructure to commercialize our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain skilled personnel; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated any revenue from the
sale of our current pharmaceutical product candidates and may never be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any of our pharmaceutical product candidates and have not generated any revenue from sales of our pharmaceutical product candidates since
the date of our inception. Although we have begun early commercialization efforts for our proprietary PEA oral tablets formulation. CannAmide&#8482;,
we do not currently expect the sale of CannAmide to result in material revenues, nor is CannAmide&#8482; our lead pharmaceutical product
candidate. We do not know whether or when we will become profitable. Our ability to generate revenue and achieve profitability depends
on our ability to successfully complete the development of, and to commercialize, our pharmaceutical product candidates and on the demand
for our pharmaceutical product candidates. Our ability to generate revenue and achieve profitability depends on our ability, alone or
with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals
necessary to commercialize, one or more of our pharmaceutical product candidates. Our ability to generate future revenue from pharmaceutical
product candidate sales depends heavily on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing research and preclinical and clinical development of our pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory and marketing approvals for pharmaceutical product candidates for which we complete clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) pharmaceutical products to support market demand for our pharmaceutical product candidates, if approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching and commercializing pharmaceutical product candidates if and when we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance of our pharmaceutical product candidates as viable treatment options;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing any competing pharmaceutical or biotechnological and market developments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and/or developing new pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring and retaining qualified personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if one or more of the
pharmaceutical product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated
with commercializing any approved pharmaceutical product candidate. Our expenses could increase beyond expectations if we are required
by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to perform clinical, nonclinical
or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory
approvals to market one or more of our pharmaceutical product candidates, our revenue will be dependent, in part, upon the size of the
markets in the territories for which we gain regulatory approval, the accepted price for the pharmaceutical product candidate, the ability
to get reimbursement at an acceptable price and whether we own the commercial rights for that territory. If the number of our addressable
patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably
expected population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant
revenue from sales of such pharmaceutical product candidates, even if approved. Additionally, if we are not able to generate revenue from
the sale of any approved pharmaceutical product candidates, we may be forced to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect that we will need to raise substantial
additional funding before we can expect to become profitable from sales of our pharmaceutical product candidates. This additional financing
may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit
or terminate our pharmaceutical product candidate development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, our
cash was approximately $2.1 million, other accounts receivable was approximately $0.5 million, we had working capital of approximately
$4.9 million and we also had an accumulated deficit of approximately $69 million. Based upon our currently expected level of operating
expenditures, we do not expect that our existing cash will be sufficient to fund operations for at least the next 12 months. We expect
that we will require substantial additional capital to commercialize our pharmaceutical product candidates. In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than
planned. Our future funding requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, rate of progress, results and cost of pharmaceutical product development, clinical studies, preclinical testing, and other related activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of regulatory approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost and timing of establishing sales, marketing, and distribution capabilities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of any collaborative, licensing, and other arrangements that we may establish.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our pharmaceutical product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts
or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders
of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause
the market price of our Ordinary Shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our
ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or pharmaceutical
product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating
results and prospects. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the commercialization of any pharmaceutical product candidates or be unable to expand our operations or otherwise capitalize
on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The report of our independent registered
public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern,
which could prevent us from obtaining new financing on reasonable terms or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The report of our independent
registered public accounting firm on our audited consolidated financial statements for the period ended&#160;December 31,&#160;2023 contains
an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.&#160;Our consolidated financial
statements do not include any adjustments that might result from the outcome of the uncertainty regarding our ability to continue as a
going concern. This going concern opinion could materially limit our ability to raise additional funds through the issuance of equity
or debt securities or otherwise. Further reports on our consolidated financial statements may include an explanatory paragraph with respect
to our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future cash
needs through debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at
all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or
commercialization efforts with respect to our products. This may raise substantial doubts about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Discovery and Development
of Our Pharmaceutical Product Candidates </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are heavily dependent on the success
of our pharmaceutical product candidates, which are in the late stages of pre-clinical development or early stages of clinical development.
We cannot give any assurance that any of our pharmaceutical product candidates will receive regulatory approval, which is necessary before
they can be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have invested
substantially all of our efforts and financial resources to design and develop our pharmaceutical product candidates, including conducting
preclinical studies and providing general and administrative support for these operations. Our future success is dependent on our ability
to successfully develop, obtain regulatory approval for, and then successfully commercialize one or more pharmaceutical product candidates.
We currently generate no revenue from sales of any pharmaceutical product candidate, and we may never be able to develop or commercialize
a marketable pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our pharmaceutical
product candidates is in the late stages of pre-clinical development or early stages of development and will require additional clinical
development (and in some cases additional preclinical development), management of nonclinical, clinical and manufacturing activities,
regulatory approval, obtaining adequate manufacturing supply, building of a commercial organization and significant marketing efforts
before we generate any revenue from pharmaceutical product candidate sales. It may be years before a pivotal study is initiated, if at
all. Any clinical trials in the United States will require the approval of an Investigational New Drug, or IND, application by the FDA,
and we cannot assure that we will obtain such approval in a timely manner, or at all. We are not permitted to market or promote any of
our pharmaceutical product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities,
and we may never receive such regulatory approval for any of our pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We as a company have never
submitted marketing applications to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our pharmaceutical
product candidates will be successful in clinical studies or receive regulatory approval or what regulatory pathway the regulatory authorities
shall designate for our pharmaceutical product candidates. Further, our pharmaceutical product candidates may not receive regulatory approval
even if they are successful in clinical studies. If we do not receive regulatory approvals for our pharmaceutical product candidates,
we may not be able to continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally plan to seek
regulatory approval to commercialize our pharmaceutical product candidates in the United States, the European Union and in additional
foreign countries. To obtain regulatory approvals we must comply with the numerous and varying regulatory requirements of such countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing and distribution of our
product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval
in any other jurisdictions. If we are unable to obtain approval for our pharmaceutical product candidates in multiple jurisdictions, our
revenue and results of operations would be negatively affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval processes of the
FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain
regulatory approval for our pharmaceutical product candidates, our business will be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to obtain
approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical
studies and depends upon numerous factors. In addition, approval policies, regulations or the type and amount of clinical data necessary
to gain approval may change during the course of a pharmaceutical product candidate&#8217;s clinical development and may vary among jurisdictions,
which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any
pharmaceutical product candidate, and it is possible that none of our existing pharmaceutical product candidates or any pharmaceutical
product candidates we may seek to develop in the future will ever obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Applications for our pharmaceutical
product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a pharmaceutical product candidate&#8217;s safety-benefit ratio for its proposed indication is acceptable;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from clinical studies of our pharmaceutical product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, in the United States or elsewhere;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This lengthy approval process,
as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market
any of our pharmaceutical product candidates, which would significantly harm our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical drug development involves a lengthy
and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study
process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results
of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer
significant setbacks in subsequent advanced clinical studies. There is a high failure rate for drugs proceeding through clinical studies,
and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed
satisfactorily through preclinical studies and initial clinical studies. A number of companies in the pharmaceutical industry have suffered
significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results
in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not know
whether any Phase I, Phase II, Phase III or other clinical studies we may conduct will demonstrate consistent or adequate efficacy and
safety sufficient to obtain regulatory approval to market our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may find it difficult to enroll patients
in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in clinical studies of our pharmaceutical product candidates is critical to our success. The timing of our clinical
studies depends in part on the speed at which we can recruit patients to participate in testing our pharmaceutical product candidates,
and we may experience delays in our clinical studies if we encounter difficulties in enrollment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the conditions for
which we plan to evaluate our current pharmaceutical product candidates are for rare diseases. Accordingly, there is a limited patient
pool from which to draw for clinical studies. Further, the eligibility criteria of our clinical studies will further limit the pool of
available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease
is either severe enough or not too advanced to include them in a study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the process
of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete
our clinical studies because of the perceived risks and benefits of the pharmaceutical product candidate under study, the availability
and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for prospective patients
and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline
for recruiting patients, conducting studies and obtaining regulatory approval of potential pharmaceutical product candidates will be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays in
the completion or termination of any clinical study of our pharmaceutical product candidates, the commercial prospects of our pharmaceutical
product candidates will be harmed, and our ability to generate pharmaceutical product candidate revenue from any of these pharmaceutical
product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies will increase our costs,
slow down our product candidate development and approval process and jeopardize our ability to commence pharmaceutical product candidate
sales and generate revenue. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition,
many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to
the denial of regulatory approval of our pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the FDA does not conclude that our pharmaceutical
product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for our pharmaceutical
product candidates under Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost significantly
more and entail significantly greater complications and risks than anticipated and in either case may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek FDA approval
through the Section 505(b)(2) regulatory pathway for our pharmaceutical product candidate- SCI-110 and potentially for our drug candidate
SCI-210. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section
505(b)(2) to the Federal Food, Drug, and Cosmetic Act of 1938, as amended, or the FDC Act, or Section 505(b)(2). Section 505(b)(2) permits
the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant
and for which the applicant has not obtained a right of reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does not allow
us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required
to obtain FDA approval, and complications and risks associated with FDA approval, would substantially increase. We may need to obtain
additional funding, which could result in significant dilution to the ownership interests of our then existing shareholders to the extent
we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms
acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in new competitive pharmaceutical
product candidates reaching the market faster than our pharmaceutical product candidates, which could materially adversely impact our
competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that
our pharmaceutical product candidates will receive the requisite approvals for commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, notwithstanding
the approval of a number of pharmaceutical product candidates by the FDA under Section 505(b)(2) over the last few years, some pharmaceutical
companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). For example, several companies have previously
petitioned the FDA regarding the constitutionality of allowing others to rely upon FDA findings that are based on their proprietary data.
If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies
and practices, which could require that we generate full data regarding safety and effectiveness for previously approved active ingredients
and delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry
is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors
of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and
mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon
for a manufacturer of an approved pharmaceutical product to file a citizen petition with the FDA seeking to delay approval of, or impose
additional approval requirements for, pending competing pharmaceutical products. If successful, such petitions can significantly delay,
or even prevent, the approval of the new pharmaceutical product. However, even if the FDA ultimately denies such a petition, the FDA may
substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section
505(b)(2) regulatory pathway for our pharmaceutical product candidates, there is no guarantee this would ultimately lead to faster pharmaceutical
product development or earlier approval. Moreover, even if these pharmaceutical product candidates are approved under the Section 505(b)(2)
pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the pharmaceutical products may
be marketed or to other conditions of approval or may contain requirements for costly post-marketing testing and surveillance to monitor
the safety or efficacy of the pharmaceutical products. Our pharmaceutical product candidates are at early stages of development and are
subject to uncertainty over what we must do on our development program in order to secure approval under Section 505(b)(2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining marketing
approval from regulatory authorities for the sale of our pharmaceutical product candidates, we must conduct extensive clinical studies
to demonstrate the safety and efficacy of the pharmaceutical product candidates in humans. Clinical testing is expensive, time consuming
and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at
all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful.
Events that may prevent successful or timely completion of clinical development include but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of a pandemic or the spread of a virus that diverts the attention of regulatory agencies from reviewing our study design or results or which, as a result of such pandemic or widespread, requires us to materially modify our planned clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching a consensus with regulatory agencies on study design;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a clinical hold by regulatory agencies, after review of an IND, application, or equivalent application, or an inspection of our clinical study operations or study sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in recruiting suitable patients to participate in our clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty collaborating with patient groups and investigators;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by our CROs, other third parties or us to adhere to clinical study requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to perform in accordance with the FDA&#8217;s Good Clinical Practices, or GCP, requirements, or applicable regulatory guidelines in other countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients dropping out of a study;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence of serious adverse events associated with the pharmaceutical product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical studies of our pharmaceutical product candidates being greater than we anticipate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical studies of our pharmaceutical product candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon pharmaceutical product candidate development programs; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our pharmaceutical product candidates for use in clinical studies or the inability to do any of the foregoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any inability to successfully
complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. We may
also be required to conduct additional safety, efficacy and comparability studies before we will be allowed to start clinical studies
with our repurposed drugs. Clinical study delays could also shorten any periods during which our pharmaceutical product candidates have
patent protection and may allow our competitors to bring pharmaceutical product candidates to market before we do, which could impair
our ability to obtain orphan exclusivity and successfully commercialize our pharmaceutical product candidates and may harm our business
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In respect of our pharmaceutical product
candidates targeting rare indications, orphan drug exclusivity may afford limited protection, and if another party obtains orphan drug
exclusivity for the drugs and indications we are targeting, we may be precluded from commercializing our pharmaceutical product candidates
in those indications during that period of exclusivity</i>.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are seeking to obtain an
orphan designation for some of our pharmaceutical product candidates in the United States. Under the Orphan Drug Act, the FDA may designate
a product as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population of
fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. Additionally, designation is granted
for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic
condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the
necessary investment in developing the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
first NDA applicant with an orphan drug designation for a particular active moiety to treat a specific disease or condition that receives
FDA approval is entitled to a seven-year exclusive marketing period in the United States for that product candidate, for that indication.
In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers
and 10 years of market exclusivity is granted following drug approval. This period may be reduced to six years if the orphan drug designation
criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market
exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we submitted
a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In a letter dated September 29, 2016, the FDA informed
us that our request could not be granted at such time, and is being held in abeyance until and subject to us providing additional information
pertaining to the overall prevalence of TS in both children and adults, and further clinical data to support our scientific rationale
for our request for orphan drug designation within 12 months. In September 2017, we responded to such FDA letter within the designated
time frame, and provided the FDA with our articulated and reasoned responses including documentation and clinical data that supports it.
On December 26, 2017, we received the FDA&#8217;s response to our response. The FDA accepted that there is adequate scientific rationale
for the treatment of TS with SCI-110 mainly through the preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide
benefit in treating TS. However, the FDA stated that it was unable to grant our request and indicated that we did not provide adequate
prevalence estimates, and any evidence to support our statement that only moderate to severe TS patients would require pharmacological
treatment. We further responded in January 2018 by providing additional information. On January 23, 2020, following additional correspondence
with the FDA, the FDA still did not grant us our request due to the fact that we have not yet provided adequate prevalence estimates.
However, the FDA did agree with our position that we could potentially qualify for orphan drug designation with respect to the moderate-to-severe
TS sub-group population only rather than the entire population. After we had provided additional prevalence estimates, the FDA raised
a concern in its letter, dated December 7, 2020, about our ability to limit the use of the pharmaceutical product to the subset of patients
we are pursuing. Due to the fact that we disagree with this concern, we requested a clarification call. In the clarification call conducted
on February 2, 2021, we agreed with the FDA concern about our ability to limit the use of the pharmaceutical product to the subset of
patients in addition to a safety concern associated with THC treatment in pediatrics population so we suggested to amend our preliminary
request and asked to include only adults in the treated population. An amendment letter was discussed and the FDA described what it would
want to see in such an amendment. In March 2021, we sent our response to the FDA. In June 2021, we received a response from the FDA explaining
that they are unable to grant our request until new information becomes available to support our request for orphan drug designation.
We will re-visit the application after we obtain clinical results from our upcoming phase IIb clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will successfully obtain orphan drug designation for TS, any future rare indications or orphan exclusivity upon approval of any of
our pharmaceutical product candidates that have already obtained designation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we do obtain orphan
exclusivity for any pharmaceutical product candidate, the exclusive marketing rights may be lost if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. Moreover,
a drug product candidate with an active moiety that is a different cannabinoid from that in our drug candidate or, under limited circumstances,
the same drug product candidate, may be approved by the FDA for the same indication during the period of marketing exclusivity. The limited
circumstances include a showing that the second drug is clinically superior to the drug with marketing exclusivity through a demonstration
of superior safety or efficacy or that it makes a major contribution to patient care. In addition, if a competitor obtains approval and
marketing exclusivity for a drug product candidate with an active moiety that is the same as that in a pharmaceutical product candidate
we are pursuing for the same indication, approval of our pharmaceutical product candidate would be blocked during the period of marketing
exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved pharmaceutical product candidate.
In addition, if a competitor obtains approval and marketing exclusivity for a drug product candidate with an active moiety that is the
same as that in a pharmaceutical product candidate we are pursuing for a different orphan indication, this may negatively impact the market
opportunity for our pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been legal challenges
to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges
could lead to changes that affect the protections afforded our pharmaceutical product candidates in ways that are difficult to predict.
In a recent successful legal challenge, a court invalidated the FDA&#8217;s denial of orphan exclusivity to a drug on the grounds that
the drug was not proven to be clinically superior to a previously approved pharmaceutical product candidate containing the same ingredient
for the same orphan use. In response to the decision, the FDA released a policy statement stating that the court&#8217;s decision is limited
just to the facts of that particular case and that the FDA will continue to require the sponsor of a designated drug that is the &#8220;same&#8221;
as a previously approved drug to demonstrate that its drug is clinically superior to that drug upon approval in order to be eligible for
orphan drug exclusivity, or in some cases, to even be eligible for marketing approval. In the future, there is the potential for additional
legal challenges to the FDA&#8217;s orphan drug regulations and policies, and it is uncertain how such challenges might affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>While orphan drug product candidates are
typically sold at a high price relative to other medications, the market may not be receptive to high pricing of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We develop our product candidates
to treat rare diseases, a space where medications are usually sold at high prices compared with other medications. However, our product
candidates are repurposed drugs, which means, among other things, that they contain drug substances available in pharmacies for the purpose
of treating indications that are different from the indications for which we plan to use. Accordingly, even if regulatory authorities
approve our product candidates, the market may not be receptive to, and it may be difficult for us to achieve, a per-patient per-year
price high enough to allow us to realize a return on our investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label or result in significant negative consequences following marketing approval, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of dronabinol has
been associated with seizures, paranoia, rapid heart rate and unusual thoughts and behaviors. Undesirable side effects caused by our product
candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive
marketing label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Potential side effects
of our cannabinoid-based treatments may include: asthenia, palpitations, tachycardia, vasodilation/facial flush, abdominal pain, nausea,
vomiting, amnesia, anxiety/nervousness, ataxia, confusion, depersonalization, dizziness, euphoria, hallucinations, paranoid reaction,
somnolence and abnormal thinking. Results of our studies may identify unacceptable severity and prevalence of these or other side effects.
In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us
to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug-related side effects
could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product candidate liability
claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product
candidates, a number of potentially significant negative consequences could result, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw approvals of such product candidate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require additional warnings on the label;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other Elements To Assure Safe Use, or ETASU;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm
our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain regulatory approval for
a product candidate, our product candidates will remain subject to regulatory scrutiny.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion,
sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including
both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#8217; facilities are required
to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good
Manufacturing Practices, or cGMP, regulations and Quality System Regulation, or QSR. As such, we and our contract manufacturers will be
subject to continual review and inspections to assess compliance with cGMP, QSR and adherence to commitments made in any NDA. Accordingly,
we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product candidate
may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase
4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain
adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for
our product candidates. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory
restrictions and must be consistent with the information in the product candidate&#8217;s approved label. As such, we may not promote
our product candidates for indications or uses for which they do not have FDA approval. The holder of an approved NDA must also submit
new or supplemental applications and obtain FDA approval for certain changes to the approved product candidate, product candidate labeling
or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our product
candidates in general or in specific patient subsets. If original marketing approval were obtained via the accelerated approval pathway,
we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our product candidates. An
unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Furthermore,
any new legislation addressing drug safety issues could result in delays in product candidate development or commercialization or increased
costs to assure compliance. Foreign regulatory authorities impose similar requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a regulatory agency discovers
previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, or problems with
the facility where the product candidate is manufactured, or disagrees with the promotion, marketing or labeling of a product candidate,
such regulatory agency may impose restrictions on that product candidate or us, including requiring withdrawal of the product candidate
from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among
other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose civil or criminal penalties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend any of our ongoing clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize or detain product candidates, or require a product candidate recall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company
and our operating results will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to numerous complex regulations
and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The research, testing, development,
manufacturing, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, marketing, distribution,
possession and use of our product candidates, among other things, are subject to regulation by numerous governmental authorities in the
United States and elsewhere. The FDA regulates drugs under the FDC Act, and implementing regulations. Noncompliance with any applicable
regulatory requirements can result in refusal to approve product candidates for marketing, warning letters, product candidate recalls
or seizure of product candidates, total or partial suspension of production, prohibitions or limitations on the commercial sale of product
candidates or refusal to allow the entering into of federal and state supply contracts, fines, civil penalties and/or criminal prosecution.
Additionally, the FDA and comparable governmental authorities have the authority to withdraw product candidate approvals that have been
previously granted. Moreover, the regulatory requirements relating to our product candidates may change from time to time and it is impossible
to predict what the impact of any such changes may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing product
candidates that are controlled substances as defined in the Controlled Substances Act of 1970, or CSA, which establishes, among other
things, certain registration, production quotas, security, recordkeeping, reporting, import, export and other requirements administered
by the Drug Enforcement Administration, or the DEA. As a result, any product candidate that is a controlled substance (or includes a controlled
substance) cannot be marketed before such substance is rescheduled by the DEA as a Schedule II, III, IV or V substance. The active ingredient
in our product candidates is dronabinol, which is a Schedule III controlled substance. See Item 4.B. &#8220;Business-Government Regulation-Controlled
Substances&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture, shipment,
storage, sale and use, among other things, of controlled substances that are pharmaceutical product candidates are subject to a high degree
of regulation. The DEA also conducts periodic inspections of registered establishments that handle controlled substances. Facilities that
conduct research, manufacture, distribute, import or export controlled substances must be registered to perform these activities and have
the security, control and inventory mechanisms required by the DEA to prevent drug loss and diversion. Failure to maintain compliance,
particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect
on our business, results of operations, financial condition and prospects. The DEA may seek civil penalties, refuse to renew necessary
registrations, or initiate proceedings to suspend or revoke those registrations. In certain circumstances, violations could lead to criminal
proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual states also have
controlled substances laws. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions,
they may separately schedule our product candidates as well. While some states automatically schedule a drug when the DEA does so, other
states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale of any product candidate
for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness
of such product candidate. We or our partners must also obtain separate state registrations, permits or licenses in order to be able to
obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory
requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal
law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Reliance on Third Parties
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual
duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates and our business could be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon and plan
to continue to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs, including Target
Health, Inc., FGK Clinical Research GmbH, or FGK, and others. We rely on these parties for execution of our preclinical and clinical studies,
and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us
of our regulatory responsibilities. We and our CROs and other vendors are required to comply with current cGMP, GCP, QSR and Good Laboratory
Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European
Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities
enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors.
If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may
be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must be conducted
with product candidates which are produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat
clinical studies, which would delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable
terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot
control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. These
risks may be heightened in the event of new uncontrolled outbreaks of the COVID-19 pandemic. If CROs do not successfully carry out their
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical
data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons,
our clinical studies may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize
our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial
prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Switching or adding additional
CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical development timelines.
Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or
delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will rely on third parties to manufacture
our API and formulations. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our needed
supplies, or fail to do so at acceptable quality levels or prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the infrastructure
or capability internally to manufacture the API formulations, and we lack the resources and the capability to manufacture any of our product
candidates on a clinical or commercial scale. We plan to rely on third parties for such supplies. There are a limited number of manufacturers
who have the ability to produce our API and there may be a need to identify alternate manufacturers to prevent a possible disruption of
our clinical studies. Any significant delay or discontinuity in the supply of these components could considerably delay completion of
our clinical studies, product candidate testing and potential regulatory approval of our product candidates, which could harm our business
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We and our collaborators and contract manufacturers
are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely
may not continue to meet regulatory requirements and have limited capacity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All entities involved in the
preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates,
are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or a product candidate
used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and
procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational
product candidates and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or
to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We,
our collaborators or our contract manufacturers must supply all necessary documentation in support of an NDA, or Marketing Authorization
Application, or MAA, on a timely basis and must adhere to GLP and cGMP QSR regulations enforced by the FDA and other regulatory agencies
through their facilities inspection program. Some of our contract manufacturers have never produced a commercially approved pharmaceutical
product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some
or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations
as a condition of regulatory approval of our product candidates or any of our other potential product candidates. In addition, the regulatory
authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our
other potential product candidates or the associated quality systems for compliance with the regulations applicable to the activities
being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners
for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval
of the product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of
the regulatory authority, if ever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulatory authorities
also may, at any time following approval of a product candidate for sale, if ever, audit the manufacturing facilities of our collaborators
and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation
of our product candidate specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant
regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and
that may include the temporary or permanent suspension of a clinical study or commercial sales, or the temporary or permanent closure
of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our collaborators,
or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose
regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an
approval or suspension of production. As a result, our business, financial condition and results of operations may be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if supply from
one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or MAA amendment, or equivalent
foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer
is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in
our desired clinical and commercial timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors could cause
us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals or commercialization
of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more
replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential
revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our reliance on third parties requires us
to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we rely on third parties
to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need
to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Commercialization of Our Pharmaceutical
Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the market opportunities for our pharmaceutical
product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our projections of both the
number of people who have our target diseases, as well as the subset of people with these diseases who have the potential to benefit from
treatment with our pharmaceutical product candidates, are based on our beliefs and estimates. These estimates have been derived from a
variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research and may prove to be
incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out
to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately
predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for
each of our pharmaceutical product candidates may be limited or may not be amenable to treatment with our pharmaceutical product candidates,
and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations
and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face intense competition and rapid technological
change and the possibility that our competitors may discover, develop or commercialize therapies that are similar, more advanced or more
effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are highly competitive. There are many pharmaceutical companies, biotechnology companies, public and private universities and
research organizations actively engaged in the research and development of products that may be similar to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first THC-based pharmaceutical,
a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company called Unimed Pharmaceuticals,
with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment for chemotherapy-related
nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market, other pharmaceuticals
containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed by SVC Pharma LP and
Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole cannabis extract administered
as an oral spray. Furthermore, to the best of our knowledge, multiple companies that are working in the cannabis therapeutic area and
are pursuing regulatory approval for their product candidates. For example, GW Pharmaceuticals PLC, or GW, which markets Sativex, a botanical
cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval in the United States in June
2018 for Epidiolex, a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s Syndrome, Lennox Gastaut
Syndrome, and various childhood epilepsy syndromes. In addition, GW is developing, among others, cannabidivarin, or CBDV, based therapy
for ASD and therapy for neonatal hypoxic-ischemic encephalopathy and schizophrenia. Zynerba Pharmaceuticals, Inc., or Zynerba, is developing
a transdermal formulation of cannabidiol for Fragile X and certain refractory epilepsies and ASD. Skye Bioscience, Inc., or Skye, is focused
on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Corbus
Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid for systemic sclerosis, cystic fibrosis, dermatomyositis
and systemic lupus erythematosus and metabolism and solid tumors. RespireRx Pharmaceutical Inc., or RespireRx, developing dronabinol for
OSA treatment. Synendos Therapeutics AG, or Synendos, is a developer of endocannabinoid modulators for the treatment of central nervous
system, or CNS, disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric
disorders. Synendos is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous
cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing
peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance,
and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More established companies
may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared to us, many of our
competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors may
have an advantage in marketing their approved products and may obtain regulatory approval of their product candidates before we are able
to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer,
more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and marketing
their products. These advantages could materially impact our ability to develop and commercialize our product candidates successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates may
also compete with medical and recreational marijuana, in markets where the recreational and/or medical use of marijuana is legal. There
is support in the United States for further legalization of marijuana. In markets where recreational and/or medical marijuana is not legal,
our product candidates may compete with marijuana purchased in the illegal drug market. We cannot assess the extent to which patients
may utilize marijuana obtained illegally for the treatment of the indications for which we are developing our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we successfully develop
our product candidates, and obtain marketing approval for them, other treatments or therapeutics may be preferred and we may not be successful
in commercializing our product candidates or in bringing them to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing
and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in
even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than
we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase
further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in
these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective
or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization
and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates
uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently have no marketing and sales
organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and
sell our product candidates, we may be unable to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our employees may
have sold other similar products in the past while employed at other companies, we as a company have no experience selling and marketing
our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result
from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates
receive regulatory approval, we intend to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize our product candidates in major markets, which will be expensive, difficult and time consuming. Any failure
or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, given our lack of
prior experience in marketing and selling pharmaceutical products, our initial estimate of the size of the required sales force may be
materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such,
we may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates
or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets,
we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable
to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient resources to commercialize
our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate
sufficient product revenue to sustain our business. We may be competing with companies that currently have extensive and well-funded marketing
and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable
to compete successfully against these more established companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The commercial success of any current or
future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the
medical community.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even with the requisite approvals
from the FDA and comparable foreign regulatory authorities, the commercial success of our product candidates will depend in part on the
medical community, patients and third-party payors accepting our product candidates as medically useful, cost-effective and safe. Any
product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical
community. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will depend on a number
of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indications for which approval is granted;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative convenience and ease of administration;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment, particularly in relation to competing treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity concerning our products or competing products and treatments; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient third-party insurance coverage and reimbursement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a potential product
displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully
known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the product candidates
may require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate
level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient
revenue to become or remain profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The insurance coverage and reimbursement
status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products
could limit our ability to market those products and decrease our ability to generate revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pricing, coverage and
reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure. Our per-patient prices
must be sufficient to recover our development and manufacturing costs and potentially achieve profitability. Accordingly, the availability
and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive
treatments such as ours, assuming approval. Sales of our product candidates will depend substantially, both domestically and abroad, on
the extent to which the costs of our product candidates will be paid for by health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. If
coverage and reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize
our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish
or maintain pricing sufficient to realize a return on our investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage
and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S.
Department of Health and Human Services, or DHHS, as CMS decides whether and to what extent a new drug will be covered and reimbursed
under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to reimbursement for products such as ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States,
international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the
increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the
pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms
as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United
States. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional
foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and
may be insufficient to generate commercially reasonable revenue and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, increasing efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate
payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates
due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.
The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has
become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures may
have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been and continue to be a number of legislative initiatives to contain healthcare costs. The following are among the provisions established
by the Patient Protection and&#160;Affordable Care Act of 2010, or ACA, of greatest importance to the pharmaceutical and biotechnology
industry:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the Average Manufacturer Price, or AMP, for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the AMP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, or MCOs;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (now 70%) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of the entities eligible for discounts under federal 340B;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. This center is currently focused on the following priorities:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">testing new payment and service delivery models;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating results and advancing best practices; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging a broad range of stakeholders to develop additional models for testing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementation of the federal physician payment transparency requirements, or the Sunshine Act. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, or the SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ACA may be modified, amended
or repealed at any time and may or may not be replaced with a different law or health care payment system. The ACA is expected to continue
to have a significant impact on the health care industry. With regard to pharmaceutical product candidates, among other things, the ACA
may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements under
the Medicare D program. Since the enactment of the ACA, numerous regulations have been issued providing further guidance on its requirements.
The ACA continues to be implemented through regulation and government activity but is subject to possible amendment, additional implementing
regulations and interpretive guidelines. Several states have decided not to expand their Medicaid programs and are seeking alternative
reimbursement models to provide care to the uninsured. The manner in which these issues are resolved could materially affect the extent
to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare, Medicaid and Tricare.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2016, CMS issued a final
rule regarding the Medicaid Drug Rebate Program that, among other things, revised the manner in which the AMP is calculated by manufacturers
participating in the program and implemented certain amendments to the Medicaid rebate statute created under the ACA. In addition, on
December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including
some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical
manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two bills affecting the implementation
of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the TCJA, included a provision that repealed,
effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year, that is commonly referred to as the &#8220;individual mandate.&#8217;&#8217; Additionally,
on January 22, 2018, then President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation
of certain ACA-mandated fees. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019,
to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In July 2018, CMS published
a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under
the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine
this risk adjustment. On April 27, 2020, the U.S. Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217;
denial of $12 billion in &#8220;risk corridor&#8221; funding. Congress may consider additional legislation to repeal, or repeal and replace,
other elements of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued that the ACA
is unconstitutional in its entirety because the individual mandate was repealed by Congress. Thus, the ACA will remain in effect in its
current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a
special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to
judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden
administration will impact the ACA and our business. We continue to evaluate the ACA and its possible repeal and replacement, as the extent
to which any such changes may impact our business or financial condition remains uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the Budget Control Act of 2011 among other
things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers of
2% per fiscal year. These reductions, known as Medicare sequestration adjustments, went into effect in 2013. However, under the Coronavirus
Aid, Relief, Economic Securities Act of 2020, and related legislation, Medicare sequestration adjustments from May 1, 2020 through March
31, 2021 have been suspended, though sequestration has been extended through 2030. Additionally, there has been heightened governmental
scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several
recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. At the federal level, including the former Administration&#8217;s budget for fiscal year 2020, there
were further drug price control measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part D,
to continue to allow some states to negotiate drug prices under Medicaid through supplemental rebate negotiations and other mechanisms,
and legislation was introduced to eliminate cost sharing for generic drugs for Part D low-income patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2020,
the U.S. DHHS, finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by
excluding rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or pharmacy benefit managers,
or PBMs, acting under contract with Medicare Part D plan sponsors from the existing discount safe harbor under the federal Anti-Kickback
Statute, or the AKS. The regulation reflects the first change to the AKS Statute discount safe harbor since the Medicare Part D program
was established. In addition to the rebate exclusions, two new safe harbors were added. One of these new safe harbors protects point-of-sale
reductions in price from a manufacturer to a plan sponsor under Medicare Part D or a MCO, for a prescription drug payable, in whole or
in part, by a plan sponsor under Medicare Part D or a MCO, provided certain conditions are met. The other protects certain fixed-fee services
arrangements between manufacturers and PBMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Congress and the executive
branch have each indicated that it will continue to seek new legislative or administrative measures to control drug costs. At the state
level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation from other countries
and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union, similar
political, economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved.
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state
level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare
in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers
have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context.
In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement
of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those
wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. Political, economic
and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has
been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between low-priced and high-priced
member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations
for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.
In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific products and therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these and other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and
in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or
other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs,
once marketing approval is obtained. We cannot predict what healthcare reform initiatives may be adopted in the future. However, it is
possible that there will be further legislation or regulation that could harm the business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The COVID-19 pandemic has resulted in delays
to our product development and may adversely affect any potential future revenues, results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">COVID-19 and the various precautionary
measures taken by many governmental authorities around the world to limit its spread had a severe effect on global markets and the global
economy. The extent to which the coronavirus impacts our business and operations will depend on future developments, which are highly
uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the nature and extent
of governmental actions taken to contain or treat its impact and the availability, costs, effectiveness and public acceptance of any FDA-approved
vaccines, among others. COVID-19 and official actions taken in response to it caused a major slowdown in overall economic activity in
the U.S. and elsewhere, curtailed consumer spending and made it more challenging to adequately staff and manage our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic impacted
our various vendors, including CROs, and caused delays in the development of our product candidates. We also experienced delays in the
preparation toward various clinical trials, including being unable to receive prioritization to conduct clinical trials, availability
of physicians and other staff members involved in our clinical trials. At this time, we do not anticipate that the COVID-19 pandemic and
official responses would cause a material adverse effect on our results of operations and financial condition but there can be no assurance
that this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our product candidates, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have relied
on trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies and product
candidates. Since 2015, we have also sought patent protection for certain of our product candidates. Our success depends in large part
on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with
respect to our proprietary technology and new product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to protect our proprietary
position by filing patent applications in the United States and in other countries, with respect to our novel technologies and product
candidates, which are important to our business. Patent prosecution is expensive and time consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not including patents and
applications which we are in the process of being assigned, we have a portfolio of seven granted patents with the U.S. Patent and Trademark
Office, or USPTO, nine patent families and two trademarks, of which four families include Patent Cooperation Treaty, or PCT, applications,
that have entered the national phase in various national entities. We cannot offer any assurances about which, if any, patent applications
will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened
by third parties. Any successful opposition to our patents after issuance could deprive us of rights necessary for the successful commercialization
of any new product candidates that we may develop and would allow other third parties to compete with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have exclusively licensed:
(i) one U.S. patent from Dekel Pharmaceuticals Ltd., or Dekel, and (ii) one U.S. patent family from Yissum Research Development Company
of the Hebrew University of Jerusalem Ltd., or Yissum. We cannot assure you that we will ever enter into definitive license agreements
with any third party licensor. See Item 4.B. &#8220;Business Overview-Intellectual Property-In-Licensed Patents and Patent Applications.&#8221;
To the extent the licensed or future licensed patents are found to be invalid or unenforceable, we may be limited in our ability to compete
and market our product candidates. Moreover, the terms of our licenses affect our ability to control the value of any of our product candidates.
If we or any of the parties that control the enforcement of licensed patents elect not to enforce any or all of the licensed patents it
could significantly undercut the value of any of our product candidates, which would materially adversely affect our future revenue, financial
condition and results of operations. Moreover, fluctuating currency rates may create inconsistencies in the royalty payments we are obligated
to make under our licenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, there is no guarantee
that the patent registration applications that were submitted by us with regard to our technologies will result in patent registration.
In the event of failure to complete patent registration, our developments will not be proprietary, which might allow other entities to
manufacture our product candidates and compete with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found. Such prior art, to the extent it exists, may
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even
if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in
such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and
any future patents may not adequately protect our intellectual property, provide exclusivity for our new product candidates, or prevent
others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which
may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Engagement in any type of
intellectual property collaboration agreement requires diligent management of intellectual property rights. Joint intellectual property
engagements may create additional administrative and financial burdens and may place us at heightened risk of disputes or litigation regarding
ownership, maintenance or enforcement of such joint intellectual property. For example, our collaboration with Clearmind Medicine Inc.,
or Clearmind, has resulted in filings of provisional patent applications related to certain combinations of our respective proprietary
compounds. As a joint-owner of intellectual property, we are generally or would be unable to use or exploit the intellectual property
without the consent of the other joint owner. If we cannot obtain sole commercial use rights for such jointly-owned intellectual property
as a result of our collaboration, our future product development and commercialization plans may be adversely affected. Moreover, if we
cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively, and our business
and results of operations may be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to identify infringements
of our patents and accordingly the enforcement of our intellectual property rights may be difficult.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug substance in some
of our product candidates is repurposed, which means that it is available in other pharmaceutical products for the purpose of treating
indications that are different from the indications for our product candidates. It is possible that if we receive regulatory approval
to market and sell our drug candidates, some patients that receive a prescription could be sold the same drug substance but not our product
candidate. It would be difficult, if not impossible, for us to identify such instances that may constitute an infringement of our patents.
In addition, because the drug substance of some of our product candidates is repurposed, such substance may not be eligible for patent
protection or data exclusivity. Even if we identify infringing parties, there is no guarantee that a court will agree with our arguments
and find that a third party is infringing our patents or that the court will issue an order for an adequate remedy for that infringement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to maintain effective proprietary
rights for our product candidates, we may not be able to compete effectively in our markets.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the protection
afforded by any patents currently owned and that may be granted, historically, we have relied on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part,
by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve
the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining physical security of our premises
and physical and electronic security of our information technology systems. Agreements or security measures may be breached, and we may
not have adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently
discovered by competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from
third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially
reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third party intellectual property rights
are held to cover our product candidates or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize product candidates or our product candidates unless we successfully pursue
litigation to nullify or invalidate the third party intellectual property right concerned, or enter into a license agreement with the
intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent applications that
if they result in issued patents, could be alleged to be infringed by our new product candidates. If such an infringement claim should
be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new product candidates or seek a
license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, certain U.S. patent applications that will not be filed
outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published
approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred
to as the priority date. Therefore, patent applications covering our new product candidates or platform technology could have been filed
by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations,
be later amended in a manner that could cover our platform technologies, our new product candidates or the use of our new product candidates.
Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will
be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on
terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in pursuing the development of and/or marketing our new product candidates. If we fail in any such
dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our new product
candidates that are held to be infringing. We might, if possible, also be forced to redesign our new product candidates so that we no
longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require
us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new product candidates.
As our industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our product candidates. There may be currently pending
patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain
patents in the future and claim that use of our technologies infringes upon these patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our formulations, processes for designs, or methods of use, the holders
of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a
license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be
available on commercially reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and
would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us
in the U.S. or any other relevant jurisdiction, we may have to pay substantial damages, including treble damages and attorneys&#8217;
fees for willful infringement, pay royalties, redesign our infringing product candidates or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of any patents that may issue
from our patent applications, or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to
the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing,
or in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed
patent or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming all
other requirements for patentability are met, in the United States prior to 2013, the first to make the claimed invention without undue
delay in filing, is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the
patent. After 2013, the United States moved to a first to file system. Changes in patent litigation could increase the uncertainties and
costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could
have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our new product
candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. The validity of U.S. patents may also be challenged in
post-grant proceedings before the USPTO. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new product candidates
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on product candidates, as well as monitoring their infringement in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries can be less extensive than those in the United States. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our product candidates. Future patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products in violation of our proprietary rights generally. Proceedings
to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly and
our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts
to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have received a termination notice for
a license agreement for certain intellectual property rights from an entity controlled by our former chairman and chief executive officer,
Dr. Ascher Shmulewitz.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we entered into
a license agreement, which, following an amendment thereto in August 2015, became effective, with Dekel, an Israeli private company controlled
by Dr. Ascher Shmulewitz, our former chairman and chief executive officer, under which we were granted an irrevocable, worldwide, exclusive,
royalty-bearing license to certain of Dekel&#8217;s technology. See Item 7.B. &#8220;Related Party Transactions-Dekel License Agreement.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any agreement
with Dr. Shmulewitz to notify us with business opportunities he may wish to pursue, subject only to his duties under Israeli law, and
we do not have proprietary rights to Dr. Shmulewitz&#8217; inventions that are not included under the consulting and services agreement
we previously had entered into with him (pertaining solely to the field of immunomodulators including cannabinoids to treat chronic pain
and inflammation).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 17, 2017, we
entered into an amendment to the license agreement, which, if certain conditions precedent were met by June 30, 2018, would provide for
an amendment to the compensation terms of such license agreement. We did not meet the conditions precedent required under such amendment
to the license agreement with Dekel by June 30, 2018, and as a result thereof, the amendment never went into effect. On July 14, 2019,
we entered into an amendment to the license agreement, which encompasses our and Dekel&#8217;s original intention to exclude certain consumer
packaged goods (including, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are sources of nutrients
or other substances which may have a nutritional effect) from the scope of the licensed products and the field of our activity, as described
in the license agreement, which intention was not reflected in the license agreement, and therefore, desired and agreed to amend the license
agreement to reflect the foregoing clarification, as well as certain additional less material matters as discussed in the amendment. The
amendment also prescribes a specific development plan under the license agreement requiring us to invest in the licensed technology (as
defined under the license agreement) formulation development and maintain a total annual investment cap of $350,000 and for a non-compete
and non-solicitation obligation by Dekel and Dr. Shmulewitz, towards our field of activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, Dr. Shmulewitz
was replaced by Mr. Amitay Weiss, who was later replaced by Mr. Oz Adler in January 2022, each of whom was appointed as our Chief Executive
Officer. In February 2021, we received a request from Dr. Shmulewitz to provide him with information relating to our compliance with the
Dekel license agreement. On February 5, 2024, we received a written notice from Dekel for the termination of the license agreement, effective
immediately, based on its allegation that we failed to provide Dekel with certain reports regarding the licensed products under the license
agreement. We reject all of Dekel&#8217;s allegations as set forth in the termination notice and intend to defend ourselves vigorously,
should it be necessary. We are assessing the effects, if any, on our business as a result of the termination notice received from Dekel.
If we are no longer able to license certain of Dekel&#8217;s technology under the Dekel license agreement or if any potential dispute
results in a determination adverse to us, our business may be impeded or materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Pharmaceutical Business
Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>From time to time, we may sign letters of
intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements. There can
be no assurance that we will enter into any such definitive agreements. Similarly, we may strategically invest in transactions from time
to time, and there can be no assurance that the value of our investment will increase or that it will not fluctuate.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation of definitive agreements.
We may never enter into definitive agreements after signing a letter of intent and/or entering into a term sheet or other similar arrangement
for a multitude of reasons, including, but not limited to, regulatory, operational, financial and other considerations. There may also
be forces outside of our control that have an effect on our ability or decision as to whether we enter into such definitive agreements.
As a result, there can be no assurance that upon signing a letter of intent and/or entering into a term sheet or similar arrangement,
that we will enter into definitive documents. This could have a material adverse effect on our reputation and could cause us to incur
expenses if any legal claims arise as a result thereof. For example, in November 2019, we entered into a memorandum of understanding with
Heavenly Rx, Ltd., or Heavenly Rx, pursuant to which we and Heavenly Rx agreed to pursue a business combination. In accordance with the
memorandum of understanding between the parties, any transaction between the parties remained subject to entry into definitive agreements,
and to shareholder and regulatory approvals. We never entered into definitive agreements and do not expect to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, we may strategically
invest into various pharmaceutical companies. However, we can offer no assurance that the value of our investment will increase or that
it will not fluctuate because the value of our investments may be adversely affected by a number of factors, such as negative changes
in a company&#8217;s results of operations, cash flows, financial position and accounting impairment. For example, on March 31, 2022,
we entered into an agreement with and invested in MitoCare X Bio Ltd., or MitoCareX, a company focused on the discovery and development
of potential drugs for cancers and other life-threatening conditions. In addition, on November 17, 2022, we invested in Clearmind, a psychedelic
pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
and underserved health problems. The potential benefits of the agreement with MitoCareX, the investment in Clearmind or other potential
investments may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse effect on our results
of operations, cash flows and financial position. The potential benefits of agreements with potential ventures may not materialize or
may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse effect on our results of operations,
cash flows and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to expand our organization
and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are so leanly staffed, we will need additional managerial, operational, sales, marketing,
financial, legal and other resources. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management may need to
divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing
these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our
infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the
development of additional pharmaceutical product candidates. If our management is unable to effectively manage our growth, our expenses
may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our
business strategy. Our future financial performance and our ability to commercialize pharmaceutical product candidates and compete effectively
will depend, in part, on our ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in our efforts
to identify, license or discover additional pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a substantial amount
of our effort will focus on the continued clinical testing, potential approval and commercialization of our existing pharmaceutical product
candidates, the success of our business also depends in part upon our ability to identify, license or discover additional pharmaceutical
product candidates. Our research programs or licensing efforts may fail to yield additional pharmaceutical product candidates for clinical
development for a number of reasons, including but not limited to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional pharmaceutical product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our pharmaceutical product candidates may not succeed in preclinical or clinical testing;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential pharmaceutical product candidates may be shown to have harmful side effects or may have other characteristics that may make the pharmaceutical products unmarketable or unlikely to receive marketing approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors may develop alternatives that render our pharmaceutical product candidates obsolete or less attractive;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market for a pharmaceutical product candidate may change during our program so that such a pharmaceutical product may become unreasonable to continue to develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a pharmaceutical product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a pharmaceutical product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these events occur,
we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license or discover
additional pharmaceutical product candidates, which would have a material adverse effect on our business and could potentially cause us
to cease operations. Research programs to identify new pharmaceutical product candidates require substantial technical, financial and
human resources. We may focus our efforts and resources on potential programs or pharmaceutical product candidates that ultimately prove
to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable
to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain FDA approval
for any of our pharmaceutical product candidates and begin commercializing those pharmaceutical products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal AKS, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among other things,
our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal
government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician sunshine requirements under the ACA requires manufacturers of drugs, devices and medical supplies to report annually to the U.S. DHHS information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these
laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud
statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the
ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal AKS constitutes
a false or fraudulent claim for purposes of the False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties,
including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare
and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to
operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Widespread public health pandemics could
have a material and adverse effect on our business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any public health pandemic
or other disease outbreak in countries where we or our CROs operate could have a material and adverse effect on our business, financial
condition and results of operations. For example, we reduced our operating expenses at the onset of the COVID-19 pandemic and our Chief
Technologies Officer was on temporary unpaid leave between May 2020 and September 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating results and
financial condition may also be materially adversely affected by laws, regulations, orders or other governmental or regulatory actions
addressing widespread public health concerns that place restrictions on, or require us to make changes to, our operations. For example,
a significant reduction in our workforce and our compliance with instructions imposed by relevant authorities may harm our ability to
continue operating our business and materially and adversely affect our operations and financial condition. In addition, the impact of
a widespread public health crisis may cause delays to our future research and development operations, including but not limited to our
pharmaceutical products development, manufacturing, pre-clinical and clinical trials, and may make it difficult for us to recruit patients
to all of our clinical trials, and keep all of our research and development projects on time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our suppliers,
disruptions resulting from the COVID-19 pandemic resulted and in the event of a future widespread public health crisis may result in cancellations
or delays and increased transport times for delivery of materials to our facilities. If such difficulties arise, we may need to seek alternate
suppliers, which may be more expensive, may not be available or may result in delays in shipments to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions to our business
as a result of a widespread public health crisis, as well as any global recession resulting from the impact of such a crisis, could materially
adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of any of our pharmaceutical product
candidates and marketed products could result in product liability or similar claims that could be expensive, damage our reputation and
harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
an inherent risk of potential pharmaceutical product liability or similar claims. The pharmaceutical and nutraceuticals industries have
historically been litigious, and we face financial exposure to pharmaceutical product liability or similar claims if the use of any of
our pharmaceutical products were to cause or contribute to injury or death. There is also the possibility that defects in the design or
manufacture of any of our pharmaceutical products might necessitate a pharmaceutical product recall. Although we plan to maintain pharmaceutical
product liability insurance, the coverage limits of these policies may not be adequate to cover future claims. In the future, we may be
unable to maintain pharmaceutical product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide
us with adequate coverage against potential liabilities. A pharmaceutical product liability claim, regardless of merit or ultimate outcome,
or any pharmaceutical product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration
and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of, our insurance
coverage could have a material adverse effect on our business, financial condition and results of operations.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of
hazardous materials, including the components of our pharmaceutical product candidates and other hazardous compounds. We and our manufacturers
and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities
pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization
efforts, research and development efforts, business operations and environmental damage resulting in costly clean-up and liabilities under
applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste pharmaceutical
products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these
materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate
the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages
and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials
and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended
to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently
carry biological or hazardous waste insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to our Intended Corporate Restructuring
Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intended Restructuring Plan, which may
involve transferring our pharmaceutical activities to a new wholly-owned subsidiary, may not be completed in accordance with the expected
plans or anticipated timeline, or at all, and may not achieve the expected results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to Jeffs&#8217;
Brand Holding Inc., a wholly owned subsidiary of Jeffs&#8217; Brands, or NewCo. As part of or independent to the Restructuring Plan, we
intend to examine the possibility of listing NewCo on a leading stock exchange, while maintaining our controlling interest in NewCo such
that we will continue to control our current business activities. We also intend to explore other potential new opportunities, activities
and investments in a variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Restructuring
Plan, on November 22, 2023, we announced the signing of a non-binding letter of intent, or LOI, to acquire a leading vehicle importer
company in Israel, or the Target Company, with certain new negotiated terms as announced on December 7, 2023. According to the new negotiated
terms, we will acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, which would in turn merge with
and into the Target Company, or the Acquisition. Following the Acquisition, if completed, it is contemplated that our shareholders will
hold approximately 50.01% of the share capital of the post-closing combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of the transactions
contemplated by this LOI, or any other potential restructuring plans or transactions in addition to the possible listing of NewCo on a
stock exchange, may be subject to, among other things, market conditions, tax or other business analyses, regulatory approvals, receipt
of any necessary consents, final approvals from our board of directors and shareholders and satisfaction of any closing conditions to
effectuate such corporate restructuring. On January 19, 2024, we announced, that we had entered into a bridge loan agreement as lender,
with the Target Company, pursuant to which the Target Company received a bridge loan from us in the amount of $1.4 million. This subjects
us to additional risk in the event of a default or partial default on payment of the bridge loan. Moreover, there can be no assurance
regarding the ultimate timing of the Acquisition or any other restructuring plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unanticipated developments
or changes, including but not limited to, changes in the general or financial market conditions, possible delays in obtaining various
regulatory and tax approvals, changes in the law, and challenges in executing the Acquisition or any other restructuring plan could delay
or prevent the completion of the Restructuring Plan and listing of NewCo, or cause the restructuring and listing of NewCo to occur on
terms or conditions that are different or less favorable than initially expected. These or other developments could cause us not to realize
some or all of the expected benefits of the Restructuring Plan and listing of NewCo or to realize them on a different timeline than expected.
If the Restructuring Plan and listing of NewCo do not occur, we could pursue other transactions involving our pharmaceutical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Restructuring Plan and listing of NewCo
may not achieve the anticipated benefits and may expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not realize the anticipated
strategic, financial, operational or other benefits of the Restructuring Plan and listing of NewCo. We cannot predict with certainty when
the benefits expected from these transactions will occur or the extent to which they will be achieved. There is no assurance that following
the Restructuring Plan and listing of NewCo that each separate company will be successful. Whether or not the Restructuring Plan and listing
of NewCo is completed, we may face material challenges in connection with the intended transactions, including but not limited to, the
diversion of management time on matters relating to the Restructuring Plan and listing of NewCo, the impact of having to operate under
the terms of any transition service agreements, the impact on our ability to retain talent and potential impacts on our relationships
with customers, suppliers, employees and other counterparties. In addition, we will incur one-time costs and ongoing costs in connection
with, or as a result of, the Restructuring Plan and listing of NewCo, including costs of operating as independent, publicly-traded companies
that the separate businesses will no longer be able to share. Those costs may exceed our estimates or could negate some of the benefits
we expect to realize. Further, we have not yet analyzed whether the Restructuring Plan and listing of NewCo will be tax-free to our shareholders
for U.S. federal income tax or Israeli tax purposes and there is no assurance that the Restructuring Plan and listing of NewCo will qualify
for this treatment. If the Restructuring Plan and listing of NewCo is ultimately determined to be taxable, any of NewCo, our shareholders
or us could incur income tax liabilities that could be significant. If we do not realize the anticipated benefits of the Restructuring
Plan and listing of NewCo it could adversely affect our business, results of operations, cash flows and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following any Restructuring Plan and listing
of NewCo, the trading price of our Ordinary Shares may fluctuate significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
the market value of our Ordinary Shares after any Restructuring Plan and listing of NewCo will be, in the aggregate, less than, equal
to or greater than the market value of our ordinary shares prior to such transactions. The trading price of our Ordinary Shares may be
more volatile around the time of the intended separation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the eCommerce&#160;Operations
of SciSparc Nutraceuticals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to successfully pursue,
integrate, or execute upon the eCommerce operations business of SciSparc Nutraceuticals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we&#160;purchased
Wellution&#8482;, a business and brand which sells hemp-based products on the Amazon.com marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management has limited
prior experience in eCommerce business operations. There can be no assurance that we will be able to successfully implement our new business
ventures or successfully operate within this industry.&#160;The successful integration of a new business also depends on our ability to
manage the new business, realize forecasted synergies and full value from the combined business. Our business, results of operations,
financial condition and cash flows could be materially adversely affected if we are unable to successfully integrate&#160;Wellution into
our existing operations and any inability to do so may also hinder our ability to grow, divert the attention of management and our key
personnel, disrupt our business and impair our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on the Amazon.com marketplace and fulfillment by Amazon.com and changes to the Amazon.com marketplace, Amazon&#8217;s services and
their terms of use may harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wellution&#8217;s products
are sold predominantly on the Amazon.com marketplace and orders are fulfilled entirely by Amazon.com utilizing the fulfilled by Amazon,
or FBA, model. In order to continue to utilize the Amazon.com marketplace and FBA, we must comply with the applicable policies and terms
of use relating to these services. Such policies and terms of use may be altered or amended at Amazon&#8217;s sole discretion, including
changes regarding the cost of securing these services, and changes that increase the burden of compliance with its requirements, may cause
us to significantly alter our business model or incur additional costs in order to comply, which could negatively impact our results of
operations. Non-compliance with applicable terms of use and policies can result in the removal of one or more products from the marketplace
and suspension of fulfillment services either of which could have a material adverse effect on our business and results of our operations.
Although we exert efforts in order to ensure ongoing compliance and no notices of non-compliance have been received to date, we cannot
assure you that events of this kind will not occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on other information technologies and systems to operate its business and to maintain its competitiveness, and any failure to invest
in and adapt to technological developments and industry trends could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on sophisticated
information technologies and systems, technology and systems used for Wellution&#8217;s websites and apps, customer service, logistics
and fulfillment, supplier connectivity, communications and administration. As our operations grow in size, scope and complexity, we will
need to continuously improve and upgrade our systems and infrastructure to offer an increasing number of consumer-enhanced services, features
and functionalities, while maintaining and improving the reliability and integrity of our systems and infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to use A.I. tools and infrastructure, including logistics and fulfillment platform which leverages, to meet rapidly evolving
eCommerce trends and demands. The emergence of alternative platforms may require us to continue to invest in new and costly technology.
We may not be successful, or we may be less successful than our competitors, in adopting technologies that operate effectively across
multiple eCommerce platforms, which would negatively impact our business and financial performance. New developments in other areas, such
as cloud computing providers, could also make it easier for competitors to enter our markets due to lower up-front technology costs. In
addition, we may not be able to maintain our existing systems or replace our current systems or introduce new technologies and systems
as quickly or cost effectively as we would like. Failure to invest in and adapt to technological developments and industry trends may
have a material adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
rely on data provided by third parties, the loss of which could limit the functionality of our platforms, cause us to invest in the wrong
product or disrupt our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use third party software
to determine market trends and what markets to enter into. Our ability to successfully use this software depends on our ability to analyze
and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google and Amazon. Some of this
data is provided to us pursuant to third-party data sharing policies and terms of use, under data sharing agreements by third-party providers
or by customer consent. The majority of this data is sourced for free or for de minimis amounts. These sources of data allow us, along
with A.I. tools, to determine trends, performance and consumer sentiment on products and searches within eCommerce platforms. This functionality
allows us to help determine which products to market, in some cases manufacture through contract manufacturers, import and sell on eCommerce
marketplaces. The connection to multiple eCommerce platforms through application programming interfaces allow us to develop the automation
of the purchase of marketing and automate the change of pricing of product listings on those eCommerce platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, any of these
third parties could change its data sharing policies, including making them more restrictive, charging fees or altering its algorithms
that determine the placement, display and accessibility of search results and social media updates, any of which could result in the loss
of, or significant impairment to, our ability to collect useful data. These third parties could also interpret our, or our service providers&#8217;,
data collection policies or practices as being inconsistent with their policies, which could result in the loss of our ability to collect
this data. Privacy concerns may cause end users to resist providing the personal data necessary to allow us to determine market trends
as well as our ability to effectively retain existing customers. Privacy advocacy groups and the technology and other industries are considering
various new, additional or different self-regulatory standards that may place additional burdens on us. Any such changes could impair
our ability to use data and could adversely impact select functionality of our proprietary software, impairing our ability to use this
data to anticipate customer demand and market trends, as well as adversely affecting our business and our ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
depend on our ability to build and maintain strong product listings on eCommerce platforms. We may not be able to maintain and enhance
our product listings if we receive a substantial number of customer complaints, negative publicity or otherwise fail to live up to customers&#8217;
expectations, any of which could materially adversely affect our business, results of operations and growth prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maintaining and enhancing
our product listings is critical in expanding and growing our business. However, a significant portion of our perceived performance to
the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services
and other third-party delivery agents and online retailers, mainly Amazon. Because our agreements with our online retail partners are
generally terminable at will, we may be unable to maintain these relationships, and our results of operations could fluctuate significantly
from period to period. Because we rely on third party logistics companies to deliver our products, we are subject to shipping delays or
disruptions caused by inclement weather, natural disasters, labor activism, health epidemics or bioterrorism. In addition, because we
rely on national, regional and local transportation companies for the delivery of some of our other products, we are also subject to risks
of breakage or other damage during delivery by any of these third parties. If these third parties do not meet our or our customers&#8217;
expectations, our brands may suffer irreparable damage. In addition, maintaining and enhancing our current and future brands may require
us to make substantial investments, and these investments may not yield sufficient returns. If we fail to promote and maintain our brands,
or if we incur excessive expenses in this effort, our business, operating results and financial condition may be materially adversely
affected. We anticipate that, as our market becomes increasingly competitive, maintaining and enhancing our brands may become increasingly
difficult and expensive. Maintaining and enhancing our brands will depend largely on our ability to anticipate market trends and customer
demand and to provide high quality products to our customers and a reliable, trustworthy and profitable sales channel to our suppliers,
which we may not be able to do successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A substantial number of customer
complaints or negative publicity about our sites, products, delivery times, customer data handling and security practices or customer
support, especially on blogs, social media websites or our sites, could rapidly and severely diminish consumer views of our products and
result in harm to our brands. Customers may also make safety-related claims regarding products sold through our online retail partners,
such as Amazon, which may result in an online retail partner removing the product from its marketplace. Such removal may materially impact
our financial results depending on the product that is removed and length of time that it is removed. We also use and rely on other services
from third parties, such as our telecommunications services, and those services may be subject to outages and interruptions that are not
within our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; efforts
of SciSparc Nutraceuticals to acquire or retain customers, and our efforts to sell new products or increase sales of our existing products,
may not be successful, which could prevent us from maintaining or increasing our sales and achieving profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not successfully
promote and sustain our new and/or existing product listings and brands through marketing and other tools, we may fail to maintain or
increase our sales and achieve profitability. Promoting and positioning our brands and product listings will depend largely on the success
of our marketing efforts, our ability to attract customers cost effectively and our ability to consistently provide a high-quality product
and maintain consumer satisfaction. We also use promotions to drive sales, which may not be effective and may adversely affect our gross
margins. Our investments in marketing may not effectively reach potential customers, potential customers may decide not to buy our products
or the spending of customers that purchase from us may not yield the intended return on investment, any of which could negatively affect
our financial results. The failure of our marketing activities could also adversely affect our ability to promote our product listings
and sell our products, and to develop and maintain relationships with our customers, retailers and brands, which may have a material adverse
effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the eCommerce operations of SciSparc
Nutraceuticals fail to offer high-quality customer support, our business and reputation may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">High-quality education and
training of customer support personnel to deliver high-quality customer support are important for the successful retention of existing
customers. Providing this education, training and support requires that our support personnel have specific knowledge and expertise of
our products and markets, making it more difficult for us to hire experienced personnel and to scale up our support operations. The importance
of high-quality customer support will increase as we expand our business and pursue new customers. If we do not provide effective and
timely ongoing support, our ability to retain existing customers may suffer, and our reputation with existing or potential customers may
be harmed, which would have a material adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; efforts
of SciSparc Nutraceuticals to expand our business into new brands, products, services, technologies and geographic regions will subject
us to additional business, legal, financial and competitive risks and may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wellution&#8217;s business
success depends to some extent on our ability to expand our consumer offerings by launching new brands, products and services and by expanding
our existing offerings into new geographic regions. Our strategy is to use our skills to determine which markets to enter and optimize
the mix of products and services that we offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Launching new brands, products
and services requires significant upfront investments, including investments in marketing (namely digital marketing and Pay Per Click
(PPC), information technology and additional personnel. We operate in highly competitive industries with relatively low barriers to entry
and must compete successfully in order to grow our business. We may not be able to generate satisfactory revenue from these efforts to
offset these costs. Any lack of market acceptance of our efforts to launch new brands, products or services or to expand our existing
offerings could have a material adverse effect on our business, prospects, financial condition and results of operations. Further, as
we continue to expand our fulfillment capability or add new businesses with different requirements, our logistics networks will become
increasingly complex and operating them will become more challenging. There can be no assurance that we will be able to operate our networks
effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also entered and may
continue to enter new markets and provide product offerings in which we have limited or no experience, which may not be successful or
appealing to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The eCommerce consumer products
goods industry is subject to evolving standards and practices, as well as changing consumer needs, requirements and preferences. Our ability
to attract new customers and increase revenue from existing customers depends, in part, on our ability to enhance and improve our existing
tools that enable us to pinpoint new markets and introduce new products. The success of any enhancements or new instruments depends on,
in part, market-accepted pricing levels and overall market acceptance. We may not be successful in these efforts, which could result in
significant expenditures that could impact our revenue or distract management&#8217;s attention from current offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increased emphasis on the
sale of new products could distract us from sales of our existing products in existing markets, negatively affecting our overall sales.
We have invested and expect to continue to invest in new businesses, products, features, services and technologies. Such endeavors may
involve significant risks and uncertainties, including insufficient revenue from such investments to offset any new liabilities assumed
and expenses associated with these new investments, inadequate return of capital on our investments, distraction of management from current
operations and unidentified issues not discovered in our due diligence of such investments that could cause us to fail to realize the
anticipated benefits of such investments and incur unanticipated liabilities. Because these new strategies and offerings are inherently
risky, no assurance can be given that they will be successful. Our new features or enhancements could fail to attain sufficient market
acceptance for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in introducing products in new markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to accurately predict market demand or end consumer preferences;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of competing products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor financial conditions for our customers or poor general macroeconomic conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in legal or regulatory requirements, or increased legal or regulatory scrutiny, adversely affecting our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of our brands, and products, digital promotion activities or negative publicity about the performance or effectiveness of our existing brands and products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions or delays in the online retailers and, or in addition to, logistics providers distributing our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
we will successfully identify new opportunities or develop and bring new products to market on a timely basis, which could materially
and adversely affect our business and operating results and compromise our ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations&#8217; use of social
media and email by SciSparc Nutraceuticals may adversely impact our reputation or subject us to fines or other penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use social media and email
as part of our digital marketing efforts. As laws and regulations rapidly evolve to govern the use of these channels, the failure by us,
our employees or third parties acting at on our behalf to abide by applicable laws and regulations in the use of these channels could
adversely affect our reputation or subject us to fines or other penalties. In addition, our employees or third parties acting on our behalf
may knowingly or inadvertently make use of social media in ways that could lead to the loss or infringement of intellectual property,
as well as the public disclosure of proprietary, confidential or sensitive personal information of our business, employees, customers
or others. Any such inappropriate use of social media or email could also cause reputational damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers value readily available
information concerning retailers and their goods and services and often act on such information without further investigation and with
no regard to its accuracy. Our customers may engage with us online through our social media platforms, including Facebook and Instagram,
by providing feedback and public commentary about all aspects of our business. Information concerning us or our retailers and brands,
whether accurate or not, may be posted on social media platforms at any time and may have a disproportionately adverse impact on our brand,
reputation or business. The harm may be immediate without affording us an opportunity for redress or correction and could have a material
adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With respect to the eCommerce operations
of SciSparc Nutraceuticals, if our emails are not delivered and accepted or are routed by email providers less favorably than other emails,
or our sites or mobile applications are not accessible or are treated disadvantageously by Internet service providers, our business may
be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If email providers or Internet
service providers, or ISPs, implement new restrictive email or content delivery or accessibility policies, including with respect to net
neutrality, or begin enforcement of existing policies, it may become more difficult to deliver emails to our customers or for customers
to access our sites, products and services. For example, certain email providers, including Google, categorize our emails as &#8220;promotional&#8221;,
and these emails are directed to an alternate, and less readily accessible, section of a customer&#8217;s inbox. If email providers materially
limit or halt the delivery of our emails, or if we fail to deliver emails to customers in a manner compatible with email providers&#8217;
email handling or authentication technologies, our ability to contact customers through email could be significantly restricted. In addition,
if we are placed on &#8220;spam&#8221; lists or lists of entities that have been involved in sending unwanted, unsolicited emails, our
operating results and financial condition could be substantially harmed. Further, if ISPs prioritize or provide superior access to our
competitors&#8217; content, our business and results of operations may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals
are subject to risks related to online payment methods.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We accept payments using a
variety of methods, including credit card, debit card, PayPal, Payoneer, credit accounts (including promotional financing) and gift cards.
For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise
our operating costs and lower profitability. In addition, our credit card and other payment processors could impose receivable holdback
or reserve requirements in the future. We rely on third parties to provide payment processing services, including the processing of credit
cards and debit cards, and it could disrupt our business if these companies become unwilling or unable to provide these services to us.
We are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers,
which could change or be reinterpreted to make it difficult or impossible for us to comply. If we fail to comply with the rules or requirements
of any provider of a payment method we accept, if the volume of fraud in our transactions limits or terminates our rights to use payment
methods we currently accept, or if a data breach occurs relating to our payment systems, we may, among other things, be subject to fines
or higher transaction fees and may lose, or face restrictions placed upon, our ability to accept credit card or debit card payments from
customers or to facilitate other types of online payments. If any of these events were to occur, our business, financial condition and
operating results could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>With respect to the eCommerce operations
of SciSparc Nutraceuticals, if we are unable to manage our inventory effectively, our operating results could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To ensure timely delivery
of products, we generally enter into purchase orders in advance with manufacturers. As a result, we are vulnerable to demand and pricing
shifts and to suboptimal selection and timing of product purchases. We rely on our procurement team to order products and we rely on our
data analytics to inform the levels of inventory we purchase, including when to reorder items that are selling well and when to write
off items that are not selling well. In these instances, we may be unable to always predict the appropriate demand for our products by
customers with accuracy, which may result in inventory shortages, inventory write offs and lower gross margins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our sales and procurement
teams do not predict demand well or if our algorithms do not help us reorder the right products or write off the right products timely,
we may not effectively manage our inventory, which could result in inventory excess or shortages, and our operating results and financial
condition could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operations of SciSparc Nutraceuticals,
including the costs and supply chain, are subject to risks associated with sourcing, importing and warehousing.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We source the products we
offer from third-party vendors and, as a result, we may be subject to price fluctuations or demand disruptions. Our operating results
could be negatively impacted by increases in the prices of our products, and we have no guarantees that prices will not rise. In addition,
as we expand into new categories and types of products, we expect that we may not have strong purchasing power in these new areas, which
could lead to higher costs than we have historically seen in our current product categories and types. We may not be able to pass increased
costs on to customers, which could adversely affect our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we cannot guarantee
that products we receive from vendors will be of sufficient quality or free from damage or defects, or that such merchandise will not
be damaged during shipping or storage. While we take measures to ensure product quality and avoid damage, including evaluating vendor
facilities, operations and product samples, conducting inventory inspections and inspecting returned products, we cannot control merchandise
while it is out of our possession or prevent all damage while in our distribution centers. We may incur additional expenses and our reputation
could be harmed if or current or potential customers believe that our merchandise is not of high quality or may be damaged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks associated with the suppliers from
whom our products are sourced could materially adversely affect our financial performance, as well as our reputation and brand.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on our ability to
provide our customers with a wide range of products from high quality suppliers in a timely and efficient manner. Our agreements with
most of our suppliers do not provide for the long-term availability of merchandise or the continuation of particular pricing practices,
nor do they usually restrict such suppliers from selling products to other buyers or directly themselves. There can be no assurance that
our current suppliers will continue to seek to sell us products on current terms or that we will be able to establish new or otherwise
extend current supply relationships to ensure product acquisitions in a timely and efficient manner and on acceptable commercial terms.
Our ability to develop and maintain relationships with reputable suppliers and offer high quality products to our customers is critical
to our success. If we are unable to develop and maintain relationships with suppliers that would allow us to offer a sufficient amount
and variety of quality products on acceptable commercial terms, our ability to satisfy our customers&#8217; needs, and therefore our long-term
growth prospects, would be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also are unable to predict
whether any of the countries in which our suppliers&#8217; products are currently manufactured or may be manufactured in the future will
be subject to trade restrictions imposed by the U.S. or foreign governments or the likelihood, type or effect of any such restrictions.
Any event causing a disruption or delay of imports from suppliers with international manufacturing operations, including the imposition
of additional import restrictions, restrictions on the transfer of funds or increased tariffs or quotas, could increase the cost or reduce
the supply of merchandise available to our customers and materially adversely affect our financial performance as well as our reputation
and brand. Our competitors may have greater existing inventory positions and other advantages that may allow them to price more competitively
relative to our products. Furthermore, some or all of our suppliers&#8217; foreign operations may be adversely affected by political and
financial instability, resulting in the disruption of trade from exporting countries, restrictions on the transfer of funds or other trade
disruptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not accurately forecast revenues,
profitability and appropriately plan our expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our current and future
expense levels on our operating forecasts and estimates of future income and operating results. Income and operating results are difficult
to forecast because they generally depend on the volume and timing of the orders we receive, which are uncertain. Additionally, our business
is affected by general economic and business conditions around the world. A softening in income, whether caused by changes in consumer
preferences, a weakening in global economies or inflation, may result in decreased net revenue levels, and we may be unable to adjust
our spending in a timely manner to compensate for any unexpected shortfall in income. This inability could cause our income (loss) from
operations after tax in a given quarter to be lower or higher than expected. We also make certain assumptions when forecasting the amount
of expenses we expect related to our share-based payments, which includes the expected volatility of our share price, and the expected
life of equity awards granted. These assumptions are partly based on historical results. If actual results differ from our estimates,
our operating results in a given quarter may be lower than expected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The eCommerce operation&#8217;s operating
results of SciSparc Nutraceuticals are subject to seasonal fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The eCommerce business is
seasonal in nature and the fourth quarter is a significant period for our operating results due to the holiday season. As a result, revenue
generally declines and loss from operations generally increases in the first quarter sequentially from the fourth quarter of the previous
year. Any disruption in our ability to process and fulfill customer orders during the fourth quarter could have a negative effect on our
quarterly and annual operating results. For example, if a large number of customers purchase our products in a short period of time due
to increased holiday demand, inefficient management of our inventory may prevent us from efficiently fulfilling orders, which may reduce
sales and harm our brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The inability to acquire, use or maintain
our marks and domain names for our sites could substantially harm our business and operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have registered
trademarks for our brands in numerous jurisdictions and have registered the Internet domain names for our websites, as well as various
related domain names. However, we have not registered our trademarks or domain names in all major international jurisdictions. Domain
names generally are regulated by Internet regulatory bodies. If we do not have, or cannot obtain on reasonable terms, the ability to use
our marks in a particular country or to use or register any of our domain names, we could be forced either to incur significant additional
expenses to market our products within that country, including the development of a new brand and the creation of new promotional materials
and packaging, or to elect not to sell products in that country. Either result could materially adversely affect our business, financial
condition and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the regulations
governing domain names and laws protecting marks and similar proprietary rights could change in ways that block or interfere with our
ability to use relevant domains or our current brand names. Furthermore, we might not be able to prevent third parties from registering,
using or retaining domain names that interfere with our consumer communications or infringe or otherwise decrease the value of our marks,
domain names and other proprietary rights. Regulatory bodies also may establish additional generic or country-code top-level domains or
may allow modifications of the requirements for registering, holding or using domain names. As a result, we may not be able to register,
use or maintain the domain names that utilize the Wellution name in all of the countries in which we currently or intend to conduct business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any significant disruption in service on
our websites or apps or in our computer systems, a number of which are currently hosted or provided by third-party providers, could materially
affect our ability to operate, damage our reputation and result in a loss of customers, which would harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to sell and market
our products relies on FBA platform whose functionality relies upon a number of third-party related services, including those relating
to cloud infrastructure, technology services, servers, open-source libraries and vendor application programming interfaces. Any disruption
or loss of any of these third-party services could have a negative effect on our business, results of operations, financial condition
and prospects. We may experience interruptions in our systems, including server failures that temporarily slow down or interfere with
the performance of our platforms and the ability to sell on eCommerce marketplaces.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interruptions in these systems,
whether due to system failures, human input errors, computer viruses or physical or electronic break-ins, and denial-of-service attacks
on us, third-party vendors or communications infrastructure, could affect the availability of our services on our platform and prevent
or inhibit the ability of selling our products. Volume of traffic and activity on eCommerce marketplaces spikes on certain days, such
as during a Black Friday promotion, and any such interruption would be particularly problematic if it were to occur at such a high-volume
time. Problems with the reliability of our systems or third-party marketplaces could prevent us from earning revenue and could harm our
reputation. Damage to our reputation, any resulting loss of customers, eCommerce confidence and the cost of remedying these problems could
negatively affect our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to maintain communications,
network and computer hardware in the countries in which they are used may in the future be subject to regulatory review and licensing,
and the failure to obtain any required licenses could negatively affect our business. Our systems and infrastructure are predominately
reliant on third parties. Problems faced by our third-party service providers with the telecommunications network providers with whom
they contract or with the systems by which they allocate capacity among their users, including us, could adversely affect the experience
of our customers. Our third-party service providers could decide to close their facilities without adequate notice. Any financial difficulties,
such as bankruptcy or reorganization, faced by our third-party service providers or any of the service providers with whom they contract
may have negative effects on our business, the nature and extent of which are difficult to predict. If our third-party service providers
are unable to keep up with our needs for capacity, this could have an adverse effect on our business. Any errors, defects, disruptions
or other performance problems with our services could harm our reputation and may have a material adverse effect on our business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Ownership of Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need additional capital in the future.
Raising additional capital by issuing securities may cause dilution to existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred losses every
year since our inception. If we continue to use cash at our historical rates of use we will need significant additional financing, which
we may seek through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, an existing shareholder&#8217;s
ownership interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely
affect the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations and may
involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt or making
capital expenditures. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third parties,
we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms
that are not favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not know whether a market for the
Ordinary Shares will be sustained or what the trading price of the Ordinary Shares will be and as a result it may be difficult for you
to sell your Ordinary Shares</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Ordinary Shares
are listed on Nasdaq, an active trading market for the Ordinary Shares may not be sustained. It may be difficult for you to sell your
Ordinary Shares without depressing the market price for the Ordinary Shares or at all. Further, an inactive market may also impair our
ability to raise capital by selling Ordinary Shares and may impair our ability to enter into strategic partnerships or acquire companies,
products, or services by using our equity securities as consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of a substantial number of our Ordinary
Shares in the public market by our existing shareholders could cause our share price to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of our Ordinary Shares in the public market, or the perception that these sales might occur, could depress the market price of our Ordinary
Shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The exercise of outstanding warrants will
cause significant dilution to holders of our equity securities and could adversely affect the price of our Ordinary Shares. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 28, 2024, holders
of warrants (including pre-funded warrants) may exercise their warrants into up to 3,268,244Ordinary Shares. In the event that such warrants
are exercised in full, the ownership interest of existing holders of our equity securities will be diluted and may have a negative effect
on the trading price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities may be
highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our Ordinary
Shares is volatile. Our Ordinary Share price is and will continue to be subject to wide fluctuations in response to a variety of factors,
including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse results or delays in preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports of adverse events in our product candidates or clinical trial failures of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain additional funding;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delay in filing a regulatory submission for any of our product or product candidates and any adverse development or perceived adverse development with respect to the review of that regulatory submission by the FDA or European or Asian authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">failure to successfully develop and commercialize
    our products or product candidates;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to enter into strategic collaborations or failure to successfully integrate acquisitions we have made;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us or strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws or regulations applicable to future products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to scale up our manufacturing capabilities through third-party manufacturers, inability to obtain adequate product supply for our products or the inability to do so at acceptable prices;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products or technologies by our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed financial projections we may provide to the public;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures or delays in our intended Restructuring Plan;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed the financial expectations of the investment community;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our platform technologies, technologies, products or product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key scientific or management personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant lawsuits, including patent or shareholder litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market valuations of similar companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in general conditions in the economy and the financial markets in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the recent attack by Hamas and other terrorist organizations from the Gaza Strip and elsewhere in the region and Israel&#8217;s war against them and the military hostilities with the Hezbollah organization along the Northern border of Israel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our securities by us or our shareholders in the future; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volumes of our securities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, companies trading
in the stock market have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of these companies. Broad market and industry factors may negatively affect the market price of our Ordinary Shares, regardless
of our actual operating performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Outstanding warrants and pre-funded warrants
to acquire our Ordinary Shares are speculative in nature. Furthermore, holders of our warrants and pre-funded warrants will have no rights
as shareholders until such holders exercise their warrants and acquire our Ordinary Shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until holders of the warrants
and pre-funded warrants acquire our Ordinary Shares upon exercise of the warrants and pre-funded warrants, holders of the warrants and
pre-funded warrants will have no rights with respect to our Ordinary Shares underlying such warrants and pre-funded warrants. Upon exercise
of the warrants and pre-funded warrants, the holders thereof will be entitled to exercise the rights of a holder of Ordinary Shares only
as to matters for which the record date occurs after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our warrants and pre-funded
warrants only represent the right to acquire Ordinary Shares at a fixed price, and in the case of the warrants, for a limited period of
time. Specifically, holders of the warrants and pre-funded warrants that we issued in private placements in March 2020, March 2021, June
2022 and October 2023 and in our November 2020 and August 2023 public offerings may exercise their right to acquire Ordinary Shares and
pay an exercise price per Ordinary Shares (in the case of the pre-funded warrants, $0.001 to $0.026 per Ordinary Share and in the case
of other warrants, ranging from $68.38 to $637.00 per Ordinary Share), subject to adjustment upon certain events, and in the case of warrants
only prior to five years from their respective issuance dates, after which date any unexercised warrants will expire and have no further
value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot assure you that our Ordinary Shares
will remain listed on Nasdaq or any other securities exchange.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs, which previously
represented our Ordinary Shares, were listed on Nasdaq from March 2017 through July 2020. On September 21, 2020, our ADSs were delisted
from Nasdaq as a result of not meeting the shareholders equity requirements of Nasdaq. Between December 2020 and August 2021, our ADSs
were quoted on the OTCQB. In August 2021, our ADR program was terminated and our ADSs were converted to Ordinary Shares on a one-for-one
basis. In September 2021, our Ordinary Shares began to be quoted for trading on the OTCQB under the ticker &#8220;SPRCF&#8221;. In December
2021, our Ordinary Shares were re-listed on Nasdaq and began trading under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on March 10,
2023, we received a written notice, or the Notice, from Nasdaq indicating that we are not in compliance with the minimum bid price requirement
for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
$1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the
minimum bid price requirement. Although we have since cured this deficiency and have regained compliance with Nasdaq Listing Rule 5550(a)(2),
there is a risk that we could be subject to additional notices of delisting for failure to comply with Nasdaq Listing Rule 5550(a)(2)
or other Nasdaq Listing Rules and no assurance can be given that we will remain eligible to be listed on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, because of the previous
delisting of our ADSs from Nasdaq, if we fall out of compliance with Nasdaq requirements in the future, our Ordinary Shares may be more
likely to be subject to Nasdaq&#8217;s delisting process and no assurance can be given that we will be able to regain compliance. Any
delisting could adversely affect our ability to obtain financing for the continuation of our operations and could result in the loss of
confidence by investors, customers and employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to achieve and maintain effective
internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, results
of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting,
which could have a material adverse effect on the price of our Ordinary Shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective internal controls
are necessary for us to provide reliable financial reports and effectively prevent fraud. We are required to document and test our internal
control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments
of the effectiveness of our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal
control, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude
on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. Disclosing deficiencies
or weaknesses in our internal control, failing to remediate these deficiencies or weaknesses in a timely fashion or failing to achieve
and maintain an effective internal control environment may cause investors to lose confidence in our reported financial information, which
could have a material adverse effect on the price of our Ordinary Shares. If we cannot provide reliable financial reports or prevent fraud,
our operating results could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not paid, and do not intend to pay,
dividends on our Ordinary Shares and, therefore, unless our traded securities appreciate in value, our investors may not benefit from
holding our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any cash
dividends on our Ordinary Shares since inception. We do not anticipate paying any cash dividends our Ordinary Shares in the foreseeable
future. Moreover, the Israeli Companies Law-1999, or the Companies Law, imposes certain restrictions on our ability to declare and pay
dividends. As a result, investors in our Ordinary Shares will not be able to benefit from owning these securities unless their market
price becomes greater than the price paid by such investors and they are able to sell such securities. We cannot assure you that you will
ever be able to resell our securities at a price in excess of the price paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unfavorable outcomes in legal proceedings
may harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of whether or not
there is merit to the claims underlying any legal proceedings to which we are subject, and regardless of whether or not we are found as
a result of such proceedings to have violated any applicable laws, such proceedings can be expensive to defend or respond to, and could
result in substantial costs and diversion of management&#8217;s attention and resources, which could harm our business, and potentially
could cause substantial and irreparable harm to our public reputation. For example, on May 2, 2023, Capital Point Ltd., or Capital Point,
filed a lawsuit in the Tel Aviv-Jaffa District Court against us as the sole defendant in connection with the warrant we issued to Capital
Point pursuant to a joint venture transaction entered into on May 15, 2020 by and between us, Capital Point and Evero Health Ltd. one
of our subsidiaries. The lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General Part), 1973, unjust
enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version), 1968. The lawsuit
claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the
lawsuit, liquidated damages according to the provisions set forth in the warrant, and seeks as well for the court to order a mandatory
injunction order for us to issue a warrant to Capital Point to purchase $340,000 of our ordinary shares, the return of any unlawful profits
received by us and punitive damages. As of March 28, 2024, in connection with the aforementioned litigation, the shares of Evero Health
Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd. As of the date of this Annual Report, we cannot predict
the likelihood of our success in the lawsuit. If we do not prevail in such lawsuit, our results of operations and reputation could be
adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of our Ordinary Shares if we are or were
to become a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, we will be treated
as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive
income&#8221; or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income.
Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account. We do not believe that we would be deemed a PFIC for 2023. If we are a PFIC
in any taxable year during which a U.S. taxpayer holds the Ordinary Shares, such U.S. taxpayer would be subject to certain adverse U.S.
federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing fund,&#8221;
or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and any gain realized
on the sale or other disposition of the Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&#8217;s
holding period for the Ordinary Shares; (2) the amount allocated to the current taxable year and any period prior to the first day of
the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable
years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest
charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.
In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have
determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers
that have held the Ordinary Shares during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be
a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. U.S.
taxpayers that hold the Ordinary Shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing
requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to the Ordinary
Shares in the event that we are a PFIC. See Item 10.E. &#8220;Taxation-U.S. Federal Income Tax Considerations-Passive Foreign Investment
Companies&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Israeli Law and Our Operations
in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We conduct our operations in Israel. Conditions
in Israel, including the recent attack by Hamas and other terrorist organizations and Israel&#8217;s war against them, may affect our
operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Israel and our headquarters and principal offices and most of our operations are located in the State of Israel.
In addition, all of our key employees and officers are residents of Israel. Accordingly, political, economic and military conditions in
Israel and the surrounding region may directly affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any hostilities involving
Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic
or financial condition of Israel, could affect adversely our operations. Ongoing and revived hostilities or other Israeli political or
economic factors could harm our operations, product development and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 7, 2023, an unprecedented
attack was launched against Israel by terrorists from the Hamas&#160;terrorist organization that infiltrated Israel&#8217;s border with
the Gaza Strip, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population.
These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. In response, the Security Cabinet of the
State of Israel declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their
continued rocket and terror attacks. To date, the State of Israel continues to be at war with Hamas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the war broke out on
October 7, 2023, our operations have not been adversely affected, except with regards to our SCI-210 ASD clinical trial at Soroka Medical
Center which was delayed by three months. At this time, it is not possible to predict the intensity or duration of the war, nor can we
predict how this war will ultimately affect Israel&#8217;s economy in general, <span>which may involve
additional credit rating agencies downgrading Israel&#8217;s credit rating score after Moody&#8217;s downgrading of Israel&#8217;s credit
rating from A1 to A2 and outlook rating from &#8220;stable&#8221; to &#8220;negative&#8221;, and we continue to monitor the situation
closely and examine the potential disruptions that could adversely affect our operations. </span>We continue to monitor the situation
closely and examine the potential disruptions that could adversely affect our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Israeli
security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand
Israeli military reservists were drafted to perform immediate military service. <span>Although many such
military reservists have been discharged, they may be called up again depending on how events unfold. </span>As of March 28, 2024, none
of our three current employees in Israel have been called to active military duty, though we rely on service providers located in Israel
and have entered into certain agreements with Israeli counterparties. Employees of such service providers or contractual counterparties
may be called for service in the current or future wars or other armed conflicts and such persons may be absent from their positions for
a period of time. As of March 28, 2024, we have not been impacted by any absences of personnel at our service providers or counterparties
located in Israel. However, military service call ups that result in absences of personnel from us, our service providers or contractual
counterparties in Israel may disrupt our operations and absences for an extended period of time may materially and adversely affect our
business, prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>In
the months since the initial attack by Hamas, other regional hostilities have become more pronounced. This includes clashes with Hezbollah
on Israel&#8217;s northern border with Lebanon, </span>with Hezbollah conducting missile, rocket, and shooting attacks against Israeli
military sites, troops, and Israeli towns in northern Israel. This clash may escalate in the future into a greater regional conflict,
<span>and attacks on </span>marine vessels thought to either be in route towards Israel or to be partly
owned by Israeli businesses <span>in the Red Sea by members of the Houthi Movement in Yemen, resulting
in shipping companies rerouting their cargo ships or ceasing shipments to Israel in the case of the latter. </span>The Red Sea is a vital
maritime route for international trade traveling to or from Israel. As a result of such disruptions, we may experience in the future delays
in supplier deliveries, extended lead times, and increased cost of freight, increased insurance costs, purchased materials and manufacturing
labor costs, regarding the business and operations of the Wellution brand. The risk of ongoing supply disruptions may further result in
delayed deliveries of our products. <span>Hostilities with Hamas, Hezbollah, the Houthi Movement, and
other terrorist organizations include and may include terror and missile and drone attacks.&#160;</span> It is possible that other terrorist
organizations, including Palestinian military organizations in the West Bank, as well as other hostile countries, such as Iran, will join
the hostilities. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners
could adversely affect our operations and results of operations. We may also be targeted by cyber terrorists specifically because we are
an Israeli company. Our insurance policies do not cover losses that may occur as a result of events associated with war and terrorism.
Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts
of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages.
Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability
in the region would likely negatively affect business conditions and could harm our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Several
countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries may
impose restrictions on doing business with Israel and Israeli companies, whether as a result of hostilities in the region or otherwise.
In addition, there have been increased efforts by certain countries, activists and organizations to cause companies, research institutions
and consumers to boycott Israeli goods and cooperation with Israeli-related entities based on Israeli government policies. In December
2023, the Republic of South Africa brought a case to the International Court of Justice, or the ICJ, about which Israel as a member of
the Convention on the Prevention and Punishment of the Crime of Genocide, falls under its jurisdiction. The claim asserted that Israel
had committed genocide against Palestinians in the Gaza Strip. Prosecutorial proceedings took place in January 2024. The ICJ issued an
interim ruling that prescribed Israel to prevent genocidal acts, prevent and punish incitement to genocide, and take steps to provide
basic services and humanitarian aid to the people of Gaza. In light of this ruling, certain companies and business have terminated commercial
relationships&#160;&#160;with Israeli companies and more may follow. If such international tribunal and ICJ rulings continue to issue
rulings against Israel, this may adversely impact our ability to cooperate with research institutions and collaborate with other third
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Political
instability in Israel, originating before October 2023, could disrupt our operations. Having held five general elections between 2019
and 2022, government policy is subject to regular disruptive changes. The current government of Israel has pursued extensive changes to
Israel&#8217;s judicial system. In response to the foregoing developments, individuals, organizations and institutions, both within and
outside of Israel, have voiced concerns that the proposed changes may negatively impact the business environment in Israel including due
to reluctance of foreign investors to invest or transact business in Israel as well as to increased currency fluctuations, downgrades
in credit rating, increased interest rates, increased volatility in securities markets, and other changes in macroeconomic conditions.
Not only have the proposed judicial reforms been put on hold due to the ongoing focus on the war, but also the Supreme Court of Israel
ruled that the judicial reform passed into legislation relating to reasonability is unconstitutional. If such changes to the judicial
system resume, however, this may have an adverse effect on our business, our results of operations and our ability to raise additional
funds, if deemed necessary by our management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law may make it easy
for our shareholders to demand that we convene a shareholders meeting, and/or allow shareholders to convene a shareholder meeting without
the consent of our management, which may disrupt our management&#8217;s ability to run our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company listed on an
exchange in the U.S., Israeli law may allow any one or more of our shareholders holding, in the aggregate, at least 10% of our voting
rights to demand that we convene a special shareholders meeting. Also, in the event that we choose not to convene a special shareholders
meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others, that such shareholders may independently
convene a special shareholders meeting within three months (or under court&#8217;s ruling) and require us to cover the costs, within reason,
and as a result thereof, our directors might be required to repay us such costs. If our shareholders decide to exercise these rights in
a way inconsistent with our management&#8217;s strategic plans, our management&#8217;s ability to run our company may be disrupted, and
this process may entail significant costs to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations are subject to currency and
interest rate fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incur expenses in U.S.
dollars and NIS, but our financial statements are denominated in U.S. dollars. U.S. dollars is our functional currency and is the currency
that represents the principal economic environment in which we operate. As a result, we are affected by foreign currency exchange fluctuations
through both translation risk and transaction risk. As a result, we are exposed to the risk that the NIS may appreciate relative to the
dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation
of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations
in Israel would increase and our dollar-denominated results of operations would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law and our amended
and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could
prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of Israeli law
and our amended and restated articles of association could have the effect of delaying or preventing a change in control and may make
it more difficult for a third party to acquire us or our shareholders to elect different individuals to our board of directors, even if
doing so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay
in the future for our Ordinary Shares. Among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli corporate law regulates mergers and requires that a tender offer be effected when more than a specified percentage of shares in a company are purchased;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli corporate law does not provide for shareholder action by written consent, thereby requiring all shareholder actions to be taken at a general meeting of shareholders; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association divide our directors into three classes, each of which is elected once every three years;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association require a vote of the holders of a majority of our outstanding Ordinary Shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision stating that each year the term of office of only one class of directors will and dividing our directors into three classes, requires a vote of the holders of 65% of the voting power represented at a general meeting of our shareholders and voting thereon has been obtained, provided the majority constitutes more than 33.33% of the total issued and outstanding share capital as of the record date of such meeting. The affirmative vote of at least three-quarters (3/4) of the directors, in addition to the approval of our shareholders, is also required in order to amend our amended and restated articles of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our amended and restated articles of association provide that director vacancies may be filled by our board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, our amended and restated articles of association restrict us from engaging in certain business combination transactions, with any shareholder who holds 15% or more of our voting power. The transactions subject to such restrictions include mergers, consolidations and dispositions of our assets with a market value of 10% or more of our assets or outstanding shares. Subject to certain exceptions, such restrictions will apply for a period of three years following each time a shareholder became the holder of 15% or more of our voting power; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, our amended and restated articles of association restrict certain transactions which may have a significant effect on the Company&#8217;s structure, assets or business, including significant mergers and acquisitions, a disposition of all or substantially all of the assets of the Company, a voluntary dissolution and material changes to the principal business of the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, Israeli tax considerations
may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty
with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral
in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two
years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted.
See &#8220;Item 10.E. Taxation-Israeli Tax Considerations and Government Programs&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a United States court against us and our officers and directors and the Israeli experts named in this Annual Report in Israel or the
United States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Israel
and our corporate headquarters are located in Israel. All of our executive officers and directors and the Israeli experts named in this
Annual Report are located in Israel. All of our assets and most of the assets of these persons are located in Israel. Service of process
upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S.
directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel
that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel, or obtain a judgment based
on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S.
securities laws against us or our non-U.S. officers and directors because Israel may not be the most appropriate forum to bring such a
claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing
the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect
on judgments rendered against us or our non-U.S. officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, an Israeli court
will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if
it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the same
matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel
at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal executive offices, most of
our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely
affected by political, economic and military instability in Israel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive offices, corporate
headquarters and principal research and development facilities are located in Israel. In addition, all of our officers and directors are
residents of Israel. Accordingly, political, economic and security conditions in Israel and the surrounding region may directly affect
our business. Any conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption
or curtailment of trade between Israel and its present trading partners could adversely affect our operations. Ongoing and revived hostilities
in the Middle East or other Israeli political or economic factors, could harm our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance does
not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government
coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have
a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business
conditions and could harm our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli government is
currently pursuing extensive changes to Israel&#8217;s judicial system. In response to the foregoing developments, individuals, organizations
and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact the business
environment in Israel including due to reluctance of foreign investors to invest or transact business in Israel as well as to increased
currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in securities markets, and other changes
in macroeconomic conditions. To the extent that any of these negative developments do occur, they may have an adverse effect on our business,
our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in the past, the
State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State
of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which
could also adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, many Israeli citizens
are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40
(or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be
called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists.
It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which
may include the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competition for skilled technical and other
personnel in Israel is intense, and as a result we may fail to attract, recruit, retain and develop qualified employees, which could materially
and adversely impact our business, financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We compete in a market marked
by rapidly changing technologies and an evolving competitive landscape. In order for us to successfully compete and grow, we must attract,
recruit, retain and develop personnel with requisite qualifications to provide expertise across the entire spectrum of our intellectual
capital and business needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal research and
development as well as significant elements of our general and administrative activities are conducted at our headquarters in Israel,
and we face significant competition for suitably skilled employees in Israel. While there has been intense competition for qualified human
resources in the Israeli high-tech industry historically, the industry experienced record growth and activity in 2021, both at the earlier
stages of venture capital and growth equity financings, and at the exit stage of initial public offerings and mergers and acquisitions.
This flurry of growth and activity has caused a sharp increase in job openings in both Israeli high-tech companies and Israeli research
and development centers of foreign companies, and intensification of competition between these employers to attract qualified employees
in Israel. As a result, the high-tech and bio-tech industry in Israel has experienced significant levels of employee attrition and is
currently facing a severe shortage of skilled human capital, including engineering, research and development, sales and customer support
personnel. Many of the companies with which we compete for qualified personnel have greater resources than we do, and we may not succeed
in recruiting additional experienced or professional personnel, retaining personnel or effectively replacing current personnel who may
depart with qualified or effective successors. Failure to retain or attract qualified personnel could have a material adverse effect on
our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a holder
of our securities will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of holders of our Ordinary Shares are governed by our amended and restated articles of association
and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in good
faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the Company and other shareholders
and to refrain from abusing his or her power in the Company, including, among other things, in voting at the general meeting of shareholders,
on amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and certain
transactions requiring shareholders&#8217; approval under the Companies Law. In addition, a controlling shareholder of an Israeli company
or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint
or prevent the appointment of a director or officer in the Company, or has other powers toward the Company has a duty of fairness toward
the Company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available to assist
in understanding the implications of these provisions that govern shareholder behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We received Israeli government grants for
certain of our past research and development activities and programs, some of which we sold or are in the process of selling. The terms
of such grants may require us, in the future, to pay royalties and to satisfy specific conditions if and to the extent we receive future
royalties or in order to complete the sale of such grant based technologies and programs. We may be required to pay penalties in addition
to payment of the royalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts with respect to some of our past activities, which was focused on developing an immunotherapeutic monoclonal antibody for the
treatment of Alzheimer&#8217;s disease, which we sold in March 2015, and our Anti-CD3 technology directed toward the treatment of inflammatory
and autoimmune diseases, which in part was returned and re-assigned to Hadasit Medical Research Services &amp; Development Ltd., or Hadasit,
and in part is still in the process of being sold, were financed in part through royalty-bearing grants from the Israeli Innovation Authority,
or the IIA. As of December 31, 2023, we had received the aggregate amount of approximately $1.1 million from the IIA for the development
of our abovementioned technologies. As of December 31, 2022, our contingent liabilities regarding IIA grants received by us were in an
aggregate amount of $1.1 million including interest. With respect to such grants, we are committed to pay certain royalties up to $1.1
million relating only to technologies in our possession and excluding any royalties for technologies that we sold to third parties. We
are required to comply with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation
Law, 5744-1984, as amended, or the Innovation Law, and related regulations, or the Research Law, with respect to those past grants. When
a company develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer
or license of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside
of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any
transfer or license to third parties inside or outside of Israel of know how or for the transfer outside of Israel of manufacturing or
manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose
certain conditions on any arrangement under which it permits us to transfer technology or development.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Innovation Law and
the regulations thereunder, a recipient of IIA grants is required to return the grants by the payment of royalties of 3% to 6% on the
revenues generated from the sale of products (and related services) developed (in whole or in part) under an IIA program up to the total
amount of the grants received from IIA plus the relevant interest rate, if any. Under IIA regulations, grants received before June 30,
2017, bear the annual interest rate that applied at the time of the approval of the applicable IIA file which will apply to all of the
funding received under such IIA approval. Grants received from the IIA after June 30, 2017, bear an annual interest rate based on the
12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%. Grants approved
after January 1, 2024, shall bear the higher interest rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or
know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our technology
assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology
outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel
of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted to and follow certain home country corporate governance practices instead of otherwise applicable SEC requirements, which
may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign private
issuer also exempts us from compliance with certain SEC laws and regulations, including the proxy rules and the short-swing profits recapture
rules. In addition, we will not be required under the Exchange Act to file current reports and financial statements with the SEC as frequently
or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and we will generally be exempt from
filing quarterly reports with the SEC. Also, although the Companies Law requires us to disclose the annual compensation of our five most
highly compensated senior officers on an individual basis, this disclosure is not as extensive as that required of a U.S. domestic issuer.
Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under
the Exchange Act. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you are
entitled as an investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>International expansion of our business
exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the
United States or Israel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), we currently have limited international operations, but
our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product
candidates. We plan to maintain sales representatives and conduct physician and patient association outreach activities, as well as clinical
trials, outside of the United States and Israel. Doing business internationally involves a number of risks, including but not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the use of our products in various countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party patent rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an outbreak of a contagious disease, such as coronavirus, which may cause us, third party vendors and manufacturers and/or customers to temporarily suspend our or their respective operations in the affected city or country;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
significantly harm our future international expansion and operations and, consequently, our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with the FCPA could subject
us to penalties and other adverse consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the FCPA,
which generally prohibits companies, such as us, whose securities are listed in the United States, from paying, offering or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign government official, political party or candidate for
public office for the purpose of influencing any act or decision of such foreign person in order to assist companies like us in obtaining
or retaining business. The FCPA also obligates companies like us, whose securities are listed in the United States, to comply with accounting
provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations. The U.S. Department of Justice and the SEC, which have responsibility for enforcement of the FCPA, both consider employees
of government-operated health care systems to be &#8220;foreign officials&#8221; for FCPA purposes. In addition, the U.S. Department of
Justice and the SEC are both engaged in a long-running FCPA compliance review of pharmaceutical companies. If our employees or agents
are found to have engaged in conduct that violates the FCPA, we would be held responsible and could suffer severe penalties and other
consequences, including adverse publicity and damage to our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cybersecurity issues, security breaches
and other disruptions could compromise our information, expose us to liability and harm our reputation and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business relies upon information
technology systems operated by us and by our third-party service providers. These systems may fail or experience operational disruption,
experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of our business we
collect and store sensitive data, including intellectual property, personal information and our proprietary business information. The
secure maintenance and transmission of this information is critical to our operations and business strategy. We rely on commercially available
systems, software, tools and domestically available monitoring to provide security for processing, transmitting and storing this sensitive
data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hackers may attempt to penetrate
our computer systems, and, if successful, misappropriate personal or confidential business information. In addition, an associate, contractor
or other third-party with whom we do business may attempt to circumvent our security measures in order to obtain such information, and
may purposefully or inadvertently cause a breach involving such information. While we continue to implement additional protective measures
to reduce the risk of and detect cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used
in such attacks change rapidly. If our third-party vendors fail to protect their information technology systems and our confidential and
proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information
and we could incur liability and reputational damage and the further development and commercialization of our product candidates could
be delayed. While we have not, to our knowledge, experienced any material IT system failures or cybersecurity attacks to date, we cannot
assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages,
breaches in our systems or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could
have a material adverse effect upon our reputation, business, operations or financial condition. If such an event were to occur and cause
interruptions in our operations, it could result in a material disruption of our development programs, business operations, a breach of
sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary information.
For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or vulnerabilities to
our or our third-party vendors&#8217; information security programs or defenses could result in legal liability, reputational damage,
business interruption, and our competitive position could be harmed and the further development and commercialization of our products
or any future products could be delayed or disrupted. Moreover, containing and remediating any IT system failure, cybersecurity attack
or vulnerability may require significant investment of resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers or breaches, employee
error or malfeasance, power outages, computer viruses, telecommunication or utility failures, systems failures, natural disasters or other
catastrophic events. Furthermore, significant security breaches or disruptions of our internal information technology systems or those
of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access,
use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property,
proprietary business information and personal information), which could result in financial, legal, business and reputational harm to
us., Any such compromise could disrupt our operations, damage our reputation and subject us to additional costs and liabilities, any of
which could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our shares, the share price and trading volume of our securities could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business,
our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our securities,
or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst
who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause the price or trading volume of our securities to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. History and Development of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial name
is SciSparc Ltd. We were incorporated in the State of Israel on August 23, 2004, and are subject to the Companies Law. Our registered
office and principal place of business is located at 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup> Floor, Tel Aviv 6971916, Israel.
Our telephone number in Israel is: +972-73-3447180.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our website address is http://www.scisparc.com.
The information contained on our website or available through our website is not incorporated by reference into and should not be considered
a part of this Annual Report, and the reference to our website in this Annual Report is an inactive textual reference only. The SEC also
maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers that file
electronically with the SEC. Our filings with the SEC will also be available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC, including the proxy rules and the short-swing profits recapture rules. In addition, we will
not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S.
domestic companies registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures for
2023, 2022 and 2021 amounted to $0, $9,200 and $35,000, respectively. These expenditures were primarily for purchases of fixed assets.
Our purchases of fixed assets primarily include, computers, and equipment used for the development of our products, and we financed these
expenditures primarily from cash on hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Business Overview </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty clinical-stage
pharmaceutical company. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With
this focus, we are currently engaged in the following development programs based on THC, and/or CBD and/or other CBR agonists: SCI-110
for the treatment of TS and for the treatment of Alzheimer&#8217;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210
for the treatment of ASD. We also hold a 50.86% controlling stake in our subsidiary SciSparc Nutraceuticals Inc., or SciSparc Nutraceuticals,
whose business focuses on the sale of hemp seeds oil-based products and others on the Amazon.com marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-110 is a proprietary drug
candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and (2) CannAmide&#8482;, a
proprietary PEA, formulation. PEA is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules
that regulate the expression of genes. We believe that the combination of THC and PEA may induce a reaction known as the &#8220;sparing
effect,&#8221; which has strong potential to treat various diseases of the central nervous system such as TS and Alzheimer&#8217;s disease
and agitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-210 is a proprietary drug
candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. We believe that the combination of CBD and PEA may also induce a
sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-160 is a novel pharmaceutical
preparation containing a cannabinoid receptor type 2, or CB2 receptor, agonist for the treatment of pain. This innovative CB2 receptor
agonist was synthesized by the late Raphael Mechoulam, who was a professor of medicinal chemistry at the Hebrew University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that modulating
CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the positive results
obtained in a phase IIa TS study conducted at Yale School of Medicine, we developed a regulatory dossier that was submitted to the German
Federal Institute for Drugs and Medical Devices, or BfArM, and the Israeli Ministry of Health, or MoH, for our SCI-110 program for TS.
We plan to submit this regulatory dossier to the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial to evaluate the safety, tolerability
and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using our proprietary cannabinoid-based technology. In
December 2021, The Israeli Medical Center for Alzheimer&#8217;s recruited the first patient to participate in the phase IIa clinical trial.
In June 2023, we announced positive topline results from our Phase IIa clinical trial of SCI-110 in patients with Alzheimer&#8217;s disease
and agitation at the Israeli Medical Center for Alzheimer&#8217;s, suggesting that SCI-110 is safe and tolerable while significantly improving
agitation symptoms over time in the elderly population with Alzheimer&#8217;s disease. This Phase IIa clinical trial was an open label
study, which included 18 patients diagnosed with Alzheimer&#8217;s disease and agitation, to evaluate the safety, tolerability and efficacy
trends of twice daily oral administration of SCI-110.&#160;Results showed that the clinical trial met its primary endpoints of the number
of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse events, with no SCI-110 related
safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically, SCI-110 did not cause delirium,
oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the clinical trial also met its secondary
end point of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory where out of the
fifteen patients treated with SCI-110 at least two consecutive times during the trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day
showed amelioration in agitation with no need to use rescue medication to control agitation. Although not significant, in the exploratory
endpoints, eleven patients reduced food intake and showed feeding difficulties, as measured by the Edinburgh Feeding Evaluation in Dementia
scale. There was not an effect observed resulting from the treatment on cognition and sleep quality, as measured by the Mini Mental State
Examination and by the Sleep Order Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we announced
that we have received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct our clinical trial for SCI-210 in
patients suffering ASD. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the clinical trial with pediatric
patients suffering from ASD. Our regulatory request to carry out this clinical trial was granted by the Israeli Medical Cannabis Agency,
or IMCA, on July 10, 2023. This randomized, double-blind placebo-controlled clinical trial to evaluate the potential efficacy, safety
and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our proprietary SCI-160,
in August 2021, we announced positive top-line results for a controlled pre-clinical trial on neuropathic and post-operative pain. The
study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat
hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from the pre-clinical trial are that
SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated animals. Daily SCI-160 injections
significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals, for up to seven days after surgery.
Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to four days post surgery
as compared with vehicle treated animals, and SCI-160 analgesic effects are prolonged in the presence of PEA. Collectively, the results
indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on the positive results, we have decided
to continue the development of SCI-160 towards a first in-human clinical study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Pharmaceutical Drug Development Programs</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">SCI-110 - TS, Alzheimer&#8217;s
disease and agitation </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our pharmaceutical
product candidate, SCI-110, offers a safe and potentially effective solution for a variety of medical concerns. Despite being in its early
phases of clinical testing, the application of SCI-110 has extended into several treatments, including TS and Alzheimer&#8217;s disease
and agitation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>TS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TS is a neuropsychiatric disorder,
characterized by physical (motor) tics and vocal (phonic) tics. Motor tics generally precede the development of phonic tics in TS, and
the onset of simple tics usually predates that of complex tics. TS ranges from mild symptoms to loud noises and forceful movements that
can result in self-injury (e.g. punching oneself in the face, repeating other people&#8217;s words or involuntary swearing). Many with
TS experience additional neurobehavioral problems and comorbidities including inattention, hyperactivity and impulsivity, anger control
problems, sleep difficulties, and obsessive-compulsive symptoms. Pharmacotherapy is used when symptoms are more severe and interfere with
the ability to function. Furthermore, according to the CDC, in most cases, the prevalence of tics decreases during adolescence and early
adulthood, and sometimes disappears entirely; therefore, there are a limited number of adults with TS and it is usually manifested mainly
through moderate to severe symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ongoing research advancements,
increased awareness and advocacy efforts, government initiatives, innovation in therapeutic approaches, patient and caregiver involvement,
and regulatory approvals drive the TS treatment market. This dynamic landscape reflects a commitment to understanding TS, developing effective
treatments, and creating a supportive environment for affected individuals, contributing to the market&#8217;s growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global TS treatment market
size was approximately $2.1 billion in 2022 and is expected to reach $3.4 billion by 2034.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the CDC, the
prevalence of moderate to severe TS is reported to be 44%, indicating a significant portion of individuals experiencing notable symptoms
of the condition. Interestingly, adolescents between the ages of 12 and 17 show a more than twofold likelihood of being diagnosed with
TS compared to children aged 6 to 11. It highlights the impact of TS on various age groups. It emphasizes the substantial demand for effective
treatments within the TS treatment market to address the diverse needs of individuals with the condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the CDC, 83%
of children diagnosed with TS also have at least one additional mental, behavioral, or developmental disorder that serves as a driver
for the TS treatment market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmacological intervention
is considered the first line of therapy for TS, but is reserved for more severe symptoms that interfere with the individual&#8217;s ability
to function. Today, a full class of drugs that interact with dopamine and non-dopamine systems in the brain are used in the treatment
of TS symptoms. Although as of the date of this Annual Report, the FDA has approved only two pharmacological treatments (for adult TS-
haloperidol and pimozide &#8211; these treatments have a &#8220;black box warning&#8221;. Many drugs approved or off-label to treat TS
are limited to the treatment of a narrow range of TS symptoms (mainly tics), and are associated with severe side effects, both of which
limit their utility. Furthermore, several of these drugs have a black box warning on their label due to their potentially lethal effect.
A black box warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable
evidence of an association of a serious hazard with the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medications commonly used
to treat symptoms of TS can be divided into the following groups:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antipsychotic medications: belong to a class of drugs primarily used to manage psychosis (including haloperidol, pimozide and fluphenazine), all of which are associated with severe side effects (including weight gain, sedation, akathisia (a state of agitation, distress, and restlessness), nausea and tardive dyskinesia (involuntary movements of the face and jaw), among others).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha2 Adrenergic Agonists: belong to a class of drugs primarily used to manage hypertension and migraine headaches prevention (including clonidine and guanfacine), which have limited utility despite common application to children with Attention Deficit Hyperactivity Disorder, or ADHD. Similar to antipsychotic medications, these also are associated with several side effects, and some of them, such as clonidine, might even be lethal.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benzodiazepines, an anticonvulsant or antiepileptic drug: belong to a class of drugs primarily used to manage seizures, panic disorder and movement disorders. Of these, Clonazepam is used off-label for the reduction of tics in TS patients, which also has associated negative side effects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the currently used medications
are managing only a small number of disease symptoms with limited efficacy and questionable safety, there is a clear unmet medical need
for the management of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-110 Solution for
TS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our SCI-110 platform is a
drug candidate for the treatment of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2018, we announced
topline results of our Phase IIa investigator-initiated study at Yale University of SCI-110 for the treatment of TS. The study was a single-arm,
open-label trial, in which each subject both received one daily treatment of SCI-110 via oral administration and was followed-up for a
period of 12 weeks. 16 subjects participated in the study and received SCI-110 at the Yale University Child Study Center at Yale University.
The primary endpoint of the study was to assess the performance of SCI-110 in the treatment of adult patients suffering from symptoms
of TS, as measured by the Yale Global Tic Severity Scale Total Tic Score, or YGTSS-TTS, the customary index for assessing symptom severity.
Treatment was given in a dose titration regimen with a maximum dose of SCI-110 consisting of 10mg dronabinol and 800mg CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The topline results of the
study showed that each of these 16 subjects with medication-refractory TS sustained a significant reduction of tic symptoms (paired t-test:
YGTSS-TTS mean difference (mean +/- SD) =7.9+/-8.4, t= 3.7, df=15, p=0.002) from baseline (YGTSS-TTS: 38.4 +/- 8.3) to endpoint YGTSS-TTS:
30.5 +/- 10.9). This resulted in an average tic reduction of 21% across the entire sample of 16 TS subjects. Six of the 16 medication-refractory
TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater than 25%. Improvement over time with
treatment was also observed when generalized linear models were used to analyze repeated measures data on the YGTSS-TTS. In the study,
SCI-110 demonstrated no significant effects on comorbid ADHD, anxiety, depression or obsessive-compulsive disorder, or OCD, symptoms.
The medication was generally well-tolerated by the subjects with only two subjects stopping treatment early (one due to sedation and another
due to lack of improvement in tic symptoms). 12 of the 16 subjects elected to proceed with a 24-week extension phase of the trial, which
was also completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Phase IIa study,
we announced in June 2023 BfArM approval for a Phase IIb clinical trial for SCI-110 in subjects suffering from TS, with a view to such
clinical trial being carried out in Germany at the Hannover Medical School. In August 2022, we received MoH approval to conduct the clinical
trial in Isarael at Sourasky Medical Center. We also received Ethics Committee approvals in 2022 from Hannover Medical School and Sourasky
Medical Center and Internal Review Board approval in 2023 at the Child Study Center at Yale School of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we initiated
the Phase IIb clinical trial at Sourasky Medical Center. The 86 patients in the clinical trial are randomized to either oral SCI-110 or
placebo at a 1:1 ratio. The overall estimated clinical trial duration is 18-24 months. We may also be required to conduct further preclinical
studies in parallel to our clinical plans as part of registration process with the FDA and EMA. Following these clinical trials, if successful,
we intend to conduct a Phase III, multinational, multicenter, randomized, double-blind, parallel-group, placebo controlled clinical trial
to evaluate the safety, tolerability and efficacy of up to twice daily oral SCI-110 in treating TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we submitted
a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. The request is still pending and we are in communication
with FDA. Our last communication was in December 2020 when we received a letter from FDA raising a concern that it will be hard to limit
the use of the pharmaceutical product to the subset of patients we are pursuing. There is no assurance that we will successfully obtain
orphan drug designation for TS. However, in light of the fact that we disagree with this concern expressed by the FDA, we requested a
clarification call. In the clarification call conducted on February 2, 2021, we agreed with the FDA concern about our ability to limit
the use of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics
population so we suggested to amend our preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March we sent our response to the FDA. In June
2021, we received a response from the FDA, explaining that they are unable to grant our request until new information becomes available
to support our request for orphan drug designation. We will re-visit the application after we obtain clinical results from our phase IIb
clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does not allow
us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required
to obtain FDA approval, and complications and risks associated with FDA approval, would substantially increase. In a pre-IND meeting we
had with FDA in February 2018, the FDA did not oppose our plans to submit an NDA via the 505(b)(2) pathway relying, in part, on clinical
and nonclinical information from literature related to dronabinol and the FDA&#8217;s previous finding of safety and efficacy for the
reference listed drug (Marinol).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Alzheimer&#8217;s disease and Agitation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzheimer&#8217;s disease
is the most common type of dementia, accounting for over two-thirds of cases of dementia. Alzheimer&#8217;s disease is a neurodegenerative
disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention,
reasoning and judgment. Symptoms of Alzheimer&#8217;s disease depend on the stage of the disease. Neuropsychiatric symptoms like apathy,
social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite and wandering are also common in the mid to late stages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Market Size </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is estimated that the global
Alzheimer&#8217;s therapeutics market is projected to reach $13.57 billion by 2027 from $7.42 billion in 2019 with a compounded annual
growth rate of 9.2% through 2027, which is primarily attributed to the increasing pipeline drug development and increasing investments
for drug development biomarkers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current pharmacological
treatment of agitation in Alzheimer&#8217;s disease has an unsatisfactory benefit/risk ratio and often involves using off-label drugs.
Antipsychotic drugs, which are the most frequently used drugs for this purpose, are only marginally better than placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-110 Solution for
Alzheimer&#8217;s disease and Agitation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product, SCI-110,
is a unique proprietary combination of dronabinol (synthetic delta-9-tetrahydrocannabinol (&#916;&#8313;-THC), and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we signed
an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial to evaluate the safety, tolerability
and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using our proprietary cannabinoid-based technology. The
study&#8217;s primary objective is the safety of SCI-110 and the secondary objective is the ability of the compound to ameliorate agitation
and other behavioral disturbances in patients with Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase IIa clinical trial
was an open label clinical trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and
efficacy trends of twice daily oral administration of SCI-110. Results showed that the clinical trial met its primary endpoints of the
number of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse events, with no SCI-110
related safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically, SCI-110 did not
cause delirium, oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the clinical trial
also met its secondary endpoint of change from baseline to end of treatment in agitation measured by the Cohen Mansfield Agitation Inventory,
or CMAI, where out of 15 patients treated with SCI-110 at least two consecutive times during the clinical trial, thirteen of them at doses
ranging between 7.5mf-12.5mg/day showed amelioration in agitation with no need to use rescue medication to control agitation. CMAI is
a standard measure for measuring agitation in people with dementia. The clinical trial showed that these subjects had amelioration in
agitation (paired t-test: CMAI mean difference (mean +/- SD) =10.6+/-14.88, t= 2.76, df=14, p=0.015) from baseline (CMAI: 45.87 +/- 15.17)
to endpoint (CMAI: 35.27 +/- 11.09). This resulted in an average reduction of 23% across the entire sample.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the exploratory endpoints,
a decrease in eating and feeding difficulties was shown in 11 patients out of the 15 patients treated at least two consecutive times during
the trial as measured by the Edinburgh Feeding Evaluation in Dementia Scale, although the increase was not significant. No effect from
the treatment was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State Exam and by the and the Sleep
Disorder Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">SCI-210 - ASD and SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our pharmaceutical
product candidate, SCI-210, offers a safe and potentially effective solution for a variety of medical concerns. Despite being in its early
phases of pre-clinical and clinical testing, the application of SCI-210 has extended into several treatments, including ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>ASD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASD is a neurodevelopmental
disorder. The specific etiologies and neural bases of autism remain largely unknown; it has been proposed that alterations in multiple
genes in combination with environmental factors constitute the cause for the development of the autism phenotype. ASD is characterized
by early dysfunction in communication and social interactions, presenting with repetitive, restrictive, stereotyped patterns of behavior
and loss of interest in diverse activities. Additionally, ASD is frequently accompanied by impairments in adaptive functioning, sensory
processing disorder, aggression, or self-injury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the World Health
Organization, or WHO, fact sheet on epilepsy in 2024, around 50 million people have epilepsy, making it one of the most common neurological
diseases globally. The risk of premature death in people with epilepsy is up to three times higher than for the general population.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Globally, an estimated 5 million
people are diagnosed with epilepsy each year. In high-income countries, there are estimated to be 49 per 100 000 people diagnosed with
epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global epilepsy market
size would grow from $7.8 billion in 2022 to $10.7 billion by 2030.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In recent years, there has been a notable increase
in the approval of drugs to treat epilepsy, marking a significant step forward in addressing the challenges posed by severe seizures.
Growing awareness of the need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies
to develop innovative treatments are leading to the development and approval of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No cure exists for ASD. The
goal of treatment is to maximize patients&#8217; ability to function by reducing ASD symptoms and supporting development and learning.
Treatment options may include: (i) behavior and communication therapies - successful programs typically include a team of specialists
and a variety of activities to improve social skills, communication and behavior; and (ii) medications - to date, no medication can improve
the core signs of ASD, specific medications can help control comorbidity symptoms. The main symptoms to be treated in patients with ASD
are: epilepsy, aggression, hyperactivity, irritability, attention deficit, sleep problems, obsessions and anxiety. Antipsychotic drugs
are sometimes used to treat severe behavioral problems and antidepressants may be prescribed for anxiety. Among the main drugs used in
the treatment of ASD are typical antipsychotics such as Haloperidol, Thioridazine, Chlorpromazine and the atypical risperidone, Olanzapine
and Clozapine, whose use is more common. These are used with the objective to treat the child&#8217;s behavioral problems by blocking
the D2 dopaminergic channels, causing a diminished reaction to stimuli known as &#8220;neuroleptic syndrome,&#8221; observed as calm and
quiet behavior in the child. In turn, some atypical antipsychotics also exhibit an antagonism of type 2A receptors for serotonin, aside
from their effect on the D2 channels. It is important to individualize the patient when these drugs are administered, since there are
no pre-established criteria for dosing and such drugs could present extrapyramidal adverse effects such as tremors, sialorrhea, sedation,
impaired liver function, etc. Serotonin reuptake inhibitors such as Fluoxetine, Paroxetine and Sertraline are given to children with autism
because they have been found to increase 25% of serotonin levels in platelets and serum. This treatment is based on suppressing symptoms
such as anxiety, depression, OCDs, and self-injurious behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfortunately, about 40% of
children with ASD and disruptive behavior do not respond well to standard behavioral and medical treatment. Consequently, an exceptionally
high percentage of parents are seeking help through unproven methods, including the use of compounds made of the cannabis plant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-210 Solution for
ASD</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product SCI-210 is
a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2022, we announced
that we have received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct our clinical trial for SCI-210 in
patients suffering ASD. On January 9, 2023, we signed an agreement with Soroka Medical Center to conduct the clinical trial on pediatric
patients suffering from ASD. Our regulatory request to carry out this clinical trial was granted by the IMCA on July 10, 2023. This randomized,
double-blind placebo-controlled clinical trial to evaluate the potential efficacy, safety and tolerability of SCI-210 in treating patients
with ASD was initiated in July 2023. We initiated patient enrollment for the clinical trial in January 2024. In February 2024, we announced
that we had successfully completed the manufacturing of the SCI-210 treatment for the clinical trial. In March 2024, the first patient
was enrolled in this clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SE</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SE is a common life-threatening
medical emergency characterized by an acute, prolonged epileptic seizure. SE can represent either the exacerbation of a pre-existing seizure
or the initial manifestation of epilepsy. In order to avoid neurological sequelae, a timely treatment should be started. When the continuous
seizure does not respond to conventional drug treatment, SE can pose serious life-threatening risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, GW&#8217;s Epidiolex,
a plant-based, pharmaceutical grade CBD extract was approved by the FDA for the treatment of seizures associated with two rare and severe
forms of epilepsy. Our study for SCI-210 previously met its endpoint (efficacy) when comparing its effect to the effect of CBD alone in
an in-vitro hepatocytes model of fat accumulation; the effect of CBD was enhanced by the addition of PEA, lowering the required effective
concentration of CBD. In this study, we hope to meet the study endpoint (efficacy) when comparing treatment using our pharmaceutical product
candidate compared to the effect of CBD alone on SE and its neurological cognitive sequelae.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the World Health
Organization, or WHO, report on epilepsy in 2019, around 50 million people have epilepsy. In addition, it has been estimated that the
global epilepsy market size would grow from $10.6 billion in 2021 to $14.9 billion towards the end of 2031. North America accounted for
approximately 50% of the global epilepsy therapeutics market in 2021. The U.S. is the largest epilepsy drug market in North America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2017, the Americas held
a 41% market share ($1.49 billion) and are projected to hold such position, estimated to be $1.6 billion in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first-line treatment for
early SE mainly comprises the administration of benzodiazepines, the most frequently used of which include Diazepam, Lorazepam, and Midazolam.
Seizures continue and progress to established SE in about 40% of patients with Convulsive Status Epilepticus (CSE) despite benzodiazepine
administration as the first-line treatment. The second-line treatment for established SE consists of a loading dose of antiepileptic drugs.
Frequently used antiepileptic drugs include Phenytoin or Fosphenytoin, Valproate, Levetiracetam, Phenobarbital, and Lacosamide. There
is no clear evidence for the relative superiority of any of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-210 Solution for
SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drug product SCI-210 is
a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 7, 2022, we announced
positive results from our pre-clinical study of SCI-210 on SE, conducted at The Sheba Fund for Health Services and Research at Chaim Sheba
Medical Center, which reaffirms the potential of its proprietary combination products to have a positive effect while minimizing adverse
side effects. Our SCI-210 platform combines PEA with CBD. The non-clinical trial objective was to study the potential therapeutic effects
of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive sequelae. A pilocarpine SE-induced mice (C57BL/6 male) model
to study SCI-210&#8217;s effects on seizure severity and mortality was used. After calibration, four groups of animals were studied: an
effective-high dose CBD group, a sub-effective dose CBD group, a SCI-210 group (a combination of sub-effective CBD dose and PEA) and a
non-treated control group. The results indicated differences in mortality rate as well as seizure rates over time. In the low-CBD group,
a higher mortality rate (although not significant) was found and therefore it is reasonable to believe that no significant impact on neuronal
protection was achieved. In the high-CBD group, higher, although not significant, levels of neuronal protection were found together with
a decreased mortality rate when compared to control. The level of neuronal protection in the SCI-210 treatment was significantly higher
compared to the control group and no mortality was found in this group. It was concluded that SCI-210 treatment may potentially be more
effective than a CBD monotherapy. Moreover, since the concentrations used in the combo treatment are significantly lower than those recommended
for CBD monotherapy, this treatment also has the potential to be safer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our SCI-160 Pain Solution</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pain is the most common reason
for physician consultation in most developed countries. It is a major symptom in many medical conditions and can interfere with a person&#8217;s
quality of life and general functioning. Opioid medications can provide short, intermediate or long-acting analgesia depending upon the
specific properties of the medication and whether it is formulated as an extended release drug. Opioids are efficacious analgesics in
chronic malignant pain and modestly effective in nonmalignant pain management. However, there are associated adverse effects, especially
during the commencement or change in dose. Prolonged opioid use may cause drug tolerance, chemical dependency, diversion and addiction.
The potency and availability of these substances, despite their high risk of addiction and overdose, have made them popular both as formal
medical treatments and as recreational drugs. Due to their sedative effects on the medulla oblongata, opioids in high doses present the
potential for respiratory depression, and may cause respiratory failure and death. In a 2013 review study published in Fundamental &amp;
Clinical Pharmacology, various studies were cited demonstrating that cannabinoids exhibit comparable effectiveness to opioids in models
of acute pain and even greater effectiveness in models of chronic pain. Cannabis produces several compounds with various known activities
known together as cannabinoids, such as THC and CBD. In general, cannabinoids bind and act through the two characterized CRP: CB1 and
CB2. However, activation of the CB1 receptor (as for example in the case of THC) leads to unwanted psychoactive &#8220;high&#8221; and
other adverse events, whereas activation of CB2 does not lead to any psychoactivity. In addition and unrelated to the above sentence,
the affinity of the cannabis derived cannabinoids to these receptors is limited and partial. Newly synthetic cannabinoid HU-433, a specific
CB2 agonist with high CB2 receptor affinity, was specifically synthesized by Prof. Raphael Mechoulam from Hebrew University of Jerusalem
and is our proprietary new chemical entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2018, we executed
a license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, for SCI-160, a synthetic cannabinoid
synthesized by Prof. Mechoulam. We completed two preliminary preclinical studies evaluating analgesic and opioid-sparing effects of this
compound in a rat model of acute and chronic pain. In the preclinical studies, SCI-160 was well tolerated and did not cause any significant
adverse clinical effects. In addition, efficacy studies demonstrated the analgesic superiority of SCI-160 over control and were comparable
to high-dose morphine analgesic effects and in some instances exerted greater potency. These preclinical studies in SCI-160 were able
to meet their endpoints - efficacy and safety - for both acute and chronic pain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Market Size</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global&#160;pain management
drugs market size&#160;was estimated at&#160;$78.14 billion in 2022&#160;and is projected to hit around&#160;$115 billion by 2032, growing
at a&#160;CAGR of 3.94% during the forecast period 2023 to 2032. On the basis of geography, North America dominated the market and captured
more than 45% revenue share in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the U.S. National
Center for Health Statistics, over 310 million major procedures are performed annually, of which approximately 40 to 50 million are in
the U.S. and 20 million in Europe. Moreover, there is a rise in the rate of surgeries worldwide which is the primary reason for the growing
consumption of pain management drugs. Subsequently, the increased cancer therapies associated with pain incidence and a rising geriatric
population having various therapies drive the market. Consumer preference for pain management therapies is influenced by their high availability,
ease of access, heightened awareness, cost-effectiveness, and rapid relief.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, rising road accidents
due to the increasing number of vehicles and traffic violations lead to related trauma injuries, which create demand for pain management
post surgeries. According to the WHO, 1.3 million people die yearly from road traffic crashes. Between 20 and 50 million people suffer
from non-fatal injuries, with many incurring a disability due to their injury.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Current Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently available treatments
are antidepressant and anticonvulsant analgesics, opioids and nonsteroidal anti-inflammatory drugs. These are inadequate to control all
pain or are associated with limiting side effects (e.g., most problematic being sedation with the antidepressant and anticonvulsant group,
constipation with the opioids and gastrointestinal and cardiovascular effects with the Non-steroidal anti-inflammatory drugs, or NSAIDs).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Our SCI-160 Solution for
pain</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SCI-160 is a newly synthetic
cannabinoid, a specific CB2 agonist with high CB2 receptor affinity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our proprietary SCI-160,
in August 2021, we announced positive top-line results for a controlled pre-clinical trial on neuropathic and post-operative pain. The
study &#8220;An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat
hind paw incision model,&#8221; was designed to help assess the potential of SCI-160. Key findings from the pre-clinical trial are that
SCI-160 significantly alleviates pain up to six hours after injection as compared with vehicle-treated animals. Daily SCI-160 injections
significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals, for up to seven days after surgery.
Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to four days post surgery
as compared with vehicle treated animals and SCI-160 analgesic effects are prolonged in the presence of PEA. Collectively, the results
indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on the positive results, we are continuing
the development of SCI-160 towards a first in-human clinical study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Our CannAmide&#8482; Anti-Inflammatory
and Chronic Pain Solution</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CannAmide&#8482; is a cannabimimetic
compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their metabolism, and is particularly
attractive therapeutically as it appears to have a very high safety profile with low or no abuse liability. Although numerous clinical
trials have shown the favorable effect of PEA as an analgesic agent it has low solubility.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we announced
the issuance of a product license for our proprietary PEA oral tablet CannAmide&#8482; by Health Canada&#8217;s Natural and NNHPD, for
the recommended use as an anti-inflammatory and to help relieve chronic pain. This license was issued by the NNHPD under the authority
of the NHPR. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended dose of one tablet
three times a day. Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the World Health Organization,
half of the most prevalent conditions responsible for living with disability is characterized by the presence of different kinds of pain.
With the NNHPD license, we are able to offer safe and beneficial non-opiate pain management products. CannAmide&#8482;&#8217;s active
compound PEA is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their
metabolism, and is particularly attractive therapeutically as it appears to have a very high safety profile with low or to no possibility
for abuse. On February 10, 2021, we announced that we had entered into an agreement with Procaps, a leader in contract development and
manufacturing services in softgel advanced technologies for the global pharmaceutical and nutraceutical industries, to develop and commercially
manufacture both of our drug candidates, SCI-110 and our proprietary PEA oral tablets CannAmide&#8482;, in softgel capsule form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cannabinoids have great therapeutic
potential and have been used for years for medicinal purposes. For example, cannabis and cannabinoids are being used to improve the quality
of life of patients with numerous and diverse indications (oncological patients, chronic pain conditions, etc.). We believe that the novel
approaches and unique mechanism of action of our proprietary technology platforms, including our drug delivery systems and unique combination
and specific dosages, may be expanded to treat additional diseases and unmet medical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may consider
expanding our pipeline to include these additional indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Collaboration with Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2022, we entered
into a cooperation agreement, or the Cooperation Agreement, with Clearmind. The Cooperation Agreement includes, among others, examination
of the benefit of integrating the core technologies of each company to explore the development of psychedelic-centric drug candidates
and targeting mental health-related diseases. Pursuant to the terms of the Cooperation Agreement, we conducted a joint pre-clinical study
with Clearmind. Under the Cooperation Agreement, we aim to pursue, develop and commercialize psychedelic-centric drug candidates. Our
collaboration with Clearmind has resulted as of the date of this Annual Report, in the filing of nine patent applications. All patent
applications refer to the combination of SciSparc&#8217;s CannAmide&#8482; with Clearmind&#8217;s 5-Methoxy-2-aminoindane, or MEAI, an
innovative proprietary psychedelic treatment for addictions and others.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2022, we announced
that our collaboration with Clearmind resulted in the filing of a provisional patent application related to a psychedelic combination
therapy treating numerous binge behaviors. The patent application referred to the combination of our CannAmide&#8482; with Clearmind&#8217;s
MEAI. The patent application followed successful pre-clinical studies that showed a significant dose dependent effect for MEAI treatment
in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide&#8482; treatment at the lower
sub-effective MEAI dose. Additionally, in May 2022, we announced positive safety profile results from our joint pre-clinical trial with
Clearmind. The clinical trial tested the proprietary combination of our CannAmide&#8482; with Clearmind&#8217;s psychedelic molecule,
MEAI, for alcohol consumption. A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas,
spleen, and thyroid gland) from all experiment groups (n=3-5 per group) to determine the safety of the proprietary combination of MEAI
and CannAmide&#8482; versus control (mice) that were not exposed to alcohol). The severity of changes was scored by a 5-point scale by
a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results indicated a high safety profile of the
combination treatment with no treatment-related changes observed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
that our collaboration with Clearmind resulted in the filing of a provisional patent application related to treating cocaine addiction.
The patent application refers to the proprietary combination of our CannAmide&#8482; with Clearmind&#8217;s MEAI, for treating cocaine
addiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, we announced
additional positive pre-clinical results of our psychedelic-based pharma collaboration for treatment for cocaine addiction using MEAI.
These pre-clinical study results added to our announcements regarding our collaboration with Clearmind for their combination treatment
based on our CannAmide&#8482; compound and Clearmind&#8217;s MEAI for various addictions, including pre-clinical studies results, the
filing of two provisional patent applications related to compositions comprised of MEAI and n-acylethanolamines and uses thereof and treating
cocaine addiction. The pre-clinical trial was led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research
Center located at Bar Ilan University (Ramat Gan, Israel) and was designed to evaluate the possible reward-like effects of MEAI with connection
to cocaine and its ability to abolish cocaine-induced conditioned place preference. In the pre-clinical trial, the self-administration
paradigm was utilized, which is the gold-standard model for examining drug addiction and is based on operant conditioning. Rats were catheterized
and trained to self-administer cocaine. The results identified a statistically significant sub-group within the study, in a non-biased
manner and high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine as compared
to non-treated control group. This sub-group, representing 60% of animals, showed a very high response within the group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we announced
that Clearmind filed a provisional patent application related to metabolic syndromes including obesity, regarding our collaboration with
Clearmind. The patent application is the third of the collaboration, each referring to the proprietary combination of our PEA and Clearmind&#8217;s
MEAI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2023, we announced
that announced that Clearmind filed three provisional patent applications were filed by Clearmind with the USPTO as a part of our ongoing
collaboration. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine
and our PEA. Additionally, in February 2023, we announced that as part of our ongoing collaboration with Clearmind, Clearmind filed three
provisional patent applications with the USPTO, for unique combinations of future psychedelic-based compounds. The patent applications
refer to novel proprietary combinations of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine each with our PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we announced
that we and Clearmind were to conduct a study evaluating our combination treatment for obesity and metabolic syndrome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2023, Clearmind
filed a patent application for the treatment of dyskinesia, a combination of the pyschadelic molecule 3-Methylmethcathinone and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, successful
results were announced from a pre-clinical trial on rodents, testing the efficacy of the combination treatment of PEA and MEAI on obesity,
performed by Joseph Tam from the Hebrew University of Jerusalem. The results indicated that there was an increase in the metabolic process
and fat burn, a reduction in appetite and meal sizes, and reductions in ambulation with affecting voluntary activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Collaboration with Polyrizon&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, we entered
into a collaboration agreement with Polyrizon Ltd., or Polyrizon, a biotech company focused on the development of innovative medical device
hydrogels delivered in the form of nasal sprays, or the Polyrizon Collaboration Agreement. As part of this collaboration, we will work
together to develop a unique technology for the treatment of pain, based on our SCI-160 platform and Polyrizon&#8217;s Trap and Target<sup>TM</sup>&#160;intranasal
drug delivery technology to target the central nervous system. We have agreed to pay development fees to Polyrizon up to a total of $2,550,000
upon the completion of certain milestones, as well as royalties in the low single digits upon sales of products under the agreement and
additional royalties for sales under any sublicense by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Acquisition of Wellution&#8482;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2022, we
entered into the Wellution Acquisition Agreement with Merhavit M.R.M Holding and&#160;Management Ltd., or M.R.M, and the other parties
named therein, to acquire from M.R.M its rights to purchase, the Wellution&#8482; brand. In connection therewith, we incorporated a new
wholly owned subsidiary,&#160;SciSparc Nutraceuticals, to hold the new assets of the Brand. The Brand sells hemp-based products, including
hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other
beauty and hair treatment products that are all manufactured in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the closing of the Wellution Acquisition Agreement
for the Brand which took place on September 30, 2022, we paid $4.59 million for the Brand and issued to M.R.M $15 million worth of warrants
to purchase up to an aggregate amount of 82,418 of our Ordinary Shares, or the M.R.M Warrants. The M.R.M Warrants had an exercise price
of $182 per share and an exercise period of five years from the closing, until September 30, 2027.The M.R.M Warrants were exercisable
during the exercise period upon the earlier of (i) an achievement of $100 million of gross sales by the Brand in the aggregate or (ii)
if the price of our Ordinary Shares closes at $10.00 or above.&#160;On March 26, 2024, M.R.M. agreed with us to waive all its rights under
the M.R.M. Warrants and have the M.R.M. warrants cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, we entered
into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to which, at the closing on March 28, 2023,
Jeffs&#8217; Holdings acquired from us 57 of common stock of SciSparc Nutraceuticals, equal to approximately a 49% interest in our wholly
owned subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup> Brand, for a cash consideration of $2.5 million. In addition
to the cash consideration upon closing, we received from Jeffs&#8217; Brands an additional amount accounting for certain purchase price
adjustments related to inventory and working capital, which adjustments increased the purchase price by approximately $489,330.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
Wellution Sale Agreement on March 28, 2023, including an equity conversion of the financing amounts we previously provided to SciSparc
Nutraceuticals for working capital, we hold approximately 51% of the outstanding capital stock of SciSparc Nutraceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Wellution
Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into a consulting agreement, or the Wellution
Management Agreement for the provision of services by Jeffs&#8217; Brands for the management of the Brand for a monthly fee of $20,000.
Jeffs&#8217; Brands also received a one-time signing bonus at the closing in the amount of $51,000. The Wellution Management Agreement
is in effect for an undefined period of time and may be terminated by either party with 30 days&#8217; advance notice.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the
Wellution Sale Agreement, at the closing, we undertook a share exchange with Jeffs&#8217; Brands, in which we acquired 35,345 ordinary
shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 of our Ordinary Shares, in each case having an aggregate value of
$288,238, or the Share Exchange. The number of shares exchanged was calculated based on the average closing price of the shares on the
Nasdaq for the 30 consecutive trading days ending on the third trading day immediately prior to the closing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Restructuring Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part of or independent to the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange,
while maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend
to explore other potential new opportunities, activities and investments in a variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any restructuring and possible
listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses, regulatory
approvals, receipt of any necessary consents, final approvals from our board of directors and satisfaction of any closing conditions to
effectuate such corporate restructuring and listing of NewCo. There can be no assurance regarding the ultimate timing of the intended
restructuring and listing of NewCo or that they will be completed at all. Other than the signing of the LOI with the Target Company on
November 22, 2023, as of the date of this Annual Report, we have not initiated the Restructuring Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Strategic Transaction Opportunity
Engagement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we engaged
Rosario Capital Ltd. to identify potential opportunities for a strategic transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Non-Binding Letter of Intent
with Leading Vehicle Importer Company in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Restructuring
Plan, on November 22, 2023, we announced the signing of the LOI to acquire the Target Company, a leading vehicle importer company in Israel,
with certain new negotiated terms as announced on December 7, 2023. This Acquisition is expected to be consummated by means of a reverse
triangular merger, pursuant to which we will establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into
the Target Company, leaving the Target Company as the surviving company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Acquisition,
all outstanding shares of the Target Company would be converted into the right to receive Ordinary Shares of SciSparc and any warrants
issued by the Target Company would be converted into the right to receive warrants of SciSparc. Following the completion of the Acquisition,
it is contemplated that SciSparc shareholders will hold approximately 50.01% of the share capital of the post-closing combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Bridge Loan with Leading
Vehicle Importer Company in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, we announced,
that we had entered into a bridge loan agreement, or the Loan Agreement, as lender, with the Target Company, pursuant to which the Target
Company received a bridge loan, or the Bridge Loan, in the amount of $1.4 million, further to the previously-announced LOI for the Company
to acquire the Target Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Agreement, signed
on January 16, 2024, states that the principal amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum
if the Acquisition is not consummated prior to the repayment date), compounded annually. The Bridge Loan amount, together with any accrued
interest, or the Owed Amount, may be repaid in part or in whole at the discretion of the Target Company prior to the repayment date. The
repayment of the Owed Amount will be due at the earlier date of: (a) the closing of the Acquisition, in which the Owed Amount shall be
deemed a part of, and set-off against, the financing amount we will provide the Target Company with upon closing, or $4,250,000; (b) if
the definitive agreement for the Acquisition is terminated, in accordance with its terms, within three months from such termination date;
or (c) July 15, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual property
portfolio comprises seven granted U.S. patents, pending patent applications in nine families, all of which are in the national phase of
examination. Of this portfolio, we have exclusively licensed one granted U.S. patent from Dekel and one patent family from Yissum. Our
intellectual property portfolio also includes two trademarks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Internally Developed Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2013, we filed a
provisional application with the USPTO for the technology of proprietary sequences of anti-CD3 antibody and the utilization of the latter
in various autoimmune diseases, as well as in hepato-pathologies. The provisional application has been converted to a PCT and then entered
a National Status in December 2014 in the U.S., with the European Patent Office, or EPO, and in China, Canada and Japan. In the U.S. it
received a grant status in June 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2015, we filed a
provisional application with the USPTO for combinations of cannabinoids, n-acylethanolamines, and inhibitors of n-acylethanolamine degradation,
which, in April 2016 was converted into an international PCT application that subsequently entered national phase in the following state
entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to utilizing the potentiating effect of n-acylethanolamines
on cannabinoids for any cannabinoid amenable indication, including but not limited to analgesia and TS. The 20-year term of any patent
issuing from this application would expire in April 2036. In August and September 2021, the patent was granted in Australia and Japan,
respectively, and a further patent was granted in Australia in November of 2023. A patent was granted in Israel in August of 2022, and
three patents have been issued in the U.S., two in December 2021 and one in February 2022. In December 2022, we were granted a patent
from the EPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we filed a provisional
application with the USPTO for combinations of opioids, n-acylethanolamines, and inhibitors of n-acylethanolamines degradation, which,
in May 2016 was converted into an international PCT application that subsequently entered national phase in the following state entities:
U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to potentiating effect of N-acylethanolamines on opioids
for opioid amenable indications. The 20-year term of any patent issuing from this application would expire in May 2036. In July 2021,
the first patent was granted in Australia and a second was granted in November 2023. A patent was issued in Japan in March 2023, and the
EPO granted a patent in November 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2016, we filed a provisional
application with the USPTO for the use of cannabinoids for potentiating the efficacy of antibiotics, which in July 2017 was converted
into an international PCT application that subsequently entered national phase in the following state entities: U.S., EPO, Canada and
China. The 20-year term of any patent issuing from this application would expire in July 2037. In November 2022, the USPTO issued this
patent called &#8220;Compositions and Methods of Potentiating Antimicrobials&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we filed
a provisional application with the USPTO directed to methods of treating OSA, which in January 2019 was converted into an international
PCT application that subsequently entered national phase in the following state entities: U.S., EPO, Canada and Australia. The 20-year
term of any patent issuing from this application would expire in January 2039.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2019, we filed a
provisional application with the USPTO directed to compositions and methods for potentiating derivatives of 4-aminophenols, which in April
2020 was converted into an international PCT application. The PCT application subsequently entered the national phase in Australia, Canada,
China, EPO, Israel, India, Japan, Mexico, Russia, and the U.S. The 20-year term of any patent issuing from this application would expire
in April 2040.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, we filed a
provisional application with the USPTO directed to methods for maintaining microvascular integrity, which in August 2021 was converted
into an international PCT application. The PCT application subsequently entered the national phase in Australia, Canada, China, EPO, Israel,
India, Japan, and the U.S. The 20-year term of any patent issuing from this application would expire in August 2041.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, we received
an Israeli patent for our core technology that treats central nervous systems disorders. The invention relates to &#8220;Pharmaceutical
compositions comprised of cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable
conditions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, the USPTO
granted us a new patent - U.S. Patent No. 11,491,172, title: COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS. This patent further
strengthens our intellectual property portfolio and protection of our core technologies, and in one of the most important markets in the
world. This is SciSparc&#8217;s seventh granted patent in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In-Licensed Patents and Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders. The agreement became effective in August 2015 immediately after we and Dekel entered
into an amendment to the license agreement. Pursuant to the license agreement, in May 2016 we issued Dekel 200,000 of our Ordinary Shares
at a price per share of NIS 0.5 on account of future royalty payments. Also, pursuant to the license agreement, we are obligated to pay
Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include: (i) $25,000 upon the successful
completion of preclinical trials (which milestone was met in November 2016, resulting in this payment becoming due, and which was paid
in March 2017); (ii) $75,000 upon the successful completion of a Phase I/IIa trial (which was paid in April 2018); and (iii) $75,000 upon
the earlier of generating net revenues of at least $200,000 from the commercialization of the technology or the approval of the FDA /
the EMA of a drug based on the licensed assets. In each case, and subject to our discretion, the respective milestone payments are payable
in cash or equity based on a price per Ordinary Share of NIS 0.5. The royalty payments are 8% for commercialization and 35% pursuant to
a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would likely be 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 14, 2019, we entered
into an amendment to the license agreement, to encompass our and Dekel&#8217;s original intention to exclude certain consumer packaged
goods (including, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are sources of nutrients or other
substances which may have a nutritional effect) from the scope of the licensed products and the field of our activity, as described in
the license agreement, which intention was not reflected in the license agreement, and therefore, desired and agreed to amend the license
agreement to reflect the foregoing clarification, as well as certain additional less material matters as discussed in the amendment. The
amendment also prescribes a specific development plan under the license agreement requiring us to invest in the licensed technology (as
defined under the license agreement) formulation development and maintenance of a total annual investment cap of $350,000 and for a non-compete
and non-solicitation obligation by Dekel and Dr. Shmulewitz, our former chairman and chief executive officer, towards our field of activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
February 5, 2024, we received written notice from Dekel for the termination of the license agreement, effective immediately, based on
our allegedly breaching our material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the
licensed products under the license agreement. We disagree and reject Dekel&#8217;s allegations as set forth in the notice and we are
assessing the effects, if any, on our business. For further information, see Item 3.D <i>&#8220;</i></span><i>Risk Factors - Risks Related
to Our Intellectual Property &#8211; We have received a termination notice for a license agreement for certain intellectual property rights
from an entity controlled by our former chairman and chief executive officer, Dr. Ascher Shmulewitz.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 29, 2018, we entered
into an exclusive, worldwide, sublicensable, royalty-bearing license agreement with Yissum for a license to make commercial use of the
licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, or the Yissum
License Agreement. According to the Yissum License Agreement, we were required to pay Yissum an initial payment of $133,000, and shall
pay Yissum royalties at the rates of 3% of net sales, subject to the royalty reductions as described in the Yissum License Agreement.
All right, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and we shall hold and make use of the
rights granted. All rights in the development results shall be solely owned by us, except to the extent that an employee of the Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by us and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Intellectual Property Protection </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patent and
trademark protection, we intend to use other means to protect our proprietary rights, including pursuing marketing or data exclusivity
periods, orphan drug status, and similar rights that are available under regulatory provisions in certain countries, including but not
limited to the United States, Europe, Canada, Japan, and China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we
be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also seek regulatory approval
for our products for indications with high unmet medical need, great market potential, and where we have a proprietary position through
patents covering various aspects of our products, including but not limited to: composition, dosage, formulation, use, and manufacturing
process. Our success depends, in part, on an intellectual property portfolio that supports future revenue streams and erects barriers
to our competitors. We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing
applications, and licensing and acquiring new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite these measures, any
of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated. Intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive one. For more information, see Item 3D &#8220;Risk Factors-Risks Related to our Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our portfolio of patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
 Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Jul-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-Oct-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THX-110</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THX-210</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-Oct-2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Oct-2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Aug-2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
 Covered</b></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Nov-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Mar-2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China (People&#8217;s Republic)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Jun-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Mar-2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Jun-2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2036</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110 THX-210</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
 Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Jun-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Oct-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China (People&#8217;s Republic)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Apr-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIODS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Apr-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Nov-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Nov-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2036</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Jul-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Aug-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
 Covered</b></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2039</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Mar-2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
 Covered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Mar-2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2018</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED ANTIBODIES TO CLUSTERS OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2033</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-Jun-2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Sep-2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Expiration&#160;Date</b></span></td>
    <td style="text-align: center; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
 Covered</b></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Jul-2017</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2037</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Compositions comprising CB receptor agonists, uses thereof and methods for their preparation</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Jul-09</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Sep-2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Patent Convention<sup>(1)</sup></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States of America</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7-Jun-2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also been granted
a trademark for CannAmide&#8482; in the United States with registration pending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validation states are not listed separately.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sales and Transfer of Intellectual Property
Assets</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transaction with Former Subsidiary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, we entered into
a share transfer agreement with our former subsidiary, Orimmune Bio Ltd., or Orimmune, and Karma Link Ltd., or Karma Link. According to
the agreement, we agreed to sell our interests in Orimmune to Karma Link, and also use our best efforts to transfer to and assign Orimmune
our rights in the Anti-CD3 technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2018, an additional
amendment to the transfer agreement was signed, or the Additional Amendment, between us, Karma Link and Orimmune, under which it was agreed
that Orimmune (and Karma Link) will be assigned certain rights in IP related to the licensed technology owned by us, subject to certain
conditions precedent. In 2021, we received the approval of the IIA to complete the assignment and we are now seeking to complete the transaction.
As of the date of this Annual Report on Form 20-F, the conditions precedent have not yet been completed and the assignment of the intellectual
property rights related to the licensed technology owned by us has not yet been transferred.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>MitoCare X </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2022, we entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, we
invested an initial amount of $700,000 in MitoCareX and agreed to invest over the next two years an additional $1,000,000, subject to
the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX.
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants and indemnification provisions and on March 31, 2022, the closing
conditions were met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, we announced
that MitoCareX has achieved its first milestone pursuant to the MitoCareX Agreement. The first milestone refers to the establishment of
MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The
system is harnessed to investigating mitochondrial carriers that are crucial for cell viability. As a result of MitoCareX meeting this
milestone, we invested an additional $400,000 in MitoCareX and increased our share ownership holdings in MitoCareX Bio from 31.48% to
41.92%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2023, we announced
that MitoCareX successfully developed its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A
mitochondrial carrier proteins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 27, 2023, we announced
that MitoCareX achieved positive results with the development of its laboratory capabilities by establishing a variety of small-molecule
screening platforms. With this development, MitoCareX achieved its second milestone pursuant to the MitoCareX Agreement <span>and
as a result, on March 11, 2024 we invested an additional $600,000 </span>and increased our share ownership holdings in MitoCareX Bio from
41.92% to 52.73%<span>.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we started early
commercialization of our proprietary PEA oral tablets CannAmide&#8482;, we intend to build a global commercial infrastructure to effectively
support the commercialization of our main pharmaceutical product candidates, if and when we believe regulatory approval of a pharmaceutical
product candidate in a particular geographic market appears imminent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To develop the appropriate
commercial infrastructure, we will likely have to invest significant amounts of financial and management resources, some of which we expect
to commit prior to completing the regulatory process for our pharmaceutical product candidates. Where appropriate, we may elect in the
future to utilize strategic partners, distributors, or contract sales forces to assist in the commercialization of our pharmaceutical
products. In certain instances we may consider building our own commercial infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023, we entered into
a license and distribution agreement with SciSparc Nutraceuticals pursuant to which we granted SciSparc Nutraceuticals an exclusive license
to sell and market its PEA oral tablets, CannAmide&#8482; on the Amazon.com marketplace in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While
we believe that our scientific knowledge, technology and development experience provide us with competitive advantages, we face potential
competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop
and commercialize will compete with existing therapies and new therapies that may become available in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first THC-based pharmaceutical,
a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company called Unimed Pharmaceuticals,
with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment for chemotherapy-related
nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market, other pharmaceuticals
containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed by SVC Pharma LP and
Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole cannabis extract administered
as an oral spray. Furthermore, to the best of our knowledge, there are multiple companies that are working in the cannabis therapeutic
area and are pursuing regulatory approval for their product candidates. For example, GW, which markets Sativex, a botanical cannabinoid
oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval in the United States in June 2018 for Epidiolex,
a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s Syndrome, Lennox Gastaut Syndrome, and
various childhood epilepsy syndromes. In addition, GW is developing, among others, CBDV based therapy for ASD and therapy for neonatal
hypoxic-ischemic encephalopathy and schizophrenia. Zynerba is developing a transdermal formulation of cannabidiol for Fragile X and certain
refractory epilepsies and ASD. Skye is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and
other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid for
systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism and solid tumors. RespireRx is developing
dronabinol for OSA treatment. Synendos is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed
pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. Synendos is developing small
molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders
caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor
antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101
(Inverse agonist of peripheral CB1) under phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors, either alone
or through their strategic partners, might have substantially greater name recognition and financial, technical, manufacturing, marketing
and human resources than we do and significantly greater experience and infrastructure in researching and developing pharmaceutical products,
obtaining FDA and other regulatory approvals of those products and commercializing those products around the world. They may also have
intellectual property portfolios that provide them with significant competitive advantages or create substantial barriers in our target
markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently contract with
third parties for the manufacturing and testing of our product candidates for preclinical trials and clinical trials and also intend to
do so in the future. We do not own or operate manufacturing facilities for the production of clinical quantities of our product candidates.
The use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient and may eliminate the need to
directly invest in manufacturing facilities and additional staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our third-party manufacturers
have met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of our product
candidates to meet anticipated full scale commercial demands. To meet our projected needs for commercial manufacturing, third parties
with whom we currently work might need to increase their scale of production, or we will need to secure alternate suppliers. We believe
that there are alternate sources of supply that can satisfy our clinical and commercial requirements, although we cannot be certain that
identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, pharmaceutical
product candidates are subject to extensive regulation by the FDA. The FDC Act, and other federal and state statutes and regulations,
govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion, marketing,
distribution, post-approval monitoring, reporting, sampling, and import and export of pharmaceutical drug product candidates. Failure
to comply with applicable U.S. rules and regulations may subject a company to a variety of administrative or judicial sanctions, such
as FDA refusal to approve pending NDAs, warning letters, product candidate recalls, product candidate seizures, total or partial suspension
of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical drug product
candidate development in the United States typically involves pre-clinical laboratory and animal testing, the submission to the FDA of
an IND Application, which must become effective before clinical testing may commence, and adequate, well-controlled clinical trials to
establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market
approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and
novelty of the product candidate or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nonclinical tests include
laboratory evaluation of an API or drug substance and drug product&#8217;s candidate chemistry, formulation and toxicity, as well as animal
trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the nonclinical toxicology
studies must comply with federal regulations and requirements, including GLP. The results of nonclinical testing are submitted to the
FDA as part of an IND along with other information, including information about product candidate chemistry, manufacturing and controls,
and a proposed clinical trial protocol. Long term nonclinical tests, such as animal tests of reproductive toxicity and carcinogenicity,
may continue after the IND is submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A 30-day waiting period after
the submission of an original IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical
hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.
In practice, a submitting party should contact the division after this 30 day period to ensure that the FDA has reviewed the IND to the
extent that they can assure there will be no hold placed on the IND if the FDA has not responded to the Company within this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the investigational product to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP, an international standard meant to
protect the rights and health of patients to ensure the quality of the trial and to define the roles of clinical trial sponsors, administrators
and monitors. Clinical protocols and details of the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated. Each protocol and any amendment involving testing of U.S. study subjects within the United States and subsequent
protocol amendments must be submitted to the FDA as part of the IND.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may order the temporary
hold of a clinical trial at any time or impose other sanctions if the FDA believes that the clinical trial either is not being conducted
in accordance with FDA requirements, regulations or presents a potentially unacceptable risk to the clinical trial subjects. The trial
protocol and informed consent information for subjects in clinical trials must also be submitted to an IRB for approval. An IRB may impose
other conditions for the protocol and may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>505(b)(2) Regulatory Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505(b)(2) of the FDC
Act, or 505(b)(2), provides a regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug
products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from
studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference, or use from the person
by or for whom the investigations were conducted. The applicant may rely upon the FDA&#8217;s prior findings of safety and efficacy for
an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants
to perform additional studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new
product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new
indication sought by the 505(b)(2) applicant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orange Book Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505 of the FDC Act
describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section 505(b)(2) NDA is
an application that contains full reports of investigations of safety and efficacy, but where at least some of the information required
for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a
right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In seeking approval for a
drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&#8217;s
product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products
with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential competitors in support
of approval of a 505(b)(2) NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any applicant who submits
a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product
that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires;
or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application
is submitted. This last certification is known as a Paragraph IV certification. Generally, 505(b)(2) NDA cannot be approved until all
listed patents have expired, except where 505(b)(2) NDA applicant challenges a listed patent through a Paragraph IV certification. If
the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use,
the 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 84 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although some of our product
candidates are based on repurposed drugs, there are at present no patents or other exclusivities listed in the Orange Book pertaining
to a product containing the active ingredient dronabinol.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three-year exclusivity is
available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product,
such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence
trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity
period protects against FDA approval of 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter, three-year
exclusivity does not prohibit the FDA from approving 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year
and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would
be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials
necessary to demonstrate safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NDA Submission and Review by the FDA</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming successful completion
of the required clinical and nonclinical testing, among other items, the results of product development, including chemistry, manufacture
and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission
of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the time of the first submission of the
application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances.
One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates,
the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of preparing and
submitting an NDA is substantial, mainly due to the non-clinical and clinical trial costs. Under federal law, the submission of most NDAs
is additionally subject to a substantial application user fee; the fee in the fiscal year 2023 was $3,242,026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has 60 or 74 days
from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination
that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth
review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug product
candidates are reviewed within 10 to 12 months, while most applications for priority review drugs are reviewed within six months. Priority
review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy
exists. The review process for both standard and priority review may be extended by FDA for three additional months to consider certain
late-submitted information, or information intended to clarify information already provided in the submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also refer applications
for novel drug product candidates, or drug product candidates that present difficult questions of safety or efficacy, to an advisory committee,
which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA
may inspect the facility or the facilities at which the drug substance and drug product are manufactured. The FDA will not approve the
drug product candidate unless compliance with or current cGMP, or cGMP, is satisfactory and the NDA contains data that provide substantial
evidence that the drug is safe and effective in the indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates the
NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally
outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider
the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the
FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
requested information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA
may require a REMS plan to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides,
communication plans for health care professionals, and ETASU. An ETASU can include, but are not limited to, special training or certification
for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The
requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product candidate approval
may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product candidate
approvals may be withdrawn if compliance with regulatory standards is not maintained related to the manufacture, safety or effectiveness
or problems are identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Clinical Trial Information</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical trials
of certain FDA-regulated product candidates, including prescription drugs, are required to register and disclose certain clinical trial
information on a public website (clinicaltrials.gov) which is maintained by the U.S. National Institutes of Health. Information related
to the product candidate, patient population, phase of investigation, study sites and investigator, and other aspects of the clinical
trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these trials after completion.
Disclosure of the results of these trials can be delayed until the product candidate drug product or new indication being studied has
been approved. Competitors may use this publicly available information to gain knowledge regarding the design and progress of our development
programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fast Track Designation and Accelerated Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has programs to facilitate
the development, and thus expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or
condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition.
These therapies for serious conditions are approved and available to patients as soon as it can be concluded that the therapies&#8217;
benefits outweigh their risk. Under the Fast Track Program, the sponsor of a new drug candidate may request that FDA designate the drug
candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA
must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#8217;s request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the FDA&#8217;s accelerated
approval regulations, FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to
patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. Accelerated approval
may also be based on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely
to predict an effect on irreversible morbidity or mortality or other clinical benefit, considering the severity, rarity or prevalence
of the condition and the availability or lack of alternative treatments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In clinical trials, a surrogate
endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a
patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A
drug product that is approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of
confirmatory or post-approval clinical trial(s) or registries to confirm the effect on the clinical endpoint. Failure to conduct required
post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market
on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior
review by FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to other benefits
such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may initiate review of sections
of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA
approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA&#8217;s
time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track
designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial
process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Term Extension</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After NDA approval, owners
of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of
the drug&#8217;s testing phase, the time between IND submission and NDA submission, and all of the review phase-the time between NDA submission
and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant did not pursue approval with
due diligence. The total patent term after the extension may not exceed 14 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For patents that might expire
during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent
term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is
reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension
is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advertising and Promotion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an NDA is approved, a
drug product will be subject to certain post-approval requirements. Products manufactured or distributed by us pursuant to FDA approvals
are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising,
promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase
4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences. For instance, FDA closely
regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising,
off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs may be marketed only
for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established
in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and
FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires
clinical data similar to that in the original application. The FDA uses the same procedures and actions in reviewing NDA supplements as
it does in reviewing NDAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse Event Reporting and GMP Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adverse event reporting and
submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as
Phase 4 testing, REMS and surveillance to monitor the effects of an approved product candidate, or the FDA may place conditions on an
approval that could restrict the distribution or use of the drug product. In addition, quality-control, drug manufacture, packaging, and
labeling procedures must continue to conform with cGMPs after approval. Drug manufacturers and certain of their subcontractors are required
to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced
inspections by the FDA, during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers
must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory
authorities may withdraw product candidate approvals or request product candidate recalls if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing or if previously unrecognized problems are subsequently discovered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pediatric Exclusivity and Pediatric Use</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Best Pharmaceuticals for
Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity-patent or non-patent-for a drug if certain conditions
are met. Conditions for exclusivity include a determination by the FDA that information relating to the use of a new drug in the pediatric
population may produce health benefits in that population; a written request by the FDA for pediatric studies; and agreement by the applicant
to perform the requested studies and the submission to the FDA; and the acceptance by the FDA, of the reports of the requested studies
within the statutory timeframe. Applications under the BPCA are treated as priority applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the Pediatric
Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from the FDA. Unless otherwise required
by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted with the exception of certain
oncological indications. The required pediatric assessment must assess the safety and effectiveness of the product candidate for the claimed
indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which
the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric
subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults
before pediatric studies are complete or that additional safety or effectiveness data need to be collected before the pediatric studies
begin. Under PREA, the FDA must send a non-compliance letter requesting a response with 45 days to any sponsor that fails to submit the
required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition-generally a disease or condition with
a prevalence of fewer than 200,000 individuals in the United States. Orphan drug designation must be requested and granted before submitting
an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly
by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.
The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with an FDA orphan drug
designation is entitled to a seven-year exclusive marketing period in the United States for that drug product candidate for that indication.
During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease,
except in limited circumstances, such as a showing of clinical superiority to the product candidate with orphan drug exclusivity. Orphan
drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different
disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA
application user fee. In addition to the potential seven years of market exclusivity after approval, orphan drug designation status qualifies
sponsors for tax credits for qualified clinical trials and exemption from user fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Special Protocol Assessment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A company may reach an agreement
with the FDA under the Special Protocol Assessment, or SPA, process as to the required design and size of clinical trials intended to
form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed to evaluate the protocol within 45
days of the request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request for
additional information. An SPA request must be made, and all open issues must be resolved before the clinical trial begins. If a written
agreement is reached, it will be documented and made part of the administrative record. Under the FDC Act and FDA guidance implementing
the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial
scientific issue essential to determining safety or efficacy after the study begins, public health concerns emerge that were unrecognized
at the time of the protocol assessment, the sponsor and FDA agree to the change in writing, or if the study sponsor fails to follow the
protocol that was agreed upon with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Controlled Substances</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CSA and its implementing
regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration, security,
recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA.
The DEA is the federal agency responsible for regulating controlled substances, and requires those individuals or entities that manufacture,
import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent
the diversion of controlled substances to illicit channels of commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DEA categorizes controlled
substances into one of five schedules-Schedule I, II, III, IV or V-with varying qualifications for listing in each schedule. Schedule
I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment in the United States and
lack accepted safety for use under medical supervision. Schedule I substances may be used only in federally approved research programs
and may not be marketed or sold for dispensing to patients in the United States. Pharmaceutical product candidates having a currently
accepted medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances, with Schedule II
substances presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances presenting the
lowest relative potential for abuse and dependence. The regulatory requirements are more restrictive for Schedule II substances than Schedule
III substances. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to a pharmacist in
most situations and cannot be refilled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following NDA approval of
a drug containing a Schedule I controlled substance, that substance must be rescheduled as a Schedule II, III, IV or V substance before
it can be marketed. In 2015, the Improving Regulatory Transparency for New Medical Therapies Act, removed uncertainty associated with
timing of the DEA rescheduling process after NDA approval. Specifically, it requires DEA to issue an &#8220;interim final rule,&#8221;
pursuant to which a manufacturer may market its product candidate within 90 days of FDA approval. The new law also preserves the period
of orphan marketing exclusivity for the full seven years such that this period only begins after DEA scheduling. This contrasts with the
previous situation whereby the orphan &#8220;clock&#8221; began to tick upon FDA approval, even though the product candidate could not
be marketed until DEA scheduling was complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Facilities that manufacture,
distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular
location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required for importation and manufacturing
activities, and each registration authorizes which schedules of controlled substances the registrant may handle. However, certain coincident
activities are permitted without obtaining a separate DEA registration, such as distribution of controlled substances by the manufacturer
that produces them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DEA inspects all manufacturing
facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration. The specific
security requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent
requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background checks
on all employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of
alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk manufacturer (not a dosage form manufacturer
or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal Register, and the application is open for 30
days to permit interested persons to submit comments, objections or requests for a hearing. A copy of the notice of the Federal Register
publication is forwarded by DEA to all those registered, or applicants for registration, as bulk manufacturers of that substance. Once
registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances.
Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III narcotic
substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and must
obtain authorization to destroy or dispose of controlled substances. As with applications for registration as a bulk manufacturer, an
application for an importer registration for a Schedule I or II substance must also be published in the Federal Register, which remains
open for 30 days for comments. Imports of Schedule I and II controlled substances for commercial purposes are generally restricted to
substances not already available from domestic supplier or where there is not adequate competition among domestic suppliers. In addition
to an importer or exporter registration, importers and exporters must obtain a permit for every import or export of a Schedule I and II
substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule III, IV and V non-narcotics. In some
cases, Schedule III non-narcotic substances may be subject to the import/export permit requirement, if it is necessary to ensure that
the United States complies with its obligations under international drug control treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For drugs manufactured in
the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be
manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific,
research and industrial needs. This limited aggregate amount of cannabis that the DEA allows to be produced in the United States each
year is allocated among individual companies, which, in turn, must annually apply to the DEA for individual manufacturing and procurement
quotas. The quotas apply equally to the manufacturing of the API/drug substance and production of dosage forms. The DEA may adjust aggregate
production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the year, although
the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual states may also
maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing
requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure to maintain
compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement
action that could have a material adverse effect on our business, operations and financial condition. The DEA may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could
lead to criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Europe/Rest of World Government Regulation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution
of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies from
country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not we obtain FDA
approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the
commencement of clinical trials or marketing of the product candidate in those countries. Certain countries outside of the United States
have a process that requires the submission of a Clinical Trial Application, or CTA, much like an IND prior to the commencement of human
clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics
committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s
requirements, clinical trial development may proceed in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements and process
governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement vary from country to country, even though
there is already some degree of legal harmonization in the European Union member states resulting from the national implementation of
underlying European Union legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain regulatory approval
of an investigational drug under the European Union. regulatory systems, we must submit a MAA. This application is similar to the NDA
in the United States, with the exception of, among other things, country-specific document requirements. Drugs can be authorized in the
European Union by using (i) the centralized authorization procedure, (ii) the Mutual Recognition Procedure, or MRP, (iii) the decentralized
procedure or (iv) national authorization procedures. The initial Sativex approvals were a consequence of an application under the De-Centralized
Procedure, or DCP, to the European Union member state of Spain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Commission implemented
the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the European
Economic Area, or EEA. This procedure results in a single marketing authorization granted by the European Commission that is valid across
the European Union, as well as in Iceland, Liechtenstein and Norway (forming together the EEA). The centralized procedure is compulsory
for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated
for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions
and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare human diseases) and (iv) advanced-therapy
medicines, such as gene- therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request of
the applicant also be used for human drugs which do not fall within the above mentioned categories if the human drug (a) contains a new
active substance which, on the date of entry into force of this Regulation, was not authorized in the Community; or (b) the applicant
shows that the medicinal product candidate constitutes a significant therapeutic, scientific or technical innovation or that the granting
of authorization in the centralized procedure is in the interests of patients or animal health at the European Community level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized procedure
in the European Union, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days (excluding clock stops, when additional
written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products
for Human Use, or CHMP, with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation
might be granted by the CHMP in exceptional cases, when a medicinal product candidate is expected to be of a major public health interest
from the point of view of therapeutic innovation, defined by three cumulative criteria: (1) the seriousness of the disease to be treated;
(2) the absence of an appropriate alternative therapeutic approach, and (3) anticipation of exceptional high therapeutic benefit. In this
circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any Member State refuse
to recognize the marketing authorization by the reference member state in a decentralized procedure, on the grounds of potential serious
risk to public health, the issue will be referred to the Committee for the Mutual Recognition and Decentralized Procedures human. Within
a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the
procedure is submitted to the CHMP for arbitration. The opinion of the CHMP is then forwarded to the Commission, for the start of the
decision making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General
and the Standing Committee on Human Medicinal Product candidates or Veterinary Medicinal Product candidates, as appropriate. Since the
initial approvals of Sativex in the United Kingdom and Spain, there have been three &#8220;waves&#8221; of additional approvals under
three separate MRPs. Each of these procedures have been completed without any referral, and therefore without any delay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other countries outside
of the European Union, the requirements governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement
vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the other applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension
or withdrawal of regulatory approvals, product candidate recalls, seizure of product candidates, operating restrictions and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, most countries
are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic control of narcotic substances,
including cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle to
our obtaining marketing approval for Sativex and our other product candidates in those countries. These countries may not be willing or
able to amend or otherwise modify their laws and regulations to permit Sativex or our other product candidates to be marketed, or achieving
such amendments to the laws and regulations may take a prolonged period of time. In that case, we would be unable to market our product
candidates in those countries in the near future or perhaps at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expanded Access to Investigational Drugs
in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investigational drug may
be eligible for clinical use outside the context of a manufacturer&#8217;s clinical trial of the drug. &#8220;Expanded access&#8221; refers
to the use of an investigational drug where the primary purpose is to diagnose, monitor, or treat a patient&#8217;s disease or condition
rather than to collect information about the safety or effectiveness of a drug. Expanded access INDs are typically sponsored by individual
physicians to treat patients who fall into one of three FDA-recognized categories of expanded access: expanded access for individual patients,
including for emergency use; expanded access for intermediate-size patient populations; and expanded access for large patient populations
under a treatment IND or treatment protocol. For all types of expanded access, the FDA must determine prior to authorizing expanded access
that: (1) the patient or patients to be treated have a serious or life threatening disease or condition and there is no comparable or
satisfactory alternative therapy; (2) the potential patient benefit justifies the potential risks of use and that the potential risks
are not unreasonable in the context of the disease or condition to be treated; and (3) granting the expanded access will not interfere
with the initiation, conduct, or completion of clinical studies in support of the drug&#8217;s approval. In addition, the sponsor of an
expanded access IND must submit IND safety reports and, in the cases of protocols continuing for one year or longer, annual reports to
the FDA. Expanded access programs are not intended to yield information relevant to evaluating a drug&#8217;s effectiveness for regulatory
purposes. If a patient enrolled in one of our clinical trials is not eligible or able to continue enrollment, we may be required to continue
to provide our product candidate to such patient through expanded access.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of pharmaceutical product
candidates in the United States will depend, in part, on the extent to which the costs of the product candidates will be covered by third-party
payors, such as government health programs, commercial insurance and managed health care organizations. These third-party payors are increasingly
challenging the prices charged for medical product candidates and services. Additionally, the containment of health care costs has become
a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government, state
legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic product candidates. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net
revenue and results. If these third-party payors do not consider our product candidates to be cost-effective compared to other available
therapies, they may not cover our product candidates after approval as a benefit under their plans or, if they do, the level of payment
may not be sufficient to allow us to sell our product candidates on a profitable basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription
drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D,
Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription
drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare
Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required
to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and
at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of
covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug
plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription
drugs may increase demand for product candidates for which we receive marketing approval. However, any negotiated prices for our product
candidates covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while
the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations
in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from
non-governmental payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ACA was enacted in March
2010. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the law. The ACA may be modified,
amended or repealed at any time and may or may not be replaced with a different law or health care payment system. The ACA is expected
to continue to have a significant impact on the health care industry. With regard to pharmaceutical product candidates, among other things,
the ACA may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements
under the Medicare Part D program. Since the enactment of the ACA, numerous regulations have been issued providing further guidance on
its requirements. The ACA continues to be implemented through regulation and government activity but is subject to possible amendment,
additional implementing regulations and interpretive guidelines. Several states have decided not to expand their Medicaid programs and
are seeking alternative reimbursement models to provide care to the uninsured. The manner in which these issues are resolved could materially
affect the extent to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare, Medicaid and
Tricare. We are unable to predict the full impact of any potential modification, amendment, or repeal of the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once approved,
and related treatments will be available from third-party payors, such as government health administration authorities, private health
insurers and managed care organizations. Third-party payors determine which medications they will cover and separately establish reimbursement
levels. Even if we obtain coverage for a given product by a third-party payor, the third-party payor&#8217;s reimbursement rates may not
be adequate to make the product affordable to patients or profitable to us, or the third-party payors may require co-payments that patients
find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,
generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely
to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our
products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical
and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available
or subsequently become available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities and
other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage
and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide
them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists
to leverage greater discounts in competitive classes and are challenging the prices charged for medical products. Further, no uniform
policy for determining coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage
and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often
a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each
payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be sure that coverage
and reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement
will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing
approval. If coverage and reimbursement are not available, or if reimbursement is available only to limited levels, we may not successfully
commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of receiving
Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their
AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs,
Medicaid payment rates for the drug, and for drugs paid under Medicare Part B, to also calculate and report their average sales price,
which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid
Drug Rebate Program, effective April 1, 2016, that, among other things, revised the manner in which the AMP is calculated by manufacturers
participating in the program and implemented certain amendments to the Medicaid rebate statute created under the ACA. Drugs that are approved
under an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#8217;s best
price for the drug and inflation penalties which can substantially increase rebate payments. On December 21, 2020, CMS issued a final
rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including some changes to the treatment of value-based
purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For NDA drugs, the Veterans
Health Care Act of 1992 requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called
the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than a statutory price
referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers to pay rebates on
these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information
to the government creates potential federal False Claims Act liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Further,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state
levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer
patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. We expect
that the pharmaceutical industry will continue to experience pricing pressures due to the trend toward managed healthcare, particularly
towards specialty pharmacy, the increasing influence of managed care organizations, and additional legislative proposals. For example,
CMS issued an interim final rule on November 27, 2020 designed to test whether a Most-Favored-Nation model will help control growth in
spending for Medicare Part B drugs without adversely affecting quality of care. This followed an Executive Order issued in September 2020
that directed the Secretary of DHHS to implement new payment models under the Medicare Part B and Part D programs to curb &#8220;unfair&#8221;
and high drug prices in the United States. Implementation of this interim final rule was blocked by a temporary restraining order and
preliminary injunctions through various court actions and CMS published a final rule on December 27, 2021 that rescinded the interim final
rule. Nonetheless, we expect that there will continue to be a number of U.S. federal and state proposals to implement governmental pricing
controls and limit the growth of healthcare costs, including the cost of prescription drugs. It is unknown what form any such changes
or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect
that changes or additions to the ACA, the Medicare and Medicaid programs, such as changes allowing the federal government to directly
negotiate drug prices, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing
or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt; text-align: justify; text-indent: 30.4pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">At
the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. On the federal level, the Trump Administration issued a final rule in 2020 for the safe importation
of drugs from Canada and other countries. Per this rule, the FDA authorized its first section 804 importation program, or SIP, a program
allowing the State of Florida to import certain prescription products from Canada. Section 804 (21 U.S.C. &#167; 384) of the Federal Food,
Drug, and Cosmetic Act provides a pathway for U.S. states and Indian tribes to allow importation of certain prescription drugs from Canada.
Programs under this pathway must significantly reduce the cost of these drugs to the American consumer without imposing additional risk
to public health and safety. As the first program of its kind, we have yet to see how this Program will be implemented and what specific
products will be imported. There is much opposition from the biopharmaceutical industry regarding this Program, but if Florida can execute
it as planned, it may signal a trend in the U.S. The practical implications of SIPs, and their implications for the biopharmaceutical
industry as a whole or our business in particular remain to be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">In
July 2021, the Biden administration issued an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple
provisions aimed at increasing competition for prescription drugs. The DHHS has released a Comprehensive Plan for Addressing High Drug
Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these
principles. While no legislation or administrative actions have been finalized to implement these principles, Congress is considering
legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations
on drug price increases and allowing Medicare to negotiate pricing for certain covered drug products. The impact of these legislative,
executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us
and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may
prevent us from being able to generate revenue, attain profitability, or commercialize any of the product candidates for which we receive
approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34.05pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
passage of the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming
Medicare drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific
implications for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, we are unable to predict potential modification,
amendment, or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">As
the first key element, the IRA created a program for Medicare drug-price negotiation, enabling the Secretary of DHHS to negotiate the
prices of certain costly, single-source drugs or biologics within the Medicare program. Certain drugs and biologics are excluded from
this negotiation process, such as drugs that are less than 9 years, and biologics less than 13 years, from their FDA-approval or licensure
date, and drugs with an orphan designation as their only FDA-approved indication. The first set of these negotiated prices will not take
effect until 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; "></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34.05pt; ">Second,
the IRA requires drug manufacturers to pay rebates to the federal government for price increases above the rate of inflation for single-source
drugs or biologics covered under Medicare Part B and most drugs under Medicare Part D, which already occurs under the Medicaid program.
This inflation-rebate provision for Medicare Part B took effect at the start of 2023, and such provision for Medicare Part D took effect
in 2022 as the starting point for measuring drug-price increases, with rebate payments required as of the beginning of 2023. DHHS will
start to send rebate invoices to drug manufacturers in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 34.05pt; ">Third,
the IRA restructures the Medicare Part D benefit to limit patients&#8217; out-of-pocket costs and rebalance the bearing of risk for Part
D plans and manufacturers. As of 2024, Medicare Part D plan buyers will no longer have to pay out-of-pocket costs for covered drugs once
they reach the catastrophic coverage level (when the policyholder&#8217;s out-of-pocket spending reaches $7,400). Other aspects of this
provision will take effect in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
bipartisan&#160;<i>Drug-Price Transparency for Consumers Act</i>&#160;was introduced to Senate on April 20, 2023, and the House of Representatives
on October 13, 2023 (S.1250 and H.R.5958, respectively). The Act is currently in committee. This Act would require that direct-to-consumer
advertisements for drugs and biologics include a disclosure of pricing information. The Act would apply to drugs and biologicals reimbursable
under Medicare or Medicaid and for which direct-to-consumer advertisements are required to include information relating to side effects,
contraindications, and effectiveness in accordance with section 202.1(e)(1) of title 21, Code of Federal Regulations. If passed, this
Act would amend the Social Security Act to allow the Secretary of DHHS to require such advertisements to disclose the wholesale acquisition
cost, or WAC, for a 30-day supply or typical course of treatment and clearly and conspicuously present such price information. If enacted,
the Act contemplates that implementing regulations would include the visual and audio components required to communicate the WAC appropriately
for the medium of the advertisement, the reasonable amount of time to update the advertisement to reflect any changes to WAC, and the
way the manufacturer may include a statement explaining that certain consumers may pay a different amount depending on their insurance
coverage. The Act would also subject advertisers to a penalty of up to $100,000 per violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
full implications of changes such as those discussed above, and their practical impact on biopharmaceutical pricing and reimbursement,
as well as advertising requirements and related costs, on the biopharmaceutical industry as a whole and our business in particular cannot
yet be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As noted above, the marketability
of any products for which we receive regulatory approval for commercial sale may suffer if the government and other third-party payers
fail to provide adequate coverage and reimbursement. We expect that an increasing emphasis on cost containment measures in the U.S. will
continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time.
Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Pricing and Reimbursement in Foreign Countries</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. For example, a member state of the European Union may approve a specific price for the medicinal
product candidate. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
product candidates will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product
candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As another example, in Canada,
for patented drugs, the Patented Medicines Prices Review Board (PMPRB) uses the median international publicly available ex-factory list
price (using prices in 11 pre-determined countries) as the maximum price the company is allowed to charge. The PMPRB is a quasi-judicial
body with a regulatory mandate to prevent pharmaceutical patentees from charging consumers excessive prices during the market exclusivity
period. This agency then monitors the prices charged by patentees for patented drugs on an ongoing basis. Under the Canadian Patent Act,
patentees are required to file price and sales information about their patented drug products at introduction and twice a year thereafter
for each strength of each dosage form of each patented drug product sold in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Other Health Care Laws and Compliance Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the United States, our
activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the
CMS, other divisions of the DHHS (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney
offices within the Department of Justice, and state and local governments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The federal AKS prohibits,
among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or purchasing,
leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable, in whole or in
part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything
of value, including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices.
There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions
and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory
safe harbor does not make the conduct per se illegal under the federal AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the ACA amended the intent requirement
of the federal AKS so that a person or entity no longer needs to have actual knowledge of the federal AKS, or specific intent to violate
it, to have violated the statute. The ACA also provided that a violation of the federal AKS is grounds for the government or whistleblower
to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes
of the civil False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, in November 2020,
DHHS finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by excluding
rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or PBMs acting under contract with
Medicare Part D plan sponsors from the existing discount safe harbor under the federal AKS. The regulation reflects the first change to
the AKS discount safe harbor since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe harbors
were added. One of these new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under Medicare
Part D or a MCO for a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided certain
conditions are met. The other protects certain fixed-fee services arrangements between manufacturers and PBMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The federal civil and criminal
false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to avoid, decrease or conceal an obligation to pay money to the federal government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The civil monetary penalties
statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented
a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or
is false or fraudulent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">HIPAA created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises, any of
the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is
public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal
investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material
fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services
relating to healthcare matters. The ACA amended the federal health care fraud criminal statute implemented under HIPAA so that a person
or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated the statute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Additionally, the federal
Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations,
require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid
or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments
or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated
on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians
and their immediate family members. The SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data
for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse
midwifes. The amendment applies to reports submitted to CMS on or after January 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, we may be subject
to data privacy and security regulation by both the federal government and the states in which we conduct our business or target consumers.
HIPAA, as amended by HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission
of individually identifiable health information on HIPAA covered entities and their business associates, including mandatory contractual
terms and the implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#8217;s security standards
directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health
information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted
by HIPAA, thus complicating compliance efforts. Most recently, fourteen states including California have adopted laws that regulate the
privacy and security of consumer personal information, and apply in instances where HIPAA and clinical trial laws do not. In addition,
other states such as Washington, have adopted laws that regulate the privacy and security of consumer health data which, again, apply
in instances where HIPAA and clinical trial laws do not.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Many states have also adopted
laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value
to physicians and other healthcare providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Enforcement actions can be
brought by federal or state governments or, in some cases, as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the
name of the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal,
civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual imprisonment,
additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of non-compliance with these laws, exclusion from government programs, refusal to allow us to enter into supply contracts,
including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our
operations, any of which could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In order to distribute product
candidates commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical
product candidates in a state, including, in certain states, manufacturers and distributors who ship product candidates into the state,
even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers
and distributors to establish the pedigree of product candidate in the chain of distribution, including some states that require manufacturers
and others to adopt new technology capable of tracking and tracing product candidate as it moves through the distribution chain. Several
states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with
the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities or register their sales
representatives. Other legislation has been enacted in certain states prohibiting pharmacies and other health care entities from providing
certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and
marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>The Foreign Corrupt Practices Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
FCPA regulates part of our business activities. The FCPA has two main provisions applicable to us: (a) the antibribery provisions, which
prohibit individuals and businesses from bribing foreign government officials in order to obtain or retain business; and (b) the accounting
provisions, which impose certain record keeping and internal control requirements on issuers, and prohibit individuals and companies from
knowingly falsifying an issuer&#8217;s books and records or circumventing or failing to implement an issuer&#8217;s system of internal
controls. Violations of the FCPA can lead to civil and criminal penalties, sanctions, and remedies, including fines, disgorgement, and/or
imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
antibribery provisions of the FCPA prohibits the paying, offering, promising, or authorizing payment or offering money or of anything
of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision
of such foreign official, political party, or candidate in his or her official capacity or to secure any improper advantage in obtaining
or retaining business. Under the statute, a company is liable when its directors, officers, employees, or agents, acting within the scope
of their employment, commit FCPA violations intended, at least in part, to benefit the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
accounting provisions of the FCPA consist of two primary components. First, under the &#8220;books and records&#8221; provision, issuers
must make and keep books, records, and accounts that, in reasonable detail, accurately and fairly reflect an issuer&#8217;s transactions
and dispositions of an issuer&#8217;s assets. Second, under the &#8220;internal controls&#8221; provision, issuers must devise and maintain
a system of internal accounting controls sufficient to assure management&#8217;s control, authority, and responsibility over the Company&#8217;s
assets. The accounting provisions do not apply only to bribery-related violations. Rather, the accounting provisions require that all
public companies account for all of their assets and liabilities accurately and in reasonable detail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">The
Company, its affiliates, and its and their operations around the world are subject to the FCPA because the Company is an &#8216;issuer&#8217;
as defined in the statute. The U.S. Department of Justice aggressively enforces the FCPA and has, at times, focused its enforcement attention
to the pharmaceutical sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Grants from the IIA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts mainly with respect to our past activities (with respect to immunotherapy programs such as the Anti-CD3)&#160; were financed in
part through royalty-bearing grants from the IIA. As of December 31, 2023, we had received the aggregate amount of approximately $1.1
million from the IIA for the development of our abovementioned technologies. With respect to such grants, we are committed to pay royalties
of up to an aggregate amount of approximately $1.1 million relating only to technologies in our possession and excluding any royalties
for technologies that we sold to third parties. We are further required to comply with the requirements of the Research Law, with respect
to those past grants. In addition, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israel
citizen or resident an &#8220;interested party&#8221; as defined in the Research Law requires prior written notice to the IIA. Non-Israeli
citizens and residents are required to execute an undertaking in favor of the IIA, in the form prescribed by the IIA. When a company develops
know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer or licensing of
such know-how inside or outside of Israel, and the transfer or licensing outside of Israel of manufacturing or manufacturing rights of
such products, technologies or know-how, without the prior approval of the IIA. None of our current projects in the field of cannabinoid
therapeutics are supported by the IIA, yet if eligible, we might apply for such support in the future.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Current Regulatory Status of SciSparc&#8217;s
Pharmaceutical Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The active ingredient in our
pharmaceutical product candidate SCI-110 is a Schedule I controlled substance. Other drug candidates in our portfolio are either not controlled
or as yet to be scheduled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our drug candidate SCI-110
is being developed, among others, for the treatment of TS. TS may be considered a serious condition with a potentially disabling nature.
Thus, it may be eligible for a fast-tracked submission. However, a request for eligibility may be filed by us later in the development
of this molecule. In June 2016, we submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In
a letter dated September 29, 2016, the FDA informed us that our request could not be granted at such time and is being held in abeyance
until and subject to us providing additional information pertaining to the overall prevalence of TS in both children and adults, and further
clinical data to support our scientific rationale for our request for orphan drug designation within 12 months. In September 2017, we
responded to such FDA letter within the designated time frame and provided the FDA with our articulated and reasoned responses including
documentation and clinical data that supports it. On December 26, 2017, we received the FDA&#8217;s response to our response. The FDA
accepted that there is adequate scientific rationale for the treatment of TS with SCI-110 mainly through the preliminary results of ongoing
clinical trials, suggesting that SCI-110 may provide benefit in treating TS. However, the FDA stated that it was unable to grant our request
and indicated that we did not provide adequate prevalence estimates, and any evidence to support our statement that only moderate to severe
TS patients would require pharmacological treatment. We further responded in January 2018 by providing the requested information. On January
23, 2020, following additional correspondence with the FDA, the FDA still did not grant us our request due to fact that we have not yet
provided adequate prevalence estimates. However, the FDA did agree with our position that we could potentially qualify for orphan drug
designation with respect to the moderate-to-severe TS sub-group population only rather than the entire population. After we had provided
additional prevalence estimates, the FDA raised a concern in its letter, dated December 7, 2020, about our ability to limit the use of
the pharmaceutical product to the subset of patients we are pursuing. Due to the fact that we disagree with this concern, we requested
a clarification call. In the clarification call conducted on February 2, 2021, we agreed with the FDA concern about our ability to limit
the use of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics
population so we suggested to amend our preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, we sent our response to the FDA. In
June 2021, we received a response from the FDA explaining that they are unable to grant our request until new information becomes available
to support our request for orphan drug designation. We will re-visit the application after we obtain clinical results from our phase IIb
clinical study in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Canada</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>NNHPD Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to a non-traditional
class III Product License Application, CannAmide&#8482;, or TheraPEA, received Health Canada approval (NPN 80093504) from the NNHPD on
July 23, 2019. In the approval letter, the NNHPD confirmed that the application was in compliance with section 7 of the NHPR. The dosage
of 1 x 400 mg tablet 3 times daily was approved for the following use: &#8220;Studies show that PEA may be used as an anti-inflammatory
to help relieve chronic pain&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Any labels used in the marketing
of TheraPEA must reflect the information outlined on the product license and must comply with the labelling requirements as per Part 5
of the NHPR. In addition, natural health products, such as TheraPEA, must be manufactured, packaged, labelled, imported, distributed and
stored in accordance with GMP as required by NHPR or in accordance with equivalent requirements if the natural health product is imported.
Furthermore, in accordance with Section 44 of the NHPR, each product for sale in Canada must comply with the finished product specifications
submitted to Health Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the NHPR, companies
are required to provide the NNHPD with the Canadian site information prior to commencing the importation and/or sale of the natural health
products in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Changes made in respect of
a licensed product require the submission of an amendment, notification or a new product license application as per sections 11, 12 and
13 of the NHPR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>C. Organizational Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">SciSparc Nutraceuticals Inc.
is our majority-owned subsidiary (approximately 51%), a company focused on e-commerce operations of Wellution&#8482;, a top- seller account
of Amazon, which sells hemp-based products. Brain Bright Ltd. is an inactive wholly-owned subsidiary. We also own 100% of the issued and
outstanding share capital of Evero Health Ltd., a company focused on the development and commercialization of SCI-110 sleep technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On November 17, 2022, we invested
$1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 230,769 ordinary
shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind. As of March 28, 2024, following a reverse stock
split of Clearmind&#8217;s outstanding shares, we hold 7,692 ordinary shares of Clearmind, representing less than 0.1% of the outstanding
share capital of Clearmind.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also hold 52.73% of MitoCareX
Bio Ltd., an Israeli private company<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We hold a minority interest
in AutoMax of approximately 4.82% and a minority interest of approximately 1.14% of Jeffs&#8217; Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>D. Property, Plants and Equipment </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our offices are located at
20 Raul Wallenberg Street,&#8239;Tower A, 2nd Floor, Tel Aviv 6971916, Israel, where we currently occupy approximately 120 square meters,
under a joint lease with a third-party for a total of 240 square meters. The lease ends on June 30, 2025. Our current monthly rent payment
is NIS 10,200 (approximately $3,300).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We consider that our current
office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. However,
we are currently assessing our future needs and have not renewed our lease as of the date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>E. Litigation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In connection with a joint
venture transaction, entered on May 15, 2020, by and between us, Capital Point and Evero Health Ltd., one of our subsidiaries, we issued
a warrant to Capital Point to purchase $340,000 of our ordinary shares, or the Warrant Shares, with an exercise price per ordinary share
equal to the closing price of our ordinary shares on the trading day on which the notice of exercise is actually received by us. Such
warrant was exercisable for 12 months starting from May 15, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On November 4, 2021, we received
from Capital Point a notice of exercise with respect to the Warrant Shares, which was rejected by the Company. On May 2, 2023, Capital
Point filed a lawsuit in the Tel Aviv-Jaffa District Court against us as the sole defendant in connection with the Warrant Shares. The
lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General Part), 1973, unjust enrichment under the
Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version), 1968. The lawsuit claims damages in
the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the lawsuit, liquidated
damages according to the provisions set forth in the warrant, and seeks as well for the court to order a mandatory injunction order for
us to issue a warrant to Capital Point to purchase $340,000 of our ordinary shares to Capital Point, the return of any unlawful profits
received by us and punitive damages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As of March 28, 2024, in connection
with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health
Ltd. As of the date of this Annual Report, we cannot predict the likelihood of our success in the lawsuit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. OPERATING AND FINANCIAL REVIEW AND
PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion and
analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report. This
discussion and other parts of this Annual Report contain forward-looking statements based upon current expectations that involve risks
and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking
statements as a result of several factors, including those set forth under Item 3.D. &#8220;Risk Factors&#8221; and elsewhere in this
Annual Report. We report financial information under IFRS as issued by the International Accounting Standards Board and none of the financial
statements were prepared in accordance with generally accepted accounting principles in the United States. Our discussion and analysis
for the year ended December 31, 2021 can be found in our Annual Report for the fiscal year ended December 31, 2022, filed with the SEC
on May 1, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following financial data
in this narrative are expressed in thousands, except for share and per share data or as otherwise noted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Operating Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, we have generated revenues through our subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482; brand. Total revenues
recognized in the year ended December 31, 2023, amounted to $2,879 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
revenue from our drug development segment from the sale of any pharmaceutical product candidates, and we do not expect to generate significant
revenue in this business within the next year at least. As of December 31, 2023, we had an accumulated deficit of approximately $69 million.
Our operating activities are described below under &#8220;Operating Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the year ended December
31, 2023, we have generated revenues in the amount of $2,879 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of goods sold </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of goods sold comprises
mainly purchase of products and transportation costs to the Company&#8217;s warehouse. In the year ended December 31, 2023, the cost of
goods sold amounted to $683 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operating expenses consist of four components - research
and development expenses, sales and marketing expenses, impairment of intangible asset and general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, research and preclinical studies, chemistry and formulations, regulatory,
professional and other related research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of research and development expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">436</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regulatory, professional and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Chemistry and formulations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">141</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">281</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,641</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,803</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our research
and development expenses will materially increase as we plan to continue clinical trials and develop new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries, professional service fees for accounting, legal, bookkeeping, investor relations, Amazon transaction
fees, advertising and promotion on Amazon, regulatory and other general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of general and administrative expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wages and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">415</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">437</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">633</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amazon fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional and directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Business development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Regulatory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance, rent and other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,031</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,972</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the year ended December 31, 2023 to the year ended
December 31, 2022 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,025</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,803</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">537</td><td style="text-align: left"><sup>(1)</sup>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,972</td><td style="text-align: left"><sup>(1)</sup>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,592</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss attributable to holders of Ordinary Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,592</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified for the year
                                                                                                                                                                 ended December 31, 2022 related to certain activities carried out by Wellution in the year ended December 31, 2023. This
                                                                                                                                                                 reclassification correlates with common practice in the industry to better reflect profit and loss across the periods presented. For
                                                                                                                                                                 further information regarding Wellution, see &#8220;Item 4.B&#8211;Business Overview -- Other Programs -- Acquisition of
                                                                                                                                                                 Wellution&#8482;&#8221;.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses for the year ended December 31, 2023, amounted to $1,641, representing a decrease of $1,162, or 41%, compared to $2,803 for the
year ended December 31, 2022. The decrease resulted primarily from a decrease in research and preclinical studies expenses, chemistry
and formulations expenses and share-based compensation expenses, which amounted for $101 thousand, $141 thousand, and $34 thousand, respectively,
in the year ended December 31, 2023 (compared to $703 thousand, $281 thousand, and $264 thousand, respectively, in the year ended December
31, 2022).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and administrative expenses totaled $5,031 thousand for
the year ended December 31, 2023, representing a decrease of $941 thousand, or 16%, compared to $5,972 thousand for the year ended December
31, 2022. The decrease resulted primarily from a decrease in investor relation and business expenses and share-based compensation expenses,
which amounted to $369 thousand and $68 thousand, respectively, in the year ended December 31, 2023 (compared to $1,486 thousand and $633
thousand, respectively, in the year ended December 31, 2022).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;Sales and marketing expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sales and marketing expenses
totaled $1,297 thousand for the year ended December 31, 2023, representing an increase of $724 thousand, or 135% compared to $537 thousand
for the year ended December 31, 2022. All sales and marketing expenses are generated by SciSparc Nutraceuticals, which owns the Wellution&#8482;
brand. SciSparc Nutraceuticals commenced activities in September 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of intangible asset</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">Our impairment of intangible asset totaled $1,042 thousand for the
year ended December 31, 2023, representing an increase of $1,042 thousand compared to $nil for the year ended December 31, 2022. The increase
resulted primarily from an impairment of an intangible asset related to the decline of the Wellution brand and its goodwill in the amount
of $1,042 thousand for the year ended December 31, 2023 (compared to $0 in the year ended December 31, 2022).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating loss for the
year ended December 31, 2023, was $6,815 thousand, representing a decrease of $1,472, or 18%, as compared to an operating loss of $8,287
thousand for the year ended December 31, 2022. The decrease resulted primarily from the decrease in research and development expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial Expense and Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expenses and income
consist of revaluations of instruments measured at fair value, exchange rate differences, bank fees, loans interest and other transactional
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial income
in the amount of $2,219 thousand for the year ended December 31, 2023, as compared to financial income of $7,832 thousand for the year
ended December 31, 2022. The decrease of financial income for the year ended December 31, 2023 resulted mainly due to the decrease in
the fair value of the Company&#8217;s warrant liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized financial expenses
for the year ended December 31, 2023, of $1,055 thousand, as compared to financial expense of $2,014 thousand for the year ended December
31, 2022. The decrease of financial expenses for the year ended December 31, 2023 resulted mainly due to the decrease in the fair value
of the Company&#8217;s financial assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total Comprehensive Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our total comprehensive loss
for the year ended December 31, 2023, was $5,883 thousand, representing an increase of $3,291 thousand, or 127%, as compared to $2,592
thousand for the year ended December 31, 2022. The increase resulted primarily from the decrease in financial income in the year ended
December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Liquidity and Capital Resources </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2004,
and through December 31, 2023, we have funded our operations principally with $64.5 million from the issuance of Ordinary Shares and ADSs,
warrants and pre-funded warrants. As of December 31, 2023, we had $2.1 million in cash, $22 thousand in trade receivables, $540 thousand
in other accounts receivable, $742 thousand in inventory, and an additional amount of $3 million in short-term bank deposits. In the event
that additional financing is required from outside sources, we may not be able to raise such financing on terms acceptable to us or at
all. If we are unable to raise additional capital when desired, our business, operating results, and financial condition would be adversely
affected, and there is substantial doubt about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents our
cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,887</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,917</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,084</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,498</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,301</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $5,887 thousand during 2023 in comparison to $7,917 thousand during 2022. The decrease resulted primarily from the decrease
in operating expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $1,109 thousand during 2023 in comparison to $7,084 thousand during 2022. Net cash used in investing activities during
2023 resulted mainly from the investment in short-term bank deposits in the amount of $3,000 thousand, investment in financial asset in
the amount of $687 thousand, and an investment in a company accounted for at equity in the amount of $400 thousand, offset by cash generated
from the sale of a minority interest in the Wellution brand in the amount of $2985 thousand.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities during 2022 resulted mainly from the purchase of the Wellution Brand in the amount of $4,861 thousand, the purchase of financial
assets in the amount of $1,500 thousand, and an investment in a company accounted for at equity in the amount of $700 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $5,498 thousand in the year ended December 31, 2023, primarily consisted of $5,547 thousand of net proceeds from the issuance
of share capital, pre-funded warrants and warrants.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $11,700 thousand in the year ended December 31, 2022, primarily consisted of $9,005 thousand of net proceeds from the issuance
of share capital, pre-funded warrants and warrants and $2,770 thousand from warrant exercises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>June 2022 Securities Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 27, 2022, we announced
the entrance into&#160;a securities purchase agreement, which closed on June 1, 2022, with a single healthcare-focused institutional investor
for aggregate gross proceeds of approximately $10,000, before deducting fees to the placement agent and other offering expenses payable
by us, or the 2022 Private Placement. In connection with the 2022 Private Placement, we issued 3,546,100 units and pre-funded units at
a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit). Each unit and pre-funded unit consisted of one Ordinary Share
(or Ordinary Share equivalent) and two non-tradable warrants each exercisable for one Ordinary Share for $2.57 (for a total of 7,092,200
shares underlying the warrants). The warrants have a term of five years from the issuance date. No actual units were issued in the 2022
Private Placement. Aegis Capital Corp. was the exclusive placement agent in connection with the 2022 Private Placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>June 2022 Letter Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
June 30, 2022, the Company and the institutional investor entered into a letter agreement and agreed, among other things, to amend: (i)
the warrants to: (a) extend the termination date for exercising the warrants from June 1, 2027 to June 1, 2029; and (b) amend the exercise
price from $2.57 per share to $2.63 per share; and (ii) the securities purchase agreement to reflect a new purchase price of $2.88 per
unit (or $0.001 less per pre-funded unit), resulting in additional gross proceeds to the Company of $212,766. On August 19, 2022, 3,211,100
of the pre-funded warrants were fully exercised at a nominal exercise price of $0.001 per share, which resulted in an issuance of 3,211,100
Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Wellution Acquisition
Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 14, 2022, we entered into the Wellution Acquisition Agreement,
pursuant to which we acquired the Wellution&#8482; brand, or the Brand. We established SciSparc Nutraceuticals, a wholly owned subsidiary,
to hold the new assets, which is also a party to the Wellution Acquisition Agreement. On September 30, 2022, we closed the acquisition
of the Brand and paid $4.59 million for the Brand. In addition, at the closing we issued the M.R.M Warrant to M.R.M (each as defined below),
to purchase up to 82,418 of our Ordinary Shares On March 26, 2024, M.R.M. agreed with us to waive all its rights under the M.R.M. Warrants
and have the M.R.M. warrants cancelled for no consideration.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Wellution Sales Agreement</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, we entered
into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to which, at the closing, which occurred
on March 28, 2023, Jeffs&#8217; Holdings acquired from us 57 shares of common stock of SciSparc Nutraceuticals, which equals approximately
a 49% interest in our wholly owned subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup>&#160;brand, for a consideration
of $2.5 million in cash, and additional deferred cash payments of approximately $489 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the closing,
we and Jeffs&#8217; Brands undertook a mutual share exchange in the amount of approximately $288 of ordinary shares from each of us and
Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s
shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, we acquired 35,345
ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 ordinary shares from us having an aggregate value of $288,238.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
transaction, which included an equity conversion of the financing amounts of approximately $700 previously provided by the Company to
SciSparc Nutraceuticals for working capital, into shares of common stock at the price per share of the Wellution Sale Agreement, we hold
approximately 51% of SciSparc Nutraceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Wellution
Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into the Wellution Management Agreement for management
services of the Wellution<sup>TM</sup> brand by Jeffs&#8217; Brands, for a monthly fee of $20, Jeffs&#8217; Brands also received a one-time
signing bonus in the amount of $51.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>At-The-Market Issuance
Sales Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 16, 2023, we entered
into an At-the-Market Issuance Sales Agreement with Aegis Capital Corp., or the ATM Agreement, pursuant to which we may offer and sell
up to $1,729,964 of our ordinary shares. Between May 16, 2023 and August, 9, 2023, we sold approximately $4,779 of ordinary shares. On
August 9, 2023, the ATM Agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>AutoMax SPA</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
June 25, 2023, we entered into a securities purchase agreement with AutoMax Motors Ltd., or AutoMax, pursuant to which, at the closing
and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, we invested NIS 2,500
thousand in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS 0.5. Following the closing, we held approximately
5.6% of the issued and outstanding share capital of AutoMax.</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 16, 2024, we entered,
as lender, into a bridge loan agreement with AutoMax, pursuant to which AutoMax received a bridge loan in the amount of $1.4 million,
or the Bridge Loan, further to the previously-announced non-binding letter of intent for us to acquire AutoMax. The agreement states that
the principal amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum if the acquisition is not consummated
prior to the repayment date), compounded annually. The Bridge Loan amount, together with any accrued interest, or the Owed Amount, may
be repaid in part or in whole at the discretion of AutoMax prior to the repayment date. The repayment of the Owed Amount will be due at
the earlier date of: (a) the closing, in which the Owed Amount shall be deemed a part of, and set-off against, the financing amount we
will provide AutoMax with upon closing, which is expected to be $4,250,000; or (b) if the definitive agreement for the acquisition is
terminated in accordance with its terms, within three months from such termination date; or (c) July 15, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Underwritten Public
Offering</i><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
August 14, 2023, we closed an underwritten public offering, or the Public Offering, of 212,500 ordinary shares, at a purchase price of
$5.20 per ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded
warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between us and Aegis, or the
Underwriter, on August 10, 2023. Pursuant to the terms of the Underwriting Agreement, we also granted the Underwriter a 45-day option
to purchase up to an additional 37,500 ordinary shares solely to cover over-allotments, if any, at the Public Offering share price less
underwriting discounts and commissions.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.026 per share. Following the Public Offering
and as of March 28, 2024, the Company issued 25,000 ordinary shares in respect of the exercise of 25,000 pre-funded warrants.</span>&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>October 2023 Private
Placement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 12, 2023, we closed
a private placement transaction, or the 2023 Private Placement, pursuant to a securities purchase agreement and a registration rights
agreement with an institutional investor for aggregate gross proceeds of approximately $5 million (representing a 30% original issue discount
to the aggregate purchase price of $7,180,000), before deducting fees to Aegis, the placement agent and other expenses payable by the
Company in connection with the transaction. We sold units to the investors at a purchase price of $3.72 per unit, consisting of 1,930,108
pre-funded Ordinary Share purchase warrants to purchase up to 1,930,108 Ordinary Shares, and an additional accompanying pre-funded warrant
to purchase up to 1,930,108 Ordinary Shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pre-funded warrants were
exercisable immediately upon issuance and have an exercise price of $0.001 per share. Following the transaction and as of March 28, 2024,
we have issued 1,078,991 Ordinary Shares in respect of the exercise of 1,078,991 pre-funded warrants.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>January 2024 Standby
Equity Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 21, 2024, we entered
into a standby equity purchase agreement, or the SEPA, with YA II PN, LTD, or YA. Pursuant to the SEPA, we will be able to sell up to
$20.0 million of our Ordinary Shares, at our sole option, any time during the three-year period following the execution date of the SEPA.
Of the $20.0 million eligible to be sold pursuant to the SEPA, to date we have sold 925,159 Ordinary Shares to YA pursuant to the SEPA.
Pursuant to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of the market price, which is defined as the lowest
daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing on the trading day immediately
following our delivery of an advance notice to YA, or the Advance Price. Any sale of Ordinary Shares pursuant to the SEPA is subject to
certain limitations, including that YA is not permitted to purchase any Shares that would result in it owning more than 9.99% of the Company&#8217;s
Shares.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share Buyback Program </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 6, 2022, we announced
that our board of directors authorized a $1 million buyback program for our Ordinary Shares. However, as of the date of this Annual Report
we have not proceeded with the buyback program and do not currently intend to do so. If we wish to effect the buyback program in the future,
Israeli law requires us to file a motion seeking a court approval in Israel for the buyback program and the effectiveness of the buyback
plan, if formally approved, will be contingent upon such approval. However, as a company listed on an exchange outside of Israel, court
approval is not required, provided we notify our creditors of the proposed buyback and allow such creditors an opportunity to initiate
a court proceeding to review the buyback. If within 30 days such creditors do not file an objection, then we may proceed without obtaining
court approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
to date primarily through proceeds from sales of our Ordinary Shares and ADSs as well as exercises of warrants and options to purchase
Ordinary Shares or ADSs, as the case may be. We have incurred losses and generated negative cash flows from operations since August 2004.
Since August 2004, we have not generated any revenue from the sale of pharmaceutical product candidates and we do not expect to generate
revenues from sale of our pharmaceutical product candidates in the next few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, our
cash, including short-term bank deposits, was $5,076 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our existing
cash resources will not be sufficient to finance our operating activities in the foreseeable future; however, we expect that we will require
substantial additional capital to complete the development of, and to commercialize, our product candidates. If we do seek to raise additional
capital, there can be no guarantee or assurance that we will be successful in raising such additional capital or that the term of such
capital raise will be on terms favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we&#160;purchased
Wellution&#8482;, a business and brand which sells hemp-based products on the Amazon.com marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, we announced
that our board of directors resolved to pursue a Restructuring Plan which may involve transferring our pharmaceutical activities to NewCo.
As part or independent of the Restructuring Plan, we intend to examine the possibility of listing NewCo on a leading stock exchange, while
maintaining our controlling interest in NewCo such that we will continue to control our current business activities. We also intend to
explore other potential new opportunities, activities and investments in a variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Restructuring Plan and
possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other business analyses,
regulatory approvals, receipt of any necessary consents, final approvals from our board of directors and shareholders and satisfaction
of any closing conditions to effectuate such corporate Restructuring Plan and listing of NewCo. There can be no assurance regarding the
ultimate timing of the Restructuring Plan and listing of NewCo or that they will be completed at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional financing sooner
than planned. Our efforts to commercialize our proprietary PEA oral tablets CannAmide&#8482; may not lead to any revenue or revenue at
the level at which we are expecting. Our future capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of our research and development activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through debt and/or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. This raises substantial doubts about our ability to continue as a going
concern.&#160;If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans
for, or commercialization efforts with respect to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Research and development, patents and licenses,
etc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item
5. Operating and Financial Review and Prospects-A. Operating Results-Operating Expenses-Research and Development Expenses, net&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects-A. Operating Results-Comparison of the year ended December 31, 2023 to
the year ended December 31, 2022-Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Trend information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trends impacting us are
described elsewhere in this Annual Report on Form 20-F, including in &#8220;Item 3.D. Risk Factors&#8221;, &#8220;Item 4.B. Business Overview&#8221;,
&#8220;Item 5.A. Operating Results&#8221;, &#8220;Item 5.B. Liquidity and Capital Resources&#8221;, and &#8220;Item 10.C. Material Contracts&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>E.
Critical Accounting Estimates</b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant
accounting policies more fully in Note 2 and the significant accounting judgments, estimates and assumptions used in the preparation of
the financial statements in Note 3 to our financial statements for the year ended December 31, 2023. We believe that the accounting policies
below are critical in order to fully understand and evaluate our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with IFRS. At the time of the preparation of the financial statements, our management is required to use estimates, evaluations,
and assumptions which affect the application of the accounting policy and the amounts reported for assets, obligations, income, and expenses.
Any estimates and assumptions are continually reviewed. The changes to the accounting estimates are credited during the period in which
the change to the estimate is made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, our
cash and cash equivalents totaled $2.1 million. In the period ended December 31, 2023, we had an operating loss of $5.9 million and negative
cash flows from operating activities of $5.9 million. Our current cash and cash equivalents position is not sufficient to fund our planned
operations for at least a year beyond the date of the filing date of the financial statements. The ability to continue as a going concern
is dependent upon our obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business
operations when they become due. While we have successfully raised funds in the past, there is no guarantee that we will be able to do
so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences
on our financial condition and results of operations. In addition, we have started recognizing revenues from sales. However, our pharmaceutical
operations are dependent on our ability to raise additional funds from existing and/or new investors. This dependency will continue until
we are able to completely finance our operations by generating revenue from our products. These above-mentioned factors raise substantial
doubt about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Intangible Assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately acquired intangible
assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets with a finite
useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contingent Liabilities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The evaluations of provisions
and contingent liabilities are based on best professional judgment, taking into consideration the stage of the proceedings, as well as
cumulative legal experience in the various topics. Whereas the results of the lawsuits shall be determined by the courts, these results
may differ from these evaluations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Share-Based Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees and other service
providers are entitled to benefits by way of share-based compensation settled with company options to shares. The cost of transactions
with employees settled with capital instruments is measured based on the fair value of the capital instruments on the granting date. The
fair value is determined using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding
expected volatility, expected lifespan, expected dividend, and a no risk interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of the transactions
settled with capital instruments is recognized in profit or loss together with a corresponding increase in the equity over the period
in which the performance and/or service takes place, and ending on the date on which the relevant employees are entitled to the benefits,
or the Vesting Period. The aggregate expense recognized for transactions settled with capital instruments at the end of each reporting
date and until the Vesting Period reflects the degree to which the Vesting Period has expired and our best estimate regarding the number
of options that have ultimately vested. The expense or income in profit or loss reflects the change of the aggregate expense recognized
as of the end of the reported period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the Black-Scholes
option-pricing model as a fair value method for our options awards. The option-pricing model requires a number of assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected dividend yield</i>
- The expected dividend yield assumption is based on our historical experience and expectation of no future dividend payouts. We have
historically not paid cash dividends and have no foreseeable plans to pay cash dividends in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Volatility </i>- The expected
volatility is based on fluctuations in the price of our Ordinary Share prices on the Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk free interest rate
</i>- The risk free interest rate is based on the U.S. Treasury yield curve, in accordance with the option&#8217;s contractual term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Contractual term </i>-
An option&#8217;s contractual term must at least include the Vesting Period and the employees&#8217; historical exercise and post-vesting
employment termination behavior for similar grants. If the amount of past exercise data is limited, that data may not represent a sufficiently
large sample on which to base a robust conclusion on expected exercise behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Share price </i>- The share
price is determined according to the last known or above closing price of our Ordinary Shares at the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Directors and Senior Management </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of March 28, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 58%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Director </span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technologies Officer</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Dayan<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach<sup>(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi<sup>(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation Committee </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (as determined by our Board of Directors, pursuant to the definition prescribed to such term under Nasdaq Stock Market rules)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Itschak Shrem </i>was
appointed to serve as our President in January 2022, prior to which he served as our Chairman from August 2020 to January 2022. Mr. Shrem
has more than 40 years of experience in financial markets and venture capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an investment
banking, management and technology company. Prior to that, he spent 15 years at Clal Israel Ltd., where he served in various capacities,
including chief operating officer, and was responsible for capital markets and insurance businesses. In 1993, Mr. Shrem founded Pitango
Venture Capital Fund (formerly, Polaris) and served as a partner of Pitango Funds I, II and III. He has been the Managing Director of
Yaad Consulting 1995 Ltd. since 1995. Previously, Mr. Shrem served on the board of Tel-Aviv Sourasky Medical Center, the Weizman Institute
Eden Spring Ltd., Rail Vision Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as chairman of Sphera Funds Management
Ltd. Mr. Shrem holds a B.A. in Economics and Accounting from Bar-Ilan University and an M.B.A. from Tel-Aviv University.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Amitay Weiss </i>has
served on our Board of Directors since August 2020 and as our Chairman since January 2022. Mr. Weiss served as our Chief Executive Officer
from August 2020 to January 2022. Mr. Weiss currently serves as chairman of the board of directors of Automax Motors Ltd. (TASE: AMX.TA),
as a director of Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR) and as an external director of Cofix Group Ltd. (TASE: CFCS). Mr. Weiss also
chairs and serves as director on the board of director of several public and private companies, including, Clearmind (Nasdaq: CMND), Maris
Tech Ltd. (Nasdaq: MTEK) and Save Foods Inc. (Nasdaq: SVFD). In 2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now serves as
its chief executive officer. From 2001 until 2015, Mr. Weiss served as vice president of business marketing &amp; development and in various
other positions at Bank Poalei Agudat Israel Ltd. from the First International Bank of Israel group. Mr. Weiss holds a B.A. in economics
from New England College, an M.B.A. in business administration from Ono Academic College in Israel, an Israeli branch of University of
Manchester and an LL.B. from the Ono Academic College.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Oz Adler, CPA, </i>was
appointed to serve as our Chief Executive Officer in January 2022 and has served as our Chief Financial Officer since April 2018 and previously
held served as our VP Finance from March 2018 until April 2018 and as our Controller from September 2017 to March 2018. Mr. Adler has
experience in a wide variety of managerial, financial, tax and accounting roles. Mr. Adler currently serves on the board of directors
of numerous private, such as Polyrizon Ltd., and public companies, including Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR), Rail Vision Ltd.
(Nasdaq: RVSN) and Clearmind (Nasdaq: CMND), (FSE: CWY), and previously served as the chief financial officer of Medigus Ltd. (Nasdaq:
MDGS) from December 2020 to April 2021. From 2012 until 2017, Mr. Adler was employed as a certified public accountant at Kost Forer Gabbay
&amp; Kasierer, a member of Ernst &amp; Young Global. Mr. Adler holds a B.A. in Accounting and Business management from The College of
Management, Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Adi Zuloff-Shani</i>,
PhD, has served as our Chief Technologies Officer since February 2016. Dr. Zuloff-Shani has more than 20 years of experience as a research
and development executive. Prior to joining us, and from 2012 to 2016, Dr. Zuloff-Shani served as a vice president development at Macrocure
Ltd. (Nasdaq: MCUR) where besides leading all research and development activities, she interacted and was involved with the activities
of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs. Dr. Zuloff-Shani
currently serves as the Chief Executive Officer of Clearmind (Nasdaq: CMND), (FSE: CWY). She has served as the Chairman of Orsus Therapeutics,
Inc. since November 2022, as a member of the scientific advisory board of Save Foods Inc. (Nasdaq: SAFD) since October 2021 and as a director
of MitoCareX since May 2022. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University, Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Amnon Ben Shay</i>
has served as a member of our Board of Directors since January 2021 and served as our external director under the Companies Law between
January 2021 and January 2022. Mr. Ben Shay has been chief financial officer of Aerodrome Group Ltd since October 2022. Mr. Ben Shay previously
served on the board of directors of Azorim Investments and Building Development Company Ltd. (TASE: AZRM), Value Capital One Ltd. (TASE:
VALU) and B.G.I. Investments (1961) Ltd. (TASE: BGI). Mr. Ben Shay was chief financial officer of Hadar Hasharon Marketing and Distributions
Ltd. from February 2019 to October 2022. From February 2017 to January 2019, Mr. Ben Shay served as the chief financial officer of Fridenson
Air &amp; Ocean Ltd. From January 2014 to January 2017, Mr. Ben Shay served as the chief financial officer of Abetrans Logistics Ltd.
Prior to that, Mr. Ben Shay served as the chief financial officer of Isline Export and Import Services Ltd. from 2010 to 2013. Prior to
the year 2009, Mr. Ben Shay served as the chief financial officer of several Israeli real estate investment groups. Mr. Ben Shay holds
a B.A. in economics and business and an M.B.A in business, both from The Hebrew University of Jerusalem, Israel, and an accounting certificate
from The College of Management Academic Studies, Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Alon Dayan</i> has
served as a member of our Board of Directors since January 2021 and served as our external director under the Companies Law between January
2021 and January 2022. Mr. Dayan is the founder of L1-Systems Ltd. and has served as its chief executive officer since 2014 and is also
the founder of Virtual Crypto Technologies Inc. (OTC: VBIX), a company he served as chief executive officer from 2018 to 2019. Mr. Dayan
is currently director at Viewbix Inc. Prior to that, he served as a business development manager at Elbit Systems Ltd. from 2006 to 2013.
Mr. Dayan holds a B.A. in electronical engineering from Ariel University, Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr.&#160;Moshe Revach</i>&#160;has
served as a member of our board of directors since September 2022. Mr. Revach also previously served as our director since August&#160;2020
until his resignation on March&#160;13, 2022. Mr.&#160;Revach has served as vice-counselor of the Ramat Gan municipality and has been
on its financial committee since March 2024. Mr.&#160;Revach serves as a director of L.L.N IT solutions, a wholly owned&#160;subsidiary
of the Jewish Agency for Israel, RPG Economic Society, ParaZero Technologies Ltd. (Nasdaq: PRZO), Plantify Foods Inc (CVE: PTFY), and
Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR). Mr.&#160;Revach previously served as a director of Biomedico Hadarim, and Jewish Experience Company
on behalf of the Jewish Agency and also served as deputy mayor of Ramat Gan, Israel from 2013 to 2023, while also heading the sports and
government relations departments in the Ramat Gan municipality. Mr.&#160;Revach holds an LL.B from the Ono Academic College, Israel, and
a B.A. in management and economics from the University of Derby.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Liat Sidi</i> has served
as our Director since August 2020. Ms. Sidi serves as the manager of the accounting department for Foresight Autonomous Holdings Ltd.
(Nasdaq and TASE: FRSX) and has served as director for Save Foods Inc. (Nasdaq: SVFD) since November 2023. Ms. Sidi previous served as
director for Plantify Foods Inc (CVW: PTFY) from September 2023 to January 2024. Ms. Sidi previously served as an accountant for Panaxia
Labs Israel Ltd. (TASE: PNAK) from 2015 to 2020 and as an accountant for Soho Real Estate Ltd. from 2015 to 2016. Ms. Sidi also served
as an accountant for Feldman-Felco Ltd. from 2006 to 2010 and as an accountant for Eli Abraham accounting firm from 2000 to 2006. Ms.
Sidi completed tax, finance and accounting studies in Ramat Gan College of Accounting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Lior Vider</i> has
served as our Director since August 2020. Mr. Vider has served as investment manager at Finessa Capital since November 2023. Mr. Vider
previously served as chief investment manager for Impact Investment Management Ltd., from the Union Bank group, from 2007 to 2010 and
as chairman of the board of directors and a member of the group&#8217;s investment committee of Rahkia Capital Markets Ltd. from 2006
to 2007. Mr. Vider also served as a director at Endymed Medical Ltd. and Apollo Power Ltd. Mr. Vider founded and managed sponser.co.il,
a financial portal specializing in services for investors from 2005 to 2017. Mr. Vider holds a B.A. in industry and management engineering
from Shenkar College in Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of eleven award winning and active physicians and scientists in the field(s) of: psychiatry and child psychiatry, TS, neurology,
Alzheimer&#8217;s disease, hospice and palliative medicine neurobiology, pharmacology and neuropsychopharmacology, organic and medicinal
chemistry, cannabinoids and drug discovery. We consult with the members of our Scientific Advisory Board on a regular basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Elon Eisenberg,</i>
is the Dean of the Faculty of Medicine at the Technion - Israel Institute of Technology. Prof. Eisenberg is a Professor of Neurology and
Pain Medicine at the Faculty of Medicine and holds the Otto Barth Family Academic Chair in Biomedical Science. Prof. Eisenberg graduated
from Sackler School of Medicine, Tel-Aviv University in Israel. Prof. Eisenberg completed a residency in Neurology, at Rambam Medical
Center, Haifa, Israel, and Neurology - Pain Fellowship at Massachusetts General Hospital, Harvard Medical School in Boston, USA. Prof.
Eisenberg has been the director of the Institute of Pain Medicine at Rambam Health Care Campus, Haifa, Israel, and the President of the
Israeli Pain Association. Prof. Eisenberg is currently the director of the Pain Research Unit at the Institute of Pain Medicine, Rambam
Health Care Campus. H Prof. Eisenberg&#8217;s main areas of research include mechanisms and treatment of pain with special emphasis on
neuropathic pain, CRPS, cancer pain, opioids and cannabinoids. Prof. Eisenberg has published about two-hundred articles, book chapters
and other manuscripts in various&#160;areas&#160;of&#160;pain.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. James Leckman, M.D.</i>
is the Neison Harris Professor of Child Psychiatry, Psychiatry, Psychology and Pediatrics at Yale University. Prof. Leckman is a well-known
child psychiatrist and patient-oriented clinical investigator. For more than 20, years he served as the Director of Research for the Yale
Child Study Center. His peers have regularly selected him as one of the Best Doctors in America. Dr. Leckman is the author or co-author
of over 430 original articles published in peer-reviewed journals, twelve books, and 140 book chapters. Dr. Leckman has a longstanding
interest in Tourette syndrome and Obsessive-Compulsive Disorder (OCD). His research on these disorders is multifaceted from phenomenology
and natural history, to neurobiology to genetics, to risk factor research and treatment studies. One area of active research interest
concerns the role of the immune system in the pathobiology of Tourette syndrome and other neuropsychiatric disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Michael Davidson
</i>currently serves, among other things, as Chairman of the Israeli Medical Centre for Alzheimer&#8217;s Disease Care and Research in
Ramat Gan and Chairman of the department of psychiatry at the Nicosia University Medical School. Prof. Davidson served as Chief Psychiatrist
at the Department of Psychiatry of the Sheba Medical Centre in Tel-Hashomer for six years. Prof. Davidson holds a secondary professorship
at the Sackler School of Medicine of Tel Aviv University and at the Mount Sinai School of Medicine in New York. Prof. Davidson is considered
an international expert on Alzheimer&#8217;s disease and schizophrenia is the author of approximately 350 publications in scientific literature.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Daniele Piomelli</i>
serves as the Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry
at University of California, Irvine. Prof. Piomelli is also the founding director of the drug discovery and development unit (D3) at the
Italian Institute of Technology in Genoa, Italy, as well as the Editor in Chief of Cannabis and Cannabinoid Research of Cannabis and Cannabinoid
Research. Prof. Piomelli&#8217;s research has resulted in several contributions to the pharmacology of lipid based signaling molecules
including endocannabinoid substances and lipid amides. Prof. Piomelli is the author of more than 400 peer reviewed articles and books
and has received several awards and honors. Prof. Piomelli studied Pharmacology and Neuroscience at Columbia University, and the Rockefeller
University, and earned his degree of Doctor of Pharmacy from University of Naples.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Kirsten M&#252;ller-Vahl
</i>is a Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School, Germany.
Prof. M&#252;ller-Vahl is a specialist in both neurology and adult psychiatry. She serves as the head of the TS outpatient department
and over the past twenty-five years, Prof. M&#252;ller-Vahl has investigated more than 4000 patients with TS, both children and adults.
She serves on the scientific advisory board of the German Tourette Syndrome Association and is the current president of the European Society
of the study of Tourette syndrome (ESSTS), the national German Association for Cannabinoid Medicines (ACM) as well as the International
Alliance for Cannabinoid Medicines (IACM). Her scientific work related to TS includes a large number of clinical trials funded by the
EU (TS-EUROTRAIN: FP7-PEOPLE-2012-ITN, No. 316978; EMTICS: EU FP7-HEALTH-2011, 278367), by the NIMH (TIC-GENETICS (1R01MH115958-01), by
the German ministry of education and research (BMBF) (ONLINE-TICS: 01KG1421) and the German Research Foundation (DFG) (CANNA-TICS: NCT03087201).
At the 9th IACM Conference on Cannabinoids in Medicine in 2017 she received the &#8220;IACM Award 2017 for Clinical Research&#8221; for
her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine. Prof. M&#252;ller-Vahl has published
more than 180 scientific articles, is the author of several book chapters and the leading German textbook on TS, and co-editor of the
leading German textbook on cannabis-based medicine. She is author of several guidelines on TS including ESSTS guidelines and treatment
guidelines published by the American Academy of Neurology (AAN).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Avi Weizman</i> is
a Professor of Child and Adult Psychiatry at the Sackler Faculty of Medicine of Tel Aviv University, a former Director of the Felsentein
Medical Research Center and the head of the Laboratory for Biological and Molecular Psychiatry and the head of the Research Unit at the
Geha Mental Health Center. Prof. Weizman&#8217;s research involves the investigation of brain mechanisms of mental disorders. Currently,
it focuses on neurodevelopmental disorders, the development of new strategies for treating psychotic disorders, and the psychopharmacology
of mental disorders. Prof. Weizman is the author of more than 760 original papers, five full books, 28 book chapters, and 60 review articles.
After completing his residency in Psychiatry, Prof. Weizman spent two years as a visiting scientist at the National Institute of Mental
Health in&#160;Bethesda,&#160;MD.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Michael H. Bloch, M.D.,
M.S.</i> graduated from Yale School of Medicine and completed his child and adult psychiatry training at Yale. His research interests
focus on studying Tourette syndrome, obsessive-compulsive disorder (OCD) and trichotillomania (TTM) across the lifespan and developing
better pharmacological treatments for children with depression, anxiety and ADHD. His research focuses on developing better treatments
for children and adults with these conditions particularly through clinical trials and meta-analysis. He has over 200 peer-reviewed publications
and is currently the Research Review Editor for the Journal of Child Psychology and Psychiatry. He also serves on the scientific advisory
boards of the Tourette Association of America and the TLC Foundation for Body-Focused Repetitive Behaviors. <i>Prof. Saoirse O&#8217;Sullivan,
PhD</i> received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow
where she began researching cannabinoid pharmacology through basic and clinical research. She was made Lecturer in 2007 and Associate
Professor in 2011 and Full Professor in 2019. Prof. O&#8217;Sullivan has over 40 peer reviewed articles, six reviews and three books chapters
on the topic of cannabinoid pharmacology, with specific interests on the cardiovascular and gastrointestinal effects of cannabinoids and
therapeutic potential of cannabis-based medicines. Prof. O&#8217;Sullivan&#8217;s research methodologies span from cellular and animal
models to human healthy volunteer studies and early phase clinical trials. In 2016, Prof. O&#8217;Sullivan was named the International
Cannabinoid Research Society Young Investigator of the year. Prof. O&#8217;Sullivan now runs an independent consulting company called
CanPharmaConsulting Ltd, and through this, acts as scientific advisor to Therapix Biosciences, Artelo Biosciences, Inc., CBD Science Group
PLC, FSD Pharma Inc., and Dragonfly Biosciences Ltd. She is the science lead for the Centre for Medicine Cannabis, working to shape the
UK&#8217;s new medicinal cannabis regime for patients. She is also secretary to the International Cannabinoid Research Society.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Mellar P. Davis, MD,
FCCP FAAHPM </i>is a Professor of Palliative Medicine, the Geisinger Commonwealth School of Medicine and a member of the Palliative Care
Department, and Section Head, Geisinger Medical System Danville, PA. He has been a member of the Geisinger Medical Staff since August
2016. In his role as Section Head, Dr. Davis is responsible for developing palliative care services throughout the Geisinger Medical System
including outpatient and inpatient services. In addition, Dr. Davis works with the Geisinger Hospice Services to develop and coordinate
care within the central region. Dr. Davis was a member of the Cleveland Clinic Palliative Care section, Taussig Cancer Institute and fellowship
director until joining the Geisinger Medical System. Dr. Davis was the co-chair of the Palliative Care Study Group of the Multinational
Association of Supportive Care (MASCC) and a past board member since 2010. Dr. Davis has been a Professor of Medicine in The Cleveland
Clinic Lerner College of Medicine, Case Western Reserve University, since 2009 and was elected as a Fellow to the American Academy of
Hospice and Palliative Medicine in 2010. Dr. Davis is Editor in Chief of Progress on Palliative Care. Dr. Davis&#8217; present duties
are as the Associate Editor in Chief of PC Fast Article Critical Summary for Clinicians in Palliative Care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Avi Schroeder</i>
is the head of the Targeted Drug Delivery and Personalized Medicine Group, at the Technion, Israel Institute of Technology, and has translational
research experience with the development of liposome-based clinical systems. He is the author of 60 scientific papers in the field of
nanotechnology and medicine and is the inventor on 17 patents, and a recipient of 30 national and international innovation awards. Prof.
Schroeder is a scientific entrepreneur, starting multiple successful Technion spin-outs. Prof. Schroeder received three degrees in Chemical
Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took&#160;place&#160;at&#160;MIT.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements for Election of Directors and
Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not a party to, and
there are no arrangements or voting agreements that we are aware of for the election of our directors and members of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our directors and senior management, as a group for the year ended December 31, 2023.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect the cost to the Company, in thousands of U.S. Dollars, for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-style: italic">USD in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary/Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension,<br/> Retirement<br/> and Other <br/> Similar<br/> Benefits<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-<br/> Based<br/> Compensation<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">All directors and senior management as a group, consisting of 9 persons</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,114</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the directors and senior management&#8217;s payment of mandatory social benefits made by the Company on behalf of such officer. Such benefits may include, to the extent applicable to the executive, payments, contributions and/or allocations for savings funds, education funds (referred to in Hebrew as &#8220;<i>Keren Hishtalmut</i>&#8221;), pension, severance, risk insurances (e.g., life or work disability insurance) and payments for social security.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed based on fair value for Ordinary Shares options granted and estimated using the Black-Scholes option pricing model.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, the table below reflects the compensation granted to our five most highly compensated officers or directors during or with respect
to the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Annual Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Executive Officer</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary/Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pension,<br/>
 Retirement<br/>
 and Other<br/>
 Similar<br/> Benefits</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share- <br/> Based<br/> Compensation&#160;<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">USD in thousands</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Amitay Weiss <br/> <i>Chairman and Former Chief
    Executive Officer</i></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;219</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Dr.
    Adi Zuloff-Shani</span> <br/>Chief Technologies Officer</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Oz Adler <br/> <i>Chief Executive Officer and Chief Financial
    Officer</i></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">379</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Itschak Shrem <br/> <i>President and Former Chairman</i></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-style: normal; font-weight: normal">Lior
    Vider</span> <br/>Director</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation includes the cost of our non-cash share-based compensation in 2023.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Services Agreements with
Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements and/or consulting agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. Most of these agreements are terminable by either party upon 30 days&#8217; prior written
notice. However, a longer 90 day notice period is required with respect to each of our executive officers. In addition, we have entered
into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount
and to the extent that these liabilities are not covered by directors and officers insurance. Members of our senior management are eligible
for bonuses each year, subject to a pre-determined target-based bonus plan, which is usually set during the first quarter of each calendar
year following the recommendation of our compensation committee and the approval of our Board of Directors. The annual bonuses are payable
upon meeting objectives and targets that are set by our Chief Executive Officer and compensation committee and approved annually by our
Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of the terms
of our options and option plans, see Item 6.E. &#8220;Share Ownership<span style="font-variant: small-caps">&#8221; </span>below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by the Companies
Law, our compensation committee and Board of Directors approved, and recommended to the shareholders of the Company to approve, amended
terms of compensation of our Chief Executive Officer, Mr. Oz Adler, our President, Mr. Itschak Shrem, and our and Chairperson of the Board
of Directors, Mr. Amitay Weiss, as set forth below. Such terms are in line with our Compensation Policy and were approved by the Company&#8217;s
shareholders on February 10, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">President and Chairperson of the Board of Directors</span> - a monthly fee in the amount of NIS 52,500 (approximately $14,919) and an annual target bonus of up to six monthly salaries, or eight in the case of overachievement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Chief Executive Officer </span>- a monthly fee in the amount of NIS 66,000 (approximately $18,755) and an annual target bonus of up to six monthly salaries, or eight in the case of overachievement, plus applicable pension, retirement and other similar benefits.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Directors&#8217; Service Contracts</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have written agreements
with any director providing for benefits upon the termination of his/her employment with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Board Practices </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Governance Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an Israeli company, we
are subject to various corporate governance requirements under the Companies Law. However, pursuant to regulations promulgated under the
Companies Law, companies with shares traded on certain U.S. stock exchanges, including the Nasdaq, may, subject to certain conditions,
&#8220;opt out&#8221; from the requirements to appoint external directors and related rules concerning the composition of the audit committee
and compensation committee of the board of directors, other than the gender diversification rule, which requires the appointment of a
director from the other gender if, at the time a director is appointed, all members of the board of directors are of the same gender.
In accordance with these regulations, following our listing on the Nasdaq, in January 2022, we elected to &#8220;opt out&#8221; from these
requirements of the Companies Law. Under these regulations, the exemptions from such Companies Law requirements will continue to be available
to us so long as: (i) we do not have a &#8220;controlling shareholder&#8221;, as such term is defined under the Companies Law, (ii) our
shares are traded on certain U.S. stock exchanges, including the Nasdaq, and (iii) we comply with the director independence requirements
and the audit committee and compensation committee composition requirements under U.S. laws, including the rules of the applicable exchange,
that are applicable to U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;foreign private
issuer&#8221;, as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we are permitted to comply with
Israeli corporate governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirement. As a foreign private issuer, we are exempt under the Exchange Act from, among
other things, the rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information regarding
our corporate governance practices and foreign private issuer status, see &#8220;Item 16.G Corporate Governance&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors presently
consists of seven members. Nasdaq listing standards require that a majority of our Board of Directors be independent. These standards
provide, among other things, that a person will be considered an independent director if he or she is not an officer of the company and
is, in the view of the company&#8217;s board of directors, free of any relationship that would interfere with the exercise of independent
judgment. We believe that Mr. Vider, Ms. Sidi, Mr. Ben Shay, Mr. Revach and Mr. Dayan are all currently considered &#8220;independent&#8221;
for purposes of the Nasdaq rules. As such, our Board of Directors is comprised of a majority of independent directors as such term is
defined in the Nasdaq rules. Our amended and restated articles of association provide that the number of directors shall be set by the
general meeting of the shareholders provided that it will consist of not less than three and not more than 12 directors. Pursuant to the
Companies Law, the overall planning and management of our business is vested in our Board of Directors. Our Board of Directors may exercise
all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are
responsible for our day-to-day management and have individual responsibilities established by our Board of Directors. Our Chief Executive
Officer is appointed by, and serves at the discretion of, our Board of Directors. All other executive officers are appointed by the Board
of Directors or by our Chief Executive Officer, provided that he was authorized by the Board of Directors to do so. Their terms of employment
are subject to the approval of our Board of Directors&#8217; Compensation Committee (see &#8220;-Compensation Committee<span style="font-variant: small-caps">&#8221;</span>)
and of the Board of Directors (and in case the terms are not compatible with the provisions of the compensation policy, to our shareholders&#8217;
approval as well), and are subject to the terms of any applicable employment agreements that we may enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one third of the total
number of directors constituting the entire board of directors. At each annual general meeting of our shareholders, the election or re-election
of directors following the expiration of the term of office of the directors of that class of directors is for a term of office that expires
on the third annual general meeting following such election or re-election, such that at each annual general meeting the term of office
only one class of directors will expire. Each director holds office until the annual general meeting of our shareholders for the year
in which his or her term expires and until his or her successor is duly appointed, unless the tenure of such director expires earlier
pursuant to the Companies Law upon the occurrence of certain events or unless removed from office by a vote of the holders of at least
65% of the total voting power of our shareholders at a general meeting of our shareholders in accordance with our amended and restated
articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
among the three classes as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class I directors consist of Ms. Liat Sidi and Mr. Amnon Ben Shay, and their terms will expire at our annual general meeting of shareholders to be held in 2024;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class II directors consist of Mr. Alon Dayan, Mr. Moshe Revach and Mr. Lior Vider and their terms will expire at our annual general meeting of shareholders to be held in 2025; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class III directors consist of Mr. Amitay Weiss and Mr. Itschak Shrem and their terms will expire at our annual general meeting of shareholders to be held in 2026.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our amended and
restated articles of association allow our Board of Directors to appoint directors to fill vacancies on our Board of Directors or in addition
to the acting directors (subject to the limitation on the number of directors and their qualifications), until the next general meeting
in which directors may be appointed or such appointment terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, nominations
for directors may be made by any shareholder holding at least 5% of our outstanding voting power. However, any such shareholder may make
such a nomination only if a written notice of such shareholder&#8217;s intent to make such nomination has been given to our Board of Directors.
Any such notice must include certain information, a description of all arrangements between the nominating shareholder and the proposed
director nominee(s) and any other person pursuant to which the nomination(s) are to be made by the nominating shareholder, the consent
of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s) declaring that there
is no limitation under the Companies Law preventing their election and that all of the information that is required to be provided to
us in connection with such election under the Companies Law has been provided.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
Board of Directors must determine the minimum number of directors who are required to have accounting and financial expertise. Our Board
of Directors has determined that the minimum number of directors of our company who are required to have accounting and financial expertise
is one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors is
required to elect one director to serve as the Chairman of the Board of Directors to preside at the meetings of the Board of Directors
and may also remove that director as Chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her
relatives is permitted to serve as the Chairman of the Board of Directors, and a company may not (subject to a certain time-limited exemption,
as described below) vest the Chairman or any of his or her relatives with the chief executive officer&#8217;s authorities. In addition,
a person who reports, directly or indirectly, to the chief executive officer may not serve as the Chairman of the Board of Directors;
the Chairman may not be vested with authorities of a person who reports, directly or indirectly, to the chief executive officer; and the
Chairman may not serve in any other position in the company or a controlled company, but he or she may serve as a director or chairman
of a controlled company. However, and notwithstanding the foregoing, the Companies Law permits the shareholders of a company to determine,
for periods not exceeding three years from each such determination, that the Chairman or his or her relative may serve as chief executive
officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or his or her relative
may serve as Chairman or be vested with the Chairman&#8217;s authorities. Such determination of a company&#8217;s shareholders requires
either: (1) the approval of at least the majority of the shares of those shareholders present and voting on the matter (other than controlling
shareholders and those having a personal interest in the determination); or (2) that the total number of shares opposing such determination
does not exceed 2% of the total voting power in the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may,
subject to the provisions of the Companies Law, delegate any or all of its powers to committees of the Board of Directors, and it may,
from time to time, revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise
expressly provided by the Board of Directors, the committees shall not be empowered to further delegate such powers. The composition and
duties of our audit committee and compensation committee, are described below. See &#8220;-Committees of the Board of Directors&#8221;
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Role of Board of Directors in Risk Oversight
Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. Our Board of Directors encourages management to promote a culture that incorporates risk management
into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management
meetings, and conducts specific strategic planning and review sessions that include a focused discussion and analysis of the risks we
face. Senior management reviews these risks with the Board of Directors focusing on particular business functions, operations or strategies,
and presents the steps taken by management to mitigate or eliminate such risks. The Board of Directors is assisted in its oversight role
by an internal auditor. The internal auditor undertakes both regular and ad hoc reviews of risk management controls and procedures, the
results of which are reported to our audit committee. See &#8220;-Committees of the Board of Directors-Internal Auditor&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leadership Structure of the Board of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law and our amended and restated articles of association, our Board of Directors is required to appoint one of its members to serve as
Chairman of the Board of Directors. Our Board of Directors has appointed Mr. Amitay Weiss to serve as Chairman of the Board of Directors,
effective January 10, 2022, and subsequently further named as the President of the Company, Mr. Itschak Shrem, the authorities of the
Chairman of the Board of Directors as well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide, consistent with the Companies Law, that any director, and with respect to external directors (to the extent required
under applicable law - see the description of the External Directors Relief Resolution under &#8220;-External Directors&#8221; below)
&#8211; only subject to certain preconditions, may appoint another person to serve as his alternate director, provided such person has
the qualifications prescribed under the Companies Law to be appointed and to serve as a director and is not already serving as a director
or an alternate director of the company. The term of an alternate director may be terminated at any time by the appointing director and
automatically terminates upon the termination of the term of the appointing director. An alternate director has the same rights and responsibilities
as a director. To date there are no alternate director appointments in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, companies
incorporated under the laws of the State of Israel that are &#8220;public companies&#8221; are required to appoint at least two external
directors who meet the qualification requirements under the Companies Law. Pursuant to regulations promulgated under the Companies Law,
companies with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a &#8220;controlling shareholder,&#8221;
may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related
Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors (other than
the gender diversification rule under the Companies Law, which requires the appointment of a director from the other gender if at the
time a director is appointed all members of the board of directors are of the same gender). In accordance with these regulations, in January
2022, following our listing on Nasdaq, our Board of Directors elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint
external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of our
board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company. &#8220;Office holders&#8221; includes the chief executive officer,
general manager, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities
of any of the above positions regardless of that person&#8217;s title, and a director, or a manager directly subordinate to the chief
executive officer or general manager.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability of a given action brought for his approval or performed by him by virtue of his position; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal affairs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any action that constitutes competition with the company&#8217;s business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
February 15, 2022, we filed a lawsuit in the Economic Division of the Tel Aviv Court against six of our former directors, including our
former interim chief executive officer and executive chairman, which included allegations of breaches of their fiduciary duties (duty
of care and duty of loyalty) under the Companies Law. See &#8220;Legal Proceedings&#8221; in Item 8.A below for additional information.</span>&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Approval of Related Party Transactions under
Israeli Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
may approve an action by an office holder from which the office holder would otherwise have to refrain, as described above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder acts in good faith and the act or its approval does not cause harm to the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at which the transaction
is first discussed, any direct or indirect personal interest that he or she may have and all related material information known to him
or her relating to any existing or proposed transaction by the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &#8220;personal interest&#8221;
includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder
with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest
in the matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction is an extraordinary
transaction, the office holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s relatives; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An office holder is not, however,
obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is
not considered an extraordinary transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
extraordinary transaction is a transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not in the ordinary course of business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not on market terms; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law does not
specify neither to who within us nor the manner in which required disclosures are to be made. We require our office holders to make such
disclosures to our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, once
an office holder complies with the above disclosure requirement, the board of directors may approve a transaction between the company
and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association provide otherwise
and provided that the transaction is in the company&#8217;s interest and is performed by the office holder in good faith. If the transaction
is an extraordinary transaction, first the audit committee and then the board of directors, in that order, must approve the transaction.
Under specific circumstances, shareholder approval may also be required. Any director (and any person, in general) who has a personal
interest in an extraordinary transaction, which is considered at a meeting of the board of directors or the audit committee, may not be
present at this meeting or vote on this matter, unless the chairman of the relevant committee or board of directors determines that he
or she should be present in order to present the transaction that is subject to approval. If a majority of the board of directors or the
audit committee, as the case may be, has a personal interest in the approval of a transaction, then all directors may participate in discussions
of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder
approval is also required for such transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, all
arrangements as to compensation and indemnification or insurance of office holders require approval of the compensation committee and
board of directors, and compensation of office holders who are directors must be also approved, subject to certain exceptions, by the
shareholders, in that order. If shareholders of a company do not approve the compensation terms of office holders, other than directors,
the compensation committee and board of directors may override the shareholders&#8217; decision, subject to certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
disclosure requirements that apply to an office holder also apply to a &#8220;controlling shareholder&#8221; of a public company. Extraordinary
transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement
in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly or
indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning
the terms of engagement of a controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office holder or an
employee, require the approval of the audit committee or the compensation committee, as the case may be, the board of directors and a
majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217; meeting.
In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the abovementioned approval every three years; however, such transactions not involving the receipt of services or compensation
can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to regulations promulgated
under the Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors, that would otherwise
require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain determinations of the audit or
compensation committee and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question.
Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, other than
by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of
the voting rights in a company or has the right to appoint the majority of the directors of the company or its general manager. The definition
a &#8220;controlling shareholder&#8221; is deemed to include any shareholder that holds 25% or more of the voting rights in a company
if no other shareholder holds more than 50% of the voting rights in the company. For the purpose of determining the holding percentage
stated above, two or more shareholders who have a personal interest in a transaction that is brought for the company&#8217;s approval
are deemed as joint holders. According to the foregoing, the Companies Law recognizes a situation where there exists a &#8220;controlling
shareholder&#8221; regarding a particular matter or in relation to a particular transaction, although such shareholder would not be considered
to have a controlling interest on an ongoing basis or in any other case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising
its rights and performing its obligations to the company and other shareholders, including, among other things, voting at general meetings
of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of &#8220;related party&#8221; transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from oppressing and discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of oppression of other shareholders,
additional remedies are available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
established two standing committees, both of which (the audit committee and the compensation committee) are mandatory (and to date comprised
of the same members and combined into one functional committee which resides as a unified committee). In addition, occasionally our Board
of Directors may form sub-committees for certain matters on an ad hoc basis, such as a pricing committee or a nomination and corporate
governance committee, with advisory powers only, operating under a framework and guidelines as outlined and defined in advance by our
Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Companies Law Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to appoint an audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Listing Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the corporate governance
rules of Nasdaq, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially
literate and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee, acting
pursuant to a written charter, consists of Mr. Vider, Mr. Ben Shay and Mr. Dayan. Mr. Ben Shay serves as chairperson of our audit committee.
All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC
and the corporate governance rules of Nasdaq. Our Board of Directors has determined that Amnon Ben Shay is an audit committee financial
expert as defined by the SEC rules and has the requisite financial experience as defined by the corporate governance rules of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Audit Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, and making recommendations to the Board of Directors to improve such practices;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) (see &#8220;-Approval of Related Party Transactions under Israeli Law&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment of our auditor;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 122 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether certain acts of an office holder not in accordance with his or her fiduciary duty owed to the company are extraordinary or material and to approve such acts and certain related party transactions (including transactions in which an office holder has a personal interest) and whether such transaction is extraordinary or material under the Companies Law (see &#8220;-Approval of Related Party Transactions Under Israeli Law&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deciding whether to approve and to establish the approval process (including by tender or other competitive proceedings) for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the process of approving of transactions that are not negligible, including determining the types of transactions that will be subject to the approval of the audit committee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted an audit committee
charter setting forth among others, the responsibilities of the audit committee consistent with the rules of the SEC and Nasdaq listing
rules, including, among others, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering and making recommendations to the Board of Directors on our financial statements, reviewing and discussing the financial statements and presenting its recommendations with respect to the financial statements to the Board of Directors prior to the approval of the financial statements by our Board of Directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the Board of Directors in accordance with Israeli law;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our Board of Directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, reviewing regulatory authorities&#8217; findings, receiving reports regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommending to our Board of Directors if so required, and overseeing our policies and procedures regarding compliance with applicable financial and accounting related standards, rules and regulations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Companies Law Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Listing Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
is acting pursuant to a written charter, and consists of Mr. Vider, Mr. Ben Shay and Mr. Dayan. Mr. Ben Shay is the Chairperson of the
compensation committee. Our Board of Directors has determined that each member of our compensation committee is independent under the
corporate governance rules of Nasdaq, including the additional independence requirements applicable to the members of a compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 123 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our Board of Directors: (1) the annual base compensation of our executive officers and directors; (2) annual
incentive bonus, including the specific goals and amount; (3) equity compensation; (4) employment agreements, severance arrangements,
and change in control agreements/provisions; (5) retirement grants and/or retirement bonuses; and (6) any other benefits, compensation,
compensation policies or arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a Compensation Policy. The Compensation Policy must be adopted by the company&#8217;s Board of Directors,
after considering the recommendations of the Compensation Committee. The Compensation Policy is then brought for approval by our shareholders
and is subject to special majority requirements. On February 10, 2022, our shareholders approved our new Compensation Policy, which unless
amended shall remain in effect until February 9, 2025. The duties of the compensation committee also include the administration of the
Company&#8217;s policy for recovery of erroneously awarded compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Policy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
serve as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including
exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The Compensation
Policy must be approved (or reapproved) not longer than every three years, and relate to certain factors, including advancement of the
company&#8217;s objectives, the company&#8217;s business and its long-term strategy, and creation of appropriate incentives for executives.
It must also consider, among other things, the company&#8217;s risk management, size and the nature of its operations. The Compensation
Policy must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the knowledge, skills, expertise and accomplishments of the relevant office holder (director or executive);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the terms offered and the average and median compensation of the other employees of the company, including those employed through manpower companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of disparities in salary upon work relationships in the company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also include the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable compensation and long-term performance and measurable criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which a director or executive would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also consider appropriate incentives from a long-term perspective and maximum limits for severance compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
is responsible for (1) recommending the Compensation Policy to a company&#8217;s Board of Directors for its approval (and subsequent approval
by our shareholders) and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders as
well as functions previously fulfilled by a Company&#8217;s Audit Committee with respect to matters related to approval of the terms of
engagement of office holders, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation policy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the compensation terms of the chief executive officer of the company need not be brought to approval of the shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
Board of Directors of an Israeli public company must also appoint an internal auditor nominated and supervised by the audit committee.
Our internal auditor is Mr. Daniel Shapira, who has been serving as our internal auditor since March 2006. Mr. Shapira is a Certified
Public Accountant and holds a B.A. degree in Economics and Accounting from Bar-Ilan University, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine whether a company&#8217;s actions comply with the law and proper business procedure. Our Chairman acts as the internal auditor&#8217;s
organizational supervisor. The internal auditor will submit his internal auditor&#8217;s work plan for the approval of our audit committee.
The internal auditor may not be an &#8220;interested party&#8221; or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the shares or voting rights of a company, any person or entity that has the right to nominate or appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not our employee, but the managing partner of a firm which specializes in internal auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter by the general
meeting of the shareholders. In case the remuneration of the directors is in accordance with regulation applicable to remuneration of
the external directors then such remuneration shall be exempt from the approval of the general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our amended and restated articles of association, a company may obtain insurance for any of its office holders for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of care to the company or to another person, including a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company&#8217;s interests;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon him or her in favor of another person concerning an act performed by such office holder in his or her capacity as an officer holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other insurable action in accordance with the Companies Law;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder relating to an administrative enforcement proceeding conducted with respect to such office holder including reasonable litigation expenses and attorneys&#8217; fees; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments to the party injured by the violation, in accordance with the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 125 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have liability
insurance providing total coverage of $5 million per claim and in the aggregate for the benefit of all of our directors and officers and
company coverage for securities claims. We also have an excess Side A difference in conditions policy providing a total coverage of $2.5
million per claim and in the aggregate for the benefit of all of our directors and officers for claims against them, which may operate
as a primary coverage in certain cases, subject to policy terms and conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law and our
amended and restated articles of association provide that we may indemnify an office holder against:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s award approved by a court; However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on a company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking must detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder: (i) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (b) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (ii) in connection with a monetary sanction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder or charged to him or her by a court relating to an act performed in his or her capacity as an office holder, in connection with: (1) proceedings that the company institutes, or that another person institutes on the company&#8217;s behalf, against him or her; (2) a criminal charge of which he or she was acquitted; or (3) a criminal charge for which he or she was convicted for a criminal offense that does not require proof of criminal thought;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder relating to an administrative enforcement proceeding conducted with regard to such office holder, including reasonable litigation expenses and including attorneys&#8217; fees;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment to the party injured by the violation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability or expense otherwise permitted as an indemnification by the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association allow us to indemnify our office holders up to a certain amount. The Companies Law also permits a company to undertake
in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her,
as described above, then the undertaking should be limited:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to categories of events that the board of directors determines are likely to occur in light of the operations of the company at the time that the undertaking to indemnify is made; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements, with each of our directors and with certain members of our senior management. Each such indemnification agreement provides
the office holder with indemnification to the fullest extent permitted under applicable law and up to a certain amount, and including
with respect to liabilities resulting from our initial public offering in the United States and any other subsequent public offerings,
and to the extent that the directors and officers insurance do not cover these liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exculpation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in advance
an office holder from his or her liability to the company, in whole or in part, and for damages caused to the company as a result of a
breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation is included
in its articles of association. A company may not exculpate a director from liability arising out of a prohibited dividend or distribution
to shareholders. Our amended and restated articles of association provide that we may exculpate any office holder from liability to us
to the fullest extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into exculpation
agreements with each of our current directors and executive officers undertaking to exculpate and release our office holders from any
and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law and including
with respect to liabilities resulting from our initial public offering in the United States and any other subsequent public offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability
incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity
or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would
not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly
(as opposed to merely negligently); (3) any action taken or omission committed with the intent to derive an illegal personal benefit;
or (4) any fine or forfeit levied against the office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Israeli Share Option Plan (2015); Israeli
Share Option Plan (2005) </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2005, we adopted the
Israeli Share Option Plan (2005), or the 2005 Plan, which was in force for a period of 10 years. Upon the expiration of the 2005 Plan,
we adopted the Israeli Share Option Plan (2015), or the 2015 Plan. There are no options outstanding under our 2005 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>We
no longer grant any awards under the 2015 Plan as it was superseded by the 2023 Share Incentive Plan, or the 2023 Plan, although previously
granted awards remain outstanding. Ordinary shares subject to outstanding options granted under the 2015 Plan that expire or become unexercisable
without having been exercised in full will become available again for future grant under the 2023 Plan. Our board of directors, or a duly
authorized committee of our board of directors administers the 2015 Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2023 Share Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 139.15pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2023 Plan was adopted
by our board of directors on December 28, 2023. The 2023 Plan provides for the grant of equity-based incentive awards to our employees,
directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of the Company
and to promote the success of the Company&#8217;s business. As of March 28, 2024, 1,013,787 &#160;Ordinary Shares were reserved for issuance
under the 2023 Plan.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Shares
Available for Grants.&#160;</i>The maximum number ordinary shares available for issuance under the 2023 Plan is equal to the sum of (i)
1,000,0000 shares and (ii) any shares subject to awards under the 2015 Plan which have expired, or were cancelled, terminated, forfeited
or settled in cash in lieu of issuance of shares or became unexercisable without having been exercised, provided that no more than 1,013,787,
ordinary shares may be issued upon the exercise of Incentive Stock Options. If permitted by our board of directors, shares tendered to
pay the exercise price or withholding tax obligations with respect to an award granted under the 2023 Plan or the 2015 Plan may again
be available for issuance under the 2023 Plan, unless determined otherwise by the Board. Our board of directors may also reduce the number
of ordinary shares reserved and available for issuance under the 2023 Plan in its discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 127 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Administration.&#160;</i>Our
board of directors, or a duly authorized committee of our board of directors, or the administrator, will administer the 2023 Plan. Under
the 2023 Plan, the administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan and any award agreements
or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including the exercise price of
an option award, the fair market value of an ordinary share, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
administrator also has the authority to approve the conversion, substitution, cancellation or suspension under and in accordance with
the 2023 Plan of any or all option awards or ordinary shares, and the authority to modify option awards to eligible individuals who are
foreign nationals or are individuals who are employed outside Israel to recognize differences in local law, tax policy or custom, in order
to effectuate the purposes of the 2023 Plan but without amending the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
administrator also has the authority to amend and rescind rules and regulations relating to the 2023 Plan or terminate the 2023 Plan at
any time before the date of expiration of its ten year term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Eligibility.&#160;</i>The
2023 Plan provides for granting awards under various tax regimes, including, without limitation, in compliance with Section 102 of the
Ordinance, and Section 3(i) of the Ordinance and for awards granted to our United States employees or service providers, including those
who are deemed to be residents of the United States for tax purposes, Section 422 of the Code and Section 409A of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Grants.&#160;</i>All
awards granted pursuant to the 2023 Plan will be evidenced by an award agreement, in a form approved, from time to time, by the administrator
in its sole discretion. The award agreement will set forth the terms and conditions of the award, including the type of award, number
of shares subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if
applicable. Certain awards under the 2023 Plan may constitute or provide for a deferral of compensation, subject to Section 409A of the
Code, which may impose additional requirements on the terms and conditions of such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless
otherwise determined by the administrator and stated in the award agreement, and subject to the conditions of the 2023 Plan, awards vest
and become exercisable under the following schedule: 25% of the shares covered by the award on the first anniversary of the vesting commencement
date determined by the administrator (and in the absence of such determination, the date on which such award was granted) and 6.25% of
the shares covered by the award at the end of each subsequent three-month period thereafter over the course of the following three years;
provided that the grantee remains continuously as an employee or provides services to the company throughout such vesting dates. Each
award will expire ten years from the date of the grant thereof, unless such shorter term of expiration is otherwise designated by the
administrator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Awards.&#160;</i>The
2023 Plan provides for the grant of share options (including Incentive Stock Options and nonqualified stock options), ordinary shares,
restricted shares, RSUs, share appreciation rights and other share-based awards. Options granted under the 2023 Plan to the Company employees
who are U.S. residents may qualify as &#8220;Incentive Stock Options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified
stock options. The exercise price of an option may not be less than the par value of the shares (if the shares bear a par value) for which
such option is exercisable. The exercise price of an Incentive Stock Option may not be less than 100% of the fair market value of the
underlying share on the date of grant or such other amount as may be required pursuant to the Code, and in the case of Incentive Stock
Options granted to ten percent stockholders, not less than 110%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise.</i>&#160;An
option award under the 2023 Plan may be exercised by providing the Company with a written or electronic notice of exercise and full payment
of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the administrator
and permitted by applicable law. An option award may not be exercised for a fraction of a share. With regard to tax withholding, exercise
price and purchase price obligations arising in connection with awards under the 2023 Plan, the administrator may, in its discretion,
accept cash or provide for net withholding of shares in a cashless exercise mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 128 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transferability.&#160;</i>Other
than by will, the laws of descent and distribution or as otherwise provided under the 2023 Plan, neither the options nor any right in
connection with such options are assignable or transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Termination
of Employment.&#160;</i>In the event of termination of a grantee&#8217;s employment or service with the Company or any of its affiliates,
all vested and exercisable awards held by such grantee as of the date of termination may be exercised within three months after such date
of termination, unless otherwise determined by the administrator, but in no event later than the date of expiration of the award as set
forth in the award agreement. After such three-month period, all such unexercised awards will terminate and the shares covered by such
awards shall again be available for issuance under the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
the event of termination of a grantee&#8217;s employment or service with the Company or any of its affiliates due to such grantee&#8217;s
death or permanent disability, or in the event of the grantee&#8217;s death within the three month period (or such longer period as determined
by the administrator) following his or her termination of service, all vested and exercisable awards held by such grantee as of the date
of termination may be exercised by the grantee or the grantee&#8217;s legal guardian, estate or by a person who acquired the right to
exercise the award by bequest or inheritance, as applicable, within one year after such date of termination, unless otherwise provided
by the administrator, but in no event later than the date of expiration of the award as set forth in the award agreement. Any awards which
are unvested as of the date of such termination or which are vested but not then exercised within the one year period following such date,
will terminate and the shares covered by such awards shall again be available for issuance under the 2023 Plan. Notwithstanding any of
the foregoing, if a grantee&#8217;s employment or services with the Company or any of its affiliates is terminated for &#8220;cause&#8221;
(as defined in the 2023 Plan), all outstanding awards held by such grantee (whether vested or unvested) will terminate on the date of
such termination and the shares covered by such awards shall again be available for issuance under the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Voting
Rights.&#160;</i>Except with respect to restricted share awards, grantees will not have the rights as a shareholder of the Company with
respect to any shares covered by an award until the award has vested and/or the grantee has exercised such award, paid any exercise price
for such award and becomes the record holder of the shares. With respect to restricted share awards, grantees will possess all incidents
of ownership of the restricted shares, including the right to vote and receive dividends on such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividends.&#160;</i>Grantees
holding restricted share awards will be entitled to receive dividends and other distributions with respect to the shares underlying the
restricted share award. Any stock split, stock dividend, combination of shares or similar transaction will be subject to the restrictions
of the original restricted share award. Grantees holding RSUs will not be eligible to receive dividend but may be eligible to receive
dividend equivalents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transactions.&#160;</i>In
the event of a share split, reverse share split, share dividend, recapitalization, combination or reclassification of the Company&#8217;s
shares, the administrator in its sole discretion may, and where required by applicable law shall, without the need for a consent of any
holder, make an appropriate adjustment in order to adjust (i) the number and class of shares reserved and available for the outstanding
awards, (ii) the number and class of shares covered by outstanding awards, (iii) the exercise price per share covered by any award, (iv)
the terms and conditions concerning vesting and exercisability and the term and duration of the outstanding awards, (v) the type or class
of security, asset or right underlying the award (which need not be only that of the Company, and may be that of the surviving corporation
or any affiliate thereof or such other entity party to any of the above transactions), and (vi) any other terms of the award that in the
opinion of the administrator should be adjusted; provided that any fractional shares resulting from such adjustment shall be rounded to
the nearest whole share unless otherwise determined by the administrator. In the event of a distribution of a cash dividend to all shareholders,
the administrator may determine, without the consent of any holder of an award, that the exercise price of an outstanding and unexercised
award shall be reduced by an amount equal to the per share gross dividend amount distributed by the Company, subject to applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
the event of a merger or consolidation of the Company or a sale of all, or substantially all, of the Company&#8217;s shares or assets
or other transaction having a similar effect on the Company, or change in the composition of the board of directors, or liquidation or
dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction, then without
the consent of the grantee, (i) unless otherwise determined by the administrator, any outstanding award will be assumed or substituted
by such successor corporation, or (ii) regardless of whether or not the successor corporation assumes or substitutes the award (a) provide
the grantee with the option to exercise the award as to all or part of the shares, and may provide for an acceleration of vesting of unvested
awards, (b) cancel the award and pay in cash, shares of the Company, the acquirer or other corporation which is a party to such transaction
or other property as determined by the administrator as fair in the circumstances, or (c) provide that the terms of any award shall be
otherwise amended, modified or terminated, as determined by the administrator to be fair in the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-size: 8pt">&#160;</span></p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Employees.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2021, we had
4 full-time employees. On December 31, 2022, we had 3 full-time employees. On December 31, 2023, we had 3 full-time employees, 2 of whom
were members of senior management: our Chief Executive Officer who is also our Chief Financial Officer and Chief Technologies Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our current employees
and officeholders is represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations
with all of our employees. However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent
rulings, as well as certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued in accordance
with relevant labor laws by the Israeli and Industry of Economy and which apply such agreement provisions to our employees even though
they are not part of a union that has signed a collective bargaining agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 129 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Share Ownership.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below. &#160;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Action to Recover Erroneously Awarded Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY
TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Major Shareholders </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">The following table sets
forth information regarding beneficial ownership of our ordinary shares as of March 28, 2024 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">each
person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding ordinary shares;</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">each
of our directors, and executive officers; and</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">all
of our directors, and executive officers as a group.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as indicated in footnotes
to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown
to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each beneficial
owner&#8217;s address is c/o SciSparc Ltd., 20 Raul Wallenberg Street, Tower A, Tel Aviv, 6971916 Israel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; padding-bottom: 1.5pt; font-weight: bold">Holders of more than 5% of our Ordinary Shares</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Ordinary Shares Beneficially Owned<sup>(1)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><sup>&#160;</sup></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent
    of Class<sup>(2)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="text-decoration:underline">Officers and Directors who are not 5% holders:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt"><sup>&#160;</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Itschak Shrem</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,136 </span></td><td style="padding-bottom: 3pt; width: 1%; text-align: left"><sup>(3)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;*</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amitay Weiss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">821 </span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Oz Adler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">856 </span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Adi Zuloff-Shani</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">840 </span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amnon Ben Shay</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alon Dayan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141
</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liat Sidi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lior Vider</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141
</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Moshe Revach</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141 </span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All directors and executive officers as a group (9 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,358</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Ordinary Shares relating to options currently exercisable or exercisable within 60 days of the date of this table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 2,586,686 Ordinary Shares issued and outstanding as of March 28, 2024, plus Ordinary Shares relating to options and warrants currently exercisable or exercisable within 60 days of the date of this table, which are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 340 Ordinary Shares and options to purchase 996 Ordinary Shares at an exercise price of $169 per share. In addition, Mr. Shrem holds options to purchase 200 Ordinary Shares that are not exercisable within 60 days. Mr. Shrem&#8217;s options have an expiration date of January 3, 2028, and a weighted average exercise price of $169.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 25 Ordinary Shares and options to purchase 996 Ordinary Shares at an exercise price of $169 per share. In addition, Mr. Weiss holds options to purchase 200 Ordinary Shares that are not exercisable within 60 days. Mr. Weiss&#8217;s options have an expiration date of January 3, 2028, and a weighted average exercise price of $169.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 996 Ordinary Shares at an exercise price of $169 per share, and options to purchase 60 Ordinary Shares at an exercise price of $5,460 per share. In addition, Mr. Adler holds options to purchase 200 Ordinary Shares that are not exercisable within 60 days. Mr. Adler&#8217;s options have an expiration date of January 3, 2028 to October 10, 2029, and a weighted average exercise price of $422.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 6 Ordinary Shares at an exercise price of NIS 77,241 (approximately $20,876) per share, options to purchase 38 Ordinary Shares at an exercise price of $5,640 per share, and options to purchase 996 Ordinary Shares at an exercise price of $169 per share. In addition, Dr. Zuloff-Shani holds options to purchase 200 Ordinary Shares that are not exercisable within 60 days. Dr. Zuloff-Shani&#8217;s options have an expiration date of February 16, 2026 to October 10, 2029, and a weighted average exercise price of $207.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 176 Ordinary Shares at an exercise price of $169 per share. Each of Amnon Ben Shay, Alon Dayan, Moshe Revach, Liat Sidi and Lior Vider holds options to purchase 35 Ordinary Shares that are not exercisable within 60 days. The options have an expiration date of January 3, 2028, and a weighted average exercise price of $169.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Percentage Ownership by Major
Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage
ownership held by any major shareholder during the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No major shareholders listed
above had or have voting rights with respect to their Ordinary Shares that are different from the voting rights of other holders of our
Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Record Holders </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 28, 2024, there
were 22 holders of record of our Ordinary Shares, 8 of which have a registered address in the United States.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These numbers are not representative
of the number of beneficial holders of our shares nor is it representative of where such beneficial holders reside, since many of these
shares were held of record by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Change in Control Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not controlled by another
corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known
to us which would result in a change in control at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Related Party Transactions </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, and Dr. Adi Zuloff-Shani, our Chief
Technologies Officer. Each of these agreements contains customary provisions regarding noncompetition, confidentiality of information
and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. These
agreements are terminable by either party upon 30 days&#8217; prior written notice. In addition, we have entered into agreements with
each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent
that these liabilities are not covered by directors and officers insurance. Members of our senior management are eligible for bonuses
each year. The bonuses are payable upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually
by our Board of Directors that also set the bonus targets for our Chief Executive Officer. See Item 6.B. &#8220;Compensation-Employment
and Service Agreements with Executive Officers&#8221; and see the descriptions of exculpation and indemnification agreements and directors
and officers insurance arrangements in Item 6.A. &#8220;Directors and Senior Management&#8221; and Item 6.C. &#8220;Board Practices-Insurance,&#8221;
- &#8220;Indemnification&#8221; and &#8220;-Exculpation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Options </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
granted options to purchase our Ordinary Shares to our employees, officers, service providers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option
plans under Item 6.E. &#8220;Share Ownership-Equity Incentive Plans.&#8221; If the relationship between us and an executive officer or
a director is terminated, except for cause (as defined in the various option plan agreements), options that are vested will generally
remain exercisable for 90 days after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commercial
Agreements</i></b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 7, 2022, we entered
into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our
President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors. See Item 4.B. &#8220;Business
Overview- <i>Collaboration with Clearmind</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2022, we invested
$1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 230,769 common
shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Polyrizon</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 31, 2022, we entered
into the Polyrizon Collaboration Agreement with Polyrizon. Mr. Adler, our Chief Executive Officer and Chief Financial Officer, serves
as a director in Polyrizon. See Item 4.B. &#8220;<i>Business Overview - Collaboration with Polyrizon</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Jeffs&#8217; Brands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, we entered
into the Secondary Purchase Agreement with Jeffs&#8217; Brands and Jeffs&#8217; Holdings. See Item 4.B. &#8220;<i>Business Overview &#8212;</i>&#160;<i>Wellution</i>&#8221;
for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Oz Adler, our Chief Executive
Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands, Mr. Amitay Weiss, our
chairman of the board of directors and Mr. Moshe Revach, a member of our board of directors, are both directors in&#160;Jeffs&#8217;&#160;Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2023, we entered
into the AutoMax SPA with AutoMax. See Item 5.B. &#8220;<i>Liquidity and Capital Resources &#8212;</i>&#160;<i>Financing Activities &#8212;</i>&#160;<i>AutoMax
SPA</i>&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss, our chairman
of the board of directors is the chairman of the board of directors of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Interests of Experts and Counsel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. FINANCIAL INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Consolidated Statements and Other Financial
Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Item 18. &#8220;Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Claims
Against our Former Directors</i></b></span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 15, 2022, we filed
a lawsuit against our former directors in the Economic Division of the Tel Aviv Court, case number 34426-02-22, or the Lawsuit. The Lawsuit
names six former directors, including our former interim chief executive officer and executive chairman, Dr. Ascher Shmulewitz, as defendants,
or the Defendants, and includes allegations of breaches of fiduciary duties (duty of care and duty of loyalty) of the Defendants under
the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Lawsuit challenges a transaction
approved by the Defendants in August 2018, to acquire, via one of our subsidiaries, Therapix Healthcare Resources, Inc., eight pain clinics
and a fully equipped laboratory from Anesthesia Services Associates PLLC. (d/b/a Comprehensive Pain Specialist), or the Transaction. The
Lawsuit claims that the Defendants breached their fiduciary duties when approving the Transaction, causing us significant harm. The Lawsuit
claims damages in the amount of NIS 13,114,200 (approximately $4.12 million), which accounts for, as of the date of the filing of the
Lawsuit, the amounts invested by the Company in the Transaction and indirect expenses arising from the Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our Board of Directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board
of Directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The distribution of dividends
may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived
over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will
prevent a company from satisfying its existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See Item 10.E. &#8220;Taxation&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_037"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this Annual Report, has occurred in our operations since the date of our consolidated financial statements
included in this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Offer and Listing Details</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are listed
on the Nasdaq Capital Market, trading under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Plan of Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_041"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are traded
on the Nasdaq under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_042"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Selling Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Dilution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_044"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Expenses of the Issue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Share Capital </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_047"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Memorandum and Articles of Association </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our amended and
restated articles of association is attached as Exhibit 1.1 to this Annual Report. The information called for by this Item is set forth
in Exhibit 2.1 to this Annual Report on Form 20-F and is incorporated by reference into this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_048"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Material Contracts </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not entered into any
material contract within the two years prior to the date of this Annual Report, other than contracts entered into in the ordinary course
of business, as otherwise described herein in &#8220;Item 4.A. History and Development of the Company&#8221; above, &#8220;Item 4.B. Business
Overview&#8221; above, &#8220;Item 5.A. Operating Results&#8221; above, or &#8220;Item 7.B. Related Party Transactions&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_049"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Exchange Controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of
war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 134 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_050"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Taxation. </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ISRAELI TAX CONSIDERATIONS AND GOVERNMENT PROGRAMS
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following also contains a description of
material relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference to its effect
on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative interpretation,
there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The discussion is not
intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our Ordinary Shares.
Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as well as any tax consequences
that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident companies
are generally subject to corporate tax, currently at the rate of 23% of a company&#8217;s taxable income. Capital gains derived by an
Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a corporation will be
considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated in Israel; or (ii) the
control and management of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Encouragement of Research, Development
and Technological Innovations in the Industry Law, 5744-1984</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Innovation Law,
research and development programs which meet specified criteria and are approved by a committee of the IIA are eligible for grants of
up to 50% of the project&#8217;s expenditure, as determined by the research committee, and subject to the benefit track under which the
grant was awarded. A company that receives a grant from the IIA, or a grant recipient, is typically required to pay royalties from the
revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a research
and development program funded by the IIA. Under the regular benefits tracks, the royalties are generally at a range of 3.0% to 5.0% of
revenues until the entire IIA grant is repaid, together with an annual interest. Under IIA regulations, grants received before January
1, 1999, bear no interest. Grants received before June 30, 2017 bear an annual &#160;interest rate that applied at the time of the approval
of the applicable IIA file, and that interest rate will apply to all of the funding received under that IIA approval. Grants received
from the IIA after June 30, 2017 bear an annual interest rate based on the 12-month Secured Overnight Financing Rate, or SOFR, or at an
alternative rate published by the Bank of Israel plus 0.71513%. Grants approved after January 1, 2024, shall bear the higher interest
rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligation to pay royalties
is contingent on actual income generated from such products and services. In the absence of such income, no payment of such royalties
is required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Innovation
Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer of manufacturing
activity outside Israel is subject to the prior approval of the IIA (such approval is not required for the transfer of a portion of the
manufacturing capacity which does not exceed, in the aggregate, 10% of the portion declared to be manufactured outside of Israel in the
applications for funding, in which case only notification is required). It should be noted that the terms of the Innovation Law do not
restrict the export of products that incorporate the funded technology. Under the regulations of the Innovation Law, assuming we receive
approval from the IIA to manufacture our IIA-funded products outside Israel, our liability to the IIA may be increased depending upon
the manufacturing volume that is performed outside of Israel as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing Volume Outside of Israel</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Royalties<br/> to the IIA as <br/> a Percentage<br/> of Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Up to 50%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">between 50% and 90%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">90% and more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 135 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the manufacturing is performed
outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured outside of Israel will
increase by 1% over the regular rates. A company requesting funds from the IIA also has the option of declaring in its IIA grant application
its intention to perform part of its manufacturing outside Israel, thus avoiding the need to obtain additional approval under the same
manufacturing scope indicated at the application. On January 6, 2011, the Innovation Law was amended to clarify that the potential increased
royalties specified in the table above will apply even in those cases where the IIA approval for transfer of manufacturing outside of
Israel is not required, namely when the volume of the transferred manufacturing capacity is less than 10% of total capacity. &#160;For
applications to manufacture abroad, submitted to the IIA after October 25, 2023, the maximum increased liability is up to 150% of the
IIA grants, plus interest accrued thereon, instead of 300%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The know-how developed within
the framework of the IIA plan may not be transferred or licensed to third parties outside Israel without the prior approval of the IIA.
The approval, however, is not required for the export of any products developed using grants received from the IIA. The IIA approval to
transfer know-how created, in whole or in part, in connection with an IIA-funded project to a third party outside Israel is subject to
payment of a redemption fee to the IIA calculated according to a formula provided under the Innovation Law that is based, in general,
on the ratio between the aggregate IIA grants and our aggregate investments in the project that was funded by these IIA grants, multiplied
by the transaction consideration taking into account a depreciation mechanism, and less royalties already paid to the IIA. According to
regulations promulgated under the Innovation Law, the maximum amount payable to the IIA in case of transfer of know how outside Israel
shall not exceed six times the amount of the grants received plus interest, with a possibility to reduce such payment to up to three times
the amount of the grants received plus interest if the grant recipient undertakes to continue the research and development activity in
Israel for a period of at least three years after the transfer of knowhow, and maintain at least 75% of the research and development employees
the company had for the six months before the know-how was transferred, subject to additional conditions specified in the regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transfer or licensing of know-how
to an Israeli entity is subject to the IIA approval and to an undertaking of the recipient Israeli entity to undertake all the transferor&#8217;s
obligations to the IIA and to comply with the provisions of the Innovation Law and related regulations, including the restrictions on
the transfer and licensing of know-how and the obligation to pay royalties, as further described in the Innovation Law and related regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions under the
Innovation Law will continue to apply even after we will repay the full amount of royalties payable pursuant to the grants. In addition,
the government of the State of Israel may from time to time audit sales of product candidates which it claims incorporate technology funded
via IIA programs and this may lead to additional royalties being payable on additional product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictions may impair
our ability to outsource manufacturing or otherwise transfer or license our know-how outside Israel and may require us to obtain the approval
of the IIA for certain actions and transactions and pay additional royalties or other payments to the IIA. If we fail to comply with certain
restrictions under the Innovation Law, we may be subject to mandatory repayment of grants received by us (together with interest and penalties),
as well as be exposed to criminal charges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed, partially, through grants that we have received from the IIA. We therefore must comply with the requirements
of the Innovation Law and related regulations. Our total outstanding obligation to the IIA, respectively, including the interest accrued
through December 31, 2023, amounts to approximately $1.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development
under the Innovation Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli tax law allows, under
certain conditions, a tax deduction for expenditures, including capital expenditures, in scientific research in the fields of industry,
agriculture, transportation or energy, for the year in which they are incurred. Expenditures are deemed related to scientific research
and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development must be for the promotion of the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 136 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of such deductible
expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development
projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested
in an asset depreciable under the general depreciation rules of the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance.
Expenditures not so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time we may apply
the IIA for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be no assurance
that such application will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Law for the Encouragement of Capital Investments, 5719-1959</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in
production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investment Law was significantly
amended effective April&#160;1, 2005 (which we refer to as the 2005 Amendment), further amended as of January&#160;1, 2011 (which we refer
to as the 2011 Amendment) and further amended as of January 1, 2017 (which we refer to as the 2017 Amendment). Pursuant to the 2005 Amendment,
tax benefits granted in accordance with the provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force
but any benefits granted subsequently are subject to the provisions of the 2005 Amendment. Similarly, the 2011 Amendment introduced new
benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However,
companies entitled to benefits under the Investment Law as in effect prior to January&#160;1, 2011 were entitled to choose to continue
to enjoy such benefits, provided that certain conditions are met, or elect instead irrevocably to forego such benefits and have the benefits
of the 2011 Amendment apply. The 2017 Amendment introduced new benefits for Technological Enterprises, alongside the existing tax benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital Gains</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gain tax is imposed
on the disposal of capital assets by an Israeli resident, and on the disposal of such assets by a non-Israeli resident if those assets
are either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly
or indirectly, rights to assets located in Israel, unless a tax treaty between Israel and the seller&#8217;s country of residence provides
otherwise. The Ordinance, distinguishes between &#8220;Real Gain&#8221; and the &#8220;Inflationary Surplus.&#8221; Real Gain is the excess
of the total capital gain over Inflationary Surplus. Inflationary Surplus is computed generally on the basis of the increase in the Israeli
Consumer Price Index or, in certain circumstances, according to the change in the foreign currency exchange rate, between the date of
purchase and the date of disposal. Inflationary Surplus is not subject to tax in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real Gain accrued by individuals
on the sale of our Ordinary Shares will be taxed at the rate of 25%. However, if the shareholder claims deduction of interest and linkage
differences expenses in connection with the purchase and holding of such shares or the individual shareholder is a &#8220;Controlling
Shareholder&#8221; (i.e., a person who holds, directly or indirectly, alone or together with such person&#8217;s relative or another person
who collaborates with such person on a permanent basis, based on a written contract, 10% or more of one of the Israeli resident company&#8217;s
&#8220;means of control&#8221; including, among other things, the right to company profits, voting rights, the right to the company&#8217;s
liquidation proceeds and the right to appoint a company director) at the time of sale or at any time during the preceding 12 months period,
such gain will be taxed at the rate of 30%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real Gain derived by corporations
will be generally subject to the regular corporate tax rate (23% in 2023).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individual and corporate shareholder
dealing in securities in Israel for whom the income from the sale of securities is considered &#8220;business income&#8221; as defined
in Section 2(1) of the Ordinance are taxed at the tax rates applicable to business income- 23% for corporations in 2023 and a marginal
tax rate of up to 47% in 2023 for individuals, unless the benefiting provisions of an applicable tax treaty applies. Certain Israeli institutions
who are exempt from tax under Section 9(2) or Section 129(I)(a)(1) of the Ordinance (such as exempt trust fund, pension fund) may be exempt
from capital gains tax from the sale of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Capital Gains Taxes is
Applicable also to Non-Israeli Resident Shareholders</i>. A non-Israeli resident (whether an individual or a corporation) who derives
capital gains from the sale of shares in an Israeli resident company may be exempt from Israeli capital gain tax so long as the following
cumulative conditions are met: (i) the shares were purchased upon or after the registration of the securities on a recognized stock exchange,
outside of Israel (such as Nasdaq) (ii) the seller does not have a permanent establishment in Israel to which the derived capital gain
is attributed, and (iii) with respect to securities listed on a recognized stock exchange outside of Israel, such shareholders are not
subject to the Israeli Income Tax Law (Inflationary Adjustments) 5745-1985. However, non-Israeli corporation will not be entitled to the
foregoing exemptions if Israeli residents (a) have a controlling interest of more than 25% in such non-Israeli corporation, or (b) are
the beneficiaries of or are entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly and indirectly.
In addition, such exemption would not be available to a person whose gains from selling or otherwise disposing of the securities are deemed
to be business income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If not exempt, a&#160;non-Israeli&#160;resident
would generally be subject to tax on capital gain at the ordinary corporate tax rate (23% in 2023) if generated by a company, or at the
rate of 25%, if generated by an individual, or 30%, if generated by an individual who is a &#8220;Controlling Shareholder&#8221;, at the
time of sale or at any time during the preceding&#160;12-month&#160;period (or if the shareholder claims a deduction for interest and
linkage differences expenses in connection with the purchase and holding of such shares).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a sale of shares
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
under the Convention Between the Government of the United States of America and the Government of the State of Israel with respect to
Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder
who is a United States resident (for purposes of the United States-Israel Tax Treaty) holding the shares as a capital asset and is entitled
to claim the benefits afforded to such a resident by the United States.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt
from Israeli capital gains tax unless either: (i) the capital gain arising from such sale, exchange or disposition is attributed to real
estate located in Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the
capital gain arising from the such sale, exchange or disposition is attributed to a permanent establishment of the shareholder which is
maintained in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more
of the voting capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or (v) such Treaty
U.S. Resident, if an individual, was present in Israel for a period or periods of 183 days or more in the aggregate during the relevant
taxable year. In any such case, the sale, exchange or disposition of such shares would be subject to Israeli tax, to the extent applicable;
however, under the United States-Israel Treaty, a U.S. resident would be permitted to claim a credit for the Israeli tax against the U.S.
federal income tax imposed with respect to the sale, exchange or disposition, subject to the limitations in U.S. laws applicable to foreign
tax credits. The United States-Israel Treaty does not provide such credit against any U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our
shareholders may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration may be subject to the
withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains
in order to avoid withholding at source at the time of sale. Specifically, in transactions involving a sale of all of the shares of an
Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require from shareholders who are not liable
for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority
to confirm their status as non-Israeli residents, and, in the absence of such declarations or exemptions, may require the purchaser of
the shares to withhold taxes at source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Either the purchaser, the
Israeli stockbrokers or financial institution through which the shares are held is obliged, subject to the above mentioned exemptions,
to withhold tax on the amount of consideration paid upon the sale of securities from the Real Gain at the rate of 25% for individuals
and 23% for corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the sale of securities
traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advance payment must be made
on January 31 and July 31 of every calendar year in respect of sales of securities made within the previous six months. However, if all
tax due was withheld at source according to applicable provisions of the Ordinance and regulations promulgated thereunder, the aforementioned
return need not be filed and no advance payment must be paid. Capital gain are also reportable on the annual income tax return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A distribution of dividends
from an Israeli company to an Israeli resident individual, will generally be subject to income tax at a rate of 25%. However, a 30% tax
rate will apply if the dividend recipient is a Controlling Shareholder (as defined above in this section) at the time of distribution
or at any time during the preceding 12 months period. If the recipient of the dividend is an Israeli resident corporation, generally,
such dividend will be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within
Israel (although, if such dividends are subsequently distributed to individuals, the aforesaid will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-Israeli residents (whether
individuals or a corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our Ordinary Shares at
the rate of 25% or 30% with respect to a Controlling Shareholder (as defined above) at the time of receiving the dividend or on any time
during the preceding twelve months. Such dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares
are registered with a Nominee Company (whether the recipient is a Controlling Shareholder or not). For example, under the United States-Israel
Tax Treaty, the rate of tax withheld at source in Israel on dividends paid to a holder of our Ordinary Shares who is a Treaty U.S. Resident
is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Approval/Beneficial/Preferred Enterprise
(as defined under the Investment Law), that are paid to a United States corporation holding 10% or more of the outstanding voting capital
throughout the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more
than 25% of the gross income for such preceding year consists of certain types of dividends and interest. The aforementioned rates will
not apply if the dividend income was generated through a permanent establishment of the U.S. resident in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-Israeli resident who
receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such
income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has no other
taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii) the taxpayer is not obligated
to pay excess tax (as further explained below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Excess Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals who are subject
to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) are also subject to an additional tax at
a rate of 3% on annual income exceeding a certain threshold (NIS 698,280 for 2023, which amount is linked to the annual changes to the
Israeli Consumer Price Index), including, but not limited to income derived from dividends, interest and capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-residents of Israel who
hold our Ordinary Shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of
our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax
is generally required to have been paid or withheld on these amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estate and Gift Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law presently does
not impose estate or gift taxes. if the Israeli Tax Authority is satisfied that the gift was made by an Israeli resident individual in
good faith and on condition that the recipient of the gift is not a non-Israeli resident. If the gift giver is a non-Israeli resident
individual, then he should be exempted under the aforementioned capital gains tax exemptions provided for a regular sale of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 139 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>U.S.
FEDERAL INCOME TAX CONSIDERATIONS</b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL
INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS
OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES
AND AMERICAN DEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE
TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &#8220;U.S. Holder&#8221; is a
holder of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an alien individual who is a
lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws; (2)
a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that
is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United States
or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income for
U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary supervision
over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust; or
(5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our Ordinary Shares. This summary generally considers only U.S. Holders that will own our
Ordinary Shares as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences
to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status as a U.S. Holder.
This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S.
Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, (including with respect to the TCJA
of 2017), and the U.S./Israel Income Tax Treaty, all as in effect as of the date hereof and all of which are subject to change, possibly
on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the IRS with regard to
the U.S. federal income tax treatment of an investment in our Ordinary Shares by U.S. Holders and, therefore, can provide no assurances
that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not address
all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s particular
circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state, local, excise or foreign tax
considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank,
life insurance company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221; (2) a
broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares in connection with employment or other
performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our Ordinary
Shares as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for
U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that
expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional currency
other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly
or constructively, at any time, Ordinary Shares representing 10% or more of our voting power. Additionally, the U.S. federal income tax
treatment of partnerships (or other pass-through entities) or persons who hold Ordinary Shares through a partnership or other pass-through
entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our Ordinary Shares, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dividends Paid on our Ordinary
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading &#8220;Passive Foreign
Investment Companies&#8221; below and the discussion of &#8220;qualified dividend income&#8221; below, a U.S. Holder will be required
to include in gross income as ordinary income the amount of any distribution paid on our Ordinary Shares (including the amount of any
Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current and accumulated
earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and
profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&#8217;s tax basis for the Ordinary Shares to
the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal income
tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will be reported as dividend
income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential tax
rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals, estates
or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified foreign
corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty
satisfies this requirement, and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends will not qualify
for the preferential rate if we are treated, in the year the dividend is paid or in the prior year, as a PFIC, as described below under
&#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder
has not held our Ordinary Shares for at least 61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend
date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days
during which the U.S. Holder has diminished its risk of loss on our Ordinary Shares are not counted towards meeting the 61-day holding
period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Code section 163(d)(4)
will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property distributed, and for U.S.
federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included
in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible
in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such
U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of it, any subsequent gain
or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of the Disposition of our Ordinary
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under the
PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition of our
Ordinary Shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s
tax basis for the Ordinary Shares in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent
determined by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency).
The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares will be long-term capital gain or loss if the
U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains
may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gain realized by a U.S. Holder
on a sale, exchange or other disposition of our Ordinary Shares will generally be treated as U.S. source income for U.S. foreign tax credit
purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of our Ordinary Shares is generally allocated to
U.S. source income. The deductibility of a loss realized on the sale, exchange or other disposition of our Ordinary Shares is subject
to limitations. An additional 3.8% net investment income tax (described below) may apply to gains recognized upon the sale, exchange or
other taxable disposition of our Ordinary Shares by certain U.S. Holders who meet certain income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 141 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Passive Foreign Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that we
would be deemed a PFIC for 2023. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections
of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value
of our Ordinary Shares. Accordingly, there can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our Ordinary Shares at a gain: (1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the Ordinary Shares, as the case may be; (2) the amount allocated to the current taxable year and any period prior
to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to
each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for
that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each
such other taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the
tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead would
be equal to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also
be subject to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described above
would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held our Ordinary Shares while
we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election
is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary earnings
as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless of whether
we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required
information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the
IRS. We do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain
a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. Therefore, the QEF election will not be available
with respect to our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
Ordinary Shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders
are strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 142 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax on Net Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain adjustments
under the PFIC rules, U.S. Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their
net investment income (including dividends on and gains from the sale or other disposition of our Ordinary Shares), or in the case of
estates and trusts on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent
the U.S. Holder&#8217;s total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax Consequences for Non-U.S. Holders of Ordinary
Shares </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided below,
an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally will not be subject
to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. Holder may be subject
to U.S. federal income tax on a dividend paid on our Ordinary Shares or gain from the disposition of our Ordinary Shares if: (1) such
item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United States and, if required by
an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2) in
the case of a disposition of our Ordinary Shares, the individual non-U.S. Holder is present in the United States for 183 days or more
in the taxable year of the disposition and other specified conditions are met. Any dividend income or gain described in clause (1) above
will be subject to U.S. federal income tax on a net income tax basis in the same manner as a U.S. Holder and, with respect to corporate
holders, a branch profits tax imposed at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) may
also apply to its effectively connected earnings and profits (subject to adjustments). Any dividend income or gain described in clause
(2) above that is not effectively connected with the conduct by a Non-U.S. Holder of a trade or business within the U.S. generally will
be subject to 30% withholding tax (or such lower rate as may be specified by an applicable income tax treaty) net of certain U.S. source
capital losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, non-U.S. Holders
will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares if payment is made through a
paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S. related
person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable IRS Form W-8 (or a substantially
similar form) certifying its foreign status, or otherwise establishes an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any backup withholding
from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may
entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Ordinary Shares. In general,
backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will
not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding
is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that
the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 143 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_051"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Dividends and Paying Agents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_052"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Statement by Experts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>H. Documents on Display</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
information reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports
with the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC will also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form
20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form
6-K, unaudited interim financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at http://www.scisparc.com. Information contained on, or that can be accessed through, our website and the other websites referenced above
do not constitute a part of this Annual Report. We have included these website addresses in this Annual Report solely as inactive textual
references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_054"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>I. Subsidiary Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_055"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>J. Annual Report to Security Holders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quantitative and Qualitative Disclosure About
Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. However, a substantial majority of our cash is held in current bank accounts that do not bear
interest. In the future, we intend to hold most of our cash in deposits that bear interest. Given the current low rates of interest we
receive, once we begin to hold most of our cash in deposits that bear interest, we do not expect to be adversely affected if such rates
are reduced. Our market risk exposure is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following
paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our results of operations
and cash flow are subject to fluctuations due to changes mainly in NIS/U.S. dollar currency exchange rates. As of December 31, 2023, the
vast majority of our liquid assets are held in U.S. dollars, and the majority of our expenses is denominated in U.S. dollars. Changes
of both 5% and 10% in the U.S. Dollar/NIS exchange rate would decrease/increase our loss for 2023 by less than 1%, respectively. However,
these historical figures may not be indicative of future exposure, as we expect that the percentage of our NIS denominated expenses will
materially decrease in the near future, therefore reducing our exposure to exchange rate fluctuations. Beginning October 1, 2018, our
functional currency is the U.S. dollar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not hedge our foreign
currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure
from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us
from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 144 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_059"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_060"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_061"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act.
Our internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with IFRS. We have a program for the review of our internal
control over financial reporting to ensure compliance with the requirements of the Exchange Act and Section 404 of the Sarbanes-Oxley
Act. Our internal control over financial reporting includes those policies and procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and our Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting
as of December 31, 2023. In conducting its assessment of internal control over financial reporting, management based its evaluation on
the Internal Control&#8201;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
as of December 31, 2023. Based on its evaluation, our management has concluded that our internal control over financial reporting was
effective as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable (we are exempt
from this requirement due to our status under the Exchange Act as a non-accelerated filer as of the current time).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the members of our
audit committee are &#8220;independent,&#8221; as such term is defined under Nasdaq rules. In addition, our Board of Directors has determined
that Amnon Ben Shay is an audit committee financial expert, as defined under the rules under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal
controller and persons performing similar functions as well as our directors. Our Code of Ethics and Conduct is posted on our website
at http://www.scisparc.com. Information contained on, or that can be accessed through, our website does not constitute a part of this
Annual Report and is not incorporated by reference herein. If we make any amendment to the Code of Ethics and Conductor grant any waivers,
including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment or waiver on our website to
the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form 20-F. We have not granted any
waivers under our Code of Business Conduct and Ethics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Kost Forer Gabbay &amp; Kasierer
(a member of EY Global), served as our principal independent registered public accounting firm for each of the two years ended December
31, 2022 and 2023. Kost Forer Gabbay &amp; Kasierer (a member of EY Global) has served as our principal independent registered public
accounting firm since 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Kost Forer Gabbay &amp; Kasierer and/or other member firms of EY Global for all services, including
audit services, for the years ended December 31, 2022 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">155,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">142,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">281,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes professional services rendered in connection with the audit of our annual financial statements, review of our interim financial statements. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes professional services rendered in connection with the fees relating to our public equity offerings and related filings.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All of the services provided above were
approved by our audit committee and by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee charter
provides, among others, that our audit committee is responsible for: (1) pre-approving audit and non-audit services provided to us by
the independent registered public accounting firm; (2) reviewing and approving disclosures relating to fees and non-audit services required
to be included in the SEC reports; and (3) establishing pre-approval policies and procedures for the engagement of independent accountants
to render us services. Subject to the Board of Directors&#8217; and shareholders&#8217; approval, if and to the extent required by applicable
law, the audit committee shall have the authority to approve all audit engagement fees and terms and all non-audit engagements, as may
be permissible, with the independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&#160;&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;foreign private
issuer&#8221;, as such term is defined in Rule 405 under the Securities Act. As a foreign private issuer we are permitted to comply with
Israeli corporate governance practices instead of the corporate governance rules of Nasdaq, provided that we disclose which requirements
we are not following and the equivalent Israeli requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on this &#8220;foreign
private issuer exemption&#8221; with respect to the following items:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum.</i> While the Nasdaq rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s common voting stock, as specified in the company&#8217;s bylaws, be no less than 33 1/3% of the company&#8217;s outstanding common voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 15% of the voting rights present in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of any number of shareholders present in person or by proxy.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder approval.</i>&#160;Although the Nasdaq rules generally require shareholder approval of equity compensation plans and material amendments thereto, we follow Israeli practice, which is to have such plans and amendments approved only by the board of directors, unless such arrangements are for the compensation of chief executive officer or directors, in which case they also require the approval of the compensation committee and the shareholders. In addition, rather than follow the Nasdaq rules requiring shareholder approval for the issuance of securities in certain circumstances, we follow Israeli law, under which a private placement of securities requires approval by our board of directors and shareholders if it will cause a person to become a controlling shareholder (generally presumed at 25% ownership) or if: (a) the securities issued amount to 20% or more of our outstanding voting rights before the issuance; (b) some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and (c) transaction will increase the relative holdings of a shareholder that holds 5% or more of our outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of more than 5% of our outstanding share capital or voting rights.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 147 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive Sessions</i>. The Nasdaq rules require that independent directors of a Nasdaq listed company must meet regularly in executive session (without members of management present), and such executive sessions should occur at least twice a year. In this regard we have elected to adopt the practices of our home country, Israel, which does not require independent directors to meet regularly in executive sessions separate from the full board of directors<i>. </i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nomination of our directors</i>. Nasdaq rules require director nominations of a Nasdaq listed company to be made or recommended solely by independent directors and the director nominations process be addressed by a formal written charter or board resolution. We follow the requirements of Israeli law, which does not require us to have a formal written charter addressing the director nominations process. The nominations for directors, which are presented to shareholders by a board of directors, are generally made by the board of directors itself, in accordance with the provisions of the Companies Law. Nominations need not be made by a nominating committee of a board of directors consisting solely of independent directors or by a vote consisting solely of our independent directors in order to determine which persons shall be nominated for election by our shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We otherwise intend to comply
with the rules generally applicable to U.S. domestic companies listed on Nasdaq. We may, however, in the future decide to rely upon the
&#8220;foreign private issuer exemption&#8221; for purposes of opting out of some or all of the other corporate governance rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
16K. CYBERSECURITY.</b></span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company engages a third-party
provider to maintain our systems and management participates in the assessment to identify any risks from cybersecurity threats. Our third-party
provider monitors our firewall, network, system security and internal and external backups and reports any issues to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Board,
together with management, is engaged in our cybersecurity monitoring managed by our third-party provider. Any issues are appropriately
addressed timely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not experienced
any cybersecurity incidents that materially affected our business strategy, results of operations or financial condition.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 148 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements and the related notes required by this Item are included in this Annual Report beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 19. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="9" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation by Reference</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/>
No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed/<br/>
Furnished</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999ex3-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Association of SciSparc Ltd.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269839&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;3.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 16, 2023&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020288201ex2-1_scisparc.htm">Description of Securities</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020007166/ea119823ex99-4_therapix.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant, pursuant to Securities Purchase Agreement, dated March 19, 2020&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 23, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020038984/ea130376ex4-2_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 24, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-4_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-5_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-6_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Warrant&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022030109/ea160740ex99-5_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Ordinary Share Purchase Warrant, pursuant to Securities Purchase Agreement, dated May 27, 2022</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 27, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022030109/ea160740ex99-6_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Ordinary Share Purchase Warrant, pursuant to Securities Purchase Agreement, dated May 27, 2022</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 27, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022060388/ea166507ex99-4_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Purchase Warrant, pursuant to Assignment and Assumption Agreement dated September 12, 2022</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023067123/ea183435ex4-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex4-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023090549/ea189134ex4-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights Agreement, dated as of November 28, 2023, between SciSparc Ltd. and VStock Transfer LLC., as rights agent, which includes the Form of Right Certificate (Exhibit A) and the Form of Summary of Rights (Exhibit B)</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 28, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024006291/ea192120ex4-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Promissory Note between SciSparc Ltd. and YA II PN Ltd, which includes the Repayment Schedule (Exhibit 1)</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390017004433/f20f2016ex4xii_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 1, 2017</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/f20f2020ex4-5_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exculpation Agreement</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7+</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022294/f20f2021ex4-3_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy for Executive Officers and Directors</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 28, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&#8224;</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390016019159/ff12016a2ex10i_therapix.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement dated May 20, 2015, by and between the Company and Dekel Pharmaceuticals Ltd.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-214458</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 6, 2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9&#8224;&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390019008868/f20f2018ex4-2_therapixbio.htm">License Agreement dated July 29, 2018, by and between the Company and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.</a> </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 29, 2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10+</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390016017994/ff12016ex10v_therapix.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli Share Option Plan (2015)&#160;</span><span style="font-size: 10pt">&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-214458</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 4, 2016</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/f20f2019ex4-8_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to License Agreement dated as of August 19, 2015, by and between the Company and Dekel Pharmaceuticals Ltd.&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020014990/f20f2019ex4-9_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to License Agreement dated as of July 14, 2019, by and between the Company and Dekel Pharmaceuticals Ltd.&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020012970/ea122045ex99-1_therapix.htm">Share Transfer Agreement, by and among Capital Point Ltd., Therapix Biosciences, Ltd. and Evero Health Ltd., dated May 15, 2020&#160;</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 19, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020012970/ea122045ex99-2_therapix.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset Purchase Agreement, by and between Therapix Biosciences, Ltd. and Evero Health Ltd., dated May 15, 2020</span><span style="font-size: 10pt">&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 19, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390020038984/ea130376ex4-1_therapixbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agent Agreement, dated November 23, 2020&#160;</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 24, 2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 149 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390021012886/ea136813ex99-3_scisparcltd.htm">Placement
    Agency Agreement</a>&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022030109/ea160740ex99-2_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Purchase Agreement between SciSparc Ltd. and the investor named therein, dated May 27, 2022.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 27, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022030109/ea160740ex99-3_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Rights Agreement between the Company and the investor named therein, dated May 27, 2022.</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 27, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022060388/ea166507ex99-3_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset
    Purchase Agreement between the Company, SciSparc Nutraceuticals Inc. and the parties named therein, dated September 12, 2022</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390022060388/ea166507ex99-2_scisparc.htm">Assignment
    and Assumption Agreement between the Company and M.R.M. Merhavit Holdings and Management Ltd, dated September 12, 2022</a></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30,
    2022</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 6%">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023014561/ea174175ex99-2_scisparc.htm">Stock
    Purchase Agreement, dated February 23, 2023, by and between SciSparc Ltd., NewCo Inc. and Jeffs&#8217; Brands Ltd.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023026713/ea176389ex10-2_scisparcltd.htm">Addendum
    No. 1 to Stock Purchase Agreement, dated March 22, 2023, by and between Jeffs&#8217; Brands Ltd, Jeffs&#8217; Brands Holdings Inc.
    and SciSparc Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 4, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023026713/ea176389ex10-3_scisparcltd.htm">Consulting
    Agreement, dated March 22, 2023, by and between Jeffs&#8217; Brands Ltd and SciSparc Nutraceuticals Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 4, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390023040610/ea178379ex99-1_scisparc.htm">At-the-Market
    Issuance Sales Agreement by and between SciSparc Ltd. and Aegis Capital Corp., dated May 16, 2023</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 17, 2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-1_scisparc.htm">Securities
    Purchase Agreement dated October 11, 2023</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-2_scisparc.htm">Registration
    Rights Agreement dated October 11, 2023</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000101376223003323/ea186598ex10-3_scisparc.htm">Form
    of Confession of Judgment</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 12, 2023</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024006291/ea192120ex10-1_scisparc.htm">Standby
    Equity Purchase Agreement dated January 21, 2024, between YA II PN Ltd. and the Company</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38041</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex10-22_scisparcltd.htm">First
    Amendment to the Standby Equity Purchase Agreement, dated as of February 26, 2024, between SciSparc Ltd. and YA II PN, Ltd</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30+</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex10-7_scisparcltd.htm">SciSparc
    Share Incentive Plan (2023)</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex21-1_scisparcltd.htm">List
    of Subsidiaries</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-277394</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020288201ex12-1_scisparc.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020288201ex13-1_scisparc.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350.</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020288201ex15-1_scisparc.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, independent registered accounting firm for the Registrant.</a>&#160;</span><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020288201ex97-1_scisparc.htm">Clawback Policy</a></span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  </table><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify">Filed herewith.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
treatment was granted with respect to certain portions of this exhibit pursuant to 17.C.F.R. &#167;240.24b-2. Omitted portions were filed
separately with the SEC.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;&#8224;
 </span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain identified information in the exhibit has been excluded from the exhibit because it is both (i) not material and (ii) is the
type that SciSparc Ltd. treats as private or confidential.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 150 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
Annual Report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCISPARC LTD.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap">/s/ Oz Adler</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date April 1, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 151 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AS OF DECEMBER 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 89%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_001">Report of Independent Registered Public Accounting Firm (PCAOB ID&#160;<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-27570">1281</ix:nonNumeric>)</a></b></span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_002">Consolidated Statements of Financial Position</a></b></span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4 - F-5</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_003">Consolidated Statements of Comprehensive Loss</a></b></span></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_004">Consolidated Statements of Changes in Equity</a></b></span></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7 </b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_005">Consolidated Statements of Cash Flows</a></b></span></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-8- F-10</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#f_006">Notes to Consolidated Financial Statements</a></b></span></td> <td>&#160;</td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-11 - F-55</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 152; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 33%"><img alt="" src="image_001.jpg"/></td>
    <td style="vertical-align: bottom; width: 34%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Kost Forer Gabbay &amp; Kasierer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">144 Menachem Begin Road,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel-Aviv 6492102, Israel</p></td>
    <td style="vertical-align: bottom; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +972-3-6232525</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +972-3-5622555</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ey.com</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD. (formerly known as THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) and its subsidiaries (the
&#8220;Company&#8221;) as of December 31, 2023, and 2022, and the related consolidated statements of comprehensive loss, changes in equity
and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the consolidated financial position of the Company at December 31, 2023, and 2022, and the consolidated results of its operations
and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting
Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company&#8217;s Ability to Continue as
a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses from operations, negative cash flows from operating activities and has stated that
substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events
and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit matter
communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to
be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 1 to the consolidated financial statements, the Company has incurred losses since inception, and expects to continue to incur losses for the foreseeable future. At December 31, 2023, the Company&#8217;s cash and cash equivalents position is not sufficient to fund the Company&#8217;s planned operations for at least a year beyond the date of the issuance of the consolidated financial statements. Those factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determined the Company&#8217;s ability to continue as a going concern is a critical audit matter due to the estimation and execution uncertainty regarding the Company&#8217;s future cash flows and the risk of bias in management&#8217;s judgments and assumptions in estimating these cash flows to conclude the Company would have sufficient liquidity to sustain itself for at least a year beyond the date of the issuance of the consolidated financial statements. This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Addressing the matter involved performing procedures
    and evaluating audit evidence in connection with our overall opinion on the consolidated financial statements.&#160;Our audit procedures
    included, among others, testing the reasonableness of the forecasted revenue, operating expenses, and uses and sources of cash used in
    management&#8217;s assessment of whether the Company has sufficient liquidity to fund operations for at least one year from the consolidated
    financial statement issuance date. This testing included inquiries with management, consideration of positive and negative evidence impacting
    management&#8217;s forecasts, the Company&#8217;s financing arrangements in place as of the report date, market and industry factors,
    we evaluated management&#8217;s analysis of their impact on the forecasted cash flows.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assessed the adequacy of the Company&#8217;s
    going concern disclosures included in Note 1 to the consolidated financial statements.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-27571">KOST FORER GABBAY &amp; KASIERER</ix:nonNumeric></span></td> <td style="width: 20%">&#160;</td> <td style="width: 40%"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-15184"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel Aviv, Israel</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KOST FORER GABBAY &amp; KASIERER</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2024</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">A Member of Ernst &amp; Young Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; width: 65%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27572">2,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27573">3,574</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Restricted deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27574">65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27575">60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Short-term deposit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-27576">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Trade receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-27577">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-27578">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other accounts receivable</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-27579">540</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-27580">131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-27581">742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-27582">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-27583">6,445</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-27584">4,510</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Intangible asset, net</td><td>&#160;</td>
    <td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-27585">3,189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-27586">4,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Investments in company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-27587">781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentsInAssociates" scale="3" unitRef="usd" id="ixv-27588">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Investments in financial assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8, 24e</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-27589">659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-27590">730</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27591">108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27592">57</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-27593">4,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-27594">6,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-27595">11,182</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-27596">10,605</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-27597">802</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-27598">1,199</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other accounts payable</td><td>&#160;</td>
    <td style="text-align: center">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-27599">185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-27600">193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">18h</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-27601">532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd" id="ixv-27602">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-27603">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-27604">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-27605">1,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-27606">4,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-27607">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td>&#160;</td>
    <td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share capital and premium</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-27608">64,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-27609">58,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reserve from share-based payment transactions</td><td>&#160;</td>
    <td style="text-align: center">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-27610">5,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-27611">5,180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-27612">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-27613">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation reserve</td><td>&#160;</td>
    <td style="text-align: center">2d</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-27614">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-27615">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Transactions with non-controlling interests</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-27616">810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-27617">559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-27618">68,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-27619">63,569</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-27620">7,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-27621">6,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-27622">1,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27623">9,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27624">6,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-27625">11,182</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-27626">10,605</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended December&#160;31,</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Note</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">USD in thousands (except per share data)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-27627">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-27628">1,347</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-27629">683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-27630">322</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-27631">2,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-27632">1,025</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">21</td><td style="text-align: left">a</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-27633">1,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-27634">2,803</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-27635">1,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-27636">1,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">537</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">(**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" scale="3" unitRef="usd" id="ixv-27638">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21</td><td style="padding-bottom: 1.5pt; text-align: left">b</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-27639">5,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">5,972</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">(**)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-27641">3,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27642">6,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27643">8,287</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27644">5,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: center">21</td><td style="text-align: left">c</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-27645">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-27646">109</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">21</td><td style="text-align: left">d</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-27647">2,219</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-27648">7,832</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">21</td><td style="padding-bottom: 1.5pt; text-align: left">e</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-27649">1,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-27650">2,014</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-27651">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-27652">5,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-27653">2,578</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-27654">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-27655">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-27656">14</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27657">5,883</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27658">2,592</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27659">5,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Attributable to:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity holders of the Company</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-27660">5,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-27661">2,592</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-27662">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-27663">761</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27664">5,883</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27665">2,592</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27666">5,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Basic loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">22</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-27667">14.43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">14.82</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">(*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares">73.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">(*)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Diluted loss per ordinary share attributable to equity holders of the Company:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">22</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-27670">14.43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares">14.82</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">(*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares">73.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">(*)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</ix:footnote></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(**)</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Attributable
    to equity holders of the Company</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Share<br/>
    capital<br/>
    and<br/>
    premium</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Reserve<br/>
    from&#160;share-<br/>
    based<br/>
    payment<br/>
    transactions</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrants</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Transactions<br/>
    with non-<br/> controlling<br/>
    interests</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign<br/>
    currency<br/>
    translation<br/>
    reserve</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-<br/>
    controlling<br/>
    interests</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<br/>
    equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">USD
    in thousands</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 23.5%; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at January 1, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27675">49,040</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27676">4,315</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27677">2,207</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27678">559</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27679">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-27680">55,188</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27681">1,430</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27682">1,430</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27683">5,789</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27684">5,789</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27685">5,789</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27686">6,110</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" sign="-" unitRef="usd" id="ixv-27687">1,352</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27688">4,758</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27689">4,758</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issue
    of share capital, net of issue expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27690">3,364</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27691">4,335</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27692">7,699</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27693">7,699</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Expiration
    of share options</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-27694">27</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" sign="-" unitRef="usd" id="ixv-27695">27</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
    of share-based payment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27696">43</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27697">43</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27698">43</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27699">58,541</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27700">4,331</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27701">5,190</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27702">559</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27703">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-27704">60,977</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27705">8,141</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27706">8,141</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27707">2,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27708">2,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27709">2,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27710">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27711">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27712">3</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
    of share-based payment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27713">48</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27714">849</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27715">897</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27716">897</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2022</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27717">58,592</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27718">5,180</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27719">5,190</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27720">559</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27721">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-27722">63,569</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27723">6,449</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27724">6,449</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27725">5,122</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27726">5,122</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27727">761</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27728">5,883</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale
    of minority interest in subsidiary</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-27729">251</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-27730">251</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-27731">2,734</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-27732">2,985</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issue
    of share capital in respect of investment in affiliate</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-27733">288</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-27734">288</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-27735">288</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issue
    of share capital, net of issue expenses&#160;(3)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27736">5,552</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27737">5,552</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-27738">5,552</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cost
    of share-based payment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27739">94</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27740">102</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27741">196</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27742">196</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2023</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27743">64,526</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27744">5,282</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27745">5,190</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27746">810</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27747">497</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-27748">68,691</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27749">7,614</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27750">1,973</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-27751">9,587</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">Loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27752">5,883</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27753">2,592</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27754">5,789</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile loss to net cash used&#160;in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Adjustments to the profit or loss items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-27755">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-27756">187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-27757">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-27758">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Cost of share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27759">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27760">897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-27761">43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Finance expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-27762">2,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-27763">6,585</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-27764">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Group&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-27765">210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" unitRef="usd" id="ixv-27766">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Losses from remeasurement of investment in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-27767">1,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-27768">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-27769">829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27770">4,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-27771">85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Working capital adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-27772">409</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-27773">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" unitRef="usd" id="ixv-27774">170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-27775">397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-27776">353</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-27777">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-27778">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-27779">120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in trade receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-27780">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" sign="-" unitRef="usd" id="ixv-27781">77</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Increase in inventory</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-27782">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-27783">668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-27784">833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-27785">703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-27786">643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net cash used in operating activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27787">5,887</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27788">7,917</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27789">5,061</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in restricted bank deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-27790">5</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-27791">15</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-27792">35</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in short-term bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-27793">3,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-27794">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-27795">35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in a company accounted for at equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-27796">400</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-27797">700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Change in fair value of investments in financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-27798">689</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Sale of minority interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-27799">2,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Purchase of financial assets at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-27800">1,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Purchase of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-27801">4,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27802">1,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27803">7,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27804">70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Proceeds from issue of share capital (net of issuance expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-27805">5,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-27806">9,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-27807">7,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Exercise of warrants (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27808">2,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-27809">2,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of issuance expenses related to previous period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-27810">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Interest paid on lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-27811">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-27812">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Repayment of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-27813">47</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-27814">70</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-27815">19</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Repayment of short-term credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ReceiptofShortTermCreditFromOthers" scale="3" sign="-" unitRef="usd" id="ixv-27816">188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-27817">5,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-27818">11,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-27819">10,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-27820">1,498</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" sign="-" unitRef="usd" id="ixv-27821">3,301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" unitRef="usd" id="ixv-27822">4,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash at the beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27823">3,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27824">6,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27825">1,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27826">2,076</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27827">3,574</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27828">6,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <span style="text-decoration:underline">Significant non-cash transactions</span>:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Right-of-use asset recognized with corresponding lease liability</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-27829">102</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-27830">78</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Registration of warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RegistrationOfWarrants" scale="3" unitRef="usd" id="ixv-27831">2,480</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Investment in financial asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentInFinancialAsset" scale="3" unitRef="usd" id="ixv-27832">288</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Unpaid issue expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:UnpaidIssueExpenses" scale="3" unitRef="usd" id="ixv-27833">290</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="ixv-19424"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under
the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (&#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1, which
became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these interim consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
of the Company for the year ended December&#160;31, 2023, were approved on March 31, 2024, and signed on April 1, 2024 (the &#8220;Approval
Date&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2023, the Group had an accumulated deficit of approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-27834">68,691</ix:nonFraction> as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
cash and cash equivalents totaled $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27835">2,076</ix:nonFraction>. In the period ended December 31, 2023, the Company had an operating loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-27836">5,883</ix:nonFraction> and negative
cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-27837">5,887</ix:nonFraction>. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities
arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no
guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms,
would have serious consequences on our financial condition and results of operations. In addition, the Group has started recognizing revenues
from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing and/or new investors.
This dependency will continue until the Group is able to completely finance its operations by generating revenue from its products. These
above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-19623"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_1" escape="true" name="sprcy:BasisOfPresentationOfFinancialStatements" id="ixv-19635"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_2" id="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_3" id="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_4" id="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_BasisOfPresentationOfFinancialStatements-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory" id="ixv-19656"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="sprcy:OperatingTerm" id="ixv-27838">one year</ix:nonNumeric>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" id="ixv-19668"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_3" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-19723"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c0_cont_1" escape="true" name="sprcy:DescriptionOfAcquisitionOfASingleAssetCompany" id="ixv-19735"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit" id="ixv-19747"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" id="ixv-19759"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" id="ixv-19835"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_3" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_4" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_5" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_6" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-19900"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" id="ixv-27839">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory-c0_cont_1"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-27840">6</ix:nonFraction>-<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-27841">50</ix:nonFraction></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-27842">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-27843">33</ix:nonFraction>-<ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-27844">50</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-27845">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-27846">20</ix:nonFraction>-<ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-27847">33</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-27848">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c75" name="ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" id="ixv-27849">see below</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="ixv-19965"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="ixv-19980"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-20029"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_28" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_29" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_30" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_29"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_31" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_32" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_31"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_33" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_34" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_33"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-20336"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="ixv-20351"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-20363"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" id="ixv-20471"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-20560"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-20591"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-20646"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-20685"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-20708"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_11" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" id="ixv-20863"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies&#8221;:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In February 2021, the IASB issued an
amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; (&#8220;the Amendment&#8221;), which replaces the requirement to disclose
&#8217;significant&#8217; accounting policies with a requirement to disclose &#8216;material&#8217; accounting policies. One of the main reasons for the Amendment
is the absence of a definition of the term &#8217;significant&#8217; in IFRS whereas the term &#8216;material&#8217; is defined in several standards and particularly
in IAS 1.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c0_cont_3" id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is applicable for annual
periods beginning on January 1, 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The application of the above Amendment
had an effect on the disclosures of the Company&#8217;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#8217;s consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c0_cont_1" escape="true" name="sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" id="ixv-20881"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c0_cont_2" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a
new definition of &#8220;accounting estimates&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c0_cont_3" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="ixv-20899"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="ixv-20912"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
Company sells products directly to customers mainly through its online Amazon stores.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span>&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" id="ixv-20934"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock-c0_cont_1" escape="true" name="sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" id="ixv-20977"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and/or termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not
exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset
to the Company&#8217;s operation and whether it is a specialized asset, the company&#8217;s past experience with similar leases, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-21120"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock" id="ixv-21130"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27850">1,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27851">3,443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27852">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27853">131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27854">2,076</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-27855">3,574</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="ixv-21211"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInvertoryTextBlock" id="ixv-21221"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-27856">73</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-27857">198</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-27858">669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-27859">470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-27860">742</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-27861">668</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-21279"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclourseOfAccountsReceivablesTableTextBlock" id="ixv-21289"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ValueAddedTaxReceivables" scale="3" unitRef="usd" id="ixv-27862">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ValueAddedTaxReceivables" scale="3" unitRef="usd" id="ixv-27863">45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-27864">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-27865">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-27866">275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-27867">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-27868">540</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-27869">131</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="ixv-21357"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of Orimmune Bio Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 22, 2016, the Company entered
into a share transfer agreement (the &#8220;Transfer Agreement&#8221;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#8220;Orimmune&#8221;)
and Karma Link Ltd. (the &#8220;Buyer&#8221;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On December 13, 2018, an additional
amendment to the Transfer Agreement was signed between the parties, under which it was agreed that Orimmune will be assigned certain rights
in intellectual property (&#8220;IP&#8221;) related to the licensed technology owned by the Company subject to certain conditions precedent
which were still not met as of December 31, 2023. As of the Approval Date, the conditions precedent have not yet been completed and the
assignment of the IP related to the licensed technology owned by us has not yet been transferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coeruleus - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On May 15, 2020, the Company entered
into a series of transactions (together, the &#8220;Joint Venture Transaction&#8221;), including a definitive share transfer agreement
with Capital Point Ltd. (&#8220;Capital Point&#8221;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital
Point sold to Evero <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesSold" scale="0" unitRef="shares" id="ixv-27870">5,952,469</ix:nonFraction> ordinary shares, NIS <ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesParValue" scale="0" unitRef="ilsPershares" id="ixv-27871">0.01</ix:nonFraction> par value each, of Coeruleus Ltd. (the &#8220;Purchased Coeruleus Shares&#8221;
and &#8220;Coeruleus,&#8221; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-27872">46</ix:nonFraction>%), engaged in,
among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce
the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic
encephalopathy. The Purchased Coeruleus Shares represented approximately <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-27873">35</ix:nonFraction>% of the issued and outstanding share capital of Coeruleus.
In consideration thereof, Evero issued and sold to Capital Point <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesSold" scale="0" unitRef="shares" id="ixv-27874">176,470</ix:nonFraction> ordinary shares, NIS <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesParValue" scale="0" unitRef="ilsPershares" id="ixv-27875">1.00</ix:nonFraction> par value each, constituting <ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-27876">15</ix:nonFraction>% of
the issued and outstanding share capital of Evero, which was valued at $<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairMarketValue" scale="3" unitRef="usd" id="ixv-27877">351</ix:nonFraction>, based on apportionment of the fair market value of the Company
as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-27878">11</ix:nonFraction>% of Coeruleus&#8217; issued
and outstanding share capital. The transaction costs of $<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" scale="3" unitRef="usd" id="ixv-27879">51</ix:nonFraction> were also capitalized as part of the investment in associate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-27880">340</ix:nonFraction>
of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is equal
to the closing price of the Company&#8217;s ordinary shares on the trading day on which the notice of exercise was actually received by
the Company and shall be paid by transferring to the Company a duly executed share transfer deed for <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="sprcy:DulyExecutedShareTransferDeedForOrdinaryShares" scale="0" unitRef="shares" id="ixv-27881">9,577</ix:nonFraction> ordinary shares of Evero. The
Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coeruleus - Joint Venture Transaction (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $<ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentFromShareholders" scale="3" unitRef="usd" id="ixv-27882">30</ix:nonFraction>. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="sprcy:IssuedAndOutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-27883">1</ix:nonFraction>% of the issued and outstanding shares of
Coeruleus. As of December 31, 2023, the fair value of the Company&#8217;s investment in Coeruleus is $<span style="-sec-ix-hidden: hidden-fact-121">nil</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitocareX - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-27884">700</ix:nonFraction>, and agreed to invest over the next two years, an additional $<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-27885">1,000</ix:nonFraction>, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a <ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27886">50.01</ix:nonFraction>% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-27887">700</ix:nonFraction> to MitoCareX. As of December 31, 2022, the Company owns
<ix:nonFraction contextRef="c95" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-27888">31.48</ix:nonFraction>% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-27889">400</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c97" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27890">31.48</ix:nonFraction>% to <ix:nonFraction contextRef="c98" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27891">41.92</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-27892">600</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27893">41.92</ix:nonFraction>% to <ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-27894">52.73</ix:nonFraction>%. Notwithstanding the above, the Company
and MitoCare X agreed for the additional $<ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInstallment" scale="3" unitRef="usd" id="ixv-27895">600</ix:nonFraction> installment to be deferred to March 25, 2024. As of the date of this report the $<ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaid" scale="3" unitRef="usd" id="ixv-27896">600</ix:nonFraction> installment
has been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-27897">210</ix:nonFraction> (for the year ended December 31, 2022
- $<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-27898">109</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="ixv-27899">The table below summarizes the fair
value of the investment in MitoCareX:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsDate" scale="3" unitRef="usd" id="ixv-27900">700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-27901">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-27902">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAchievementOfFirstMilestone" scale="3" unitRef="usd" id="ixv-27903">400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromInvestment" scale="3" unitRef="usd" id="ixv-27904">210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-27905">781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="ixv-21542"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2022, the Company invested $<ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAmount" scale="3" unitRef="usd" id="ixv-27906">1,500</ix:nonFraction> in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedButNotFullyPaid" scale="0" unitRef="shares" id="ixv-27907">230,769</ix:nonFraction> common shares of Clearmind, resulting in the Company holding <ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-27908">9.33</ix:nonFraction>% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; &#160; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company&#8217;s shares in Clearmind was reduced from <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-27909">230,769</ix:nonFraction> common shares to <ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-27910">7,692</ix:nonFraction>. As of December 31, 2023, the listed share price of Clearmind on Nasdaq was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="0" unitRef="usdPershares" id="ixv-27911">2.81</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2023, of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-27912">727</ix:nonFraction> on its investment (for the year ended December 31, 2022 - $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-27913">771</ix:nonFraction>). &#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2023, the Company entered into an investment agreement (the &#8220;Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), an Israeli company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS <ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="ils" id="ixv-27914">2,500,000</ix:nonFraction> in cash, in exchange for ordinary shares, NIS <ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-27915">0.05</ix:nonFraction> par value, of AutoMax based on a price per share of NIS <ix:nonFraction contextRef="c110" decimals="1" format="ixt:num-dot-decimal" name="sprcy:PricePerShare" scale="0" unitRef="ilsPershares" id="ixv-27916">0.5</ix:nonFraction>. As of December 31, 2023, the listed share price of AutoMax on the TASE was NIS <ix:nonFraction contextRef="c110" decimals="3" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="0" unitRef="ilsPershares" id="ixv-27917">0.384</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLoss" scale="3" unitRef="usd" id="ixv-27918">158</ix:nonFraction> on its investment.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-21570"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 1, 2020, the Company entered
into a one-year lease agreement with a third party for an area of approximately <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-27919">100</ix:nonFraction> square meters for the Company&#8217;s offices in the
district of Tel Aviv, Israel. The yearly lease fee was set at approximately $<ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LeaseFee" scale="3" unitRef="usd" id="ixv-27920">44</ix:nonFraction>, linked to the NIS. The lease expired on <ix:nonNumeric contextRef="c112" format="ixt:date-monthname-day-year-en" name="sprcy:ExpireTerm" id="ixv-27921">August 31, 2021</ix:nonNumeric>.
The Company did not exercise its option to extend the lease until August 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 1, 2021, the Company entered
into a two-year joint lease agreement with a third party and for a total area of approximately <ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-27922">240</ix:nonFraction> square meters, whereby the Company
occupies approximately <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SquareMeters" scale="0" unitRef="pure" id="ixv-27923">120</ix:nonFraction> square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company and the third
party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LeaseFee" scale="3" unitRef="usd" id="ixv-27924">40</ix:nonFraction>, linked to the NIS.
On July 7, 2023, the lease was extended until June 30, 2025.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="ixv-21609"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-21619"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assets owned and used by the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27925">11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27926">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27927">78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27928">122</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">New lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27929">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27930">103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27931">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27932">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27933">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27934">225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27935">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27936">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27937">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27938">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27939">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27940">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27941">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27942">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27943">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27944">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27945">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27946">117</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27947">5</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27948">28</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27949">75</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27950">108</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27951">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27952">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27953">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27954">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27955">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27956">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27957">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27958">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27959">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27960">78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" scale="3" unitRef="usd" id="ixv-27961">122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27962">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27963">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27964">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27965">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27966">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27967">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27968">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-27969">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27970">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27971">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27972">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" scale="3" unitRef="usd" id="ixv-27973">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27974">8</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27975">30</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27976">19</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" scale="3" unitRef="usd" id="ixv-27977">57</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2023, 2022 and 2021 amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-27978">52</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-27979">43</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-27980">32</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-22244"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the Company
incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for
the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-27981">4,540</ix:nonFraction> and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" scale="3" unitRef="usd" id="ixv-27982">1,120</ix:nonFraction> during the 12-month period following the closing of the Acquisition.
The Company paid an additional $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseCosts" scale="3" unitRef="usd" id="ixv-27983">321</ix:nonFraction> as purchase costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsToPurchase" scale="3" unitRef="usd" id="ixv-27984">15,000</ix:nonFraction> worth of warrants to purchase ordinary shares of the Company at an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-27985">7.00</ix:nonFraction> per share (with a cashless exercise
mechanism) and with an exercise period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="sprcy:ExercisePeriod" id="ixv-27986">five years</ix:nonNumeric> from the closing of the Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $<ix:nonFraction contextRef="c132" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" unitRef="usd" id="ixv-27987">100</ix:nonFraction> million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $<ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="sprcy:pricePerShare" scale="0" unitRef="usdPershares" id="ixv-27988">10.00</ix:nonFraction> or above.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AmountTotal" scale="3" unitRef="usd" id="ixv-27989">4,861</ix:nonFraction> as an intangible asset, to be amortized over a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-27990">10</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-27991">1,042</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="sprcy:RevenueTerm" id="ixv-27992">8.7</ix:nonNumeric>
years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined based
on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s expectations that
revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-27993">13.8</ix:nonFraction>% and a
declining growth rate for the long term, reaching <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-27994">2</ix:nonFraction>% at the terminal year. Theoretical royalties arising from the brand were capitalized
at a discount rate of <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" unitRef="pure" id="ixv-27995">20.6</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock-c0_cont_1" escape="true" name="sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock" id="ixv-27996">The table below
summarizes the fair value of the intangible asset:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseofAssets" scale="3" unitRef="usd" id="ixv-27997">4,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost" scale="3" unitRef="usd" id="ixv-27998">144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-27999">4,717</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28000">1,042</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost" scale="3" unitRef="usd" id="ixv-28001">486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28002">3,189</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2023, the Company recognized depreciation expenses in respect to intangible asset in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28003">486</ix:nonFraction> (for the year ended December 31,
2022 - $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-28004">144</ix:nonFraction>).&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-22368"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfTradePayables" id="ixv-22378"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccruedExpenses" scale="3" unitRef="usd" id="ixv-28005">538</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AccruedExpenses" scale="3" unitRef="usd" id="ixv-28006">901</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28007">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28008">298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28009">802</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-28010">1,199</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfOtherAccountsPayableTextBlock" id="ixv-22459"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="ixv-22469"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-28011">48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-28012">102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-28013">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-28014">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-28015">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-28016">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28017">185</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-28018">193</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-22537"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_1" escape="true" name="sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities" id="ixv-22556">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_2" id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28019">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28020">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28021">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28022">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28023">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28024">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28025">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-28026">659</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-28027">591</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28028">6,065</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28029">4,316</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28030">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28031">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28032">532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28033">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28034">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28035">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28036">656</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28037">2,866</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of
    financial assets and financial liabilities: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:continuation continuedAt="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_3" id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_2">The tables below are a comparison between the carrying amount
and fair value of the Company&#8217;s financial instruments as of December 31, 2023, and 2022, which are presented in the financial statements
not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation continuedAt="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_4" id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28039">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28040">2,141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28041">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-28042">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28043">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28044">62</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28045">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28046">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-28047">659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-28048">659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28049">6,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28050">6,065</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28051">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28052">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28053">532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28054">532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28055">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28056">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28057">656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28058">656</ix:nonFraction></td><td style="text-align: left"/></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28059">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-28060">3,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28061">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GovernmentAuthorities" scale="3" unitRef="usd" id="ixv-28062">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28063">46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-28064">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-28065">591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsInFinancialAssets" scale="3" unitRef="usd" id="ixv-28066">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28067">4,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-28068">4,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28069">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-28070">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28071">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-28072">2,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28073">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-28074">27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28075">2,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-28076">2,866</ix:nonFraction></td><td style="text-align: left"/></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_3" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dekel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#8220;Dekel&#8221;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#8220;Private Placement&#8221;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#8220;Notes&#8221;), with an aggregate original principal amount of approximately
$<ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="3" unitRef="usd" id="ixv-28077">350</ix:nonFraction>, at an aggregate purchase price of $<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" scale="3" unitRef="usd" id="ixv-28078">315</ix:nonFraction> to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-28079">12,088</ix:nonFraction> ordinary shares of the Company (the &#8220;Private Placement Warrant&#8221;) and <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-28080">1,538</ix:nonFraction> ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="3" unitRef="usd" id="ixv-28081">220</ix:nonFraction> at a purchase price of $<ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchasePrice" scale="3" unitRef="usd" id="ixv-28082">5,148</ix:nonFraction>. The Notes are unsecured,
have a maturity date of <ix:nonNumeric contextRef="c133" format="ixt:date-monthname-day-year-en" name="sprcy:MaturityDate" id="ixv-28083">March 23, 2021</ix:nonNumeric>, bear interest at a rate of <ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-28084">12</ix:nonFraction>% per annum, and may be converted, at the election of the holder,
into ordinary shares at an initial conversion price of $<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InitialConversionPrice" scale="0" unitRef="usdPershares" id="ixv-28085">0.35</ix:nonFraction> per ordinary share (the &#8220;Fixed Conversion Price&#8221;), subject to
adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed
Conversion Price or <ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ConversionPrice" scale="-2" unitRef="pure" id="ixv-28086">70</ix:nonFraction>% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary
shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received
by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and
on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $<ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinaryShareExercisePrice" scale="0" unitRef="usdPershares" id="ixv-28087">0.35</ix:nonFraction> per ordinary
share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dekel (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock-c0_cont_1" escape="true" name="sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" id="ixv-28088">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-28089">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-28090">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="sprcy:DividendYield" scale="-2" unitRef="pure" id="ixv-28091">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-28092">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-28093">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ExpectedVolatility" scale="-2" unitRef="pure" id="ixv-28094">122.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28095">3.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28096">4.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="4" format="ixt:num-dot-decimal" name="sprcy:RiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28097">0.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-28098">4.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-28099">19.66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingAdsPrice" scale="0" unitRef="usdPershares" id="ixv-28100">11.18</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28101">637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28102">637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExercisePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28103">637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-28104">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-28105">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsFairValueinDollarsPerShares" scale="0" unitRef="usdPershares" id="ixv-28106">0.36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Refer to Note 14a for more information.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-23565"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. <ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" id="ixv-28107">These contributions and contributions for compensation represent defined contribution plans.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses in respect of defined contribution plans</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-28108">105</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-28109">115</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-28110">98</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-23639"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-28111"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-28112"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-28113">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2023, 2022, and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
net carryforward tax losses are estimated to grow to approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:OperatingLossCarryforwardsTaxAmount" scale="3" unitRef="usd" id="ixv-28114">62,000</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-23706"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
<ix:nonNumeric contextRef="c0" name="sprcy:DekelLicenseAgreementDescription" id="ixv-28115">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for a
specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under
the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AnnualInvestment" scale="3" unitRef="usd" id="ixv-28116">350</ix:nonFraction>. The Amendment also
included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive Chairman
of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $<ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalMilestoneAmount" scale="3" unitRef="usd" id="ixv-28117">75</ix:nonFraction>, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentAmount" scale="3" unitRef="usd" id="ixv-28118">122</ix:nonFraction> out of a total estimated amount of
approximately $<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-28119">776</ix:nonFraction>. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $<ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-28120">1,385</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $<ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-28121">370</ix:nonFraction>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-28122">340,000</ix:nonFraction> of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="3" unitRef="ils" id="ixv-28123">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c4" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="6" unitRef="usd" id="ixv-28124">2.75</ix:nonFraction> million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of December 31, 2023, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot
predict the likelihood of success of the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-23861"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-23877"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-28125">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28126">706,683</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-28127">75,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28128">261,494</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to <ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28129">75,000,000</ix:nonFraction> ordinary shares with <span style="-sec-ix-hidden: hidden-fact-181">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, <ix:nonNumeric contextRef="c152" name="sprcy:DescriptionOfReverseShareSplit" id="ixv-28130">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1 (the &#8220;Third Reverse Split&#8221;).</ix:nonNumeric> Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of <ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28131">75,000,000</ix:nonFraction> ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-182">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfIssuedAndOutstandingShareCapital-c0_cont_1" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-23996"><i>Issued and outstanding share capital:</i></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of<br/> ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28132">261,494</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; in respect of investment in affiliate (Note 18f)</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" scale="0" unitRef="shares" id="ixv-28133">13,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share issued to a consultant (Note 19(a)(5))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ShareIssuedToAConsultant" scale="0" unitRef="shares" id="ixv-28134">7,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of shelf prospectus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus" scale="0" unitRef="shares" id="ixv-28135">296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of August 2023 financing round (Note 18i)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-28136">237,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of rounding errors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors" scale="0" unitRef="shares" id="ixv-28137">2,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of October 2023 financing round (Note 18j)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" scale="0" unitRef="shares" id="ixv-28138">182,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28139">706,683</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28140">923</ix:nonFraction> ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28141">1,423</ix:nonFraction> ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 22, 2023, the Company issued
<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28142">13,858</ix:nonFraction> ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered into
by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also note 25a)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_4" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $<ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-28143">8,150</ix:nonFraction>, providing for the issuance of an
aggregate of <ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-28144">44,332</ix:nonFraction> units, as follows: (a) <ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-28145">35,243</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-28146">183.82</ix:nonFraction> per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series B Warrant
(the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase half
the number of units, and (b) <ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-28147">9,089</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-28148">183.79</ix:nonFraction> per unit, consisting of (i) one pre-funded warrant to purchase
one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The 2021 Series A Warrants have an
exercise price of&#160;$<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28149">183.82</ix:nonFraction>&#160;per ordinary share and the 2021 Series B Warrants have an exercise price of&#160;$<ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28150">275.60</ix:nonFraction>&#160;per
ordinary share). Both were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c158" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-28151">five years</ix:nonNumeric> from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2021, the Company issued <ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28152">4,929</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-28153">385</ix:nonFraction> 2021 Series A Warrants and the exercise of <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-28154">4,544</ix:nonFraction> of pre-funded
warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued <ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28155">3,846</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-28156">3,846</ix:nonFraction> pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GrossProceeds" scale="3" unitRef="usd" id="ixv-28157">10,210</ix:nonFraction>(the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-28158">136,388</ix:nonFraction> units and pre-funded units, as follows: (a) <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-28159">12,885</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-28160">74.88</ix:nonFraction> per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-28161">123,504</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-28162">73.29</ix:nonFraction> per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$<ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="sprcy:WarrantsExercisePrice" scale="0" unitRef="pure" id="ixv-28163">68.38</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c167" format="ixt-sec:durwordsen" name="sprcy:DateOfIssuance" id="ixv-28164">seven years</ix:nonNumeric> from the
date of issuance.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFairValueOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="ixv-28165">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfFairValueOfFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28166">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28167">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28168">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28169">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28170">3.872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-28171">3.97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28172">4.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28173">19.656</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28174">68.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28175">68.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-28176">192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-28177">2,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued <ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28178">123,504</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-28179">123,504</ix:nonFraction> pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of <ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28180">212,500</ix:nonFraction> ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28181">5.20</ix:nonFraction> per
ordinary share and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28182">37,500</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction contextRef="c173" decimals="3" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-28183">5.174</ix:nonFraction> per pre-funded warrant,
for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateGrossProceeds" scale="3" unitRef="usd" id="ixv-28184">1,300</ix:nonFraction>, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28185">37,500</ix:nonFraction> ordinary shares solely to
cover over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $<ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-28186">5,026</ix:nonFraction>, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28187">1,930,108</ix:nonFraction> units, each unit consisting of two pre-funded warrants, or Pre-Funded Warrants. The Pre-Funded
Warrants have an exercise price of $<ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-28188">0.001</ix:nonFraction>, are immediately exercisable upon issuance and have a term of five years from the date of issuance.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-24422"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock-c0_cont_1" escape="true" name="sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" id="ixv-28189">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentsExpenses" scale="3" unitRef="usd" id="ixv-28190">34</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentsExpenses" scale="3" unitRef="usd" id="ixv-28191">264</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentsExpenses" scale="3" unitRef="usd" id="ixv-28192">27</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-28193">68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-28194">633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd" id="ixv-28195">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-28196">102</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-28197">897</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExpensesDueToSharebasedCompensation" scale="3" unitRef="usd" id="ixv-28198">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2005 and 2015 ESOP and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span>The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board approved
to reserve for <span>issuance under the 2023 Plan <span style="-sec-ix-hidden: hidden-fact-183">1,000,0000</span> Ordinary Shares. As </span>of the date of
this report, no shares were issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board approved and granted <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesGranted" scale="0" unitRef="shares" id="ixv-28199">45</ix:nonFraction> ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $<ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-28200">10,920.00</ix:nonFraction> per share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_1" escape="true" name="sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" id="ixv-24590"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_2" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-28201">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-28202">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28203">2.61</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-28204">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
was set at $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOption" scale="3" unitRef="usdPershares" id="ixv-28205">5,824</ix:nonFraction> per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2019 (the &#8220;2019 Grant Date&#8221;), the Board approved the grant of 3 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 1 Share Options was not granted. Out of the 2 Share Options that were granted, 1 Share Options didn&#8217;t require the general meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-28206">5,460.00</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">According to IFRS 2, &#8220;<i>Share-based
Payment</i>&#8221;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#8217;s approval was calculated based on parameters as of December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><ix:continuation continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_3" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_2"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_4" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-28207">2,031.12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-28208">4,004</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-28209">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-28210">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-28211">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-28212">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28213">1.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28214">1.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c185" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-28215">9.78</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-28216">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the 2019 General Meeting (valuated as of December 31, 2019) was
set at $<ix:nonFraction contextRef="c181" decimals="1" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOption" scale="0" unitRef="usdPershares" id="ixv-28217">2,966.6</ix:nonFraction> and $<ix:nonFraction contextRef="c182" decimals="1" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOption" scale="0" unitRef="usdPershares" id="ixv-28218">1,328.6</ix:nonFraction>, per Share Option, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ShareOptionsGranted" scale="0" unitRef="shares" id="ixv-28219">6,851</ix:nonFraction> Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-28220">169</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><ix:continuation continuedAt="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_5" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_4"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;10,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-28221">129.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="sprcy:UnderlyingOrdinarySharePrices" scale="0" unitRef="usdPershares" id="ixv-28222">174.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-28223">0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" scale="-2" unitRef="pure" id="ixv-28224">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-28225">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-28226">134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28227">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-28228">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c186" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-28229">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c187" format="ixt-sec:duryear" name="sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" id="ixv-28230">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $<ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-28231">158.34</ix:nonFraction> per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $<ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-28232">114.66</ix:nonFraction> per Share Option. The Share Options&#8217; vesting period was set to commence retroactively from April 21, 2021, and
end at April 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company issued to consultants <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-28233">7,942</ix:nonFraction> ordinary shares in respect of services rendered. The ordinary shares were granted at a discount rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesGrantedDiscountRate" scale="-2" unitRef="pure" id="ixv-28234">25</ix:nonFraction>% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:FairValueOfOrdinarySharesGranted" scale="0" unitRef="usd" id="ixv-28235">94</ix:nonFraction>. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock-c0_cont_1" escape="true" name="sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" id="ixv-24889"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-28236">7,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28237">166.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-28238">47</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28239">144.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-28240">7,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28241">166.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-28242">5,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28243">165.58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-28244">209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28245">76.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-28246">6,851</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28247">169</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfOutstandingShareOption" scale="0" unitRef="shares" id="ixv-28248">7,060</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28249">166.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-28250">4,141</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-28251">163.80</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Share Options were granted during 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption" id="ixv-28252">4.03</ix:nonNumeric> years and <ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption" id="ixv-28253">5.03</ix:nonNumeric> years as of December 31, 2023, and 2022, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-28254">169</ix:nonFraction> - $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-28255">21,944</ix:nonFraction> (inclusive) as of December 31, 2023, and 2022, respectively.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-25093"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company sells products directly
to customers mainly through its online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return, the Company recognizes
revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a
significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable
if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its
estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31,
2023, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right
of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company evaluates
the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining the nature
of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon
its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment
of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on
its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, sales are recorded
on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock-c0_cont_1" escape="true" name="sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" id="ixv-28256">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock-c0_cont_2" id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022(*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amazon fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchased goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd" id="ixv-28257">672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd">301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd" id="ixv-28259">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd" id="ixv-28261">683</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="sprcy:CostOfGoodsSold" scale="3" unitRef="usd">322</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-25266"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:- </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss-c0_cont_1" escape="true" name="sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss" id="ixv-25276"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year ended December&#160;31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research and development expenses:</span></i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages and related expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c200" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28264">392</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c201" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28265">436</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c202" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28266">357</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c203" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28267">34</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c204" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28268">264</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c205" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28269">27</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory, professional and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28270">719</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c207" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28271">750</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28272">934</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and preclinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28273">101</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28274">703</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28275">165</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28276">254</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28277">369</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c214" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28278">172</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry and formulations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28279">141</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28280">281</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28281">335</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28282">1,641</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28283">2,803</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses1" scale="3" unitRef="usd" id="ixv-28284">1,990</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">General and administrative expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages and related expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c200" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28285">415</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c201" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28286">437</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c202" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28287">256</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c203" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28288">68</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c204" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28289">633</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c205" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28290">16</ix:nonFraction></span></td>
    <td>&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon fees</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28291">1,042</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28292">424</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28293">145</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28294">90</ix:nonFraction></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional and directors&#8217; fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28295">2,594</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28296">2,499</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28297">2,417</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business development expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28298">86</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28299">161</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28300">5</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28301">202</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28302">162</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28303">165</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office maintenance, rent and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28304">110</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)<ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd">80</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28306">135</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor relations and business expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28307">369</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28308">1,486</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28309">784</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28310">5,031</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28311">5,972</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-28312">3,778</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Other expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s share of losses of company accounted for at equity, net</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28313">210</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28314">109</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Finance income:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change in fair value of financial liabilities designated at fair value through profit or loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28315">2,205</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28316">7,832</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate differences, net</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28317">14</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28318">2,219</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-28319">7,832</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance expenses:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance expenses related to warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28320">1,204</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28321">6</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate differences, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28322">4</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c243" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28323">3</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses from remeasurement of investment in financial assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28324">1,046</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28325">770</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance expense in respect of leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c250" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28326">9</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c251" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28327">15</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c252" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28328">4</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance expenses from interest and commissions</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-202; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c254" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28329">21</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c255" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28330">8</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28331">1,055</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28332">2,014</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-28333">21</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-26135"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE/ADS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:EarningsPerShareExplanatory" id="ixv-26151"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_EarningsPerShareExplanatory-c0_cont_2" id="_EarningsPerShareExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>thousands</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares" id="ixv-28334">408</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-28335">5,883</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares">176</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-28337">2,592</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrs-full:WeightedAverageShares" scale="3" unitRef="shares">79</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-28339">5,789</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares" id="ixv-28340">408</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-28341">5,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares">176</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-28343">2,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" id="ix_13_fact" name="ifrs-full:AdjustedWeightedAverageShares" scale="3" unitRef="shares">79</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-28345">5,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerShareExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable warrants to investors.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-26451"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried out
according to the results of the segment&#8217;s activity. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="ixv-28347">The Group&#8217;s CODM is the CEO
of the Company.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_2" id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-28348">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-28349">2,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-28350">2,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-28351">2,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28352">5,359</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28353">414</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28354">5,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28355">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-28356">1,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-28357">1,164</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-28358">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28359">5,883</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_3" id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-28360">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-28361">1,347</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-28362">1,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromSaleOfGoods" scale="3" unitRef="usd" id="ixv-28363">1,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28364">8,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-28365">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28366">8,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-28367">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-28368">5,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:TaxExpense" scale="3" unitRef="usd" id="ixv-28369">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28370">2,592</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1"><ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_4" id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">External</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28371">5,768</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-28372">5,768</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" unitRef="usd" id="ixv-28373">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-28374">5,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_5" id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-28375">7,069</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-28376">4,113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-28377">11,182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-28378">1,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-28379">154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-28380">1,595</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-28381">9,664</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c265" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-28382">941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-28383">10,605</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-28384">4,021</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c265" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-28385">135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-28386">4,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-27125"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" id="ixv-27141"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c269" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-28387">121</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c269" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-28388">108</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c268" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28389">95</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c270" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28390">70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c271" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-28391">55</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" id="ixv-27246"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-28392">40</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-28393">208</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-28394">2,985</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-27305"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-28395">1,204</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-28396">1,940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-28397">962</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-28398">220</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-28399">84</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-28400">779</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-28401">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands. Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands (see also note 25a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-28402">40</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-28403">208</ix:nonFraction>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, we invested $<ix:nonFraction contextRef="c266" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="6" unitRef="usd" id="ixv-28404">1.5</ix:nonFraction> million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for <ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExchangeOfCommonShares" scale="0" unitRef="shares" id="ixv-28405">7,692</ix:nonFraction> common shares of Clearmind, representing <ix:nonFraction contextRef="c267" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-28406">9.33</ix:nonFraction>% of the outstanding share capital of Clearmind (see also note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitai Weiss, our chairman of the board of directors, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" id="ixv-27455"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px; text-align: left"><b>NOTE 25:- </b></td><td style="text-align: justify"><b>SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a <ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestPercentgae" scale="-2" unitRef="pure" id="ixv-28407">49</ix:nonFraction>% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution<sup>TM</sup>, for $<ix:nonFraction contextRef="c273" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-28408">2,500</ix:nonFraction> in cash, and additional deferred cash payments of approximately $<ix:nonFraction contextRef="c272" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DeferredCashPayments" scale="3" unitRef="usd" id="ixv-28409">489,330</ix:nonFraction> accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately <ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-28410">51</ix:nonFraction>% of the share capital of SciSparc US.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the agreement, at the closing
of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands provides
management services to SciSparc US for the Wellution<sup>TM </sup>brand for a monthly fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FeeExpenses" scale="3" unitRef="usd" id="ixv-28411">20</ix:nonFraction> and Jeffs&#8217; Brands received a one-time
signing bonus in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BonusAmountReceived" scale="3" unitRef="usd" id="ixv-28412">51</ix:nonFraction>. The consulting agreement is for an undefined period of time and may be terminated by either party
with 30 days advance notice. On November 2023 the monthly fee reduced to $<ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:FeeExpenses" scale="3" unitRef="usd" id="ixv-28413">10</ix:nonFraction> thousand. For the year ended December 31, 2023, the Company
has recorded management services expenses in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-28414">220</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, in connection with the closing
of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MutualShareExchangeAmount" scale="3" unitRef="usd" id="ixv-28415">288,238</ix:nonFraction> of ordinary shares
from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing
price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the
closing. Accordingly, the Company acquired <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-28416">35,345</ix:nonFraction> ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired <ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesAcquired" scale="0" unitRef="shares" id="ixv-28417">13,858</ix:nonFraction> ordinary
shares of the Company having an aggregate value of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValue" scale="3" unitRef="usd" id="ixv-28418">288,238</ix:nonFraction>, which was adjusted from $<ix:nonFraction contextRef="c276" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustedAmountOfAggregateValue" scale="3" unitRef="usd" id="ixv-28419">300,000</ix:nonFraction> according to the <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OwnershipPercentage" scale="-2" unitRef="pure" id="ixv-28420">4.99</ix:nonFraction>% ownership limit included
in the definitive agreements. As of December 31, 2023, the listed share price of Jeff&#8217;s Brands on the NASDAQ was $ <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ListedSharePrice" scale="0" unitRef="usdPershares" id="ixv-28421">3.05</ix:nonFraction>, and the
Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLossOnInvestment" scale="3" unitRef="usd" id="ixv-28422">180</ix:nonFraction> on its investment.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. (FORMERLY THERAPIX BIOSCIENCES
LTD.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-27504"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $<ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" unitRef="usd" id="ixv-28423">20,000</ix:nonFraction> of the Company&#8217;s Ordinary Shares (the &#8220;Advance Shares&#8221;). Of the $<ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-28424">20,000</ix:nonFraction>
eligible to be sold pursuant to the SEPA, or the Commitment Amount, Company has sold <ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28425">925,159</ix:nonFraction> ordinary shares as of the issuance date of
these financial statements. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of <ix:nonFraction contextRef="c277" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePricePercentage" scale="-2" unitRef="pure" id="ixv-28426">97</ix:nonFraction>% of
the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PrepaidAdvance" scale="3" unitRef="usd" id="ixv-28427">5,000</ix:nonFraction>, each a Pre-Paid Advance. Each Pre-Paid Advance will
be evidenced by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and
shall accrue interest on the outstanding principal balance thereon at a rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AccruedInterestPercentage" scale="-2" unitRef="pure" id="ixv-28428">5</ix:nonFraction>% per annum, increasing to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:CommitmentPercentage" scale="-2" unitRef="pure" id="ixv-28429">18</ix:nonFraction>% per annum upon an Event
of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to YA
a monthly installment payment of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaymentPercentage" scale="-2" unitRef="pure" id="ixv-28430">10</ix:nonFraction>% of the original principal amount of the Promissory Note and accrued interest, payable in cash or
by submitting an advance notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of the
monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash, the installment amount shall also include
a payment premium in the amount of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PaymentPremiumPercentage" scale="-2" unitRef="pure" id="ixv-28431">5</ix:nonFraction>% of the principal amount of the installment payment. The Promissory Note contains the Company&#8217;s
customary representations and warranties and Events of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the SEPA, the
Company issued to YA an aggregate of <ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-28432">55,293</ix:nonFraction> of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-28433">200</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and commissions
and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA The Company will pay the expenses
(except brokerage fees and commissions and similar expenses) incurred to register under the Securities Act the offer and sale of the Ordinary
Shares pursuant to the SEPA by YA.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - - - - - - - - - - - -
-</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 206; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>









</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c5" id="hidden-fact-0" name="ifrs-full:NoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-1" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-2" name="ifrs-full:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-3" name="ifrs-full:SalesAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-4" name="ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-5" name="ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-7" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-8" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-9" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-10" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-11" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-12" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-13" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-14" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-15" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-16" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-17" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-19" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-20" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-21" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-22" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-25" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-26" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-27" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-28" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-29" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-30" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-31" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-32" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-33" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-34" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-35" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-36" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-37" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-38" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-39" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-40" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-41" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-42" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-43" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-44" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-45" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-46" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-47" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-48" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-49" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-50" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-51" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-52" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-53" name="sprcy:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-54" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-55" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-56" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-57" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-58" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-59" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c50" id="hidden-fact-60" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c51" id="hidden-fact-61" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-62" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-63" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-64" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c50" id="hidden-fact-65" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c51" id="hidden-fact-66" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-67" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-68" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-69" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c51" id="hidden-fact-70" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-71" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-72" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-73" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-74" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-75" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c51" id="hidden-fact-76" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-77" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-78" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-79" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-80" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-81" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-82" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-83" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-84" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-85" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-86" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-87" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-89" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-91" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-92" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-93" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-95" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-96" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-97" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-98" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-99" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-100" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-101" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-102" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-103" name="sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-104" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-105" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-106" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-107" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-108" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-109" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-110" name="sprcy:ReceiptofShortTermCreditFromOthers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-111" name="sprcy:ReceiptofShortTermCreditFromOthers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-112" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="sprcy:RegistrationOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-114" name="sprcy:RegistrationOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-115" name="sprcy:InvestmentInFinancialAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-116" name="sprcy:InvestmentInFinancialAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="sprcy:UnpaidIssueExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-118" name="sprcy:UnpaidIssueExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-119" name="sprcy:LeaseholdImprovements" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-120" name="ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-121" name="sprcy:FairValueOfInvestment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-122" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c71" id="hidden-fact-123" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-124" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c120" id="hidden-fact-125" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-126" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-127" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-128" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-129" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-130" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c125" id="hidden-fact-131" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-132" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c131" id="hidden-fact-133" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-134" name="ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c125" id="hidden-fact-135" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-136" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-137" name="sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-138" name="ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-139" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-140" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-141" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-142" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-143" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-144" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-145" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-146" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-147" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-148" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-149" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-150" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-151" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-152" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-153" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-154" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-155" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-156" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-157" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-158" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-159" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-160" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-161" name="ifrs-full:RestrictedCashAndCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c141" id="hidden-fact-162" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-163" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-164" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c144" id="hidden-fact-165" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-166" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-167" name="sprcy:GovernmentAuthorities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-168" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-169" name="ifrs-full:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-170" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-171" name="sprcy:InvestmentsInFinancialAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-172" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-173" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-174" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-175" name="sprcy:CreditFromOthers" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-176" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-177" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-178" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-179" name="ifrs-full:LeaseLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-180" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c151" id="hidden-fact-181" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c153" id="hidden-fact-182" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c178" decimals="0" id="hidden-fact-183" name="ifrs-full:NumberOfSharesIssued" unitRef="shares">10000000</ix:nonFraction>
<ix:nonFraction contextRef="c188" id="hidden-fact-184" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c189" id="hidden-fact-185" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c190" id="hidden-fact-186" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c193" id="hidden-fact-187" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c194" id="hidden-fact-188" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c195" id="hidden-fact-189" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c196" id="hidden-fact-190" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c199" id="hidden-fact-191" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-192" name="sprcy:CostOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c220" id="hidden-fact-193" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-194" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c240" id="hidden-fact-195" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c242" id="hidden-fact-196" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c243" id="hidden-fact-197" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-198" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c244" id="hidden-fact-199" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c241" id="hidden-fact-200" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c249" id="hidden-fact-201" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c253" id="hidden-fact-202" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-203" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-204" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-205" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c256" id="hidden-fact-206" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c256" id="hidden-fact-207" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c258" id="hidden-fact-208" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c258" id="hidden-fact-209" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c260" id="hidden-fact-210" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c261" id="hidden-fact-211" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-212" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c260" id="hidden-fact-213" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c261" id="hidden-fact-214" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-215" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c261" id="hidden-fact-216" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c268" id="hidden-fact-217" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-218" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c271" id="hidden-fact-219" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c268" id="hidden-fact-220" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-221" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c271" id="hidden-fact-222" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c269" id="hidden-fact-223" name="ifrs-full:CurrentLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-224" name="sprcy:ResearchAndDevelopmentExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-225" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-226" name="ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-227" name="sprcy:KeyManagementPersonnelCompensationManagementFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-228" name="sprcy:KeyManagementPersonnelCompensationManagementFees" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-28665">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-28666">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-28667">0001611746</ix:nonNumeric>
<ix:nonNumeric contextRef="c3" name="dei:NoTradingSymbolFlag" id="ixv-28668">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="sprcy-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship fromRefs="ix_4_fact ix_5_fact ix_9_fact" toRefs="ix_1_footnote"/>
<ix:relationship fromRefs="hidden-fact-185 ix_6_fact hidden-fact-189 ix_7_fact ix_8_fact" toRefs="ix_2_footnote"/>
<ix:relationship fromRefs="ix_10_fact ix_11_fact hidden-fact-204 hidden-fact-205 ix_12_fact ix_13_fact" toRefs="ix_3_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:RightsToPurchaseOrdinarySharesNoParValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CoeruleusMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-15</xbrli:startDate>
    <xbrli:endDate>2020-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-11-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-29</xbrli:startDate>
    <xbrli:endDate>2020-11-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-25</xbrli:startDate>
    <xbrli:endDate>2023-06-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2rrxj3CSwJLmBwgVp4ELjMNRo7Ve3askr7l8vAUsTfxuXtxV64bILHQEWEsJHfnBzJLxq1y4L5qpSYP8eTZ7I6aoGMJYOubthFZ+/qctYcrhFIPuz707yKa1TpecqMWR8L1VoIQ3AYyQ=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-30</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-19</xbrli:startDate>
    <xbrli:endDate>2020-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-19</xbrli:startDate>
    <xbrli:endDate>2020-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-11-13</xbrli:startDate>
    <xbrli:endDate>2019-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-04-11</xbrli:startDate>
    <xbrli:endDate>2017-04-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-02</xbrli:startDate>
    <xbrli:endDate>2021-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-27</xbrli:startDate>
    <xbrli:endDate>2022-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-15</xbrli:startDate>
    <xbrli:endDate>2022-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-18</xbrli:startDate>
    <xbrli:endDate>2023-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-02</xbrli:startDate>
    <xbrli:endDate>2022-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-22</xbrli:startDate>
    <xbrli:endDate>2022-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-04</xbrli:startDate>
    <xbrli:endDate>2021-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-03-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-10-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-10</xbrli:startDate>
    <xbrli:endDate>2019-10-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-15</xbrli:startDate>
    <xbrli:endDate>2020-01-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-31</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-10</xbrli:startDate>
    <xbrli:endDate>2022-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-03</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:NewCoIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-31</xbrli:startDate>
    <xbrli:endDate>2024-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-01</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-21</xbrli:startDate>
    <xbrli:endDate>2024-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea020288201ex2-1_scisparc.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of SciSparc Ltd.&rsquo;s (the &ldquo;Company&rdquo;) share capital and provisions of the amended and restated articles of association
(the &ldquo;Articles&rdquo;) are summaries and do not purport to be complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration number and purposes of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registration number with
the Israeli Registrar of Companies is 51-358165-2. Our purpose as set forth in our Articles is to engage in any lawful activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Type and class of securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized share capital
consists of 75,000,000 ordinary shares, of no par value (the &ldquo;Ordinary Shares&rdquo;). All of our outstanding Ordinary Shares have
been validly issued, are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preemptive rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares are not
redeemable and are not subject to any preemptive right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer of shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our fully paid Ordinary Shares
are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by another
instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our Ordinary
Shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership
by nationals of certain countries that are, or have been, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liability to further capital calls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Election of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our board
of directors must consist of at least three (3) and not more than eight (8) directors, including, if applicable, two external directors
appointed as required under the Companies Law 5759-1999 (the &ldquo;Companies Law&rdquo;). Other than our external directors (if any),
our directors are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible,
of one third of the total number of directors constituting the entire board of directors. At each annual general meeting of our shareholders,
the election or re-election of directors following the expiration of the term of office of the directors of that class of directors is
for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2020 and
after, at each annual general meeting the term of office only one class of directors will expire. Each director, holds office until the
annual general meeting of our shareholders for the year in which his or her term expires and until his or her successor is duly appointed,
unless the tenure of such director expires earlier pursuant to the Companies Law upon the occurrence of certain events or unless removed
from office by a vote of the holders of at least 65% of the total voting power of our shareholders at a general meeting of our shareholders
in accordance with our amended and restated Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further<FONT STYLE="background-color: white">,&nbsp;our&nbsp;</FONT>shareholders&nbsp;<FONT STYLE="background-color: white">approved
an approval mechanism similar to a mechanism that exists in the Delaware Generate Corporate Law, which requires an affirmative vote of
the board of directors (by 75% of the members) in addition to the approval of our shareholders in order to amend such provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&rsquo;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the board of directors shall not
be permitted to act, other than for the purpose of convening a general meeting of the Company&rsquo;s shareholders for the purpose of
appointing additional Directors. For further information on the election and removal of directors see &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&rdquo; of the Company&rsquo;s annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contested election</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, in the
event of a contested election, our board of directors in its discretion, will set the method of calculation of the votes and the manner
in which the resolutions will be presented to our shareholders at the general meeting. In the event that our board of directors does not
or is unable to make a determination on such matter, then the directors will be elected by a plurality of the voting power represented
at the general meeting in person or by proxy and voting on the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend and liquidation rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our Ordinary Shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions
are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&rsquo;s Articles
provide otherwise. Our Articles do not require shareholder approval of a dividend distribution and provide that dividend distributions
may be determined by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court approval;
as a company listed on an exchange outside of Israel, however, court approval is not required if the proposed distribution is in the form
of an equity repurchase, provided that we notify our creditors of the proposed equity repurchase and allow such creditors an opportunity
to initiate a court proceeding to review the repurchase. If within 30 days such creditors do not file an objection, then we may proceed
with the repurchase without obtaining court approval. In each case, we are only permitted to distribute a dividend if our board of directors
and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our Ordinary Shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution
rights to the holders of a class of shares with preferential rights that may be authorized in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exchange controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have been, in a
state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special general meetings. Our board of directors may call special general meetings whenever it sees fit, at such
time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors
is required to convene a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our
board of directors or (ii) as a company listed on an exchange in the U.S., one or more shareholders holding, in the aggregate, either
(a) 10% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 10% or more of our outstanding
voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, one
or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a
matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel, a matter relating to the appointment
or removal of a director may only be requested by one or more shareholders holding at least 5% of the voting rights at the general meeting
of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and 60 days prior to the date
of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting
of our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments
to our Articles;</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment
or termination of our auditors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment
of external directors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: 32.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
of certain related party transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: 32.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
or reductions of our authorized share capital;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mergers;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: 32.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
exercise of our board of directors&rsquo; powers by a general meeting, if our board of directors is unable to exercise its powers and
the exercise of any of its powers is required for our proper management.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual general meeting or extraordinary general meeting be provided to shareholders at least 21 days
prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with
office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must
be provided at least 35 days prior to the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All our Ordinary Shares have identical voting and
other rights in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Quorum requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Articles,
holders of our Ordinary Shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at
a general meeting. The quorum required for our general meetings of shareholders consists of at least two shareholders, present in person
or by proxy, holding at least fifteen percent (15%) of the voting rights of the Company. A meeting adjourned for lack of a quorum will
be adjourned for one day at the same time and place, or to such other day, time or place if such is stated in the notice of the meeting.
At the reconvened meeting, if a quorum is not present within a half an hour, any number of shareholders present in person or by proxy
will constitute a lawful quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Vote requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of
employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even if
not extraordinary) requires the approval described under &ldquo;<FONT STYLE="background-color: white">Item 6. Directors, Senior Management
and Employees</FONT>&mdash;C. Board Practices&mdash;Approval of Related Party Transactions under Israeli Law&mdash;Disclosure of Personal
Interests of a Controlling Shareholder&rdquo; of the Company&rsquo;s annual report on Form 20-F. Certain transactions with respect to
remuneration of our office holders and directors require further approvals described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash; Approval of Related Party Transactions under Israeli
Law&mdash; Disclosure of Personal Interests of an Office Holder&rdquo; of the Company&rsquo;s annual report on Form 20-F. Another exception
to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization,
of the company pursuant to Section 350 of the Companies Law, which requires the approval of the majority of the shareholders voting their
shares, other than abstainees, holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting
deed and voting on the resolution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Articles amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to amend the Articles,
in addition and prior to the approval of a general meeting of shareholders, the approval of the board of directors with the affirmative
vote of at least three-quarters (3/4) of the directors then in office and entitled to vote thereon is required in order to approve any
amendment to the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Access to corporate records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our Articles, our
financial statements and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel
Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction requiring
shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has
not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Modification of class rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
our Articles, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be amended by adoption
of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance
with the rights attached to such class of shares, as set forth in our Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acquisitions under Israeli law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Full tender offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share
capital is required by the Companies Law to make a tender offer to all of the company&rsquo;s shareholders for the purchase of all of
the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result
hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the
shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the
shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that
the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted
if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the
applicable class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a tender offer is not accepted
in accordance with the requirements set forth above, the acquirer may not acquire shares of the company that will increase its holdings
to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable class from shareholders who accepted
the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Special tender offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already
another holder of at least 25% of the voting rights in the company. Alternatively, such an acquisition may be approved pursuant to a private
placement approved by the company&rsquo;s shareholders with the purpose of approving the acquisition of 25% or more, or 45% or more of
the company&rsquo;s voting rights. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made
by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting
rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject
to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability of the offer, or shall
abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the
board of directors must disclose any personal interest each member of the board of directors has in the offer or stems therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&rsquo;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding
the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or any person having a personal
interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such
person&rsquo;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common
control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the
target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the
purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&rsquo;s board of directors and, unless certain requirements described under the Companies
Law are met, by a majority vote of each party&rsquo;s shares, and, in the case of the target company, a majority vote of each class of
its shares voted on the proposed merger at a shareholders meeting. The board of directors of a merging company is required pursuant to
the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger,
the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial
status of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the
shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in
concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors
of the other party, vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders (as described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash;Approval of Related Party Transactions under Israeli
law&mdash;Disclosure of Personal Interests of a Controlling Shareholder&rdquo; of the Company&rsquo;s annual report on Form 20-F).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction would have
been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain
shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights
of a company, if the court holds that the merger is fair and reasonable, taking into account the value to&nbsp;the parties to the merger
and the consideration offered to the shareholders of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders
of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Majority Board Approvals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, at least
three-quarters (3/4) of our serving directors are required to vote in favor of certain transactions which may have a significant effect
on the Company&rsquo;s structure, assets or business, including mergers acquisitions, consolidations and issuance of equity securities
or debt securities convertible into equity in each case that would reasonably be expected to result in change of beneficial ownership
of above than fifteen percent (15%) in the Company, material changes to the principal business of the Company and any resolution to transfer
the headquarters of the Company outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approval of business combinations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles restrict certain
business transactions with any shareholder and/or its affiliates and/or investors for a period of three years following (i) with respect
to any shareholder of the Company holding fifteen percent (15%) or more of the voting power of the ordinary shares as of September 15,
2022, the effective date of the Articles, and (ii) with respect to all shareholders of the Company, each time as such shareholder and/or
any of its affiliates and/or investors become(s) (other than due to a buyback, redemption or cancellation of shares by the Company) the
holder(s) (beneficially or of record) of fifteen percent (15%) or more of the issued and outstanding voting power of the ordinary shares.
The restricted business transactions include mergers, consolidations and dispositions of assets with an aggregate market value equal to
10% or more of the Company&rsquo;s assets or outstanding shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Borrowing powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our board of directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution
duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the
declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board
of directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forum for adjudication of disputes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our Articles,
the federal district courts of the United States of America, shall be the exclusive forum for the resolution of any complaint asserting
a cause or causes of action arising under the U.S. Securities Act of 1933, as amended, including all causes of action asserted against
any defendant to such complaint. The competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or
proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer
or other employee of the Company to the Company or the Company&rsquo;s shareholders, or (iii) any action asserting a claim arising pursuant
to any provision of the Companies Law or the Securities Law 5728-1968. The Company retains the ability to consent to an alternative forum
in circumstances where the Company determines that its interests and those of its shareholders are best served by permitting a particular
dispute to proceed in a forum other than the federal district courts or State of Israel, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer agent and registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
transfer agent and registrar is Vstock Transfer LLC (&ldquo;Vstock&rdquo;). Vstock&rsquo;s address is 18 Lafayette Place, Woodmere, New
York 11598 and its telephone number is (212) 828-8436.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rights to purchase Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 27, 2023, our
board of directors declared the issuance of one special purchase right (a &ldquo;Right&rdquo;) for each outstanding Ordinary Share and
in connection therewith has entered into that certain Rights Agreement, dated as of November 28, 2023 (the &ldquo;Rights Agreement&rdquo;),
by and between the Company and VStock, in its capacity as the Rights Agent (the &ldquo;Rights Agent&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors authorized
the issuance of a Right with respect to each outstanding Ordinary Share on December 8, 2023 and with respect to each Ordinary Share that
will become outstanding prior to the earlier of the expiration of the Rights or the redemption thereof. The Rights will initially trade
with, and will be inseparable from, the corresponding Ordinary Share. The Rights are evidenced only by the balances indicated in the book-entry
account system of the transfer agent for our Ordinary Shares or, in the case of certificated shares, the certificates that represent such
Ordinary Shares. New Rights will accompany any new Ordinary Shares we issue after December 8, 2023 until the earliest of the Issuance
Date described below, the Redemption Date and the Final Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Right will allow its
holder to purchase from our Company one (1) Ordinary Share, at a purchase price of $0.001 per one Ordinary Share, once the Rights become
exercisable. Prior to exercise, the Right does not give its holder any dividend, voting, or liquidation rights. The number of Ordinary
Shares into issued upon the exercise of a Right and the purchase price may be adjusted from time to time, as further detailed in the Rights
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights will not be exercisable
until the tenth day after the first date of public announcement or public disclosure by the Company or an Acquiring Person (as such term
is defined in the Rights Agreement) that an Acquiring Person has become such, including as a result of such person becoming a &ldquo;beneficial
owner&rdquo; (as such term is defined in the Rights Agreement) of 10% or more of the Ordinary Shares then outstanding (we refer to such
date as the &ldquo;Issuance Date&rdquo;). The definition of the term beneficial owner in the Rights Agreement captures also circumstances
that are beyond the definition of beneficial ownership under the Exchange Act. &nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a person&rsquo;s beneficial
ownership of the then-outstanding Ordinary Shares as of the time of the public announcement of the rights plan is at or above 10%, that
person or group&rsquo;s then-existing ownership percentage would be grandfathered, but the Rights would become exercisable if at any time
after such announcement, such person increases its ownership percentage by 0.5% or more, or following the date hereof such person&rsquo;s
beneficial ownership of Ordinary Shares of the Company as a percentage of the then-outstanding Ordinary Shares of the Company is reduced
to an amount that is less than 10% and thereafter such person becomes an Acquiring Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until the Issuance Date, the
balances in the book-entry accounting system of the transfer agent for our Ordinary Shares or, in the case of certificated shares, Ordinary
Shares certificates will also evidence the Rights, and any transfer of Ordinary Shares or, in the case of certificated shares, certificates
for Ordinary Shares will constitute a transfer of Rights. After that date, the Rights will separate from the Ordinary Shares and be evidenced
solely by Rights certificates that we will mail to all eligible holders of Ordinary Shares; provided, however, that the Company may choose
to use book-entry in lieu of physical certificates. Any Rights held by an Acquiring Person or any Associate or Affiliate (as such terms
are defined in the Rights Agreement) thereof are void and may not be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Consequences of a Person or Group Becoming
an Acquiring Person</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Flip In&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a person or group becomes
an Acquiring Person, all holders of Rights except the Acquiring Person or any Associate or Affiliate thereof may, for a purchase price
of $0.001 per one Ordinary Share, purchase one (1) Ordinary Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Flip Over</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our Company is later acquired
in a merger or similar transaction after the Issuance Date, all holders of Rights except the Acquiring Person or any Associate or Affiliate
thereof may, for a purchase price of $0.001 per share, purchase one (1) times the number of shares of the acquiring corporation, that
each shareholder of the Company is entitled for each Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expiration</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights will expire on
November 27, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Redemption</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
redeem the Rights for no consideration at any time prior to such time that any person or group becomes an Acquiring Person. If our board
of directors redeems any Rights, it must redeem all of the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exchange</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a person or group becomes
an Acquiring Person, but before an Acquiring Person owns 50% or more of our outstanding Ordinary Shares, our board of directors may extinguish
the Rights by exchanging one (1) Ordinary Share or an equivalent security for each Right, other than Rights held by the Acquiring Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Anti-Dilution Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may
adjust the purchase price of the Ordinary Shares, the number of Ordinary Shares issuable and the number of outstanding Rights to prevent
dilution that may occur from a share dividend, a share split, a reclassification of the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Rights Agreement
may be amended by our board of directors without the consent of the holders of the Rights. After a person or group becomes an Acquiring
Person, our board of directors may not amend the Rights Agreement in a way that adversely affects holders of the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">8</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>ea020288201ex12-1_scisparc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) OR 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Oz Adler, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20&ndash;F of
SciSparc Ltd. (the &ldquo;Company&rdquo;);</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this annual report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this annual report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or
persons performing the equivalent functions):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt; text-align: justify">Date: April 1, 2024</TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: justify">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">Chief Executive Officer and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>ea020288201ex13-1_scisparc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2023 (the &ldquo;Report&rdquo;) by SpiSparc Ltd. (the &ldquo;Company&rdquo;),
the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section
1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">(1)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">(2)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt; text-align: justify">Date: April 1, 2024</TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: justify">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">Oz Adler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">Chief Executive Officer and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>5
<FILENAME>ea020288201ex15-1_scisparc.htm
<DESCRIPTION>CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We consent
to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-225773) pertaining to SciSparc Ltd.&rsquo;s
(the &ldquo;Company&rdquo;) Israeli Share Option Plan (2005) and Israeli Share Option Plan (2015) and in the </FONT>Registration Statements
on Form F-3 (File Nos. 333-269839, 333-266047, 333-233417, 333-248670, 333-255408 and 333-275305) of our report dated <FONT STYLE="background-color: white">April
1, 2024, with respect to the consolidated financial statements of the Company and its subsidiaries, included in this Annual Report (Form
20-F) of SciSparc Ltd. for the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Tel Aviv, Israel</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: April 1, 2024</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>By:</B></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">/s/ Kost Forer Gabbay &amp; Kaiserer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Kost Forer Gabbay &amp; Kaiserer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">A member firm of EY Global</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>6
<FILENAME>ea020288201ex97-1_scisparc.htm
<DESCRIPTION>CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 97.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCISPARC LTD.<BR>
POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc Ltd. (the &ldquo;<B><I>Company</I></B>&rdquo;)
has adopted this Policy for Recovery of Erroneously Awarded Compensation (the &ldquo;<B><I>Policy</I></B>&rdquo;), effective as of October
2, 2023 (the &ldquo;<B><I>Effective Date</I></B>&rdquo;). Capitalized terms used in this Policy but not otherwise defined herein are defined
in Section 11.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD><U>Persons Subject to Policy</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall apply to
<FONT STYLE="background-color: white">current and former Officers&nbsp;of the Company. Each Officer shall be required to sign an acknowledgment
pursuant to which such Officer will agree to be bound by the terms of, and comply with,&nbsp;this Policy; however, any Officer&rsquo;s
failure to sign any such acknowledgment shall&nbsp;not&nbsp;negate the&nbsp;application&nbsp;of this Policy to the Officer</FONT>. In
addition, the Committee and the Board may apply this Policy to persons who are not Officers, and such application shall apply in the manner
determined by the Committee and the Board in their sole discretion.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">2.</FONT></TD><TD><U>Compensation Subject to Policy</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall apply to
Incentive-Based Compensation received on or after October 2, 2023. For purposes of this Policy, the date on which Incentive-Based Compensation
is &ldquo;received&rdquo; shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is
&ldquo;received&rdquo; in the Company&rsquo;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied,
without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD><U>Recovery of Compensation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
is required to prepare a Restatement, the Company shall recover, reasonably promptly and in accordance with Section 4 below, the portion
of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee and the Board have determined that
recovery from the relevant current or former Officer would be Impracticable. Recovery shall be required in accordance with the preceding
sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for
the Restatement and regardless of whether or when restated financial statements are filed by the Company. For clarity, the recovery of
Erroneously Awarded Compensation under this Policy will not give rise to any Officer&rsquo;s right to voluntarily terminate employment
for &ldquo;good reason&rdquo; or due to a &ldquo;constructive termination&rdquo; (or any similar term of like effect) under any plan,
program or policy of or agreement with the Company or any of its affiliates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">4.</FONT></TD><TD><U>Manner of Recovery; Limitation on Duplicative Recovery</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee and the Board
shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation,
reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation or Erroneously Awarded Compensation,
reimbursement or repayment by any person subject to this Policy, and, to the extent permitted by law, an offset of the Erroneously Awarded
Compensation against other compensation payable by the Company or an affiliate of the Company to such person. Notwithstanding the foregoing,
unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation
already recovered by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount
of Erroneously Awarded Compensation already recovered by the Company from the recipient of such Erroneously Awarded Compensation may be
credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">5.</FONT></TD><TD><U>Administration</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall be administered,
interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such
purpose. The Board may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable
law, and in such event references herein to the &ldquo;Committee&rdquo; shall be deemed to be references to the Board. Subject to any
permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and
decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including
the Company and its affiliates, shareholders and employees. The Committee may delegate administrative duties with respect to this Policy
to one or more directors or employees of the Company, as permitted under applicable law, including any Applicable Rules.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">6.</FONT></TD><TD><U>Interpretation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy shall be interpreted
and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent
with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">7.</FONT></TD><TD><U>No Indemnification; No Liability</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall not indemnify
or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall the Company directly
or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to
fund such person&rsquo;s potential obligations under this Policy. None of the Company, an affiliate of the Company or any member of the
Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">8.</FONT></TD><TD><U>Application; Enforceability</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise determined
by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any Other Recovery
Arrangements. Without limiting the foregoing, in the event of a conflict between this Policy and the Compensation Policy, the latter shall
prevail, except with respect to the recovery of any portion of Incentive-Based Compensation that is Erroneously Awarded Compensation that
would not be recoverable under the Compensation Policy, in which case this Policy shall prevail. Subject to Section 4, the remedy specified
in this Policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available
to the Company or an affiliate of the Company or is otherwise required by applicable law and regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">9.</FONT></TD><TD><U>Severability</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions in this Policy
are intended to be applied to the fullest extent of the law; provided, however, to the extent that any provision of this Policy is found
to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically
be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable
law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">10.</FONT></TD><TD><U>Amendment and Termination</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board or the Committee
may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will
terminate automatically when the Company does not have a class of securities listed on a national securities exchange or association in
the U.S.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="text-decoration: none; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">11.</FONT></TD><TD><U>Definitions</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Applicable Rules</I></B>&rdquo;
means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association
on which the Company&rsquo;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and
Exchange Commission or any national securities exchange or association on which the Company&rsquo;s securities are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Board</I></B>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Compensation
Policy</I></B>&rdquo; means the Company&rsquo;s compensation policy for officers and directors, as adopted in accordance with the Israeli
Companies Law 5759-1999 and as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Committee</I></B>&rdquo;
means the Compensation Committee of the Board or, in the absence of such a committee, a majority of the independent directors serving
on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Erroneously Awarded
Compensation</I></B>&rdquo; means the amount of Incentive-Based Compensation received by a current or former Officer that exceeds the
amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting
Measure, as determined on a pre-tax basis in accordance with the Applicable Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Exchange Act</I></B>&rdquo;
means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Financial Reporting
Measure</I></B>&rdquo; means any measure determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s
financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP/IFRS financial
measures, as well as stock price and total shareholder return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>GAAP</I></B>&rdquo;
means United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>IFRS</I></B>&rdquo;
means international financial reporting standards as adopted by the International Accounting Standards Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Impracticable</I></B>&rdquo;
means (a) the direct expense paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation;
provided that the Company has (i) made reasonable attempt(s) to recover the Erroneously Awarded Compensation, (ii) documented such reasonable
attempt(s) and (iii) provided such documentation to the relevant listing exchange or association, (b) the recovery would violate the Company&rsquo;s
home country laws adopted prior to November 28, 2022 pursuant to an opinion of home country counsel; provided that the Company has (i)
obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in
such a violation and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an
otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements
of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Incentive-Based
Compensation</I></B>&rdquo; means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or
in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after such person began service
as an Officer; (b) who served as an Officer at any time during the performance period for that compensation; (c) while the Company has
a class of securities listed on a national securities exchange or association; and (d) during the applicable Three-Year Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Officer</I></B>&rdquo;
means each person who the Company determines serves as a Company officer, as defined in Section 16 of the Securities Exchange Act of 1934,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&ldquo;<B>Other Recovery
Arrangements</B>&rdquo;</I> means any clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates,
including any such policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based
plan or award agreement thereunder or similar plan, program or agreement of the Company or an affiliate or required under applicable law
(including, without limitation, the Compensation Policy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Restatement</I></B>&rdquo;
means an accounting restatement to correct the Company&rsquo;s material noncompliance with any financial reporting requirement under securities
laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued
financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected
in the current period<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Three-Year Period</I></B>&rdquo;
means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the
Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably
should have concluded, that the Company is required to prepare such Restatement, or, if earlier, the date on which a court, regulator
or other legally authorized body directs the Company to prepare such Restatement. The &ldquo;Three-Year Period&rdquo; also includes any
transition period (that results from a change in the Company&rsquo;s fiscal year) within or immediately following the three completed
fiscal years identified in the preceding sentence. However, a transition period between the last day of the Company&rsquo;s previous fiscal
year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACKNOWLEDGMENT AND CONSENT TO</B><BR>
<B>POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned has received a copy of the Policy
for Recovery of Erroneously Awarded Compensation (the &ldquo;Policy&rdquo;) adopted by SciSparc Ltd. (the &ldquo;Company&rdquo;) and has
read and understands the Policy. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a condition of receiving Incentive-Based Compensation
from the Company, the undersigned agrees that any Incentive-Based Compensation received on or after the Effective Date is subject to recovery
pursuant to the terms of the Policy. To the extent the Company&rsquo;s recovery right conflicts with any other contractual rights the
undersigned may have with the Company, the undersigned understands that the terms of the Policy shall supersede any such contractual rights.
The terms of the Policy shall apply in addition to any right of recoupment against the undersigned under the Compensation Policy or applicable
law and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned further acknowledges and agrees
that the undersigned is not entitled to indemnification in connection with any enforcement of the Policy and expressly waives any rights
to such indemnification under the Company&rsquo;s organizational documents or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"></TD>
    <TD STYLE="width: 2%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 39%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 23%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>Date</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: left">Signature</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: left">Name</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: left">Title</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 $<# 2(  A$! Q$!_\0
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M>VUPTMNLK3*LQ=0K9ZY!;/!]@*M7M_=7RRM"DAB^81N$(.,+_7-3KXEOC</
M;#)C+@L,X)3.['Z8^M/M];U"\DBAA^S.SDYF4$IC;NP/?M0!4:[OI;]RY<F-
M64P>60J#>H'/?(YJ7[?K,<#R2,2'#,,0\P@/C\?EI-/UJ[>QC$R.9(Y5 WL0
MT@^;YO<<8I[:]?+"(YUMT:8(1(0=B*P.0WOQ^M #QJUV_A]+I79I6G:,3*G
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+,444 2T444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sprcy-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 20:47:26 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://trpx.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:sprcy="http://trpx.com/20231231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedBalanceSheet" id="sprcy_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatement" id="sprcy_r_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatementAlt0" id="sprcy_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>002 - Statement - Consolidated Statements of Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareholdersEquityType2or3" id="sprcy_r_ShareholdersEquityType2or3">
        <link:definition>003 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedCashFlow" id="sprcy_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/General" id="sprcy_r_General">
        <link:definition>005 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPolicies" id="sprcy_r_SignificantAccountingPolicies">
        <link:definition>006 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" id="sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
        <link:definition>007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Cash" id="sprcy_r_Cash">
        <link:definition>008 - Disclosure - Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Inventory" id="sprcy_r_Inventory">
        <link:definition>009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivable" id="sprcy_r_OtherAccountsReceivable">
        <link:definition>010 - Disclosure - Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociates" id="sprcy_r_InvestmentinAssociates">
        <link:definition>011 - Disclosure - Investment in Associates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssets" id="sprcy_r_InvestmentinFinancialAssets">
        <link:definition>012 - Disclosure - Investment in Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Leases" id="sprcy_r_Leases">
        <link:definition>013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNet" id="sprcy_r_PropertyandEquipmentNet">
        <link:definition>014 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAsset" id="sprcy_r_IntangibleAsset">
        <link:definition>015 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayables" id="sprcy_r_TradePayables">
        <link:definition>016 - Disclosure - Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayable" id="sprcy_r_OtherAccountsPayable">
        <link:definition>017 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstruments" id="sprcy_r_FinancialInstruments">
        <link:definition>018 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilities" id="sprcy_r_EmployeeBenefitLiabilities">
        <link:definition>019 - Disclosure - Employee Benefit Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncome" id="sprcy_r_TaxesonIncome">
        <link:definition>020 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens">
        <link:definition>021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Equity" id="sprcy_r_Equity">
        <link:definition>022 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactions" id="sprcy_r_ShareBasedPaymentTransactions">
        <link:definition>023 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenues" id="sprcy_r_RevenuesandCostofRevenues">
        <link:definition>024 - Disclosure - Revenues and Cost of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLoss">
        <link:definition>025 - Disclosure - Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareAds" id="sprcy_r_LossPerShareAds">
        <link:definition>026 - Disclosure - Loss Per Share/Ads</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegments" id="sprcy_r_OperatingSegments">
        <link:definition>027 - Disclosure - Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" id="sprcy_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>028 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" id="sprcy_r_SignificantEventsduringtheReportingPeriod">
        <link:definition>029 - Disclosure - Significant Events during the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsAftertheReportingDate" id="sprcy_r_EventsAftertheReportingDate">
        <link:definition>030 - Disclosure - Events After the Reporting Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AccountingPoliciesByPolicy" id="sprcy_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables" id="sprcy_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/CashTables" id="sprcy_r_CashTables">
        <link:definition>996002 - Disclosure - Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InventoryTables" id="sprcy_r_InventoryTables">
        <link:definition>996003 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivableTables" id="sprcy_r_OtherAccountsReceivableTables">
        <link:definition>996004 - Disclosure - Other Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesTables" id="sprcy_r_InvestmentinAssociatesTables">
        <link:definition>996005 - Disclosure - Investment in Associates (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetTables" id="sprcy_r_PropertyandEquipmentNetTables">
        <link:definition>996006 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetTables" id="sprcy_r_IntangibleAssetTables">
        <link:definition>996007 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayablesTables" id="sprcy_r_TradePayablesTables">
        <link:definition>996008 - Disclosure - Trade Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayableTables" id="sprcy_r_OtherAccountsPayableTables">
        <link:definition>996009 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsTables" id="sprcy_r_FinancialInstrumentsTables">
        <link:definition>996010 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" id="sprcy_r_EmployeeBenefitLiabilitiesTables">
        <link:definition>996011 - Disclosure - Employee Benefit Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityTables" id="sprcy_r_EquityTables">
        <link:definition>996012 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables" id="sprcy_r_ShareBasedPaymentTransactionsTables">
        <link:definition>996013 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables" id="sprcy_r_RevenuesandCostofRevenuesTables">
        <link:definition>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables">
        <link:definition>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareAdsTables" id="sprcy_r_LossPerShareAdsTables">
        <link:definition>996016 - Disclosure - Loss Per Share/Ads (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegmentsTables" id="sprcy_r_OperatingSegmentsTables">
        <link:definition>996017 - Disclosure - Operating Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/GeneralDetails" id="sprcy_r_GeneralDetails">
        <link:definition>996019 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails" id="sprcy_r_SignificantAccountingPoliciesDetails">
        <link:definition>996020 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" id="sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
        <link:definition>996021 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCashTable" id="sprcy_r_ScheduleofCashTable">
        <link:definition>996022 - Disclosure - Cash (Details) - Schedule of Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofInventoryTable" id="sprcy_r_ScheduleofInventoryTable">
        <link:definition>996023 - Disclosure - Inventory (Details) - Schedule of Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" id="sprcy_r_ScheduleofOtherAccountsReceivableTable">
        <link:definition>996024 - Disclosure - Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesDetails" id="sprcy_r_InvestmentinAssociatesDetails">
        <link:definition>996025 - Disclosure - Investment in Associates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable">
        <link:definition>996026 - Disclosure - Investment in Associates (Details) - Schedule of Fair Value of the Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails" id="sprcy_r_InvestmentinFinancialAssetsDetails">
        <link:definition>996027 - Disclosure - Investment in Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LeasesDetails" id="sprcy_r_LeasesDetails">
        <link:definition>996028 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails" id="sprcy_r_PropertyandEquipmentNetDetails">
        <link:definition>996029 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" id="sprcy_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996030 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetDetails" id="sprcy_r_IntangibleAssetDetails">
        <link:definition>996031 - Disclosure - Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable">
        <link:definition>996032 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTradePayablesTable" id="sprcy_r_ScheduleofTradePayablesTable">
        <link:definition>996033 - Disclosure - Trade Payables (Details) - Schedule of Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" id="sprcy_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996034 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsDetails" id="sprcy_r_FinancialInstrumentsDetails">
        <link:definition>996035 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
        <link:definition>996036 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" id="sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
        <link:definition>996037 - Disclosure - Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" id="sprcy_r_ScheduleofDefinedContributionPlansTable">
        <link:definition>996038 - Disclosure - Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncomeDetails" id="sprcy_r_TaxesonIncomeDetails">
        <link:definition>996039 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
        <link:definition>996040 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityDetails" id="sprcy_r_EquityDetails">
        <link:definition>996041 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofShareCapitalTable" id="sprcy_r_ScheduleofShareCapitalTable">
        <link:definition>996042 - Disclosure - Equity (Details) - Schedule of Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable">
        <link:definition>996043 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
        <link:definition>996044 - Disclosure - Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" id="sprcy_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>996045 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" id="sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable">
        <link:definition>996046 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" id="sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable">
        <link:definition>996047 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" id="sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
        <link:definition>996048 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2rrxj3CSwJLmBwgVp4ELjMNRo7Ve3askr7l8vAUsTfxuXtxV64bILHQEWEsJHfnBzJLxq1y4L5qpSYP8eTZ7I6aoGMJYOubthFZ+/qctYcrhFIPuz707yKeEObG4pK4oo1j1gF7PMqOA=] CSR-->
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" id="sprcy_r_ScheduleofCostofSalesandGrossProfitTable">
        <link:definition>996049 - Disclosure - Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
        <link:definition>996050 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" id="sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
        <link:definition>996051 - Disclosure - Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable" id="sprcy_r_ScheduleofOperatingSegmentsTable">
        <link:definition>996052 - Disclosure - Operating Segments (Details) - Schedule of Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>996053 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="sprcy_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>996054 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" id="sprcy_r_ScheduleofTransactionswithRelatedPartiesTable">
        <link:definition>996055 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" id="sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable">
        <link:definition>996056 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" id="sprcy_r_SignificantEventsduringtheReportingPeriodDetails">
        <link:definition>996057 - Disclosure - Significant Events during the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsAftertheReportingDateDetails" id="sprcy_r_EventsAftertheReportingDateDetails">
        <link:definition>996058 - Disclosure - Events After the Reporting Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
  <xs:element name="ScheduleOfCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCashAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheIntangibleAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
  <xs:element name="ScheduleOfTradePayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTradePayablesAbstract"/>
  <xs:element name="DisclosureOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
  <xs:element name="ScheduleOfDefinedContributionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfExpensesDueToShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfFairValueForShareOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
  <xs:element name="ScheduleOfCostOfSalesAndGrossProfitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
  <xs:element name="DisclosureOfAdditionalInformationTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
  <xs:element name="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOperatingSegmentsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfTransactionsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract7"/>
  <xs:element name="EquityAttributableToEquityHoldersOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract31"/>
  <xs:element name="AdjustmentsToTheProfitOrLossItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract34"/>
  <xs:element name="WorkingCapitalAdjustmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WorkingCapitalAdjustmentsAbstract"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract53"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostAbstract"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract54"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract55"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract56"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract57"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract60"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract61"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract62"/>
  <xs:element name="UnlabeledAbstract63" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract63"/>
  <xs:element name="UnlabeledAbstract64" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract64"/>
  <xs:element name="UnlabeledAbstract65" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract65"/>
  <xs:element name="UnlabeledAbstract66" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract66"/>
  <xs:element name="UnlabeledAbstract67" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract67"/>
  <xs:element name="UnlabeledAbstract68" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract68"/>
  <xs:element name="UnlabeledAbstract69" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract69"/>
  <xs:element name="UnlabeledAbstract70" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract70"/>
  <xs:element name="UnlabeledAbstract71" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract71"/>
  <xs:element name="UnlabeledAbstract72" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract72"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract"/>
  <xs:element name="UnlabeledAbstract73" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract73"/>
  <xs:element name="UnlabeledAbstract74" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract74"/>
  <xs:element name="UnlabeledAbstract75" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract75"/>
  <xs:element name="UnlabeledAbstract76" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract76"/>
  <xs:element name="UnlabeledAbstract77" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract77"/>
  <xs:element name="UnlabeledAbstract78" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract78"/>
  <xs:element name="UnlabeledAbstract79" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract79"/>
  <xs:element name="UnlabeledAbstract80" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract80"/>
  <xs:element name="UnlabeledAbstract81" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract81"/>
  <xs:element name="a2022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_a2022Abstract"/>
  <xs:element name="UnlabeledAbstract82" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract82"/>
  <xs:element name="UnlabeledAbstract83" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract83"/>
  <xs:element name="CostOfGoodsSoldAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostOfGoodsSoldAbstract"/>
  <xs:element name="UnlabeledAbstract84" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract84"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract85" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract85"/>
  <xs:element name="UnlabeledAbstract86" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract86"/>
  <xs:element name="BGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract87" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract87"/>
  <xs:element name="UnlabeledAbstract88" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract88"/>
  <xs:element name="COtherExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_COtherExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract89" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract89"/>
  <xs:element name="DFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DFinanceIncomeAbstract"/>
  <xs:element name="UnlabeledAbstract90" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract90"/>
  <xs:element name="EFinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EFinanceExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract91" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract91"/>
  <xs:element name="ContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContinuingOperationsAbstract"/>
  <xs:element name="UnlabeledAbstract92" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract92"/>
  <xs:element name="UnlabeledAbstract93" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract93"/>
  <xs:element name="UnlabeledAbstract94" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract94"/>
  <xs:element name="UnlabeledAbstract95" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract95"/>
  <xs:element name="UnlabeledAbstract96" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract96"/>
  <xs:element name="UnlabeledAbstract97" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract97"/>
  <xs:element name="UnlabeledAbstract98" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract98"/>
  <xs:element name="UnlabeledAbstract99" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract99"/>
  <xs:element name="UnlabeledAbstract100" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract100"/>
  <xs:element name="UnlabeledAbstract101" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract101"/>
  <xs:element name="UnlabeledAbstract102" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract102"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExerciseOfWarrants"/>
  <xs:element name="IssueOfShareCapitalNetOfIssueExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
  <xs:element name="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
  <xs:element name="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
  <xs:element name="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
  <xs:element name="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
  <xs:element name="ReceiptofShortTermCreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReceiptofShortTermCreditFromOthers"/>
  <xs:element name="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
  <xs:element name="RegistrationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegistrationOfWarrants"/>
  <xs:element name="InvestmentInFinancialAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentInFinancialAsset"/>
  <xs:element name="UnpaidIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnpaidIssueExpenses"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfOtherAccountsPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
  <xs:element name="EmployeeBenefitLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EmployeeBenefitLiabilitiesTable"/>
  <xs:element name="EmployeeBenefitLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EmployeeBenefitLiabilitiesLineItems"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
  <xs:element name="BasisOfPresentationOfFinancialStatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BasisOfPresentationOfFinancialStatements"/>
  <xs:element name="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
  <xs:element name="DescriptionOfAcquisitionOfASingleAssetCompany" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
  <xs:element name="DescriptionOfAccountingPolicyForRestrictedDeposit" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
  <xs:element name="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
  <xs:element name="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
  <xs:element name="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
  <xs:element name="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
  <xs:element name="DisclosueOfCashAndCashEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
  <xs:element name="DisclosureOfInvertoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInvertoryTextBlock"/>
  <xs:element name="DisclourseOfAccountsReceivablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
  <xs:element name="InvestmentinAssociatesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesTablesTable"/>
  <xs:element name="InvestmentinAssociatesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesTablesLineItems"/>
  <xs:element name="DisclosureOfFairValueOfTheIntangibleAssetTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
  <xs:element name="DisclosureOfTradePayables" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfTradePayables"/>
  <xs:element name="DisclosureOfFinancialAssetsAndFinancialLiabilities" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
  <xs:element name="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
  <xs:element name="EmployeeBenefitLiabilitiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
  <xs:element name="EmployeeBenefitLiabilitiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
  <xs:element name="DisclosureOfIssuedAndOutstandingShareCapital" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
  <xs:element name="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
  <xs:element name="ShareBasedPaymentTransactionsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsTablesTable"/>
  <xs:element name="ShareBasedPaymentTransactionsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
  <xs:element name="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
  <xs:element name="DisclosureOfInformationToTheItemsOfProfitOrLoss" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
  <xs:element name="OperatingSegmentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsTablesTable"/>
  <xs:element name="OperatingSegmentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingSegmentsTablesLineItems"/>
  <xs:element name="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
  <xs:element name="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
  <xs:element name="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
  <xs:element name="LeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseholdImprovements"/>
  <xs:element name="CashDetailsScheduleofCashTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_CashDetailsScheduleofCashTable"/>
  <xs:element name="CashDetailsScheduleofCashLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashDetailsScheduleofCashLineItems"/>
  <xs:element name="InvestmentsDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsDate"/>
  <xs:element name="EquityLossesFromInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesFromInvestment"/>
  <xs:element name="InvestmentAchievementOfFirstMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAchievementOfFirstMilestone"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentAccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
  <xs:element name="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
  <xs:element name="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
  <xs:element name="PurchaseofAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseofAssets"/>
  <xs:element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccruedExpenses"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GovernmentAuthorities"/>
  <xs:element name="InvestmentsInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsInFinancialAssets"/>
  <xs:element name="CreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFromOthers"/>
  <xs:element name="WarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsLiability"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <xs:element name="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems"/>
  <xs:element name="DividendYield" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DividendYield"/>
  <xs:element name="ExpectedVolatility" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpectedVolatility"/>
  <xs:element name="RiskFreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RiskFreeInterestRate"/>
  <xs:element name="UnderlyingAdsPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingAdsPrice"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePricePerShare"/>
  <xs:element name="WarrantsFairValueinDollarsPerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsFairValueinDollarsPerShares"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
  <xs:element name="ShareIssuedToAConsultant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareIssuedToAConsultant"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfShelfProspectus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfRoundingErrors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
  <xs:element name="ResearchAndDevelopmentsExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentsExpenses"/>
  <xs:element name="GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GeneralAndAdministrativeExpenses"/>
  <xs:element name="ExpensesDueToSharebasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpensesDueToSharebasedCompensation"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
  <xs:element name="UnderlyingOrdinarySharePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnderlyingOrdinarySharePrices"/>
  <xs:element name="NumberOfOutstandingShareOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOutstandingShareOption"/>
  <xs:element name="NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable"/>
  <xs:element name="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems"/>
  <xs:element name="CostOfGoodsSold" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostOfGoodsSold"/>
  <xs:element name="IncomeStatementsLocationsDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IncomeStatementsLocationsDomainDomain"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpenses1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses1"/>
  <xs:element name="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
  <xs:element name="ExternalRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExternalRevenues"/>
  <xs:element name="TaxExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxExpense"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndDevelopmentExpenses"/>
  <xs:element name="KeyManagementPersonnelCompensationManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_KeyManagementPersonnelCompensationManagementFees"/>
  <xs:element name="SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="OperatingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingTerm"/>
  <xs:element name="InvestmentinAssociatesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesDetailsTable"/>
  <xs:element name="InvestmentinAssociatesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesDetailsLineItems"/>
  <xs:element name="OrdinarySharesSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesSold"/>
  <xs:element name="OrdinarySharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesParValue"/>
  <xs:element name="PercentageOfSharesIssuedAndOutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
  <xs:element name="FairMarketValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairMarketValue"/>
  <xs:element name="PurchaseOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseOfOrdinaryShares"/>
  <xs:element name="DulyExecutedShareTransferDeedForOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
  <xs:element name="InvestmentFromShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentFromShareholders"/>
  <xs:element name="IssuedAndOutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuedAndOutstandingSharesPercentage"/>
  <xs:element name="FairValueOfInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfInvestment"/>
  <xs:element name="InitialInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialInvestment"/>
  <xs:element name="AdditionalInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInvestment"/>
  <xs:element name="OwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OwnershipPercentage"/>
  <xs:element name="OutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingSharesPercentage"/>
  <xs:element name="AdditionalInstallment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInstallment"/>
  <xs:element name="InstallmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPaid"/>
  <xs:element name="InvestmentinFinancialAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinFinancialAssetsDetailsTable"/>
  <xs:element name="InvestmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAmount"/>
  <xs:element name="ShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareCapitalPercentage"/>
  <xs:element name="SharePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePerShare"/>
  <xs:element name="ComprehensiveLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLoss"/>
  <xs:element name="PricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PricePerShare"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeasesDetailsLineItems"/>
  <xs:element name="SquareMeters" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SquareMeters"/>
  <xs:element name="LeaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseFee"/>
  <xs:element name="ExpireTerm" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExpireTerm"/>
  <xs:element name="PropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetDetailsTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PropertyandEquipmentNetDetailsLineItems"/>
  <xs:element name="PurchaseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseCosts"/>
  <xs:element name="WarrantsToPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsToPurchase"/>
  <xs:element name="ExercisePrice1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePrice1"/>
  <xs:element name="ExercisePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExercisePeriod"/>
  <xs:element name="pricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_pricePerShare"/>
  <xs:element name="AmountTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmountTotal"/>
  <xs:element name="RevenueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenueTerm"/>
  <xs:element name="GrowthRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrowthRatePercentage"/>
  <xs:element name="LongTermPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LongTermPercentage"/>
  <xs:element name="FinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsDetailsTable"/>
  <xs:element name="PurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePrice"/>
  <xs:element name="MaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MaturityDate"/>
  <xs:element name="InitialConversionPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialConversionPrice"/>
  <xs:element name="ConversionPrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConversionPrice"/>
  <xs:element name="OrdinaryShareExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinaryShareExercisePrice"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsTaxAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingLossCarryforwardsTaxAmount"/>
  <xs:element name="DekelLicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DekelLicenseAgreementDescription"/>
  <xs:element name="AnnualInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AnnualInvestment"/>
  <xs:element name="AdditionalMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalMilestoneAmount"/>
  <xs:element name="InstallmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentAmount"/>
  <xs:element name="EstimatedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EstimatedAmount"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityDetailsLineItems"/>
  <xs:element name="DescriptionOfReverseShareSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfReverseShareSplit"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrossProceeds"/>
  <xs:element name="IssuanceOfAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfAggregateShares"/>
  <xs:element name="AggregateUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnits"/>
  <xs:element name="AggregateUnitsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnitsPerShare"/>
  <xs:element name="DateOfIssuance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DateOfIssuance"/>
  <xs:element name="WarrantsAndExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsAndExercise"/>
  <xs:element name="WarrantsExercisePrice" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsExercisePrice"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePerShare"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateGrossProceeds"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
  <xs:element name="OrdinarySharesGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesGranted"/>
  <xs:element name="FairValueOfShareOption" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfShareOption"/>
  <xs:element name="ShareOptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareOptionsGranted"/>
  <xs:element name="FairValueOfShareOptionsGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfShareOptionsGranted"/>
  <xs:element name="OrdinarySharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesIssued"/>
  <xs:element name="OrdinarySharesGrantedDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesGrantedDiscountRate"/>
  <xs:element name="FairValueOfOrdinarySharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfOrdinarySharesGranted"/>
  <xs:element name="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="ExchangeOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeOfCommonShares"/>
  <xs:element name="OutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingShareCapital"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
  <xs:element name="InterestPercentgae" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestPercentgae"/>
  <xs:element name="DeferredCashPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DeferredCashPayments"/>
  <xs:element name="FeeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FeeExpenses"/>
  <xs:element name="BonusAmountReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BonusAmountReceived"/>
  <xs:element name="MutualShareExchangeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MutualShareExchangeAmount"/>
  <xs:element name="OrdinarySharesAcquired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesAcquired"/>
  <xs:element name="AggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValue"/>
  <xs:element name="AdjustedAmountOfAggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustedAmountOfAggregateValue"/>
  <xs:element name="ListedSharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ListedSharePrice"/>
  <xs:element name="ComprehensiveLossOnInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLossOnInvestment"/>
  <xs:element name="EventsAftertheReportingDateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EventsAftertheReportingDateDetailsTable"/>
  <xs:element name="EventsAftertheReportingDateDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EventsAftertheReportingDateDetailsLineItems"/>
  <xs:element name="SharePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePercentage"/>
  <xs:element name="PrepaidAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrepaidAdvance"/>
  <xs:element name="AccruedInterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccruedInterestPercentage"/>
  <xs:element name="CommitmentPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CommitmentPercentage"/>
  <xs:element name="InstallmentPaymentPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPaymentPercentage"/>
  <xs:element name="PaymentPremiumPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentPremiumPercentage"/>
  <xs:element name="IncomeStatementsLocationsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_IncomeStatementsLocationsAxis"/>
  <xs:element name="AmazonFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmazonFeesMember"/>
  <xs:element name="BusinessDevelopmentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BusinessDevelopmentExpensesMember"/>
  <xs:element name="CapitalPointMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalPointMember"/>
  <xs:element name="CapitalPointWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalPointWarrantMember"/>
  <xs:element name="ChemistryAndFormulationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ChemistryAndFormulationsMember"/>
  <xs:element name="ClearmindMedicineIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClearmindMedicineIncMember"/>
  <xs:element name="ClinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClinicalStudiesMember"/>
  <xs:element name="CoeruleusMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CoeruleusMember"/>
  <xs:element name="DrugDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DrugDevelopmentMember"/>
  <xs:element name="EveroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EveroMember"/>
  <xs:element name="ExchangeRateDifferencesNetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeRateDifferencesNetMember"/>
  <xs:element name="FinanceExpenseInRespectOfLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpenseInRespectOfLeasesMember"/>
  <xs:element name="FinanceExpensesFromInterestAndCommissionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
  <xs:element name="FreightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FreightMember"/>
  <xs:element name="InvestorRelationsAndBusinessExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestorRelationsAndBusinessExpensesMember"/>
  <xs:element name="IssuanceExpensesRelatedToWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
  <xs:element name="JeffsBrandsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_JeffsBrandsMember"/>
  <xs:element name="June2022WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_June2022WarrantsMember"/>
  <xs:element name="LeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseMember"/>
  <xs:element name="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
  <xs:element name="March2021FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_March2021FinancingRoundMember"/>
  <xs:element name="MitoCareXBioLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXBioLtdMember"/>
  <xs:element name="MitoCareXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXMember"/>
  <xs:element name="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
  <xs:element name="NewCoIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NewCoIncMember"/>
  <xs:element name="OfficeEquipmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeEquipmentsMember"/>
  <xs:element name="OfficeMaintenanceRentAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
  <xs:element name="OnlineSalesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesMember"/>
  <xs:element name="OrdinarySharesNoParValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesNoParValueMember"/>
  <xs:element name="OverAllotmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OverAllotmentMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrefundedWarrantsMember"/>
  <xs:element name="PrivatePlacementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrivatePlacementsMember"/>
  <xs:element name="ProfessionalAndDirectorsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProfessionalAndDirectorsFeesMember"/>
  <xs:element name="PurchasedGoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasedGoodsMember"/>
  <xs:element name="RegulatoryExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryExpensesMember"/>
  <xs:element name="RegulatoryProfessionalAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
  <xs:element name="ResearchAndPreclinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndPreclinicalStudiesMember"/>
  <xs:element name="RightsToPurchaseOrdinarySharesNoParValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember"/>
  <xs:element name="SEPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SEPAMember"/>
  <xs:element name="SeriesAWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SeriesAWarrantsMember"/>
  <xs:element name="SeriesBWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SeriesBWarrantsMember"/>
  <xs:element name="ShareBasedPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentMember"/>
  <xs:element name="StorageMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StorageMember"/>
  <xs:element name="TwoThousandTwentyThreePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TwoThousandTwentyThreePlanMember"/>
  <xs:element name="WagesAndRelatedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WagesAndRelatedExpensesMember"/>
  <xs:element name="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
  <xs:element name="FinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsAbstract"/>
  <xs:element name="GeneralAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GeneralAbstract"/>
  <xs:element name="InventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InventoryAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
  <xs:element name="SegmentReportingRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SegmentReportingRevenueAbstract"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
  <xs:element name="SignificantNonCashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantNonCashTransactionsAbstract"/>
  <xs:element name="TransactionsAndBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sprcy-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 20:47:26 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedIncomeStatementAlt0" roleURI="http://trpx.com/role/ConsolidatedIncomeStatementAlt0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentWarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_WarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_RetainedEarnings" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_NoncontrollingInterests" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatementAlt0">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2rrxj3CSwJLmBwgVp4ELjMNRo7Ve3askr7l8vAUsTfxuXtxV64bILHQEWEsJHfnBzJLxq1y4L5qpSYP8eTZ7I6aoGMJYOubthFZ+/qctYcrhFIPuz707yKScH/511cy+RKS1FeUxsmBA=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20231231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_FinishedGoods" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20231231.xsd#sprcy_AccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="sprcy_AccruedExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_Accruals" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherPayables" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable">
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20231231.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ResearchAndDevelopmentsExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_GeneralAndAdministrativeExpenses" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sprcy-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 20:47:26 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinAssociates" roleURI="http://trpx.com/role/InvestmentinAssociates"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_LossPerShareAds" roleURI="http://trpx.com/role/LossPerShareAds"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EventsAftertheReportingDate" roleURI="http://trpx.com/role/EventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinAssociatesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_LossPerShareAdsTables" roleURI="http://trpx.com/role/LossPerShareAdsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinAssociatesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_FinancialInstrumentsDetails" roleURI="http://trpx.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EventsAftertheReportingDateDetails" roleURI="http://trpx.com/role/EventsAftertheReportingDateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CurrentTradeReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_Inventories" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CurrentAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20231231.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_SharePremium" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_WarrantLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_RetainedEarnings" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_Equity" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherEquityInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ParentMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20231231.xsd#sprcy_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_ExerciseOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20231231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_WorkingCapitalAdjustmentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20231231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20231231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegistrationOfWarrants" xlink:href="sprcy-20231231.xsd#sprcy_RegistrationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_RegistrationOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentInFinancialAsset" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentInFinancialAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_InvestmentInFinancialAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnpaidIssueExpenses" xlink:href="sprcy-20231231.xsd#sprcy_UnpaidIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_UnpaidIssueExpenses" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/General">
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAbstract" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Cash">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociates">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssets">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAsset">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities">
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTable" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens">
    <loc xlink:type="locator" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/Equity">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenues">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAds">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsAftertheReportingDate">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20231231.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/CashTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAbstract" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvertoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfInvertoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InventoryAbstract" xlink:to="sprcy_DisclosureOfInvertoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivableTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesTables">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesTablesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayablesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayables" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfTradePayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="sprcy_DisclosureOfTradePayables" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables">
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAdsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegmentsTables">
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20231231.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20231231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovements" xlink:href="sprcy-20231231.xsd#sprcy_LeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_LeaseholdImprovements" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCashTable">
    <loc xlink:type="locator" xlink:label="sprcy_CashDetailsScheduleofCashLineItems" xlink:href="sprcy-20231231.xsd#sprcy_CashDetailsScheduleofCashLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashDetailsScheduleofCashTable" xlink:href="sprcy-20231231.xsd#sprcy_CashDetailsScheduleofCashTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_CashDetailsScheduleofCashLineItems" xlink:to="sprcy_CashDetailsScheduleofCashTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_CashDetailsScheduleofCashTable" xlink:to="srt_CurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_ILS" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CashDetailsScheduleofCashLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfInventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_Inventories" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentsDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_InvestmentsDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20231231.xsd#sprcy_EquityLossesFromInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_EquityLossesFromInvestment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20231231.xsd#sprcy_OfficeEquipmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="sprcy_OfficeEquipmentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20231231.xsd#sprcy_CostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_CostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_CostAbstract" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_AccumulatedDepreciationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:href="sprcy-20231231.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable">
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:href="sprcy-20231231.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:href="sprcy-20231231.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseofAssets" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseofAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_PurchaseofAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20231231.xsd#sprcy_AccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="sprcy_AccruedExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_CarryingAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20231231.xsd#sprcy_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="sprcy_GovernmentAuthorities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="sprcy_InvestmentsInFinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_CreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="sprcy_CreditFromOthers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="sprcy_WarrantsLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2rrxj3CSwJLmBwgVp4ELjMNRo7Ve3askr7l8vAUsTfxuXtxV64bILHQEWEsJHfnBzJLxq1y4L5qpSYP8eTZ7I6aoGMJYOubthFZ+/qctYcrhFIPuz707yKdl0lPldxPcGvggJGQ/MC68=] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DividendYield" xlink:href="sprcy-20231231.xsd#sprcy_DividendYield"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_DividendYield" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpectedVolatility" xlink:href="sprcy-20231231.xsd#sprcy_ExpectedVolatility"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_ExpectedVolatility" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RiskFreeInterestRate" xlink:href="sprcy-20231231.xsd#sprcy_RiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_RiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingAdsPrice" xlink:href="sprcy-20231231.xsd#sprcy_UnderlyingAdsPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_UnderlyingAdsPrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_ExercisePricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfSharesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="sprcy_NumberOfSharesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20231231.xsd#sprcy_ShareIssuedToAConsultant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ShareIssuedToAConsultant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ResearchAndDevelopmentsExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_GeneralAndAdministrativeExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20231231.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ExpensesDueToSharebasedCompensation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20231231.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrices" xlink:href="sprcy-20231231.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_UnderlyingOrdinarySharePrices" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOutstandingShareOption" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="sprcy_NumberOfOutstandingShareOption" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable">
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:href="sprcy-20231231.xsd#sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:href="sprcy-20231231.xsd#sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_AmazonFeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20231231.xsd#sprcy_PurchasedGoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_PurchasedGoodsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageMember" xlink:href="sprcy-20231231.xsd#sprcy_StorageMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_StorageMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20231231.xsd#sprcy_FreightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_FreightMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSold" xlink:href="sprcy-20231231.xsd#sprcy_CostOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:to="sprcy_CostOfGoodsSold" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20231231.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20231231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AmazonFeesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageMember" xlink:href="sprcy-20231231.xsd#sprcy_StorageMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_StorageMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_RegulatoryExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20231231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20231231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ExchangeRateDifferencesNetMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20231231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20231231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20231231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_ResearchAndDevelopmentExpenses1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_COtherExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_COtherExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_COtherExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20231231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DFinanceIncomeAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DFinanceIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_DFinanceIncomeAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_DFinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EFinanceExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_EFinanceExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_EFinanceExpensesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EFinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_ContinuingOperationsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20231231.xsd#sprcy_DrugDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="sprcy_DrugDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20231231.xsd#sprcy_OnlineSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsMember" xlink:to="sprcy_OnlineSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_SegmentReportingRevenueAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20231231.xsd#sprcy_ExternalRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_ExternalRevenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20231231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20231231.xsd#sprcy_TaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_TaxExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ResearchAndDevelopmentExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20231231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAbstract" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralAbstract" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_GeneralAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="sprcy_SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20231231.xsd#sprcy_OperatingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="sprcy_OperatingTerm" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InvestmentinAssociatesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EveroMember" xlink:href="sprcy-20231231.xsd#sprcy_EveroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_EveroMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointMember" xlink:href="sprcy-20231231.xsd#sprcy_CapitalPointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_CapitalPointMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CoeruleusMember" xlink:href="sprcy-20231231.xsd#sprcy_CoeruleusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_CoeruleusMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20231231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXBioLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20231231.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_MitoCareXMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20231231.xsd#sprcy_CapitalPointWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_CapitalPointWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesSold" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OrdinarySharesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesParValue" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OrdinarySharesParValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairMarketValue" xlink:href="sprcy-20231231.xsd#sprcy_FairMarketValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_FairMarketValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfOrdinaryShares" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_PurchaseOfOrdinaryShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:href="sprcy-20231231.xsd#sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentFromShareholders" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentFromShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InvestmentFromShareholders" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20231231.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfInvestment" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_FairValueOfInvestment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20231231.xsd#sprcy_InitialInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InitialInvestment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_AdditionalInvestment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OwnershipPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_OutstandingSharesPercentage" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInstallment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_AdditionalInstallment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InstallmentPaid" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20231231.xsd#sprcy_EquityLossesFromInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_EquityLossesFromInvestment" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="currency_ILS" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAmount" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_InvestmentAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20231231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_SharePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_SharePricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLoss" xlink:href="sprcy-20231231.xsd#sprcy_ComprehensiveLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ComprehensiveLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_Cash" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_PricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_PricePerShare" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20231231.xsd#sprcy_LeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_LeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SquareMeters" xlink:href="sprcy-20231231.xsd#sprcy_SquareMeters"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_SquareMeters" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseFee" xlink:href="sprcy-20231231.xsd#sprcy_LeaseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeaseFee" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpireTerm" xlink:href="sprcy-20231231.xsd#sprcy_ExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_ExpireTerm" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCosts" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_PurchaseCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsToPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_WarrantsToPurchase" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice1" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ExercisePrice1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePeriod" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_ExercisePeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_pricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_pricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_pricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmountTotal" xlink:href="sprcy-20231231.xsd#sprcy_AmountTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_AmountTotal" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenueTerm" xlink:href="sprcy-20231231.xsd#sprcy_RevenueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_RevenueTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20231231.xsd#sprcy_GrowthRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_GrowthRatePercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20231231.xsd#sprcy_LongTermPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="sprcy_LongTermPercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrivatePlacementsMember" xlink:href="sprcy-20231231.xsd#sprcy_PrivatePlacementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="sprcy_PrivatePlacementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePrice" xlink:href="sprcy-20231231.xsd#sprcy_PurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_PurchasePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MaturityDate" xlink:href="sprcy-20231231.xsd#sprcy_MaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_MaturityDate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialConversionPrice" xlink:href="sprcy-20231231.xsd#sprcy_InitialConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_InitialConversionPrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionPrice" xlink:href="sprcy-20231231.xsd#sprcy_ConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_ConversionPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareExercisePrice" xlink:href="sprcy-20231231.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="sprcy_OrdinaryShareExercisePrice" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20231231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
    <loc xlink:type="locator" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20231231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_DekelLicenseAgreementDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20231231.xsd#sprcy_AnnualInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_AnnualInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_AdditionalMilestoneAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_InstallmentAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20231231.xsd#sprcy_EstimatedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_EstimatedAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20231231.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_JeffsBrandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesAWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_SeriesAWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesBWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_SeriesBWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_SeriesBWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_June2022WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="sprcy_June2022WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="sprcy_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20231231.xsd#sprcy_OverAllotmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="sprcy_OverAllotmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_March2021FinancingRoundMember" xlink:href="sprcy-20231231.xsd#sprcy_March2021FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="sprcy_March2021FinancingRoundMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfReverseShareSplit" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DescriptionOfReverseShareSplit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceeds" xlink:href="sprcy-20231231.xsd#sprcy_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_GrossProceeds" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_IssuanceOfAggregateShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20231231.xsd#sprcy_AggregateUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateUnits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20231231.xsd#sprcy_AggregateUnitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateUnitsPerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DateOfIssuance" xlink:href="sprcy-20231231.xsd#sprcy_DateOfIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_DateOfIssuance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsAndExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_WarrantsAndExercise" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExercisePrice" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_WarrantsExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_PurchasePricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20231231.xsd#sprcy_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_AggregateGrossProceeds" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20231231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGranted" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOption" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfShareOption" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsGranted" xlink:href="sprcy-20231231.xsd#sprcy_ShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareOptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfShareOptionsGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesIssued" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfOrdinarySharesGranted" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfOrdinarySharesGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_FairValueOfOrdinarySharesGranted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20231231.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClearmindMedicineIncMember" xlink:href="sprcy-20231231.xsd#sprcy_ClearmindMedicineIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_ClearmindMedicineIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_ResearchAndDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20231231.xsd#sprcy_ExchangeOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_ExchangeOfCommonShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_OutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_OutstandingShareCapital" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewCoIncMember" xlink:href="sprcy-20231231.xsd#sprcy_NewCoIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_NewCoIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20231231.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_JeffsBrandsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentgae" xlink:href="sprcy-20231231.xsd#sprcy_InterestPercentgae"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_InterestPercentgae" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayments" xlink:href="sprcy-20231231.xsd#sprcy_DeferredCashPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_DeferredCashPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20231231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FeeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_FeeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_FeeExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20231231.xsd#sprcy_BonusAmountReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_BonusAmountReceived" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeAmount" xlink:href="sprcy-20231231.xsd#sprcy_MutualShareExchangeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_MutualShareExchangeAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_OrdinarySharesAcquired" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20231231.xsd#sprcy_AggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_AggregateValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20231231.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_AdjustedAmountOfAggregateValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_OwnershipPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20231231.xsd#sprcy_ListedSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ListedSharePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20231231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_ComprehensiveLossOnInvestment" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsAftertheReportingDateDetails">
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EventsAftertheReportingDateDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_EventsAftertheReportingDateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20231231.xsd#sprcy_SEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="sprcy_SEPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePercentage" xlink:href="sprcy-20231231.xsd#sprcy_SharePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_SharePricePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrepaidAdvance" xlink:href="sprcy-20231231.xsd#sprcy_PrepaidAdvance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_PrepaidAdvance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedInterestPercentage" xlink:href="sprcy-20231231.xsd#sprcy_AccruedInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_AccruedInterestPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentPercentage" xlink:href="sprcy-20231231.xsd#sprcy_CommitmentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_CommitmentPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaymentPercentage" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentPaymentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_InstallmentPaymentPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentPremiumPercentage" xlink:href="sprcy-20231231.xsd#sprcy_PaymentPremiumPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_PaymentPremiumPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://trpx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesNoParValueMember" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesNoParValueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="sprcy_OrdinarySharesNoParValueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember" xlink:href="sprcy-20231231.xsd#sprcy_RightsToPurchaseOrdinarySharesNoParValueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12gTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12gTitle" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="41" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sprcy-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 20:47:26 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Profit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Total adjustments to the profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US">Increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash for immediate withdrawal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAbstract" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GeneralAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAbstract" xlink:to="sprcy_GeneralAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract_lbl" xml:lang="en-US">Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAbstract_lbl" xml:lang="en-US">Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_CashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCashAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCashAbstract_lbl" xml:lang="en-US">Schedule of Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_ScheduleOfCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_InventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InventoryAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InventoryAbstract" xlink:to="sprcy_InventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfInventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfInventoryAbstract" xlink:to="sprcy_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Total Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsReceivableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsReceivableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsReceivableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl0" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl" xml:lang="en-US">Investment in Associates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Investment in Financial Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl" xml:lang="en-US">Cost, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl0" xml:lang="en-US">Cost, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:href="sprcy-20231231.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl0" xml:lang="en-US">Accumulated depreciation, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl" xml:lang="en-US">Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Intangible asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTradePayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTradePayablesAbstract" xlink:to="sprcy_ScheduleOfTradePayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableAbstract" xlink:to="sprcy_DisclosureOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsAbstract" xlink:to="sprcy_FinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US">Business combinations [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract_lbl" xml:lang="en-US">Contingent Liabilities Commitments Claims and Liens [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Balance at January 1, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Balance at December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl2" xml:lang="en-US">Issuance of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl3" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl3"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" xml:lang="en-US">Share-Based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20231231.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="sprcy_ExpensesDueToSharebasedCompensation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ExpensesDueToSharebasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOutstandingShareOption" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Number of Share Options , Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl0" xml:lang="en-US">Number of Share Options, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Revenues and Cost of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="sprcy_DisclosureOfAdditionalInformationTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl" xml:lang="en-US">Income Statements Locations [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share/Ads [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel[Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract_lbl" xml:lang="en-US">Significant Events during the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Events After the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12gTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Short-term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract0" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract1" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract2" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xml:lang="en-US">Investments in company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract3" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract4" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract4" xlink:to="sprcy_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract5" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract5" xlink:to="sprcy_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract6" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract6" xlink:to="sprcy_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract7" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract7" xlink:to="sprcy_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20231231.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract8" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract8" xlink:to="sprcy_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract9" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract9" xlink:to="sprcy_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract10" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract10" xlink:to="sprcy_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract11" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract11" xlink:to="sprcy_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract12" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract12" xlink:to="sprcy_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9_lbl" xml:lang="en-US">Impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" xlink:to="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract13" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract13" xlink:to="sprcy_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract14" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract14" xlink:to="sprcy_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract15" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract15" xlink:to="sprcy_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract16" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract16" xlink:to="sprcy_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract17" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract17" xlink:to="sprcy_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract18" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract18" xlink:to="sprcy_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract19" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract19" xlink:to="sprcy_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract20" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract20" xlink:to="sprcy_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract21" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract21" xlink:to="sprcy_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract22" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract22" xlink:to="sprcy_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract23" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract23" xlink:to="sprcy_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract24" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract24" xlink:to="sprcy_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract25" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract25" xlink:to="sprcy_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExerciseOfWarrants" xlink:href="sprcy-20231231.xsd#sprcy_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20231231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl" xml:lang="en-US">Issue of share capital, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Expiration of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract26" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract26" xlink:to="sprcy_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract27" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract27" xlink:to="sprcy_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract28" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract28" xlink:to="sprcy_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Issue of share capital in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract29" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract29" xlink:to="sprcy_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract30" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract30" xlink:to="sprcy_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract31" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract31" xlink:to="sprcy_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract32" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract32" xlink:to="sprcy_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1" xml:lang="en-US">Impairment to its intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US">Group&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract33" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract33" xlink:to="sprcy_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract34" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract34" xlink:to="sprcy_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_WorkingCapitalAdjustmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract_lbl" xml:lang="en-US">Working capital adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract35" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract35" xlink:to="sprcy_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US">Decrease (increase) in other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Increase in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract36" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract36" xlink:to="sprcy_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract37" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract37" xlink:to="sprcy_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract38" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract38" xlink:to="sprcy_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Investment in restricted bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Investment in short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Purchase of financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract39" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract39" xlink:to="sprcy_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract40" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract40" xlink:to="sprcy_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract41" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract41" xlink:to="sprcy_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20231231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl" xml:lang="en-US">Payment of issuance expenses related to previous period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers_lbl" xml:lang="en-US">Repayment of short-term credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceiptofShortTermCreditFromOthers" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract42" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract42" xlink:to="sprcy_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract43" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract43" xlink:to="sprcy_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract44" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract44" xlink:to="sprcy_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl" xml:lang="en-US">(a) Significant non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract45" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract45" xlink:to="sprcy_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20231231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract46" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract46" xlink:to="sprcy_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegistrationOfWarrants" xlink:href="sprcy-20231231.xsd#sprcy_RegistrationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegistrationOfWarrants_lbl" xml:lang="en-US">Registration of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract47" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract47" xlink:to="sprcy_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentInFinancialAsset" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentInFinancialAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentInFinancialAsset_lbl" xml:lang="en-US">Investment in financial asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAsset" xlink:to="sprcy_InvestmentInFinancialAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract48" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract48" xlink:to="sprcy_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnpaidIssueExpenses" xlink:href="sprcy-20231231.xsd#sprcy_UnpaidIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnpaidIssueExpenses_lbl" xml:lang="en-US">Unpaid issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Equity holders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US">Finance expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investment in a company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Change in fair value of investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl" xml:lang="en-US">Proceeds from issue of share capital (net of issuance expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest paid on lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesNoParValueMember" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesNoParValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesNoParValueMember_lbl" xml:lang="en-US">Ordinary Shares, no par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesNoParValueMember" xlink:to="sprcy_OrdinarySharesNoParValueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember" xlink:href="sprcy-20231231.xsd#sprcy_RightsToPurchaseOrdinarySharesNoParValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember_lbl" xml:lang="en-US">Rights to Purchase Ordinary Shares, no par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember" xlink:to="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterestMember_lbl" xml:lang="en-US">Transactions with non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParentMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20231231.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20231231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl" xml:lang="en-US">Straight-line basis over the useful life of the assets, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovements" xlink:href="sprcy-20231231.xsd#sprcy_LeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold improvements (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract49" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract49" xlink:to="sprcy_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvertoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfInvertoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInvertoryTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvertoryTextBlock" xlink:to="sprcy_DisclosureOfInvertoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl" xml:lang="en-US">Goods in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract50" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract50" xlink:to="sprcy_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ValueAddedTaxReceivables_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract51" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract51" xlink:to="sprcy_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl" xml:lang="en-US">INVESTMENT IN ASSOCIATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentsDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentsDate_lbl" xml:lang="en-US">Investment date March 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract52" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract52" xlink:to="sprcy_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract53" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract53" xlink:to="sprcy_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl" xml:lang="en-US">Investment following achievement of first milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl" xml:lang="en-US">INVESTMENT IN FINANCIAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20231231.xsd#sprcy_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">New lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract54" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract54" xlink:to="sprcy_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract55" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract55" xlink:to="sprcy_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract56" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract56" xlink:to="sprcy_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract57" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract57" xlink:to="sprcy_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl" xml:lang="en-US">Depreciated cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract58" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract58" xlink:to="sprcy_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract59" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract59" xlink:to="sprcy_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract60" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract60" xlink:to="sprcy_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract0" xlink:href="sprcy-20231231.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract61" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract61" xlink:to="sprcy_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract62" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract62" xlink:to="sprcy_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US">INTANGIBLE ASSET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseofAssets" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseofAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseofAssets_lbl" xml:lang="en-US">Purchase date September 30, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseofAssets" xlink:to="sprcy_PurchaseofAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract63" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract63"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract63_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract63" xlink:to="sprcy_UnlabeledAbstract63_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract64" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract64"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract64_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract64" xlink:to="sprcy_UnlabeledAbstract64_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayables" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfTradePayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfTradePayables_lbl" xml:lang="en-US">Schedule of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedExpenses" xlink:href="sprcy-20231231.xsd#sprcy_AccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedExpenses" xlink:to="sprcy_AccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Open debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract65" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract65"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract65_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract65" xlink:to="sprcy_UnlabeledAbstract65_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accrued vacation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract66" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract66"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract66_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract66" xlink:to="sprcy_UnlabeledAbstract66_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GovernmentAuthorities" xlink:href="sprcy-20231231.xsd#sprcy_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentsInFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsInFinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract67" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract67"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract67_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract67" xlink:to="sprcy_UnlabeledAbstract67_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xml:lang="en-US">Total financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract68" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract68"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract68_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract68" xlink:to="sprcy_UnlabeledAbstract68_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract69" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract69"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract69_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract69" xlink:to="sprcy_UnlabeledAbstract69_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_CreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFromOthers_lbl" xml:lang="en-US">Credit from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsLiability_lbl" xml:lang="en-US">Warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract70" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract70"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract70_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract70" xlink:to="sprcy_UnlabeledAbstract70_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract71" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract71"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract71_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract71" xlink:to="sprcy_UnlabeledAbstract71_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract72" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract72"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract72_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract72" xlink:to="sprcy_UnlabeledAbstract72_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DividendYield" xlink:href="sprcy-20231231.xsd#sprcy_DividendYield"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DividendYield_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpectedVolatility" xlink:href="sprcy-20231231.xsd#sprcy_ExpectedVolatility"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpectedVolatility_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RiskFreeInterestRate" xlink:href="sprcy-20231231.xsd#sprcy_RiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingAdsPrice" xlink:href="sprcy-20231231.xsd#sprcy_UnderlyingAdsPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingAdsPrice_lbl" xml:lang="en-US">Underlying Share Price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingAdsPrice" xlink:to="sprcy_UnderlyingAdsPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares_lbl" xml:lang="en-US">Warrants fair value ($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShares" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">EMPLOYEE BENEFIT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Expenses in respect of defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract73" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract73"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract73_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract73" xlink:to="sprcy_UnlabeledAbstract73_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract74" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract74"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract74_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract74" xlink:to="sprcy_UnlabeledAbstract74_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultant" xlink:href="sprcy-20231231.xsd#sprcy_ShareIssuedToAConsultant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareIssuedToAConsultant_lbl" xml:lang="en-US">Share issued to a consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract75" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract75"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract75_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract75" xlink:to="sprcy_UnlabeledAbstract75_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of shelf prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract76" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract76"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract76_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract76" xlink:to="sprcy_UnlabeledAbstract76_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of August 2023 financing round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract77" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract77"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract77_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract77" xlink:to="sprcy_UnlabeledAbstract77_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of rounding errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract78" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract78"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract78_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract78" xlink:to="sprcy_UnlabeledAbstract78_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of October 2023 financing round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract79" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract79"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract79_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract79" xlink:to="sprcy_UnlabeledAbstract79_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Underlying share price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentsExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentsExpenses" xlink:to="sprcy_ResearchAndDevelopmentsExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GeneralAndAdministrativeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAndAdministrativeExpenses" xlink:to="sprcy_GeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract80" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract80"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract80_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract80" xlink:to="sprcy_UnlabeledAbstract80_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20231231.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl" xml:lang="en-US">Expected life of share options (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnderlyingOrdinarySharePrices" xlink:href="sprcy-20231231.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl" xml:lang="en-US">Underlying ordinary share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Exercise Prices of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">2023:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract81" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract81"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract81_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract81" xlink:to="sprcy_UnlabeledAbstract81_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2022Abstract" xlink:href="sprcy-20231231.xsd#sprcy_a2022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_a2022Abstract_lbl" xml:lang="en-US">2022:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_a2022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract82" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract82"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract82_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract82" xlink:to="sprcy_UnlabeledAbstract82_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract83" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract83"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract83_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract83" xlink:to="sprcy_UnlabeledAbstract83_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">REVENUES AND COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSoldAbstract" xlink:href="sprcy-20231231.xsd#sprcy_CostOfGoodsSoldAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSold" xlink:href="sprcy-20231231.xsd#sprcy_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSold" xlink:to="sprcy_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract84" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract84"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract84_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract84" xlink:to="sprcy_UnlabeledAbstract84_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl" xml:lang="en-US">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract85" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract85"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract85_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract85" xlink:to="sprcy_UnlabeledAbstract85_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract86" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract86"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract86_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract86" xlink:to="sprcy_UnlabeledAbstract86_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">b. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract87" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract87"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract87_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract87" xlink:to="sprcy_UnlabeledAbstract87_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract88" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract88"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract88_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract88" xlink:to="sprcy_UnlabeledAbstract88_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_COtherExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_COtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_COtherExpensesAbstract_lbl" xml:lang="en-US">c. Other expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_COtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20231231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract89" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract89"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract89_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract89" xlink:to="sprcy_UnlabeledAbstract89_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DFinanceIncomeAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DFinanceIncomeAbstract_lbl" xml:lang="en-US">d. Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DFinanceIncomeAbstract" xlink:to="sprcy_DFinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract90" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract90"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract90_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract90" xlink:to="sprcy_UnlabeledAbstract90_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EFinanceExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_EFinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EFinanceExpensesAbstract_lbl" xml:lang="en-US">e. Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceExpensesAbstract" xlink:to="sprcy_EFinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract91" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract91"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract91_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract91" xlink:to="sprcy_UnlabeledAbstract91_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE/ADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ContinuingOperationsAbstract_lbl" xml:lang="en-US">Continuing operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract92" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract92"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract92_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract92" xlink:to="sprcy_UnlabeledAbstract92_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Basic loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl" xml:lang="en-US">Basic loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract93" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract93"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract93_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract93" xlink:to="sprcy_UnlabeledAbstract93_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US">Effect of potential dilutive ordinary shares, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract94" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract94"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract94_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract94" xlink:to="sprcy_UnlabeledAbstract94_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Diluted loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl" xml:lang="en-US">Diluted loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">OPERATING SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">Schedule of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20231231.xsd#sprcy_ExternalRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExternalRevenues_lbl" xml:lang="en-US">External</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract95" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract95"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract95_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract95" xlink:to="sprcy_UnlabeledAbstract95_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl" xml:lang="en-US">Segment loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRevenueExpense_lbl" xml:lang="en-US">Finance expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxExpense" xlink:href="sprcy-20231231.xsd#sprcy_TaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TaxExpense_lbl" xml:lang="en-US">Tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract96" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract96"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract96_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract96" xlink:to="sprcy_UnlabeledAbstract96_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract97" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract97"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract97_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract97" xlink:to="sprcy_UnlabeledAbstract97_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract98" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract98"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract98_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract98" xlink:to="sprcy_UnlabeledAbstract98_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract99" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract99"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract99_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract99" xlink:to="sprcy_UnlabeledAbstract99_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract100" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract100"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract100_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract100" xlink:to="sprcy_UnlabeledAbstract100_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Segment Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US">Segment Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndDevelopmentExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Recognized expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract101" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract101"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract101_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract101" xlink:to="sprcy_UnlabeledAbstract101_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20231231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl" xml:lang="en-US">Management fees (see also note 25a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract102" xlink:href="sprcy-20231231.xsd#sprcy_UnlabeledAbstract102"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract102_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract102" xlink:to="sprcy_UnlabeledAbstract102_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl" xml:lang="en-US">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">EVENTS AFTER THE REPORTING DATE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromInvestment" xlink:href="sprcy-20231231.xsd#sprcy_EquityLossesFromInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_EquityLossesFromInvestment_lbl" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityLossesFromInvestment_lbl0" xml:lang="en-US">Equity losses from the investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_ILS_lbl" xml:lang="en-US">NIS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="currency_ILS_lbl0" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20231231.xsd#sprcy_OfficeEquipmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeEquipmentsMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US">Carrying amount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_AmazonFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmazonFeesMember_lbl" xml:lang="en-US">Amazon fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_AmazonFeesMember_lbl0" xml:lang="en-US">Amazon Fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20231231.xsd#sprcy_PurchasedGoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasedGoodsMember_lbl" xml:lang="en-US">Purchased goods [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageMember" xlink:href="sprcy-20231231.xsd#sprcy_StorageMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StorageMember_lbl" xml:lang="en-US">Storage [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageMember" xlink:to="sprcy_StorageMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20231231.xsd#sprcy_FreightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FreightMember_lbl" xml:lang="en-US">Freight [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl" xml:lang="en-US">Wages and related expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share-based payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl" xml:lang="en-US">Regulatory, professional and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl" xml:lang="en-US">Research and preclinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20231231.xsd#sprcy_ClinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20231231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl" xml:lang="en-US">Chemistry and formulations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl" xml:lang="en-US">Professional and directors&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl" xml:lang="en-US">Business development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_RegulatoryExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryExpensesMember_lbl" xml:lang="en-US">Regulatory expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl" xml:lang="en-US">Office maintenance, rent and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl" xml:lang="en-US">Investor relations and business expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20231231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl" xml:lang="en-US">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20231231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl" xml:lang="en-US">Exchange rate differences, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl" xml:lang="en-US">Issuance expenses related to warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20231231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20231231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl" xml:lang="en-US">Finance expense in respect of leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20231231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl" xml:lang="en-US">Finance expenses from interest and commissions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20231231.xsd#sprcy_DrugDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DrugDevelopmentMember_lbl" xml:lang="en-US">Drug Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20231231.xsd#sprcy_OnlineSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesMember_lbl" xml:lang="en-US">Online Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US">Key management personnel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xml:lang="en-US">Other related parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20231231.xsd#sprcy_OperatingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingTerm_lbl" xml:lang="en-US">Operating term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesSold" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesSold_lbl" xml:lang="en-US">Ordinary shares sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesSold" xlink:to="sprcy_OrdinarySharesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesParValue" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesParValue_lbl" xml:lang="en-US">Ordinary shares par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesParValue" xlink:to="sprcy_OrdinarySharesParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Percentage of issued and outstanding share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairMarketValue" xlink:href="sprcy-20231231.xsd#sprcy_FairMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairMarketValue_lbl" xml:lang="en-US">Fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseOfOrdinaryShares" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl" xml:lang="en-US">Purchase of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:href="sprcy-20231231.xsd#sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl" xml:lang="en-US">Duly executed share transfer deed for ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentFromShareholders" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentFromShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentFromShareholders_lbl" xml:lang="en-US">Investment from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFromShareholders" xlink:to="sprcy_InvestmentFromShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20231231.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl" xml:lang="en-US">Issued and outstanding shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfInvestment" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfInvestment_lbl" xml:lang="en-US">Fair value of Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfInvestment" xlink:to="sprcy_FairValueOfInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20231231.xsd#sprcy_InitialInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialInvestment_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInvestment_lbl" xml:lang="en-US">Additional investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OwnershipPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipPercentage" xlink:to="sprcy_OwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInstallment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInstallment_lbl" xml:lang="en-US">Additional installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPaid_lbl" xml:lang="en-US">Installment paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAmount" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAmount_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl" xml:lang="en-US">Received shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20231231.xsd#sprcy_ShareCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl" xml:lang="en-US">Share capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_SharePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePerShare_lbl" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLoss" xlink:href="sprcy-20231231.xsd#sprcy_ComprehensiveLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLoss_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash (in New Shekels)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Par value per share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_PricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PricePerShare_lbl" xml:lang="en-US">Price Per Share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SquareMeters" xlink:href="sprcy-20231231.xsd#sprcy_SquareMeters"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SquareMeters_lbl" xml:lang="en-US">Square meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SquareMeters" xlink:to="sprcy_SquareMeters_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseFee" xlink:href="sprcy-20231231.xsd#sprcy_LeaseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseFee_lbl" xml:lang="en-US">Lease fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseFee" xlink:to="sprcy_LeaseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExpireTerm" xlink:href="sprcy-20231231.xsd#sprcy_ExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExpireTerm_lbl" xml:lang="en-US">Lease expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpireTerm" xlink:to="sprcy_ExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl" xml:lang="en-US">Exceeds amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCosts" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseCosts_lbl" xml:lang="en-US">Purchase costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCosts" xlink:to="sprcy_PurchaseCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsToPurchase" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsToPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsToPurchase_lbl" xml:lang="en-US">Warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePrice1" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePrice1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice1" xlink:to="sprcy_ExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExercisePeriod" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExercisePeriod_lbl" xml:lang="en-US">Exercise period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePeriod" xlink:to="sprcy_ExercisePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Gross sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_pricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_pricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_pricePerShare_lbl" xml:lang="en-US">Ordinary shares price closes (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_pricePerShare" xlink:to="sprcy_pricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmountTotal" xlink:href="sprcy-20231231.xsd#sprcy_AmountTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmountTotal_lbl" xml:lang="en-US">Amount total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmountTotal" xlink:to="sprcy_AmountTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl" xml:lang="en-US">Amortized over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenueTerm" xlink:href="sprcy-20231231.xsd#sprcy_RevenueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RevenueTerm_lbl" xml:lang="en-US">Revenue term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenueTerm" xlink:to="sprcy_RevenueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20231231.xsd#sprcy_GrowthRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrowthRatePercentage_lbl" xml:lang="en-US">Growth rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20231231.xsd#sprcy_LongTermPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LongTermPercentage_lbl" xml:lang="en-US">Long term, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl" xml:lang="en-US">Discount rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Cash paid for principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Issued of warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePrice" xlink:href="sprcy-20231231.xsd#sprcy_PurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePrice" xlink:to="sprcy_PurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MaturityDate" xlink:href="sprcy-20231231.xsd#sprcy_MaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MaturityDate" xlink:to="sprcy_MaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialConversionPrice" xlink:href="sprcy-20231231.xsd#sprcy_InitialConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialConversionPrice_lbl" xml:lang="en-US">Initial conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConversionPrice" xlink:href="sprcy-20231231.xsd#sprcy_ConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConversionPrice_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionPrice" xlink:to="sprcy_ConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinaryShareExercisePrice" xlink:href="sprcy-20231231.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinaryShareExercisePrice_lbl" xml:lang="en-US">Ordinary share exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareExercisePrice" xlink:to="sprcy_OrdinaryShareExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20231231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl" xml:lang="en-US">Carryforward tax losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20231231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl" xml:lang="en-US">Milestone payments, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20231231.xsd#sprcy_AnnualInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AnnualInvestment_lbl" xml:lang="en-US">Annual investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalMilestoneAmount_lbl" xml:lang="en-US">Additional milestone amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentAmount_lbl" xml:lang="en-US">Installment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20231231.xsd#sprcy_EstimatedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EstimatedAmount_lbl" xml:lang="en-US">Estimated amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl" xml:lang="en-US">Capital purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalCommitments_lbl" xml:lang="en-US">Capital warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfReverseShareSplit" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfReverseShareSplit_lbl" xml:lang="en-US">Description of reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfReverseShareSplit" xlink:to="sprcy_DescriptionOfReverseShareSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrossProceeds" xlink:href="sprcy-20231231.xsd#sprcy_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfAggregateShares_lbl" xml:lang="en-US">Issuance of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20231231.xsd#sprcy_AggregateUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnits_lbl" xml:lang="en-US">Number of units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20231231.xsd#sprcy_AggregateUnitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnitsPerShare_lbl" xml:lang="en-US">Units Per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DateOfIssuance" xlink:href="sprcy-20231231.xsd#sprcy_DateOfIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DateOfIssuance_lbl" xml:lang="en-US">Expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DateOfIssuance" xlink:to="sprcy_DateOfIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsAndExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsAndExercise_lbl" xml:lang="en-US">Warrants and exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExercisePrice" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsExercisePrice_lbl" xml:lang="en-US">Warrants exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20231231.xsd#sprcy_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Gross cash proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGranted" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesGranted_lbl" xml:lang="en-US">Ordinary shares granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGranted" xlink:to="sprcy_OrdinarySharesGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOption" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfShareOption_lbl" xml:lang="en-US">Fair value of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOption" xlink:to="sprcy_FairValueOfShareOption_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareOptionsGranted" xlink:href="sprcy-20231231.xsd#sprcy_ShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareOptionsGranted_lbl" xml:lang="en-US">Share options granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsGranted" xlink:to="sprcy_ShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl" xml:lang="en-US">Fair value of share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesIssued" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesIssued" xlink:to="sprcy_OrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl" xml:lang="en-US">Ordinary shares granted discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfOrdinarySharesGranted" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfOrdinarySharesGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfOrdinarySharesGranted_lbl" xml:lang="en-US">Fair value of ordinary shares granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfOrdinarySharesGranted" xlink:to="sprcy_FairValueOfOrdinarySharesGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20231231.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Invested amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20231231.xsd#sprcy_ExchangeOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeOfCommonShares_lbl" xml:lang="en-US">Exchange of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_OutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingShareCapital_lbl" xml:lang="en-US">Outstanding share capital, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentgae" xlink:href="sprcy-20231231.xsd#sprcy_InterestPercentgae"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestPercentgae_lbl" xml:lang="en-US">Interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayments" xlink:href="sprcy-20231231.xsd#sprcy_DeferredCashPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DeferredCashPayments_lbl" xml:lang="en-US">Deferred cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FeeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_FeeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FeeExpenses_lbl" xml:lang="en-US">Fee expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20231231.xsd#sprcy_BonusAmountReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BonusAmountReceived_lbl" xml:lang="en-US">Bonus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US">Management services expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2rrxj3CSwJLmBwgVp4ELjMNRo7Ve3askr7l8vAUsTfxuXtxV64bILHQEWEsJHfnBzJLxq1y4L5qpSYP8eTZ7I6aoGMJYOubthFZ+/qctYcrhFIPuz707yKQvhIGY98ieNoB0pP5dIPXA=] CSR-->
    <loc xlink:type="locator" xlink:label="sprcy_MutualShareExchangeAmount" xlink:href="sprcy-20231231.xsd#sprcy_MutualShareExchangeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MutualShareExchangeAmount_lbl" xml:lang="en-US">Mutual share exchange amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesAcquired" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesAcquired_lbl" xml:lang="en-US">Acquired ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValue" xlink:href="sprcy-20231231.xsd#sprcy_AggregateValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValue_lbl" xml:lang="en-US">Aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustedAmountOfAggregateValue" xlink:href="sprcy-20231231.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl" xml:lang="en-US">Adjusted amount of aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20231231.xsd#sprcy_ListedSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ListedSharePrice_lbl" xml:lang="en-US">Listed share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20231231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl" xml:lang="en-US">Loss on investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US">Provided sale (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US">Commitment amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePercentage" xlink:href="sprcy-20231231.xsd#sprcy_SharePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePercentage_lbl" xml:lang="en-US">Shareprice, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePercentage" xlink:to="sprcy_SharePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrepaidAdvance" xlink:href="sprcy-20231231.xsd#sprcy_PrepaidAdvance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrepaidAdvance_lbl" xml:lang="en-US">Prepaid advance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrepaidAdvance" xlink:to="sprcy_PrepaidAdvance_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccruedInterestPercentage" xlink:href="sprcy-20231231.xsd#sprcy_AccruedInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccruedInterestPercentage_lbl" xml:lang="en-US">Accrued interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedInterestPercentage" xlink:to="sprcy_AccruedInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentPercentage" xlink:href="sprcy-20231231.xsd#sprcy_CommitmentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CommitmentPercentage_lbl" xml:lang="en-US">Increasing per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentPercentage" xlink:to="sprcy_CommitmentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaymentPercentage" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentPaymentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPaymentPercentage_lbl" xml:lang="en-US">Installment payment percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaymentPercentage" xlink:to="sprcy_InstallmentPaymentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentPremiumPercentage" xlink:href="sprcy-20231231.xsd#sprcy_PaymentPremiumPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentPremiumPercentage_lbl" xml:lang="en-US">Payment premium percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentPremiumPercentage" xlink:to="sprcy_PaymentPremiumPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Payment commitment fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20231231.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl" xml:lang="en-US">Basis of presentation of the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl" xml:lang="en-US">The operating cycle</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl" xml:lang="en-US">Consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Functional currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl" xml:lang="en-US">Acquisition of a single asset company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl" xml:lang="en-US">Investment in joint arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl" xml:lang="en-US">Investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US">Finance income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl" xml:lang="en-US">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl" xml:lang="en-US">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EveroMember" xlink:href="sprcy-20231231.xsd#sprcy_EveroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EveroMember_lbl" xml:lang="en-US">Evero [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EveroMember" xlink:to="sprcy_EveroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointMember" xlink:href="sprcy-20231231.xsd#sprcy_CapitalPointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalPointMember_lbl" xml:lang="en-US">Capital Point [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointMember" xlink:to="sprcy_CapitalPointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CoeruleusMember" xlink:href="sprcy-20231231.xsd#sprcy_CoeruleusMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CoeruleusMember_lbl" xml:lang="en-US">Coeruleus [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CoeruleusMember" xlink:to="sprcy_CoeruleusMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalPointWarrantMember" xlink:href="sprcy-20231231.xsd#sprcy_CapitalPointWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalPointWarrantMember_lbl" xml:lang="en-US">Capital Point Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointWarrantMember" xlink:to="sprcy_CapitalPointWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20231231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXBioLtdMember_lbl" xml:lang="en-US">MitoCare X Bio Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20231231.xsd#sprcy_MitoCareXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXMember_lbl" xml:lang="en-US">MitoCareX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20231231.xsd#sprcy_LeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseMember_lbl" xml:lang="en-US">2021 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrivatePlacementsMember" xlink:href="sprcy-20231231.xsd#sprcy_PrivatePlacementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrivatePlacementsMember_lbl" xml:lang="en-US">Private Placements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_PrivatePlacementsMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20231231.xsd#sprcy_JeffsBrandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_JeffsBrandsMember_lbl" xml:lang="en-US">Jeffs&#8217; Brands [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesAWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_SeriesAWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_SeriesAWarrantsMember_lbl0" xml:lang="en-US">Series A Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_SeriesBWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_SeriesBWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesBWarrantsMember" xlink:to="sprcy_SeriesBWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_March2021FinancingRoundMember" xlink:href="sprcy-20231231.xsd#sprcy_March2021FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_March2021FinancingRoundMember_lbl" xml:lang="en-US">March 2021 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_March2021FinancingRoundMember" xlink:to="sprcy_March2021FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_June2022WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_June2022WarrantsMember_lbl" xml:lang="en-US">June 2022 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20231231.xsd#sprcy_OverAllotmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OverAllotmentMember_lbl" xml:lang="en-US">Over Allotment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20231231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClearmindMedicineIncMember" xlink:href="sprcy-20231231.xsd#sprcy_ClearmindMedicineIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClearmindMedicineIncMember_lbl" xml:lang="en-US">Clearmind Medicine Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindMedicineIncMember" xlink:to="sprcy_ClearmindMedicineIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NewCoIncMember" xlink:href="sprcy-20231231.xsd#sprcy_NewCoIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NewCoIncMember_lbl" xml:lang="en-US">NewCo Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewCoIncMember" xlink:to="sprcy_NewCoIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20231231.xsd#sprcy_SEPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SEPAMember_lbl" xml:lang="en-US">SEPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTable" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesTable_lbl" xml:lang="en-US">Employee Benefit Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTable" xlink:to="sprcy_EmployeeBenefitLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesLineItems_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesTablesTable_lbl" xml:lang="en-US">Investment in Associates (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesTablesTable" xlink:to="sprcy_InvestmentinAssociatesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesTablesLineItems_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesTable_lbl" xml:lang="en-US">Employee Benefit Liabilities (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesTable" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesTable" xlink:to="sprcy_ShareBasedPaymentTransactionsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsTablesLineItems_lbl" xml:lang="en-US">Share-based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsTablesLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesTable_lbl" xml:lang="en-US">Operating Segments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesTable" xlink:to="sprcy_OperatingSegmentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashDetailsScheduleofCashTable" xlink:href="sprcy-20231231.xsd#sprcy_CashDetailsScheduleofCashTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashDetailsScheduleofCashTable_lbl" xml:lang="en-US">Cash (Details) - Schedule of Cash [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashDetailsScheduleofCashTable" xlink:to="sprcy_CashDetailsScheduleofCashTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashDetailsScheduleofCashLineItems" xlink:href="sprcy-20231231.xsd#sprcy_CashDetailsScheduleofCashLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashDetailsScheduleofCashLineItems_lbl" xml:lang="en-US">Cash (Details) - Schedule of Cash [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashDetailsScheduleofCashLineItems" xlink:to="sprcy_CashDetailsScheduleofCashLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:href="sprcy-20231231.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable_lbl" xml:lang="en-US">Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:href="sprcy-20231231.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US">Entity&apos;s total for business combinations [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US">All levels of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable_lbl" xml:lang="en-US">Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems_lbl" xml:lang="en-US">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:href="sprcy-20231231.xsd#sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable_lbl" xml:lang="en-US">Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:to="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:href="sprcy-20231231.xsd#sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_lbl" xml:lang="en-US">IncomeStatementsLocationsDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsMember_lbl" xml:lang="en-US">Segments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsMember" xlink:to="ifrs-full_SegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable_lbl" xml:lang="en-US">Operating Segments (Details) - Schedule of Operating Segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US">Schedule of Operating Segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems_lbl" xml:lang="en-US">Schedule of Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesDetailsTable" xlink:to="sprcy_SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesDetailsTable_lbl" xml:lang="en-US">Investment in Associates (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesDetailsTable" xlink:to="sprcy_InvestmentinAssociatesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesDetailsLineItems_lbl" xml:lang="en-US">Investment in Associates [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesDetailsLineItems" xlink:to="sprcy_InvestmentinAssociatesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US">Geographical areas [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl" xml:lang="en-US">Investment in Financial Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US">Investment in Financial Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsTable" xlink:to="sprcy_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsTable" xlink:to="sprcy_PropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetDetailsLineItems_lbl" xml:lang="en-US">Disclosure of property, plant and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetDetailsLineItems" xlink:to="sprcy_PropertyandEquipmentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US">Assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsDetailsTable" xlink:to="sprcy_FinancialInstrumentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="sprcy_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Disclosure of income tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember_lbl" xml:lang="en-US">Entity&apos;s own equity instruments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsTable" xlink:to="sprcy_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsLineItems" xlink:to="sprcy_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Significant Events during the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems_lbl" xml:lang="en-US">Significant Events During the Reporting Period [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable_lbl" xml:lang="en-US">Events After the Reporting Date (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="sprcy_EventsAftertheReportingDateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EventsAftertheReportingDateDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsAftertheReportingDateDetailsLineItems_lbl" xml:lang="en-US">Events After the Reporting Date [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsAftertheReportingDateDetailsLineItems" xlink:to="sprcy_EventsAftertheReportingDateDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AccruedInterestPercentage_lbl0" xml:lang="en-US">Accrued interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedInterestPercentage" xlink:to="sprcy_AccruedInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInstallment_lbl0" xml:lang="en-US">The amount of additional installment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInvestment_lbl0" xml:lang="en-US">The amount of additional investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl0" xml:lang="en-US">The adjusted amount of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0" xml:lang="en-US">Adjustments for losses from remeasurement of investment in financial assets&#xd;
  to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateGrossProceeds_lbl0" xml:lang="en-US">Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnits_lbl0" xml:lang="en-US">Number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnitsPerShare_lbl0" xml:lang="en-US">Per share of aggregate units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValue_lbl0" xml:lang="en-US">The amount of ordinary shares of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AnnualInvestment_lbl0" xml:lang="en-US">Amount of annual investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes inrBasis of presentation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BonusAmountReceived_lbl0" xml:lang="en-US">Bonus amount received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CommitmentPercentage_lbl0" xml:lang="en-US">Commitment percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentPercentage" xlink:to="sprcy_CommitmentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLoss_lbl0" xml:lang="en-US">Comprehensive loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl0" xml:lang="en-US">Amount of comprehensive loss on investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CostOfGoodsSold_lbl0" xml:lang="en-US">The amount of cost of goods sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSold" xlink:to="sprcy_CostOfGoodsSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFromOthers_lbl0" xml:lang="en-US">The amount of credit of others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DeferredCashPayments_lbl0" xml:lang="en-US">Deferred cash payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl0" xml:lang="en-US">Dekel license agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl0" xml:lang="en-US">Description of Accounting Policy Amendment to IAS 1, &#8220;Disclosure of Accounting Policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Description of accounting policy cost of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in Consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for investments in associates. The description of the entity&apos;s material accounting policy information for investments accounted for using the equity method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in operating cycle Explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for acquisition of a single asset company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for changes to accounting estimates and errors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">The entire disclosue of cash and cash equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about balance with relate parties explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about defined contribution plans explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about transactions with relate parties explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of expenses due to share-based compensation explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of fair value for share options granted explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl0" xml:lang="en-US">Disclosure of fair value of the intangible asset text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl0" xml:lang="en-US">The tabular disclosure of financial assets and financial liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl0" xml:lang="en-US">Tabular disclosure of disclosure of information to the items of profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInvertoryTextBlock_lbl0" xml:lang="en-US">Disclosure of inventory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvertoryTextBlock" xlink:to="sprcy_DisclosureOfInvertoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">Disclosure of detailed inforamtion about issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The tabular disclosure of share options and weighted average exercise prices of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfTradePayables_lbl0" xml:lang="en-US">The disclosure of trade payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl0" xml:lang="en-US">The entire disclosure for useful life of the assets at annual rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of accounts receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DividendYield_lbl0" xml:lang="en-US">The percentage of an expected dividend used to calculate the fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl0" xml:lang="en-US">Number of duly executed share transfer deed for ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesFromInvestment_lbl1" xml:lang="en-US">Amount of equity losses from investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExchangeOfCommonShares_lbl0" xml:lang="en-US">Number of shares exchanged.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExerciseOfWarrants_lbl0" xml:lang="en-US">Amount of exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExpectedVolatility_lbl0" xml:lang="en-US">The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExternalRevenues_lbl0" xml:lang="en-US">Amount of external revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairMarketValue_lbl0" xml:lang="en-US">Fair market value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfInvestment_lbl0" xml:lang="en-US">The amount of fair value of Investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfInvestment" xlink:to="sprcy_FairValueOfInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfOrdinarySharesGranted_lbl0" xml:lang="en-US">The amount of fair value of ordinary shares granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfOrdinarySharesGranted" xlink:to="sprcy_FairValueOfOrdinarySharesGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfShareOption_lbl0" xml:lang="en-US">Fair value Of share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOption" xlink:to="sprcy_FairValueOfShareOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl0" xml:lang="en-US">Fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FeeExpenses_lbl0" xml:lang="en-US">Fee expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GovernmentAuthorities_lbl0" xml:lang="en-US">Government authorities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialConversionPrice_lbl0" xml:lang="en-US">Initial conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialInvestment_lbl0" xml:lang="en-US">Initial investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentAmount_lbl0" xml:lang="en-US">Amount of installment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPaid_lbl0" xml:lang="en-US">The amount of installment paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPaymentPercentage_lbl0" xml:lang="en-US">Installment payment percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaymentPercentage" xlink:to="sprcy_InstallmentPaymentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestPercentgae_lbl0" xml:lang="en-US">Interest percentgae.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl0" xml:lang="en-US">The amount of investment following achievement of first milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAmount_lbl0" xml:lang="en-US">Investment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentFromShareholders_lbl0" xml:lang="en-US">The amount of investment from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFromShareholders" xlink:to="sprcy_InvestmentFromShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentInFinancialAsset_lbl0" xml:lang="en-US">The amount of investment in financial asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAsset" xlink:to="sprcy_InvestmentInFinancialAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentsDate_lbl0" xml:lang="en-US">The amount of investment date,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfAggregateShares_lbl0" xml:lang="en-US">The issuance of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of investment in affiliate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl0" xml:lang="en-US">Number of share capital issued in respect of October 2023 financing round.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl0" xml:lang="en-US">Number of share capital issued in respect of rounding errors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of shelf prospectus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0" xml:lang="en-US">Issue of share capital, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl0" xml:lang="en-US">Issued and outstanding shares, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0" xml:lang="en-US">The amount of compensation to key management personnel in the form of management fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LeaseholdImprovements_lbl0" xml:lang="en-US">Leasehold improvements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ListedSharePrice_lbl0" xml:lang="en-US">Amount of listed shares price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LongTermPercentage_lbl0" xml:lang="en-US">The percentage of long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MutualShareExchangeAmount_lbl0" xml:lang="en-US">Mutual share exchange amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl1" xml:lang="en-US">The number of share option outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable at the end of the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options granted during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options cancelled during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0" xml:lang="en-US">The amount of net operating loss carryforward tax as of the reporting date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesAcquired_lbl0" xml:lang="en-US">Ordinary shares acquired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesGranted_lbl0" xml:lang="en-US">Number of ordinary shares granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGranted" xlink:to="sprcy_OrdinarySharesGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl0" xml:lang="en-US">Ordinary shares granted discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesParValue_lbl0" xml:lang="en-US">Ordinary shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesParValue" xlink:to="sprcy_OrdinarySharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesSold_lbl0" xml:lang="en-US">Number of ordinary shares sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesSold" xlink:to="sprcy_OrdinarySharesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingShareCapital_lbl0" xml:lang="en-US">Percentage of outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingSharesPercentage_lbl0" xml:lang="en-US">Outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentPremiumPercentage_lbl0" xml:lang="en-US">Payment premium percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentPremiumPercentage" xlink:to="sprcy_PaymentPremiumPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">The percentage of shares issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">The useful lives or depreciation rates used for property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PrepaidAdvance_lbl0" xml:lang="en-US">The amount of prepaid advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrepaidAdvance" xlink:to="sprcy_PrepaidAdvance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PricePerShare_lbl0" xml:lang="en-US">price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl0" xml:lang="en-US">The amount of proceeds from issue of share capital and warrants net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl1" xml:lang="en-US">Represents the amount of accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Purchase of financial assets at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl0" xml:lang="en-US">Purchase of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePerShare_lbl0" xml:lang="en-US">The purchase price is the price an investor pays for an investment, and the price becomes the investor&apos;s cost basis for calculating gain or loss when selling the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RegistrationOfWarrants_lbl0" xml:lang="en-US">Registration of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl0" xml:lang="en-US">The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ResearchAndDevelopmentsExpenses_lbl0" xml:lang="en-US">The amount of research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentsExpenses" xlink:to="sprcy_ResearchAndDevelopmentsExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RevenueTerm_lbl0" xml:lang="en-US">Revenue term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenueTerm" xlink:to="sprcy_RevenueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RiskFreeInterestRate_lbl0" xml:lang="en-US">The risk-free interest rate for the option contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareCapitalPercentage_lbl0" xml:lang="en-US">Share capital percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareIssuedToAConsultant_lbl0" xml:lang="en-US">The shares were issued to a consultant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareOptionsGranted_lbl0" xml:lang="en-US">Number of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsGranted" xlink:to="sprcy_ShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePerShare_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePercentage_lbl0" xml:lang="en-US">Share price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePercentage" xlink:to="sprcy_SharePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl0" xml:lang="en-US">The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_TaxExpense_lbl0" xml:lang="en-US">Tax expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl0" xml:lang="en-US">Underlying ordinary share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_UnpaidIssueExpenses_lbl0" xml:lang="en-US">Unpaid issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsExercisePrice_lbl0" xml:lang="en-US">Warrants exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl0" xml:lang="en-US">The weighted average remaining contractual lifes of outstanding share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses" xlink:to="sprcy_ResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl0" xml:lang="en-US">Wages And Related Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract102_lbl0" xml:lang="en-US">Unlabeled Abstract102</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract102" xlink:to="sprcy_UnlabeledAbstract102_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract101_lbl0" xml:lang="en-US">Unlabeled Abstract101</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract101" xlink:to="sprcy_UnlabeledAbstract101_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract100_lbl0" xml:lang="en-US">Unlabeled Abstract100</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract100" xlink:to="sprcy_UnlabeledAbstract100_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1" xml:lang="en-US">Key Management Personnel Compensation Management Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1" xml:lang="en-US">Adjustments For Losses From Remeasurement Of Investment In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl0" xml:lang="en-US">Exchange Rate Differences Net Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0" xml:lang="en-US">Categories of financial assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract61" xlink:to="sprcy_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract62" xlink:to="sprcy_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract60" xlink:to="sprcy_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Useful Life Of Assets At Annual Rates Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:to="sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract65_lbl0" xml:lang="en-US">Unlabeled Abstract65</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract65" xlink:to="sprcy_UnlabeledAbstract65_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsInFinancialAssets_lbl0" xml:lang="en-US">Investments In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsInFinancialAssets" xlink:to="sprcy_InvestmentsInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract66_lbl0" xml:lang="en-US">Unlabeled Abstract66</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract66" xlink:to="sprcy_UnlabeledAbstract66_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract63_lbl0" xml:lang="en-US">Unlabeled Abstract63</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract63" xlink:to="sprcy_UnlabeledAbstract63_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract64_lbl0" xml:lang="en-US">Unlabeled Abstract64</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract64" xlink:to="sprcy_UnlabeledAbstract64_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRevenueExpense_lbl0" xml:lang="en-US">Interest income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract69_lbl0" xml:lang="en-US">Unlabeled Abstract69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract69" xlink:to="sprcy_UnlabeledAbstract69_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfAggregateShares_lbl1" xml:lang="en-US">Issuance Of Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract67_lbl0" xml:lang="en-US">Unlabeled Abstract67</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract67" xlink:to="sprcy_UnlabeledAbstract67_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract68_lbl0" xml:lang="en-US">Unlabeled Abstract68</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract68" xlink:to="sprcy_UnlabeledAbstract68_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BasisOfPresentationOfFinancialStatements_lbl1" xml:lang="en-US">Basis Of Presentation Of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BasisOfPresentationOfFinancialStatements" xlink:to="sprcy_BasisOfPresentationOfFinancialStatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuedAndOutstandingSharesPercentage_lbl1" xml:lang="en-US">Issued And Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharesPercentage" xlink:to="sprcy_IssuedAndOutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl1" xml:lang="en-US">Israel, New Shekels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract72_lbl0" xml:lang="en-US">Unlabeled Abstract72</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract72" xlink:to="sprcy_UnlabeledAbstract72_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract73_lbl0" xml:lang="en-US">Unlabeled Abstract73</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract73" xlink:to="sprcy_UnlabeledAbstract73_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesMember_lbl0" xml:lang="en-US">Online Sales Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract70_lbl0" xml:lang="en-US">Unlabeled Abstract70</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract70" xlink:to="sprcy_UnlabeledAbstract70_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract71_lbl0" xml:lang="en-US">Unlabeled Abstract71</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract71" xlink:to="sprcy_UnlabeledAbstract71_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegistrationOfWarrants_lbl1" xml:lang="en-US">Registration Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegistrationOfWarrants" xlink:to="sprcy_RegistrationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract76_lbl0" xml:lang="en-US">Unlabeled Abstract76</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract76" xlink:to="sprcy_UnlabeledAbstract76_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract77_lbl0" xml:lang="en-US">Unlabeled Abstract77</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract77" xlink:to="sprcy_UnlabeledAbstract77_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract74_lbl0" xml:lang="en-US">Unlabeled Abstract74</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract74" xlink:to="sprcy_UnlabeledAbstract74_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract75_lbl0" xml:lang="en-US">Unlabeled Abstract75</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract75" xlink:to="sprcy_UnlabeledAbstract75_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract78_lbl0" xml:lang="en-US">Unlabeled Abstract78</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract78" xlink:to="sprcy_UnlabeledAbstract78_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract79_lbl0" xml:lang="en-US">Unlabeled Abstract79</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract79" xlink:to="sprcy_UnlabeledAbstract79_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl1" xml:lang="en-US">Proceeds From Issue Of Share Capital And Warrantsnet Of Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:to="sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingOrdinarySharePrices_lbl1" xml:lang="en-US">Underlying Ordinary Share Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingOrdinarySharePrices" xlink:to="sprcy_UnderlyingOrdinarySharePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentExpenses1_lbl1" xml:lang="en-US">Research And Development Expenses1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentExpenses1" xlink:to="sprcy_ResearchAndDevelopmentExpenses1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract38" xlink:to="sprcy_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract39" xlink:to="sprcy_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl0" xml:lang="en-US">Income Statements Locations Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AnnualInvestment_lbl1" xml:lang="en-US">Annual Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl0" xml:lang="en-US">Segment Reporting Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl4" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ValueAddedTaxReceivables_lbl0" xml:lang="en-US">Value added tax receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxReceivables" xlink:to="ifrs-full_ValueAddedTaxReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContinuingOperationsAbstract_lbl0" xml:lang="en-US">Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExerciseOfWarrants_lbl1" xml:lang="en-US">Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExerciseOfWarrants" xlink:to="sprcy_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustedAmountOfAggregateValue_lbl1" xml:lang="en-US">Adjusted Amount Of Aggregate Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustedAmountOfAggregateValue" xlink:to="sprcy_AdjustedAmountOfAggregateValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_a2022Abstract_lbl0" xml:lang="en-US">a2022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2022Abstract" xlink:to="sprcy_a2022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract40" xlink:to="sprcy_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract43" xlink:to="sprcy_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of all instruments on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl0" xml:lang="en-US">Operating Segments Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract44" xlink:to="sprcy_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Reversal of impairment loss recognised in other comprehensive income, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract41" xlink:to="sprcy_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract42" xlink:to="sprcy_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract47" xlink:to="sprcy_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract48" xlink:to="sprcy_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract45" xlink:to="sprcy_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalPointWarrantMember_lbl0" xml:lang="en-US">Capital Point Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointWarrantMember" xlink:to="sprcy_CapitalPointWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract46" xlink:to="sprcy_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpectedVolatility_lbl1" xml:lang="en-US">Expected Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpectedVolatility" xlink:to="sprcy_ExpectedVolatility_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl1" xml:lang="en-US">Property, plant and equipment, revalued assets, at cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SEPAMember_lbl0" xml:lang="en-US">SEPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract49" xlink:to="sprcy_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl0" xml:lang="en-US">Chemistry And Formulations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of accrued expenses and other liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0" xml:lang="en-US">Communication and network equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MutualShareExchangeAmount_lbl1" xml:lang="en-US">Mutual Share Exchange Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MutualShareExchangeAmount" xlink:to="sprcy_MutualShareExchangeAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReceiptofShortTermCreditFromOthers_lbl0" xml:lang="en-US">Receiptof Short Term Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceiptofShortTermCreditFromOthers" xlink:to="sprcy_ReceiptofShortTermCreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Investment In Affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestPercentgae_lbl1" xml:lang="en-US">Interest Percentgae</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentgae" xlink:to="sprcy_InterestPercentgae_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Disclosure Of Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:to="sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract50" xlink:to="sprcy_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract51" xlink:to="sprcy_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl1" xml:lang="en-US">Investment Achievement Of First Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract54" xlink:to="sprcy_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of October2023 Financing Round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract55" xlink:to="sprcy_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract52" xlink:to="sprcy_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract53" xlink:to="sprcy_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract58" xlink:to="sprcy_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostOfGoodsSold_lbl1" xml:lang="en-US">Cost Of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSold" xlink:to="sprcy_CostOfGoodsSold_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract59" xlink:to="sprcy_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl0" xml:lang="en-US">Intangible asset fair value used as deemed cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesAcquired_lbl1" xml:lang="en-US">Ordinary Shares Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesAcquired" xlink:to="sprcy_OrdinarySharesAcquired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl1" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract56" xlink:to="sprcy_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract57" xlink:to="sprcy_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract18" xlink:to="sprcy_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract19" xlink:to="sprcy_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract16" xlink:to="sprcy_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExternalRevenues_lbl1" xml:lang="en-US">External Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract17" xlink:to="sprcy_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Exercisable In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1" xml:lang="en-US">Issue Of Share Capital Net Of Issue Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingSharesPercentage_lbl1" xml:lang="en-US">Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Cost Of Sales Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NewCoIncMember_lbl0" xml:lang="en-US">New Co Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NewCoIncMember" xlink:to="sprcy_NewCoIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParentMember_lbl0" xml:lang="en-US">Parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Share Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfShareCapitalAbstract" xlink:to="sprcy_ScheduleOfShareCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SquareMeters_lbl0" xml:lang="en-US">Square Meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SquareMeters" xlink:to="sprcy_SquareMeters_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl0" xml:lang="en-US">Commitments made by entity, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract21" xlink:to="sprcy_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract22" xlink:to="sprcy_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsFairValueinDollarsPerShares_lbl0" xml:lang="en-US">Warrants Fair Valuein Dollars Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsFairValueinDollarsPerShares" xlink:to="sprcy_WarrantsFairValueinDollarsPerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DrugDevelopmentMember_lbl0" xml:lang="en-US">Drug Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract20" xlink:to="sprcy_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract25" xlink:to="sprcy_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract26" xlink:to="sprcy_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0" xml:lang="en-US">Finance Expense In Respect Of Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract23" xlink:to="sprcy_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract24" xlink:to="sprcy_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract29" xlink:to="sprcy_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract27" xlink:to="sprcy_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ListedSharePrice_lbl1" xml:lang="en-US">Listed Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract28" xlink:to="sprcy_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0" xml:lang="en-US">Key management personnel of entity or parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Percentage Of Shares Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:to="sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePricePerShare" xlink:to="sprcy_ExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl4" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl0" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesNoParValueMember_lbl0" xml:lang="en-US">Ordinary Shares No Par Value Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesNoParValueMember" xlink:to="sprcy_OrdinarySharesNoParValueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EveroMember_lbl0" xml:lang="en-US">Evero Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EveroMember" xlink:to="sprcy_EveroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract32" xlink:to="sprcy_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract33" xlink:to="sprcy_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract30" xlink:to="sprcy_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract31" xlink:to="sprcy_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareIssuedToAConsultant_lbl1" xml:lang="en-US">Share Issued To AConsultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultant" xlink:to="sprcy_ShareIssuedToAConsultant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_March2021FinancingRoundMember_lbl0" xml:lang="en-US">March2021 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_March2021FinancingRoundMember" xlink:to="sprcy_March2021FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract36" xlink:to="sprcy_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract37" xlink:to="sprcy_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract34" xlink:to="sprcy_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract35" xlink:to="sprcy_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsToPurchase_lbl0" xml:lang="en-US">Warrants To Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsToPurchase" xlink:to="sprcy_WarrantsToPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl1" xml:lang="en-US">Comprehensive Loss On Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1" xml:lang="en-US">Description Of Accounting Policy For Consolidatedfinancialstatements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Other property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl0" xml:lang="en-US">Current inventories in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0" xml:lang="en-US">Disclosure of associates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentPremiumPercentage_lbl1" xml:lang="en-US">Payment Premium Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentPremiumPercentage" xlink:to="sprcy_PaymentPremiumPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl2" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) other than changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInvestment_lbl1" xml:lang="en-US">Additional Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember_lbl0" xml:lang="en-US">Rights To Purchase Ordinary Shares No Par Value Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember" xlink:to="sprcy_RightsToPurchaseOrdinarySharesNoParValueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Shelf Prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract10" xlink:to="sprcy_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract11" xlink:to="sprcy_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract14" xlink:to="sprcy_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract15" xlink:to="sprcy_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasedGoodsMember_lbl0" xml:lang="en-US">Purchased Goods Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract12" xlink:to="sprcy_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract13" xlink:to="sprcy_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl0" xml:lang="en-US">Title of 12(g) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialConversionPrice_lbl1" xml:lang="en-US">Initial Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialConversionPrice" xlink:to="sprcy_InitialConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl0" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeOfCommonShares_lbl1" xml:lang="en-US">Exchange Of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0" xml:lang="en-US">Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Other Accounts Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfOrdinarySharesGranted_lbl1" xml:lang="en-US">Fair Value Of Ordinary Shares Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfOrdinarySharesGranted" xlink:to="sprcy_FairValueOfOrdinarySharesGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConversionPrice_lbl0" xml:lang="en-US">Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConversionPrice" xlink:to="sprcy_ConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract4" xlink:to="sprcy_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OwnershipPercentage_lbl0" xml:lang="en-US">Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OwnershipPercentage" xlink:to="sprcy_OwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract3" xlink:to="sprcy_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePeriod_lbl0" xml:lang="en-US">Exercise Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePeriod" xlink:to="sprcy_ExercisePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract9" xlink:to="sprcy_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Percentage Of Useful Lives Or Depreciation Rates Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract6" xlink:to="sprcy_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract5" xlink:to="sprcy_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract8" xlink:to="sprcy_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract7" xlink:to="sprcy_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl0" xml:lang="en-US">Actuarial assumption of discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareOptionsGranted_lbl1" xml:lang="en-US">Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareOptionsGranted" xlink:to="sprcy_ShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl0" xml:lang="en-US">Other related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl0" xml:lang="en-US">Cost Of Goods Sold Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0" xml:lang="en-US">Disclosure Of Significant Events During The Reporting Period Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl0" xml:lang="en-US">Current trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Operating Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:to="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfTradePayables_lbl1" xml:lang="en-US">Disclosure Of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayables" xlink:to="sprcy_DisclosureOfTradePayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Balance With Relate Parties Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SeriesAWarrantsMember_lbl1" xml:lang="en-US">Series AWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesAWarrantsMember" xlink:to="sprcy_SeriesAWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Investment Accounted For Using The Equity Methodtext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Amendment To IAS1 Disclosure Of Accounting Policies Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl1" xml:lang="en-US">Other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9_lbl0" xml:lang="en-US">Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" xlink:to="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0" xml:lang="en-US">Payment Of Issuance Expenses Related To Previous Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseMember_lbl0" xml:lang="en-US">Lease Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsDate_lbl1" xml:lang="en-US">Investments Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_pricePerShare_lbl0" xml:lang="en-US">price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_pricePerShare" xlink:to="sprcy_pricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DateOfIssuance_lbl0" xml:lang="en-US">Date Of Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DateOfIssuance" xlink:to="sprcy_DateOfIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl0" xml:lang="en-US">No Trading Symbol Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl0" xml:lang="en-US">Property, plant and equipment, gross carrying amount of fully depreciated assets still in use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0" xml:lang="en-US">Proceeds from contributions of non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US">Disclosue Of Cash And Cash Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0" xml:lang="en-US">Short-term employee benefits accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinaryShareExercisePrice_lbl0" xml:lang="en-US">Ordinary Share Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinaryShareExercisePrice" xlink:to="sprcy_OrdinaryShareExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl0" xml:lang="en-US">Issued capital, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl0" xml:lang="en-US">Employee Benefit Liabilities Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="sprcy_EmployeeBenefitLiabilitiesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsLiability_lbl0" xml:lang="en-US">Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl1" xml:lang="en-US">Dekel License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1" xml:lang="en-US">Description Of Acquisition Of ASingle Asset Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl0" xml:lang="en-US">Research And Preclinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnits_lbl1" xml:lang="en-US">Aggregate Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Options Cancelled In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WorkingCapitalAdjustmentsAbstract_lbl0" xml:lang="en-US">Working Capital Adjustments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WorkingCapitalAdjustmentsAbstract" xlink:to="sprcy_WorkingCapitalAdjustmentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl0" xml:lang="en-US">BGeneral And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_BGeneralAndAdministrativeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Share Options And Weighted Average Exercise Prices Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:to="sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrossProceeds" xlink:to="sprcy_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccruedExpenses_lbl0" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedExpenses" xlink:to="sprcy_AccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SeriesBWarrantsMember_lbl0" xml:lang="en-US">Series BWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SeriesBWarrantsMember" xlink:to="sprcy_SeriesBWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Defined Contribution Plans Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInstallment_lbl1" xml:lang="en-US">Additional Installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExercisePrice1_lbl0" xml:lang="en-US">Exercise Price1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExercisePrice1" xlink:to="sprcy_ExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitments_lbl0" xml:lang="en-US">Capital commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl0" xml:lang="en-US">Applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareCapitalPercentage_lbl1" xml:lang="en-US">Share Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentInFinancialAsset_lbl1" xml:lang="en-US">Investment In Financial Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentInFinancialAsset" xlink:to="sprcy_InvestmentInFinancialAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrepaidAdvance_lbl1" xml:lang="en-US">Prepaid Advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrepaidAdvance" xlink:to="sprcy_PrepaidAdvance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInAssociates_lbl0" xml:lang="en-US">Investments in associates reported in separate financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RiskFreeInterestRate_lbl1" xml:lang="en-US">Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RiskFreeInterestRate" xlink:to="sprcy_RiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialInvestment_lbl1" xml:lang="en-US">Initial Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1" xml:lang="en-US">Description Of Accounting Policy Foroperatingcycle Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information To The Items Of Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl2" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnderlyingAdsPrice_lbl0" xml:lang="en-US">Underlying Ads Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnderlyingAdsPrice" xlink:to="sprcy_UnderlyingAdsPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfInvestment_lbl1" xml:lang="en-US">Fair Value Of Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfInvestment" xlink:to="sprcy_FairValueOfInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingShareCapital_lbl1" xml:lang="en-US">Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXMember_lbl0" xml:lang="en-US">Mito Care XMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrowthRatePercentage_lbl0" xml:lang="en-US">Growth Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Lifes Of Outstanding Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:to="sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0" xml:lang="en-US">Losses From Remeasurement Of Investment In Financial Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesExpense_lbl0" xml:lang="en-US">Services expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MaturityDate_lbl0" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MaturityDate" xlink:to="sprcy_MaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalPointMember_lbl0" xml:lang="en-US">Capital Point Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalPointMember" xlink:to="sprcy_CapitalPointMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value Of The Intangible Asset Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:to="sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClinicalStudiesMember_lbl0" xml:lang="en-US">Clinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl1" xml:lang="en-US">Fair Value Of Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0" xml:lang="en-US">Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePercentage_lbl1" xml:lang="en-US">Share Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePercentage" xlink:to="sprcy_SharePricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl0" xml:lang="en-US">Equity Attributable To Equity Holders Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CommitmentPercentage_lbl1" xml:lang="en-US">Commitment Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentPercentage" xlink:to="sprcy_CommitmentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Range Of Dividend Used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPaymentPercentage_lbl1" xml:lang="en-US">Installment Payment Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaymentPercentage" xlink:to="sprcy_InstallmentPaymentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl1" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalMilestoneAmount_lbl0" xml:lang="en-US">Additional Milestone Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0" xml:lang="en-US">Investor Relations And Business Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterestMember_lbl0" xml:lang="en-US">Other equity interest [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesSold_lbl1" xml:lang="en-US">Ordinary Shares Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesSold" xlink:to="sprcy_OrdinarySharesSold_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnpaidIssueExpenses_lbl1" xml:lang="en-US">Unpaid Issue Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnpaidIssueExpenses" xlink:to="sprcy_UnpaidIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Warrants Fair Value Using Blackscholes Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0" xml:lang="en-US">Financial assets at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Notes and other explanatory information [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl0" xml:lang="en-US">Amount by which unit&apos;s recoverable amount exceeds its carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingTerm_lbl0" xml:lang="en-US">Operating Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrivatePlacementsMember_lbl1" xml:lang="en-US">Private Placements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrivatePlacementsMember" xlink:to="sprcy_PrivatePlacementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GovernmentAuthorities" xlink:to="sprcy_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl0" xml:lang="en-US">Description Of Accounting Policy For Restricted Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:to="sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DFinanceIncomeAbstract_lbl0" xml:lang="en-US">DFinance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DFinanceIncomeAbstract" xlink:to="sprcy_DFinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl0" xml:lang="en-US">Carrying amount [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseholdImprovements_lbl1" xml:lang="en-US">Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovements" xlink:to="sprcy_LeaseholdImprovements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0" xml:lang="en-US">Office Maintenance Rent And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesGranted_lbl1" xml:lang="en-US">Ordinary Shares Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGranted" xlink:to="sprcy_OrdinarySharesGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1" xml:lang="en-US">Operating Loss Carryforwards Tax Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl0" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl2" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl0" xml:lang="en-US">Significant Non Cash Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FreightMember_lbl0" xml:lang="en-US">Freight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Purchase Of Financial Assets At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Weighted average share price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl0" xml:lang="en-US">Business Development Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0" xml:lang="en-US">Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl4" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl1" xml:lang="en-US">Ordinary Shares Granted Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentWarrantLiability_lbl0" xml:lang="en-US">Current warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Fair Value Using Black Scholes Opm Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseofAssets_lbl0" xml:lang="en-US">Purchaseof Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseofAssets" xlink:to="sprcy_PurchaseofAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl0" xml:lang="en-US">Earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfShareOption_lbl1" xml:lang="en-US">Fair Value Of Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOption" xlink:to="sprcy_FairValueOfShareOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PricePerShare_lbl1" xml:lang="en-US">Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PricePerShare" xlink:to="sprcy_PricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0" xml:lang="en-US">Impairment loss recognised in other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXBioLtdMember_lbl0" xml:lang="en-US">Mito Care XBio Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl0" xml:lang="en-US">Prices specified in forward agreements to purchase financial assets for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxExpense_lbl1" xml:lang="en-US">Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxExpense" xlink:to="sprcy_TaxExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StorageMember_lbl0" xml:lang="en-US">Storage Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageMember" xlink:to="sprcy_StorageMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EstimatedAmount_lbl0" xml:lang="en-US">Estimated Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CoeruleusMember_lbl0" xml:lang="en-US">Coeruleus Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CoeruleusMember" xlink:to="sprcy_CoeruleusMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseFee_lbl0" xml:lang="en-US">Lease Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseFee" xlink:to="sprcy_LeaseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentMember_lbl0" xml:lang="en-US">Share Based Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">General And Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GeneralAndAdministrativeExpenses" xlink:to="sprcy_GeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Rounding Errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl1" xml:lang="en-US">Description Of Amendment To IAS8 Accounting Policies Changes To Accounting Estimates And Errors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:to="sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl2" xml:lang="en-US">Property Plant And Equipment Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1" xml:lang="en-US">Disclourse Of Accounts Receivables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets And Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsAndExercise_lbl0" xml:lang="en-US">Warrants And Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0" xml:lang="en-US">Finance Expenses From Interest And Commissions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfReverseShareSplit_lbl0" xml:lang="en-US">Description Of Reverse Share Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfReverseShareSplit" xlink:to="sprcy_DescriptionOfReverseShareSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DeferredCashPayments_lbl1" xml:lang="en-US">Deferred Cash Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayments" xlink:to="sprcy_DeferredCashPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Three Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl1" xml:lang="en-US">Disclosure Of Information To The Items Of Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:to="sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl2" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesParValue_lbl1" xml:lang="en-US">Ordinary Shares Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesParValue" xlink:to="sprcy_OrdinarySharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOutstandingShareOption_lbl2" xml:lang="en-US">Number Of Outstanding Share Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOutstandingShareOption" xlink:to="sprcy_NumberOfOutstandingShareOption_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value For Share Options Granted Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_COtherExpensesAbstract_lbl0" xml:lang="en-US">COther Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_COtherExpensesAbstract" xlink:to="sprcy_COtherExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseCosts_lbl0" xml:lang="en-US">Purchase Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCosts" xlink:to="sprcy_PurchaseCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Revenues And Cost Of Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl0" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl1" xml:lang="en-US">Disclosure Of Financial Assets And Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:to="sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0" xml:lang="en-US">Issuance Expenses Related To Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAmount_lbl1" xml:lang="en-US">Investment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAmount" xlink:to="sprcy_InvestmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Other cash receipts from sales of interests in joint ventures, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl0" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Reserve of exchange differences on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccruedInterestPercentage_lbl1" xml:lang="en-US">Accrued Interest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccruedInterestPercentage" xlink:to="sprcy_AccruedInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsExercisePrice_lbl1" xml:lang="en-US">Warrants Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExercisePrice" xlink:to="sprcy_WarrantsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLoss_lbl1" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLoss" xlink:to="sprcy_ComprehensiveLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BonusAmountReceived_lbl1" xml:lang="en-US">Bonus Amount Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl1" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairMarketValue_lbl1" xml:lang="en-US">Fair Market Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairMarketValue" xlink:to="sprcy_FairMarketValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Categories of financial liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_June2022WarrantsMember_lbl0" xml:lang="en-US">June2022 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePrice_lbl0" xml:lang="en-US">Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePrice" xlink:to="sprcy_PurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EFinanceExpensesAbstract_lbl0" xml:lang="en-US">EFinance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceExpensesAbstract" xlink:to="sprcy_EFinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0" xml:lang="en-US">Regulatory Professional And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl0" xml:lang="en-US">Proceeds from issue of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:to="sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0" xml:lang="en-US">Reserve of exchange differences on translation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePerShare_lbl1" xml:lang="en-US">Share Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPaid_lbl1" xml:lang="en-US">Installment Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseOfOrdinaryShares_lbl1" xml:lang="en-US">Purchase Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseOfOrdinaryShares" xlink:to="sprcy_PurchaseOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0" xml:lang="en-US">Adjustments for finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenueTerm_lbl1" xml:lang="en-US">Revenue Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenueTerm" xlink:to="sprcy_RevenueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndDevelopmentsExpenses_lbl1" xml:lang="en-US">Research And Developments Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndDevelopmentsExpenses" xlink:to="sprcy_ResearchAndDevelopmentsExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmountTotal_lbl0" xml:lang="en-US">Amount Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmountTotal" xlink:to="sprcy_AmountTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl0" xml:lang="en-US">Number of shares issued but not fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInvertoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Invertory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvertoryTextBlock" xlink:to="sprcy_DisclosureOfInvertoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl0" xml:lang="en-US">Adjustments To The Profit Or Loss Items Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="sprcy_AdjustmentsToTheProfitOrLossItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl0" xml:lang="en-US">Professional And Directors Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Intangible Asset Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OverAllotmentMember_lbl0" xml:lang="en-US">Over Allotment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryExpensesMember_lbl0" xml:lang="en-US">Regulatory Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFromOthers_lbl1" xml:lang="en-US">Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl0" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpireTerm_lbl0" xml:lang="en-US">Expire Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpireTerm" xlink:to="sprcy_ExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentAmount_lbl1" xml:lang="en-US">Installment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_JeffsBrandsMember_lbl0" xml:lang="en-US">Jeffs Brands Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Granted In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Companys Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0" xml:lang="en-US">Increase (decrease) in number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl1" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investment in associates and joint ventures [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClearmindMedicineIncMember_lbl0" xml:lang="en-US">Clearmind Medicine Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClearmindMedicineIncMember" xlink:to="sprcy_ClearmindMedicineIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesIssued" xlink:to="sprcy_OrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnitsPerShare_lbl1" xml:lang="en-US">Aggregate Units Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl0" xml:lang="en-US">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmazonFeesMember_lbl1" xml:lang="en-US">Amazon Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DividendYield_lbl1" xml:lang="en-US">Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DividendYield" xlink:to="sprcy_DividendYield_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Exercise Prices Of Share Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl0" xml:lang="en-US">Revenue from sale of goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Number Of Shares And Loss Used In The Computation Of Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1" xml:lang="en-US">Rightofuse Asset Recognized With Corresponding Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LongTermPercentage_lbl1" xml:lang="en-US">Long Term Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FeeExpenses_lbl1" xml:lang="en-US">Fee Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FeeExpenses" xlink:to="sprcy_FeeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl1" xml:lang="en-US">Financial assets measured at fair value through other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl" xml:lang="en-US">Schedule Of Cost Of Sales And Gross Profit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract80_lbl0" xml:lang="en-US">Unlabeled Abstract80</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract80" xlink:to="sprcy_UnlabeledAbstract80_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract83_lbl0" xml:lang="en-US">Unlabeled Abstract83</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract83" xlink:to="sprcy_UnlabeledAbstract83_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract84_lbl0" xml:lang="en-US">Unlabeled Abstract84</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract84" xlink:to="sprcy_UnlabeledAbstract84_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract81_lbl0" xml:lang="en-US">Unlabeled Abstract81</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract81" xlink:to="sprcy_UnlabeledAbstract81_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract82_lbl0" xml:lang="en-US">Unlabeled Abstract82</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract82" xlink:to="sprcy_UnlabeledAbstract82_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract87_lbl0" xml:lang="en-US">Unlabeled Abstract87</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract87" xlink:to="sprcy_UnlabeledAbstract87_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl1" xml:lang="en-US">Significant Accounting Judgments Estimates And Assumptions Used In Preparation Of Financial Statements Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract88_lbl0" xml:lang="en-US">Unlabeled Abstract88</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract88" xlink:to="sprcy_UnlabeledAbstract88_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract85_lbl0" xml:lang="en-US">Unlabeled Abstract85</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract85" xlink:to="sprcy_UnlabeledAbstract85_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract86_lbl0" xml:lang="en-US">Unlabeled Abstract86</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract86" xlink:to="sprcy_UnlabeledAbstract86_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesFromInvestment_lbl2" xml:lang="en-US">Equity Losses From Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromInvestment" xlink:to="sprcy_EquityLossesFromInvestment_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract89_lbl0" xml:lang="en-US">Unlabeled Abstract89</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract89" xlink:to="sprcy_UnlabeledAbstract89_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl1" xml:lang="en-US">Duly Executed Share Transfer Deed For Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares" xlink:to="sprcy_DulyExecutedShareTransferDeedForOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExpensesDueToSharebasedCompensation_lbl0" xml:lang="en-US">Expenses Due To Sharebased Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExpensesDueToSharebasedCompensation" xlink:to="sprcy_ExpensesDueToSharebasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeEquipmentsMember_lbl0" xml:lang="en-US">Office Equipments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Current restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Transactions With Relate Parties Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl0" xml:lang="en-US">Non-controlling interests [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract90_lbl0" xml:lang="en-US">Unlabeled Abstract90</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract90" xlink:to="sprcy_UnlabeledAbstract90_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract91_lbl0" xml:lang="en-US">Unlabeled Abstract91</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract91" xlink:to="sprcy_UnlabeledAbstract91_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValue_lbl1" xml:lang="en-US">Aggregate Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValue" xlink:to="sprcy_AggregateValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract94_lbl0" xml:lang="en-US">Unlabeled Abstract94</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract94" xlink:to="sprcy_UnlabeledAbstract94_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract95_lbl0" xml:lang="en-US">Unlabeled Abstract95</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract95" xlink:to="sprcy_UnlabeledAbstract95_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract92_lbl0" xml:lang="en-US">Unlabeled Abstract92</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract92" xlink:to="sprcy_UnlabeledAbstract92_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentFromShareholders_lbl1" xml:lang="en-US">Investment From Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentFromShareholders" xlink:to="sprcy_InvestmentFromShareholders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract93_lbl0" xml:lang="en-US">Unlabeled Abstract93</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract93" xlink:to="sprcy_UnlabeledAbstract93_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract98_lbl0" xml:lang="en-US">Unlabeled Abstract98</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract98" xlink:to="sprcy_UnlabeledAbstract98_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract99_lbl0" xml:lang="en-US">Unlabeled Abstract99</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract99" xlink:to="sprcy_UnlabeledAbstract99_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract96_lbl0" xml:lang="en-US">Unlabeled Abstract96</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract96" xlink:to="sprcy_UnlabeledAbstract96_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract97_lbl0" xml:lang="en-US">Unlabeled Abstract97</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract97" xlink:to="sprcy_UnlabeledAbstract97_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sprcy-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 20:47:26 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinAssociates" roleURI="http://trpx.com/role/InvestmentinAssociates"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_LossPerShareAds" roleURI="http://trpx.com/role/LossPerShareAds"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EventsAftertheReportingDate" roleURI="http://trpx.com/role/EventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinAssociatesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_LossPerShareAdsTables" roleURI="http://trpx.com/role/LossPerShareAdsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofWarrantsFairValueUsingBlackScholesOPMTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinAssociatesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_FinancialInstrumentsDetails" roleURI="http://trpx.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#sprcy_r_EventsAftertheReportingDateDetails" roleURI="http://trpx.com/role/EventsAftertheReportingDateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20231231.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CurrentTradeReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_OtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_Inventories" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsInAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:href="sprcy-20231231.xsd#sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="EquityAttributableToEquityHoldersOfTheCompanyAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_WarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_RetainedEarnings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_Equity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAttributableToEquityHoldersOfTheCompanyAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLoss_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquityInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherEquityInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ParentMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="8.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="sprcy-20231231.xsd#sprcy_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ExerciseOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20231231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssueOfShareCapitalNetOfIssueExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsToTheProfitOrLossItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsToTheProfitOrLossItemsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalAdjustmentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_WorkingCapitalAdjustmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToTheProfitOrLossItemsAbstract" xlink:to="WorkingCapitalAdjustmentsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WorkingCapitalAdjustmentsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20231231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptofShortTermCreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_ReceiptofShortTermCreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ReceiptofShortTermCreditFromOthers" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="SignificantNonCashTransactionsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20231231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegistrationOfWarrants" xlink:href="sprcy-20231231.xsd#sprcy_RegistrationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RegistrationOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInFinancialAsset" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentInFinancialAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="InvestmentInFinancialAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidIssueExpenses" xlink:href="sprcy-20231231.xsd#sprcy_UnpaidIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="UnpaidIssueExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/General">
    <loc xlink:type="locator" xlink:label="GeneralAbstract" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract" xlink:to="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Cash">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociates">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssets">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Leases">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAsset">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherAccountsPayableAbstract" xlink:to="DisclosureOfOtherAccountsPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstruments">
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesTable" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="EmployeeBenefitLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesTable" xlink:to="EmployeeBenefitLiabilitiesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens">
    <loc xlink:type="locator" xlink:label="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/Equity">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenues">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss">
    <loc xlink:type="locator" xlink:label="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAds">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegments">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties">
    <loc xlink:type="locator" xlink:label="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsAftertheReportingDate">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="BasisOfPresentationOfFinancialStatements" xlink:href="sprcy-20231231.xsd#sprcy_BasisOfPresentationOfFinancialStatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BasisOfPresentationOfFinancialStatements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAcquisitionOfASingleAssetCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForRestrictedDeposit" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForRestrictedDeposit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/CashTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAbstract" xlink:to="DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInvertoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfInvertoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="DisclosureOfInvertoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsReceivableTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="DisclourseOfAccountsReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesTablesTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesTablesTable" xlink:to="InvestmentinAssociatesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesTablesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueOfTheIntangibleAssetTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="DisclosureOfFairValueOfTheIntangibleAssetTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TradePayablesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradePayables" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfTradePayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="DisclosureOfTradePayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFinancialAssetsAndFinancialLiabilities" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="DisclosureOfFinancialAssetsAndFinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitLiabilitiesTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EmployeeBenefitLiabilitiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="EmployeeBenefitLiabilitiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesTablesTable" xlink:to="EmployeeBenefitLiabilitiesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitLiabilitiesTablesLineItems" xlink:to="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfIssuedAndOutstandingShareCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsTablesTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesTable" xlink:to="ShareBasedPaymentTransactionsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesLineItems" xlink:to="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesLineItems" xlink:to="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsTablesLineItems" xlink:to="DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfAdditionalInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInformationToTheItemsOfProfitOrLoss" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfAdditionalInformationTextBlockAbstract" xlink:to="DisclosureOfInformationToTheItemsOfProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/LossPerShareAdsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/OperatingSegmentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesTable" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesTable" xlink:to="OperatingSegmentsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:href="sprcy-20231231.xsd#sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20231231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovements" xlink:href="sprcy-20231231.xsd#sprcy_LeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems" xlink:to="LeaseholdImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashDetailsScheduleofCashTable" xlink:href="sprcy-20231231.xsd#sprcy_CashDetailsScheduleofCashTable"/>
    <loc xlink:type="locator" xlink:label="CashDetailsScheduleofCashLineItems" xlink:href="sprcy-20231231.xsd#sprcy_CashDetailsScheduleofCashLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="CashDetailsScheduleofCashTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashDetailsScheduleofCashTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_ILS" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashDetailsScheduleofCashTable" xlink:to="CashDetailsScheduleofCashLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashDetailsScheduleofCashLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_Inventories" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOtherAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_ValueAddedTaxReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueOfTheInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsDate" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentsDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentsDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromInvestment" xlink:href="sprcy-20231231.xsd#sprcy_EquityLossesFromInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="EquityLossesFromInvestment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheInvestmentAbstract" xlink:to="InvestmentAchievementOfFirstMilestone" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeEquipmentsMember" xlink:href="sprcy-20231231.xsd#sprcy_OfficeEquipmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="OfficeEquipmentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable" xlink:to="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="sprcy-20231231.xsd#sprcy_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:href="sprcy-20231231.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="PropertyPlantAndEquipmentAccumulatedDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentAccumulatedDepreciation_0" xlink:href="sprcy-20231231.xsd#sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="PropertyPlantAndEquipmentAccumulatedDepreciation_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:href="sprcy-20231231.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:href="sprcy-20231231.xsd#sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable" xlink:to="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseofAssets" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseofAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="PurchaseofAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradePayablesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfTradePayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedExpenses" xlink:href="sprcy-20231231.xsd#sprcy_AccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="AccruedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradePayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="sprcy-20231231.xsd#sprcy_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="GovernmentAuthorities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsInFinancialAssets" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentsInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="InvestmentsInFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2rrxj3CSwJLmBwgVp4ELjMNRo7Ve3askr7l8vAUsTfxuXtxV64bILHQEWEsJHfnBzJLxq1y4L5qpSYP8eTZ7I6aoGMJYOubthFZ+/qctYcrhFIPuz707yKZeAZcD0e/n5gFtVDh8aDkY=] CSR-->
    <loc xlink:type="locator" xlink:label="CreditFromOthers" xlink:href="sprcy-20231231.xsd#sprcy_CreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="CreditFromOthers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract" xlink:to="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable" xlink:to="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DividendYield" xlink:href="sprcy-20231231.xsd#sprcy_DividendYield"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="DividendYield" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedVolatility" xlink:href="sprcy-20231231.xsd#sprcy_ExpectedVolatility"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="ExpectedVolatility" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RiskFreeInterestRate" xlink:href="sprcy-20231231.xsd#sprcy_RiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="RiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingAdsPrice" xlink:href="sprcy-20231231.xsd#sprcy_UnderlyingAdsPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="UnderlyingAdsPrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="ExercisePricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsFairValueinDollarsPerShares" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsFairValueinDollarsPerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems" xlink:to="WarrantsFairValueinDollarsPerShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfSharesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="NumberOfSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToAConsultant" xlink:href="sprcy-20231231.xsd#sprcy_ShareIssuedToAConsultant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ShareIssuedToAConsultant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfShelfProspectus" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfShelfProspectus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfRoundingErrors" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfRoundingErrors" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentsExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentsExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ResearchAndDevelopmentsExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="GeneralAndAdministrativeExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesDueToSharebasedCompensation" xlink:href="sprcy-20231231.xsd#sprcy_ExpensesDueToSharebasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ExpensesDueToSharebasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" xlink:href="sprcy-20231231.xsd#sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderlyingOrdinarySharePrices" xlink:href="sprcy-20231231.xsd#sprcy_UnderlyingOrdinarySharePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="UnderlyingOrdinarySharePrices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfOutstandingShareOption" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfShareOptionsCancelledInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingShareOption_0" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfOutstandingShareOption_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" xlink:href="sprcy-20231231.xsd#sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="NumberOfShareOptionExercisableInSharebasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:href="sprcy-20231231.xsd#sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:href="sprcy-20231231.xsd#sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AmazonFeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedGoodsMember" xlink:href="sprcy-20231231.xsd#sprcy_PurchasedGoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="PurchasedGoodsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StorageMember" xlink:href="sprcy-20231231.xsd#sprcy_StorageMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="StorageMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FreightMember" xlink:href="sprcy-20231231.xsd#sprcy_FreightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="FreightMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable" xlink:to="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostOfGoodsSold" xlink:href="sprcy-20231231.xsd#sprcy_CostOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems" xlink:to="CostOfGoodsSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20231231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryProfessionalAndOtherExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20231231.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20231231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AmazonFeesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StorageMember" xlink:href="sprcy-20231231.xsd#sprcy_StorageMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="StorageMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20231231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20231231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20231231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDifferencesNetMember" xlink:href="sprcy-20231231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ExchangeRateDifferencesNetMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IssuanceExpensesRelatedToWarrantsMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20231231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20231231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpenseInRespectOfLeasesMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20231231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpensesFromInterestAndCommissionsMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="AResearchAndDevelopmentExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses1" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AResearchAndDevelopmentExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenses1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_BGeneralAndAdministrativeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="BGeneralAndAdministrativeExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BGeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="COtherExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_COtherExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="COtherExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20231231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COtherExpensesAbstract" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DFinanceIncomeAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DFinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="DFinanceIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DFinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="EFinanceExpensesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_EFinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems" xlink:to="EFinanceExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EFinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ContinuingOperationsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:href="sprcy-20231231.xsd#sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentMember" xlink:href="sprcy-20231231.xsd#sprcy_DrugDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="DrugDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesMember" xlink:href="sprcy-20231231.xsd#sprcy_OnlineSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsScheduleofOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SegmentReportingRevenueAbstract" xlink:href="sprcy-20231231.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="SegmentReportingRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExternalRevenues" xlink:href="sprcy-20231231.xsd#sprcy_ExternalRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ExternalRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingRevenueAbstract" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20231231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxExpense" xlink:href="sprcy-20231231.xsd#sprcy_TaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="TaxExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20231231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="KeyManagementPersonnelCompensationManagementFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBenefitsToKeyManagementPersonnelAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="GeneralAbstract" xlink:href="sprcy-20231231.xsd#sprcy_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="SignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingTerm" xlink:href="sprcy-20231231.xsd#sprcy_OperatingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems" xlink:to="OperatingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinAssociatesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinAssociatesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalPointWarrantMember" xlink:href="sprcy-20231231.xsd#sprcy_CapitalPointWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="CapitalPointWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EveroMember" xlink:href="sprcy-20231231.xsd#sprcy_EveroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="EveroMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalPointMember" xlink:href="sprcy-20231231.xsd#sprcy_CapitalPointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CapitalPointMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CoeruleusMember" xlink:href="sprcy-20231231.xsd#sprcy_CoeruleusMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CoeruleusMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXBioLtdMember" xlink:href="sprcy-20231231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXBioLtdMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20231231.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsTable" xlink:to="InvestmentinAssociatesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesSold" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OrdinarySharesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesParValue" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OrdinarySharesParValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSharesIssuedAndOutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="PercentageOfSharesIssuedAndOutstandingShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValue" xlink:href="sprcy-20231231.xsd#sprcy_FairMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="FairMarketValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfOrdinaryShares" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="PurchaseOfOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DulyExecutedShareTransferDeedForOrdinaryShares" xlink:href="sprcy-20231231.xsd#sprcy_DulyExecutedShareTransferDeedForOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="DulyExecutedShareTransferDeedForOrdinaryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentFromShareholders" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentFromShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="InvestmentFromShareholders" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingSharesPercentage" xlink:href="sprcy-20231231.xsd#sprcy_IssuedAndOutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="IssuedAndOutstandingSharesPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfInvestment" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="FairValueOfInvestment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialInvestment" xlink:href="sprcy-20231231.xsd#sprcy_InitialInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="InitialInvestment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInvestment" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="AdditionalInvestment" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OwnershipPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="OutstandingSharesPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInstallment" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalInstallment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="AdditionalInstallment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPaid" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="InstallmentPaid" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromInvestment" xlink:href="sprcy-20231231.xsd#sprcy_EquityLossesFromInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesDetailsLineItems" xlink:to="EquityLossesFromInvestment" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="InvestmentinFinancialAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="currency_ILS" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestmentAmount" xlink:href="sprcy-20231231.xsd#sprcy_InvestmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="InvestmentAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedButNotFullyPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20231231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ShareCapitalPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_SharePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="SharePricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLoss" xlink:href="sprcy-20231231.xsd#sprcy_ComprehensiveLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ComprehensiveLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_Cash" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_PricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="PricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseMember" xlink:href="sprcy-20231231.xsd#sprcy_LeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="LeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SquareMeters" xlink:href="sprcy-20231231.xsd#sprcy_SquareMeters"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="SquareMeters" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseFee" xlink:href="sprcy-20231231.xsd#sprcy_LeaseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="LeaseFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpireTerm" xlink:href="sprcy-20231231.xsd#sprcy_ExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="ExpireTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_PropertyandEquipmentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="PropertyandEquipmentNetDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/IntangibleAssetDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseCosts" xlink:href="sprcy-20231231.xsd#sprcy_PurchaseCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="PurchaseCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchase" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsToPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="WarrantsToPurchase" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice1" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ExercisePrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePeriod" xlink:href="sprcy-20231231.xsd#sprcy_ExercisePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ExercisePeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="pricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_pricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="pricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountTotal" xlink:href="sprcy-20231231.xsd#sprcy_AmountTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="AmountTotal" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueTerm" xlink:href="sprcy-20231231.xsd#sprcy_RevenueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="RevenueTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrowthRatePercentage" xlink:href="sprcy-20231231.xsd#sprcy_GrowthRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="GrowthRatePercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermPercentage" xlink:href="sprcy-20231231.xsd#sprcy_LongTermPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="LongTermPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ActuarialAssumptionOfDiscountRates" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/FinancialInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsAbstract" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_FinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementsMember" xlink:href="sprcy-20231231.xsd#sprcy_PrivatePlacementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="PrivatePlacementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePrice" xlink:href="sprcy-20231231.xsd#sprcy_PurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="PurchasePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityDate" xlink:href="sprcy-20231231.xsd#sprcy_MaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="MaturityDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialConversionPrice" xlink:href="sprcy-20231231.xsd#sprcy_InitialConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="InitialConversionPrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPrice" xlink:href="sprcy-20231231.xsd#sprcy_ConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ConversionPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareExercisePrice" xlink:href="sprcy-20231231.xsd#sprcy_OrdinaryShareExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="OrdinaryShareExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20231231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="OperatingLossCarryforwardsTaxAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
    <loc xlink:type="locator" xlink:label="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:href="sprcy-20231231.xsd#sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract"/>
    <loc xlink:type="locator" xlink:label="DekelLicenseAgreementDescription" xlink:href="sprcy-20231231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="DekelLicenseAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInvestment" xlink:href="sprcy-20231231.xsd#sprcy_AnnualInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="AnnualInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestoneAmount" xlink:href="sprcy-20231231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="AdditionalMilestoneAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentAmount" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="InstallmentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedAmount" xlink:href="sprcy-20231231.xsd#sprcy_EstimatedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="EstimatedAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SeriesAWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_SeriesBWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="SeriesBWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2022WarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_June2022WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="June2022WarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="March2021FinancingRoundMember" xlink:href="sprcy-20231231.xsd#sprcy_March2021FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="March2021FinancingRoundMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20231231.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysOwnEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysOwnEquityInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_EntitysOwnEquityInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20231231.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverAllotmentMember" xlink:href="sprcy-20231231.xsd#sprcy_OverAllotmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="OverAllotmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfReverseShareSplit" xlink:href="sprcy-20231231.xsd#sprcy_DescriptionOfReverseShareSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfReverseShareSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="sprcy-20231231.xsd#sprcy_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="GrossProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfAggregateShares" xlink:href="sprcy-20231231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="IssuanceOfAggregateShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnits" xlink:href="sprcy-20231231.xsd#sprcy_AggregateUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateUnits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnitsPerShare" xlink:href="sprcy-20231231.xsd#sprcy_AggregateUnitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateUnitsPerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DateOfIssuance" xlink:href="sprcy-20231231.xsd#sprcy_DateOfIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DateOfIssuance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndExercise" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsAndExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantsAndExercise" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisePrice" xlink:href="sprcy-20231231.xsd#sprcy_WarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantsExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20231231.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PurchasePricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="sprcy-20231231.xsd#sprcy_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateGrossProceeds" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20231231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="TwoThousandTwentyThreePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ShareBasedPaymentTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesGranted" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfShareOption" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfShareOption" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsGranted" xlink:href="sprcy-20231231.xsd#sprcy_ShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="ShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfShareOptionsGranted" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesIssued" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="OrdinarySharesGrantedDiscountRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfOrdinarySharesGranted" xlink:href="sprcy-20231231.xsd#sprcy_FairValueOfOrdinarySharesGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FairValueOfOrdinarySharesGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" xlink:href="sprcy-20231231.xsd#sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="WeightedAverageRemainingContractualLifesOfOutstandingShareOption" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsAndBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClearmindMedicineIncMember" xlink:href="sprcy-20231231.xsd#sprcy_ClearmindMedicineIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ClearmindMedicineIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="sprcy-20231231.xsd#sprcy_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfCommonShares" xlink:href="sprcy-20231231.xsd#sprcy_ExchangeOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ExchangeOfCommonShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingShareCapital" xlink:href="sprcy-20231231.xsd#sprcy_OutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="OutstandingShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract" xlink:to="SignificantEventsduringtheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NewCoIncMember" xlink:href="sprcy-20231231.xsd#sprcy_NewCoIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="NewCoIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20231231.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="SignificantEventsduringtheReportingPeriodDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestPercentgae" xlink:href="sprcy-20231231.xsd#sprcy_InterestPercentgae"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="InterestPercentgae" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredCashPayments" xlink:href="sprcy-20231231.xsd#sprcy_DeferredCashPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="DeferredCashPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20231231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ShareCapitalPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FeeExpenses" xlink:href="sprcy-20231231.xsd#sprcy_FeeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="FeeExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAmountReceived" xlink:href="sprcy-20231231.xsd#sprcy_BonusAmountReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="BonusAmountReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ifrs-full_ServicesExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MutualShareExchangeAmount" xlink:href="sprcy-20231231.xsd#sprcy_MutualShareExchangeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="MutualShareExchangeAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesAcquired" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="OrdinarySharesAcquired" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValue" xlink:href="sprcy-20231231.xsd#sprcy_AggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="AggregateValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustedAmountOfAggregateValue" xlink:href="sprcy-20231231.xsd#sprcy_AdjustedAmountOfAggregateValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="AdjustedAmountOfAggregateValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OwnershipPercentage" xlink:href="sprcy-20231231.xsd#sprcy_OwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="OwnershipPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ListedSharePrice" xlink:href="sprcy-20231231.xsd#sprcy_ListedSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ListedSharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossOnInvestment" xlink:href="sprcy-20231231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsLineItems" xlink:to="ComprehensiveLossOnInvestment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/EventsAftertheReportingDateDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20231231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EventsAftertheReportingDateDetailsLineItems" xlink:href="sprcy-20231231.xsd#sprcy_EventsAftertheReportingDateDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="EventsAftertheReportingDateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SEPAMember" xlink:href="sprcy-20231231.xsd#sprcy_SEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SEPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="EventsAftertheReportingDateDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePercentage" xlink:href="sprcy-20231231.xsd#sprcy_SharePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="SharePricePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidAdvance" xlink:href="sprcy-20231231.xsd#sprcy_PrepaidAdvance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="PrepaidAdvance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterestPercentage" xlink:href="sprcy-20231231.xsd#sprcy_AccruedInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="AccruedInterestPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentPercentage" xlink:href="sprcy-20231231.xsd#sprcy_CommitmentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="CommitmentPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPaymentPercentage" xlink:href="sprcy-20231231.xsd#sprcy_InstallmentPaymentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="InstallmentPaymentPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentPremiumPercentage" xlink:href="sprcy-20231231.xsd#sprcy_PaymentPremiumPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="PaymentPremiumPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://trpx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="sprcy-20231231.xsd#sprcy_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValueMember" xlink:href="sprcy-20231231.xsd#sprcy_OrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="OrdinarySharesNoParValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightsToPurchaseOrdinarySharesNoParValueMember" xlink:href="sprcy-20231231.xsd#sprcy_RightsToPurchaseOrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="RightsToPurchaseOrdinarySharesNoParValueMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12gTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12gTitle" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654494825632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SCISPARC LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">706,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A, 2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg St.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A, 2nd Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Oz Adler<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-7175777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">oz@scisparc.com<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_OrdinarySharesNoParValueMember', window );">Ordinary Shares, no par value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12gTitle', window );">Title of 12(g) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_RightsToPurchaseOrdinarySharesNoParValueMember', window );">Rights to Purchase Ordinary Shares, no par value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12gTitle', window );">Title of 12(g) Security</a></td>
<td class="text">Rights to Purchase Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12gTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(g) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection g<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12gTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_OrdinarySharesNoParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=sprcy_OrdinarySharesNoParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=sprcy_RightsToPurchaseOrdinarySharesNoParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=sprcy_RightsToPurchaseOrdinarySharesNoParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450218448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted deposit</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposit</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">4,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociates', window );">Investments in company accounted for at equity</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">4,737<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Warrants</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liability</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract', window );"><strong>EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share capital and premium</a></td>
<td class="nump">64,526<span></span>
</td>
<td class="nump">58,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve from share-based payment transactions</a></td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrants</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Foreign currency translation reserve</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Transactions with non-controlling interests</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(68,691)<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total</a></td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">1,973<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">9,587<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 11,182<span></span>
</td>
<td class="nump">$ 10,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates in an entity's separate financial statements. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654441000192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(683)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,196<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9', window );">Impairment of intangible asset</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,778<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,768<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="nump">5,861<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total comprehensive loss</a></td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Equity holders of the Company</a></td>
<td class="nump">5,122<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">761<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit loss</a></td>
<td class="nump">$ 5,883<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</a></td>
<td class="nump">$ 14.43<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 73.58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)</a></td>
<td class="nump">$ 14.43<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 73.58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss, impairment gain or reversal of impairment loss that is recognised in profit or loss in accordance with paragraph 5.5.8 of IFRS 9 and that arises from applying the impairment requirements in Section 5.5 of IFRS 9.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph ba<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_ba&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654448463248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share capital and premium</div></th>
<th class="th"><div>Reserve from share-based payment transactions</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Transactions with non- controlling interests</div></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non- controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 49,040<span></span>
</td>
<td class="nump">$ 4,315<span></span>
</td>
<td class="nump">$ 2,207<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (55,188)<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">6,110<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,352)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issue of share capital, net of issue expenses</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,335<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Expiration of share options</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">58,541<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(60,977)<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issue of share capital in respect of investment in affiliate</a></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issue of share capital, net of issue expenses</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 64,526<span></span>
</td>
<td class="nump">$ 5,282<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (68,691)<span></span>
</td>
<td class="nump">$ 7,614<span></span>
</td>
<td class="nump">$ 1,973<span></span>
</td>
<td class="nump">$ 9,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueOfShareCapitalNetOfIssueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of share capital, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueOfShareCapitalNetOfIssueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439880096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="num">$ (5,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract', window );"><strong>Adjustments to the profit or loss items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance expenses (income), net</a></td>
<td class="num">(2,205)<span></span>
</td>
<td class="num">(6,585)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="nump">829<span></span>
</td>
<td class="num">(4,622)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WorkingCapitalAdjustmentsAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="num">(409)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade payables</a></td>
<td class="num">(397)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase (decrease) in other accounts payable</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Working capital</a></td>
<td class="num">(833)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,887)<span></span>
</td>
<td class="num">(7,917)<span></span>
</td>
<td class="num">(5,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents', window );">Investment in restricted bank deposits</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Investment in short-term bank deposits</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Investment in a company accounted for at equity</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Change in fair value of investments in financial assets</a></td>
<td class="num">(689)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Sale of minority interest in subsidiary</a></td>
<td class="nump">2,985<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Purchase of financial assets at fair value through profit or loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,861)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(7,084)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses', window );">Proceeds from issue of share capital (net of issuance expenses)</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="nump">9,005<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod', window );">Payment of issuance expenses related to previous period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid on lease liability</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ReceiptofShortTermCreditFromOthers', window );">Repayment of short-term credit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,498<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">10,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase (decrease) in cash</a></td>
<td class="num">(1,498)<span></span>
</td>
<td class="num">(3,301)<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash at the beginning of the period</a></td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">6,875<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash at the end of the period</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">6,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantNonCashTransactionsAbstract', window );"><strong>(a) Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RegistrationOfWarrants', window );">Registration of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentInFinancialAsset', window );">Investment in financial asset</a></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnpaidIssueExpenses', window );">Unpaid issue expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses from remeasurement of investment in financial assets

  to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsToTheProfitOrLossItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsToTheProfitOrLossItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentInFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentInFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from issue of share capital and warrants net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReceiptofShortTermCreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReceiptofShortTermCreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RegistrationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registration of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RegistrationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset recognized with corresponding lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantNonCashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantNonCashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnpaidIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid issue expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnpaidIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WorkingCapitalAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WorkingCapitalAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654471649904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GeneralAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">GENERAL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#8217;s disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated under
the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (&#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1, which
became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these interim consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
of the Company for the year ended December&#160;31, 2023, were approved on March 31, 2024, and signed on April 1, 2024 (the &#8220;Approval
Date&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2023, the Group had an accumulated deficit of approximately $68,691 as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
cash and cash equivalents totaled $2,076. In the period ended December 31, 2023, the Company had an operating loss of $5,883 and negative
cash flows from operating activities of $5,887. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities
arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no
guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms,
would have serious consequences on our financial condition and results of operations. In addition, the Group has started recognizing revenues
from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing and/or new investors.
This dependency will continue until the Group is able to completely finance its operations by generating revenue from its products. These
above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221; and is not a Subsidiary.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Parties</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GeneralAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GeneralAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654471715856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2:-</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">20-33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies&#8221;:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In February 2021, the IASB issued an
amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; (&#8220;the Amendment&#8221;), which replaces the requirement to disclose
&#8217;significant&#8217; accounting policies with a requirement to disclose &#8216;material&#8217; accounting policies. One of the main reasons for the Amendment
is the absence of a definition of the term &#8217;significant&#8217; in IFRS whereas the term &#8216;material&#8217; is defined in several standards and particularly
in IAS 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is applicable for annual
periods beginning on January 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The application of the above Amendment
had an effect on the disclosures of the Company&#8217;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a
new definition of &#8220;accounting estimates&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
Company sells products directly to customers mainly through its online Amazon stores.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440075408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract', window );"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock', window );">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and/or termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not
exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset
to the Company&#8217;s operation and whether it is a specialized asset, the company&#8217;s past experience with similar leases, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450085984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,443</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,076</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,574</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450094096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">INVENTORY</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447027200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER ACCOUNTS RECEIVABLE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">131</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654441118240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Investment in Associates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">INVESTMENT IN ASSOCIATES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN ASSOCIATES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of Orimmune Bio Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 22, 2016, the Company entered
into a share transfer agreement (the &#8220;Transfer Agreement&#8221;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#8220;Orimmune&#8221;)
and Karma Link Ltd. (the &#8220;Buyer&#8221;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On December 13, 2018, an additional
amendment to the Transfer Agreement was signed between the parties, under which it was agreed that Orimmune will be assigned certain rights
in intellectual property (&#8220;IP&#8221;) related to the licensed technology owned by the Company subject to certain conditions precedent
which were still not met as of December 31, 2023. As of the Approval Date, the conditions precedent have not yet been completed and the
assignment of the IP related to the licensed technology owned by us has not yet been transferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coeruleus - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On May 15, 2020, the Company entered
into a series of transactions (together, the &#8220;Joint Venture Transaction&#8221;), including a definitive share transfer agreement
with Capital Point Ltd. (&#8220;Capital Point&#8221;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital
Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the &#8220;Purchased Coeruleus Shares&#8221;
and &#8220;Coeruleus,&#8221; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in,
among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce
the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic
encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus.
In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of
the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company
as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus&#8217; issued
and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#8220;Capital Point Warrant&#8221;) to purchase $340
of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is equal
to the closing price of the Company&#8217;s ordinary shares on the trading day on which the notice of exercise was actually received by
the Company and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero. The
Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of
Coeruleus. As of December 31, 2023, the fair value of the Company&#8217;s investment in Coeruleus is $<span style="-sec-ix-hidden: hidden-fact-121">nil</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitocareX - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $600 in MitoCareX and increase its share ownership in MitoCareX Bio from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCare X agreed for the additional $600 installment to be deferred to March 25, 2024. As of the date of this report the $600 installment
has been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $210 (for the year ended December 31, 2022
- $109).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">781</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440472208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Investment in Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory', window );">INVESTMENT IN FINANCIAL ASSETS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT IN FINANCIAL ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; &#160; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company&#8217;s shares in Clearmind was reduced from 230,769 common shares to 7,692. As of December 31, 2023, the listed share price of Clearmind on Nasdaq was $2.81, and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2023, of $727 on its investment (for the year ended December 31, 2022 - $771). &#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2023, the Company entered into an investment agreement (the &#8220;Agreement&#8221;) with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), an Israeli company traded on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) and the leading parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS 2,500,000 in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax based on a price per share of NIS 0.5. As of December 31, 2023, the listed share price of AutoMax on the TASE was NIS 0.384, and the Company has recorded a loss in its statements of comprehensive loss of $158 on its investment.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450213088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 1, 2020, the Company entered
into a one-year lease agreement with a third party for an area of approximately 100 square meters for the Company&#8217;s offices in the
district of Tel Aviv, Israel. The yearly lease fee was set at approximately $44, linked to the NIS. The lease expired on August 31, 2021.
The Company did not exercise its option to extend the lease until August 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 1, 2021, the Company entered
into a two-year joint lease agreement with a third party and for a total area of approximately 240 square meters, whereby the Company
occupies approximately 120 square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company and the third
party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately $40, linked to the NIS.
On July 7, 2023, the lease was extended until June 30, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439746032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assets owned and used by the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">New lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2023, 2022 and 2021 amounted to $52, $43 and $32, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440127376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSET</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the Company
incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for
the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#8220;September 2022 Warrants&#8221;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,042.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 8.7
years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined based
on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s expectations that
revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter of 13.8% and a
declining growth rate for the long term, reaching 2% at the terminal year. Theoretical royalties arising from the brand were capitalized
at a discount rate of 20.6%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,189</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2023, the Company recognized depreciation expenses in respect to intangible asset in the amount of $486 (for the year ended December 31,
2022 - $144).&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440532864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE PAYABLES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">901</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,199</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440127376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654441043216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,065</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison between the carrying amount
and fair value of the Company&#8217;s financial instruments as of December 31, 2023, and 2022, which are presented in the financial statements
not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left"></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left"></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dekel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#8220;Dekel&#8221;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#8220;Private Placement&#8221;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#8220;Notes&#8221;), with an aggregate original principal amount of approximately
$350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to 12,088 ordinary shares of the Company (the &#8220;Private Placement Warrant&#8221;) and 1,538 ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $5,148. The Notes are unsecured,
have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder,
into ordinary shares at an initial conversion price of $0.35 per ordinary share (the &#8220;Fixed Conversion Price&#8221;), subject to
adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed
Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary
shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received
by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and
on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35 per ordinary
share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Refer to Note 14a for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439730800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EmployeeBenefitLiabilitiesLineItems', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">EMPLOYEE BENEFIT LIABILITIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses in respect of defined contribution plans</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EmployeeBenefitLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EmployeeBenefitLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440532864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2023, 2022, and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2023, the Company&#8217;s
net carryforward tax losses are estimated to grow to approximately $62,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447023344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract', window );"><strong>Contingent Liabilities Commitments Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for a
specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under
the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also
included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive Chairman
of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of
approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $340,000 of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As of December 31, 2023, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot
predict the likelihood of success of the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449910928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">EQUITY</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 18:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">261,494</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to 75,000,000 ordinary shares with <span style="-sec-ix-hidden: hidden-fact-181">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1 (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-182">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of<br/> ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">261,494</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; in respect of investment in affiliate (Note 18f)</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">13,858</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share issued to a consultant (Note 19(a)(5))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of shelf prospectus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of August 2023 financing round (Note 18i)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of rounding errors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,688</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of October 2023 financing round (Note 18j)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,905</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">706,683</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional issuance of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 2, 2022, the Company issued
a consultant 923 ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 1, 2022, the Company issued
a consultant 1,423 ordinary shares in respect of services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 22, 2023, the Company issued
13,858 ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered into
by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also note 25a)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 44,332 units, as follows: (a) 35,243 units at a price of $183.82 per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#8220;2021 Series A Warrants&#8221;) and a Series B Warrant
(the &#8220;2021 Series B Warrants&#8221; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase half
the number of units, and (b) 9,089 pre-funded units at a price of $183.79 per unit, consisting of (i) one pre-funded warrant to purchase
one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The 2021 Series A Warrants have an
exercise price of&#160;$183.82&#160;per ordinary share and the 2021 Series B Warrants have an exercise price of&#160;$275.60&#160;per
ordinary share). Both were exercisable upon issuance and will expire five years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2021, the Company issued 4,929 ordinary shares in respect of the exercise of 385 2021 Series A Warrants and the exercise of 4,544 of pre-funded
warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued 3,846 ordinary shares in respect of the exercise of 3,846 pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210(the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,885 units at a price of $74.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 123,504 pre-funded units at a price of $73.29 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.656</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 14, 2023, the Company closed
an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to
cover over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants, or Pre-Funded Warrants. The Pre-Funded
Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from the date of issuance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654496121616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 19:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2005 and 2015 ESOP and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span>The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board approved
to reserve for <span>issuance under the 2023 Plan <span style="-sec-ix-hidden: hidden-fact-183">1,000,0000</span> Ordinary Shares. As </span>of the date of
this report, no shares were issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board approved and granted 45 ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $10,920.00 per share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
was set at $5,824 per Share Option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 10, 2019 (the &#8220;2019 Grant Date&#8221;), the Board approved the grant of 3 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2019 General Meeting&#8221;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 1 Share Options was not granted. Out of the 2 Share Options that were granted, 1 Share Options didn&#8217;t require the general meeting&#8217;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $5,460.00 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">According to IFRS 2, &#8220;<i>Share-based
Payment</i>&#8221;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#8217;s approval was calculated based on parameters as of December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,031.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,004</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the 2019 General Meeting (valuated as of December 31, 2019) was
set at $2,966.6 and $1,328.6, per Share Option, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of 6,851 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $169 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;10,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">129.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">174.98</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of the Share Options
granted on January 3, 2022, was set at $158.34 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $114.66 per Share Option. The Share Options&#8217; vesting period was set to commence retroactively from April 21, 2021, and
end at April 21, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company issued to consultants 7,942 ordinary shares in respect of services rendered. The ordinary shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $94. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">166.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,851</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,060</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,141</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">163.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Share Options were granted during 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was 4.03 years and 5.03 years as of December 31, 2023, and 2022, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 120px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices of Share Options outstanding at the end of the year was $169 - $21,944 (inclusive) as of December 31, 2023, and 2022, respectively.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654441043216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">REVENUES AND COST OF REVENUES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES AND COST OF REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company sells products directly
to customers mainly through its online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return, the Company recognizes
revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a
significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable
if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its
estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31,
2023, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right
of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company evaluates
the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining the nature
of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon
its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment
of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on
its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, sales are recorded
on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022(*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amazon fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchased goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">683</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439752416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory', window );">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:- </b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year ended December&#160;31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research and development expenses:</span></i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages and related expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">392</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">436</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">357</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory, professional and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">719</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">934</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and preclinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">703</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry and formulations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">281</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">335</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,803</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,990</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">General and administrative expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages and related expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td>
    <td>&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon fees</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">424</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional and directors&#8217; fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,594</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,499</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,417</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business development expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office maintenance, rent and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor relations and business expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,486</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">784</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,031</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,972</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,778</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Other expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s share of losses of company accounted for at equity, net</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Finance income:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change in fair value of financial liabilities designated at fair value through profit or loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,205</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate differences, net</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,219</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance expenses:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance expenses related to warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,204</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate differences, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses from remeasurement of investment in financial assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,046</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">770</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance expense in respect of leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance expenses from interest and commissions</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-202; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,014</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAdditionalInformationTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654582524208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share/Ads [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE/ADS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 22:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS PER SHARE/ADS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>thousands</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,883</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">79</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,789</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">408</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,883</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,789</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable warrants to investors.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450189328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">OPERATING SEGMENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried out
according to the results of the segment&#8217;s activity. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,359</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,773</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">External</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,789</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,182</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,595</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440541984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">962</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands. Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands (see also note 25a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2023 and 2022, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $40 and $208, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, we invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Amitai Weiss, our chairman of the board of directors, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440330720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract', window );"><strong>Significant Events during the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock', window );">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px; text-align: left"><b>NOTE 25:- </b></td><td style="text-align: justify"><b>SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution<sup>TM</sup>, for $2,500 in cash, and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately 51% of the share capital of SciSparc US.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the agreement, at the closing
of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands provides
management services to SciSparc US for the Wellution<sup>TM </sup>brand for a monthly fee of $20 and Jeffs&#8217; Brands received a one-time
signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party
with 30 days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31, 2023, the Company
has recorded management services expenses in the amount of $220.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, in connection with the closing
of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $288,238 of ordinary shares
from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing
price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the
closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 ordinary
shares of the Company having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership limit included
in the definitive agreements. As of December 31, 2023, the listed share price of Jeff&#8217;s Brands on the NASDAQ was $ 3.05, and the
Company has recorded a loss in its statements of comprehensive loss of $180 on its investment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440541984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Events After the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">EVENTS AFTER THE REPORTING DATE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On January 21, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $20,000 of the Company&#8217;s Ordinary Shares (the &#8220;Advance Shares&#8221;). Of the $20,000
eligible to be sold pursuant to the SEPA, or the Commitment Amount, Company has sold 925,159 ordinary shares as of the issuance date of
these financial statements. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97% of
the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000, each a Pre-Paid Advance. Each Pre-Paid Advance will
be evidenced by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and
shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event
of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to YA
a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest, payable in cash or
by submitting an advance notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of the
monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash, the installment amount shall also include
a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains the Company&#8217;s
customary representations and warranties and Events of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, pursuant to the SEPA, the
Company issued to YA an aggregate of 55,293 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and commissions
and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA The Company will pay the expenses
(except brokerage fees and commissions and similar expenses) incurred to register under the Securities Act the offer and sale of the Ordinary
Shares pursuant to the SEPA by YA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439887696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BasisOfPresentationOfFinancialStatements', window );">Basis of presentation of the financial statements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory', window );">The operating cycle</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements', window );">Consolidated financial statements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany', window );">Acquisition of a single asset company</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit', window );">Restricted deposits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory', window );">Investment in joint arrangements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint ventures:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint operations:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock', window );">Investments accounted for using the equity method</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">20-33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual cash flow terms of the financial asset.</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at amortized cost when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity instruments and other financial assets held for trading:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized only
when:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities:</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at amortized cost:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 168px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial liabilities measured at fair value through profit or loss:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition of financial liabilities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of a unit of securities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and other
service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings (loss) per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefit liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term employee benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company as a lessee:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease extension and termination options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 120px; text-align: justify">&#160;</td>
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease modifications:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock', window );">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 1, &#8220;Disclosure of Accounting Policies&#8221;:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In February 2021, the IASB issued an
amendment to IAS 1, &#8220;Presentation of Financial Statements&#8221; (&#8220;the Amendment&#8221;), which replaces the requirement to disclose
&#8217;significant&#8217; accounting policies with a requirement to disclose &#8216;material&#8217; accounting policies. One of the main reasons for the Amendment
is the absence of a definition of the term &#8217;significant&#8217; in IFRS whereas the term &#8216;material&#8217; is defined in several standards and particularly
in IAS 1.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is applicable for annual
periods beginning on January 1, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The application of the above Amendment
had an effect on the disclosures of the Company&#8217;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors', window );">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to IAS 8, &#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221;:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In February 2021, the IASB issued an amendment to IAS 8,
&#8220;Accounting Policies, Changes to Accounting Estimates and Errors&#8221; (&#8220;the Amendment&#8221;), in which it introduces a
new definition of &#8220;accounting estimates&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Accounting estimates are defined as
&#8220;monetary amounts in financial statements that are subject to measurement uncertainty&#8221;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">y.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
Company sells products directly to customers mainly through its online Amazon stores.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">z.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BasisOfPresentationOfFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes inrBasis of presentation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BasisOfPresentationOfFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Accounting Policy Amendment to IAS 1, &#8220;Disclosure of Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in Consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for investments in associates. The description of the entity's material accounting policy information for investments accounted for using the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in operating cycle Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for acquisition of a single asset company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAcquisitionOfASingleAssetCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for changes to accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654448374240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory', window );">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</a></td>
<td class="text">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mainly %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">6-50</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Computers</td><td>&#160;</td>
    <td style="text-align: center">33-50</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">20-33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">see below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for useful life of the assets at annual rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654471705920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,443</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,076</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,574</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosue of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440541984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfInvertoryTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Goods in transit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">470</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInvertoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInvertoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654476722928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock', window );">Schedule of Other Accounts Receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">131</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounts receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclourseOfAccountsReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654423024464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesTablesLineItems', window );"><strong>Investment in Associates and Investments in Investees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of Fair Value of the Investment</a></td>
<td class="text">The table below summarizes the fair
value of the investment in MitoCareX:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Investment date March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(109</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment following achievement of first milestone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">781</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440114480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Assets owned and used by the Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Right-of-<br/> use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lab<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture<br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> office</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">New lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">117</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">75</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Balance at January&#160;1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Depreciated cost at December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447453648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock', window );">Schedule of Fair Value of the Intangible Asset</a></td>
<td class="text">The table below
summarizes the fair value of the intangible asset:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Purchase date September 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,189</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value of the intangible asset text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449880336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfTradePayables', window );">Schedule of Trade Payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">901</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">802</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,199</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfTradePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfTradePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449949936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447432560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Financial assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investments in financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial assets at amortized cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,065</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Financial liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total financial and lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>The tables below are a comparison between the carrying amount
and fair value of the Company&#8217;s financial instruments as of December 31, 2023, and 2022, which are presented in the financial statements
not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,065</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">656</td><td style="text-align: left"></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Carrying amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Fair Value</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">December&#160;31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and restricted deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investments in financial assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total financial assets at amortized cost</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Credit from others</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total financial and lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,866</td><td style="text-align: left"></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock', window );">Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM</a></td>
<td class="text">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March&#160;23,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Underlying Share Price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.36</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of financial assets and financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450175376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EmployeeBenefitLiabilitiesTablesLineItems', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory', window );">Schedule of Defined Contribution Plans</a></td>
<td class="text">These contributions and contributions for compensation represent defined contribution plans.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses in respect of defined contribution plans</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 4.5pt double; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about defined contribution plans explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EmployeeBenefitLiabilitiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EmployeeBenefitLiabilitiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450237888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December&#160;31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Issued and outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">706,683</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">75,000,000</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">261,494</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital', window );">Schedule of Issued and Outstanding Share Capital</a></td>
<td class="text"><i>Issued and outstanding share capital:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of<br/> ordinary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">261,494</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of share capital &#8211; in respect of investment in affiliate (Note 18f)</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">13,858</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share issued to a consultant (Note 19(a)(5))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of shelf prospectus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of August 2023 financing round (Note 18i)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital &#8211; in respect of rounding errors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,688</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Issuance of share capital &#8211; in respect of October 2023 financing round (Note 18j)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,905</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">706,683</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</a></td>
<td class="text">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Underlying share price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.656</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Warrants fair value ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed inforamtion about issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450211904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsTablesLineItems', window );"><strong>Share-based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock', window );">Schedule of Expenses Due to Share-Based Compensation</a></td>
<td class="text">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">633</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock', window );">Schedule of Fair Value for Share Options Granted</a></td>
<td class="text"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expected life of share options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table><i>Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">October&#160;10,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,031.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,004</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">February&#160;10,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 3,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Underlying ordinary share price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">129.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">174.98</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life of Share Options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock', window );">Schedule of Weighted Average Exercise Prices of Share Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Share<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">2023:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">166.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options cancelled during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share Options granted during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,851</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options outstanding at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,060</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share Options exercisable at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,141</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">163.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expenses due to share-based compensation explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value for share options granted explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of share options and weighted average exercise prices of share options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654441024672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock', window );">Schedule of Cost of Sales and Gross Profit</a></td>
<td class="text">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022(*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic"><span style="text-decoration:underline">Cost of goods sold</span></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Amazon fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#160;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchased goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Storage</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Freight</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">683</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654445861920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss', window );">Schedule of Additional Information to the Items of Profit or Loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year ended December&#160;31,</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research and development expenses:</span></i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages and related expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">392</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">436</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">357</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory, professional and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">719</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">934</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and preclinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">703</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical studies</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">254</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry and formulations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">281</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">335</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,803</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,990</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">General and administrative expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages and related expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">415</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td>
    <td>&#160;</td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amazon fees</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">424</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional and directors&#8217; fees</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,594</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,499</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,417</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business development expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">161</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office maintenance, rent and other expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)80</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor relations and business expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">369</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,486</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">784</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,031</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,972</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,778</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Other expenses:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company&#8217;s share of losses of company accounted for at equity, net</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Finance income:</span></i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net change in fair value of financial liabilities designated at fair value through profit or loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,205</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate differences, net</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,219</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,832</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance expenses:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance expenses related to warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,204</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate differences, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses from remeasurement of investment in financial assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,046</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">770</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance expense in respect of leases</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance expenses from interest and commissions</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-202; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,014</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfAdditionalInformationTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfAdditionalInformationTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disclosure of information to the items of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450351760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share/Ads [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Amounts used in the computation of basic and diluted&#160;loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> number of<br/> shares (*)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>thousands</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In<br/> thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Basic loss per share</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,883</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,592</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">79</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,789</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of potential dilutive ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">408</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,883</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,592</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5,789</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654565186240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingSegmentsTablesLineItems', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Operating Segments</a></td>
<td class="text">The Group&#8217;s CODM is the CEO
of the Company.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt">Segment loss (gain)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,359</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,773</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on impairment of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,164</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">External</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,347</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Company&#8217;s share of losses of company accounted for at equity, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,818</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic"><span style="text-decoration:underline">Revenues</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">External</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment loss</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,768</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,789</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,182</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,595</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Drug<br/> Development</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Online<br/> Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Segment Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Segment Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingSegmentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingSegmentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449236304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory', window );">Schedule of Balances with Related Parties</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Key<br/> management<br/> personnel</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other<br/> related<br/> parties</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">121</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">55</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sale of minority interest in subsidiary</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,985</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Schedule of Benefits to Key Management Personnel</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Short-term benefits</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,204</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,940</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">962</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Management fees (see also note 25a)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">220</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cost of share-based payment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about balance with relate parties explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about transactions with relate parties explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439796048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GeneralAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (68,691)<span></span>
</td>
<td class="num">$ (63,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Operating loss</a></td>
<td class="num">(5,883)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">$ (5,887)<span></span>
</td>
<td class="num">$ (7,917)<span></span>
</td>
<td class="num">$ (5,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GeneralAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GeneralAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439839040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingTerm', window );">Operating term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447968288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife', window );">Straight-line basis over the useful life of the assets, description</a></td>
<td class="text">see below<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeaseholdImprovements', window );">Leasehold improvements (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful lives or depreciation rates used for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450155104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash (Details) - Schedule of Cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashDetailsScheduleofCashLineItems', window );"><strong>Cash (Details) - Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashDetailsScheduleofCashLineItems', window );"><strong>Cash (Details) - Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">3,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CashDetailsScheduleofCashLineItems', window );"><strong>Cash (Details) - Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashDetailsScheduleofCashLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashDetailsScheduleofCashLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450274224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of Inventory - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfInventoryAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInventoriesInTransit', window );">Goods in transit</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total Inventory</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInventoriesInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInventoriesInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440397376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsReceivableAbstract', window );"><strong>Schedule of Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAddedTaxReceivables', window );">Government authorities</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to a value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450860960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2020 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairMarketValue', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentFromShareholders', window );">Investment from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuedAndOutstandingSharesPercentage', window );">Issued and outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfInvestment', window );">Fair value of Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInstallment', window );">Additional installment</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentPaid', window );">Installment paid</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember', window );">Evero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesSold', window );">Ordinary shares sold (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,952,469<span></span>
</td>
<td class="nump">5,952,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesParValue', window );">Ordinary shares par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DulyExecutedShareTransferDeedForOrdinaryShares', window );">Duly executed share transfer deed for ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember', window );">Capital Point [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesSold', window );">Ordinary shares sold (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,470<span></span>
</td>
<td class="nump">176,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesParValue', window );">Ordinary shares par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CoeruleusMember', window );">Coeruleus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital', window );">Percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OutstandingSharesPercentage', window );">Outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember', window );">Capital Point Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesDetailsLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseOfOrdinaryShares', window );">Purchase of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional installment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DulyExecutedShareTransferDeedForOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of duly executed share transfer deed for ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DulyExecutedShareTransferDeedForOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity losses from investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of Investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of installment paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentFromShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment from shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentFromShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuedAndOutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding shares, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuedAndOutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_EveroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CapitalPointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CoeruleusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_CoeruleusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_CapitalPointWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654441009936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates (Details) - Schedule of Fair Value of the Investment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueOfTheInvestmentAbstract', window );"><strong>Schedule of Fair Value of the Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at beginning</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsDate', window );">Investment date March 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityLossesFromInvestment', window );">Equity losses from investment in MitoCareX</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Balance at ending</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentAchievementOfFirstMilestone', window );">Investment following achievement of first milestone</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity losses from investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment following achievement of first milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment date,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueOfTheInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueOfTheInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449664416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets (Details)<br> &#8362; / shares in Units, $ / shares in Units, &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Nov. 17, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentAmount', window );">Investment amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid', window );">Received shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharePricePerShare', window );">Share price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ComprehensiveLoss', window );">Comprehensive loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash (in New Shekels) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in New Shekels per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PricePerShare', window );">Price Per Share (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=currency_ILS', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash (in New Shekels) | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has not been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedButNotFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439797920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SquareMeters', window );">Square meters</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeaseFee', window );">Lease fee (in Dollars)</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExpireTerm', window );">Lease expired</a></td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember', window );">2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SquareMeters', window );">Square meters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SquareMeters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SquareMeters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439768656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Disclosure of property, plant and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyandEquipmentNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyandEquipmentNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449206336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Beginning balance</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">New lease</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets', window );">Cost, Ending balance</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Beginning balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">Accumulated depreciation, Ending balance</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated', window );">Depreciated cost</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 77<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_77_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449618640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount', window );">Exceeds amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseCosts', window );">Purchase costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsToPurchase', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePrice1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePeriod', window );">Exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Gross sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_pricePerShare', window );">Ordinary shares price closes (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AmountTotal', window );">Amount total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Amortized over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment to its intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenueTerm', window );">Revenue term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GrowthRatePercentage', window );">Growth rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_LongTermPercentage', window );">Long term, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_f_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AmountTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AmountTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrowthRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrowthRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LongTermPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of long term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LongTermPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_pricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_pricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450276192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems', window );"><strong>Schedule of Fair Value of the Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning</a></td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchaseofAssets', window );">Purchase date September 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost', window );">Depreciation of intangible asset</a></td>
<td class="num">(486)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at ending</a></td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="num">$ (1,042)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseofAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseofAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449974656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Payables (Details) - Schedule of Trade Payables - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfTradePayablesAbstract', window );"><strong>Schedule of Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Open debts</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTradePayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTradePayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447899856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of Other Accounts Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accrued vacation</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439839536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 19, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal amount</a></td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash', window );">Purchase price</a></td>
<td class="nump">$ 315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued of warrant (in Shares) | shares</a></td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MaturityDate', window );">Maturity date</a></td>
<td class="text">Mar. 23,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InitialConversionPrice', window );">Initial conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinaryShareExercisePrice', window );">Ordinary share exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash paid for principal amount</a></td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Issued of warrant (in Shares) | shares</a></td>
<td class="nump">12,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 5,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prices specified in forward agreements to purchase financial assets for cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinaryShareExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinaryShareExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sprcy_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654448906832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="nump">$ 2,141<span></span>
</td>
<td class="nump">$ 3,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short term deposits</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InvestmentsInFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">4,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of credit of others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450253360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems', window );"><strong>Schedule of Warrants Fair Value Using Black&#8211;Scholes OPM [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DividendYield', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExpectedVolatility', window );">Expected volatility (%)</a></td>
<td class="nump">122.01%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">3.84%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnderlyingAdsPrice', window );">Underlying Share Price ($)</a></td>
<td class="nump">$ 11.18<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 19.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExercisePricePerShare', window );">Exercise price ($)</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsFairValueinDollarsPerShares', window );">Warrants fair value ($)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate for the option contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingAdsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingAdsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsFairValueinDollarsPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsFairValueinDollarsPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440527600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfDefinedContributionPlansAbstract', window );"><strong>Schedule of Defined Contribution Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Expenses in respect of defined contribution plans</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDefinedContributionPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDefinedContributionPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440256784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OperatingLossCarryforwardsTaxAmount', window );">Carryforward tax losses (in Dollars)</a></td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingLossCarryforwardsTaxAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net operating loss carryforward tax as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingLossCarryforwardsTaxAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440163088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract', window );"><strong>Contingent Liabilities Commitments Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DekelLicenseAgreementDescription', window );">Milestone payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AnnualInvestment', window );">Annual investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdditionalMilestoneAmount', window );">Additional milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentAmount', window );">Installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EstimatedAmount', window );">Estimated amount</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Capital purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Capital warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">&#8362; 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AnnualInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AnnualInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DekelLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dekel license agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DekelLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EstimatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EstimatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of installment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654420710688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 21, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 25, 2023 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">212,500<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value (in Dollars per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DescriptionOfReverseShareSplit', window );">Description of reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#8217;s share capital
up to a ratio of 30:1 (the &#8220;Third Reverse Split&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GrossProceeds', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DateOfIssuance', window );">Expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateGrossProceeds', window );">Aggregate gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross cash proceeds (in Dollars) | $</a></td>
<td class="nump">$ 5,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="nump">1,930,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,504<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember', window );">Over Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember', window );">March 2021 Financing Round [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember', window );">June 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EquityDetailsLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WarrantsExercisePrice', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share of aggregate units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfReverseShareSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfReverseShareSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The issuance of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAndExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAndExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=sprcy_March2021FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654471634496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Share Capital - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, issued and outstanding</a></td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439736848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Issued and Outstanding Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at January 1, 2023</a></td>
<td class="nump">261,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate', window );">Issuance of share capital &#8211; in respect of investment in affiliate</a></td>
<td class="nump">13,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareIssuedToAConsultant', window );">Share issued to a consultant</a></td>
<td class="nump">7,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus', window );">Issuance of share capital &#8211; in respect of shelf prospectus</a></td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Issuance of share capital &#8211; in respect of August 2023 financing round</a></td>
<td class="nump">237,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors', window );">Issuance of share capital &#8211; in respect of rounding errors</a></td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound', window );">Issuance of share capital &#8211; in respect of October 2023 financing round</a></td>
<td class="nump">182,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at December 31, 2023</a></td>
<td class="nump">706,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of investment in affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share capital issued in respect of October 2023 financing round.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share capital issued in respect of rounding errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of shelf prospectus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareIssuedToAConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares were issued to a consultant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareIssuedToAConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447811936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract', window );"><strong>Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">3.872%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price ($) (in Dollars per share)</a></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 19.656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 68.38<span></span>
</td>
<td class="nump">$ 68.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 2,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447554416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2020</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Mar. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
<td class="nump">925,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesGranted', window );">Ordinary shares granted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 21,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 10,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfShareOption', window );">Fair value of share options</a></td>
<td class="nump">$ 1,328.6<span></span>
</td>
<td class="nump">$ 2,966.6<span></span>
</td>
<td class="nump">$ 5,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareOptionsGranted', window );">Share options granted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfShareOptionsGranted', window );">Fair value of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.66<span></span>
</td>
<td class="nump">$ 158.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesIssued', window );">Ordinary shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesGrantedDiscountRate', window );">Ordinary shares granted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FairValueOfOrdinarySharesGranted', window );">Fair value of ordinary shares granted (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">5 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfOrdinarySharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of ordinary shares granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfOrdinarySharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value Of share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesGrantedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares granted discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesGrantedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual lifes of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440127680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract', window );"><strong>Schedule of Expenses Due to Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentsExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExpensesDueToSharebasedCompensation', window );">Total</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExpensesDueToSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExpensesDueToSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654439907600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 10, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract', window );"><strong>Schedule of Fair Value for Share Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">133.00%<span></span>
</td>
<td class="nump">134.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.91%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1', window );">Expected life of share options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">9 years 9 months 10 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_UnderlyingOrdinarySharePrices', window );">Underlying ordinary share price (in Dollars per share)</a></td>
<td class="nump">$ 129.74<span></span>
</td>
<td class="nump">$ 174.98<span></span>
</td>
<td class="nump">$ 2,031.12<span></span>
</td>
<td class="nump">$ 4,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_UnderlyingOrdinarySharePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying ordinary share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_UnderlyingOrdinarySharePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654422968736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>2023:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfOutstandingShareOption', window );">Number of Share Options , Share Options outstanding at the beginning of the year</a></td>
<td class="nump">7,060<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the beginning of the year</a></td>
<td class="nump">$ 166.14<span></span>
</td>
<td class="nump">$ 76.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options granted during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options granted during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options cancelled during the year</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options cancelled during the year</a></td>
<td class="nump">$ 144.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfOutstandingShareOption', window );">Number of Share Options, Share Options outstanding at the end of the year</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the end of the year</a></td>
<td class="nump">$ 166.28<span></span>
</td>
<td class="nump">$ 166.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options exercisable at the end of the year</a></td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options exercisable at the end of the year</a></td>
<td class="nump">$ 165.58<span></span>
</td>
<td class="nump">$ 163.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share option outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options exercisable at the end of the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options cancelled during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447462208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 683<span></span>
</td>
<td colspan="2" class="nump">$ 322<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AmazonFeesMember', window );">Amazon fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_PurchasedGoodsMember', window );">Purchased goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">672<span></span>
</td>
<td colspan="2" class="nump">301<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_StorageMember', window );">Storage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_FreightMember', window );">Freight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 11<span></span>
</td>
<td colspan="2" class="nump">$ 21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_PurchasedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_PurchasedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_StorageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_StorageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_FreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_FreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654420587680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_COtherExpensesAbstract', window );"><strong>c. Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DFinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses1', window );">Research and development expenses</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember', window );">Amazon Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageMember', window );">Storage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BGeneralAndAdministrativeExpensesAbstract', window );"><strong>b. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember', window );">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DFinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(2,205)<span></span>
</td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember', window );">Exchange rate differences, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DFinanceIncomeAbstract', window );"><strong>d. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember', window );">Issuance expenses related to warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember', window );">Losses from remeasurement of investment in financial assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember', window );">Finance expense in respect of leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember', window );">Finance expenses from interest and commissions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EFinanceExpensesAbstract', window );"><strong>e. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_COtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_COtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EFinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EFinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_StorageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654448532768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic loss per share, Weighted number of shares</a></td>
<td class="nump">408,000<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">79,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument', window );">Basic loss per share, Loss (in Dollars)</a></td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,789)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares', window );">Effect of potential dilutive ordinary shares, Weighted number of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share, Weighted number of shares</a></td>
<td class="nump">408,000<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">79,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument', window );">Diluted loss per share, Loss (in Dollars)</a></td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,789)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#8220;Reverse Split&#8221; (see note 18a).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity&#8217;s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654450845632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Details) - Schedule of Operating Segments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Finance expense (income), net</a></td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(5,818)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TaxExpense', window );">Tax expense</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">10,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember', window );">Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">7,069<span></span>
</td>
<td class="nump">9,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember', window );">Online Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SegmentReportingRevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Total</a></td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">414<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">4,113<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExternalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of external revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExternalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SegmentReportingRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SegmentReportingRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654423000624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses', window );">Recognized expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ClearmindMedicineIncMember', window );">Clearmind Medicine Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Invested amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ExchangeOfCommonShares', window );">Exchange of common shares (in Shares)</a></td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OutstandingShareCapital', window );">Outstanding share capital, percentage</a></td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExchangeOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExchangeOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ClearmindMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_ClearmindMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654471636192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems', window );"><strong>Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems', window );"><strong>Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">121<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654448945872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract', window );"><strong>Schedule of Transactions with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Sale of minority interest in subsidiary</a></td>
<td class="nump">$ 2,985<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654440127680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract', window );"><strong>Schedule of Benefits to Key Management Personnel[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_KeyManagementPersonnelCompensationManagementFees', window );">Management fees (see also note 25a)</a></td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based payment</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_KeyManagementPersonnelCompensationManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_KeyManagementPersonnelCompensationManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654449086048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InterestPercentgae', window );">Interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_DeferredCashPayments', window );">Deferred cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_FeeExpenses', window );">Fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_BonusAmountReceived', window );">Bonus amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Management services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_MutualShareExchangeAmount', window );">Mutual share exchange amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AggregateValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ListedSharePrice', window );">Listed share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_ComprehensiveLossOnInvestment', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember', window );">NewCo Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_OrdinarySharesAcquired', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AdjustedAmountOfAggregateValue', window );">Adjusted amount of aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustedAmountOfAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjusted amount of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustedAmountOfAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of ordinary shares of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BonusAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus amount received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BonusAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of comprehensive loss on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DeferredCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DeferredCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FeeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FeeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestPercentgae">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest percentgae.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestPercentgae</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ListedSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of listed shares price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ListedSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MutualShareExchangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mutual share exchange amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MutualShareExchangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_NewCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139654447500320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Date (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsAftertheReportingDateDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Provided sale (in Dollars)</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Commitment amount (in Dollars)</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="nump">925,159<span></span>
</td>
<td class="nump">706,683<span></span>
</td>
<td class="nump">261,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_SharePricePercentage', window );">Shareprice, percentage</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PrepaidAdvance', window );">Prepaid advance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_AccruedInterestPercentage', window );">Accrued interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_CommitmentPercentage', window );">Increasing per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_InstallmentPaymentPercentage', window );">Installment payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_PaymentPremiumPercentage', window );">Payment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Payment commitment fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember', window );">SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sprcy_EventsAftertheReportingDateDetailsLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccruedInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccruedInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EventsAftertheReportingDateDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EventsAftertheReportingDateDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Installment payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PrepaidAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PrepaidAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ':(@5@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !VB(%8,_ 7CNT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VG%0^CVLN))07!!\1:2V=U@DX9DI-VW-XV[740?0,@E,W^^
M^0;2Z2#U&/$YC@$C64PWLQM\DCILV)$H2("DC^A4JG/"Y^9^C$Y1OL8#!*4_
MU &AX?P.')(RBA0LP"JL1-9W1DL=4=$8SWBC5WSXC$.!&0TXH$-/"40M@/7+
MQ'":APZN@ 5&&%WZ+J!9B:7Z)[9T@)V3<[)K:IJF>FI++N\@X.WI\:6L6UF?
M2'F-^56RDDX!-^PR^;7=WN\>6-_PYK;B^8A=(R1O92O>%]<??E=A-QJ[M__8
M^"+8=_#K7_1?4$L#!!0    ( ':(@5B97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M=HB!6#I?E(1<!P  8"4  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MFFUSVD84A?_*#IW)M%/;H#>P$YNIC$W*Q+$IN,VXG7Y82VO01-+2W96Q\^M[
M5Q):G(HKX:1?$I"EHT?[<L[=1:=K+C[+)6.*/"5Q*L\Z2Z56;[M=&2Q90N41
M7[$4_O+ 14(5?!6+KEP)1L/\HB3NVKU>OYO0*.T,3_-C4S$\Y9F*HY1-!9%9
MDE#Q?,YBOC[K6)W-@5FT6"I]H#L\7=$%FS/U^VHJX%NW4@FCA*4RXBD1[.&L
MXUMOS[V!OB _XX^(K>769Z(?Y9[SS_K+)#SK]#01BUF@M 2%_Q[9B,6Q5@*.
M?TK13G5/?>'VYXWZ.']X>)A[*MF(QY^B4"W/.L<=$K('FL5JQM>_LO*!/*T7
M\%CF_Y)U<:[G=$B02<63\F(@2**T^)\^E0VQ=8%[LN,"N[S SKF+&^64%U31
MX:G@:R+TV:"F/^2/FE\-<%&J>V6N!/PU@NO4\(('&32R(GX:DLM41>J93-*B
MMZ'53KL*;J)/[0:EX'DA:.\0M&SRD:=J*4$M9.%+@2[058CV!O'<1A4O6'!$
M'.N V#W;(7))!9.(K%,]N9/+.DU/OO6XY I.(A/%$EGWY(6@6R^HY\];N:(!
M.^O !)%,/++.\,T/5K_W#L%U*UP74Q^6?3-CBT@J08'[FB:LCA+7F8\F\ZD_
M&Y&KVXLCA,NKN#Q4KVK&V^=5+0Y^N=T['",4_8JBC\J,,B$TQ#B2 8W)':-"
MCS\"<Z(6"E<[/+3L0\="N 85UZ!-KXUXDL#HFBL>?#X@\WP(DYM,2473,$H7
M=8B%L)<+:V]]' YZ_?ZQ<]I]K $ZKH".42 ?^BK,^VL<T]K[XM<_T%@RI&%.
M*HZ35@T#) (Z; )>\40^L.<Z(ERIU^M9?<L:N'T$R^H9/^RU BL'U(RMN%#0
M1=!Y5&6UMM"@>(?:E;7EU%8;LC]XG*4*$A0&>\Q$/1&N=,TQ(-L V6V <@PR
M@IFVX**V QMTKGEZ2(, DEJ 2%@(8H3&XBW4DC>$GR#T#S^G? U3D%')4[C)
M1,KLZ[N4M+@FWGC&SBW<ARO?G#(1\1!UJR:I34#F"8G1&5.W6KKZMJ&.X6#]
M<&OR>)S*F+R%^_+75&73[>;"Y<9W&)6Q>*N5QU\F3"RT4;P'!;74GK^B:?U\
MP 6;/-8R9F_A;EVBS9<P 5"@;S-]R[B^A9OU9#2>$3\+(\4%\95BD(!YX;4K
MC1KTFLALX_LV[M+5V-I46#F6-GVF#]>Q-2@VLAGGMW&_WBK2TPS&?1%*M4BX
MD!(92F2LW\8MVU1]4(K**&\KA H7:VPHX_<V[LT5UHL1CY'A>HUDQN[M5N6[
MCC9RG27W]='3( *5SJ%SW'.QRM0V'F_CMERM]@(NH'WR 7]0C'@"LW/$H<P0
MNG8-:T.I0?T*LWS;6+Z->W0)Z8<AE,SR8/.A6*C=I/5DN*3=(S-8M)-/-(Y9
M"CVA:SML*62;*+!;14$][>V:U]+BDK=\#=65#ZM?*!#&,>=8962;9+!;)4-%
M.M+?H-?A=K6+_@:Y6Q83_S%ZQ-A,2-BMU@85VY1#2L3DSVBU>S#BBOV3@75B
M80L$QP2%TVJ!8%JNF">U^P6XTN0* S+IX+1:%TQ2!?5SOLFE"TFZ6<+4@N&*
M^(K%,2GAM$R)<932-(B@$ZM )9="Y"X#D,4&W5^Z!OB[%O?;\L/9VA)JF1]^
M$.AN+==]:4A%6 N&R^5=DN;&"H]N&N'%HC(71]O;A(R#Y\.FL!I'(B&3BUIB
M7,&RC[%P<4RX.+C];U!V;5(U7/[A9GY+QC>SRQEY[Y^?^W?D#4U6[\@'?SZY
MA*,8H\D6!P^"#>,5#W9N=C9(;'SO -:3@K(8XS(IXN"6?YY). *Q,>*PT _J
M9S J\<J]2,?$AW/\W3=/T01Y+;$)%6>_4&E32#1([EU(N"9DW/U"IDTAT2"Y
M5R'AFO1Q6Z5/ZT*B0:Y%(>&:_'%;;5#M4T@T*#87$JX)&[?5YE2;0J)!"2TD
MW*U?&'#S+^U&;ZM(GJ;0$SM_8L"%;K[ 4^%[>*Y)$A>/@GQ ^8+1W7V&"_Q\
M,K Q$I,7+F[V.B=B,EWR%%O#-8@XAP-KX T& PS)1(6+1\5_N^PRH5&\&52U
M?+@B__*+#")P8A$<!3S!*$U:N/CJX$:$4/N(Y_*7CP.2<@(W((\T_GH_HF3\
M/[+"-5GAGGSO='/1J'@EL6?RPFLP=T'#O)Y\3NYY7 ?8(#"?SD88B<D#K\'
M(Q4SPA^(9?^X^(G,69 )F,&U2+C2'J/F):O)!P]W\PT<N7P*EC1=L)V&UR!T
M[<\O_-\P)I,*'N[E^7L1DBA.IID *@G5R;[3![_%:P>CR1'/_=[3QT,#Y;7$
M6[]AXQ&QSZ#%E;ZM^U[BFV#R\$S98QSC0LWCV"23A^?(-2<O36GG%G^#T*X]
MZ^[62R_ZIY?\U1Y)\G5[\?Y+=;1Z?<@O7IHQIQ?O'GVD^I<;26+V )?VC@;0
MQZ)XG:?XHO@J?X7FGBO%D_SCDM&0"7T"_/V!<[7YHF]0O50U_!=02P,$%
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M8!?R+!D,6'U4?R5K']7;-$0[O!M:[Y*(<ZR_7 JP<[U)$Y4_P\?HG60,91Q
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MDB4M:X!XOF*,OUW47Z3N/^T>_P]02P,$%     @ =HB!6'Y+\/X<"0  33$
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M   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULI5G;;MNX%GW75Q!N4;2
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M?6'W??:P!93,GGC%(($NZG*BN^)0U/9Z[D.E $&001II;'8 ")892)(W0)9
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M(WZ5 0PQ"1&FFJ:>=ZLND5W,$$+Q(SL5][;RFL1O&BVW\/YF()]=COD360"
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M("G#PU&>*[0+2DM1S \XJ8G7H)T#45+%!!*PQ+1!UR-I<0B2MC?)9;"[#QX
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M3SS4507!^]OWORC_1T3+=5&5("F*+KFMSAS'9IN.4LA&A@$?L+N4?B$GD=M
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M_KFU.6 >'X#OUVW;ZQ^XP4/;?2+P7O\?4$L#!!0    ( ':(@5B.]&^D PH
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M&EZ-!@14.X6M863M.W\MC9TCORWMPX7*!=CSC93F8+@+NJ<P^P-02P,$%
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MV<#S#4Y6!E^G<TN&S?_[6)&!8GB<PAV(*UN+#,<1[WB+9H71Y.6+_GGR^H3
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M+W=O<FMS:&5E=',O<VAE970Q-BYX;6R-6%%3VT@2?M>OF/(F6U#EV);L )<
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M!SMQL-$((GD'<N5<9Q(5"H%*[8I#WNJPKN\RU T^EU!N\:BD!0>L*7Y20'%
M-VBCDLG')W(3L<7W)E-^&G\\#,5^81$@Y;E8J-04JH4E24;J"E$H""#E&F8
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MW#:CEPJ5#:#SM93F8-@+VK<O_ M02P,$%     @ =HB!6/\'$)IJ @  3 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULE53;;MLP#'W/5Q#:L*>M
MOK;-LL2 DV;H@+4)>MDP#'M0;"8VJHLG*4WS]Y/DQ,N -,!>;)'B.3HD10TW
M4CWI"M' "V="CTAE3#,( EU4R*D^DPT*N[.4BE-C3;4*=*.0EA[$61"'X47
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M"*9Y C43ITO_[%AJ1X\8_YO1JQ$-"]#^2FNWG;"!]ATZ^1=02P,$%     @
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M!+H0P.NUM71P0H'C?V?^#U!+ P04    " !VB(%89E<,Y,$.  #F)0  &0
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MD9F8&Z+9_1)PA"L&/-T*1$(.$!N3#7#T>^30'#!+C4/BZQ0JIT8V ?U9D_K
M4M"_=01&^WE["$0Z<::Q:0A!U2!].0 (O<&I2/9"&\B*!D2V 4<NY#UR+ RG
M\^!L@9F?K[+5I4BD+2RL&4;?Y%H5 &R>L*XE",<IK3\SA>S0,RZ'3S%[BR_+
M?,R%D#F= ?#41!H$"5UPA@(@@+V:&P)?6DA+M"]#;@(@2\AN^K\-FLRRU@%(
M5,:M(@*D/SP50!G2NW%N=8 .4L'D[A&A=89X/APX5%B9=,4G0[0+4_/0N@"V
M&VA0^^31+-$")U+?I3BPKNY!+*U%77AZ3+I/IJM<4T+P1LD3&STG6\NFB"G=
M,Y05@V3D$XJ &F\\'"2KJN&4(#O:,""54^0Y<0;(_^AXM,M#22R>&2'05 >4
MALHKWHF>G<%QM(^T'LH[_3EK:WLH 4,QI=;0BML%#%?02[\/=M(SG0S#+G^H
MM"%2%N<+J2'GJB0B];V1-A26.)0359<8J%7>FWB3(XS*8ANSQ!2W>[N8$*)-
M"":VKIR/C_KDUL&O5RG^$!6#-NRR- V<BKU0I ?,@)9*%T7\SY=]%/U6F"1<
M_4/06K"QS/!K,JC=%Q(.1:J(9YJ,ALGL42']3^U C^(+6@S6*1<]C+5;Q7A\
M4#.+-OIK!9];%RGE%V4;)PM5LO@6^Y'>P[(MM[_N:LCD%;OYY4YAGI P%^O"
MO-/B Z+,D%!!I<?R>C"#X92);9GL'XLSO?L&BY?R>U_PB&:[KB:K9.6(LN2F
MN3']H%AF3%*@,\I,4N:M+D(! (";'!AKK*('^UT!&!D)(CUKD$ZPR!';K4J&
M+ HV.J*'@9JT/ ['H!;0'J8J'I@L,V2E+9E 6L!U,>V7V.B#)SJ#:9JRAIFW
M$FI]2M*#=C]<D#MT !2L.'ZEUZ4/4JL5'WE#CF E2BAQ@TW1UHHDA+_ABYC
M[;WBE&P;MEF=>GT'<_U6\]%!1X4.Q#2^#7OO*Y(*0)J-/<84A[1T:X/3:U\H
MC@ES4*1XCM$NQ_62+/B*BP((E'05)H;1@ZY8KSMV88HL\CO VD,H&^.2V%CV
M#'0M$/H5 E8V!;X*BZ($Q/W-DI #UN[M/*"44W47%?6#Y:1?2,_Y"((R#XH-
MB;;':M&60!OY@U@846@]2<6DXF*$S+:!WH(6C3K[/@HWI+#KZ=*=)^%L#&*)
M>@"B4&JPNB7@L8!+MKVG:UD5'1K;R>"4;FIH.UJB9T7GJN"C;U KGI3PFJ]X
MHRZ"+N0^^!9K#Y+5=UWA"<T!3.?->,W.D&Y#V7@#;4-DSQ")E3B&]5'T)^EP
MD] _0 &@J%G!G18H[C9=&%,P!<>RP+=BX].G.3@H"$HC8P]0AKSFA'*^R1XH
MOGRQ]>2673&X_O"AY9QP\U%1KHLLM")4#@@6L>K--JI>R+VLZQO$%_C8E/IW
M!:%^89"]ZN ]9N#I<R%3-3/!.E,4G;G8]!+LW. $?.9;F2L/T-\A(VRXS MA
MO20E(5.N;%]KFG>WA-.3"ZD1EAM+9SN_.AB/1Q2:N_:69IIQIK$S[B#[%42J
MN'VH,J!9Q:-S+-L)C)D?FF0M%<71:I:+LUJ>),F-<\!%Z&U.T%E^[7K^H']6
M[?JJ"OA=.B'7EFD+;4=1\+!MN3*>3%IN; 4E@:#DT'?CDG7SGYV>G@S%1:."
MXE\516K1Z1Y S:&R<72'5%P'708)GL7[L(6LYB$\(6BH 6@; R/L!F/2(C5K
ML _H$ZYQAD@GZJ6+@+";U)MX90/0R[9SX(Z7F@Z)$DO=?4/W87ZI5+65[X!P
MQ]8%]R \55<L35&N9S2;&^IX$*8C$2IU$,J%XGG.!PRPZV?(F] B1ZE.&YF^
M+@V"Z73(WRR(;]+OE5D"W(0+9FAJSB((DGZ4RX[#NWNI3=JG*L8B@)L(!C!]
M'UQ<K" %(:8#4S4NQ,LI?V#R/*(")779-C3HK2KHQ!4<P;SM[& $CK!Q:<-B
M/%X\1BG^!QIQXTJ6O-/CEI5V7E& ZE. BQ3@-RE ]2@@X[0W&VG?9G$B=Z5]
MF\#=5<#Z30C:?O2.BNM*4V><6(CWA4KCM2)+]G&(3+4K^Y"E@Z.78()LB_O_
M"8G5T^<]V7W*RTX>OP_?X=*-U1YQ[RHUVR)< -4V4 "]M]!IVW)#%JZH.PO4
M/0O470?J/EA1]T"DUJ#UY\+R?XNA>#*&3W#V^$]RMCB)MX&/LND&=VNWL=.S
MHU/TZXHSA-]KA'=: W$N:TUK?F9)L=9^K7W5U=Y<4TGLDOP.3>ST7M\?_"+S
M7(H+[E%2:OL:N]Y)\"?=,G0KJ8&!N22:6><3%F95$V_(CT<'H^.#R=':8K>8
MO/YR@CX1E2PW;_S"(\E6NC%152;CQ4?41Z3V"S6/&@^>G(4VF__N),J&>ENU
M\5?.2E5H<1Y'.O%1+@=@W%,XMZF^$1>I"BY9<&"V)WX-8RY78]H%7K&9?7.>
M-N'.6&Q_P_?)(&):X^1ESSDIZ42%LN(H]>(EV1)U2S)B7+.EZ EZZP!9"^C:
M-[^&A?H:K6X@YBF6SXY>C :CT8C.L'[?O76L_@9Q27'+(]?#O7-S9D=(&K3E
MW-\S8XPGH@ROA5D%$/KIG5X@2"J6JP\F['&NR<$=X>JWBF_W.] '_4V"G_I2
MQ+UR,@WWD"T=FJJ_\&A GN5P;FN#S21D#0G",N*#0EN[X*PDR5'*;\;RE0EW
M%E0&=*;)E^M.Y(XB1[;1#=K6%>WFG=8751O+%S[T$P1Q<O#W04SR]@ROX@U0
M#TKA+37+@G50%G*9-]1^6)6W51[B@-O"1\,60X:D-Y[>BTB&12=?7H1H!374
MWC84ZTC--%TP1AQOXY:&KL-I^S29+"4EQY:BI1<R8P8P@WA_@UHGP]-CND K
M (#N#039R9(&$!S$ W%+2G4G_@TO4TV(3V3*8,7C&5_IT455_&5)[Y;E-@)R
MLI\]IY>4;?AW.7<0U.VWIDKCNS3BC3R^4NO?.@?/;3EJRYD#Q!; K]KW0FW0
MZ38JUY[N*5.%@K_%)A2_NB%5>*]:;]--+RW4:9?VYQ:#QY)/TCN ,C3;V(-^
M0S&7JQ=T*UK9RB&QH-M;&+61;\CAC'Y]$W-OB00F!^5*^W"([96F74"G[=O,
M"^K=U\Z;4DOKD]I21^OC_>!W4/6"7G9B?KR_[2-@N.N'&8>]W]Z4RL[Y%T9T
M00*$A9_A=)]V/V*:AM_NK(:'7T!=2SM'Q44?D6/J"-#="]<_[8,W-?^29V:\
M-R7_N5 2F*$!^#XWQK</M$'WTZZS_P!02P,$%     @ =HB!6!M#8L+""P
MI2$  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULK5IM;]RX$?ZN7T'X
MK@<;4&1)^^XD!NR\M#G@DC0O=RB*?N!*W%V=)5$A*6_<7]]G2$FKW94=NRV0
MV"N1',X,9YYY..L76ZEN]$8(P[X7>:E?GFR,J2[.SW6R$077@:Q$B9&55 4W
M>%3K<UTIP5.[J,C/XS"<GA<\*T\N7]AW']7E"UF;/"O%1\5T711<W5V+7&Y?
MGD0G[8M/V7ICZ,7YY8N*K\5G8;Y6'Q6>SCLI:5:(4F>R9$JL7IY<11?78YIO
M)_R>B:WN?69DR5+*&WIXE[X\"4DAD8O$D 2.7[?BE<AS$@0UOC4R3[HM:6'_
M<RO]K;4=MBRY%J]D_D>6FLW+D_D)2\6*U[GY)+=_$XT]$Y*7R%S;GVSKYD:8
MG-3:R*)9# V*K'2_^??&#[T%\_">!7&S(+9ZNXVLEJ^YX9<OE-PR1;,AC3Y8
M4^UJ*)>5="B?C<)HAG7F\LVW.C-W+\X-9-&;\Z19=^W6Q?>LBV+VFRS-1K,W
M92K2?0'G4*+3)&XUN8X?E/A:) $;13Z+PWCT@+Q19]G(RAL]:!G[Y]52&X7#
M_]>0D4[$>%@$)<2%KG@B7IX@XK50M^+D\I>?HFGX_ $%QYV"XX>D7[[Y^]=W
M7_XQI-7#Z]Y_^/*&1?.+9\Q)8#Q@KV1129W90)<KIC=<"9;P*C,\O_#@6E$L
MA>K<RP[?Q-Y5;3929?\6*7NG=8U?O$P9TE@;?,C*-?OA#.]];66V"FCO@\)[
MY'KSS&83/PQ#^L]FX=2?SD?]5_$T\L>+,?LD;H72@GVV5GRN\LQH]J%DGT5E
MG-;1Q&GM,[,1UGA>WGF)+&]%:?7"O[+F.5OC6>%W@?P@&Z :";/J;&2>8A^?
M;3="B>6=E=4?8;RJE+R%0"-95B8 /6C5V_&7G^9Q-'NN]_WM87;/*GG@@VUF
M-JR49-!5O4:&XRS=J>Q9PUIK//Y_LL*'#0;.XWG&?<8!J<[-FAQ,,G]L65V1
M*["4(])HR2B\B-@I+:05<?C\RR93Z>X$2;0=B9Z?!>RMS%$$R ):D155+H#O
MAK=A2V\'!/A#FGE\%XY[2K(MA\WIG_ LAFJ@DQJT[$J9+,F%]5R6;!A6-2JD
MW A&WL0S3D%GVMBQ@4/UW*'ZS8'V(G0\<*:=[M>2PT@LE+D-KPTW=MX*0O/&
MNRBX]SD$,93G;"F0,1=1J_]2)+P03*Q6PE8Z)OOZQ$V,$5246GRKX??\#F$
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MQ0A1$#B?.,?*<B($"7"?C29^/!ZY4<(7[BJNW2Z:CX)Y3'72COLM-6D(X2D
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M:R3FDX'S*H^Y]LB%GW!P2&9-\THR&]F#X7L9K>(9?H2SBC*M&:FK,^M(>B)
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M;B,F;F [?H%>1&B_=GNL+:PC^4BSARH*S#E-,X<I^L/^UMR"K<0YM* N4&I
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MMU_SF<9=I]$2BXQ+(Y0$S=<7K5'W]+)'\D[@F^ [<[ &\F2EU _:3.*+ED^
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MU<'A(Z<$M,AP;D*MKMXSM""^88U.DH.4(19*S%G1)&NLTZ/JOH/AV[7Y=;!
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M'JP"[RLAOGA W+RB=GB2#IBEMU/3CI5?YQ]6G*!8%CRY",D/, ^X4^PF=!M
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MZKG-5R/=B/@B>7#AH6>D#QZY^8PCC]<5)["Z7&9#)O\05RB<&B:Y1J3C6_(
MN6U9*CJ2(E415."^*TJN[GR#([&KCHX0]A\CM6'9CSM\$QZ^%U_YQ$*P@HZ]
MJ[:*[*Y!LO;< E/%/B3F\00FMN:F.0CFL],ZO?-3=D3Y6*#@,):$GG MP =Y
M#)B8EG'[%D)P;:'9>J\ +1B5O2I6]HI*:(N6&:$T=5; E%CMBQ3.B.@].^OP
MH)7F:N39'#-@_SFJ*&V]&K+HQ?53&X6B9<H4UPBP$G03D^+IP<!@J$O ^,=V
MPK=="Z=F4&0&GQTE#E R*GQ#A)@I4JH9]YI3FW"8"'GBAN X(A5R8#2S6P"
MNV&FON?D.=Q(^&:_Y[:H<T"-Q&@B"=TJ[\*I6^-][)$W4KLZCCW>T0?AXXER
MJ:!$]]WMA^1JL])N?: 4$6P,ZP07EI">QN+,P[$X#0)&@E>B9N3!&3[SY^AJ
MIV(X_)Z1!SL]DC XI6<Z@=S]BJ]+_6C?'>J&3F&I;[MO@[19;H/T 9LG7+"4
MD"34J)_!E/:U/.2,]O7[.GEHKNE$7V#?97VVH3_>2%Q8^Q$V+<7#-%L&5/V^
MTI)BSU2.%( 8P]"ZMH^<J'<APC."37L_KI.%EVZB;@MV_D5#.I!?V2 A<>QS
M"Z(RH4.?:E?Y&_JGR.:!XR(..$AM!I43@OZ**&ZDPE*=#YP+KKORU_<_^]7?
MLN@<'<"XG]VPU^:#"S2CL+_W=7%KYJ!2?.=TXZD-63_Z(&))/'8[NFZ&4HZ6
MU0V*]IKRK9'_-53 ZM,R@^"V5(5%?;LD@$FN6,#GEWZU)G#O(W_BZ$P+RVTI
MB\/RE).MI%E!D]Y;'JVVEE@@6JV\<@G0D(KT'/\I1_PWRWWWWA/$[K0IQB]E
MU<6=B[F%.^;/87)_7?DI=[H8Z$NR052,3Z_="1RT.JT0,J%R%-;CQ%#S)0"<
MD^B8YZAJ !T)6CRKF%KUQRT73$U@%,M&4#P--AXX<GGH'3G1_E*['8G1B&K]
M*&.0'45Y3>)Y,$"4T<6OHY[?^&TH6A_S 2F,Q33>[>:>K +3DGH_,;VX01JO
MBQJJ6+'BE;"CH<AT4(Q;*77GX@7 AE#TJ0X=8.QSY0B"U &>O^!8OPY+G3>#
MLT%NP\4O713C,@Z[!;_"4[G';1)B7PV4E84S<;.%A9Y*Q Q 5W<P1A#!T'8K
M$\(K[,=&"4K!O0WLY"334?5[H<N7O(E#%NH<[2& TFD3W;+,X&>T*4.%')+%
MM1)M<=2UM*"6IVC<2"2J5NN7OO13NDIUW4N-& XV%#]FN*+--L7Q:/."4'V=
M_$=]CS69*YP>,Y#NY1/@ ^CP;T,08%Q^2*4OK6NGQBB=ZC>TX[(A50 %PKZ*
MQZ.Z?3?I5,T]#1SMNAPYZ%G[ C&*/I4.<FT&JBV"@RGV2PZOC>]!MEGN0?:C
MFB7/4>2\0-IA=)M4OI[2:ZP!M65NDIOY1^+"U=X69GMF,T(%G*C_\MDPMW:Q
M7[RZ%>[I=B;,QW9,V.6$$0QM6. DTM5XZ<HWX&0LK!'P^&MUM+:<2#D<FID[
M\I+Q)$DXB;]C8CA$V.!&4]'80$R]Z562<V@.1G7N<#&:YA1YMC3W'8=J*>.L
M)]7 -95<-@Y\*YG-<BN9'X5C:<0F]'9/XN93>LD L$OSW(SRYEOD)LCGY:L+
M^<H :ZBX3/6#;YAK!V-CGX>%IW2>^H</\X0>.=3*1-7!?E_8/)D3D[I[B_:\
M]N*E[.) ^2'52]J[#%6@2$?T"ER#Q<M\$8D6B*ENO)9[G!S@@H18VTWW2*PX
M&"PSEC:]L_(3T,M'_0&8MK;@ILS/FIV=G$L5=.PFB:P-G>),!)=&(/X?I[WS
MJQ6U'<=TXCE?;\IU"-NZZEN.K+(2?J'=8/%@!Q+&.41#S!#[G5*::Y*-[(&+
MBQ^.&&NF-'@GQUFTT!T0Z'O&#@PJGG4!U'FF\@A#>V'@5+C5YU"GE.Q@[(&^
M13TKM^3#?H^=#7D,FMDC)25R(0)+M 5T)T0M=D#3]"8Z#';V@$5%IH2_284:
MLD5=7+3K:?BY3,723U]0ZJ-GXPNVIL9AFM-VL(&I/B@?];7]Y(,^4<0#-J@Y
M+XI0WRIFL]PJYKWKS3;)EY[2(Z:C'E<R*H9;?-'JU)UHMQ_,]5?>^^0_7='-
M2Y(4_%-8K@$G%3RZ9=?S6Y>;F$K3Y.Y\LE(8K&.:84NUZ:NG?B)J &PHCH,5
M[+@S&?S^.+K2:VL>I*\!*:5,3)+_S&HI-1HOBX]H!U%HE%R7Q&DKE,-8CV0H
MP-W6?4-]X8_;.J?PS#B'0&,"&FP:7H/E$^!)I0L@%3_]D( #DC4Q,:M:Z,98
MQ%W?E66SW)6%6FM-X^U3.J_T:V[6->RN4@Y"2IQ?Y#!*VQ1>?>F1F,>9["AY
M)A0JI<<4=]4S/C.+5)/_3$'T@+9"]T)>?</-EGU+LP@\&9^]2[YTS0A73UNO
M)OD2 *Y()YU)@E3JJM4RO"#U 45(:$V@VY8G$QF,QUL<V9>CV7D[077G>*)(
M; 0X PC#@2;]UN_)9+?V@IT9_'I4%N5IT-T6IM>''25;Q,D6Z9+/J[VH=Q>X
M0E^]H?L59 WYMDT,'9!YK6W7X%#P1JPZN=J$UPC(,GR<C+:RHMPQOJ)! I$
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M8;'LA*^[9J ?^F QLLWI)^Q[/W%K7A'K8014[F'2Z#%/'2(5Q@'!TN1R)%=
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M<]N"QAPJZT#W&RG-T; !^L&9_@%02P,$%     @ =HB!6 LC]*ZZ @  608
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M?P][$R:8S!"8A1],UC05H+GE!';@:Z]S3SG=#UPSG97KAY# 413U+IYJ;E]
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MBJ#1<$1NU)U?N\"JQGMDJ2PYSD\K>N)0NP3:7REE#X$[H'\T\S]02P,$%
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MQM!D].XX8K9O!OW"FS848&$\EG.8-M@_P9(#[M?&^.V"#A@Z<OX;4$L#!!0
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MFE"Z9P1,Y'9 DPHS.1/\']K,A9.?<L%$QED!VC"#-E3:KI%7%16XI<%N<WZ
MK%S%5P43FP7/\L#$&KBF/7(E&KVRH+[$Q0R,S?,N5;1AO"##DS6-*Z:,LW7N
M_4$(C@#P+(#:?^N[=T\T,97-'9H<E]3V*I=8#66O($[H$:7N.?#>HD!%P*P
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MAHDU'/O#X&A1]W:N%I2?,W>!HA#*A3#U+:.9;>YH5_75Y&E[?<%[QQ2QI:'
M*8D&_H ^&51]::I?C*S<164B#5U[W'!.]TQ4=@.M3Z4TVQ=KH+FYCO\%4$L#
M!!0    ( ':(@5@^8#/Y\ (  #D&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;)U546_3,!!^SZ^P D(,;4V3=-U4VDC=QH"'254[0 CQX"27Q)IC
M!]M9-WX]9R<-1>KZ@-HFMN_NN^]L?]?Y5JH'70$8\E1SH1=^94PS"P*=55!3
M/9(-"+044M74X%25@6X4T-P%U3R(QN-I4%,F_&3NUE8JF<O6<"9@I8ANZYJJ
MYRO@<KOP0W^WL&9E9>Q"D,P;6L(&S)=FI7 6#"@YJT%H)@514"S\93B[FEA_
MY_"5P5;OC8FM))7RP4X^YPM_; D!A\Q8!(JO1[@&SBT0TOC58_I#2ANX/]ZA
MW[K:L9:4:KB6_!O+3;7P+WV20T%;;M9R^PGZ>LXM7B:Y=D^R[7PGL4^R5AM9
M]\'(H&:B>].G?A_V B['+P1$?4#D>'>)',L;:F@R5W)+E/5&-#MPI;IH),>$
M/92-46AE&&>2-3R":$$3*G)R+;4ALB##XMM[FG+0)_/ 8"X;$60][E6'&[V
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MAHY'%^<^45VCZB9&-JXYI-)@JW'#"GL[*.N ]D)*LYO8!,._1?('4$L#!!0
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M&9=;8(7:22(J0Y-JGI AE_!%681XD%Y,.W\ATX"N+U\+Y#K+M5?L+KW./27
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MU]0HNIJQU<:JTL^U1%F:DGZ9TV<):F= [S>*BJPW#J#YT%E\!U!+ P04
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M$9U.YAQA&OQBZX.\]YRK8QW2=[P6\K-:(6KXFO%<38*5UL5E&*IDA1E5)Z+
MW-Q9")E1;4[E,E2%1)I6DS(>DL%@&&:4Y<%T7%V[D].Q*#5G.=Y)4&664?EM
MAERL)T$4/%_XR)8K;2^$TW%!EWB/^J&XD^8L;**D+,-<,9&#Q,4DN(HN9W%L
M)U0C?F>X5EO'8*D\"O'9GKQ/)\' (D*.B;8AJ/EZPFODW$8R.+[408,FIYVX
M??P<_9>*O"'S2!5>"_X'2_5J$HP"2'%!2ZX_BO6O6!,ZL_$2P57U">MZ[""
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MAZKB-A8':Z R0+Q?$,)?!O)D51_5_;]02P,$%     @ =HB!6&H.&DM@ @
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M;W)K<VAE971S+W-H965T-38N>&ULK55=;],P%/TK5IC0)K'E.T.CC;2U@O&
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M>^0T%DSFZ3H7/#38A6H,JG&H%D U =4D2M,+ODZ ;7,"3!]5FI#/[T^OE,Q
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MYRHM'U#\_CY)\N<;Y01/2?IU^W2F_P-02P,$%     @ =HB!6(?F%< , P
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MOM]=D*/W'\E["_<MEZ6F(M43WR!7NZ.?;'G-*E[1 5YA1&ZD,+DFER*%]#F
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MTC>@;2;ZC0+"!.CY%>=JWS'78/7JB?X 4$L#!!0    ( ':(@5B+^#1W@0(
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M9TUIKN7J.W;YG%J^3);:?6'5V@XC#[)&&UEU8(J@XJ+]LX>N#AN 8+@#$':
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M4Z&I64H&]_L<9_2;;O33BJ56B:"-&J,D8!\F8%!E^#IEZG=HX!>,;&0B*9C
M% PJ"-AW:#F-08-6)T32.($W&OKJ#&*X>+#JGHP9C&QU1"3=$CR=T" C%O-
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MM3)C:X$E#@/.MHCK:,6F!R8W!JW<D$)_Q97D:I<HG R?.4X +?$;CB@(=+L
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M4=H <W\IA'X<V 7:_C?]!5!+ P04    " !VB(%8BX^?<98"  #D!@  &0
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M'*<@30"^7PFA=QN3H!O0T1]02P,$%     @ =HB!6/CZ\R'!!0  .!D  !D
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M3(#[,R'T>F 4;'XL&?P/4$L#!!0    ( ':(@5@08QJ@( X  )70   9
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M?%U%-;ZQ#WZM]]7^N!TXTD*= X?4#%0S4<U"-1O5'%1S4<U#-?_4R_S$H6:
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MW99=/)2%DKLM=I2TOJ:=>5 GU3JG#ZE-4,U -1/5+%2S4<U!-1?5/%3S42U
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M4I87D-^OLDSL3_( =6[_XE]02P,$%     @ =HB!6&>(*GOD @  =@@  !D
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M+W-H965T-SDN>&ULK5==;]LV%/TK%]HZI,!B?5JV,]M $EOM!A0-DK5[*/9
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M@S03\/Y*"/W8,0O4Q7CX$U!+ P04    " !VB(%8."2O@ $#  !S#   &0
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MINT_B]?)V7VF/BYT.J+L0['1:TD3MBS[RV0C &/W<7:2YWSU@;.92*E)OG'
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M8*LD"*+(C@!F5Q $& *K$4<P!: !0X*@? _NO8^\]7O*J_^=,?H#4$L#!!0
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MF[J/GA;;;VT=+HEA\U:[%YIIT8'S05ZY8U/JPGUZ(68>PK^A%68N/NE:$L@
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ':(@5@Z7Y2$7 <  & E   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !VB(%8S'WTRA8&  !G&P  &               @(&>#P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ =HB!6#I\JYYU!@  LQL
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M965T-RYX;6Q02P$"% ,4    " !VB(%8CO1OI ,*   (&0  &
M    @(&+7P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M=HB!6"]_V)A' @  %@4  !@              ("!Q&D  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ':(@5CBW]Z.0@(  /,$   9
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M970Q-"YX;6Q02P$"% ,4    " !VB(%8W_U.TEX#  #\!P  &0
M    @('!A0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M ':(@5A&BDT)?@<  /X1   9              " @5:)  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ =HB!6'5[COI- @  !P4  !D
M             ("!"Y$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !VB(%8_P<0FFH"  !,!0  &0              @(&/DP  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ':(@5B,S$#EL0L
M  D>   9              " @3"6  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ =HB!6-Z]>])X!   DPH  !D              ("!
M&*(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !VB(%8
MM 1Q>@T#  "#!@  &0              @(''I@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ':(@5AF5PSDP0X  .8E   9
M      " @0NJ  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ =HB!6!M#8L+""P  I2$  !D              ("! [D  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !VB(%81CL>?@()  "C&@
M&0              @('\Q   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( ':(@5B3IRCV\P4  &\-   9              " @37.  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ =HB!6*7JD \>
M!0  V0H  !D              ("!7]0  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !VB(%8'0MT(,L#   T"   &0
M@(&TV0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ':(
M@5BV,+KL;P0  * *   9              " @;;=  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ =HB!6#WCQO"#!0  LPP  !D
M         ("!7.(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !VB(%8"OK%,0\%  #!"P  &0              @($6Z   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ':(@5B8\HW_508  / .
M   9              " @5SM  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ =HB!6.#CB0.]*@  &9@  !D              ("!Z/,
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !VB(%8^/NM
M>KH"  #\!0  &0              @('<'@$ >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( ':(@5@H]I;S2P(  !T%   9
M  " @<TA 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M=HB!6-6ZNA5  @  ]00  !D              ("!3R0! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !VB(%8_\,%2U8"  !$!0  &0
M            @('&)@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( ':(@5@+(_2NN@(  %D&   9              " @5,I 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ =HB!6,D!OGL7 P
MB@<  !D              ("!1"P! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !VB(%8S*]34*("   9!@  &0              @(&2
M+P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ':(@5BD
M?SG!1 (   ,%   9              " @6LR 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ =HB!6#%0WI58 @  0 4  !D
M     ("!YC0! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ':(@5@^8#/Y\ (  #D&   9              "
M@>Y) 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ =HB!
M6'C1@93Q!   K@H  !D              ("!%4T! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !VB(%8)FEKU#D#   W!P  &0
M        @($]4@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( ':(@5AC*LJ!IP,  /$(   9              " @:U5 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ =HB!6'WMDOU] P  ] @
M !D              ("!BUD! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !VB(%8J"1V>QH#  #)"@  &0              @($_70$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ':(@5A^D'*'
M$P(  +@$   9              " @9!@ 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ =HB!6"0K0UYP!   (1P  !D
M ("!VF(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !V
MB(%83 .U*0(#  "V#P  &0              @(&!9P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ':(@5AJ#AI+8 (  #L&   9
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M970U.2YX;6Q02P$"% ,4    " !VB(%8_)'K0I,"   !"0  &0
M    @('3A0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M ':(@5B+^#1W@0(  * &   9              " @9V( 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ =HB!6(Q>-#JD!@  YBX  !D
M             ("!58L! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " !VB(%8S5_:6^H$   E'0  &0              @($PD@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ':(@5AL@J5H*@,
M #L+   9              " @5&7 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ =HB!6#G[DA-C @  1P8  !D              ("!
MLIH! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !VB(%8
M5&/G<8P"   /!P  &0              @(%,G0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( ':(@5B8R&/A50,  !8+   9
M      " @0^@ 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%
M  @ =HB!6/H4;U-%!P  HC8  !D              ("!FZ,! 'AL+W=O<FMS
M:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " !VB(%8&D?1T&P#   +"P
M&0              @($7JP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+
M 0(4 Q0    ( ':(@5B+CY]QE@(  .0&   9              " @;JN 0!X
M;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ =HB!6!@7X;F=
M @  K <  !D              ("!A[$! 'AL+W=O<FMS:&5E=',O<VAE970W
M,2YX;6Q02P$"% ,4    " !VB(%8^/KS(<$%   X&0  &0
M@(%;M $ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( ':(
M@5@08QJ@( X  )70   9              " @5.Z 0!X;"]W;W)K<VAE971S
M+W-H965T-S,N>&UL4$L! A0#%     @ =HB!6%K'Q<D_ @  MP4  !D
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M=#<X+GAM;%!+ 0(4 Q0    ( ':(@5@BH9<=P@,  )T-   9
M  " @27; 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @
M=HB!6-;'Q\:5 P  3PX  !D              ("!'M\! 'AL+W=O<FMS:&5E
M=',O<VAE970X,"YX;6Q02P$"% ,4    " !VB(%8>8&F,FX$  !D&   &0
M            @('JX@$ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4
M Q0    ( ':(@5@>7S^$[@H  +U:   9              " @8_G 0!X;"]W
M;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ =HB!6,;4H(;R P
MX@T  !D              ("!M/(! 'AL+W=O<FMS:&5E=',O<VAE970X,RYX
M;6Q02P$"% ,4    " !VB(%8&F&U!E,%  !)'0  &0              @('=
M]@$ >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( ':(@5A%
MX. '?P,  )@/   9              " @6?\ 0!X;"]W;W)K<VAE971S+W-H
M965T.#4N>&UL4$L! A0#%     @ =HB!6#@DKX ! P  <PP  !D
M     ("!'0 " 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ':(@5@.E%+%@ ,  -L8   -              "
M >H3 @!X;"]S='EL97,N>&UL4$L! A0#%     @ =HB!6)>*NQS     $P(
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9>&UL4$L%!@    !B &( Y1H  !DD @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>280</ContextCount>
  <ElementCount>403</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Cash</Role>
      <ShortName>Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivable</Role>
      <ShortName>Other Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Investment in Associates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociates</Role>
      <ShortName>Investment in Associates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Investment in Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssets</Role>
      <ShortName>Investment in Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayables</Role>
      <ShortName>Trade Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Employee Benefit Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilities</Role>
      <ShortName>Employee Benefit Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Revenues and Cost of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenues</Role>
      <ShortName>Revenues and Cost of Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</Role>
      <ShortName>Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Loss Per Share/Ads</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareAds</Role>
      <ShortName>Loss Per Share/Ads</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegments</Role>
      <ShortName>Operating Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Significant Events during the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</Role>
      <ShortName>Significant Events during the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Events After the Reporting Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsAftertheReportingDate</Role>
      <ShortName>Events After the Reporting Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/CashTables</Role>
      <ShortName>Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Cash</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Inventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivableTables</Role>
      <ShortName>Other Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsReceivable</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Investment in Associates (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesTables</Role>
      <ShortName>Investment in Associates (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociates</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAsset</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Trade Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayablesTables</Role>
      <ShortName>Trade Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TradePayables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsPayable</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Employee Benefit Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilitiesTables</Role>
      <ShortName>Employee Benefit Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/EmployeeBenefitLiabilities</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Equity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenuesTables</Role>
      <ShortName>Revenues and Cost of Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/RevenuesandCostofRevenues</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Loss Per Share/Ads (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareAdsTables</Role>
      <ShortName>Loss Per Share/Ads (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/LossPerShareAds</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Operating Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegmentsTables</Role>
      <ShortName>Operating Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegments</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996019 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/General</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Cash (Details) - Schedule of Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCashTable</Role>
      <ShortName>Cash (Details) - Schedule of Cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/CashTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Inventory (Details) - Schedule of Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of Inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InventoryTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsReceivableTable</Role>
      <ShortName>Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsReceivableTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Investment in Associates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesDetails</Role>
      <ShortName>Investment in Associates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Investment in Associates (Details) - Schedule of Fair Value of the Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable</Role>
      <ShortName>Investment in Associates (Details) - Schedule of Fair Value of the Investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Investment in Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssetsDetails</Role>
      <ShortName>Investment in Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinFinancialAssets</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/Leases</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetDetails</Role>
      <ShortName>Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable</Role>
      <ShortName>Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Trade Payables (Details) - Schedule of Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTradePayablesTable</Role>
      <ShortName>Trade Payables (Details) - Schedule of Trade Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TradePayablesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of Other Accounts Payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable</Role>
      <ShortName>Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black???Scholes OPM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable</Role>
      <ShortName>Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black???Scholes OPM</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDefinedContributionPlansTable</Role>
      <ShortName>Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EmployeeBenefitLiabilitiesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TaxesonIncome</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Equity (Details) - Schedule of Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Equity (Details) - Schedule of Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable</Role>
      <ShortName>Equity (Details) - Schedule of Issued and Outstanding Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable</Role>
      <ShortName>Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/RevenuesandCostofRevenuesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable</Role>
      <ShortName>Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/LossPerShareAdsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Operating Segments (Details) - Schedule of Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOperatingSegmentsTable</Role>
      <ShortName>Operating Segments (Details) - Schedule of Operating Segments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegmentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Significant Events during the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails</Role>
      <ShortName>Significant Events during the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0202882-20f_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Events After the Reporting Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsAftertheReportingDateDetails</Role>
      <ShortName>Events After the Reporting Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EventsAftertheReportingDate</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: ifrs-full:NumberOfSharesIssued -  ea0202882-20f_scisparc.htm 22889</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0202882-20f_scisparc.htm">ea0202882-20f_scisparc.htm</File>
    <File>sprcy-20231231.xsd</File>
    <File>sprcy-20231231_cal.xml</File>
    <File>sprcy-20231231_def.xml</File>
    <File>sprcy-20231231_lab.xml</File>
    <File>sprcy-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="739">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0202882-20f_scisparc.htm": {
   "nsprefix": "sprcy",
   "nsuri": "http://trpx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0202882-20f_scisparc.htm"
     ]
    },
    "schema": {
     "local": [
      "sprcy-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sprcy-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sprcy-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sprcy-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sprcy-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 240,
   "keyCustom": 163,
   "axisStandard": 15,
   "axisCustom": 1,
   "memberStandard": 24,
   "memberCustom": 45,
   "hidden": {
    "total": 233,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 153,
    "http://trpx.com/20231231": 76,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 280,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 645,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 739,
    "http://xbrl.sec.gov/dei/2023": 48
   },
   "report": {
    "R1": {
     "role": "http://trpx.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://trpx.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CurrentRestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://trpx.com/role/ConsolidatedIncomeStatement",
     "longName": "002 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://trpx.com/role/ShareholdersEquityType2or3",
     "longName": "003 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://trpx.com/role/ConsolidatedCashFlow",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://trpx.com/role/General",
     "longName": "005 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://trpx.com/role/SignificantAccountingPolicies",
     "longName": "006 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements",
     "longName": "007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "shortName": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://trpx.com/role/Cash",
     "longName": "008 - Disclosure - Cash",
     "shortName": "Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://trpx.com/role/Inventory",
     "longName": "009 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://trpx.com/role/OtherAccountsReceivable",
     "longName": "010 - Disclosure - Other Accounts Receivable",
     "shortName": "Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://trpx.com/role/InvestmentinAssociates",
     "longName": "011 - Disclosure - Investment in Associates",
     "shortName": "Investment in Associates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssets",
     "longName": "012 - Disclosure - Investment in Financial Assets",
     "shortName": "Investment in Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://trpx.com/role/Leases",
     "longName": "013 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://trpx.com/role/PropertyandEquipmentNet",
     "longName": "014 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://trpx.com/role/IntangibleAsset",
     "longName": "015 - Disclosure - Intangible Asset",
     "shortName": "Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://trpx.com/role/TradePayables",
     "longName": "016 - Disclosure - Trade Payables",
     "shortName": "Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://trpx.com/role/OtherAccountsPayable",
     "longName": "017 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://trpx.com/role/FinancialInstruments",
     "longName": "018 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilities",
     "longName": "019 - Disclosure - Employee Benefit Liabilities",
     "shortName": "Employee Benefit Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://trpx.com/role/TaxesonIncome",
     "longName": "020 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens",
     "longName": "021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://trpx.com/role/Equity",
     "longName": "022 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactions",
     "longName": "023 - Disclosure - Share-Based Payment Transactions",
     "shortName": "Share-Based Payment Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenues",
     "longName": "024 - Disclosure - Revenues and Cost of Revenues",
     "shortName": "Revenues and Cost of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss",
     "longName": "025 - Disclosure - Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://trpx.com/role/LossPerShareAds",
     "longName": "026 - Disclosure - Loss Per Share/Ads",
     "shortName": "Loss Per Share/Ads",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://trpx.com/role/OperatingSegments",
     "longName": "027 - Disclosure - Operating Segments",
     "shortName": "Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "028 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriod",
     "longName": "029 - Disclosure - Significant Events during the Reporting Period",
     "shortName": "Significant Events during the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://trpx.com/role/EventsAftertheReportingDate",
     "longName": "030 - Disclosure - Events After the Reporting Date",
     "shortName": "Events After the Reporting Date",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://trpx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:BasisOfPresentationOfFinancialStatements",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:BasisOfPresentationOfFinancialStatements",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://trpx.com/role/CashTables",
     "longName": "996002 - Disclosure - Cash (Tables)",
     "shortName": "Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://trpx.com/role/InventoryTables",
     "longName": "996003 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInvertoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInvertoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://trpx.com/role/OtherAccountsReceivableTables",
     "longName": "996004 - Disclosure - Other Accounts Receivable (Tables)",
     "shortName": "Other Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://trpx.com/role/InvestmentinAssociatesTables",
     "longName": "996005 - Disclosure - Investment in Associates (Tables)",
     "shortName": "Investment in Associates (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetTables",
     "longName": "996006 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://trpx.com/role/IntangibleAssetTables",
     "longName": "996007 - Disclosure - Intangible Asset (Tables)",
     "shortName": "Intangible Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://trpx.com/role/TradePayablesTables",
     "longName": "996008 - Disclosure - Trade Payables (Tables)",
     "shortName": "Trade Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfTradePayables",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfTradePayables",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://trpx.com/role/OtherAccountsPayableTables",
     "longName": "996009 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://trpx.com/role/FinancialInstrumentsTables",
     "longName": "996010 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilitiesTables",
     "longName": "996011 - Disclosure - Employee Benefit Liabilities (Tables)",
     "shortName": "Employee Benefit Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://trpx.com/role/EquityTables",
     "longName": "996012 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsTables",
     "longName": "996013 - Disclosure - Share-Based Payment Transactions (Tables)",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenuesTables",
     "longName": "996014 - Disclosure - Revenues and Cost of Revenues (Tables)",
     "shortName": "Revenues and Cost of Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables",
     "longName": "996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)",
     "shortName": "Additional Information to the Items of Profit or Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://trpx.com/role/LossPerShareAdsTables",
     "longName": "996016 - Disclosure - Loss Per Share/Ads (Tables)",
     "shortName": "Loss Per Share/Ads (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://trpx.com/role/OperatingSegmentsTables",
     "longName": "996017 - Disclosure - Operating Segments (Tables)",
     "shortName": "Operating Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "996018 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://trpx.com/role/GeneralDetails",
     "longName": "996019 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996020 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
     "longName": "996021 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
     "shortName": "Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c68",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c68",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://trpx.com/role/ScheduleofCashTable",
     "longName": "996022 - Disclosure - Cash (Details) - Schedule of Cash",
     "shortName": "Cash (Details) - Schedule of Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c77",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://trpx.com/role/ScheduleofInventoryTable",
     "longName": "996023 - Disclosure - Inventory (Details) - Schedule of Inventory",
     "shortName": "Inventory (Details) - Schedule of Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInvertoryTextBlock",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInvertoryTextBlock",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable",
     "longName": "996024 - Disclosure - Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable",
     "shortName": "Other Accounts Receivable (Details) - Schedule of Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ValueAddedTaxReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://trpx.com/role/InvestmentinAssociatesDetails",
     "longName": "996025 - Disclosure - Investment in Associates (Details)",
     "shortName": "Investment in Associates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c83",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c83",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
     "longName": "996026 - Disclosure - Investment in Associates (Details) - Schedule of Fair Value of the Investment",
     "shortName": "Investment in Associates (Details) - Schedule of Fair Value of the Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:InvestmentsDate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
     "longName": "996027 - Disclosure - Investment in Financial Assets (Details)",
     "shortName": "Investment in Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c104",
      "name": "sprcy:InvestmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c104",
      "name": "sprcy:InvestmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://trpx.com/role/LeasesDetails",
     "longName": "996028 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c111",
      "name": "sprcy:SquareMeters",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c111",
      "name": "sprcy:SquareMeters",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetDetails",
     "longName": "996029 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996030 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net",
     "shortName": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c33",
      "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://trpx.com/role/IntangibleAssetDetails",
     "longName": "996031 - Disclosure - Intangible Asset (Details)",
     "shortName": "Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
     "longName": "996032 - Disclosure - Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset",
     "shortName": "Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "sprcy:PurchaseofAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://trpx.com/role/ScheduleofTradePayablesTable",
     "longName": "996033 - Disclosure - Trade Payables (Details) - Schedule of Trade Payables",
     "shortName": "Trade Payables (Details) - Schedule of Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "sprcy:AccruedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayables",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "sprcy:AccruedExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayables",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996034 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable",
     "shortName": "Other Accounts Payable (Details) - Schedule of Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://trpx.com/role/FinancialInstrumentsDetails",
     "longName": "996035 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c133",
      "name": "ifrs-full:CashOutflowForLeases",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "ifrs-full:CashOutflowForLeases",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "longName": "996036 - Disclosure - Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities",
     "shortName": "Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable",
     "longName": "996037 - Disclosure - Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
     "shortName": "Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c145",
      "name": "sprcy:DividendYield",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c145",
      "name": "sprcy:DividendYield",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://trpx.com/role/ScheduleofDefinedContributionPlansTable",
     "longName": "996038 - Disclosure - Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans",
     "shortName": "Employee Benefit Liabilities (Details) - Schedule of Defined Contribution Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://trpx.com/role/TaxesonIncomeDetails",
     "longName": "996039 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails",
     "longName": "996040 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://trpx.com/role/EquityDetails",
     "longName": "996041 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c152",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c152",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://trpx.com/role/ScheduleofShareCapitalTable",
     "longName": "996042 - Disclosure - Equity (Details) - Schedule of Share Capital",
     "shortName": "Equity (Details) - Schedule of Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
     "longName": "996043 - Disclosure - Equity (Details) - Schedule of Issued and Outstanding Share Capital",
     "shortName": "Equity (Details) - Schedule of Issued and Outstanding Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
     "longName": "996044 - Disclosure - Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
     "shortName": "Equity (Details) - Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
     "longName": "996045 - Disclosure - Share-Based Payment Transactions (Details)",
     "shortName": "Share-Based Payment Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c179",
      "name": "sprcy:OrdinarySharesGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
     "longName": "996046 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of Expenses Due to Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ResearchAndDevelopmentsExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ResearchAndDevelopmentsExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
     "longName": "996047 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of Fair Value for Share Options Granted",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c186",
      "name": "sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c186",
      "name": "sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable",
     "longName": "996048 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of Weighted Average Exercise Prices of Share Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "sprcy:NumberOfOutstandingShareOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c33",
      "name": "sprcy:NumberOfOutstandingShareOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
     "longName": "996049 - Disclosure - Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit",
     "shortName": "Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:CostOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:CostOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "longName": "996050 - Disclosure - Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ResearchAndDevelopmentExpenses1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ResearchAndDevelopmentExpenses1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
     "longName": "996051 - Disclosure - Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
     "shortName": "Loss Per Share/Ads (Details) - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
     "longName": "996052 - Disclosure - Operating Segments (Details) - Schedule of Operating Segments",
     "shortName": "Operating Segments (Details) - Schedule of Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "996053 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c266",
      "name": "ifrs-full:CurrentInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "996054 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c268",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c268",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
     "longName": "996055 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Transactions with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ResearchAndDevelopmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
     "longName": "996056 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Benefits to Key Management Personnel",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
     "longName": "996057 - Disclosure - Significant Events during the Reporting Period (Details)",
     "shortName": "Significant Events during the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c272",
      "name": "sprcy:InterestPercentgae",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c272",
      "name": "sprcy:InterestPercentgae",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://trpx.com/role/EventsAftertheReportingDateDetails",
     "longName": "996058 - Disclosure - Events After the Reporting Date (Details)",
     "shortName": "Events After the Reporting Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c277",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c277",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202882-20f_scisparc.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "sprcy_AResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AResearchAndDevelopmentExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "a. Research and development expenses:",
        "label": "AResearch And Development Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued vacation",
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sprcy_AccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccruedInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AccruedInterestPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest percentage",
        "documentation": "Accrued interest percentage.",
        "label": "Accrued Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AccumulatedDepreciationAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Acquisitions through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRates",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate, percentage",
        "label": "Actuarial assumption of discount rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information to the Items of Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdditionalInformationtotheItemsofProfitorLossDetailsScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss (Details) - Schedule of Additional Information to the Items of Profit or Loss [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdditionalInstallment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional installment",
        "documentation": "The amount of additional installment.",
        "label": "Additional Installment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdditionalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional investment",
        "documentation": "The amount of additional investment.",
        "label": "Additional Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdditionalMilestoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone amount",
        "label": "Additional Milestone Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New lease",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustedAmountOfAggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdjustedAmountOfAggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted amount of aggregate value",
        "documentation": "The adjusted amount of aggregate value.",
        "label": "Adjusted Amount Of Aggregate Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in inventory",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in other accounts receivable",
        "label": "Adjustments for decrease (increase) in other operating receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses (income), net",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on impairment of intangible asset",
        "negatedLabel": "Loss on impairment of intangible asset",
        "verboseLabel": "Impairment to its intangible asset",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in other accounts payable",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets",
        "documentation": "Adjustments for losses from remeasurement of investment in financial assets\r     \n  to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Losses From Remeasurement Of Investment In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s share of losses of company accounted for at equity, net",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments to the profit or loss",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile loss to net cash used in operating activities:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Working capital",
        "label": "Adjustments to reconcile profit (loss) other than changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "sprcy_AdjustmentsToTheProfitOrLossItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AdjustmentsToTheProfitOrLossItemsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to the profit or loss items:",
        "label": "Adjustments To The Profit Or Loss Items Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AggregateGrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "documentation": "Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AggregateUnits",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units",
        "documentation": "Number of shares issued.",
        "label": "Aggregate Units"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AggregateUnitsPerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units Per share (in Dollars per share)",
        "documentation": "Per share of aggregate units.",
        "label": "Aggregate Units Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value",
        "documentation": "The amount of ordinary shares of aggregate value.",
        "label": "Aggregate Value"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r111"
     ]
    },
    "sprcy_AmazonFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AmazonFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amazon fees [Member]",
        "verboseLabel": "Amazon Fees [Member]",
        "label": "Amazon Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeds amount",
        "label": "Amount by which unit's recoverable amount exceeds its carrying amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74"
     ]
    },
    "sprcy_AmountTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AmountTotal",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount total",
        "label": "Amount Total"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AnnualInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "AnnualInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual investment",
        "documentation": "Amount of annual investment.",
        "label": "Annual Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r112",
      "r150",
      "r153"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "sprcy_BGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "BGeneralAndAdministrativeExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "b. General and administrative expenses:",
        "label": "BGeneral And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "sprcy_BasisOfPresentationOfFinancialStatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "BasisOfPresentationOfFinancialStatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation of the financial statements",
        "documentation": "The description of the entity's accounting policy changes inrBasis of presentation of the financial statements.",
        "label": "Basis Of Presentation Of Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BonusAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "BonusAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus amount",
        "documentation": "Bonus amount received.",
        "label": "Bonus Amount Received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [Member]",
        "verboseLabel": "Bottom of Range [Member]",
        "netLabel": "Bottom of range [member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r121",
      "r128",
      "r182",
      "r183",
      "r224"
     ]
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198"
     ]
    },
    "sprcy_BusinessDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "BusinessDevelopmentExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development expenses [Member]",
        "label": "Business Development Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_COtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "COtherExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "c. Other expenses:",
        "label": "COther Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital warrant",
        "label": "Capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of future capital expenditures that the entity is committed to make."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "sprcy_CapitalPointMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CapitalPointMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Point [Member]",
        "label": "Capital Point Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalPointWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CapitalPointWarrantMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Point Warrant [Member]",
        "label": "Capital Point Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [Member]",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r77",
      "r82",
      "r83",
      "r84",
      "r134",
      "r141",
      "r142"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash (in New Shekels)",
        "verboseLabel": "Cash payments",
        "netLabel": "Cash",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_CashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails",
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at the beginning of the period",
        "periodEndLabel": "Cash at the end of the period",
        "totalLabel": "Cash for immediate withdrawal",
        "terseLabel": "Cash",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r89",
      "r107"
     ]
    },
    "sprcy_CashDetailsScheduleofCashLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CashDetailsScheduleofCashLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash (Details) - Schedule of Cash [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashDetailsScheduleofCashTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CashDetailsScheduleofCashTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash (Details) - Schedule of Cash [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in restricted bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in short-term bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for principal amount",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Categories of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sprcy_ChemistryAndFormulationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ChemistryAndFormulationsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry and formulations [Member]",
        "label": "Chemistry And Formulations Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r113",
      "r118"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r113",
      "r118"
     ]
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sprcy_ClearmindMedicineIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ClearmindMedicineIncMember",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clearmind Medicine Inc [Member]",
        "label": "Clearmind Medicine Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical studies [Member]",
        "label": "Clinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CoeruleusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CoeruleusMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coeruleus [Member]",
        "label": "Coeruleus Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CommitmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CommitmentPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increasing per annum",
        "documentation": "Commitment percentage.",
        "label": "Commitment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount (in Dollars)",
        "label": "Commitments made by entity, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommunicationAndNetworkEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Communication and network equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CompanysShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Company\u2019s share of losses of company accounted for at equity, net.",
        "label": "Companys Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sprcy_ComprehensiveLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ComprehensiveLoss",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "documentation": "Comprehensive loss.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ComprehensiveLossOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ComprehensiveLossOnInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investment",
        "documentation": "Amount of comprehensive loss on investment.",
        "label": "Comprehensive Loss On Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "sprcy_ConsolidatedStatementsOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ConsolidatedStatementsOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Email Address",
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ContingenciesLiabilitiesCommitmentsClaimsAndLiensAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities Commitments Claims and Liens [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ContinuingOperationsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations:",
        "label": "Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ConversionPrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CostAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost:",
        "label": "Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CostOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold",
        "documentation": "The amount of cost of goods sold.",
        "label": "Cost Of Goods Sold"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of goods sold",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r32"
     ]
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ]
    },
    "sprcy_CreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "CreditFromOthers",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit from others",
        "documentation": "The amount of credit of others.",
        "label": "Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r181"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInventoriesInTransit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInventoriesInTransit",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods in transit",
        "label": "Current inventories in transit"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested amount",
        "label": "Current investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liability",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r105",
      "r181"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "",
        "verboseLabel": "CURRENT LIABILITIES:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposit",
        "label": "Current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166"
     ]
    },
    "ifrs-full_CurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Current warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "sprcy_DFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DFinanceIncomeAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "d. Finance income:",
        "label": "DFinance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DateOfIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DateOfIssuance",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire term",
        "label": "Date Of Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ]
    },
    "sprcy_DeferredCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DeferredCashPayments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash payments",
        "documentation": "Deferred cash payments.",
        "label": "Deferred Cash Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DekelLicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DekelLicenseAgreementDescription",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments, description",
        "documentation": "Dekel license agreement description.",
        "label": "Dekel License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43"
     ]
    },
    "ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over the useful life of the assets, description",
        "label": "Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to IAS 1, \u201cDisclosure of Accounting Policies",
        "documentation": "Description of Accounting Policy Amendment to IAS 1, \u201cDisclosure of Accounting Policies.",
        "label": "Description Of Accounting Policy Amendment To IAS1 Disclosure Of Accounting Policies Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "documentation": "Description of accounting policy cost of sales.",
        "label": "Description Of Accounting Policy Cost Of Sales Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForConsolidatedfinancialstatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated financial statements",
        "documentation": "The description of the entity's accounting policy changes in Consolidated financial statements.",
        "label": "Description Of Accounting Policy For Consolidatedfinancialstatements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit liabilities",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and expenses",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency and foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of non-financial assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "documentation": "The description of the entity's accounting policy for investments in associates. The description of the entity's material accounting policy information for investments accounted for using the equity method.",
        "label": "Description Of Accounting Policy For Investment Accounted For Using The Equity Methodtext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in joint arrangements",
        "label": "Description of accounting policy for investment in associates and joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Associates [member]; Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenditures",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForRestrictedDeposit": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForRestrictedDeposit",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "label": "Description Of Accounting Policy For Restricted Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Description of accounting policy for taxes other than income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForoperatingcycleExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The operating cycle",
        "documentation": "The description of the entity's accounting policy changes in operating cycle Explanatory.",
        "label": "Description Of Accounting Policy Foroperatingcycle Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAcquisitionOfASingleAssetCompany": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAcquisitionOfASingleAssetCompany",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of a single asset company",
        "documentation": "The description of the entity's accounting policy for acquisition of a single asset company.",
        "label": "Description Of Acquisition Of ASingle Asset Company"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to IAS 8, \u201cAccounting Policies, Changes to Accounting Estimates and Errors\u201d",
        "documentation": "The description of the entity's accounting policy for changes to accounting estimates and errors.",
        "label": "Description Of Amendment To IAS8 Accounting Policies Changes To Accounting Estimates And Errors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "sprcy_DescriptionOfReverseShareSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DescriptionOfReverseShareSplit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of reverse share split",
        "label": "Description Of Reverse Share Split"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of potential dilutive ordinary shares, Weighted number of shares",
        "label": "Dilutive effect of all instruments on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity\u2019s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosueOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash",
        "documentation": "The entire disclosue of cash and cash equivalents.",
        "label": "Disclosue Of Cash And Cash Equivalents Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Disclosure of accrued expenses and other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_DisclosureOfAdditionalInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationExplanatory",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS",
        "label": "Disclosure of additional information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_DisclosureOfAdditionalInformationTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfAdditionalInformationTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "documentation": "Disclosure of detailed information about balance with relate parties explanatory.",
        "label": "Disclosure Of Detailed Information About Balance With Relate Parties Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Contribution Plans",
        "documentation": "Disclosure of detailed information about defined contribution plans explanatory.",
        "label": "Disclosure Of Detailed Information About Defined Contribution Plans Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143",
      "r144"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions with Related Parties",
        "documentation": "Disclosure of detailed information about transactions with relate parties explanatory.",
        "label": "Disclosure Of Detailed Information About Transactions With Relate Parties Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareAds"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE/ADS",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT LIABILITIES",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING SEGMENTS",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EVENTS AFTER THE REPORTING DATE",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Due to Share-Based Compensation",
        "documentation": "Disclosure of expenses due to share-based compensation explanatory.",
        "label": "Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value for Share Options Granted",
        "documentation": "Disclosure of fair value for share options granted explanatory.",
        "label": "Disclosure Of Fair Value For Share Options Granted Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Investment",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN FINANCIAL ASSETS",
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
        "label": "Disclosure of fair value of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "sprcy_DisclosureOfFairValueOfTheIntangibleAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfFairValueOfTheIntangibleAssetTextBlock",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Intangible Asset",
        "documentation": "Disclosure of fair value of the intangible asset text block.",
        "label": "Disclosure Of Fair Value Of The Intangible Asset Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES AND COST OF REVENUES",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFinancialAssetsAndFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilities",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "documentation": "The tabular disclosure of financial assets and financial liabilities.",
        "label": "Disclosure Of Financial Assets And Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://trpx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefits to Key Management Personnel",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "sprcy_DisclosureOfInformationToTheItemsOfProfitOrLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfInformationToTheItemsOfProfitOrLoss",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information to the Items of Profit or Loss",
        "documentation": "Tabular disclosure of disclosure of information to the items of profit or loss.",
        "label": "Disclosure Of Information To The Items Of Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/IntangibleAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSET",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://trpx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "sprcy_DisclosureOfInvertoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfInvertoryTextBlock",
     "presentation": [
      "http://trpx.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "documentation": "Disclosure of inventory.",
        "label": "Disclosure Of Invertory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfIssuedAndOutstandingShareCapital": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Issued and Outstanding Share Capital",
        "documentation": "Disclosure of detailed inforamtion about issued and outstanding share capital.",
        "label": "Disclosure Of Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Segments",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Segments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfOtherAccountsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfOtherAccountsPayableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Disclosure Of Other Accounts Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Financial Liabilities [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://trpx.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "sprcy_DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Exercise Prices of Share Options",
        "documentation": "The tabular disclosure of share options and weighted average exercise prices of share options",
        "label": "Disclosure Of Share Options And Weighted Average Exercise Prices Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT EVENTS DURING THE REPORTING PERIOD",
        "label": "Disclosure Of Significant Events During The Reporting Period Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN ASSOCIATES",
        "label": "Disclosure of associates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64",
      "r109"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023:",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://trpx.com/role/TradePayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "sprcy_DisclosureOfTradePayables": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfTradePayables",
     "presentation": [
      "http://trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Payables",
        "documentation": "The disclosure of trade payables.",
        "label": "Disclosure Of Trade Payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "sprcy_DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life",
        "documentation": "The entire disclosure for useful life of the assets at annual rates.",
        "label": "Disclosure Of Useful Life Of Assets At Annual Rates Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyLineItems",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclourseOfAccountsReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DisclourseOfAccountsReceivablesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Receivable",
        "documentation": "The disclosure of accounts receivables.",
        "label": "Disclourse Of Accounts Receivables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DividendYield",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted.",
        "label": "Dividend Yield"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "sprcy_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r200"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DrugDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DrugDevelopmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Development [Member]",
        "label": "Drug Development Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DulyExecutedShareTransferDeedForOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "DulyExecutedShareTransferDeedForOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duly executed share transfer deed for ordinary shares (in Shares)",
        "documentation": "Number of duly executed share transfer deed for ordinary shares.",
        "label": "Duly Executed Share Transfer Deed For Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EFinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EFinanceExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "e. Finance expenses:",
        "label": "EFinance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share/Ads [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareAdsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "sprcy_EmployeeBenefitLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EmployeeBenefitLiabilitiesLineItems",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EmployeeBenefitLiabilitiesTable",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EmployeeBenefitLiabilitiesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Liabilities [Abstract]",
        "label": "Employee Benefit Liabilities Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EmployeeBenefitLiabilitiesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EmployeeBenefitLiabilitiesTablesTable",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDefinedContributionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses in respect of defined contribution plans",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r32",
      "r161"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ifrs-full_EntitysOwnEquityInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysOwnEquityInstrumentsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's own equity instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r17",
      "r94",
      "r97",
      "r110",
      "r111",
      "r112"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "sprcy_EquityAttributableToEquityHoldersOfTheCompanyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EquityAttributableToEquityHoldersOfTheCompanyAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:",
        "label": "Equity Attributable To Equity Holders Of The Company Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "sprcy_EquityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EquityDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesFromInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EquityLossesFromInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity losses from investment in MitoCareX",
        "terseLabel": "Equity losses from the investment",
        "documentation": "Amount of equity losses from investment.",
        "label": "Equity Losses From Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sprcy_EstimatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EstimatedAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amount",
        "label": "Estimated Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsAftertheReportingDateDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EventsAftertheReportingDateDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsAftertheReportingDateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EventsAftertheReportingDateDetailsTable",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EveroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "EveroMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evero [Member]",
        "label": "Evero Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExchangeOfCommonShares",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of common shares (in Shares)",
        "documentation": "Number of shares exchanged.",
        "label": "Exchange Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeRateDifferencesNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExchangeRateDifferencesNetMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences, net [Member]",
        "label": "Exchange Rate Differences Net Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "documentation": "Amount of exercise of warrants.",
        "label": "Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExercisePeriod",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise period",
        "label": "Exercise Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExercisePrice1",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise Price1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "sprcy_ExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExercisePricePerShare",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($)",
        "label": "Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($) (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "sprcy_ExpectedVolatility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExpectedVolatility",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.",
        "label": "Expected Volatility"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExpensesDueToSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExpensesDueToSharebasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Expenses Due To Sharebased Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExpireTerm": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExpireTerm",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expired",
        "label": "Expire Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExternalRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ExternalRevenues",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External",
        "documentation": "Amount of external revenue.",
        "label": "External Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FairMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value",
        "documentation": "Fair market value.",
        "label": "Fair Market Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FairValueOfInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Investment",
        "documentation": "The amount of fair value of Investment.",
        "label": "Fair Value Of Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfOrdinarySharesGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FairValueOfOrdinarySharesGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of ordinary shares granted (in Dollars)",
        "documentation": "The amount of fair value of ordinary shares granted.",
        "label": "Fair Value Of Ordinary Shares Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfShareOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FairValueOfShareOption",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options",
        "documentation": "Fair value Of share options.",
        "label": "Fair Value Of Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfShareOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FairValueOfShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options granted",
        "documentation": "Fair value of share options granted.",
        "label": "Fair Value Of Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment commitment fee (in Dollars)",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sprcy_FeeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FeeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee expense",
        "documentation": "Fee expenses.",
        "label": "Fee Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "sprcy_FinanceExpenseInRespectOfLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinanceExpenseInRespectOfLeasesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense in respect of leases [Member]",
        "label": "Finance Expense In Respect Of Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinanceExpensesFromInterestAndCommissionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinanceExpensesFromInterestAndCommissionsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses from interest and commissions [Member]",
        "label": "Finance Expenses From Interest And Commissions Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "negatedTerseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "label": "Financial assets measured at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "sprcy_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of Financial Assets and Financial Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value Using Black\u2013Scholes OPM [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinancialInstrumentsDetailsScheduleofWarrantsFairValueUsingBlackScholesOPMTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) - Schedule of Warrants Fair Value Using Black\u2013Scholes OPM [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FinancialInstrumentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial and lease liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r214"
     ]
    },
    "sprcy_FreightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "FreightMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Freight [Member]",
        "label": "Freight Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of investments in financial assets",
        "label": "Gains (losses) on financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "sprcy_GeneralAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "GeneralAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "sprcy_GeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "GeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "sprcy_ExpensesDueToSharebasedCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r172",
      "r184",
      "r187"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r172",
      "r184",
      "r187"
     ]
    },
    "sprcy_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "documentation": "Government authorities.",
        "label": "Government Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "documentation": "Gross proceeds.",
        "label": "Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "sprcy_GrowthRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "GrowthRatePercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Growth rate, percentage",
        "label": "Growth Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "ILS",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS [Member]",
        "verboseLabel": "Israel [Member]",
        "label": "Israel, New Shekels"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "ifrs-full_ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible asset",
        "label": "Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss, impairment gain or reversal of impairment loss that is recognised in profit or loss in accordance with paragraph 5.5.8 of IFRS 9 and that arises from applying the impairment requirements in Section 5.5 of IFRS 9."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment loss (gain)",
        "label": "Impairment loss recognised in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IncomeStatementsLocationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statements Locations [Axis]",
        "label": "Income Statements Locations Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IncomeStatementsLocationsDomainDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeStatementsLocationsDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r34",
      "r35",
      "r36",
      "r59",
      "r108",
      "r149"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of August 2023 financing round",
        "label": "Increase (decrease) in number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration of share options",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_InitialConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InitialConversionPrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion price (in Dollars per share)",
        "documentation": "Initial conversion price.",
        "label": "Initial Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InitialInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InitialInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "documentation": "Initial investment.",
        "label": "Initial Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InstallmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment amount",
        "documentation": "Amount of installment amount.",
        "label": "Installment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InstallmentPaid",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment paid",
        "documentation": "The amount of installment paid.",
        "label": "Installment Paid"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InstallmentPaymentPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment payment percentage",
        "documentation": "Installment payment percentage.",
        "label": "Installment Payment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IntangibleAssetDetailsScheduleofFairValueoftheIntangibleAssetTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset (Details) - Schedule of Fair Value of the Intangible Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetFairValueUsedAsDeemedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetFairValueUsedAsDeemedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "label": "Intangible asset fair value used as deemed cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Intangible asset, net",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r77"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid on lease liability",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "sprcy_InterestPercentgae": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InterestPercentgae",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest percentage",
        "documentation": "Interest percentgae.",
        "label": "Interest Percentgae"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r154",
      "r211"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inventory",
        "terseLabel": "Inventory",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r164"
     ]
    },
    "sprcy_InventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAchievementOfFirstMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentAchievementOfFirstMilestone",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement of first milestone",
        "documentation": "The amount of investment following achievement of first milestone.",
        "label": "Investment Achievement Of First Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment amount",
        "documentation": "Investment amount.",
        "label": "Investment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentFromShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentFromShareholders",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment from shareholders",
        "documentation": "The amount of investment from shareholders.",
        "label": "Investment From Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentInFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentInFinancialAsset",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in financial asset",
        "documentation": "The amount of investment in financial asset.",
        "label": "Investment In Financial Asset"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentinAssociatesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentinAssociatesDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentinAssociatesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentinAssociatesTablesTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinFinancialAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentinFinancialAssetsDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentsDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentsDate",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment date March 31, 2022",
        "documentation": "The amount of investment date,",
        "label": "Investments Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in company accounted for at equity",
        "label": "Investments in associates reported in separate financial statements"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "sprcy_InvestmentsInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestmentsInFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "label": "Investments In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestorRelationsAndBusinessExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "InvestorRelationsAndBusinessExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and business expenses [Member]",
        "label": "Investor Relations And Business Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceExpensesRelatedToWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuanceExpensesRelatedToWarrantsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses related to warrants [Member]",
        "label": "Issuance Expenses Related To Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuanceOfAggregateShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of aggregate shares",
        "documentation": "The issuance of aggregate shares.",
        "label": "Issuance Of Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of investment in affiliate",
        "documentation": "Issuance of share capital \u2013 in respect of investment in affiliate.",
        "label": "Issuance Of Share Capital In Respect Of Investment In Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of October 2023 financing round",
        "documentation": "Number of share capital issued in respect of October 2023 financing round.",
        "label": "Issuance Of Share Capital In Respect Of October2023 Financing Round"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfRoundingErrors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuanceOfShareCapitalInRespectOfRoundingErrors",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of rounding errors",
        "documentation": "Number of share capital issued in respect of rounding errors.",
        "label": "Issuance Of Share Capital In Respect Of Rounding Errors"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfShelfProspectus": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuanceOfShareCapitalInRespectOfShelfProspectus",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of shelf prospectus",
        "documentation": "Issuance of share capital \u2013 in respect of shelf prospectus.",
        "label": "Issuance Of Share Capital In Respect Of Shelf Prospectus"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueOfShareCapitalNetOfIssueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssueOfShareCapitalNetOfIssueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of share capital, net of issue expenses",
        "documentation": "Issue of share capital, net of issue expenses.",
        "label": "Issue Of Share Capital Net Of Issue Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuedAndOutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "IssuedAndOutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding shares percentage",
        "documentation": "Issued and outstanding shares, percentage.",
        "label": "Issued And Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital purchase",
        "label": "Issued capital, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "sprcy_JeffsBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "JeffsBrandsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffs\u2019 Brands [Member]",
        "label": "Jeffs Brands Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_June2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "June2022WarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022 Warrants [Member]",
        "label": "June2022 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_KeyManagementPersonnelCompensationManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "KeyManagementPersonnelCompensationManagementFees",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees (see also note 25a)",
        "documentation": "The amount of compensation to key management personnel in the form of management fees.",
        "label": "Key Management Personnel Compensation Management Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel [Member]",
        "label": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "sprcy_LeaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LeaseFee",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease fee (in Dollars)",
        "label": "Lease Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "sprcy_LeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LeaseMember",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Lease [Member]",
        "label": "Lease Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LeaseholdImprovements",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements (in Dollars)",
        "documentation": "Leasehold improvements.",
        "label": "Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "sprcy_LeasesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LeasesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r111"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r111"
     ]
    },
    "sprcy_ListedSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ListedSharePrice",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listed share price (in Dollars per share)",
        "documentation": "Amount of listed shares price per share.",
        "label": "Listed Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LongTermPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LongTermPercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term, percentage",
        "documentation": "The percentage of long term.",
        "label": "Long Term Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "LossesFromRemeasurementOfInvestmentInFinancialAssetsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets [Member]",
        "label": "Losses From Remeasurement Of Investment In Financial Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_March2021FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "March2021FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2021 Financing Round [Member]",
        "label": "March2021 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "MaturityDate",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXBioLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "MitoCareXBioLtdMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCare X Bio Ltd [Member]",
        "label": "Mito Care XBio Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "MitoCareXMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCareX [Member]",
        "label": "Mito Care XMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MutualShareExchangeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "MutualShareExchangeAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual share exchange amount",
        "documentation": "Mutual share exchange amount.",
        "label": "Mutual Share Exchange Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]",
        "label": "Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NewCoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NewCoIncMember",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewCo Inc. [Member]",
        "label": "New Co Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r99",
      "r101"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r104",
      "r181"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and other explanatory information [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfOutstandingShareOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NumberOfOutstandingShareOption",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Share Options , Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Number of Share Options, Share Options outstanding at the end of the year",
        "documentation": "The number of share option outstanding in a share-based payment arrangement.",
        "label": "Number Of Outstanding Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NumberOfShareOptionExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options exercisable at the end of the year",
        "documentation": "Number of share options exercisable at the end of the year.",
        "label": "Number Of Share Option Exercisable In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options granted during the year",
        "documentation": "Number of share options granted during the year.",
        "label": "Number Of Share Option Granted In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfShareOptionsCancelledInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NumberOfShareOptionsCancelledInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options cancelled during the year",
        "documentation": "Number of share options cancelled during the year.",
        "label": "Number Of Share Options Cancelled In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "NumberOfSharesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, 2023",
        "periodEndLabel": "Balance at December 31, 2023",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of ordinary shares (in Shares)",
        "netLabel": "Shares issued (in Shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued of warrant (in Shares)",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedButNotFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedButNotFullyPaid",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received shares (in Shares)",
        "label": "Number of shares issued but not fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has not been received."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued and outstanding",
        "verboseLabel": "Common shares (in Shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "sprcy_OfficeEquipmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OfficeEquipmentsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipments Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OfficeMaintenanceRentAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OfficeMaintenanceRentAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance, rent and other expenses [Member]",
        "label": "Office Maintenance Rent And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OnlineSalesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales [Member]",
        "label": "Online Sales Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingLossCarryforwardsTaxAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OperatingLossCarryforwardsTaxAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses (in Dollars)",
        "documentation": "The amount of net operating loss carryforward tax as of the reporting date.",
        "label": "Operating Loss Carryforwards Tax Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsDetailsScheduleofOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OperatingSegmentsDetailsScheduleofOperatingSegmentsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Details) - Schedule of Operating Segments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OperatingSegmentsTablesLineItems",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Abstract]",
        "label": "Operating Segments Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OperatingSegmentsTablesTable",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OperatingTerm",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating term",
        "label": "Operating Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinaryShareExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinaryShareExercisePrice",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share exercise price (in Dollars per share)",
        "label": "Ordinary Share Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesAcquired",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ordinary shares (in Shares)",
        "documentation": "Ordinary shares acquired.",
        "label": "Ordinary Shares Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares granted (in Shares)",
        "documentation": "Number of ordinary shares granted.",
        "label": "Ordinary Shares Granted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesGrantedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesGrantedDiscountRate",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares granted discount rate",
        "documentation": "Ordinary shares granted discount rate.",
        "label": "Ordinary Shares Granted Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued (in Shares)",
        "label": "Ordinary Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesNoParValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesNoParValueMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares, no par value",
        "label": "Ordinary Shares No Par Value Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesParValue",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares par value (in New Shekels per share)",
        "documentation": "Ordinary shares par value.",
        "label": "Ordinary Shares Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OrdinarySharesSold",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares sold (in Shares)",
        "documentation": "Number of ordinary shares sold.",
        "label": "Ordinary Shares Sold"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Other cash receipts from sales of interests in joint ventures, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of interests in joint ventures (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts receivable",
        "terseLabel": "Other accounts receivable",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_OtherEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEquityInterest",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_OtherEquityInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEquityInterestMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non- controlling interests",
        "label": "Other equity interest [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Liabilities",
        "label": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties [Member]",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "sprcy_OutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding share capital, percentage",
        "documentation": "Percentage of outstanding share capital.",
        "label": "Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares",
        "documentation": "Outstanding shares percentage.",
        "label": "Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OverAllotmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OverAllotmentMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Allotment [Member]",
        "label": "Over Allotment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "OwnershipPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in New Shekels per share)",
        "verboseLabel": "Par value (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParentMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PaymentOfIssuanceExpensesRelatedToPreviousPeriod",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of issuance expenses related to previous period",
        "label": "Payment Of Issuance Expenses Related To Previous Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PaymentPremiumPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment premium percentage",
        "documentation": "Payment premium percentage.",
        "label": "Payment Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "sprcy_PercentageOfSharesIssuedAndOutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PercentageOfSharesIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issued and outstanding share capital",
        "documentation": "The percentage of shares issued and outstanding share capital.",
        "label": "Percentage Of Shares Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates",
        "documentation": "The useful lives or depreciation rates used for property, plant and equipment.",
        "label": "Percentage Of Useful Lives Or Depreciation Rates Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrepaidAdvance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PrepaidAdvance",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid advance (in Dollars)",
        "documentation": "The amount of prepaid advance.",
        "label": "Prepaid Advance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price Per Share (in New Shekels per share)",
        "documentation": "price per share.",
        "label": "Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Prices specified in forward agreements to purchase financial assets for cash"
       }
      },
      "en": {
       "role": {
        "documentation": "Prices specified in forward agreements to purchase financial assets for cash."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "sprcy_PrivatePlacementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PrivatePlacementsMember",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placements [Member]",
        "verboseLabel": "Private Placement [Member]",
        "label": "Private Placements Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Proceeds from contributions of non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provided sale (in Dollars)",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "sprcy_ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from issue of share capital (net of issuance expenses)",
        "documentation": "The amount of proceeds from issue of share capital and warrants net of issuance expenses.",
        "label": "Proceeds From Issue Of Share Capital And Warrantsnet Of Issuance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross cash proceeds (in Dollars)",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "sprcy_ProfessionalAndDirectorsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ProfessionalAndDirectorsFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and directors\u2019 fees [Member]",
        "label": "Professional And Directors Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/GeneralDetails",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Total comprehensive loss",
        "negatedTotalLabel": "Profit loss",
        "terseLabel": "Loss",
        "negatedLabel": "Loss",
        "verboseLabel": "Operating loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r24",
      "r86",
      "r95",
      "r98",
      "r150",
      "r152",
      "r181",
      "r186"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to:",
        "label": "Profit (loss), attributable to [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r100"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity holders of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r136",
      "r161",
      "r162",
      "r190",
      "r191"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r175",
      "r211"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r41"
     ]
    },
    "sprcy_PropertyPlantAndEquipmentAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PropertyPlantAndEquipmentAccumulatedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accumulated depreciation, Beginning balance",
        "periodEndLabel": "Accumulated depreciation, Ending balance",
        "documentation": "Represents the amount of accumulated depreciation.",
        "label": "Property Plant And Equipment Accumulated Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cost, Beginning balance",
        "periodEndLabel": "Cost, Ending balance",
        "label": "Property, plant and equipment, revalued assets, at cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciated cost",
        "label": "Property, plant and equipment, gross carrying amount of fully depreciated assets still in use"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross carrying amount of fully depreciated property, plant and equipment that is still in use. [Refer: Gross carrying amount [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r176",
      "r185"
     ]
    },
    "sprcy_PropertyandEquipmentNetDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PropertyandEquipmentNetDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PropertyandEquipmentNetDetailsScheduleofPropertyandEquipmentNetTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r102"
     ]
    },
    "sprcy_PurchaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase costs",
        "label": "Purchase Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of financial assets at fair value through profit or loss",
        "documentation": "Purchase of financial assets at fair value through profit or loss.",
        "label": "Purchase Of Financial Assets At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible asset",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in a company accounted for at equity",
        "label": "Purchase of investments other than investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "sprcy_PurchaseOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchaseOfOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of ordinary shares",
        "documentation": "Purchase of ordinary shares.",
        "label": "Purchase Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "sprcy_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchasedGoodsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased goods [Member]",
        "label": "Purchased Goods Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaseofAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "PurchaseofAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase date September 30, 2022",
        "label": "Purchaseof Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r121",
      "r128",
      "r182",
      "r183",
      "r224"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r121",
      "r128",
      "r182",
      "r183",
      "r224"
     ]
    },
    "sprcy_ReceiptofShortTermCreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ReceiptofShortTermCreditFromOthers",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of short-term credit",
        "label": "Receiptof Short Term Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegistrationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RegistrationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration of warrants",
        "documentation": "Registration of warrants.",
        "label": "Registration Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RegulatoryExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory expenses [Member]",
        "label": "Regulatory Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryProfessionalAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RegulatoryProfessionalAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory, professional and other expenses [Member]",
        "label": "Regulatory Professional And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized over period",
        "label": "Remaining amortisation period of intangible assets material to entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "sprcy_ResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Recognized expenses",
        "label": "Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndDevelopmentExpenses1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ResearchAndDevelopmentExpenses1",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.",
        "label": "Research And Development Expenses1"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndDevelopmentsExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ResearchAndDevelopmentsExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "sprcy_ExpensesDueToSharebasedCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of research and development expenses.",
        "label": "Research And Developments Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ResearchAndPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ResearchAndPreclinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and preclinical studies [Member]",
        "label": "Research And Preclinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r163"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and restricted deposits",
        "label": "Restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r163"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r106",
      "r136",
      "r147",
      "r151",
      "r156",
      "r157",
      "r159",
      "r161",
      "r162",
      "r181"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "sprcy_RevenueTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RevenueTerm",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue term",
        "documentation": "Revenue term.",
        "label": "Revenue Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cost of Sales and Gross Profit [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RevenuesandCostofRevenuesDetailsScheduleofCostofSalesandGrossProfitTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues (Details) - Schedule of Cost of Sales and Gross Profit [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Reversal of impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross sales",
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RightofuseAssetRecognizedWithCorrespondingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Right-of-use asset recognized with corresponding lease liability.",
        "label": "Rightofuse Asset Recognized With Corresponding Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RightsToPurchaseOrdinarySharesNoParValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RightsToPurchaseOrdinarySharesNoParValueMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rights to Purchase Ordinary Shares, no par value",
        "label": "Rights To Purchase Ordinary Shares No Par Value Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "RiskFreeInterestRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "documentation": "The risk-free interest rate for the option contractual term.",
        "label": "Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SEPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SEPAMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA [Member]",
        "label": "SEPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information To The Items Of Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBenefitsToKeyManagementPersonnelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfBenefitsToKeyManagementPersonnelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefits to Key Management Personnel[Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfCostOfSalesAndGrossProfitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cost Of Sales And Gross Profit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDefinedContributionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfDefinedContributionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Contribution Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfExpensesDueToShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Expenses Due to Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfFairValueForShareOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value for Share Options Granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfFairValueOfTheIntangibleAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Intangible Asset Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfFairValueOfTheInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfFinancialAssetsAndFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Financial Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfInventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfInventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfIssuedAndOutstandingShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfIssuedAndOutstandingShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued and Outstanding Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Number Of Shares And Loss Used In The Computation Of Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Segments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsReceivableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfOtherAccountsReceivableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost of Sales and Gross Profit",
        "label": "Schedule Of Revenues And Cost Of Revenues Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Capital Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTradePayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfTradePayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfTransactionsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transactions with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfWarrantsFairValueUsingBlackScholesOpmAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Fair Value Using Black Scholes Opm Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Fair Value Using Black\u2013Scholes OPM",
        "label": "Schedule Of Warrants Fair Value Using Blackscholes Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesOptionPricingModelAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Exercise Prices Of Share Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(g) Security",
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "sprcy_SegmentReportingRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SegmentReportingRevenueAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Segment Reporting Revenue Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r115",
      "r150",
      "r173",
      "r188"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r115",
      "r155",
      "r173",
      "r188"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sprcy_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Warrants [Member]",
        "verboseLabel": "Series A Warrants [Member]",
        "label": "Series AWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Warrants [Member]",
        "label": "Series BWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management services expenses",
        "label": "Services expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from services."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Volatility Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Range Of Dividend Used"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedPaymentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment [Member]",
        "label": "Share Based Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedPaymentTransactionsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedPaymentTransactionsTablesLineItems",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareBasedPaymentTransactionsTablesTable",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareCapitalPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital percentage",
        "documentation": "Share capital percentage.",
        "label": "Share Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of share capital in respect of investment in affiliate",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_ShareIssuedToAConsultant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareIssuedToAConsultant",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued to a consultant",
        "documentation": "The shares were issued to a consultant.",
        "label": "Share Issued To AConsultant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Company\u2019s share of losses of company accounted for at equity, net",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r148",
      "r154"
     ]
    },
    "sprcy_ShareOptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "ShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options granted (in Shares)",
        "documentation": "Number of share options granted.",
        "label": "Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sprcy_SharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SharePricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "documentation": "Share price.",
        "label": "Share Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SharePricePercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareprice, percentage",
        "documentation": "Share price percentage.",
        "label": "Share Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life of share options (years)",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposit",
        "verboseLabel": "Short term deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS",
        "documentation": "The entire disclosure for significant accounting judgments estimates and assumptions used in the preparation of the financial statements.",
        "label": "Significant Accounting Judgments Estimates And Assumptions Used In Preparation Of Financial Statements Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantAccountingPoliciesDetailsScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events During the Reporting Period [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsTable",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantNonCashTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SignificantNonCashTransactionsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Significant non-cash transactions:",
        "label": "Significant Non Cash Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SquareMeters": {
     "xbrltype": "integerItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "SquareMeters",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square meters",
        "label": "Square Meters"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StorageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "StorageMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Storage [Member]",
        "label": "Storage Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates mainly",
        "label": "Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense",
        "documentation": "Tax expense.",
        "label": "Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TaxesonIncomeDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [Member]",
        "verboseLabel": "Top of Range [Member]",
        "netLabel": "Top of range [member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r121",
      "r128",
      "r182",
      "r183",
      "r224"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts payable",
        "terseLabel": "Other accounts payable",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open debts",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r210"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade payables",
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsAndBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TransactionsAndBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balances with Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) - Schedule of Balances with Related Parties [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand Twenty Three Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnderlyingAdsPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "UnderlyingAdsPrice",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Share Price ($)",
        "label": "Underlying Ads Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnderlyingOrdinarySharePrices": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "UnderlyingOrdinarySharePrices",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying ordinary share price (in Dollars per share)",
        "documentation": "Underlying ordinary share price.",
        "label": "Underlying Ordinary Share Prices"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_UnpaidIssueExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "UnpaidIssueExpenses",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid issue expenses",
        "documentation": "Unpaid issue expenses.",
        "label": "Unpaid Issue Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "label": "Value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to a value added tax."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "sprcy_WagesAndRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WagesAndRelatedExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and related expenses [Member]",
        "label": "Wages And Related Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "sprcy_WarrantsAndExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WarrantsAndExercise",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and exercise",
        "label": "Warrants And Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsExercisePrice": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WarrantsExercisePrice",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price",
        "documentation": "Warrants exercise price.",
        "label": "Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsFairValueinDollarsPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WarrantsFairValueinDollarsPerShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValueUsingBlackScholesOPMTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($)",
        "label": "Warrants Fair Valuein Dollars Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WarrantsLiability",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants liability",
        "label": "Warrants Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "sprcy_WarrantsToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WarrantsToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase",
        "label": "Warrants To Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options exercisable at the end of the year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options cancelled during the year",
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options granted during the year",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Weighted average exercise price, Share Options outstanding at the end of the year",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r126"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "sprcy_WeightedAverageRemainingContractualLifesOfOutstandingShareOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WeightedAverageRemainingContractualLifesOfOutstandingShareOption",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "The weighted average remaining contractual lifes of outstanding share options.",
        "label": "Weighted Average Remaining Contractual Lifes Of Outstanding Share Option"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price ($) (in Dollars per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "sprcy_WorkingCapitalAdjustmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "WorkingCapitalAdjustmentsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustments:",
        "label": "Working Capital Adjustments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_pricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20231231",
     "localname": "pricePerShare",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares price closes (in Dollars per share)",
        "label": "price Per Share"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "ba",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_ba&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "77",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_77_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_30&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "A14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_A14&doctype=Appendix&subtype=A",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001213900-24-028859-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-028859-xbrl.zip
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MAT'"0!/Y5DZSX>R79^HM>3;]CD]] =?N;L/_/U.7A7EF+L*A?!]D\6::G;^
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M20['.2),LXH9L',O0K_,=Z^'QKX<"W0U*L+M/=_^R0=?F"0Z](,X-F+MROM
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M#X9#$2OZ(Q15=&"2VM^"<9ALU/P!]@G< 8<,CO+</\_2RWR,X28$+&S"1W!
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M0OB^SLGZYG"WP3:HOB5*0H'W;VV^C)*U82#<:\@&)[5D@PW;8)UL+9):^I_
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M'EW@J2-&(_I[6O,QRN-< QE8@R'<Z\M[)?E0*NCK9G_3"Y'!/),U&NJ_S.]
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MSIP'8]TD'3!.=[Z$N]Z/W/.C7!W-6)R&Y:,Y4VHWP%S(DA/'3M!R]&.&/,7
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MSF_63#%75.-[8.:J;[5IN_KA<;;,;G#5LD\/45*"NAQYXU867F6S5.)_*MJ
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M&MHL]:E%CH(H?CPX;94$CBW"6I3#>1&%1.? ?I'"_JC^H8V@-H):9P=JIL/
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M;BQFI1-/DRC-#Y3.&M>2L1U7RKNTWO0RT',>/FG#2T%:H6H_U/=%+7MC=3*
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M+%-\Q)PMC>KKF2-IO!3%=(0@>=.HCDI7DYFG00A* =,D,(K+=!"M?*8(GWS
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MZ:ATEA,QUZ2GE"5,PMH68,L[E39VB6U_Y[?1(1/Q8#$@8J.78J62S7)(H6/
M .VD#QON+XNM#_K<8<NM+S'1%7OF:1PT2%V5.APX(:+745R97"]7RY6KQC;#
M,R.FZ)\8=0@ED'/LA(Z.<#J_Y [L*?AL-FK*\3HH <UR(!RR_P&TJ_(UFF8I
M2C!\B>72J&1N*C:$G33[2/9#)2&C@W;O-=R[)?4??^A)_2</2?WW7Z!%#)#3
M_P'<5#\HL2EI F80IW^*(TG*X=6VZM:TPR #SWZ-M+H]W6]5X.C8]L,H\9OO
MB\ZHIT-K_8'IZ<N@U0L_,]YWV5LPH5%;P4LM#/@HTTJ,D=Y&&_Z2N:6KHNN8
M.]OXUBVC25Y5MCZ(;PQ[P47P%4:[D#VH,9Q2Z89C0^=,%X;K7(P6[P[FB7'K
MU&RSHU6++4SP!$$PE-IZR\$JZL3WKW[SHPZSXH'/W .]MP"I+IHL]O!K]%/K
MS%G(SAG+SG%Q^</SWK<:*WL!:S3:A2)T_AEJ85:":0.ONF*70*I>@1,Z^Q:\
M<SF%1ZOS?/'U-_^]N+1?_:"!^>*;W?);A&#TY]PU_L-9BV>+1=^$?H-875/N
ML19T^PG+,TG"2_R- =@6LJ6#O^C$Q#C^G+:.:U3;LD:\JE,*%1429@6EQ!!E
M0>\U8AF7@><ZJISO"<:#I%KI_3>>[M6N."F'7N4\.5/LJ6&V*[I-^4"LBVX=
MSTWG]#$2OKS5B!OXO$)DKAD(8]S&R2G7%]-L"G;!KHOKQ'PLN=OKMDMY-<9E
M6^.Z$&*(;RX=.P337RS^6I!O(GYJRGWQS5]?6$)2KI^28( W4526.K%^#FRN
M>6Z>?(D\L"NQ:)_:]R48E+68IQ]^=> Y%G2"OJ*]:G>TN!?D7^3C\LT=+.P;
M)4:?9X[VX[Q=R?7<4J7C$2OZBJ<E[1#HS275I,%61WJAGD>'M-HCO6H *OQ!
MOU@%_:NC"<1T\,"&3/KVC/Q]$T6BC;+P=EU]<6127 ;6.89<6MOLX!,S248G
MXPDQ)1DB'C$!45_6-N-,=_^K[]^1.-\3QPI S&RQ2TB/'R;31+[8.$.0)JW*
M ;(LS>I2"]"VX&-[$'4!U1SWC>68EH*CV:G'/6K+JHOP8K$0:*HP:UKSNG&W
M3I;3;Q,=SK02G=#M3.]&9$A0S88K31%)A9,L?\3F<6S(BB&]+7N4;PL"F=BX
MKJ03/&0GZM_R$VXRS:@*&IOLE6#@E[?P[X7O\&SC94+*O;26VVK?9VZ93YT%
M&U$QY_[!$9<*.[F@7,F5I(-H@9K^V$CJR;0&>:^<=VF<6UCS?A8\$@1E8[KE
ME"2*):(]YR?@#TH2DO98VI"\\@UST4$3L\LJ'G:8JH4I5RI_0%-R\<(]*LX7
MWP(O*J?6TH^<C(-JI$OSS85VH[QNAV3H^@285,OI;7.6=LSDG(Y/7!?ORIAW
MA81W7V9"#JQT-N2L7&W)PL7:KE0):&LYX7UH7(Z)X@$$R\'873[_Q[.G9X^_
M(+>*5H*,'8(,]17NC"HR%U4L)*I "FA9*R87_YP),W*=8\^<#>(SH+!"SNLJ
MH$WY$0URQ#9G1:Z$H[ZQ!<I@.' MC3XJ46L=V6^,93N$D9Q.JP@UE>V)7VVX
M77T^%_J@_3_0)HNHDF\Y9ZPP59*YQ=;<X0^U,Y[W8J,B?E8\E6[16P17Y[+#
M@7$I@)FYC@>+WTO%C>.)P'XP*I>+WIBC84RSLUFHV=S& !5FKDM,I_8&SQ+8
MLT&O$9Q1!X$.[V" YQ OZH+?^ZSC2])KJZV5 =;2>14GE$(DR"%L:QYGXET>
MQE:*&L,1Z#5$W"4Z;M.N#F,M'4:C%@N2\D.';'9!D84P2\%=E<)& 5U%CY!!
M:) %9YZWD<PI/PL+;LNZ("57MV)!G  _DA%H(OX,8U?*]:0#CE>"ACK/M*0$
M \"51+ZTQL<G9E/Q_6J8[.6Y;+ID$R4>GW![L4=VHQQ=?-KI?=L#[*:1OK@Y
MKFV715J:(0R>%1R+H*CZTE:F37X:;C!73;%E&E=D9TJO\1C?H\/DLGS*A#J3
MZG/@ NC=BQ?/]&1TN]2S/<UIB<83D]>>)/@LH%+>?G9<U$<)O@992=+4%MSR
M[=FJ H:$_@T)J.U"XG,5@:^738W9V9J/0B^<-AR)W]?4FJ=14[:WKNB'[J [
MS%/W]J9<,&$0>,^1)."G+ E>"L)D*-1@) (Q#S$8SWCQT16=WSX%?F5E&O3:
MJ&I('TD!U :]3@OS1IR*[<*$!XYG)VFO(@R(B@.HDD;)[&;;.A!K? F-^A;^
M<(B65">I"*Y@&)%E$4.9WL/#87B2NB!,N;+*8QXE(SCICS%C63HD*PYM9!(I
M9$QE1Z7T*8#@P([-7F7;N#(JB &YM+FL7<6<"<YN>8HI3+7B[W7:MTUNFW+[
M;@&^>W-XTN20:2QRZK+=(W7^2U1DGWSH%=F/'RJROQN!]FU6@>:YKBVG;C-M
MIUK:LQ&0TZM%UQ\S)EI-F3CG0LP4KLK?=#3<?%6#"K$-RBSP]34KN.MS(;AA
M*X,U8H.)]MO[Z*]<D&-:F@.H09SE@[CN##23%LK8Y!9[P'M'4"/+64QAC6)=
M#ZFV-Y58JQE&\?DH/Q\+761=][#ARVAGP6VX80S_MES[IP]7#P0AF],G%\S;
M*5H-8V08ZDK_..L'5AFSJ6U/T;B8J-MQ_EIS<TEB6EI\IIEKQ=7+'#O\1YY<
MD6^PT,Z(/P6G,'2,%0$-&XPXKY/Y\#UHX0V $,#&6G1(LFJ;M(M><C53Q7C]
MN$]7NX='^:)5IFR457U;EWM=#H4-="8.]1"_IK#T@O-ADF'+,+A;N@-1/=2V
MH,BT;-/F^3$&-RQW)KV$:-DEV+A$LI+8AY&*UL:%GZDSQKZRYO42E:K2/2/\
M$!MU'+D&&##'%%.L#G'[,$]C+\!ST#'_C>M6=.WO0_E(BY;",)M=Q&*2?.^"
MO\\./W(6Y$,7?>5XJV."\YN_OA [P)46+KYZ,9THGB8=-RG3)A>]K.(HE7*G
MUUT%2Y/6YXN7C'$-7 "3*P9%WG"1/9:&BK0@$(FCD_:$(*TAF$ Y3B[(=0%C
M5)8HBPP(ES<G:VJ^CTY#9+%B?GR$(_^W0\855GK%+*WXGMI@7TMQ-579JGW!
M<'Z.:<XBKT)<S(UA<JI9M$#20ZV]2)JZF9E#/W]4TOJN3?68G28]D?>;*DUJ
M.CQ?:$%29C44I/(&@=^+AU%,NPW':-<<+VYBV>;?AN%7=[^&]8;17K2K"GGY
M\6;/;42"38B;8JSG 4N2+4LUFU(L132NJ093H,.)YZ1*E-Y14@>%,4J7 )VO
M2\R0YZ*/56E/SQFNHX#G[([7&'M;#GKF#H,^]I3H<GYA< *<3PE@-D<7W'LU
MK9VK,G#J> H LWK*@3ZH(5>NW4(6JNND]J2[T=,?^TUAAB<;EX!CD;W:<#&M
MN_?A\:OI%6)Y1@%I?*KIF'#7=4)P/TU1'9R(L-BF$4Y/@8\?)I1L=HN2A0"'
M#F.G6%G3X7::<8*2GX,>3&M;K5464>YFY\6'\0#QEW/7Y/(&VU-WMK6EH6BF
M7B!77(X(<UU>TP'))LV<ATM(89PG$I1%#R\T>$G+TL:::*\[-I;378<==@.@
M5'&O8_H0B;[@ID);9>&2-OV6GY&T*7D^[!1QIKDDD][(N 1/#U",QQ2<^O>1
M V3FBLSLAH0MP@BU)9H&% S-> F$/$X!E0>U"CX_FHPC"JKVI @UQ3)RO_4(
MT&/YZ='-L]3C\*=X%%AJ!2/T-\Y,<C(_-E3IIVGEXZG@Z$0VWI^:V P3@K/I
MMMH)IHUBBM]2@(&H=J*M2U5$/F+1+YHL*LYNEC1CHB1_9Q%OIF@?AB,EXOM0
M-O^OE,RCVEADQXU/6=NXD39>4D%]P6E:KD?(<,L$_91\5X /#@8#KW-3(6R1
M2$NB0PWZ2 ))LD3!,O"8=#D)"K?Y3T <-Y6P\OC20&SDW<@ %?&B)-R9"/@B
M5"1P%T9\0$ W;U2P_;MEH#2(^/11AL:+<L0GC,+I(KC^WO539 B:J/M%7;TN
MI?@6WZW0>DS59)-%?T7TVK/$NO]]%_E7YNDC/M4Z%W?&9@*O)%U(ZYF A2(S
M8FRA#94UPSE9HN>D&N8U;I@RB<\541Y#\ZG1.[/^5I]."&(1!1Y?RIK>G'"J
MV:/93G+-"OH_-!;7H9^?X?5PN_CZF:+7=N+(V#U0R4W(BJ")93R3CV3B.<:B
MSN%M15$[&%D8 U4S=" $N$;]>._%^=V*>Q]_Z,6]3QZ*>[\;@;;BWO.3CAX?
MCP1@WJ'GK'F_94T%/[KC(:NDJ;IR".@ 0U'VDGP!=D(Q&F@5@!]=#F@(DUX"
MG:[%W]\%W-G)]0.-*^EOZ.M]AQQ:IM@*UD[WLU'O2^65N)EI%.5-4P3B>(CQ
M/-*C1.(8:9=!GE+V?;PGDMG;(=$(CA1!X@Q&(RP;50[,B4(?;INV;J^ ?^&G
MXYI RIN',8%K,3'(FD?@/#V>C7376"N/F$,@/S>E1]KG+@J4 J#T V;I5QIC
MIG&W"G&=(2;'^/W3&)-1CY5T0(5. 2N.\QU0=Z*E:)7#@;::>1 S>ZI%E&/-
MR=JZ)3156@=TSS,<]TKJ@5JUI&@8M!]@^"=80O!;QF.#_+5?^'2NMHVO2[;^
M?/&T[/?54"H6._HV@!'V4OJ1A5 4+B-N;:);^DP24'.$$A5,*FA)O]CD<XX4
M#S<QB";!XZ=76Y8KKAK) +_E,?!(BUK2(K*K#M9(+K4=)X"D=4QSO4ZBV4E$
M5RF")G#JF5;24:HH[H8L7@1]Q;T\7WR#GBS3@)F7 E*E$F53/++D*9"YG:+<
M(+;\0F?;5L9IC[2S5[QA;*SIWI@:2=;)CD%&?JF6"LOU2'I8BTB$R7#?JDL6
M$\SE]MRB>XYO0;[RJV:U?MWF_MN(#BY/AWYN@.A]D18E7ZC"O@P*^X,G09 "
MD78^+EJ4M0]-;(:%J9DNW8Z9Y78,8.^D_^2&J4RE5QG]/4576NN)M'D8=/2$
M.CX_I1  5].!_M[=2S?DN5C[GUQK,/GG< ^RB.7=E^V>HM4 XH7202L_*Q3H
M[]QHK&!TMJ4..?:_CBV$]J-% @N.95C86ATTS"FU@6S$@! ZV/$[&0F%W1DZ
M-V@GEIJ-4C33HNP"*HT5F7T0R7+) >LJH%J8T*C(W*1PA69[#!1>.K;?DR/$
MB51A9>0Q[L<^)CH8[5O(,.A->VC6KC-.#DMP,$S_2OX8"Y/!K''],J0R<B39
M?#I :7C1^Z=OAF8IML*K4J#\)3(+JS):-=L8R?HY 9"'E4O3._%Z#IDD)NOV
MQDZF=?3)S\DT,([%0[?#=;"/40RB&XJMEDSIH@0I(8!8$1]OS=+H^^-2=V8$
MPL/T(PL'&3-2!2G:L:?%SVXH\?/%*3]S$$=6(#(R6B@8=./V[=[0D#RMWI,[
MW$V7J2K*@(I:R+8V/WK( !7X.:*/LB=+1+)OZD"IRT4BRY7RBMM%.#GJMXD>
MYZH04!OKR*%-NZ0G1X],EA"RL;Z]1XDG!\*EP W8-J:%BVZ6U5Z*?;6.3BG,
MH)Y>P_B=!.0CWQ?;:VYA8.L_X=51H*21H8IEE5@I1[:2=Y;3">N0OA3WKH*&
M+J!%0\X ^?\I29@K,HTZ[^9;5.<2M_?10+,B75:MBUD O$R])OK-@?D#U5OB
M++RLJ?GSOEEG!ZK&5(?(/!X$=>G-W!]DF)'B/JMKABZ0,P<R6,/!^;CXBG[V
M3X/<0(0XG=U<%5>Q*SVQ<K[?,N;%4_2!1?:S%/3W2+_,R\NFZGJZP;>79^+^
MI)M-UF&QY[1<W]9K-X?"E;V:0N"9WY/#0X*P^,CY-0URQY$>_$\\':*WW1/$
M:*%RPR5TD S\O:FXES$-B<A.P:9M#E(2UU;&@#G]FZ*/.61:T4,^:^B]AP/S
M=3YK%H^_^/S3/#PA>4,E7#4 50.=*%?"HP5%H7%;[EK1@\>S3L*XK.%47 $I
MO&[)(@/F^ZI=,X3)[E#UB\C4?EQ<+)?_J$JAL%J\K*2']Q3 ''YMR0>Y1FX
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M7.";Z:-6<:X\='W1/W3BOE/IYN-''WKIYO%#Z>;]%V@1 X0)/U3]:^8R#</
MGY/J>$9_1I\2-WB\X(PL4[#_&LZY/=EO$B\]V]B,V6A.-.TJCH8V!L9&--;C
M7+EG;&M_RY1-6 !':1)FV+:[?3F4T=4#G3TNH@[X^6+JJ137DHG'W6R$;+:H
MU6WEWR-32L[LJBNE/,0 Y[-M>Y,+*%_:_Z12X-UC#=HM+RO.HW_6XHI1^9R0
MN)<AV[=5/[2=3*+'MFH%I:[8DVJ2=;=]LGS#>*O $N]!ZX.1;%3^!.[M!';Q
MF&*+;9R@PRBSX&7>[Q+FEB>/'G\:GQ:.6,\8U,%$V#TIB['%5[<X=*PH2)*
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ME_E;ZUL!-,"\8MH,2^+9)0R)__;[)]L-1-;[X"G\CBJ63S[TBN7'#Q7+W[E
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M27$%KEUV]_LX0E,-F$J*L6-.&?&+7HN!ZT,O3"ID,:0*O19N1M_<*J\A7:8
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M"$V8Q>?NP3YEZ_+DD_&SW9"^Y)96BY_QB+B>C>[S47:J/+WN"@%71KY:N:[
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M=4VVY& 7[*B22TDG8IV'" ""X'9-VAWY#(T"K[ZH^14#R#G/PCG)C4(G&)K
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MEY'UP@^&9[DQT-B&I" 1PGU)APYPQ?N(@Y#U58[:KY]>A/R@=*&*VGR[9(\
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M#6L9&!G; 4NUD2]6&)Y!-S=C% U L6)K5BD'LDRG\B3^&+448F";"M"7Y>M
MF5%F<;$<??52V8_%SZ1'R)-F,4O"&4-,?%5],TZT;JN])L$Y%+_WFO>IDT3=
M0/,ULM%PW#M]@F0:.D?Y5W6[1"Z$^[\DT7\BZ\'GL(9[NY;$-M'7R2;]G)\?
MH=Z;R-3R ]PNHIGP.WN3LE%ODA10_(1HHV.W(V9-3>01Q_EU-@U.:WKPWD.R
MVYUBR6--#'/+@H\<VE[N8Z?9<Q\"T+HAS0M'->.&@X9S!!RT5/WK13*9::;S
M[)9-TND[Z>]8!)H#TP_I)[W5-UFA<_XAVU8]A74Z273)43D;@2MN',N-8A[]
M@_&<XD78;J&<]ZX/RF/\AK%(9_,BS:I)[J4%(1W&6"VY-H"VCY\.G8Y=+(:M
MS72LE!X8-4&4=3188V'F4>6N#X_4(VVFC!L*9<^W.G!DG)E71\>!5"A*SC;&
MDT*E93Y?!")F6EN>SR)!;]6@$CG#0!Q7M#*09JZ\S*1>^10B!K,J O<>HL.F
M3 9)%6MR2HM!^4Z8CU)=$!.B9XV.5I)A$B'AG<4)"#-/.K'WX4DY8'+4$CQZ
MLE=J"<?!PHP36J1CDQ)_;2^@19WLH%.DPMN$-2BN"@[GW4FRIZFT*G77,V,A
MD!TING6M%<4=J0$DR:U9FI-^3"*39UI*N'7'3Y2N[\65M]8"@RI4M>A1I^:A
MQ9/3CCU]UF]TEB/2!-T!PQUL'%-*\(U1&@8'=',MPI 47AA'H"NEJ27:2X>P
MI ><%JZF8DT$K!"&I.8ZPD^W+ L[\BX#07^V4Q#'#/\K[,MO9/>E3=GHPSUL
MI6RNJZ[5]%R>J3-GU6UM7AAWV;I^<"5 <C4LU*'0<V=%*NFB6R%?U@^)#S"S
MF5G<S%LXV^^M'S"75<I&@XAXL3P2*@'B&,^;*$D-M<*'\4)5<XT1AT;<W[5U
MS?W29.KI4.8POGB.BF+$GG.\&W+9_DDJCQO&0VSH4WV##N=J&T.,O7V+O*)\
MP@UPG4.S%I8+>^OD3;/D%<<CKJ<$?(0#.O2ESS&6>7S[+?VRMG9QMP1J."<6
MXCPCPP@XR(JB:Z&HF?XFKFF=]S=%/YQB!P3@B2W@MZ*GX@2!%D^GUL(V.(;H
M&=!0\J9V+?<N6%;: TS/K5%_'D08S-5DH2AV.F@XG;(G;A;\4WHGC3+C'.SQ
M@#F%+.7S:=/P#3=\*LER)_K,;&!<--35>N[Y7?%HNK.#0&Z=91>L3>9@L6\K
M(&\K$^G^*AR%M@T[/..S]:FGMZ2=**_=-%U5UN"R7P/81K^7"9?+X^UZ .F<
MB4?6TKW @N(SRV"IP!;BT(^8&TTRW*,%34$2@E#LIU?1!@6S;%T="C+W0QE>
MB@?M";!HI:W60?PR+W[D#*(500Q\E$2Q.O#G[:CXQ8=_*OF&1O)H'I,!N'4M
MO0W&Y!&E2#$76? OG<\'N6?7I@S0!&77B5!#AN\HPB>4R9S C8M$BJ[ Y334
M,:QA>!U^EG_'&^M!&PT-]"4ONAS=D=-H^>B\3(HZ:Q;L=?DF-]+$38>,]*#U
M)X$GHL]%8#1P"I"HXP"1?L&#C:,B(0%9,QQU(OMCQ3J4;>3;S$*G[ZNJPR*-
M4'[#Q77&-RU7AT?+5D5'N[^L4%)6RO*H9^6\Q=# _,Q[GQ!\MU+,%Q]X*>;C
M1P^EF/=?H$4,$._\0(:A7_P0 >6L,9XUHIX6EVW'.!(Z^3]XE%KVHBZ:?U7,
M]R\.*N],^5;V\LDK+_B576TE"YZ^HNTC+^XH%1B# RZ)HSGW9DMAP?&,D=-K
M9 RJ=55TQZ0Z(T9$I[B3V:83'Z$3.L(4R!*=- R[J^A%WDE: >Z32&9Q>Y \
M]U:5UV5R*0OS[V>LV"R^(U>/05-//LT9#/4QG!PVJP=:>3+66PT6EBU91735
M@0:'$>WLN=37VI-QZ/H#1^JG$N2*<S]/@+XCI][BDNS+CG?TV[9&2/*L69WG
M7'6"="W&TL7/ZW^]P*^%19(6\[(EK[F726[L.(#E!Q/>%/?-@C)Y),I,CHS,
M*F>7LCQ)_M(5:QT]AWLA,<FH-#PY!0-DO\@/A#N#4U:7(=]IZV+QM(0FTNO'
MAT,NR/Z0[)"-S?:\TOI;)6V#RS/562!A,6>O_2OM:S01C/IZ^""/AOFZ%H6T
M-Q$IO +A:2FKT8O<_%KNTWMQPE[PN2AFI"D3:2*Y^!NYEH)'?#)U#"5\8NB9
MQ%RD4EOR!2J)RTEE#C*;3SH6(-Y_??XL]W.AHN1=EW0>:_C5M)$4RDK+&I_.
MQ;.^*\HZ7^B8\5?TUN5 )A%?4-9'<[59&)KRJATJT;Y(M*.J:T]-+_:T7,F+
M?2;O=0YVAV[M6LO3ZV2X3AP$;\_/5#<&$TT?2\+ZGM/]5;^=,C?R5E5B=CS%
M*U=FF+]K5])U\9(JR_J$XV70U;G@1^L5*/>U#3L<_RGG(E2P;-;\PX>3AUG+
MTIF2[4D-EO3D $CRZV?\#^&,?&/,J9\^.G_T.*P%?A+&6^N'I(:&LU4M,3K=
MFR2E7&MKXO'>AR^7LAFNG0;VR,"FR=;(\(M>CE/2RN&[';V%"*Z)ORATH>(H
M Z6"]7^9E:"'B88B&QN(DV:0Z7XK'7,02AF</RS>Q#2"0XD6]1'Y10^X57;2
M7HGR]IC5RB\M14=I36UZX<[>H-<D_$:'I4\["TAN>/&6$H(K+NF-HMC:&W )
M6_+]*,!)%B!XZ<GJGR^<2_/X"^B<3U)=FB_,8FX+3@<.&'*"LUXLEEW%76%U
MR_ST5UVIQ:N>E"=G_?(LN*)CG;!WBEYTRX2FTG%1Z]&=L&Z'4"&6(;F\'O_V
M^/R3Q8ZG +**>85&-=G_/A,,JN.U1K[K%/>U+C<%T#F=]/IPUM,^:@+M4VA]
M#$\UZG2#DFE8 AM,(]3:F]0N0YK32I8#)^(L/>BU87J&)D[.O==.?V]\3.-R
MV\#?:?;K=EQT'I)D*@Z:DT5>,50[)S1%4$D1#"?4Q? ;I-"0>77![B)I%Z<V
M1G>NBQN)P4*OJI9VC8+I'>5#\Z=XO@S$\"+J5C%*]?I$,"+9_%3A!I(TK5LD
MOYKZ 9(&3&]/1R@+" .OL8P13=JYM>T-)?Y-<4V*2_M^N?!1*4>\1:1&41R;
M?YP,)'434@&\\8"B<Y&DS*2+N#.$>1+H*I-5_XZ+ U,6[L"_W$DD$U_- F]Y
MH_ >V;-WNY&F9V5N0*P@:VCI&OVC4>5P\LX8\L.AE'_U]JN9324]O&8)XF 9
M$L&,+2;MRK\R/?)>:-T?(_+'2;I?L RHE_*J6CG(2!X+)[Y6\S./VE0%Q(=<
M%$;?;,L&U:UPBW"^71$K.24(HU1;=:H2K+$]>"I'^1J&IT!>U@[;YBV^J+8P
MVCU[EP..GX+4HB_)%Q$TE7A&=G<W"&+QX[;$:M)30\W=>:<LW*GJ?<BE93M
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MQP;6Z< &'EC8<HX#(/KJ#6(N!KJU:"RJ#+"O*U H$9BM)W0NRU<=+10SOL5
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M<WK(<X'$H-"F8^7#-Y2@%407Q_9;D-5!F52T=%704P;QZ]"/)@^G<60B1+9
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MU;%3E>,EHSJTG[B;/(QS![%.XRF8([07DN/1R.17)4,MTN611FN:[D=^' "
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M]J2+IEO$(55:8<QF:S%)=*\JO<NH%$4I?'G7+8A\F(5?D6S!M['>EMX]$(=
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MZG8AK#MRG4S/DO&24/RCJ"G"Y0Z5]8JCD_2L2](0U.D3KYM (\5PR+Q)MFQ
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M)H]T5F@5JI9UID3@PE?! ]6J2@@^D5"K^R'UEZ[6R=9':]D)NQMF'<:V*K7
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M9\!]LP]R@ORHE!U=G#>HMO/\ZWJ@;JK<2TF,R& [D_EU796O:$>JI#30O[;
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MSC@^@:OO80;J2-!G@\W$M$72D0P4_0.]>ZC+ZTS+C@DX&<EKZ2K1HJ)^&&*
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M0B]H8IDAQT*9IOJRXP0N'V5P-%L2AL5(HS=BM4MG2[X9PD*9L'%<:<;8D!M
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M  ITV2,_?6"/I,P)\U4A;"-T/N0.\@&1EU%:@@2(U*K>2]N$DC3]PGGV(GT
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M[$C9LU_._G>0<61:,HTQ&[AV%+/;T_Z%7;^LRE7P!'NCC0X>1TO D8:B":C
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MC8.Q)%[N@IXB*XH,*N(FT?KDJMLVO!%A.2!A#;HV:+$KSZ1PQTE]&%1WJP;
M871DX\C+]A3'RKBA?3@PY-VPEN7_3D*P_KGPHV$E!W.VNT;-CE"II!Y+O=BU
MPE= .\&C'9)D#'8GT[^D3F_!DX3)9$871SZG9#1ZEBM##Q_J!CGT#3P*^Z@5
MM?74[:(7GJ-W=,]\(!?;"S4C,F=&Q- K:9WZ@F0']PK"7DEC$@7QS(=GSX,#
M!-.<BQ0IFZ ->17S/9@-_NC!PR^AQ*D#2G&@:/?DM;AJ@' =4=&5^6_AV=+W
M5Y22!/+=<R)Z(#B?S"3!+0@%@:%]@\<NF\1]_AV\'P1_AWTXU9L$<7%8[>#@
M0W">4">Y"[9_,0.S]'):A#N+#.Z:*BW9*]R-A+;SJ"GF0NGJ)9N$00%H5E(J
M0+EV1B<SZ5HHARAQHCVC8HRZ1Z=OM4/9<5 8P=G5!HIIF;80+_(/.3<40"UG
M?(OK;!S]07S'0@C8LK#3OOEC80GM"O&)) V>1AFD2+'G9BOQ+U?$&V.2[0I.
MI=-SX1"QKG?TIESVG<''HI%\GOVS&[E?$:M7O^PF*6!IVPQL"6V!N^!*CM4N
M=J>44,2Z6^X,/P2'9K$;V5D$]F6W19-,LPGD<J7ZC57<^LFK402KF;8F&&\#
MZWMN46UDGE3H:N>>[GFRH50BRR:J^'@ZDK=E?"1@.V[0@$YR1Z;!V>-IWTB7
M?#.5PD3MH\C6V<>9%N.NM;PL<O$N&%/HR6GICNS*?A4=T"#!=XI'^T5D0#&)
MJ@F9+'FR8,"$8Q;$8X\>#@<=E,&FM&'0KO8-('.3G-OD@]*0!8?L#^2XD^5P
M\*S9+ULS%]*(017"JD6146N@Y[BK2ATS31?.\30Y0=JQ'&HXY81=1S!9EL/U
M3PAFM)7?BZE.M53%@>SP!J.W4HNB8%B-RK;B]UT*=@NC#+JXH#@O8?ZL OUA
M)$:X0IXDDP9^-PH@A="FC.DB3-1G8^CLG6DAV?*R([^:(DFI4,X\,%/I])Q4
M',<$,3;H$%ZJF?/9D[///C4WR_,OJG^0D"V X">,B5$.R300_F5L"$)3V>WF
MK6:%A]7E]XB<"*X=*(WL@+!9?E]"FMPE;B<'58NP)3(OC^6;I,B8@R &$T;N
MR\CJW51MOH$WLTA9S8G8#*$ROG#H^;A_#@1G5<&-G+1V'*RY8]UF1+/$)=3!
MN!LH8B=6_[Q&&  HO@@7?7 J6[F-WDIS*/)#5$_%9*\9,VQ(NPKD8"C<V"08
M>B:8"X_<?6BPU=N !AY_[*"!)R?0P/L&#<26R@=E3IZ]0QT(.GB)/Y"X%+_B
M'?\!N/4H/D/J0;@OV9M!9?F*8B!23_;/YR_9ST@;AEB&AE<W/+C3X)$\)9>G
MG"<_D?. )PG['86LW7: +\;<\N4^$P"95!H-XD5IB9NY71/?U)@4).@S81S6
M4G#!J9/EKWZJ#<:,&"\2F;8EA ,.YU6])4H;P\IP[)+TR_E7AR6''ZAL%=98
MBWXB(D182)&<FYVQ*W4)98<H4& ,%?0MBA)0ZGU5(6\V3+^7Z_?L776[UAD(
MW,.AZ0B^7PEP46D_^-$,B>[LS85EQ>@78[T16#E##.)7\-BFI"!1L 96[O4.
M5_A<N=6(5^L*)GL<NR$(TAA2K&Z5?);Z]>85\M?/O*3.NY&16>9$P7>3 VCN
M-G<]R22O/3+Y+M$=-8R!T$RQU6@24B(&RWVJB )/%>@Y-E5_(= I+B=LN0^Q
M\045WJI*J',S"\/GD0?,>I2 703T)!#5BJ(O*JEE<GS!/6P<T["[;-+>SB3H
MSMTCUSLJ&-E$,/);"89+>\/?DNC/FJ4%ZL3ZGC!+2'0RM>>+PEXH+)$1-PYY
ME*N:TO/D8S U#B+YP&SL?7/K':.W9^(7B$'C,57/]XM%:K68Z3!(9"PV&2=;
MAR[JE:5PB+#^7U3";(1[E4CGN\VL'US8_-"77*_"9:7UCKYCPX*A"Q*_(_K]
M%,FEP9J#;C1/#YC\_OA^Q.SAY^=??#HQ8Y-!,)O3LFJ:+07XVHO__<F#3_#S
ML"V7^O-;#_2Z7HV7]-$'OS=O TFA[1#,<OW7)V1(_\_8Z_.I$R\E2'1.P6+_
M1&SM<:4?DD<_^6+[FNA@VO%LJ'^J>%AQGN/JV!<?/:$OSB[=P=, -?.S/UN7
MF[K9__%-\Y\9UY>???ZE L-FQ_>NAQ33CD*;@ N)<SUC-<CE,?BXA$*&<D 4
M>^9:!/.[6H&X$Z RT VB5(05EPB0_UCR53(8Q5 ,@-%=87C%9*W"?WH(RQ\@
ML"+$[^=Z^$T?F?_JA+S_ _'KR_^JJZ3859J(H7#)Q<E+HRK35L\2)1=0SD+[
MGN.";9J9+VLA-9-ZXD!IKE8#B'I"Y-KZ4WXZ#:?3\&N.X*UM368DGH2:D0"5
M$L@&;2D+H\P4/MR!;4$D.I;("?1:?PX>PI/>/TGZAR7IFI0I*2MF%2>.39X@
MQO_N4'.M,97=B'ZGI,JG5)( /$K=+QZH#$ T&,Z[*3YA@ZJ66]T0^;T>'*]2
M3TP5742D:2.[7QCK$R:O*)V2'2%*XN\$T.@Z=L1B@=%W\D#DTM!].. @8]5@
M )8!1%9<!=)P?M+(;*/" /A;VOW4U@WO9H42.^$>VY#/F#2>?BL+NNVN46@B
M:TV[?611#[Q7MRV<8&N!:0+8A-N24_Y)S(65[)N(@P$\R)XVJ_CQX_/'CVV$
M8T<M.@Q N4J$AZG'E]+'(_9F">L35(4UY< N6=*5,%EE6'XP8P+!Q)^R1"\6
M],PHS^X]_L.3^];G(WK?=40<:^P3_62NRF;>MZ92*T+26*+1=T*&V+UU3.-T
M'9RN@P_K.E#' +I/3TM^52Y+YI61R-&Z!N^! *(.@UOO3K!/,ORQR_!,5X7(
MX%V\?1S92FEV0AE7M1?EA?0^US>XFJ;-HF9 >M)7A/$JG(9R/C#1AW/WB(=T
M3:>8)7]=\T66="IQ$^6$FB_*T4)-"5P5N'T)SN"@C:Y=@I662AL/'JP 56/-
M'$!1Z2"U[T=_>%4/Y_G+FS?C<-QL Z%"EJ/KCDPC^D52!P!:/#*X4,><0OBH
M@'%3.6,(X[]YD='R8%85W?)DWG0*;[Q0?\;G?_6QG93"+92"/BTYF1$/*E67
M'G058<@1D;?W>#!"!U"?[7BR(E8Y@N/](WUTVN4T*<$S[8D"OMW>-_=L]DK"
M"YO6VOBXT17P+II=RWQ,P3SOI,Z=$TA24CI!:D=4A6G']+'G'ZHY^VOEOP]>
M=!.\[<G'#F_[] 1O^R %=3X[_XSY*2+L6ML-QN85F2'X8ZEZHA<)\3O4'OW
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M1>F6'KI\;!BU 8$,RT(500,+E(F7PXLB#.3 =1RDO:B'L;IAL((*Q?P$5M/
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MO_PFE,+V?4<I['0HA4T7Z%LZ2(?*,G)F-$(77I82!0UPH !ZS$S;%30J!UM
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MTD4NUEUW@+L#[$;P,L[^R"=)]$>\P-4@7:))5,E1OJC3$D%];LI8)?2!-%Y
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M+6M.\,5TCE@98:Q88G/T?7E39]-%NGYV;*GH$GH9.P+C(+)L2\PJ7"S@D7
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M(6J!Z*UX@$2@TW_9Q8T_>@P+'S/O"-V=X:OS9L-*' 3.@V=:K;)0+-@.V@5
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MZP;D1D165;$7;&Q=EY5N&'QB9_9<D*.U+,8"37_%*;$&):T+M>5C!0J@:)3
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MI1HBO?Z@+*H_<,HR#ZY(!;&B_FF79A-*[4WTYD=C^!VNR%T:%H!?03B$Z["
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M\<;JJ:O$1[\=5["+ZH_9\)140.Q5G\.0?$2%E(5O+!#^A]?C8$XL M*%9>R
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M%N-2612]7.(=LWO!XILQB"]E]^QA+(>R99L(B9'1 G<V2-:(5O=W)GHY?!Q
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M3EUT3#MRIP7#:$<2Z8NYH\ ]ZKG:,1"?,%\IPD&XJ2*(&;8D%KZ:AU])\JN
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MQS>!B*+4+_1U\,Q:X>*4! \HG@0*7&65RT;7F>HRRV(EH<92ZGCT7^IT6M"
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MON9D! @JAVU=+:S3ZVVD)&$"- 5>8GVF]H:O%P6[N*).^N1F?X+_*^[8C!2
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M9%KFQ>6/FJ"9.)+5?LIJFD6KZ9VOF8U>4R:1JXB;(C7FF4E]JI;HB=T5E\$
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MZQOM0?!2E6 NO9;^'+XW>UL8Q(QQRLF7:,A#7E34RA-"DWL4Q.[SQ]),:SM
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M)AI>Q9-/SLK//_L2%>D,>1>#8*'#QL<1N(XU>,&7IY]\$H_E.\]B?((!]S5
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M_$86156><O$N2#.ONH+MWH]+!-:+)ZP%C-KLLE??Y;J^L8@G+"*')4;>29@
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M"B_,B=D26B+N4PH:'Y#=K^<#689GEU&I(W)=8_ASA0H:)RE+^P 6+1P3)DK
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M)F4<ZV!%?Z_*OWA"\"H;(X;_@<"8(%U(2!R7HTMH3%2\$K.J3),!0(OK5".
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M^0',5,)^1G-2P"6TFC*(!D4:N>(R2Z^B,3>.D#"-=AF,2X(D*D@-@RU/QZO
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MTWH5#NT!R7WGB:L<5EPAK"0%U)1J[]: !O:CO%X4?W&2$,?N+R=XN,#X,&]
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MO#H2Q;0W965TKZ+>7DFN9Y[61HCUDK%CJF<I&/82=_/TS#<1JACF@<[62)4
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M<FTZ4Q1VK]K)1TR_RP-.(48MQ/?'[]3G<$J(!KA;?:6A2IZ!J,P:G$>XT'0
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M0W_9I3?K7RDW2W\P+PZ=_3K#>+_[&?OX(P:E4@;QN"I;$@U;.5P(9A6^\[$
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MT3G>>4:']MG?/<B[V\^G@WR-@_S\SA[DG>>??P[VD08(?A_V1B2QPUN#7?-
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M1<A!<IJE<5D8"_1L9W6V@'>9X;KAQE6Z!@G]W<!;.Z&W:5,C">*$MI*8F C
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M<VI$(,3G&NNK_)&5P7:5K%YQV8N4H%=DS.%%+\YCHBIV>PR&V-O9R,\3PK/
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M:X^WI_K:W1=IEH//YM4G<T5(TE_W7^\?[KV)#]Z^>O?'?OQA[W_'K]Z]/3K
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MQ9UY]P&?$9?Z9N^O(UH'W.#H +\$JWS[VSZ^+;QRI!]Z4'2V1Z/@[J@W*;:
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MEV>T 574V'OP03!\E[69HI%ZO.O><.LI:GF88X-Z/A?O%REQ?E% 6):\F7C
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M\+N/.'*&'\QP-KPKMO<]-B.8O3$-ZN/LX2Y>V1@$S9;Q+IX%89586J"AR@M
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MKUA4 $,DR,;T)AE$^"A?-WY13"*RYX$;&,.KB=@F-HJ603_1!S.A"XP#7&V
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M6/P7D"&N=CQMQ(+QRU7)K'80.B=7K#F'_"$0^$,Q0GAS_-A=/N@!"[GUIV=
MIPE.3/ SZH*R@0+%L:$Y(B_ <+NAYQ#EGY='L8%O'B+PF![&DU]1PO7N!.<5
M:(8H<O/7N6Z>+OTGU:G^K K&21Y>"B4%&R*S3(B(EGR!,M_@)1Z/ [6Z:$K%
MS)7F\,%!U.@^BQ+("<P'\.OHHU *;#BCGXZSXN8@@_1ZL+94YY#YU6*.L/%+
MGF8$1D#\G2_"*WO&)3+L9NCM)=J$O2H'=3VAI&+TF[R: 8J<7MB4902Q@2YP
ME$[DV$"4FA>IB.>P'!2T.0:BX"RKR<B*,6_#L7)+DVH=WIBV!L$*<[QOWE:
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M#P2DG\AY2TMI/B[BFE82<DV[]$(C"N]?@]QQ+;W33-YIJ@DQSE^O([)'U?N
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MW\<$G4%I\$;-%?'FK;DZMR)(C'5E'+!5@#ZRUPKPS:U?40A:9C:6&'%K X+
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M*_L0GWY)F5CTGDVVLI$[/4/HV4JLGHU9_OZLE]:]EQKJD?8>6_^<V<OP7GT
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MMA]NV_W;0>ZNUX_6$<O*QVS"A"8+@%_K7"N/W_LW7]L#0+R_4Y:0[I7/?^2
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M+D9(@2.!CATQ$$\,+T8 K\(GW(A )=?<SV ?,<%MOQ:XZR&\1 \-1% LGE@
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M?(FG'7'%HV<=HN$R!>69'O=,=SK4(^8"%[:I.\]DD@NP2$"KQ7&*5 NI9"%
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MN:W_H-]6+%L9!R0V*7E(=I#CNNFBU>+%3Q=5Y731'1@0_]"H_/Z6U_Y5K#>
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MW=RVQF2RL%DR60.'U6%F37?^=%8*A9#B.)':(#"%H#@#K_A+8%W+S#1.F!4
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MO< D(X_"4Y,PAI#3F""YF&JAET;(]H6"XJ[%ONN%[_E%%_P7AQ!DONG"I1J
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M:0KE=&U.6DZ7E2R9,I:4TV4E2Z:,)=_6=%G)DAE@R7./(TTY=25+)L^2YQY
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M\Q;DA=1H;RWD12%G.QS+)IV>;,IUF6HX\A\%8<;IF%GPS !SN,B1CX1IWB@
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M9)]GX).2EX8YN MZ<$:0Y2GR P=V"<X$_91 7#8)T!"',_2?&B#ME966?Y!
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MP5T2,?4\\;%<EUUS,WH62"LPA7%/X$'C2.(^)(:*$%P>;(2[C*3*0,U2'%@
M/Q6!(5%BA#51N$A">(;:P&7DS PMUPH<7!UJ(RW?Z KK2<@_A<[H=_6'0&!H
MC&M[89BASW138A1CE2^)2UJG3OG;+#4K0[<PFQLJ&HH$N<E?Q1D@M<O=2F9
MRQQ9X<0<^EX<<L-?QO*=HAM)BP2"LI +3IB.])M*%E#C,Q I"K8I,[;X0Y
M"7?P05I^AT'&L-@)B(&3P&'L,E.A%48)-D%- -,(F"-7 D-K8<"N.*30%Z%I
MS,Z%"6.4EZEE5YC5;88>*(H[+:93VHORN#D.O_AA=,J'A8[8*[\DBV(OBQVT
M6@A,,/&%!K[LBQ!,B9F"*0E)'1J9RX$Y<,(X((3TB+2R(VNA1JX5A@G>QH:9
M81&"_G/Y*L;-J"\H!Y(^:Y;Z+&TSZV$77'3I\K: W3EF8L\4L\'$ D[$2YX0
MN+<1U<0\@3.B98>9!X?G7R\M"/8% 8EA957 N8_/!+ZN+]K UXXW3W2HP%>Z
MJR\LS+7^-!0-<&TZ4[6TA&2HL00%2-5&%Q95"=W?/1B#*YT?*QUT!Q0H30BM
MF5^T7I)XP6D?W1'CI,:EU5E 8:_P7&;(O8?(T\17,=[D>C-O%]T5BQT6(M]3
M(-TLV28(N!]'8]=_YB:HH1\'Z*")Z="WB7@8AN?Y4]";B3NIN#D3RG?0_NSV
M,HHU=:D40>:B)Z3Y/@M>D4+")L\X,_^UN"KL<<-,K("0Y50/,98E10P?9E\\
M$,YT& <A(I2IJ.F[!7>7,&//9CH]W2J!:\H:11U9=R5_2 9J=I-HB4,!+V<V
M?"39@FO2)  1[J"1^X0G)XABLI-&H$LMQ^,ZS'PXOD2X)-3.3)*?*6+SA,1F
MS[/O.M!-FP\.KDRS% V];M)/=6B6C[X+QXNJ:@,^(=%\)D*YIW)X1M*&;PW!
M]S$'U-?O1-%(X2:IJ*DD_Q?2ON"[.-,&UN"7L)+U%/3J=R[J9U[08N$\=2EN
M#.L5N!*G&*)UG=^Q() Z9!)Q:_9Z-':^'A7*6(U_G]O2V'1;'EH02_.S?B%4
M9B4^UM*C=?_JJGO=^E<[NCGQH?PKWM$7YENM/@%%_:IU9ZANN(!P%QI2$'P^
MM7] E=U__/I@]BYU)XMGH+E,">V(_++B-3#3[E>R8A9[#T2!GW#S3T4T\6WS
M#;ISH--1F>OF-84E$=C]) S5R[5!=WI9HE/4<%XG?'6)CI4,2Q&JHY'@,EP?
MA0@VV1#CL=Q@ NK_PX(5"^9FKV/VN[T;\K M)*5!&_RH#>C5.U+4>%XG%76K
M [FW3!=D)>ZW(5.UR+^2&'[J0Q/S\B%7;\B6,HH F[[B,^$(-F_FJN5,,2_Z
MZ?PRF5A'XPFF0SPOWT<$K60K5&<2>ATU'EN7<PS:<HZ\<HY^6\[1DEFWE1MM
MY49;N='TRHWF2T^S(43Q(2%$TM\'.8-/4,YJDK%#% +U]B\$HE8V57D?1<%]
MZ_R7IA_'(X#T'13[GO'LV(,#?RN'>.7H$7VKI;@HCF_=2:H#\/4QC:%DH.5J
M_QPFY^0=[&0^2K(R84+DY4^GZ.)0%,W60,[LPEOLH9_ZXU/TRF5'*DIS\!<2
MW#=Q,+HQ@<EX=,;SQ,=,/F+QG=",9^CG]_H)AAZ>(J>1-O@D]Q^3^R[W3%:M
M;F%0B' @RKHS\R,3B85"OE.H)W66\DPR:HD(AV3R<N@)\SH*O)<F\I?H9HDK
M,HP"BY;"=3R!/75Q5$^R"H ?2#-] XMN?O)A(6_>GIGWGN1%EK%-8VG55@QX
M,<R*C'(CR?YG.X)[)LH0*J/[): AU :$(5'?HSE2;(UX57WOE#XUM$_?$&3>
M0@9[SY*,?_C0J>6 STVHT 3Z#QL=C<[>FGJ^V\*&BH]N&NDY$FK*U4>Y* ?E
M.G52AS+XO.(8=U(Q,/3:#";+(<1-[%'%R,)AL,%*D51WDK$110!C[=R@VIG.
MT$Z)%,R!?M[A7G>6_([,=P;"LN$VTLC).P:<J91$,@WY+U("$ZL+#@A$?N@'
M <,O F(_OTN*;U;,.F'>9$9R_40D2V&D[TX#T-F9<KZAL>T2RY+THEVMUYV5
MPTNZ?DT96H=T'9&%/*J<=A=_Q"EQZ8)DF#,W#I>N"!>%>2X!;QY>#:HP+/<2
M!>5I<-=8%TY4@,50W-T3!!N[.-H,'LNY7#-,^G@!*#$EXG1F[D?5;(L9/-:A
MNK'D'@JQ^HWYSQ#( $\=QRZ<_[%(R+?3J^J@0+.*A;IH$^IUQZ)N\#[<W3*=
M CK6<@*9V#06Q5L*"F97A-QX2;+G>+8D)"6+27N,WBDVF[?%+V+OV$$F;7NO
MCV 9]_HR4ZN%.Q*OD[O6$S[NXC;:6^YL$"I,%YLO+&S<2N4EUKJM.1B]_?$J
M]31COB/_AJF<Z1AJGEG"%#D$"U0C?\2$])-6!BR;Y2#W*$J!?FU21MN1IH45
M^AZ\(\&#LP&<],4(4VE)$(7BNPA&3LBD[K:Q:@S:J+-B5W0 >;_$(2 L4A_&
M"]7C)<"K2L17K1'7>[9I"<NJB@$DD$&Z5XJ<P%![EHW/+$D:6@_97]*)R/_U
MLI@LAHN672C-F^1N 3*0%(@GE"C]P,E.5,E'RK4T9>&%&HP>=DIGS^-G:X:M
M9>Y=P-]8[A'$'.Y!P(&C#+PVQWKB]C;J)-GQB$,N?XK [R1<]N,XH%X&] 4V
MJ[(4"<92L.B%GJC]46>]EB"G!.MD<'C32.][\,K,H/UQ>KUZ6'"H_8>[M%VF
M[<-+T A@E4<&".CDV6+4'^,+Z5>I\H*CO*IJ3D;]-ET6YHK+(D'X\I7"L,"B
MU\52!QD:+RIE[/N4O43R1L+A?LO&U9J*Q"<VEF^)QL;^]I7"$JN#=I!"%C[:
M*F-9^E9FK"SS$8U<E96Q H<$)LEL8#4I4X^;6$62WMJ);;'9.C#2#%>.Z+ 9
MHH86QL.0 (*1NR3]*UZU)(J+_ M2]HW4BH+5ET;] <[%BMC3F0:B>.G(VG+8
MT\];N&T>W';0PFU;]O06@]MB<%L,;C,PN-O8I>OQDWM#'GO;D9^'LV T7V\3
MWX%58U./1O_^[J&G#VYY3/R3;_"^GUU_]/NFXF5Z_?K"Y7U>KQ<X7U\.&E[@
M7*26N<S#]'2HLN5D2]%^QRQJ+TFBIMM+&=2T$E+ML$REUEKSO$V@I*X#)8/U
M]9W?6OJO>N9',0RHDK7?[??8J851_VPZ81A3,W3#6BT]7Y@<PU+NZ\>$3.8A
M(9-9+*C&-R1+I,JJ54OK3.M426RA7FWS0@I#P:]@+N1)\F/@+TN5O$B.1;1:
MUJJ'T4QZES\A 48  U_SI#/SLY?$ !!R*'-;8=(Q-ID6AOV)/@-<;_04B ^$
M& \=W=.G],/JV2CH)/4(E\S&Z4^6Q^RDK(KP4\693^WDJ-<X^MD4?< 6AX$[
MQ[0 [6=C^\H=Y*0/ZCWI]=6YI]> (^O:1W0[<U-NY.@V5)IW*.#A'K6A\[*U
M[OU!8Z6ESEVKKY)=;I2N-ZA%LZ9ML/$U0L,)(:J"UW8RK\5VI E\-4?)=8AC
MSG9L"JI;_$12>!PWG!*=D0QWJE3N3+L&#)D?=D#]ARJ&M_AB+'W'\ _! O,8
MR)HD8_N8]AE1NUX6+^EM?//3CSY(.J;PSK,_!($?A+L8]:6\.&/.7S>]577=
MYOQS8\SYZ\0@RS'@.Z;<:_RV]GFRW607\(8?PMCG?YZEY]'QD$[C1_.TUSWK
M9:.=NY@(Y1[!-6Y V6>]U NFF*UO+MGZUQVC5-':Y 8DI6)4NA$%/N?@+,.#
M&6<M:/D@[1)33'9AY?C?JNW:<F5IC45;]NFHA<XQ9\<)\:2\'RM40COU/1&A
MQ'."DPR2/'O#3-KLA/'P/V3S^+K)8\:>1"]&<R5<9M:F'F'/F[$C?5>POF"
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MM@6)DN#?AX',=?F,?Y*L8,RXI,9N\NT6*?[;+%)+[J4U%=J9P"F!LG^RP):
M)ZP@'3]HP&U]G>T&=EF]#ZD53L 7Q?_Y )L#*[S@:6JUJ3U0MHWW,FN-]9TW
M(=;W[N[AOYM1,+J]4$K"*2F0*^7Q&TXBKURZUQM4*)(R.3;R7=>:A;#FZM^V
MDE9.&*4"J]LEFJ#0UCX3*PK^QK5_,N5DTI03YN7R[1H8&>[^?YU<)O/<E-J3
MTI1]95[.2-%.\GL'O<[BT'/'F?/XS- 3$6W*RO7+7SGLK5'.8AW);/OUB@8<
M41CL8^"#<X7'U ]^-(/'X9M^][S3'UQW^A<7;U??%)<_9.?ABC'RI8'J(=_,
M 9?.)G9(#"W8@?4,YMTIF@R_/;Q?G*?2!S\4<3MZN2_^RXIGWBQ\FTI/DG;@
M'P.V9;+J]NKJ!*E<P?9RP_\Z.1V<X(S $$.U&?WHQ=-3VX].Y3>6+81\+0P2
M SL 7X3'Q9[#KXI#6]/'5]<7H(][G>O+2P6M4 .\7;ED>8N1+_M-6^7K@ZUR
M[^1VT#D_'Y2WRL7/W/*)6GSR2I54X'!]NG\HI$36BL!FG594Y+9[4B&IN3F8
MU/1!2?>Z&V5FA=(NNF0O:[NNNP?;K@&HTD&OFNVJYHI=V)5U>UYT1W/V:_,7
M\Q[8H,'LHVL7=_M\5O@@+GZUT#&$'YFVC\'L0M?I5L\H<O[.#W;\SD%;=KI7
MFRV9G'7>75L>Y29='&R3+M 0NK@ZKV*3%K$EBV#A?/#P:V8GO6KQR7GXY,L6
MG]SBDUM\<HECVH::NYK,B=;Z<46ZI-]K/BBOUG3)11/2)?>?_@E'Y?/7_ZD^
M9U)R>D1)7;"*/+;7[U<H<6TVI,V&M-F0%YL-N<Z-$/^=&E/A'8^P"2>J,2*_
M.* :@@6,%-%N]GOO&\^[F#-Z>7)[56)(OK'+O*>[O^\R7YW<]FZNCRSU\='Q
MG'"B>KV][)CY?L=0K13IGF(2<7UR>WEYTR8VZCO$.VS2S<GM^55%V:<VG=&F
M,XXB4KZ?:M3NS$)G[A)\T*OS?IO!J%@;;KTO/;RP-ILPM24MZJB8+27L!H:B
M+>X\^S/6%GU-VH.OC,%=W;0Q.#T&=]F$&-QG#*XK8H('\^N'=Q_N_WGW\R\?
MCBPF%P>A2!HZAIHTK@8L]Z\K%,@V1->&Z-H0W:L+T<&[J-F&:<71!%GO';$4
M8&A8!&D_,Y@P!G>V+>QOUG=-[1:SO?I@>VTVB5][E&Z_-1Z KW_1S C=R2W9
MCEC0J>94L4]=X4E8-(.+[0XBV[J; ]4'"D%4*-2[+=<%"/-F%. A E1;1Z&)
M8\A):;E?=HBSE'207+(/<L6*B<PEG+"KS0JP#4B7G57::;>NX( ?/##=AITK
M"SOOHE+;P/36%ZL\@EO?K]<GMQ<[G+\V2%WC'MWL5HO4](!UJ>#13'O[?^M1
M:XT5\IX(UHAZY]Z["T-_1$3Y6OQZ4X_Z_,#X5J_0(Y*#B[;C?"9$?M6$$#G"
M5!^^(:H;N7CO'AX^O[LGNMYF4'T<K;@TA!3LH$W('T#=(SG4Y\"93F-/F#\[
MOOE+9)^]'"ZP-84!GSWS'SCI?K]C]KN]RVR+$@H-"]O@CANRD(' C]BJPGH,
M!)-^O<$?(1EEO_O3-_7QG?J8/NC]])99*1UN]HP=2WW7G9O^,Q+XA:IQRKRS
MO!/F&_EL]8EZ(C&4_1\+KGWS%\?[77Y9&\S/\1PS'_SM#K-S+31TXI;2(1Q6
M&IKJ[D<XSV0DDKN3'J=U,D%>,6S>0DU+Q!@,$$DDIM8 EXV)FV'9T\?ABV33
M5$FZ=0>7Y>F[]P.F,0.S_'%^A%R=ZP5-9:+,WH"$[;I#+1]M[A.-W;- 6FR]
M>=:R+)G/DJZ26F!%ST)2V<VL@/NM$;-DV@T7OTYR*EDEDRT@'MRAD%L#'RO^
M3=X7$'D2!=<5HRBF)C)(U!K-$UF\_Y+(-36^Y49!W&EHA.ZVK>VEE/(%T0.A
M_P^VHL$&0_+M6MOLI&V-P;-Y1F8Y6$T8-_+*346$U)V@N9)U'?1P7?N#,_,N
MZ:Y[-T,23YC ^X05->\=W!@/GSL7DM\3:4I=@?.2;=(,7BM%\X>/NO^RU>3C
M$-X39E^CS@KHF;:=F7YG%[V>7PS9_3M?!+$K0$A.S7_X</K,?X*H@3W/>H"=
MK%H:[J(>.X2&_-6:F[T+.L3=]3>QH YC> IU!L<WD?](/,/\8ZFI5JYE>C&F
M#;<M<*K'U*#W2:R\\ VZR=]9,R<"S?*%GI^YJ#,?I:\!0;D/ TNX3M)%7)$A
M1PAE2HB$O]T]?.![]@,<&[]CSN(@C"V^&5@=RE<8_/80"8OA,_JZN9[#I*<'
M#KJ%X@:,<_F,[8/!1'G 90D?,/&MP@5=+5Q JQ9F(@97W9/;B\[-1;]SGH/,
M-GWY8%YPD*!/]P\;)M'7)]'?>1)?K(!RF[D3<=SPBPCRIM,[N>V>=9<C('@/
M2^I688TF'930]%@OF6=?XF TH=;1Z9=X7%)FR,!3,J6^TI$?JE9N(*GN/"M=
MH[0U'YZ6Q+BD\63$]@U<3B%VT*/N=7"3@4FZ?N4'VZ]\&J3X F8$=B#%KA:?
MX5J$U75F]]+FO/>2_H'S9$-.^]J.P#$0V9WHYZ;C?H#E$-ZC]4C\LHLM_6P!
M*X8= K&7G@?6 ;/P"EOVP VY$V#2'9=9>A^%1X$>7$VB.#?';CRU_A2>XV8U
M"+)]P[^AV00R9Q%;/RBO>"0,9LNWA6S 2RIL,I^!18!/=H68:>/HI/NW]#Q)
M3FZ.8V^4L.?_ 5^1'0FIBS<85#-X$A&8D\J:"/SOD8&, [.)!8M@19,YT^RN
M%D9L&PO_@SK8KEI4^)#"L4-<#NS?YS&/X1Z[$]J(]8PC7'Y<:OI$BG-1>1F<
MW Z64W$_*(..FB"RQ>>G+Y(7P4B>'/U0GQGW-&MJ]R"9F-'+\L<=J8RU1RHM
MG3V"Z]?P_ #:^OSDMG=UV<DKT-A%5U\<5%=?P&3.NCDS6=35N(N1$\5$(UW1
M[5.=8%_"-/,%V]A&L*6](5TN<%9HA6QL(/V7+0Y[P7P$+PH2T_]*A-S9_5V7
M@[BZPH.\? -W4MT-FHJO&MUC(W9QR?Z=<.'KO3(L5'=C='OY*9^LT+;^D*ZF
M;J">F1]]U_6?58-=S1+M+)SPB7"W4YR7S9.O:Y"OY>7^(:,,51-;%C9CK;#Q
MI:,M&BQ!R!=B!8*66B!WHS]BAVGYI>O^#M_[T0\TS^"K&/F/G@."],!MN&#+
M/@;^5/OQY_$==0G(-._Z//XE[1)P[_V,C/TB#$&VAK(-23'AO@%S.<>ZI! (
M1=[D(LJ^.!3^2:ZP).%#S=E5QN=EA=/NLG->Z>)UC$S7I#36DCI+U+?ZW?UI
MK]>5%E@:NNG@UX9H9:6AVN%<*4F.M:F..K*Q4QI<HK[0LOG13!I7J0]Y9MZG
MP;^LLRMU]9*A8(%"#@)K(>"<_<Z_^!M); [;(:AW;SA7N] $2ZTCWP V?>;&
M+B3LU^ ;#G(R_MB;?,'86-#59VBS)FYQN@_J6WD+PRN=]!&B5A'8.&?A5=BA
M0J YK=I686H5=1C_(#N.M)?5XG ]=3.0_K/A]O ]>;?B!V3VT].2 5' ED*N
M[ERB4DGF,G),MN3$X@@N0?B&FG#++AB9'YAV#,^#MXQBO-<6 ANVX*8:&VZE
MZUU-T??P\@_RW209*K#]'EX,FG>%U&PP4Z_!"[_I7%Q=;312$\.&+ATC5S!H
MQWD7*#1*'=>>A8N>(:S") 2=AD%V[%""C44T4Z"'JB!R7/UO_9?7M'QK L#K
ME@ PCP#PJB4 W*)6M"7[:\G^VF;D+Q_*=(BNX2].EMJ<:9X36'NO\.V!I$L-
MQ$M!C-9!K?K9,S]AEU0$8/1O]-PM7068YQ1!:&02810*>Z)PI!ZN(+L:W7']
ME^1&9T)G&]S873IJL)N2KBW&>AZT011S9/O@R"[[L1SH4IZ8[7 +60+L</M8
MODB=,!NY,;3E8OQ)0!9?1X8B52==5ZCNMM3-5C:?]!ZS(06*0+HBI.:0WGH_
M[Z:[:_1Q9:PQ3..2!>.-U]CO8K<\#2Y/NGH*#+2$$NHL] !=Y=1GXVGIKL"&
M_26CR$Y#,3IUOI].'-L6<$3X?T^QZ?=I#\E8/<>5*JA%^AP/.G=TR/OM5R?R
M1R#3_^]PF*## ($"T&6]+H=2UD*!/OH4AF4MF6IP'3*)F>_W 2@"%U3=@^."
M%J!1^AR\Q35^1VM\EP9G%R.+.5^B81E)T)9>K>XT)Z(^PE/D@MF<TKCI[7%G
MT:O2B1>[JLY/;J]R<J(2<2 !H[Z<E(FD$ARPA"&;T;-OSH6%2(H,?G73)/L[
M3_(N><>V\\3D;Z>;.U,-?<HHCXDCN-L[&BL*D#H+Q*G6:!U.,;S?]T#<4V1M
M/$.CS5LM)QA+C&>$AMYP]69R6^?;I,H5F&;[F_;RY/8B%\WT V4\Z*DXO71J
M2\#TY".5=S@STF_#13GV1[&&J+'!MD69XDBVA..H+.W,C^#?\/C80?P8TN*-
M$&\CSSBA> C?<AI- @$&E,= .I5X88,K>;^1:@).G<&"P\Z&)@PI G45S%-\
M"\-_.BK/0HAJ'"G85%'(A\,!;3-E:YSV#RU9)^3W)II+VAA2<\G<@:'EABB3
M-Q511QEWB7JC<#[G\5B):/9'87VR2_WF7OKD*E^?H,@G&['*$EO0[PA(,]9/
M[V+G4[*_77H-1G[O['R9KB^Q37,-4C.YR<NR_;;I>E'7O?U1#(,83U3O2AG9
MJ1Z0&A9N;G#QQDX %TNB3C, 5UV/FIE;&03(0MAC[$9J3?G94R&X^SOZ4<E3
MLX)%)0_R1K,\H_C%=7F BPOY<?,.5$8/LSX:@1+D0AP9?5VCM<G%7C_;J_JO
MH)ONZD,5;8 SWUP?8+S@S)WWSFZ6B:-^>,FG.XWS7&PXW> )PUUW),=[]X#1
MSL?[!FG'#G*\P5\_P'D9K#PO&\]WK]L[P(#!/[KHG^7T;_CA#(Y!A"YE<L>3
M]S"$LY&11T*_:6(N?86Q=#H+BV>O6X[?!,-UW>(">K%20),'26R4+5)$%5N_
M4CV<ZW5X-@8ZZ=\=PI/[041_KV[RVI2_@$U=;-J7FZ=M8 D?E>ZAJ?YB]?W[
M.%#"C<Z^*3RL3])M=R.-HBH='(#>#_![XH\8"Q' \0EA3*26EK&)FHLH*RT*
M^C>][NY@XP\TLE]H8!CFWU9S7^6WS3;?J).]8K7(TS%.-UU&N["ZE#,Q!/AV
MEXNSWKXLX.C.K"T(4B<TTZ]P'<-?<&$S<-^]25NV>4-VZ\!9(# U1?J'PO6?
MS3">PLHX?XHP27,8F33'BJ/XXS+ESB'TV\:4Z([;<11LVUOV)?G9<JD<S8K,
M?U@>N]^L;G;C:5NBKLICIM+P:.OS7N#:G<H\=VU]1!1/[C4LN)82(!LD&Z"K
M@+5W+1WPS0[4O;N''S2P -(?%+D';KK=_%!>#72]E9*=?EBV2%:HP*,GUGQ3
MD3CM9V'<@".7:V'L3*WY]B6R:E;4O$J[)):LT@JOB4I[CB'0Q7*Y#$N: 6"W
M)9;!MPDLSN.$F0[!00G$1'BA\R3NO9$_+:@-^R>W%S>;J0Y?$^]KO0H]<X./
MDXI++5V+%NU".N&0I.3=$J[KNW1V8.KBW'Y54RLFMH/\]$%])EA[+V][+^\N
M-_O>R^?Y(8WZ[N72*)G7W'(;6]E40 *\A>P<CJVYIHOT MR*Z]HX@_7@0=Y?
M2BU)V2:V4?>;MRS9NVE+]O)*]J[;DKT&27U;TE?%R'8HZ3N\*)75232YZSZ/
M/X!KD5I0]QY;5YA-#&(.I0FD 47FD+L=;LL5Q.L7Y_V6>%VO5KQN7K5B>DKO
M'AX^J!-:$Q]G4TH]-@I/D=+$G.]TSXATM"I6]1KE1D=*21SD L0UJ178E.;>
M!\>;Q!(HJ5[,2$<2L<[%"F"2#DJ>(27AR/3'8T$P 2SO<X6%*'G;_!49#!U/
MF*#Q-$Y4]7G"38,(F83B9,-*7&S//9)J>K@?8#.RC%@_Q]$G/_J(Q#X9>,AZ
MTI&;+N;_!]W.51Z/*>CW*0P]!?TF<^Y(6!MS3F9+\R03[#:BL T*2B?[VA8(
M==.]/KF].1ODX*"HXG")%E'-]TP3!P=1?;-P/IH(6Z#4S"9(63\2,2D/<^CX
MR+B4D)9N4RS@P2>N_G!8@X#D":]?N/SQ'<1)#][&$]*>VP*615A<.\BE0R+
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M<R12/R 4DK@[^XK+EU7R1IZ=JXJ">FL50O3LLT+X#Y&-%5 +:"*1:H#EQ2S
M3OIA4)]^Z/?!=\EI-Y#5#[F]<@U_-(IG& S?:G([=W#:87+(FMC?5_EUE%.Z
M6?OI'0G(V47),%@RJ*4JW!A+IT_=)&D)/!(YR9L(W>6R->ONU<+;:=9S1%T7
MTJR&.I17&:>*IHK3Y)5";C'23Q29&3 =WL799M[_F@ELJP(E;85=O.ZVV,4\
M[.)-BUULJGRW@,57T8.@K%#$%]F#_8MK>=&=9R,RD9 0*Z(3EYC";:,3:72B
MUVU">.++U\]?/GS]]C_FW:?WYH?_^]O]%SP^'?/3AV_5QRR6>19*$<WW(K(<
M5]CW'IM68/?<#?TXVEID>Q6*;)D<#2L+-3-2\BRP? =_X]HK*^#R:HY@9"@%
M_W722R>ZN>8LYYW+U@8VS\-"']G.CG)5(?>UTWR"@L5?2V]<5?14TG+TRU^-
MK_B%4W]\^K=A\-=;PGA1S[ZP["78;[YY0]_U/85+\^J2\@JV%>4X1F_W]4CR
M+]:095@H+?MZYOZ90A<\_7$<@(L.]Q+_)VBX5[LL%+] A#&O  =X7L_TOV%(
MLISI;J\RURP/FX7X\8\F]?$=H<(*HQ_7$A?L="L4X9%H'USB@ZLM>U>=3[J*
M=PGYZ-$ /KV9:20+6"7]HWFS4!.?I0=;JH@O@?QJB11F/>\5OV;_?VZ(_^['
M-+/2AWEG!<$<5ILK;.XB/,&?QU\%(8-LMK*+!8XO<INK[TRY=<@M+<X,UR]C
M_U=PRQW%4E4BZ[MT\:Y5UB]/;G/JB8YR S=LQ7YHS!JV KMV+*._7MY6-%[_
M(PZOOUR=LO-.U,#<5-3\P&@<Y36/GKZI^,TV6,EY6IA#:>\0TK&MV7F[9ENO
MV46[9D74_]5^^E]U40B)TN/;Q/(DQ<?/<8@EN.$[?SIT/.X=MO*R*'81$'AQ
MLW74;N^>%8,'V=U!M\+=K8&5<^-=WUC*TG8P[6"JH[G=3$ZYE<6\#XGE<6MR
M[)+=;$]MT"L4J7MU]W-AD_6R-5F+G81=,,NUGH1^H3A>NZNZ([(+]T.MFXKU
M SNP]+[J7=V/?KF&3<5J_?YRA7?K=KPJ>[8=S%$,9A^WHQ#29/E$%W5,[D:C
M>"H)Z&PQ"T"E45AD/6JEW=-V,,<QF";<9<MH'1[A@O]?T:I5@*-1!#4KK!Q-
MI[S75$HQP^8"7) ]>]Q4MY2%7>*K'3LD'DH*=D&85"D%ETV6@O(1(E4NY15V
M.SO*M6R::KH^N;W<['(U- *M3_=E^^Y7^P6<]87:,S=X4T2+O;JX2^%+]+J-
M*Q>+*^^7+2]/X,^[)[>;$6_MYI6'8REQ[WHGM^?+E,GMYE6&4BEQ[["C;44'
MKPD.=&.C"^U@VL&T&)3&Z^G=,"@5NI+G W EV[MV9\_@IO4,JD.<5"GWYV"H
MM')?.;ZDRBW$NM9NJ[PJAY-4N8?8$[!7D;/7.@S'8HFV@SF*P93I,)SOD#"@
MGH9A5,AO*$ ;<[Z+'H<?F;8?#UVQD2=F:\V^Q;,/"GC_>^"'819!2*U.M8TJ
MIOVO=C'"SG/Y=(HO_2N1C*(N#-:-%71AVI4OX4Q6!+TO[4Q>G]SV-],VM*)1
MNFA4A=\O33)N3FZO6G5] ,FHJ :@+,&XH,KCNG1&Z]4=B[O0#N8H!K,WG<_N
M)(']W99CB;UI>RNLZ655%SVX;&O&2A9:UL)N1:\FX'$)PM#TPLD+["I5-W*V
MA'5M.EO@Q: 015W#UG70].+MBW,,ZB\W :SJ6MK%SML+O_ E#D83;-SZLG-%
MB'O=B_QH!*(5,O]19;1'%Q<GMYM%[=7E  M?T_T6P%#H+ SV) *KY2Q<MF=A
MG[/0,FL6.@O[F<OUG(2KD]OM U(EHPK:Z%([F%<_F :;\6M@R/V7K<&;W[3B
MXKJEPMO+ECEO;9GJ" =J/0DW+17>]KO:].X8E]U"H<=V5X^HT<9EKUBCC=;M
M.&)[MAW,40RF6K>CI<)KYJZW@SF*P1P"<<+OWPMV4GA-*L">5%B#==D'LZ6Q
MM%R%'=[5[8H.-?3R02=52L&@R5)0/LZDRJ4\/[GM=X]R+7?"EE2YE!?(+OYR
MD22OAPMO7S!)>1Q%EY<M-]@^%VW;9*46Q$B) G_5"OS6F]<4ZL[+ZY/;P6;L
M;[M[I0%42MR[FY/;\X-W9&SCP>U@7OU@&NP#M#"4QKB;5]V6)WL?UV!ULXE7
MMV9'U>7BJM?*?2T0DRKWL%^HO4:[B<WMZW$U*-37H_47CM@0;0=S%(.IUU\H
MF0QOR6UH.72J@[R7Q:)S=;Y+R5++KE0N&5[Q3C_MRI=P)BL"WY=V)K$'Y.9,
M?BL:%8A&10C^TD0#F:NW=[=:T=A;-)I^CR.I[?:,YON1X?TULF!Y;]5;/\53
M$3BC6\/XVTR7'/ 5N[ 9WYRI",U/XMG\ZD\MK\-_Z)@/\*/Q3^;4"AX=>!U^
MM9N^;U;&X_B?9U<7CI>=VW_B,'+&\RPDQA3?9\(+X>FPQV8T$>9<6$%H"+"2
M[64.:#9^3<NS\5]ZID6["-^,?/,O-?7/^L C_O_LO6USXDBR!OJ=7Z'CLW/"
M?0,S(-Z[YQ!!V^X9]G;;OK9[]\RG"0&%K6TAL9*PV_OK;V9624A(@"0D(; B
M=J<-Z*4J*S,K*U^>C,8JO=!N6=4=@TTOO!EKL.'!3*+V]O'NM\DG'6\/??EA
MQ#69M6#PX85I;S5DZW6I06L1>9V;@2EQ_&:&7\F7_\6^0078%3^K.A8H 2'_
MNE*MB6982Y/=SD:ZK>A/*N@#7KL$1 -=I]B&^78QJ?^%-_[5.),8T'"!YV!S
MR4*H'NV!'HK+,O94^8T4D31AFB8TW/^>X6CAL[50)L[GV"1]5:?V,UY:_^5L
MQ\'<-A;!$[>XORLO?FY8AM]@?+IOFYTI<U5[^[AK:+SR0_T/XS.!)XT'-[>/
MUU*C\1'.$F/@+WST8*=;(YNAC&X>AS>_CSY_O9:&#P_7C^LC6M]#\M#Q.6\I
MMSK<N+#%9E'GVT25]I-+8PZ4>*LHN@Y[Q03W"O@661]853)F]%%909;@5_\$
M9EY2QJ:U7 P>OP$UX=^JI"#K21;\"J\9SI7_&'IM8LRE;XKY@]D@,QCDG4QP
M3Y+.\;G_\]\]6:Y_^FR"#J6_&Y\^5"M#$GA@@)EA )\L%PN-H8%BD:J=&-:<
M ;];TAAOH^]L4YDRH,D/WV,]0"O.PVO2B'2SSKB:?E7M9YJAYUH_751]8I@+
MPR1_DR+IL"*OSP:819+QJM,>K"FOBLE@G&-+G:J*^0:K-%$?%HHYD6Z6,+0)
M6Y)\6O#R2:V*FS$\@1,:GZ>04JE)C_!YRF8J*'30S9+R9#*:-VX7E9!EP*^(
M=-*K8DEP(3-A0*H.SZ=Y?6/FL_*BVM*WVGWMF_0'O!/7%&_X!NKKB3_\*\CB
MN: 87>C2*C?VS%D:AK:7QWW+#6<)%9:Y,E8LN$"QGN&+-R(3T'O[)K\?H.HE
MO"O:KH[-8:OM5O!03@NKZE)#EN8PL&>T&37->,4U]\HT\169A# WN$G";0J?
MH&C(?LQ$+O+-G?U[";_!#8HT7VJV"O)8 7HT)9O6A5B3+$UI_ ;2H4Z>5[R)
MW-3H?K*DZ\^CQZLA&+03>+N5*3'YX>7SVS]Q*-^!DM8]FQBP3:)^YS]>\V&,
M[+433[0UP(*A:B.DQ$&:+DV'W@WY@M9!@N.6"HHL?#6$''OT3ZWR&&!(WR*E
M;\F+D)Y =<3Z[V@%W[TFFIC!JAE0:=)"/(V<]-;)*I/1:FG\FD2UK"6)686K
MWZQ6[9_ OW"2MQX-9_VB+1W8JHUVM5X/8>)7PP2V!<Y\%<\F9>&LIV'"-H(0
MUM8S['N6P\'.O!4;V97]9.9$A:L7L)6SW=K3-W\YQO2OQ8ON\#T-=^IU_]3O
MF,E'ZZ=!^VS0K851 $263T\ZIZU4(86H,<MR9U:9,Z"'KEKS#Z1Y^77>F7.Q
MAZGO.,EXYHJ^^8^@0V %IA;3-TR5'NR?2>=L,$.C@=P#Z^<Y:6:"%;9=Z_@L
MIY6Q2/X$A\5<RX TU(:+@!":)HU!X<Z90PPZ$BT7\!9\"0Q14^$V&,2Y^H&4
MV^1992\LVD:+D)U>8>G$W!WNX4VFI6APK@..54U\ZU?#HCWB"=:334>8]CQ3
M[5L3OU\__=W"',Q'6/K?P3S%R;I,U]DF;UWL$1'":G"NT81!]X0>. F&!E(%
M.ZF[AX(1RC?9)]BZG\ 2!1D$T@'M5+Z.KI 92U.Z=>3S@<LGKCG\ W(9BZYQ
MA)#>#VQ);XPI@XAS50\50IBD,H9MN^9Q$.2Y?VQWBZ3J(_&/94*V/!Q> RZ1
M_[JXD+ZH3)M^E.[ @/\$#_OWDL&Q#=[9:WR2_H&0+?"W='$A[J3CMCMB9YC\
MY1=P7(.+9?2\BF\<;VP'O]N5;W26:.+!F;IOI_'40X9#9_DO%][Y.S/_)#V^
M+6#.0[#N$'/B!OB24^?&0#(TZ]Z[?G5N(PK1(J]6,YQ68Y,I/R[&#*0!'KP@
MLGO'VPD9+]+42QW/8OLY+/3EWO'B1%:KF2V_;7+$I?NVE9=G/'BX'#W<#>\O
MI:^/5S7I_,OM_;?K^Z]_2H]_7-\/[T;_)WT>W<(UUS>7UP\5O.8#]][D-T)T
M9#U(C[?2Y>W-P^W7T=7P\?I*^C*Z&=Y<CH9?I8='^.+;]<WC0]XC^_YP)='&
M8"PMV"0LZ1S/5BB;9+A,%5O)EUJ;V*?TB!;<(RJ= W,_.K*UV3/*E_4P3 1;
ML?#X\\ 8FA )O/YY6!#>X[O)7E3V*KRJ-AAS%K=N*GADF*)_;RJI-IZOQHR;
M<NXQ:R8<@Q3Z$VY3M-WAB@59=$L==F?IB>G,5- A"=>@23[U76RJ^@0=-L*_
MN#XN\BL^+=4I5>#P)XZ^W#](33?BZ!FUQ$<-F\5<U6E2"O>ES<".E@@OSCE:
M<%M6S( <E^A60D<EK 1N.-RC"@I,D?!(HK&*BIE_ZDPE=4%WHDN9O+PU.*I,
MZ.#YI+WYS]DV;,]VD,#H@L"3!3[&ZSBM2;>Z[R@T)7LZX.>N5KPOP8,#$HU.
M"/\1;_.Z8X7_RS9L18MYVHUUVN=>JD=\3;1C/@8MJ[U.N(\&"*2Z8N.0G/,B
M3 AT*$X5'6>P#OL<9_%4&G80FRNJSEUO\"Z+%YS2:X+B_ V6R505[=&X!B:Q
MW^1ZH^^;:9^:\ 6.OG0@/F7ODYL4((4G!<C5BL@':%8](0/D91.OM^")('03
M.+M+(!(6:HHA>75"T@N\,@%:RJ\+&%@=% F!)](#@(,U^(U;*:SBTP^?W>"-
M1ZH4&@%Q)D:IEQJY U3WF(Z\J8(^66?:;"3.XU">(L4I!O7%,-?=!O'<"9'$
MMH](FM5Z*QB^/UE6QMW)L]+$"*\^%J.H#&@@SO.P@S%]B;X/XU\\FF?Y>*LJ
M+2W'V6XR364S[@8SC3=%LV&W7,"=RN2Y)GVG76_7=55WHULQLMB=)-4G">XP
MIV">B 2<V=(&*\5]J(BL6'P'Q4BBZ>Y!Q-"OQE*;@HB],%#&3(>1B1U4A&W4
M6475+9LII)&%T>!,-R >:O"!FCK!3)(IGZP"]ZGF%!YMVF\UZ9[3%A8 95I0
M&*\UTMP)^(XFWO4(U/.+@'PVZ-6Z@8PNKNLFQAP(")8?[MYN%-=T=A2) 5?-
MR2Y86@QD&.8["]$]=*=N2'SM8.NFI>6FDI>QB [K2UP1G#A9FB:RK*"+8$P0
M!"#^<DXA-S2'7N%5-%S'L+*>8=NC5W,V4,DVLE185G@:#6WNQFG=.!IFA$UL
MWB.$[JLX+W2FQWF2W+"H1.=D6()]ME L&V['I^/8G,L= \AK>;J/J:Z-G;2\
M,K,YOT97N7%LG-_I???P.C &T%0$$KA:\T+VJ$T8,O,S#8*X-6O!,H)?:+F5
M"M^2<$W"5D0S4()@03!)"IW2\#&;L,57>!.R?/P9ML*P;'Z1A"'N,C**"?&Q
M83(Z"PO=HZ(KV%1)5[AA <$QR.0394'HK; =5S"4XRHQ3JE=B]Z*O^C>SCCV
M4D$C;XB"L\"GW\ZNQ/N1'ZRH1$+4M'JM$Z33<6^?\J;7K15/4;;=6:P,.F)+
MWX'Z"VQUY$^^G0$;K=GCC_"@SYHQ^;$KHXZS>_SG^M>SP^T#[DD:,\UXK0"'
M (F 3ZT-)]#U7?!CP)^?SMI$6?\P[T4*%,_,MR8\_Q-#TY2%Q3Y*SE^QW&Y)
M*@0/TRLY<GE4/R'(ZC[5QX+BO=XOJ\Z;?-<.)O6MC\I9K5^V5D2X5T4O=!"W
M]'^)7[^P!_"KF+TQB]&5H-_=Y +92*ST:LF3%,>NOSM8X2) !WR5 GA07M-X
M1X]=<)YA'<R:>G5U[W<+>UY<D6L6,Z&B\1A&L5LIMI[\D%QMO+>:\DCX41GL
M&;FQYI:,DZT\2:[?;F-W*5;&P!F^)Z,+#'TC'E?/%LV5$?-NURM'Y2OLU>OU
M3;["W>L<6\V4^UEV^]E^2<\I[F? 4YAEW@N>G\O][* 8*5NQ$IL1*FSWJXN.
ML%'&>D:4G315H4BTDX(TR&>#9K712UCM'K^"V>LK.%YOU;8:YU69!#HJ0T*7
ME6# T1,HG(;62*NZ4]M*@<) %$3WEJID'#*,LM43-^+L3/8,,U!?V$C'M.F4
MN+89KL.E<V\M^0;2R])%ID78!2!/*_S(]L&;;AP0QH,FTFUWYT:O9W[$<LFA
M/B7"W2EOJ'@V%34W$7^]3.'SI/#)14CA>[P?7EU+=\,_AY^_7C]D7](<]&?'
MY,1@'("XT.$^'\MU,V2Y-#W;&VW4&& U6\XL,#)<4JHKB7SJV(&@XJ1Z._J>
MOQ>4?D3+/O#X9!9Q7I23TZ=<%$L[&K&.9+;1,-A38XUDAR5G)^B$^NZ'DXF)
MQ9B.I9A!E"1P$MHC0)*\/Z*8J(")B>@_:I\-VLW=R(O)@T1%H6MRM.-$=.V<
M#?KU@T2=]O#!W<(,@4IC.R D1^=MR]"OX+.@+WG^EV/*/!KTZP/BEJAPR(G&
M+-BBJI-B *E$+\]_#<%LE?OQ(6Q3AB^/%3LKK&^U4(/91_/N\L*6#MN-0KF?
M-/;/!KUZ_+9_$5RV)[9B*:K1O5:L08',1C\W-[LO%S!+",00EUY^T &1L /D
M$CL@##N@46('1&'F$B>@Q DX1'@CZ%2F76C(ZY\ML1N%Y93+K7:_C&OXXAK-
M(L0U;E&BI>'EY>UW$!4GP'$$\8WP2-N:W\@QD[ZJL-]H*A;C; B[M3H9LF<9
M REC(&4,Y%W%0*)VU[J>+S3CC3&.M;Q0WDQ0#0@H8B[A>%AP__Y^KH<'+,?%
M^DF'!I^9SF:J;0W%[*,=8BESL@RFY$-L!.*-X.,Y4(@EFL@YP<D794(Y1AG[
M/[/$78ZU=EBJ7=\=\3B0FSA#WH]'IM;9H)M?"4>&^?U1Y8$L9-QZR)-XVA&L
M_>3-YW*-QDW8SZUL=)VCL"=8(VRLEE$DN&R"7(S!%+:[[@F'N;++^(@FU@@
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MA0CL&5IE?6BB)H.R^'02<M0L"].8JY8%:@?>;,/:>6ER@]\X=*CR5X 0*4]
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M"\@(6U1%F:*M3'LQ6(DS6% BJZ7^%/L@+(J*C\$W"9KCSJ?H$U?5D1SQS3%
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MR_&_!/1CB!>(NM.:1$ZN.46B)"J&$+9$BQ\^D 4A5@\'CT5[]MMJ:(IH2+!
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M*?OFYBC^.79L46Y6(&S:!-7)PS-0EL&QY3^A@1^:.5QV_9--EKC12Y?/BHK
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M!X28<'1!F*15>6ST7TM](I 0<,^>"4 $;P$J%Z. U 0DJXI=@)>F[E3U.QH
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MX(UP,2">(1RG0%!UM]<+)Z-SQ=2'I$:Z<OV!;MM[[EMP?O_L_%[9](3/ZT_
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M-O9*F.[URCY347?/\,(?CW'V^6UUB6.ZH==ZA6WL=O>[QWMN9PX%OUM1VT[
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M=[_G*-8:3J6'6L"-Q#D;X#[P<6LT.]':10F3[__@O!+GD_?+],<MC549F0.
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MFMH4;112]1^7U%86S)^SP:78O[@U").:^MQ,&Q(J/13=#[XJN[MS0;CJM/9
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M$%'8IH<^ 14[=;1]&I/=&_'CH\=(]"21Z&R(WL$*@_AYEL=(]"31UFR(WL7
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MLXKB:?6:W%9U__5H7O V!;2<X3:9^]![-M$4RU)G*D]4FA@F3UN" =O/Y-4
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MV?$,X446-T*DE>E_QA)68PL\!*T/T\7>%B"5<(QZ]+$A\(E&8R*=X:8N>;+
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M)4/&"&WK']HUM7>\#]J5"794%:9=A&F;VX1IQ4=*4TI9^)]5'@XL;SHVYQ_
MA+8)ZZTY(B8P[$33Z/UKK+5U^-?: [+)#JUH(^P:QT1P;'S*!?\=/('%;:3)
MX^_%LS[8UCB(L[T_09*^/GQ[=7A]=?A; D8A1NXV#I=Y-&-UM$^NXWE@X XM
M?_.(F0>L<U*=\9)7,#18#R,@\,+.V$S>#1-HK4Z@L3J!2S@I+1>M*LS26?[U
M"4QZF!>2WX5SZWH8_^$98=GW"(BPE%!T#K_#"7YY<7O7%4"\IL)S;W$8C\?^
M]9#)&DV0&O; J>HCYHL"$;OKM\=J#,G@PG&_(3[$8G9?B#]R!CF("F?*;8Y)
M3 ,.Y!+TP225@&8>M,/A,1WMWGP)-L8I:Y0+-+@.V^^ET$69=TJ7&RP,6-7S
M?==ZF-%(\;VSO8+,KA\Y^CG_:6V8E\XY-W2.YF8RFL-X/$)P=/>2$#N37N]P
MAN1H[SR'['*&Y.CK'(<T:IPA.6HVSR%USI <[9CGD W.D!SM)EI\.G%0[_R%
MN'W+@R/@.P/!=M9B7'9VA8_*X:A1$SZJP1E5%SXJ1Y0,0_2H/&DRZHE0 TM>
MB=9+?R4^&#[X>7XF)4_$C$8Q4^')7;.8J?"$L57,5'@2VBYD*KP#S> ;>!CT
M)&>$_>_]R'5FCZ/5?93>GMA&BCD&7P$SXPAUG6/S%3 SCHS7.49? 3.K<V;&
M,0\+F!EG,]8Y5N3^9\;#)GC80/X3RV[JUSD6Z;)EB0<>\<K]+JF<G"W45YUC
MJ>YA*CQ]5>=8L/N8"D]!<93Z/J;"TT@<+;Z/J7 V>H.CMO<PE3J'*@V!SGF=
MMW2QSGF=@S\TQ#KG=1Z6*M8YKW-484.L<U[G.!H-L<YY@Z-/&F*=<Z[X"'?.
MN1(DW#GG"5%3N'/.DZ.F<.>\SCFPF\*=<YX -^M%2%.3HX_V<>#P1*P8DXTK
M=\68;%QA+,9DXTIH,29;@T<5CLF6EW'2Y!C.K5=#*#N?+DT.M5L<^RO/(3DF
M7TNL"=;D^-PML298DV-HML2:8%SQX9M@BRI"#$_2(!S&):^'HF*#7#'CFVI[
MGQI/'/DFW=ZGQI,ACBHL8FH<J[3%#T++(&MMCA:E1P8%D8-J4;Q&/ <ESI&G
M-D>CBAJ>H^K:'.TJ:GB.R+9Y>42"AN>(99NC=44-STM,X6A@4</S)+^8P YW
M%Q03V.'NB$XQ4^'MCFXQ4^'LE$ZMF*GP,JMT:<2VP]&>>W ^>&+;X6C2?4R%
M([:=8MQWKM@6X[YSQ;88]YT#KW0V>N_Q)--UR:>W[')A#Y-/F:]R[>;BK?"H
MM]'-EW#.&T,X.#+Q,,?7N[;/+&_JT"FC^<NNK.W!][F( 6=ZW81*YTT-;?-;
M,B$FMI7"KX">BV:%E_;BYN[T\\R>OLHQD!.<3\1V+^U[UQR0(-/XAA4$BV!P
M=Z/Z7TZ)-S76@C[5[++/;>-YL#JWR^!.%XL(TCQ=SLF 5]A<C)UG*FO?Z,9<
MG=G=R'%]3'4_([!'+!_3RF/7.0O9()S#0Y+9<N"<+@\S"7KCT.3\*7']^<W8
M!*UB#Q"7I/>5GXY-S[.&%AGT/#9'\+A[,.03+?T3LFUX$,IBIA%"76-/C/N1
M&>FWNFO]0':1Y1P\5&$S!7F=U($]_P*.&]IJ-,@QR7C,;$-0SD%3Z!PY=-1K
M')R%,ABW%-6$4Y_N*EI'A'(0H#Z7=JR 9%>!W:)2@7,"R3=S7LIT+1$T7.ZR
MW"5B"[+6)9D<EW(\/#ZBHWS3ILW>V QW5Z);$9 'X!<X1RX=-R#YVP24MYE&
M E\*'"P&$F E6'A_30"ZW3LWP:5GK&NJ@$(ZO=:1<$[<W.&@391I#:)"=!%>
M%"=4A>D)+R70M\Z0&EGW8&2=NF1@^2A,5"GO+D"\TTO7Y9A&0J'?8D,_9SCS
MV"8/O-N_R0!+0$\=\"'!IZ0=QZ[0-+VRS =KG$_B+9=9]225L*L$*VW,L,.W
MH$NCJ(&3=1IKO6-!AX">!/%%3H#+\X1J_69CDZPH^"IH*W3$C]OF#IQ Y>G.
MPJLD+R?8 9BD\_$V)-UP$%[=X%C0"5/I"T-J!JLF$S-8HU=9Y%7\S!.*9 ';
M8C91_RZ/U':=QR&#GS*RQ@$&Y3#'4XRV#.OY&&^['MX2>CW0("6PM4&,>*6B
M!A>@"2ZJ7GB^ ?<^SL#5)9X'#'S >P+Q-VM7E$/Q K>$U^#B^ON:\:8I<VM&
M#2[^+\V4.2$EW>!;S(4)[YHMEC2HU\VPU^_/)NQRN#-LFX==(6 ,83+*@6NB
MX^[ SZV8V2V<3-QY\2KQULZ-=I*)2]H%=L9=3)3DT;B#[M75B?(3#HO;#09/
MZGA%>O1V.X]IFH*T>)UW[O#*]B28*U?+\"KYBN4^5T:;Q6]RKE1R3I+]Z$(^
M,R4X,KCSXJ=-%JD+N>8_KR(P"?(M3)I/CC/ EI&[LI(G[[QZP)605Q0I0IP<
M*0@[,5W\:Y->XS4EX94&WH*GX5I]S**#*6 3U+QGPFUUPSD-Q,^$2Q-N>F6>
MG-J20MR\R_W.BTNOA";_!.Z\:U.=-/-A?BF1\JU(TMK+T-Q5<^*Q5)$L\Q-V
M/CCY:^9HWMP'YJXXF5BYC"\+2&KA+SY9O"AZ#CPZ-#DZ<R7X!J><ZV/&5-I,
MY.W(P5&:>Y@*ERH)%#L[LK\5 1JB1^6N-:'Q0J@\2Z1@J]6VQ(_+72]'U\5"
M([M'L=8LF*/K<A^8NV*.V;C86%D&3[&=&CRL@5>F*-P<:O L:%[UHOB9</L$
M<LMN]FH \7E5O,'(YUSQ!F.#UWR15T,I!1_W8DWR6=7>R]#<5>_!GN2OF:-C
M<Q^8M^+V?HU([N+;R7H<P7/@TJ$0ZY%/#HX*W<-4N%01;5+R"= 4/2IWK>(-
M2OYJV^+'Y:YW#_8D?\$<79?[P+P5=UY+?\C9D.65R^H=7BS*9'D--X25;\4'
MAT_#VZ:VF@6/_KR:0Z&S6+ED>'5*')7'OXYK,:U@0B=ZC?UG]=ZMS1/K<'M3
M)W4>C0(A'.[=.>/-X/RF,7F^72>I\?(=L\NE>4OLF%S1:XL=DV=A=SIBQ^0%
M.#I=L6/RHE#):KR\Q^3);5<7.28O6[%K[#;B1J5@\%O'\]Q:0IN+?"(V<<$P
MLP>]P<2R@ZS1IPR%XUM0845'T3O>O. BE:!J9QA\'*UXZOFLW.EKFG3.#91J
M<"G%<6BS7I:R:5S>X<ZK7LM[7)Y*X]6BY3LN5P XQENV43>ME:=*>65BP:BX
M#W<VS T>U&7PZK[R'977G9U7LY7KJ#S;S*BM=4/S&977[;W&T6UGUGA&E=AP
M2/J@8'OC,=[@[,Y86:7]G6#= !GTGNBED:&M%E[D>!=8BTEK+:=20(-77"71
ME'GWJ_%JK22:LM'DTCEA(YZ_^,2US7%P$5T.FX [*D>E!B.&19+!D;_[^+S[
M1))U5?FOFCLJ1[D*6G6+IP:2=5*YK[K%4^[)LJB\1^5MQ60-5/8Q-V\G/HDY
MFE84B[G$YJA-,>-SR<[1@-N.GH(!7 )PC,3U[5UVJ7C9.#V>"N!=Q76:L8_+
MAG';7+GD6)-YC\ME!T?EY3PNE\Z\.JBO65OF;$-H@V-4YCXPC]*\@J:\!V[Q
MS&A>D5+ XFR(:W9]D[R,ZY9XQ'3[&*(_ [4S=F@^;H92ORT,55[YD'R='[C4
MXZA*^6;.I7D"9/R5S+^8-MC/R&Z$LAW;)F/4Z\!XFAB^_/J"B#$YC,Z^Y@1.
M G&M_HK;QT8?$.M##UXZH"\>FX]LKM;+TY'1:;6:[TZ&YM@C(9@>O"RZ_S:_
M_\SI4P?FPO+ZYIBU&KB S[SX6*UW)Q<_5@=*/\ZY[5O^_!1&<DWPFP;D!:@:
M'Z/][J16J^DM76\W6BMCO3I4/3K45P>[;H'@WLTG#\YXE7"==R?("2[=\#,F
M# LZNF0(FP6<>N_DGV/+_O.#UQ^1B0DC:R_T[Y%+_3F4%00%ZCK\__$+Y3S]
MWI]/49:LR72,[*=C1%ZZ&,9S9BX=A?XU9E4X(VNJ#6E?MJ&'2_B?VO^@E&KP
M+WWQ+V/QKSK]USO-=Z(/.(YO.WY,,ZX?H+%X67/QK^[J:_7D:U]];R*"@N]L
ML;<GL'C\IKT8M[,ZKA$?=\-B] BY]-4!C5HC\3>=FKXDJ,ZA:#TVA8-_OCRX
M8^M#()%4U$#X&:DU+?B6T UP0C]:?&@-\&/0MZY&A0K$9.3[TP_OWS\_/Q][
MI'_\Z#R]/[W\-;XUD@\OAGJ?&"LR_I1N[<3XGF^Z_IGIDQ.4VZ.:#O\?OF3Y
MG1:\/K*6P?(AW3BJZ\N1V3?1V2Q&QNT5(]4)CW+ZN\6 >R3=DB3D$?5A9-'!
M5P.8R,MT;/4M_PM!;$<;6!/T-!P[JN)Z@P'L9+!1@G_<P^;OO5C>NQ/\S;+.
MSO9!JMB+V*Q6WG\2S.M]8F)E8;2A(J,CAC':2FA,15L1,TXSLR&._'UUPK#]
M!J9K)6=[O>1LITUZO'MGT9MK6S$HN1PT"I&#S*2S;" 0T'V5!N$W.]"@J1P-
MC-QIT%*#!K$M9&RSA8S<MU!;0=+IVY!.SYUT'<5/(6<R=6P:>!RR'!%V!"5N
M%KEQR<2:338=-?D=-!%-4<M=4W3+SC,$/=VG\':+V-T )6&ACGYQ:?D79H/O
MT<(7RRV]S-RB #G[*L3#]VF3B^6<46;.+?3D^0NX6/8C.;.&(9QZC7<NV![#
M _>&KXAE9KW<S/1-RR:#<].U+?MQD_)4A6>-,O/LQL28<$DXU2PSI[[R[]8L
MC872VCOS)"- N\S26XP3*R->H7?*S&<I'%\IV=XM,]L+\)=E9+)1:E"D8#=;
M2H:7&E>1SSN74@9*CM 4Y-1+R>I2XS=[Q@*D9'"IP9[B(00I>5YJV*CPZ+&>
M.U)B[!\J>FL>M%C^E1KI*C9T+(!;I<:KY D="^!<J2$G^9Q3H<RLEQI:DB%T
M+(!GI4:'B@L="^!4J3&<XOT^L<S;/RHC&0%*C5I($#J6I$J@7FJD0@K'5TJV
MEQKO*#IT+ N32PV*R!0ZEH7AI<95Y//.I92!DB,T,H2.)6%UH]3X39&A8UD8
M7&JPIW@(04J>EQHV*CQTG'^+@D:I$WBD\*#%\J_42%>QH6,!W"HU7B5/Z%@
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MQ:6&SQ)AT3/+)7W@NI=&@9=];Y<:29.0\=+L^%*#:A(R7AJ#K=2XVL>99]G
M^3/R1,;.%'^8,@&F[(J^U,":=&R71LV7&EF3CNW2*/E2XVS+A,<JQ9FRNUYJ
MM$T:=LNBU.NEQMRD8;<LRKQ>:OSM>CBT^N2+:<&2\29<<@L_S9B\7G;U7FIT
M3F(!D$;AEQJEDU@ I#D"2HW67=I/Q(,#GW8@H%_:@]"U2VL#+.9<WE.@U,"=
MW#(@S4%0:A1/;AF0YBPH-:3WE?BG([R-[=*^,"WW-W,\(]?#"PL- \L<7UGF
M@S6VL!W9&?&L1QM>-NCYBY_>CUQG]CC"^(_E7[M7CO?6?8=2(X%ED199SI=&
MJ8'$LDB++"=1H]0XY/E+GPK++?SJS!H.B4O -_5 B"I?I%%J2%)&SDMS0I0:
MBY21\])H^U*#D)>>-T/L,?0S@VZ8]T[*>[]+K_'+C4!*RGUIM'ZYL4=)N2^-
MYB\UZHA^'/$N7&=R"[\RO9E+?WP]9' D_AO\Q=!)[,&/-PI$V<^"4B.0ZLB#
M-*=#J3%&=>1!EO.B66H4D;$Z-!8N[5OB34D?Y.$*A*,*5 /[2PT+2LM^64Z#
M9JFQ06G9+XWR+S5 &&<_M0HN8?4N& (]>W#J3"86+3NLC@&C66J\4 %!D.9
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MZ[DG!WS#X-RE;]S$K^#0-W5^!U!+ P04    " !WB(%8,GGI=#D#  "-#
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M/.LR-QE,X20>D181TN3)#_#6@0E,*ZW>[4PUB'B8Y9)F'4[JWL"<<*(?^LJ
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MG?'&?(+LXI<\N__6$C].<W0GE(2@,/# D!H*$HNM'[BSY4 "$CFG*E'8>__
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M 4RDH,:C:S#0Q >8TJ6LWXQ*7-)YI]\IH^!*9@6;&*O;:5" S<\ST*)?=*5
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MIK<8AO*Q<T>7A2G:1COCNQLUF@R9Y)R'L:>H0.A[/OR;2;_/^7@TV&*%.GN
M5LK*M%VX+F'2^:*3LJ$K#[#_QK*=YC#RRI\T:\YY4@0W7U7!3\:C4W=?4W+$
ML(AFU:F?C-845<R443*'[?UP]C8C0C<)),HULPZ]!%X5*:+!GD>^U?I:0-'
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MCK@,Y]M2%BQ&]+>L'%QY%,0,X_W@SI#<X*.03N,$::#@)2+JR!$A&4RJ4;F
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M#:.S*_GXL.3C\S;Y^)XL4IQ\#TH[X@167.[4J%0<%LZDO5;E,X]=>@X6RP\
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MJ>VSP7P_0XC.&IZ;"OS/\)_24C]E'\T^NVGUG^B$14W,/>U;W #0?^>KV?Q
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M"K' (!NA'JUL(.0IMS#>=8R>HE,?.U\ ";X%:#W;(JX,C].(WU$:\3OB$;^
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ML$IG#?F+UUZ07*((8!6N@U)E!;:Z#@QNE]Y"!!E1/+6)QZ_)1(0^E,\7(-I
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M686S2?7+#P9Z97EP2ZG]LS;Z)@W[(N+)K_/)5L:CD'(S:D/X!Y*#/!"6AVJ
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M@"Z+[2FZ0RS1%[500QQPB6*;WZ9-]'*#?JMM^6=+(>L8IODKX-&=[23857M
M8D';8U<&.-&% 4\J/L1S.C' .6XJ0::T5& /?RM.>-?E_3A?LC@*BH&^&\WH
MW+# (<^GP1&"';?;2;"K]H T;K?'KLPQDJ103V.(IO:S"<PNPC0JF%2C]0Q-
M4$C)P] FLW1=!_D N!"NZHY']%W<79*'*5UOGN(@)LD.UQURD+<$3BE%>!6J
MNHD9PTKC61*K\QV<]I.CUEL$#9ROL1="7,NMD6EMGX#/?U)"JG"[NG_&9+V7
MG-M-@B^B&KDR1-<C64(1*/&&%4CZ)S='P:LD4]A)=E@Y<'D731C,8$(M?9[
ML#TKL%14%_-SI(9$.$W0*F\VRK:+X(3."V&I#\2AA>VY W=9W=\%9L]+4%49
M-!R'5NV6^#8,#<FQJ=3$EO@>GWM "2.$I1F3EZX10,FCA">;"K*2(9I[,:R3
M-%)HJD,.DILB!D_>ZT_>U&RYWIQ9X<3IK'6G!4>J8)%S^R\<L+2R-XC=J?/-
M+^>H %*-H-.84./$;CFHI \&(DX]0M7!E#2S"?:""(@\ DB: J3Q,0#E*"*3
MCY7AC,X<%-MJ$+ 4AO/83X88%)'4\!1R^<@.YU[@WE!2XC"V%SA09))#4S($
MWPL\Q_;OH]CUP,P%8E1JIH/"V$<Q& E*>.1]ZBR,I[DY#PA^,2IE&/X2A1@(
M^CP6=>:5Q,''H@#.O,F$<FNV]_<105%#+4!Y+!,_-9PYH7,7IR<)@H#(IX=2
M4TC"4LAF*Z0!NY6.+C,( 61X3/'*!0]Y: ,4L0IH:E/XXY!OK'/.';@9[P-&
M1PV@RE-6IL'F6?DTGF",LPAH*+)JXI0M93^@R82<TI(N%(FJB*1*^A 'J'W8
M;@/3B026.K4>$.QY+.HT(B2=!>_H8YO$(?\UGT'ZJIQ@%(J(VT-7[9BR2WZH
MUEOIF\'T#L>,TH.068U.FK/#B_#0#M%OIQZ^CL#((D2EZJSK-Z!)4+O"H&QQ
MR%DD[9&;H-!UY[SV[ ?/]Y(0-^)- W[N-EH7'<\HC.DLN>URQ&^[!-($+R:8
M8HA^1(]##&?97X(C#5&83#QJW[.,@% 4*($EO[Z*E[^Q66)2SJ3OZ&_LBH5H
MAD)@!-($JRK??N!3SLGOSH8B6 617%^%^)./.+N&"(HD:GB*%"Y+% Y\'T>
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MTNA3O0Z$34QMU<%3T W4GJ$%:9%)=83H'$5+,2]DHTLXQU6Y'HG' V<RL2#
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M89#FJPQN7_VO8ON_7[UYM2F*W?=OWSX\//PE1+^3AS$$>5;"$.3X!Z_>O$$
M&Y#'$&" W[^ZS-)7BQU\]>[]JP_OOO_K-]]_^/K5Y]MC])</?ZV6_,??DSC]
M_2[(P2M$=YK_\+J%Z?$.)G_)X/KMAW?OOGK;_.+KZC>_?\0_Z/S^PU?DM]]_
M]]UW;\F_[G\UCVF_B,"^?_O/RXN;< .VP9LXS8L@#3&"//X^)S^\R,*@()P4
MTO6*^1OX;V^:7WN#?_3F_8<W7[W_RV,>[4E$OQ,5>S1M '][6_WC:\RO5Z_^
M#K,$7(/5*_*)WQ=/._##ZSS>[A),.?G9!H(5^MD.AD\(W8>OWG^HD/U/\J-?
MX:_'69IG21QA,1T%"?[JFPT Q>M7&/CGZ_,](07</6()O\7_\):Y[FTE?O/4
MG2/=W8*; OUY"U(E OM+*QI-$7FS"2#89$F$MMKI'V5</-TB,!\R^)6(1LY*
M0J(%+AX'^>8LR1Y4V+=?@X@R1%)E:Q(1%<VO&198O$[C51P&:;$(PZQ,"V02
MK]#7AC'(A3+C+C:J_514/Y;1&BMQ?IH7\1:))P_2:)'GY7:'S5/^.0?(PA<;
M< 7!+H#$9F4K]/>S.$6[- Z2_3[0^U:C!)@5+%94H6+CWS$JIO/T'GU+!I]$
MJ ^_:!3_$O$6UO+)KT$(XOO@#J_G4\-:]M;<X8(_."^PI.,4:4B&A%^(=QAC
ME5E5:2/9*R;"!L2[@K?4+)$7 +D)0GKJWS)Y8ES!; =@\81V-CZ7=OAC/XF=
M M8RHRJ%/+-UC!25<%PLJ^ZOFSO!D&,<@:O@">\9H8BZOVR0'9U-7"-0VOC-
M&G.,V6^)<^1%PU+JH*&N,4?2*?KM[ F (^1.K.+B(@[NXB0N)$Y[SDJ3^^TV
M>$27J+3R4X7*U/EE@\J$?#Y\P"/FM[X3702W,;%V^7$2Q%M\VE_$(!6R3A&:
M2796OK10MM5OF41,'/HC9(XCM*_P5Y+K<Q 2QTCJ-L!<;-1EN ;($RF)YW:<
MY46V:GX@HI&]T-QN7411C+\96P,<>2 >9)$AJW6.W,8\6Z%C!NW%#%YDN9!@
M-6#F/@*#NP*0R'01B<_PWJ^;(V2YPT$=M!%OP%K*%@\7F'5JVEJ-U*@.'N0/
M<;&Y!@F^;UX%4,8VRP,RNL4/=Z)3[,[G40D1LY!"78-=!LEM$, XBQ0N5P)
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MJ8&&UJ^*P2/(L[1ZWQAS5;P,?LO(FTF65BU;$.2Z+*P"[OS:*$_1F(ZPW<
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MF\I18D55U?995\Y"+GL3\*_OIB1BR_(%JZ!,"@\"QEP67X\TG_QQCU6G)OZ
MT>(S^:SL>$L&QA/0>EARQX:Y@]3^%N6:X(&J4Z202YO4\4)P:#S[8K!^%O)M
MI8(DY&R?[IXXRHHBVRY7!*/CK4'#[3UQB&(CNK*A<DSNG5>GPTRV\R.< 6(O
M 385P0Q99?$L.<ZVVS)%YR9A0AI] L5#!G_WY?Y+DN,CP5GYKM2[XDDRVM)Q
MA3/FRP) CX*EXI^G).FLM%2$MUPAOQ;X$AP=NV<CJB4W!A]E*N;T!$>&"&ZR
M)#K?[F!V3P* KMUV'@T^<].T),AEJ$Q*O\;SP16Z?2(TP;HUA>0>Y$O8OD.2
M(23,3Y)\$3"!R5O%UR3"_49D938^4[.G_JJD_56"F3:7B..);#+#" 0>B\4F
MH31C9"/W5JV3Z7 8-T:FPT#XA'BSV&(FX5?U;K=3_$)_GM;2:WVUNY0',^1Z
M2U'TK8GF!2]9X*9HQZ@'L*2)HJ_U690X"?/#8&DM/_8(2*<Y,/M19AI=AJO/
MQ! &/,4_'+!&H$82@+1]/29LE<0. 1#'_1CD^7Y021$;W/=>@,6OQR6$( V?
M!"]<JR"_(_Q!:\B1]A8D18[_1F15R:D/SI9,)-^NY-2.R&? "./=F<(:_*^+
M)*E187/8>8^A\#T'X5_6V?W;9GG%^^9O!]YSP=L,FG.?EE@*AGG.9XCI!WL>
M-NXSDS$!>'A/TF6_^>?T/;;/-R<FF8W!^;AHR>SF#I?)=YMM\[N'?7YQ8Y*G
M&-PL>$J^VU;:!WV J+NX/AV]KSB4FKLCYJ+D@[4[3[P[A%7;'3^TC="=R,J#
MH/]*1;9,T4",\<QH4I40.QQ_S*'!6WA5+*Z>/O,8:=:\'Y">(9;DB% \><>=
M!>IB]1C-5)51CUT2ID9/+"TE<":4-DZ?(1Y5F71X)=--S)WEY\U%UNV <. /
M [KVH2""-^9=E;2%6T2(@;?!8VM@KS/M9A+@)^M+4Y9=S6<SU5I.6']2L[N<
MAC[B29@H+;$->6@S6:SR*JX@V 7Q?A22:\^LC]Z_4Z8E.18SC?:P["E*C=/;
MGJ/@GX+#IK_S: P5/[TY]1OVC52S%>ZNMY\@;>H"V9^<V<#7=AV$ +7W0&_,
M53W].EH4>Y2W&YB5ZTTEVVR[@V"# Y?WB S$6G</ZN,I]?>6KJP9@VO16"%9
M&EEQ^(+\)"ADWP/[JV8F&,:G&\UUK<<!D;$(N.TAR,\0W0><DISF )B$@Z?.
M=AY+Q+E'8S1\$6YB4&4CX*D3,"\N8W2Z%5FJKO<\6/Z=MS&;@<LEB10<IXY
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M8F# O$Y/HN,@^K.>G\+/]U;Y-9<#5*Q PHBBTTMVS8UT?5/U56D-_QL_(6\
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M77+XM@%2!+'(BXQ^)],K8NO+H<%RR\"B;6FE >OO:SI@G!^%# HI?[S99+!
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MO47S9F[]X;:Z$UX#9/;S(%FNSK>[((;8><:I$X>F<^=I-7E]"?'/^Q^S+#8
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M[>Y)ED?#K#>/))MM%=S6Z%HD.WQE'Z#VUV[-L"QI;)4K8K5](ZF&-(^\:72
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M-?YR!V79VOM&<<\'K<IV9+70T066J\5Z#<$:G7:T5%UV;CIS_>35EO/I1MM
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M_P$@*;X $@ I -ISJI+:L0TT&MW-1J/1CS__O[>U!UY@&+F!_Y<_G'QW_ <
M?3MP7'_YES]\F1T-9S?C\1_^WW\"\+_^_+^/CL!GZ,/0BJ$#GM_!3;#>S&P7
MS$/+CQ9!N ;?Q.MOP1%8Q?'F^X\?7U]?O[/1F,AV0Q@%V]"&$?X%.#I" #.0
M-R'$ +\'#X$/AIL0')^ P?'W9Q??#\[!E_D-^F%PEDSY7W_V7/_79RN" .'M
M1W_Y0V&EM^?0^RX(EQ\'Q\>G'[.!?TA&?O^&?U$:_WI*1I]<75U])'_=#8U<
MVD $]N3CWQ_N9_8*KJTCUX]BR[?Q I'[?41^>1_85DPHV8H78([ /QUEPX[P
MKXY.!D>G)]^]1<X?$KH!\.<P\. 4+@#!_/OX?0/_\H?(76\\C!#YW2J$"SHB
M7AA^Q/,_^G")28\7N<*+G)SC1?Z8_GJ.Q +>6\_0^P/ P[],Q\R-794 %F9^
M5(IQ$%N>',;YS-XQCNO8QJ)(QCENBF@I1<8J!3W\\SW"IX0I?(NA[T GPQ5#
M:/ADR +D \W@8LB!78+IX4\O"#.09.&__,&![K]&?NS&[T/'03HH@E'ZCSF:
M-7QSHSJ](H0$02""]G?+X.4C H(0&9SB?QSA?Q R<8!.N971H81OIA"%:)"P
M1'"'__*>/:+:T!2LU:%_]&7VA_],)H'=K _9/P&>"/Z)I_[7GY,U_Q.4-C(,
MR[2W0CO#"OVS92?IB(]V@)3G)CXJ;6H1!FL1KL4!-P4^"@N/NPBCH\76\_YU
MXUD8[&0Q6UDAO+$V+M(6+=*#9Y-=Q]9;X ?K=R)#1TB;(TDB4/&(_%]'=A#^
M*Q]"9(P' Q5"QH$'0\K2\2!8@ C/ '8R!?S3TB=? HS% L:[>\0)2?':AB'T
MXR&"'2L4J=*J'RL\Z"Q'<>$LYMDW0X#(P0SL9"2PR-""U.B2&QK'*K)2VUS?
M7VI<L,]X*7Q,^T9_!\0]+@FPX/?WB+#2\@G6%BX=4JH^PRH6C5^B'_A'K*]1
MB[2PF%<6&.H>^]=Y[5\D#1':1_GX^Z'S<2?;2_$GJ?-#Y/C\3-'133+ ^,+D
MC*)[UWIV/3=VH7++J+BT1O.H@ :7C>2EX]^U&]=,#E(/\^H^]9E+%4R:;"8O
M'ZK_H^Q&\$XFU.C?6WP!C^/0?=[&UK,'Y\'DU4<DGRR>++R:LJ^7 Y6/-2:I
M^)[;$6OZOG?BI46T^/E;%C7./7<Q$)(E%(N7'@,A6;OQ%(!DB'Y=5.8*32CV
M8X)O8.@&SBRVPIB7EC3]?FUY^'%'L\W-1\3C/0AC0L:1[_ 2\82'B&8+XTD/
M:FB(**;!8J4NWKL!Q7W$E?!H5%<%^PE8OF.8^J)SDWK"U;<L[0[^' 91]!0&
M"U>=T51<4\O15D" (3!D!-B0(?H%A,*DLEQ4-]3!N$Z@W"-X=PB+R09'8+C^
M<FC'[HM:/=..27\'.O.!7II,#,':C00>FJO7SN9F=5G8^+9>.!"D)? :+H(0
MSJTW#3*7K]WG!:Z#G.T08D@6'@.>R2#@^G:PA@"1!.IVY39PDR56Y9UVL9-R
MF!HDJ#^;B!GPU+[O9B]>L-Z$< 7]R'V!986D75K:A*1B]FC[+%F7NF2$45J>
MAZ3'.ERA911HM[O[DFP> !U/]O7UBU!RT$K)@Z#EH'>9?('A<R FE:?\QMQA
M4/6T@XF&@[$#'_IQ-%FD=U*E 6KTY?LZ#?B"TZ@XL"+3=H-Q<%KB=ZA&I>EY
MQ6ED9.4EA[WCLHDL^NCN_+*-XC4&?!>$4X@1=SVHP79KQT3'TVPK5LV/^/EL
M$ <@7L'4K0&"T RUQ<W_RLL_%UGD=5P!_CR@@)\@4H;SE>7?H/\O833VOP;A
MK^@P2$,U=4BM'*)Z7BB[HLV0^G10%ONK5[WV)4-,R9>G7*<0=2M:W7G!*W$
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M&N+>M9Y=CS1A1.NNW20?_\:SW#6.]KEWH;#*E(>O3(-*H\B,DT_AQ:  #13
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MU@(&8[]V'1EB9\62]/T>')]<*;N][PO_O;Q4<3P5[FD_#-68K0:L9#D T_7
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M^Z_;P";5).=H7(-\1]#^;AF\?$13B&3C?Q#=3B2W!JCO3@4LYW=U889094,
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MSHT5K88^^<_HWUOWQ?+0GQ7VK^7$1\_9PHD=LW=R-@TX<!-$;JSIFB+-?JI
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MK?69.MA:PX+!UF0D>;'*GZMT?M4-I"\RF[X_^<"@((HG"Q(5J^Q5O;AFC\>
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MRJ2JO*J.3+<2!NRBOF1,TJ)&NY^:RJI:=?[*KGJR?3\=R]J^GXY-L'T_'1^
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M\BHB'FP1YB93/V;:+:Y9ZN&\P'+5-&-EO1/">OWW75#G<&=F8$@?CAT,])5
MH[R9?4@<^_/I3&/I)\V;((JSBSKG/;HT1>UUN;@T*V\4#?E>;Y 6C:;YE;:V
M!WF5.'0<E^1([_K!IW9LWAIM_>SZ1)YXJX+M42'VA*Z&A.9^,&=5\X6O24='
MO1>^?H6IK.MZI%]/WN$S:>_PF1'>X;-#\ Z?U;4?:R<]L?63-%L_&<'63X?
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M+0DR2FSU_)<%8!KULCS3&=%'_-3KTE[+BN&2]%^NKT@MVK'/7EL<N&C(AN5
MB]UK.151BPS75?A#BMV5GER<1) V,*8007'M&#HW5K1"TH[_@W/&7BP/*V=E
M4MB*B'K3H TE5CT]-(JHRG W'R>>!)$;ZU&4XMPN"R$7':1/[;QKYS!OVLEY
M,-/G*G^EH*(AUZ14^?G92/[\B&1O49KQI29=%>7&R?]&$.H<%>W(M#:DB(#K
M@T7EX-)H5O$PA]IMB+[U_EZPI4O(G!M10N;\$$K(G/.4D#GO6$*F:L[$PW40
MQFZ$3ID@4F?]MJ"AP?!MQH@5NQG$2&U4%0BPT"E#9O]6*P"CQ0#A8WK9_."@
M1T]!Y-(U7,Z-J.%R?@@U7,YY:KB<=ZSA0KTV%:[O9MRQ:0B9<M&FX-9ZV_;R
M.89>N1M$@./>S:))3]I'NJ+*N1$55<X/H:+*.4]%E?,.%55N0NBX\1W"@;SN
M\5YD:M.4WV&K&+"<&V08P$0& 1FHD;TL8A=:!]!V)7UC_6J%H87N.)DB>.?D
M;GV>VLHIM?49S,W&[33YN\X>MTQJY^RE;TP^OH+TE6*^#^W1/J@MK*4'=Q4+
M5@<Q/$RWC+0SK7RB4_?65T?D"^FR61=&E,VZ.(2R61<\9;,NI,IF42Z;.K2
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MO>!I!'HAU0@T393 PI,<;?-@>!/XT=9#AQNO0X4Y73V#6:BPS!BB/M)K2AP
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MYS^,P'3T-)F2=/&GT70\N=5W O<C#G0?L"0Q^TD?3U8<+A#S*ZOI]A7Q869
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M4^"Y]OM=$ 99VS[[W?9P?"#B P;VSBF \O!5=]J3Q),AH?,5SKQ/YP R26N
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M]P<8KP(GAF_Q-5KJUY[.")F53;O-2NRA]>N)@)7!PJ8ZV)+G4.Q%A 0>6!.
M1AE ?8H5_TDE2_U]7HV?B*\I?G]"W(UQPQ6$Q0:C:.()QH6LCD></A!GQ\N2
MJ4D+GVS>!^!#/2TU]R-:8B<2-SGEXV[;O^48<<E]3N\^^#C\' 3.J^MY)GXY
MG.AJR +O!W-V^9=T<G(;U^5WW9=<B1IRW*3<W_5IO;'<$'^KD\5CX.^\P0E&
M1GXZW!B;>/)P8\_Z@G;SL6_+#_RC_#GC4#XI49$3_*J$*+R_$VGWJHVCN,(M
M,<U-_)[:\#3Q*VK!F?6@L?M2W'R:X:\7?$(D^&[!0;W]?1=3&$%$HQ4Z[6[A
M"_2"S%+$848F?B#<"*O/J>H+=;;KFDPG=QTG!Y 4_'%<XF@R^P,2E3:Q+TF(
MOIW:5?%]TW#LV\$Z">"+3#YN&A U]"&]!>W&(P>B P?/2]O^UHIE&?GE\$J4
MS-G30L>]QIYD9>\?H!4A_66J;ZT-3R/-LF:<VULMK/-YACO3.,5(\./@H-_^
M#+.Y]0:C2;R"X7QE^<D7BGYGXL?!@:J1;Z7M>+-B;_'$I# (GF/ZV<$O2F(?
M""?]A-\Z^3$@J=C/5H3S\$GJ1S$3W\1/A1MA\VXOO*@WY?L?D?F[',"X ,'L
MBXNHH(E]2$*DW>O%962%N%U+E#64-_$;:L+1S.M* \:L3AWI#/"-%T31MWDE
M,K,_$P[Q$?LRVBBWS[O):+WQ@G<(KZ$/%ZZ9]_<F' W]%M@8L[Z%= 9X3J8
MS[6>7<^-76C^\PJ'$ E^$2WTVW,XS(L;F6I;T;$S\69.Q;2I(EQ4LI",%?9&
M^1 .8F&0:']7[GMTSS<S.+F.F9G*O88GJ[ F&6>X4XDI#F*23*=)3SE(Y=6&
MZ.[@D/M#,![.3G O6F0^;D-8&XJ.SF3*O,\XX$[K&Y93TF4OK%2H#"2( X"
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M0Z,0_2?N#X,B='2A'^#?7N0;7"-JEI^A+7A96'RT*N#=X+ZVH>41+,QB.-K
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MVA5M65\429TG8\!T6 "=M&U+V8P*LZ3$KR3B<E+'F$P):WI>,R5L1V5<9)0
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M 2->7D(YC"C5NV>@"8W?@49!WI?*X6JL<UU^?&Z8]JZ&G#%,,TL?R"Q'$$T
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M6=."N_Z,68O$MV6"AEHREYZP))IQ+3%S:0J+:^C;23%^]8VD9=1[K"_8;WG
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M1=K2V A5F&P(C)W>V/N[2L^A[ZT%N-C%BT!?LH)3X%U@ TT/2<' CWH[# K
M7X60]@/_ 6^B!(P5- N7J*2[*/V<+'$Y7W9OO+FQ@D(/?ZRFC"32B-*&1V1?
M&9BWRRP$>5,>*IW^)CR.O'W5&&\@$++':E-]+(J\N,Z+ B]@+*:2XQ+Z@[",
MUA9 1.F@AA#Z'4@%BN2PXU.G< ])QJ/'$Y[,F#Z\R*K"$5RV,$+9SM$-S1_
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M;!H>V(Q?*)(@=9>]D$.7'+CZ$@+R<48>S5WHZ#U:DN-L(PA278)3G))I>(1
M- _MT:+U=I-]!DUFG:?QW69;D)NU5EQ4*D/=&,FM ZH,RM'WCS@#D]X$/5\N
MDP7^$H';G)ZW#Q2DI?876425,A)(HH$>&#Q-C%CHHBZNU+]=T)Y;A=70551>
MLP_:K_D!,*=N1&,?P"EP5*,6MLG IK\](\S'8!6A]R6Y/R##J7R*OC<>$J7@
M:P,Y!>]I=490N+D3&A]B(H:Y,UC4AT3B/7NZ!4W+H(@_D2U<SK.;I"1:?)3.
MEQ!_TTVK&,+U!94A91C//ZR X(^(:!<QIPEJ1@:121-+,!DE#HW_<+QD/>OO
M3_EVOJ2IALWIK"JY2MK!O-%$1E5X?: YZPY?/1UJ)KT7?AE0+<E_.%EE+(EI
ML7\BLBY9DH:-Z\M&C5^R+Z %_P2JFF],K4#,,80U3L5WF >_P")D4 E1L\BU
M3HX.L';2H44+YN88L'A(O1'ICJAU62:@M('X#^^U8K)_R;H(Q[N7H%.<X^-W
M7"R2DD&HM"$VR0I+"K!<]PJX2$GDIQ].?M5-<Z^P+.8?0UN*,B/JW*"<XY-B
M]D7F/^@5P$%1\]G 9IHW$*+Z?'BSV?)\M7=!R<POU1[N6O^6GP0 F^F>-W'L
M#T*XH.O'+&W>*/BCOS78_JFJX,7KE7=/2*W)MI*@3$6\N0F[5.OXYN3:"+,<
M'LH&43;HU3A2& H7^B%2]8_[3"]RFFANB?W<=.CA/P="?^ZR(,_),*N>[PU5
M;79Z^2FPP)U4$:9X4#WD74<+676-;%-0,08YM](?+.7G,>9 Y/LKJH68;ZT:
M#$%90R4\,,(@8_VST%(6?A]ZY*T"2XC\!9"BDG).5M*W$I/5!37\R*-5Y%PQ
MP/BH(H,EBD^JM0[(%!$EB8 F8D1IM40:RU#?A (^'T@C1CNL:WR\3!1OQ0/E
MZQF0KZR&WO;09AK/=WFT?<'W>?&=*+>#+<T?<27-[*8.DG.%4%G;^L%<HH0V
M#YPZJV! ?0OI6?6-'C]0_\[&H: O%!@>RG6(/QL/@58L/I-85-Y#R#L ^^@#
M+_OFX#!%HB^]18*>2H.L6?I2^]((@@!@@][VU>!@"Y;T/^PX4[/G'?&2#8&#
M0H@<4*UV)9#R7EG[.GUV'_:NT'"A%KR19?D4LLKD%]=]5N9I$D.QF;I(<SE?
MLDHUY5W&09&5F?R4Q'O(QC\A_]%<_'%4O1G^' >FR<27J32EK2DT-B<$U9($
MG/8$ +)'SK*L%;K+S15:P@'OY9'AO<RW&\>%.9;ZQ-"$^B/4K%0')"'$B2)"
M5;%HIPDBI%\(C@A"&HGZ3!#C%M]\:0[B:=IQ6T#(C+#.F/5V[#977I-@P59$
MDQXX2O>L;,!]-:43E0!TG R*!79Z5$)2**<T:"T-I-,Y<J_6/$:)T.\D<W>B
M*,)F$8XCNC0EZ"84+6_@1S-%0P+P.AVMDKUR(@PWW#H#!2QY+A '#/@!(+E^
MU,9#!4<-&.!9/87.0O-X.ZG+S>I>MOIBNP$O*S4+"H>Z@56_">.T>%-=4U*3
M)L[*4C$AATT.;X:KT /ZW'C'\GU<XS3EY7L&8&9I4U'C*)1713WRKE]:QYM?
MH)&(;9G!]1H5Z(6>"ZJZKV%P-#I#5Y_-:@9]&[WNR/PF!;R]P?P,%NE5EM L
M>IK$ _-?X#6Y*Y(7?G5HH?1K2C0+@)KN&2V(,F2(*0N9'+]Y@]^R[B)03^A8
M4?KUS-P7.84P [@$$>38O&,-4#H,!8YB4M31I42-XN;/T(9F,UN:'6@ABH I
MON*)](\<XM!3>B2[ORU?ZMX6[\D)1/U;<:W1=D=*+QS"YX@W9OL1@RU?G.'?
M+\[/3R<Y>0W.^))4^349Q3^ODOQS%9NCIZ Q9#5B!,T1:=\/F0J@7"MYZ"O9
M!E:#O?[KS,I'O*). ^==D]<YIR4GH7OW!]\V)F:']\VPJ'S?;T0%6B0BK<J$
M52HWG0A*J6+TNHM(PZ;WP 'Z2"X?R568+!-016]9$O)L56#F<7O*A4&]$Q9.
M6D)"E5XC!,JH%*1!R><9SBBJJ5,T11%_O^Q"XD-V(E1Q#*^"'"XGG8IY'/G[
MK*K&,$;%HE6]N2$M_V-W2X:XQ9JA]J^N+ALM$8YR'U]%*5A0R]^2:DTKJ4'B
M5P&H9J-]QA8D_08A.XS,PD$LB""@@C@9Q.E,RR5L/[DJ/["EM+Q%I3R2U1S)
MB>_J^'#:*'@Z6FNP"BGW>?&Z)SZ65;*!&37#ZM?-^H@E(0K8MP?=EZJ2*Y_7
MS'6."[)W=@/9)W6S23R;.H/NBU7)E4^Q4@BM6ZS5J^G?$6D0;K^+(?:EUQZ\
M?US??+/=5:P8)TT*&EJ:K#E%"&=I45,I0:KA1*VD&MGVZ)^DIITK*9]^X/JB
MYB[:OJX4'CX;3<.$XEHS<1NT^,)3$<58P+B1P0&&NKN1I0(J4G&I+2<T65/+
M$-O#YA8[P?F?VT$47^JJ8G]_P"\XVQG,,A:(0T5#D,)',9*3LDR/$(F%T\%)
MN!X> ^#-G^WBI (XLD4DHDZ4B5>L&1+MPNQ,Q8"[T0E*?KP^"#[A#!=12C;Z
M+-XD60(/O"IY:96+58F8]Z,PH.V>_?*X_D'=!YCJ7V!V8O"H/T"Z([S">935
M=;1-JBB]RQXP6"DKLOW(YHRA DA1Y(4VB4J0:0+-."5(P>"TX&^"&F+DPDV=
M(]_]F1PE.(\3VSYCB:X44]B,_&[V^$OGR$UPR3-(GO+F3^*Q"W4?S)/?Q?D7
M'T-/.8+/]9#_P9 E4G1(&^G/]4?IAN\LDM#E (XBQ/Y*>K.9FIS21)^J5EJQ
MC<:44FK34HU=!3!./]+(,8"G3.1@MTM'.1;?;M4<>]>K+)9-LS:W(_,Z7]<(
M"0:+(KA.P0E9MJ\\]W*ZC$H#L+C@JL*D=K(#V\./7#O!3:$F%W>H9JO9@NBE
M2=<;XU9]:RF(H:BFIBJ,':B8B0OS&BO@" 'Z-&R3XV6+BVI_3R8,B@S4UDIR
MJ>PV.^ISDP,O=)C6@@ZBA)AN5MMO)5I()A;6Z^#*>E\O&R<\KZ]J=L;L"HC!
MY7H"!%'CY(6:T9[H94(.U2LX4[7J>TU$JM)5(HD.HH004$*45.#B3RY<*_1M
M=Z$='@?1Q8_,XOHW4N7TT3$1CN1]GD%C!VD1*M%')B4'4_-+B>BTXB;&+095
M#,4(D7H]H$1B !R?/%M "X(I@!'H[<(;!P5#4@R^/Q=:#OV!5? L56%#!%U$
MO!A:1=\'H@9$H;\:IA(((4&)3HM$2Q%:X#^7U(WQ_N2-DEPH(QXX0LBE19\0
MC]O4NNXF[\?MLK3G9$IL]G@:,(]I9!"V'E"_=BYS:C+=HE$M; L":8H6<^>P
MT,^*FF[8=]0X6:C?4X?(U:_BC9>X*' ,#T >BF PC[.VK)"(:!W.]:$:NVK;
MZ3CT&E?]FC^M\UT99?'3*QG"_HFHQ%#2/#/?9:0?$AT1ZXEH5_J"G4#(RQ!C
M_0FQ$X5GF%AQ6]Y'24R-7#1D?U8JK"#:'&BA8&P)C7?,.LBR(Z)2:4$*G_G@
MP+7ZG',6FT^=0[);WF7D/MI0Z\8367WXKL*;<KZTJ2 AV7R)#B(1 H\?(84H
M+?B;KG!$(+N"-><ZRX*CZ+Q,;0-1\8!7-.H@J[Y&>F "#L#1-$;0.I"RKQM\
M-\I%S^!D/&/SUXSHKV091( A.M(AEE,BX#_94C*A?25VS+HYP%2"\GRW7>55
ME6^L:CZRIH:RCT'F1<& >A*TG'K:-Z+*XK^^/=[H]L2W+*EQ7NG:GVUPD2RB
M=^@F3]-(#A/Q*6UYZ+)P^RQY]=JZ5&:C?X)=Y[667OU5IWIZH8ZX-Y*G>CN^
MZ>1YBJ"]!AQB\FJ_SF.MDG%-@9E)(P2MP@7/RF/MZA1]/KP7PY642CE\X &7
MN'BA05^L=CS%?A8O"^>HC%8HQCM4<.I2,@)F2-HB_&:ZL(^CI#0<Q'& \/WY
M MK5& 1>FFU!"@"&HQW"6:?4#/3?6B9&/;Z61?&8^:XJJX@&_';@*E7Z(J^8
M0QZ_4C\-0J?_*3#SU)\*&QGX*X981]#>IM%*:W*O8Y2A5<!W;6NTW<M'P8JW
M;/@6#*[ 8KW-"P4BF'3<60:;"+.0A%!+2+<V0%,=1R(_L1"4T=(QFXY&B]MO
MN35V\7'7Z6"0(&W=^)95-=@"I*8K>>C/CHE7SU8)7B03;Y+=QISENV6-0EN'
MY &KE:P^2]Y..8$C!/7V!FL](-HJG&K4&FQ_D2IX"5AT2Q-^I)*O7($KE6*V
MIA(I;&1*O:0MY! (HXBGTY8TOJ6LFE_TXQZ51XL4?B=Z\M"@LFK]4ALS&C#P
MSI+Y_MX:*3_/!207BV(7I?HZD?SOP1_K8B":() 6&X$\GW:!E99:KG68ZH24
M6BO^!_18!QGZ#"H1J;M"G^/@8T^YB.4TQY;4N<ZU,BM VI[RIKQ7-\0D6(;S
M )?]*702CS_+UEWV@EEL6(.^I4Q%K]OU0,7\ST%GS IA*[GRZBMB2/M1N:81
M==N*AL$^1E"';5EG'MYE?\N3K/H'&2C9VZ4<M,)8L(KU88] @"]EX8O;BN>,
ME? Y,$/7R9W@%OHW?!*]\&]V8X,2\5UU;%"0F^T-9*F^)-]LTCP_9RD?G=M
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MOW_WEC=78#M:$?9;WG7&BU:,!;I,U6,B?K/DR9CPV8DW3"7Y?_AI^>CXV6L
M6XR6+Y]Y05AL[I3]&E];R ?%V$'*>\?BK8BZ^5M]3"XKXE.19!S6=Q)*JM/]
M5 ;4<L.C:\,< @9K>\%< V:NN)L>Q\S?(=XLQA(*+:2F)1EZ],[%XQV:>.2"
M+$HZCB5+ULU#8_TB^)D"RUMIF'/W_7#NFC%75+\<3)5]YK:M/R7FMM(P9^[W
M6,PM*B.I18:6UT3WR'6X6"%6SKD_HCIH16<1C*AJ4@I8HU?.O#\9,"],''^P
MVGT, Q<U/FY% -]/,H^1VZD*YR&9FMG*/4<LSH/EQ@D^A*'W1'W?HO'MPP1;
MK?MTHVZ3>RF+GR,YWES&\TK'*HLGKFS]J;&ZA8J \<\0'_FXFT;G+YNN<CL:
M;_YK0MSN(RE86&3&\>)BG9=IBRN)XG;=&K/;,9@4GSL("18<P3AI:,X9?I2D
MQ](FX08$2R#^MF4&3I-M8PF.\EBM5!^"=7TH0P&=J8/O$*6$-3].'TGT$ ZW
MMB+QR>R_./</[P)#\>/[=+?S*;/IU@1 #9M1W#)VZ$F5_8H4QKUYK""9[_#8
M#A6#^W4DL(.F06QO4!0L=AIDZ_-7:L6>]K8-?6/]J3&YE8[(85*Q#UX=7>F/
M:_D@KZ\_4?XVZ8@<(S7W@>BC39:K$H8.#Y6&!KV8_G<W%B_CCJ++#4>[#RZA
MAV6R.U! C[V4M*.5X6W&&^!F0H?;V:.&69*UFA#-3,+L9__(9@8M5LOL_:L3
M[.6JWUJ,;@8;.6&IJ\V&!(2J&#"NX6.DN(W(EJ9;BS5ZI44QPN5!PEXORBL3
M$$=WC]C<,1)&CV21/5]_*#T#LF>JNW"8.+,[R8M=3H 6+LOCY$DS>G0A\T'R
M+I_=C1.LR05=,1P(?QJW",2;.3]_,&5;S7LQFKXX:% ?.?06^;QLE_. 022Q
MO?A,MC965 ;(?"E)P=RV 4=]XO#V<)=.%-!@;?-\KRW\$O2[3LL!UYT0:BS;
MV^(I$)NZ%12QQFX%5%Z DJL0/)>)/P^_ A^2B.'=($.?_?NZL$9VLS"R]7%2
MK(#L;R5LSO,?T%Y1%>/EK&K["S#I!=UR!OX%*7.>[XAW+K&?-)4NCI)6@[?4
M-8KF;/YQ*)MYLX@W]6X1_W6Z)A+U:?'#"LHKL*S?S[2M/RB?)4:56/1ML_5P
M:WAZ&%GW77,28><>>=?31=;UU-YU;VE-]'L@+;95J&60.OPQ8UU UMR,#/<S
M2EUJK7&OO.:TN%>AUH#4((2+P9-3;*/\U>,%LP5^* KE\X[75M.![5C@7\YK
MVM1.DL+=QQM?VW&[P;"[<:+?"&_*99O=K0A,C-/MA,3/\,V9-TPCO@?>:?KX
MMP\.#1C*_."/8L=?K*J_>$%XCQ">SIH'O-MLY/$V95]HLIE?W=W_:,\=/ WZ
MTSHH3L5#Y/QDWG"9[6#F,30I)T%"'XEM,]2'Q[2$I9>J S*00,\;^9A0)I]7
M;)N'QO(SER%I-[/1CPEVU:<6XQ4(:Y"(K(8(RWJ>P[1::+$ZHKM8'9]<,[']
M*:1!\IEM-V4DSSN=$^\JC,1(F2QS<T.23>C9<U3@4)Z::P/(+(,L:EN :B9Y
M60D>R0A@37BJJT[*I-0(9I ?;6'@(/[QK(>]4Z*RZ(12>E5B%<DAO$:/1Q-R
MQJ=.D:7SC'#2']>>F"&6DJ_@JGG.;QE"O*O.=L)0RIW,K!5_RDZ W T) YLM
M:120F99/KT;?0AK0^CD>911!L[%+_0VU^<@VG4Q@38FA+73UCM7Z'6 O(A,Z
MAON)6O ?(DD(RWBD8C%%=+ ]:55U49.'ECHQ'7^M_38/6"ZP*\AT\<(U%[!R
MTE=DAGG]>\3YE[=8'L"D30(GF\%%<+=+;\C,,R>F;E'+7)Y2:HVS[1A,R=7K
MH&.ALE@7,!?43Y-CP3H*D[MPF)";UTG*@L_#KUQ>6:DM%&AOLIK*+(6[9"#>
MA]'WWVD;E'*=XH&6S,\Y%T^@XGF0EV+J/0;7A3JL3N+XB+L&/Y^!:^L6H@>/
M06-86F$S0<I&=(]@GT=<4$X 0UFNW:CT29/Y$V!_6'J=5TZ'0;:E?"?/U&89
MIG1YW$- 4??K99ER0J)QMMQ?X(;PV?1VKTZK2V,'[MURWMZ9H: <=HUT1P,!
MR\SMQV1*O%:@ZTC:,]CF<VU9_*LS';;6:08W]0KN>;UE?K9C@!Q9Z_"U@XSX
MM=7*S1ZP++8B7LA]B$VLMRK%D9MFU=L%6!<$Z?)3XK><?LA%S=G]C65F5A:=
M#@NKM$*N2VZY6+',R6XLIN5X]5!T)%T1+#.XLNAT5+5*JU(E+_J=FU&&1BG=
M:1XH^$"R:5DJQ\S,1AJZLU.'06YF1R(:\K1NE("63GR%I7#&7)25Q2$6,[J$
M>.(Q#:^W%-?YO-!RL1I!_8LN:A.6"&TN8(\U%^G#>1RGY([X_*Z(U^#;3;@W
M5I^N96^A)F"*1ZO#^3.)7!J3Q:I(*RK>6$L^G)9.RG:.,:E<B$*>HS]W=C1Q
M_(^$[4'\7/ITN)4G2J"P;S TV:1&'K DR8 7(Q$?6G!!LO\N-U&8KC=-(;/L
M".OB-=;;Z1ZCJDU^L.2,L<3,O%_3?$;S51@AMJ;O162B,M%/8,",S:"PV&)U
M\;35_$@N\PZ665Q\&30>%%AM<7CNQ)LK/WSZ;H!;7J)B#LW^^*E.)(;TS2N
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MKGEKD8".\O$^(D\I:)YYGK RE2Y-2<C\&9&R"U?9!,(PFT XY-)?NM+AJGC
M];\B8)#:;NE:V!K6BQ163MB<_>W:U\^!23G;7*UN222.[)DWY"2[=** !NLC
M-.MN<!L"8,%P?05LQ>O"![^&K4\@.JYANN@\I=-ML2.\PT^POB=KT^9;<A(U
M(*.^KFC'!N34NPP2FNQ9L+(+HX3?Y!;+H"N@"F+8#J:6V'0HI1(3IA71E0-D
M%M6=.3[WK.,GFFSRF7*W3F16%E3IU7L$_:4!6M/SU(<+=1%:7OF,)$^$!-45
ML;51"T&DIL[&8M%9[*W!EVDI:*G[PB7O>11[:<2L%PL/,SO$.WYFLQZUA;RE
MR4.VS(589ME89D"8J+^&=I;5:+DA%>4&BXPA%C1F=[WZW(3(4_)?LTW-5FSE
MLLI=,.,"YLE^9+&T]VLJQKV7UE-2/$L'BR:*0+<C[2MA'[1JF.%'H,/%K,,=
M5N/.U'I.-CMIG^W%GPR*(M+X]=IQ=K\T82IH\\J)'P1%<BA">-\0/XF+GXC#
M24BIPD*:<>B9$].8/R O-XR0-=-6.S.5P6'<):JSB6N#.F501B-=D-B-Z"Y#
MJ[8C?K$9%@&PNW?]]@1>N_=C#!_+'.JQ=P#]X.8O@7+\G(5%[,\>#XA6A9S&
MNAH\=!64.B-8UO<2$FS4D[G[U+,%]C_"7/;SE&$6N'L1.?MX=V@@V$[#KH#S
M"&JLU0!3\WM*8YK_Y9YM(>]PP>OAG<#P0.F!.7[_0)-&YI-M3^@DW!&V+^HR
M.W?!7'N&/] AT82+E(6$/1@DY#*?8FNNG>HFIMQQL=03-O!^"FF0?&8_9R$>
M3CH;'/-)2-A)60<WDQ?2QAPWDO\C\=A//\59^C"KY;XAR2;T$MT$[0E6?@'N
MJQ'!<]GY8;PN[;@:#D(@BW-??BJ#I=6#\"_CE;..7G!CE#1%="=@U^!9E O;
MCU9];HUML-" 1EQ%1-9^56VS/4IA4\;X9=DV#4X5R4&(:\]3)(;&TG5J()XO
M2[Y4NTZ]&YQS/HU4\1>:C'I\+MT%>21^6!S\:.]BH! >?Q[J%%PJQ&W,&>[R
MXZ!9]E!MQ):L ]$7E]?NY4PA7H-SVJ>2K6+J2#Z(9*Q19A^>+^R0[.-*(5:#
M<^RGD2K1J4HT,%ANG "WV])P5%]8NE6%.85\#4[VG^Q0['P8/T9!4T;X)?EA
MZEPJ) X@I7\JD1O%4\$!.+XT[TOE2>&[X6G^$PG3&/I_#L#QQ0F30IO0=\-S
M^2>[,'JD\5A//CEV+\MC;^% (3B#\_*GD1O$L8+:F+TT@],^<?#]B,JK9\QI
M\X3C%LYG]^\J73,:!,D^T7Y\=K+U)Q&XG9#\A3P-+]\VEZ?*!O[21/I\P]N(
MQ<OP^$^7<4*W>0G0912%D5E!-\S*$[A-/@G!"]D9G!<_S<F5)<;83W@)4, @
M\0?]8SF\I,B]I+!>3OU"9(;GND\6PI=Z("Z*5G^C$1LI<B]);.34+\1F>+TX
M9#DGO\I9K.X=_R1N30?T\3/<F&X%IP&RRI8;530)LRPFAH+TR,_.Y'D@.Y,Q
M7\DK(3:HI\6GF+!5K^F*N[19B5LR"X+4\>_X(@:O.<V (\4*P^6AWK]"AZ!3
M>\E^[L2;P8K'@5A7JLJBAO-#N6!P,(''_\.+CA^9F0V2S!:9]GQ1A8K?^D'&
MN++T*]-G4MT\"Q=[;RCXA^\U^QPUOS-QL2K3@!Y))#8RH#N1! B&P]1*U+HU
MEFUZ:E:W,H\WZRXO%.H@CV9VN#+0^@@6>6ZZ#!$C>YTR5AW<XQ+9AEAK59BX
MXPM4&7O4%65:34UUC@_4:.EIXT%S ,9M'&.4XUIQY1TE9OR@@9[!Z=)%79UI
MM?UP='/@71"O-0?6JL'"=\^&B24W!@K\A!G?BN,P*(EJ'QVN@4?9 @P(D12K
M+E8C&N^GA2!2'D#+8'3,$='BQ93:5A9O;IW2<]N/)!GJA):)U_JL%_4([<<*
M9L[/!4D<ZA.O,F4\3)-Q/4:'0AC70S:2NG:M'\:ZZ?G4E2?1I;2(H19TO+&V
MKODJN&@79,@.B,5JN2%U4@Y(S"@"QM4[#4[7$SFJA)M6+W81JM\Z^Z,?"I70
M*8#B9G,:6 S,85;H9: EU>]'E*9I8U==#6H$F%0FO9+'S/=@>GI4!K!(X X8
M*M )#F;BG.M&*?'RY]"'8<,C"MGT,,30(UT!Z)@^I\>-J;EKLH8/IEHG@Z6I
M:9T@!GE6U4XIC(V'GY18:>)9J0'&4 (5?C0<*44Z 28GE/EY[VZ(E_H,RR\.
MGV^<Q >W3S25._,=][?8W82FUS@#%D I1%9E\!#"P?88/_W\E.I#L9+,EJV:
MX2G],4R.)T#)[%<B>\L.M0Y.VBGE/FKJ7..HP3*( /H Z][HJ,/#GC-H((_<
M'"AR%? "PR)UM$16A1H@5SH#.J K9!(O&.(!\<[#((GH0\I_SI.* \LSAZPV
M3MY+KVK "#PUUS]KP MP+&: [$^?KBX+-G/ZW'>8[QLO5J)MP;FSHXF#TW%5
M!RG\"@.Y&+1'UOUTQ@@R*N6!<<Q"?W[ IDF<.(''?.4RLB85DGT@T2O=V]FH
M1QJ,P[+GVKT4WF)W'35#;WI*KD-[J&E&5EX?<5D_:VF=-/@11)YMO&+$[^S1
M- ^^;*B[X;=D\2*Z)]$C=4E>H4F\"^JQ".&_4\>GJ]H#OUF<YW>L']K6=Z8=
M]"JP5B?N50:GFPWKAZL;^6J!Q#^HL)1$I-24A00@C+9.9%T54*0(2"A]3"Z8
MNG7%7<Y%2I;A$6T^(8O]O#[X;$C9A>E*6.>\B4VI>X;&U 6,GP?7WQ3-$1?B
M'77\@2?-B0<D%2:KH-PO0(B#$4D!+QV,9:&,+(MSOA"ZWC"$9X\D<M;D\IE$
M+HW);<0/D_(NAKSVA%L7)P$'(3! =(<;C6HCG,C;;<1.UJ4\+/IO&-_%']VD
M'))U3[^^KNZ)?;RT+&B1MW!?5(EC?LFK"A?=TVUA8?5J5YE*DZH*FWF>\,5Y
MUN"0DT_"9),9D9 7:*\HDY[K,#96EDJ]CVS! _4&%(XI AZ2KBS!#9<YA18Y
MA1:"0B892P6H6/ZJ.>.:+\$5:#>U&QZ.==%^>>8!G"7UGL[VTT=M" RZ_1E#
MZ_">UN"8>98>IE>3ORIMOX%"O-.7).^8S\G;^]R3=;4R<OBE1 ,VZC.V=FPT
MSZ,6DNDD3#M!Z'J1+<!T,Z.]8/!O9K2$B^ML-ZNF6?VC(GX=>P=)4 Z98:W(
M3NPKRTZ$4%)5JGK>?E/93>2IN7[EQ(L3>&>.ST>AQ4\TV=P1WTEXAB8:5!9;
M7F%V7.%+8P7-F$D?[K"<;UO-5[[P<=U\V=,4U:FLAF-2C?FL6ERG1&C0AYN@
M<E*FCR5A45[RA4J,.LG'=(K7=_%/LK]AB*Y%&Q 6+L5A$!#T0D-]+)'2HX.D
M#(Q#T[IF*++%(5,M!I.WL6$0:7SN^&XJ:!8&SCVC%K]SX;[3F1/3>,&;)&[(
ML75MYDYKG[K'7'5Y]7EI]44PDZZ^+*^NZ4] KZKO;71VJLYL7 S*&47"V$;+
M($=G$4?=E  *:DC7NJ=17'%_95TW8'K4&3:W+DK>V]L*/5-[DU(4T4$2.B2K
M674/5#F&V.WO/-QNTX 12C E\#Z2Y"F,?CL@>$.V#R2R)U1JZ&"_G=13Q9I0
M*%(<J:*M@N@N9; 094&Z_L29+Z<I[$MY VXO5LQ<$BQ>RU='KYT9PNH6@H+%
M?&9L%J,I-Z'OS;>[*'P4P6ELF=E=..#>5@_A=R=E<ZX#C$\SK./C0V>LNH?'
M%='JT4?A Y8H;Z[ZPX,'@89M1:\LBJO9#060<*FNK=SU,GY#>A8F2;A=K 1D
MRW27K8U?8]## BG!<-\!+\,=#@,;"Z-[0CW,:U(*-+?]]1P<.#E+<_?$-]&P
M6Q*YG)?KTDR[1^9V1>7]B)%VK7Z88IX58J6OP']II*^Y*()P":757[Y?O[S?
MGMF)-PX-?-5K]@$+X#S%0Y:D(0P!2XP8WL$?!^**X8-1M&>TFVTY$?F=;[7I
M.+\_G@<>;_A$DQ)5[%W&PZ#[54HI/-/A?" MZ95F(A1-F_S;%^^'206BA8YP
MN1S;=1N'&;NZ@P".=[CM$W85:BCJDW)U!9M_W^#[<5-JZ/0 T?0U6J$U),H4
MK6N*W#2EF_E<4?KX CK938TO<93\<IZR=0)WWY/W7#GQ@UB6?2,.WS?$3V+^
M-\&GC$=U<"@GI)K\<XXTMV^_<L'-U_]EYOLY+MQNAUOFV76P(R;N'];AXYOB
M\XPEQ=^.+.D$CQ6SM8D=YTDW/:HY1U-2?[J_@"0M!X=S]BL14NP6(T5XP&!^
M?0]);PYNQ/06NP5LM#=6ZZERJ$-<YAC69?!3F(<E\88G6AX=O^G?G[(L0[[\
MJ#C:$]^U47! LBI,'-_V"^/CG@\SZP=Z]P<XQBY^$\*@Q_6924H*J.R\G >B
M=I_:>^K<A0-*?[U^=M7$O8N(D U=#!A\15FPSO8C&BQ:8VEU5>RZ:$4VUDB%
M_3JI)$[6^%9>$ST:5F1;A4X#G*?*"6/W>*D,0<MZGQX&[&GVLSB2KP6H\<G3
M!V^ J(L6A#./D6WI/!]!VY/[5@30[B9UV5C5B7:"XCS5+55M\NU@L+BQ,+I]
M,^)LDWY8[3@;_L]M1'8./0QCM.T_UI?'=1V-F-M&2-B4@)'*YJBA::YD?6RW
MTEQ_9<0<<.M5C8WMNBZ'#L+ABK=]9+Y8G(C>LL,"Y?K(\ *LL??2"W"0!:P-
MYKPA#G^S[LV2P[++312FZTW&_G#+&+%ARDT?&2J,JO8*&(9CBE.[H"T9C=AN
M*(/,/:<=B6CHW2=.E!B9XN,FXPLG4;V'K7^%>Q[JL*VQ7RP7)YNGPQMUDIA/
MLC@BILB##@#8IY<.0[KH8.";_)CQ)B!K7C\R.*08K-N_O)V8^9V,X  SR=Q'
MRDSP9> --, S1AJ252KQF5E1G-Q0YKXE8:!OEKM@X><=S QV)WUR]OUQ$KW-
MCRYN47WME JO/Y)D6':N #JK C7V;_O@:=O7EETWK@,[J:.V"Y"E=*](!B[:
MN $][1ZO*78O6VW1%4\<0(3(]CBJ;RUA3 0$TF @MGDQE)16U"R_;.S# _VA
MXY 6 +U$'E3D]ZTSRU?:F85''&/17R5D)JW$:N1&:>-2:RDC;>?0/H5 _C%^
M7P!]9K71 ;O+RK?F.IC-=8;'[=-W2N&B1I!F-5HOJ<)8-[U0^03+D$$'ZJ(
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MO-<)\KB;IF#=,ZU7KE3[8CF!=_C)-74>J$\3.C3 KJTQDZ]A7LJB!UX[$#A
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MUO=D+0AR#/]-$P -D,:A?3LDS>1T U CY]="!S6,C<$#C9AN0&\D):T.D>Y
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M:"J0-'W);I"Z09PJM%$EL)3E,$NB*# 3,-JS2!T-.>VG1-/O0:@=OR!L/?Y
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M"^O&HU22RR,-_NR0")3N=SY5K3#K 8)^_2KE1M_.L6HN/T1A'-]&H9C8I<B
MZC?XYYB4X+6-@5UNZ%6T,F/I!"Y9K&;K=436++*6E>NU5[:V?C].*>_8+U;U
MY $1,:M.D>ZUCT9KX^N; RM0'$)CS4DW+1]C9<5TB=XX5(?7#1KF0LH/Q 5*
M"W'<Q!]X'$D\JZ-5E) 9K5KI$M6\8<) =XH)X6)5&%U5]ZGZT6B94-\<^F C
M6:<L:PHE77RDKE<?R>!&!^FQLDBIS0*OT&M%G9%].5K%D6YSP) <&**;-'21
M?XN32%>GN[Q3"\"P'.,&>IH>F?S;L9*]9:=P<W&,/&&3N+KEXPEXPO)@&V :
MCG&_V@R5*[81?NK08&WYF5P[!J,_M#N(!S;9QL;+*('T&;,,WJVSY]<W2V:>
M8\<5_GME2(AIP"6Z G$RB:4>6I::!U\VU-WP$2OQ(KHGT2-OSWM'7$(?B7=!
MO8]A\M^IX]/57M2JB#$N0B;BO$>Z]6=9UG>F7SNOP%R=YV#J\$Z":D,E ="]
M+C\JPWQ0AJ4GXKV!NIS@M:M:LM^*\RBI3)T9=RC7Q'X!DS)"*(>9MNY7SS=U
M:F/.8^E$SW)QDPHNR+4VNBI4%0DE8@^K%UT^A<M-F/+65LLG!G:_9&SC<TX"
MK<*:7C#XU:0FK.BG#GR9Z=@MEJ;? /$(Z%MJ].1L'I(QA9APK<GC:O%/?NNA
M6@0H_18GCV3,FA8" )HC@.N^Q6J1)G'"K&<1K.?75'B7?MTH840D -JI0W2L
MBIXKAV;E7KD16>BTB6SY>,SGII1E;42 *P,RR %4KXYU(OW:ETA73\;<D.X>
MK"!HN')HLJ0'R*1L6Q]!X"J*S+T.F3^IZ'0<O<'IL*2SWAJF*]DP]Z\\[GZ(
M*UB!,RV'78$N4%-4#,W;$,>]%\R4_8%NAQYJH(IZ?02AZPWO,LHB-6=-[LC6
MH0%S*'FC0Y[,3AW_FJYX0D7N;:J64@Q=9FH^QW"Z@I4I69FO4R(+V\N9X_.J
MN?B))IOJBVZS3I%E\+,C^"\-\)JM]/7A&DS/T22-UF0=(]BZ7JON*KJWB>;P
ML0X"8WD4R68S@<!M=?FM(8R*+&CKMU'/F"$B\*UGC(4KJ)'VC#GWB1-M*6\S
MY5&7&]' U;K]ZP" WEY"F>1=5 !/JT_)#@TXYD$N_W1$^8Z1E9%DPP[?"_)(
M_'#'G?.\U$?5[^@!@C*::ZBKQ1G91QS ZSQ#;R*-. &.8WDL>A#-I7%,%PBG
MNTF*TT7P\MG=\$*+Q8J/-0@#K1?'+1^/P<\W9E(;08#;N"AF5&O9AGP"A6H>
MM>7K23C>\DQJ&SU 7^R?OMB<K@.ZHJ[#[/PCUWXOC=B6D@VY([LPXC-+;DE$
M0\\L_U*>']U8ZD(LM6PLI9F+&;:&?EFT)L6TJKF-8.NJLNXJNFD9<_A8YAI$
M3,6-L9EPX)5P?\O/M*?PARCZM_S,M_R,M?S,1_)T'NKF9&H?X7<Y5*9M?;N0
M@Z2_]5$V[*,,6"\X)1L_P)>RGON:!XSB+,IG"+D,U;6CZI9*/IS$B2P-W&14
M )NR;>R%Q1N+OA9;;"H*UY>]$H0S. !^S-@7D,3,_%_DJW $\@H/U?!(^BE*
MI1\$+^2$P"HB+Z=B<@5WUEIOJ9L?3UI5V@B",C3KBA#-FY;R%T@/<""X4-DX
M5 &Y#N7/PB"-LX'@Q<-T10[(OL2JJ8-@A9022/TG2P]Y\ZX!N918\P7JZT[7
MK>N@)5P)NN:HLI17:PH+7%SE9(*GJ'KMWT_66^@@"53=N2Z7JG75,_?WE$:&
MKS8.'T_:96@C"%BEN5%C,E$%K\B5VD=3/J[J^P?L0:G%!N_7-.95Z4)92VVR
MM=C2#62R1JV/.& ]++7,VE/ OMW0G788)/MRRBHDI01<=TM-3;JF7%2$;=5I
M*=KX;,+14),$.$TO^<CIB&R8D\BB@.LPCA?!L0Q*M;*U$\:4U::'.H"],NU4
MNF24F*W8ZF5"\';=I::*9N%;N7[@8Q@XXD!@P$MK*M6XG##2&X"B?B5?+ZEU
MBF)4H>E[-?V0&YHQ&-?K2K$+XJ7?<)D5-8JJK/[V"FF<52Z:NFJ]KN5;88L-
M8S#2PI;[R]N95G5%Z0/<YK'J!"WO$;KP?MQV1.OXA6D3"-27O=&.P9HMZ<=D
MK.SOR=HKD!BN2L/4C0BW6YH]DKEQ/'*VSTQ@2;_WY;<%]OP*3;Q0AO -%1!M
MXN.\8OK67!2:\9VM177. UG-CT%Y23&PQ:"XI/[IA!11OG6H,A*M$4$1V3G4
MFWF/&M/C:A]A#<$RHWU]QV@S25TW8LI7JZ!4UX'V[R>D"!U$@"HCT4QBY\>B
M-CNDGTZ($_*M0U5[Z%56QRP(]@4J60VD-C,Z04SIX.ZF!6"5A]:9D6,2D2U-
MM]K,:?U\8N=(*Q6PN@@>O;PK0F:!)U0ZCAD%;5?"M:T_T7"ZE9RP!20GO[6[
M"-U4#.$(O"S>FP>K,-H*N+IOT3M Z3XY5P&E'3IZA!X@EP!*[LHJ>A 3]P_K
M\/$-^UQH /^#0%H@W G40&-;X+5<E U'M'I?AO T7$-JN IV,[&4DQB4B/*=
M.#X,J\G+^^U>9;5B@.*KJ*A.+9W43D*TU]A2G"Q?5G7A@'RETB?T"@QNN98R
MKQ?^&-XZ68=FK7NJ'B 3('0?&7"RKW>\>7*\#(OARB#,T@2*WM%0A7VZA )\
MT*?K;63'[LSS&&)L7_D?ENRKGA.OW]_H 3WJHTR%- B7IARM$AX7(>]?/HA)
M36@8YE%=$@OF2*@PK!J" SU+8^80QS%O!\\\SU[GH)^\<HA(B0U]*K<0!+@G
MR$CUOSL0*UW.&$I;<<6ZICS0"9*/SG98)"H%."8R2],J[:1 *DG@""TC1S0?
MW&\?0G\04ZJ0<-P777;4=H_2 JB,,S=/(*D/ 0CK@-/A0'7G4/ZA+OWS]K57
M-'8=_V?B1)>!=]&8[Z3)BU:@6.\Z=7G33A70[J0&9TG>R38)W=^R4*/41Q7@
M9.D$/Q7NJ5 *K@1 V[EGV_#X5JY\9QC+JI"F<>[4=@_6.,)0FP@?"N7/ X\\
M_Y/L(12H!A$Q#C!0F3HYL#H_E%#*+/'A!N^>D2^%2%JT )Z&%G73!JQ&P(QE
MGT,_962+]E?49_  >%6'."FE:I #JU;@B)+ )']A 6'TJO"FY2;4: %WO6_&
MFB_$]_\9A$_!/7'B,"">J-<=EJ'JACPM=K72!ZQ)Q(#[_.R9)T0$)8<X$;O7
M0@ZPEA&F[#F&<U?L)S"5%G68T_ ?6BD"UTAB()<RV8'F4QGJ)+*F'42!;B!A
M<%A=;DFT9H[GARA\2C:\X8430/@3<KA32.IUTJ7@V/"D@QF[[C?L\(3C4@7<
M-.R>C X%5P":5^JR9>ZNHEGJ4?:OLR0A<4:SP7FA#K 3\2"Z"%/PR^H#A?(&
MBCLLCA(/N4FSW9'A(26'/!4'O8<^!=]L/UTHHS8+@M3QLX0)",<J "?E451)
M43 ')2EQN GCSX\IQQZ00PV@4U.G)E4*9MEN8EG&JGR& G)+ G8B1U8788K+
M7:L-+*LIKNP1.%"N+P<V$<XTB5#PPWHFXC)_ >&&$9.,XPEYSAN?1OOST(,H
M#^J&/XE32HE0!1NM3\DX8I@7U^7_X=MY!\! &=0)L4U*E()9B.F*)E[O3\*L
M]]-FUOLCLZQW2&C@=<[^N(B6X=.P&N@VF%-*6T@H4O )(7=1P>DVY&_6_TUW
M0">8%.RDW TY80I^6<]=5"4H.T0!%2H'.#VS=R!%P1GKXS,X2GGM_2T#% 8!
M\0>7B4L!3H([<E(4W$%)3W"#.XN(,]BV50!-X3:CNO.""</3#KH<N [YY=<F
M#"#"V :PB9PK32(4M<C6TPIU);W<.M3/+2JHW:H GH:OUDV;@F66G_5RQ.Z)
MFT9,H=^]7R]I,K C1@/81)2H282"(]9?7A2H%'.\!A_Z4H"3./3EI"@X@Y@Q
M$$WJ>$/41W+A)$Y>< N2HI,"GH:)ZZ9-P3:$IQ7':IG@/MDFEU$41N<A6]X%
MN5=7 #^URZ4N2A6,M#W5LW)+Z;H\0LN*VP//B;HZ &M<VS;!3N0 ZR),P3#K
MV86\5..*1MOY, 95(4W#'-9V7W !()-@R(?!GD09SD3THK+U@@6#TP6&#."A
MFFBP!\"$ ZQ)>'(- A2L@*A5T&;'Q[#RS'VP R"#-Y437TJ+XA4LT*,)>3?+
MO[WAB#PX,>%_^_\!4$L! A0#%     @ =XB!6,S9"GJ7P@0 (Q8H !H
M         ( !     &5A,#(P,C@X,BTR,&9?<V-I<W!A<F,N:'1M4$L! A0#
M%     @ =XB!6"=$K';N!@  L",  !X              ( !S\($ &5A,#(P
M,C@X,C Q97@Q,BTQ7W-C:7-P87)C+FAT;5!+ 0(4 Q0    ( '>(@5@R>>ET
M.0,  (T,   >              "  ?G)! !E83 R,#(X.#(P,65X,3,M,5]S
M8VES<&%R8RYH=&U02P$"% ,4    " !WB(%8TM[.%D0#  #^"0  '@
M        @ %NS00 96$P,C R.#@R,#%E>#$U+3%?<V-I<W!A<F,N:'1M4$L!
M A0#%     @ =XB!6*N^I T3+   3_8  !T              ( ![M $ &5A
M,#(P,C@X,C Q97@R+3%?<V-I<W!A<F,N:'1M4$L! A0#%     @ =XB!6" &
M4R82%P  TH   !X              ( !//T$ &5A,#(P,C@X,C Q97@Y-RTQ
M7W-C:7-P87)C+FAT;5!+ 0(4 Q0    ( '>(@5C%%7BEB08  !,'   -
M          "  8H4!0!I;6%G95\P,#$N:G!G4$L! A0#%     @ =XB!6(0V
MO7EW*   :AT" !(              ( !/AL% '-P<F-Y+3(P,C,Q,C,Q+GAS
M9%!+ 0(4 Q0    ( '>(@5A:K7S_)PX  'BP   6              "  >5#
M!0!S<')C>2TR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ =XB!6&O+@Q?\
M5@  !E8% !8              ( !0%(% '-P<F-Y+3(P,C,Q,C,Q7V1E9BYX
M;6Q02P$"% ,4    " !WB(%8R@^*I8[Q  !H!0P %@              @ %P
MJ04 <W!R8WDM,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( '>(@5AF,23,
MJED  !VP!0 6              "  3*;!@!S<')C>2TR,#(S,3(S,5]P<F4N
9>&UL4$L%!@     ,  P 3@,  !#U!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>ea0202882-20f_scisparc_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sprcy="http://trpx.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sprcy-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">sprcy:RightsToPurchaseOrdinarySharesNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CapitalPointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:CoeruleusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-15</startDate>
            <endDate>2020-05-15</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:CapitalPointWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:EveroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-11-29</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-11-29</startDate>
            <endDate>2020-11-29</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-25</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-25</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-06-25</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-06-25</startDate>
            <endDate>2023-06-25</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-03-19</startDate>
            <endDate>2020-03-19</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2020-03-19</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-19</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sprcy:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-19</startDate>
            <endDate>2020-03-19</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-23</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2017-04-11</startDate>
            <endDate>2017-04-11</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-02</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-22</startDate>
            <endDate>2022-03-22</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">sprcy:March2021FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-03-12</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2019-10-10</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-10-10</startDate>
            <endDate>2019-10-10</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2020-01-15</startDate>
            <endDate>2020-01-15</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:ClearmindMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:NewCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-01-21</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-27538">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-27539">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-27540">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-27541">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-27542">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-27543">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-27544">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-27545">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-27546">001-38041</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-71">SCISPARC LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-27547">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-93">20 Raul Wallenberg St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-97">Tower A, 2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-27548">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-27549">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-27550">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-110">Oz Adler</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1" id="ixv-27551">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-27552">3-7175777</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c1" id="ixv-27553">oz@scisparc.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-123">20 Raul Wallenberg St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-127">Tower A, 2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-27554">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-27555">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-27556">IL</dei:EntityAddressCountry>
    <dei:Security12gTitle contextRef="c2" id="ixv-27557">Ordinary Shares, no par value</dei:Security12gTitle>
    <dei:TradingSymbol contextRef="c2" id="ixv-165">SPRC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c2" id="ixv-27558">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12gTitle contextRef="c3" id="ixv-172">Rights to Purchase Ordinary Shares, no par value</dei:Security12gTitle>
    <dei:SecurityExchangeName contextRef="c3" id="ixv-27559">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-27560"
      unitRef="shares">706683</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-27561">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-27562">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-27563">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-27564">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-27565">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-260">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-27566">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-27567">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-27568">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-27569">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0" id="ixv-27570">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-27571">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-15184">Tel Aviv, Israel</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-27572" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-27573" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-27574" unitRef="usd">65000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-27575" unitRef="usd">60000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c4" decimals="-3" id="ixv-27576" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c4" decimals="-3" id="ixv-27577" unitRef="usd">22000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c5" decimals="-3" id="ixv-27578" unitRef="usd">77000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-27579" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c5" decimals="-3" id="ixv-27580" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:Inventories contextRef="c4" decimals="-3" id="ixv-27581" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c5" decimals="-3" id="ixv-27582" unitRef="usd">668000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c4" decimals="-3" id="ixv-27583" unitRef="usd">6445000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c5" decimals="-3" id="ixv-27584" unitRef="usd">4510000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-27585" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c5" decimals="-3" id="ixv-27586" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentsInAssociates contextRef="c4" decimals="-3" id="ixv-27587" unitRef="usd">781000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates contextRef="c5" decimals="-3" id="ixv-27588" unitRef="usd">591000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c4" decimals="-3" id="ixv-27589" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c5" decimals="-3" id="ixv-27590" unitRef="usd">730000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-27591" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-27592" unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c4" decimals="-3" id="ixv-27593" unitRef="usd">4737000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c5" decimals="-3" id="ixv-27594" unitRef="usd">6095000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c4" decimals="-3" id="ixv-27595" unitRef="usd">11182000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="-3" id="ixv-27596" unitRef="usd">10605000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-27597" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-27598" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c4" decimals="-3" id="ixv-27599" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="-3" id="ixv-27600" unitRef="usd">193000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c4" decimals="-3" id="ixv-27601" unitRef="usd">532000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentWarrantLiability contextRef="c5" decimals="-3" id="ixv-27602" unitRef="usd">2737000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-27603" unitRef="usd">52000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c5" decimals="-3" id="ixv-27604" unitRef="usd">27000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c4" decimals="-3" id="ixv-27605" unitRef="usd">1571000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c5" decimals="-3" id="ixv-27606" unitRef="usd">4156000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c4" decimals="-3" id="ixv-27607" unitRef="usd">24000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:SharePremium contextRef="c4" decimals="-3" id="ixv-27608" unitRef="usd">64526000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c5" decimals="-3" id="ixv-27609" unitRef="usd">58592000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c4" decimals="-3" id="ixv-27610" unitRef="usd">5282000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c5" decimals="-3" id="ixv-27611" unitRef="usd">5180000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c4" decimals="-3" id="ixv-27612" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c5" decimals="-3" id="ixv-27613" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c4" decimals="-3" id="ixv-27614" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c5" decimals="-3" id="ixv-27615" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c4" decimals="-3" id="ixv-27616" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c5" decimals="-3" id="ixv-27617" unitRef="usd">559000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c4" decimals="-3" id="ixv-27618" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c5" decimals="-3" id="ixv-27619" unitRef="usd">-63569000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c4" decimals="-3" id="ixv-27620" unitRef="usd">7614000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c5" decimals="-3" id="ixv-27621" unitRef="usd">6449000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-27622" unitRef="usd">1973000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-27623" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-27624" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c4" decimals="-3" id="ixv-27625" unitRef="usd">11182000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c5" decimals="-3" id="ixv-27626" unitRef="usd">10605000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-27627" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c6" decimals="-3" id="ixv-27628" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-27629" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c6" decimals="-3" id="ixv-27630" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="-3" id="ixv-27631" unitRef="usd">2196000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c6" decimals="-3" id="ixv-27632" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-27633" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-27634" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-27635" unitRef="usd">1990000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-27636" unitRef="usd">1297000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c6" decimals="-3" id="ix_4_fact" unitRef="usd">537000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9 contextRef="c0" decimals="-3" id="ixv-27638" unitRef="usd">1042000</ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-27639" unitRef="usd">5031000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ix_5_fact" unitRef="usd">5972000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-27641" unitRef="usd">3778000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-27642" unitRef="usd">-6815000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c6" decimals="-3" id="ixv-27643" unitRef="usd">-8287000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c7" decimals="-3" id="ixv-27644" unitRef="usd">-5768000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-27645" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-27646" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-27647" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c6" decimals="-3" id="ixv-27648" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-27649" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c6" decimals="-3" id="ixv-27650" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c7" decimals="-3" id="ixv-27651" unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-27652" unitRef="usd">-5861000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c6" decimals="-3" id="ixv-27653" unitRef="usd">-2578000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c7" decimals="-3" id="ixv-27654" unitRef="usd">-5789000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-27655" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c6" decimals="-3" id="ixv-27656" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-27657" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-27658" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-27659" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="-3" id="ixv-27660" unitRef="usd">-5122000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c6" decimals="-3" id="ixv-27661" unitRef="usd">-2592000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c7" decimals="-3" id="ixv-27662" unitRef="usd">-5789000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-27663" unitRef="usd">-761000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-27664" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-27665" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-27666" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-27667"
      unitRef="usdPershares">14.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c6"
      decimals="2"
      id="ix_0_fact"
      unitRef="usdPershares">14.82</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c7"
      decimals="2"
      id="ix_1_fact"
      unitRef="usdPershares">73.58</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-27670"
      unitRef="usdPershares">14.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c6"
      decimals="2"
      id="ix_2_fact"
      unitRef="usdPershares">14.82</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c7"
      decimals="2"
      id="ix_3_fact"
      unitRef="usdPershares">73.58</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-27675" unitRef="usd">49040000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-27676" unitRef="usd">4315000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="-3" id="ixv-27677" unitRef="usd">2207000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c11" decimals="-3" id="ixv-27678" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c12" decimals="-3" id="ixv-27679" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c13" decimals="-3" id="ixv-27680" unitRef="usd">-55188000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-27681" unitRef="usd">1430000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" id="ixv-27682" unitRef="usd">1430000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c22" decimals="-3" id="ixv-27683" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c23" decimals="-3" id="ixv-27684" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-27685" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <sprcy:ExerciseOfWarrants contextRef="c17" decimals="-3" id="ixv-27686" unitRef="usd">6110000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c19" decimals="-3" id="ixv-27687" unitRef="usd">-1352000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c23" decimals="-3" id="ixv-27688" unitRef="usd">4758000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c7" decimals="-3" id="ixv-27689" unitRef="usd">4758000</sprcy:ExerciseOfWarrants>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c17" decimals="-3" id="ixv-27690" unitRef="usd">3364000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c19" decimals="-3" id="ixv-27691" unitRef="usd">4335000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c23" decimals="-3" id="ixv-27692" unitRef="usd">7699000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c7" decimals="-3" id="ixv-27693" unitRef="usd">7699000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c17" decimals="-3" id="ixv-27694" unitRef="usd">27000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c18" decimals="-3" id="ixv-27695" unitRef="usd">-27000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c18" decimals="-3" id="ixv-27696" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c23" decimals="-3" id="ixv-27697" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-27698" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c25" decimals="-3" id="ixv-27699" unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c26" decimals="-3" id="ixv-27700" unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="-3" id="ixv-27701" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" id="ixv-27702" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-27703" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c30" decimals="-3" id="ixv-27704" unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-27705" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c33" decimals="-3" id="ixv-27706" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c39" decimals="-3" id="ixv-27707" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c40" decimals="-3" id="ixv-27708" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-27709" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <sprcy:ExerciseOfWarrants contextRef="c34" decimals="-3" id="ixv-27710" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c40" decimals="-3" id="ixv-27711" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <sprcy:ExerciseOfWarrants contextRef="c6" decimals="-3" id="ixv-27712" unitRef="usd">3000</sprcy:ExerciseOfWarrants>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c34" decimals="-3" id="ixv-27713" unitRef="usd">48000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c35" decimals="-3" id="ixv-27714" unitRef="usd">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c40" decimals="-3" id="ixv-27715" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-27716" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-27717" unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-27718" unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c44" decimals="-3" id="ixv-27719" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c45" decimals="-3" id="ixv-27720" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c46" decimals="-3" id="ixv-27721" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c47" decimals="-3" id="ixv-27722" unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c48" decimals="-3" id="ixv-27723" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="-3" id="ixv-27724" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c55" decimals="-3" id="ixv-27725" unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c56" decimals="-3" id="ixv-27726" unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c57" decimals="-3" id="ixv-27727" unitRef="usd">-761000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-27728" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c53" decimals="-3" id="ixv-27729" unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c56" decimals="-3" id="ixv-27730" unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c57" decimals="-3" id="ixv-27731" unitRef="usd">2734000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-27732" unitRef="usd">2985000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ShareIssueRelatedCost contextRef="c50" decimals="-3" id="ixv-27733" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c56" decimals="-3" id="ixv-27734" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c0" decimals="-3" id="ixv-27735" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c50" decimals="-3" id="ixv-27736" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c56" decimals="-3" id="ixv-27737" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c0" decimals="-3" id="ixv-27738" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c50" decimals="-3" id="ixv-27739" unitRef="usd">94000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c51" decimals="-3" id="ixv-27740" unitRef="usd">102000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c56" decimals="-3" id="ixv-27741" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-27742" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c58" decimals="-3" id="ixv-27743" unitRef="usd">64526000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c59" decimals="-3" id="ixv-27744" unitRef="usd">5282000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c60" decimals="-3" id="ixv-27745" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c61" decimals="-3" id="ixv-27746" unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c62" decimals="-3" id="ixv-27747" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c63" decimals="-3" id="ixv-27748" unitRef="usd">-68691000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c64" decimals="-3" id="ixv-27749" unitRef="usd">7614000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c65" decimals="-3" id="ixv-27750" unitRef="usd">1973000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c4" decimals="-3" id="ixv-27751" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-27752" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-27753" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-27754" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c0" decimals="-3" id="ixv-27755" unitRef="usd">538000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c6" decimals="-3" id="ixv-27756" unitRef="usd">187000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c7" decimals="-3" id="ixv-27757" unitRef="usd">33000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-27758" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-27759" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c6" decimals="-3" id="ixv-27760" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c7" decimals="-3" id="ixv-27761" unitRef="usd">43000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-27762" unitRef="usd">2205000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c6" decimals="-3" id="ixv-27763" unitRef="usd">6585000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c7" decimals="-3" id="ixv-27764" unitRef="usd">-9000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-27765" unitRef="usd">210000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-27766" unitRef="usd">109000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c0" decimals="-3" id="ixv-27767" unitRef="usd">1048000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c6" decimals="-3" id="ixv-27768" unitRef="usd">770000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-27769" unitRef="usd">829000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c6" decimals="-3" id="ixv-27770" unitRef="usd">-4622000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c7" decimals="-3" id="ixv-27771" unitRef="usd">85000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c0" decimals="-3" id="ixv-27772" unitRef="usd">-409000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c6" decimals="-3" id="ixv-27773" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c7" decimals="-3" id="ixv-27774" unitRef="usd">170000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-27775" unitRef="usd">-397000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c7" decimals="-3" id="ixv-27776" unitRef="usd">353000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="-3" id="ixv-27777" unitRef="usd">-8000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c6" decimals="-3" id="ixv-27778" unitRef="usd">39000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c7" decimals="-3" id="ixv-27779" unitRef="usd">120000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c0" decimals="-3" id="ixv-27780" unitRef="usd">55000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c6" decimals="-3" id="ixv-27781" unitRef="usd">-77000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="-3" id="ixv-27782" unitRef="usd">-74000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c6" decimals="-3" id="ixv-27783" unitRef="usd">-668000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c0" decimals="-3" id="ixv-27784" unitRef="usd">-833000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c6" decimals="-3" id="ixv-27785" unitRef="usd">-703000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c7" decimals="-3" id="ixv-27786" unitRef="usd">643000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-27787" unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-27788" unitRef="usd">-7917000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-27789" unitRef="usd">-5061000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-27790" unitRef="usd">-5000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c6" decimals="-3" id="ixv-27791" unitRef="usd">-15000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c7" decimals="-3" id="ixv-27792" unitRef="usd">-35000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="-3" id="ixv-27793" unitRef="usd">-3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c6" decimals="-3" id="ixv-27794" unitRef="usd">8000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c7" decimals="-3" id="ixv-27795" unitRef="usd">35000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-27796" unitRef="usd">400000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c6" decimals="-3" id="ixv-27797" unitRef="usd">700000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c0" decimals="-3" id="ixv-27798" unitRef="usd">689000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-27799" unitRef="usd">2985000</ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c6" decimals="-3" id="ixv-27800" unitRef="usd">-1500000</sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c6" decimals="-3" id="ixv-27801" unitRef="usd">4861000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-27802" unitRef="usd">-1109000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-27803" unitRef="usd">-7084000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-27804" unitRef="usd">-70000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c0" decimals="-3" id="ixv-27805" unitRef="usd">-5552000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c6" decimals="-3" id="ixv-27806" unitRef="usd">-9005000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses contextRef="c7" decimals="-3" id="ixv-27807" unitRef="usd">-7699000</sprcy:ProceedsFromIssueOfShareCapitalAndWarrantsnetOfIssuanceExpenses>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c6" decimals="-3" id="ixv-27808" unitRef="usd">2770000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c7" decimals="-3" id="ixv-27809" unitRef="usd">2568000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c6" decimals="-3" id="ixv-27810" unitRef="usd">3000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-27811" unitRef="usd">7000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c6" decimals="-3" id="ixv-27812" unitRef="usd">8000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-27813" unitRef="usd">47000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c6" decimals="-3" id="ixv-27814" unitRef="usd">70000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c7" decimals="-3" id="ixv-27815" unitRef="usd">19000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <sprcy:ReceiptofShortTermCreditFromOthers contextRef="c7" decimals="-3" id="ixv-27816" unitRef="usd">-188000</sprcy:ReceiptofShortTermCreditFromOthers>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-27817" unitRef="usd">5498000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c6" decimals="-3" id="ixv-27818" unitRef="usd">11700000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-27819" unitRef="usd">10060000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c0" decimals="-3" id="ixv-27820" unitRef="usd">-1498000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c6" decimals="-3" id="ixv-27821" unitRef="usd">-3301000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c7" decimals="-3" id="ixv-27822" unitRef="usd">4929000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-27823" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c33" decimals="-3" id="ixv-27824" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c16" decimals="-3" id="ixv-27825" unitRef="usd">1946000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-27826" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-27827" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c33" decimals="-3" id="ixv-27828" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c0" decimals="-3" id="ixv-27829" unitRef="usd">102000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c7" decimals="-3" id="ixv-27830" unitRef="usd">78000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RegistrationOfWarrants contextRef="c7" decimals="-3" id="ixv-27831" unitRef="usd">2480000</sprcy:RegistrationOfWarrants>
    <sprcy:InvestmentInFinancialAsset contextRef="c0" decimals="-3" id="ixv-27832" unitRef="usd">288000</sprcy:InvestmentInFinancialAsset>
    <sprcy:UnpaidIssueExpenses contextRef="c7" decimals="-3" id="ixv-27833" unitRef="usd">290000</sprcy:UnpaidIssueExpenses>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c0" id="ixv-19424">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d; or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#x2019;s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in development programs based on &#x394;9-tetrahydrocannabinol (&#x201c;THC&#x201d;) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer&#x2019;s disease and agitation, pain, autism spectrum disorder and Status Epilepticus. The headquarters of the Company are located in Tel Aviv, Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#x201c;SPRC&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2023, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated under
the laws of the State of Delaware: Scisparc US (together with Evero and Brain Bright, the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
board of directors (&#x201c;Board&#x201d;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1, which
became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these interim consolidated financial statements for all periods presented.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
of the Company for the year ended December&#160;31, 2023, were approved on March 31, 2024, and signed on April 1, 2024 (the &#x201c;Approval
Date&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2023, the Group had an accumulated deficit of approximately $68,691 as a result of recurring operating losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2023, the Company&#x2019;s
cash and cash equivalents totaled $2,076. In the period ended December 31, 2023, the Company had an operating loss of $5,883 and negative
cash flows from operating activities of $5,887. The Company&#x2019;s current cash and cash equivalents position is not sufficient to fund
the Company&#x2019;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities
arising from normal business operations when they become due. While the Company has successfully raised funds in the past, there is no
guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially reasonable terms,
would have serious consequences on our financial condition and results of operations. In addition, the Group has started recognizing revenues
from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing and/or new investors.
This dependency will continue until the Group is able to completely finance its operations by generating revenue from its products. These
above-mentioned factors raise substantial doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Definitions and Meanings:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Companies that are controlled by the Company, as defined in IFRS 10, &#x201c;&lt;i&gt;Consolidated Financial Statements&lt;/i&gt;&#x201d;, and whose accounts are consolidated with those of the Company (if active).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Associates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An entity over which the Company has significant influence, as defined in IAS 28, &#x201c;&lt;i&gt;Investment in Associates and Joint Ventures&lt;/i&gt;&#x201d; and is not a Subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related Parties&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As defined in IAS 24, &#x201c;&lt;i&gt;Related Party Disclosures&lt;/i&gt;&#x201d;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International Accounting Standards issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International Financial Reporting Standards issued by the IASB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings contextRef="c4" decimals="-3" id="ixv-27834" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-27835" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-27836" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-27837" unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-19623">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following accounting policies have
been applied consistently in the financial statements for all periods presented, unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized only
when:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and other
service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 1, &#x201c;Disclosure of Accounting Policies&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In February 2021, the IASB issued an
amendment to IAS 1, &#x201c;Presentation of Financial Statements&#x201d; (&#x201c;the Amendment&#x201d;), which replaces the requirement to disclose
&#x2019;significant&#x2019; accounting policies with a requirement to disclose &#x2018;material&#x2019; accounting policies. One of the main reasons for the Amendment
is the absence of a definition of the term &#x2019;significant&#x2019; in IFRS whereas the term &#x2018;material&#x2019; is defined in several standards and particularly
in IAS 1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is applicable for annual
periods beginning on January 1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The application of the above Amendment
had an effect on the disclosures of the Company&#x2019;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 8, &#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -10.1pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;In February 2021, the IASB issued an amendment to IAS 8,
&#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d; (&#x201c;the Amendment&#x201d;), in which it introduces a
new definition of &#x201c;accounting estimates&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Accounting estimates are defined as
&#x201c;monetary amounts in financial statements that are subject to measurement uncertainty&#x201d;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;y.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;The
Company sells products directly to customers mainly through its online Amazon stores.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;z.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <sprcy:BasisOfPresentationOfFinancialStatements contextRef="c0" id="ixv-19635">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;</sprcy:BasisOfPresentationOfFinancialStatements>
    <sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory contextRef="c0" id="ixv-19656">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory>
    <sprcy:OperatingTerm contextRef="c0" id="ixv-27838">P1Y</sprcy:OperatingTerm>
    <sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements contextRef="c0" id="ixv-19668">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-19723">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S.
Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial
statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <sprcy:DescriptionOfAcquisitionOfASingleAssetCompany contextRef="c0" id="ixv-19735">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;</sprcy:DescriptionOfAcquisitionOfASingleAssetCompany>
    <sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit contextRef="c0" id="ixv-19747">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForRestrictedDeposit>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory contextRef="c0" id="ixv-19759">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists only
when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The Company
recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a joint
operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory>
    <sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock contextRef="c0" id="ixv-19835">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of the
Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the acquisition
date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForInvestmentAccountedForUsingTheEquityMethodtextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-19900">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory contextRef="c0" id="ixv-27839">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mainly %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;33-50&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20-33&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;see below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfUsefulLifeOfAssetsAtAnnualRatesExplanatory>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="c66" decimals="2" id="ixv-27840" unitRef="pure">0.06</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="c67" decimals="2" id="ixv-27841" unitRef="pure">0.50</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c68" decimals="2" id="ixv-27842" unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="c69" decimals="2" id="ixv-27843" unitRef="pure">0.33</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="c70" decimals="2" id="ixv-27844" unitRef="pure">0.50</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c71" decimals="2" id="ixv-27845" unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="c72" decimals="2" id="ixv-27846" unitRef="pure">0.20</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="c73" decimals="2" id="ixv-27847" unitRef="pure">0.33</sprcy:PercentageOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c74" decimals="2" id="ixv-27848" unitRef="pure">0.25</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife contextRef="c75" id="ixv-27849">see below</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c0" id="ixv-19965">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c0" id="ixv-19980">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to record
an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The
recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash
flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that
does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are
recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-20029">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt instrument
does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments do
not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized only
when:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the
recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not
be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that
will cause the right to expire.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities involves
the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial
derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities
that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs
are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-20336">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when
incurred.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c0" id="ixv-20351">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c0" id="ixv-20363">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="c0" id="ixv-20471">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or
substantively enacted by the reporting date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary
differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset
is recognized to the extent that their utilization is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the
investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-20560">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and other
service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0" id="ixv-20591">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0" id="ixv-20646">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a
reliable estimate of the amount can be made.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c0" id="ixv-20685">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required
to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part or all of
the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when
the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-20708">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and
the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the expected
exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease
liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change
is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to
the right-of-use asset.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <sprcy:DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock contextRef="c0" id="ixv-20863">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 1, &#x201c;Disclosure of Accounting Policies&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In February 2021, the IASB issued an
amendment to IAS 1, &#x201c;Presentation of Financial Statements&#x201d; (&#x201c;the Amendment&#x201d;), which replaces the requirement to disclose
&#x2019;significant&#x2019; accounting policies with a requirement to disclose &#x2018;material&#x2019; accounting policies. One of the main reasons for the Amendment
is the absence of a definition of the term &#x2019;significant&#x2019; in IFRS whereas the term &#x2018;material&#x2019; is defined in several standards and particularly
in IAS 1.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is applicable for annual
periods beginning on January 1, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The application of the above Amendment
had an effect on the disclosures of the Company&#x2019;s accounting policies, but did not affect the measurement, recognition or presentation
of any items in the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyAmendmentToIAS1DisclosureOfAccountingPoliciesPolicyTextBlock>
    <sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors contextRef="c0" id="ixv-20881">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendment to IAS 8, &#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;In February 2021, the IASB issued an amendment to IAS 8,
&#x201c;Accounting Policies, Changes to Accounting Estimates and Errors&#x201d; (&#x201c;the Amendment&#x201d;), in which it introduces a
new definition of &#x201c;accounting estimates&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Accounting estimates are defined as
&#x201c;monetary amounts in financial statements that are subject to measurement uncertainty&#x201d;. The Amendment clarifies the distinction
between changes in accounting estimates and changes in accounting policies and the correction of errors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment is to be applied prospectively
for annual reporting periods beginning on or after January 1, 2023, and is applicable to changes in accounting policies and changes in
accounting estimates that occur on or after the start of that period. Early application is permitted.&lt;/p&gt;</sprcy:DescriptionOfAmendmentToIAS8AccountingPoliciesChangesToAccountingEstimatesAndErrors>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c0" id="ixv-20899">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost is
determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c0" id="ixv-20912">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;y.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;The
Company sells products directly to customers mainly through its online Amazon stores.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2022, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is a principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock contextRef="c0" id="ixv-20934">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;z.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock>
    <sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock contextRef="c0" id="ixv-20977">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 3:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Judgments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount rate for a lease liability:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing
rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security,
the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no
financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the
lease term and other economic variables deriving from the lease contract&#x2019;s conditions and restrictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective control:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#x2019;
meetings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determining the fair value of share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price
and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates and assumptions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal claims:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its
management&#x2019;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based,
among others, on management&#x2019;s familiarity of and proximity to the circumstances, and also on the legal counsels&#x2019; best professional
judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the
claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease extension and/or termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In evaluating whether it is reasonably
certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company
considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not
exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset
to the Company&#x2019;s operation and whether it is a specialized asset, the company&#x2019;s past experience with similar leases, etc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;After the commencement date, the Company
reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether
the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease
term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying
asset for a period that exceeds the end of the previously determined lease period, etc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When the fair values of financial assets
and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined
using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable
markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for
validity by calibrating to prices from any observable current market transactions in the same instrument when available.&lt;/p&gt;</sprcy:SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInPreparationOfFinancialStatementsExplanatoryTextBlock>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-21120">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 4:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CASH&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,574&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-21130">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,574&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c77" decimals="-3" id="ixv-27850" unitRef="usd">1866000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c78" decimals="-3" id="ixv-27851" unitRef="usd">3443000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c79" decimals="-3" id="ixv-27852" unitRef="usd">210000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c80" decimals="-3" id="ixv-27853" unitRef="usd">131000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-27854" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-27855" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c0" id="ixv-21211">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 5:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <sprcy:DisclosureOfInvertoryTextBlock contextRef="c0" id="ixv-21221">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;470&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInvertoryTextBlock>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c4" decimals="-3" id="ixv-27856" unitRef="usd">73000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c5" decimals="-3" id="ixv-27857" unitRef="usd">198000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:FinishedGoods contextRef="c4" decimals="-3" id="ixv-27858" unitRef="usd">669000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c5" decimals="-3" id="ixv-27859" unitRef="usd">470000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c4" decimals="-3" id="ixv-27860" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c5" decimals="-3" id="ixv-27861" unitRef="usd">668000</ifrs-full:Inventories>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c0" id="ixv-21279">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <sprcy:DisclourseOfAccountsReceivablesTableTextBlock contextRef="c0" id="ixv-21289">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;131&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclourseOfAccountsReceivablesTableTextBlock>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c4" decimals="-3" id="ixv-27862" unitRef="usd">62000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c5" decimals="-3" id="ixv-27863" unitRef="usd">45000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:OtherReceivables contextRef="c4" decimals="-3" id="ixv-27864" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c5" decimals="-3" id="ixv-27865" unitRef="usd">46000</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c4" decimals="-3" id="ixv-27866" unitRef="usd">275000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c5" decimals="-3" id="ixv-27867" unitRef="usd">40000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="-3" id="ixv-27868" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c5" decimals="-3" id="ixv-27869" unitRef="usd">131000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="c0" id="ixv-21357">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 7:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN ASSOCIATES &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sale of Orimmune Bio Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On June 22, 2016, the Company entered
into a share transfer agreement (the &#x201c;Transfer Agreement&#x201d;) with its then wholly owned subsidiary, Orimmune Bio Ltd. (&#x201c;Orimmune&#x201d;)
and Karma Link Ltd. (the &#x201c;Buyer&#x201d;), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its
best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On December 13, 2018, an additional
amendment to the Transfer Agreement was signed between the parties, under which it was agreed that Orimmune will be assigned certain rights
in intellectual property (&#x201c;IP&#x201d;) related to the licensed technology owned by the Company subject to certain conditions precedent
which were still not met as of December 31, 2023. As of the Approval Date, the conditions precedent have not yet been completed and the
assignment of the IP related to the licensed technology owned by us has not yet been transferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Coeruleus - Joint Venture Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On May 15, 2020, the Company entered
into a series of transactions (together, the &#x201c;Joint Venture Transaction&#x201d;), including a definitive share transfer agreement
with Capital Point Ltd. (&#x201c;Capital Point&#x201d;), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital
Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the &#x201c;Purchased Coeruleus Shares&#x201d;
and &#x201c;Coeruleus,&#x201d; respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in,
among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce
the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic
encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus.
In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of
the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company
as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus&#x2019; issued
and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As part of the Joint Venture Transaction,
the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset
purchase agreement. In addition, the Company issued to Capital Point a warrant (the &#x201c;Capital Point Warrant&#x201d;) to purchase $340
of ordinary shares of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ordinary share is equal
to the closing price of the Company&#x2019;s ordinary shares on the trading day on which the notice of exercise was actually received by
the Company and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero. The
Capital Point Warrant is exercisable for twelve months starting from May 15, 2021, until May 15, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 29, 2020, the shareholders
of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in
Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of
Coeruleus. As of December 31, 2023, the fair value of the Company&#x2019;s investment in Coeruleus is $&lt;span style="-sec-ix-hidden: hidden-fact-121"&gt;nil&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MitocareX - Joint Venture Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $600 in MitoCareX and increase its share ownership in MitoCareX Bio from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCare X agreed for the additional $600 installment to be deferred to March 25, 2024. As of the date of this report the $600 installment
has been paid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2023, the Company recorded equity losses from the investment in MitoCareX in the amount of $210 (for the year ended December 31, 2022
- $109).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;781&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <sprcy:OrdinarySharesSold
      contextRef="c81"
      decimals="0"
      id="ixv-27870"
      unitRef="shares">5952469</sprcy:OrdinarySharesSold>
    <sprcy:OrdinarySharesParValue
      contextRef="c82"
      decimals="2"
      id="ixv-27871"
      unitRef="ilsPershares">0.01</sprcy:OrdinarySharesParValue>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c83" decimals="2" id="ixv-27872" unitRef="pure">0.46</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital contextRef="c83" decimals="2" id="ixv-27873" unitRef="pure">0.35</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <sprcy:OrdinarySharesSold
      contextRef="c84"
      decimals="0"
      id="ixv-27874"
      unitRef="shares">176470</sprcy:OrdinarySharesSold>
    <sprcy:OrdinarySharesParValue
      contextRef="c85"
      decimals="2"
      id="ixv-27875"
      unitRef="ilsPershares">1</sprcy:OrdinarySharesParValue>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital contextRef="c82" decimals="2" id="ixv-27876" unitRef="pure">0.15</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <sprcy:FairMarketValue contextRef="c83" decimals="-3" id="ixv-27877" unitRef="usd">351000</sprcy:FairMarketValue>
    <sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital contextRef="c86" decimals="2" id="ixv-27878" unitRef="pure">0.11</sprcy:PercentageOfSharesIssuedAndOutstandingShareCapital>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination contextRef="c83" decimals="-3" id="ixv-27879" unitRef="usd">51000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <sprcy:PurchaseOfOrdinaryShares contextRef="c87" decimals="-3" id="ixv-27880" unitRef="usd">340000</sprcy:PurchaseOfOrdinaryShares>
    <sprcy:DulyExecutedShareTransferDeedForOrdinaryShares
      contextRef="c88"
      decimals="0"
      id="ixv-27881"
      unitRef="shares">9577</sprcy:DulyExecutedShareTransferDeedForOrdinaryShares>
    <sprcy:InvestmentFromShareholders contextRef="c89" decimals="-3" id="ixv-27882" unitRef="usd">30000</sprcy:InvestmentFromShareholders>
    <sprcy:IssuedAndOutstandingSharesPercentage contextRef="c90" decimals="2" id="ixv-27883" unitRef="pure">0.01</sprcy:IssuedAndOutstandingSharesPercentage>
    <sprcy:InitialInvestment contextRef="c91" decimals="-3" id="ixv-27884" unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:AdditionalInvestment contextRef="c92" decimals="-3" id="ixv-27885" unitRef="usd">1000000</sprcy:AdditionalInvestment>
    <sprcy:OwnershipPercentage contextRef="c93" decimals="4" id="ixv-27886" unitRef="pure">0.5001</sprcy:OwnershipPercentage>
    <sprcy:InitialInvestment contextRef="c94" decimals="-3" id="ixv-27887" unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:OutstandingSharesPercentage contextRef="c95" decimals="4" id="ixv-27888" unitRef="pure">0.3148</sprcy:OutstandingSharesPercentage>
    <sprcy:AdditionalInvestment contextRef="c96" decimals="-3" id="ixv-27889" unitRef="usd">400000</sprcy:AdditionalInvestment>
    <sprcy:OwnershipPercentage contextRef="c97" decimals="4" id="ixv-27890" unitRef="pure">0.3148</sprcy:OwnershipPercentage>
    <sprcy:OwnershipPercentage contextRef="c98" decimals="4" id="ixv-27891" unitRef="pure">0.4192</sprcy:OwnershipPercentage>
    <sprcy:AdditionalInvestment contextRef="c99" decimals="-3" id="ixv-27892" unitRef="usd">600000</sprcy:AdditionalInvestment>
    <sprcy:OwnershipPercentage
      contextRef="c100"
      decimals="4"
      id="ixv-27893"
      unitRef="pure">0.4192</sprcy:OwnershipPercentage>
    <sprcy:OwnershipPercentage
      contextRef="c101"
      decimals="4"
      id="ixv-27894"
      unitRef="pure">0.5273</sprcy:OwnershipPercentage>
    <sprcy:AdditionalInstallment
      contextRef="c102"
      decimals="-3"
      id="ixv-27895"
      unitRef="usd">600000</sprcy:AdditionalInstallment>
    <sprcy:InstallmentPaid
      contextRef="c102"
      decimals="-3"
      id="ixv-27896"
      unitRef="usd">600000</sprcy:InstallmentPaid>
    <sprcy:EquityLossesFromInvestment
      contextRef="c103"
      decimals="-3"
      id="ixv-27897"
      unitRef="usd">210000</sprcy:EquityLossesFromInvestment>
    <sprcy:EquityLossesFromInvestment contextRef="c95" decimals="-3" id="ixv-27898" unitRef="usd">109000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0" id="ixv-27899">The table below summarizes the fair
value of the investment in MitoCareX:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;781&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <sprcy:InvestmentsDate contextRef="c6" decimals="-3" id="ixv-27900" unitRef="usd">700000</sprcy:InvestmentsDate>
    <sprcy:EquityLossesFromInvestment contextRef="c6" decimals="-3" id="ixv-27901" unitRef="usd">109000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-27902" unitRef="usd">591000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <sprcy:InvestmentAchievementOfFirstMilestone contextRef="c0" decimals="-3" id="ixv-27903" unitRef="usd">400000</sprcy:InvestmentAchievementOfFirstMilestone>
    <sprcy:EquityLossesFromInvestment contextRef="c0" decimals="-3" id="ixv-27904" unitRef="usd">210000</sprcy:EquityLossesFromInvestment>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-27905" unitRef="usd">781000</ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="c0" id="ixv-21542">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 8:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT IN FINANCIAL ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol &#x201c;CMND&#x201d; and the Frankfurt Stock Exchange under the symbol &#x201c;CWY.&#x201d; &#160; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company&#x2019;s shares in Clearmind was reduced from 230,769 common shares to 7,692. As of December 31, 2023, the listed share price of Clearmind on Nasdaq was $2.81, and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2023, of $727 on its investment (for the year ended December 31, 2022 - $771). &#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 25, 2023, the Company entered into an investment agreement (the &#x201c;Agreement&#x201d;) with AutoMax Motors Ltd. (&#x201c;AutoMax&#x201d;), an Israeli company traded on the Tel Aviv Stock Exchange (&#x201c;TASE&#x201d;) and the leading parallel importer and distributor of vehicles in Israel, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, the Company will invest NIS 2,500,000 in cash, in exchange for ordinary shares, NIS 0.05 par value, of AutoMax based on a price per share of NIS 0.5. As of December 31, 2023, the listed share price of AutoMax on the TASE was NIS 0.384, and the Company has recorded a loss in its statements of comprehensive loss of $158 on its investment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <sprcy:InvestmentAmount
      contextRef="c104"
      decimals="-3"
      id="ixv-27906"
      unitRef="usd">1500000</sprcy:InvestmentAmount>
    <ifrs-full:NumberOfSharesIssuedButNotFullyPaid
      contextRef="c105"
      decimals="0"
      id="ixv-27907"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssuedButNotFullyPaid>
    <sprcy:ShareCapitalPercentage
      contextRef="c104"
      decimals="4"
      id="ixv-27908"
      unitRef="pure">0.0933</sprcy:ShareCapitalPercentage>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c106"
      decimals="0"
      id="ixv-27909"
      unitRef="shares">230769</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c107"
      decimals="0"
      id="ixv-27910"
      unitRef="shares">7692</ifrs-full:NumberOfSharesOutstanding>
    <sprcy:SharePricePerShare
      contextRef="c0"
      decimals="2"
      id="ixv-27911"
      unitRef="usdPershares">2.81</sprcy:SharePricePerShare>
    <sprcy:ComprehensiveLoss contextRef="c0" decimals="-3" id="ixv-27912" unitRef="usd">727000</sprcy:ComprehensiveLoss>
    <sprcy:ComprehensiveLoss contextRef="c6" decimals="-3" id="ixv-27913" unitRef="usd">771000</sprcy:ComprehensiveLoss>
    <ifrs-full:Cash
      contextRef="c108"
      decimals="-3"
      id="ixv-27914"
      unitRef="ils">2500000000</ifrs-full:Cash>
    <ifrs-full:ParValuePerShare
      contextRef="c109"
      decimals="2"
      id="ixv-27915"
      unitRef="ilsPershares">0.05</ifrs-full:ParValuePerShare>
    <sprcy:PricePerShare
      contextRef="c110"
      decimals="1"
      id="ixv-27916"
      unitRef="ilsPershares">0.5</sprcy:PricePerShare>
    <sprcy:SharePricePerShare
      contextRef="c110"
      decimals="3"
      id="ixv-27917"
      unitRef="ilsPershares">0.384</sprcy:SharePricePerShare>
    <sprcy:ComprehensiveLoss
      contextRef="c110"
      decimals="-3"
      id="ixv-27918"
      unitRef="usd">158000</sprcy:ComprehensiveLoss>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0" id="ixv-21570">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 9:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 1, 2020, the Company entered
into a one-year lease agreement with a third party for an area of approximately 100 square meters for the Company&#x2019;s offices in the
district of Tel Aviv, Israel. The yearly lease fee was set at approximately $44, linked to the NIS. The lease expired on August 31, 2021.
The Company did not exercise its option to extend the lease until August 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 1, 2021, the Company entered
into a two-year joint lease agreement with a third party and for a total area of approximately 240 square meters, whereby the Company
occupies approximately 120 square meters for the Company&#x2019;s offices, in the district of Tel Aviv, Israel. The Company and the third
party have an option to extend for an additional three-year term. The yearly lease fee was set at approximately $40, linked to the NIS.
On July 7, 2023, the lease was extended until June 30, 2025.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <sprcy:SquareMeters
      contextRef="c111"
      decimals="0"
      id="ixv-27919"
      unitRef="pure">100</sprcy:SquareMeters>
    <sprcy:LeaseFee
      contextRef="c111"
      decimals="-3"
      id="ixv-27920"
      unitRef="usd">44000</sprcy:LeaseFee>
    <sprcy:ExpireTerm contextRef="c112" id="ixv-27921">2021-08-31</sprcy:ExpireTerm>
    <sprcy:SquareMeters
      contextRef="c113"
      decimals="0"
      id="ixv-27922"
      unitRef="pure">240</sprcy:SquareMeters>
    <sprcy:SquareMeters
      contextRef="c114"
      decimals="0"
      id="ixv-27923"
      unitRef="pure">120</sprcy:SquareMeters>
    <sprcy:LeaseFee
      contextRef="c113"
      decimals="-3"
      id="ixv-27924"
      unitRef="usd">40000</sprcy:LeaseFee>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-21609">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 10:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPERTY AND EQUIPMENT, NET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Assets owned and used by the Company&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Right-of-&lt;br/&gt; use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lab&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; office&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;New lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Depreciation expenses for the years
ended December 31, 2023, 2022 and 2021 amounted to $52, $43 and $32, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-21619">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Assets owned and used by the Company&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Right-of-&lt;br/&gt; use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lab&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; office&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;New lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Purchases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Balance at January&#160;1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Depreciated cost at December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c115"
      decimals="-3"
      id="ixv-27925"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c117"
      decimals="-3"
      id="ixv-27926"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c118"
      decimals="-3"
      id="ixv-27927"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c5" decimals="-3" id="ixv-27928" unitRef="usd">122000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c75" decimals="-3" id="ixv-27929" unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-27930" unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c121"
      decimals="-3"
      id="ixv-27931"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c123"
      decimals="-3"
      id="ixv-27932"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c76" decimals="-3" id="ixv-27933" unitRef="usd">181000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c4" decimals="-3" id="ixv-27934" unitRef="usd">225000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c115"
      decimals="-3"
      id="ixv-27935"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c117"
      decimals="-3"
      id="ixv-27936"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c118"
      decimals="-3"
      id="ixv-27937"
      unitRef="usd">59000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c5" decimals="-3" id="ixv-27938" unitRef="usd">65000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c71" decimals="-3" id="ixv-27939" unitRef="usd">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c120"
      decimals="-3"
      id="ixv-27940"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c75" decimals="-3" id="ixv-27941" unitRef="usd">47000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-27942" unitRef="usd">52000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c121"
      decimals="-3"
      id="ixv-27943"
      unitRef="usd">6000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c123"
      decimals="-3"
      id="ixv-27944"
      unitRef="usd">5000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c76" decimals="-3" id="ixv-27945" unitRef="usd">106000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c4" decimals="-3" id="ixv-27946" unitRef="usd">117000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c121"
      decimals="-3"
      id="ixv-27947"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c123"
      decimals="-3"
      id="ixv-27948"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated contextRef="c76" decimals="-3" id="ixv-27949" unitRef="usd">75000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated contextRef="c4" decimals="-3" id="ixv-27950" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c124"
      decimals="-3"
      id="ixv-27951"
      unitRef="usd">7000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c126"
      decimals="-3"
      id="ixv-27952"
      unitRef="usd">29000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c127"
      decimals="-3"
      id="ixv-27953"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c33" decimals="-3" id="ixv-27954" unitRef="usd">114000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c128"
      decimals="-3"
      id="ixv-27955"
      unitRef="usd">4000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c130"
      decimals="-3"
      id="ixv-27956"
      unitRef="usd">4000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-27957" unitRef="usd">8000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c115"
      decimals="-3"
      id="ixv-27958"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c117"
      decimals="-3"
      id="ixv-27959"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c118"
      decimals="-3"
      id="ixv-27960"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets contextRef="c5" decimals="-3" id="ixv-27961" unitRef="usd">122000</ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c124"
      decimals="-3"
      id="ixv-27962"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c126"
      decimals="-3"
      id="ixv-27963"
      unitRef="usd">1000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c127"
      decimals="-3"
      id="ixv-27964"
      unitRef="usd">20000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c33" decimals="-3" id="ixv-27965" unitRef="usd">22000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c128"
      decimals="-3"
      id="ixv-27966"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c130"
      decimals="-3"
      id="ixv-27967"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c131"
      decimals="-3"
      id="ixv-27968"
      unitRef="usd">39000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-27969" unitRef="usd">43000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c115"
      decimals="-3"
      id="ixv-27970"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c117"
      decimals="-3"
      id="ixv-27971"
      unitRef="usd">3000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c118"
      decimals="-3"
      id="ixv-27972"
      unitRef="usd">59000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation contextRef="c5" decimals="-3" id="ixv-27973" unitRef="usd">65000</sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c115"
      decimals="-3"
      id="ixv-27974"
      unitRef="usd">8000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c117"
      decimals="-3"
      id="ixv-27975"
      unitRef="usd">30000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c118"
      decimals="-3"
      id="ixv-27976"
      unitRef="usd">19000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated contextRef="c5" decimals="-3" id="ixv-27977" unitRef="usd">57000</ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated>
    <ifrs-full:DepreciationExpense contextRef="c0" decimals="-3" id="ixv-27978" unitRef="usd">52000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c6" decimals="-3" id="ixv-27979" unitRef="usd">43000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c7" decimals="-3" id="ixv-27980" unitRef="usd">32000</ifrs-full:DepreciationExpense>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c0" id="ixv-22244">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 11:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INTANGIBLE ASSET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 30, 2022, the Company
announced the closing of the acquisition of Wellution&lt;sup&gt;TM&lt;/sup&gt;, a top seller Amazon.com Marketplace account (the &#x201c;Brand&#x201d;),
American food supplements and cosmetics brand and trademark (the &#x201c;Acquisition&#x201d;). In connection with the Acquisition, the Company
incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement for
the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#x2019;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In addition, the Company issued to
M.R.M $15,000 worth of warrants to purchase ordinary shares of the Company at an exercise price of $7.00 per share (with a cashless exercise
mechanism) and with an exercise period of five years from the closing of the Acquisition (the &#x201c;September 2022 Warrants&#x201d;).
The September 2022 Warrants will become exercisable upon the earlier of (i) an achievement of $100 million of gross sales by the Brand
in the aggregate or (ii) if the price of our Ordinary Shares closes at $10.00 or above.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the years ended December 31, 2022,
and 2023, the Brand recorded significant losses. As of December 31, 2023, the Company has determined there are signs of decline in the
value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,042.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 8.7
years commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections were determined based
on the current period revenues, assuming a growth rate for the short term that is consistent with management&#x2019;s expectations that
revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter of 13.8% and a
declining growth rate for the long term, reaching 2% at the terminal year. Theoretical royalties arising from the brand were capitalized
at a discount rate of 20.6%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Purchase date September 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the year ended December 31,
2023, the Company recognized depreciation expenses in respect to intangible asset in the amount of $486 (for the year ended December 31,
2022 - $144).&#160;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:Cash contextRef="c4" decimals="-3" id="ixv-27981" unitRef="usd">4540000</ifrs-full:Cash>
    <ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount contextRef="c4" decimals="-3" id="ixv-27982" unitRef="usd">1120000</ifrs-full:AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount>
    <sprcy:PurchaseCosts contextRef="c0" decimals="-3" id="ixv-27983" unitRef="usd">321000</sprcy:PurchaseCosts>
    <sprcy:WarrantsToPurchase contextRef="c0" decimals="-3" id="ixv-27984" unitRef="usd">15000000</sprcy:WarrantsToPurchase>
    <sprcy:ExercisePrice1
      contextRef="c0"
      decimals="2"
      id="ixv-27985"
      unitRef="usdPershares">7</sprcy:ExercisePrice1>
    <sprcy:ExercisePeriod contextRef="c0" id="ixv-27986">P5Y</sprcy:ExercisePeriod>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c132"
      decimals="-6"
      id="ixv-27987"
      unitRef="usd">100000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:pricePerShare
      contextRef="c132"
      decimals="2"
      id="ixv-27988"
      unitRef="usdPershares">10</sprcy:pricePerShare>
    <sprcy:AmountTotal contextRef="c0" decimals="-3" id="ixv-27989" unitRef="usd">4861000</sprcy:AmountTotal>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c0" id="ixv-27990">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-27991" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <sprcy:RevenueTerm contextRef="c0" id="ixv-27992">P8Y8M12D</sprcy:RevenueTerm>
    <sprcy:GrowthRatePercentage contextRef="c0" decimals="3" id="ixv-27993" unitRef="pure">0.138</sprcy:GrowthRatePercentage>
    <sprcy:LongTermPercentage contextRef="c0" decimals="2" id="ixv-27994" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="c4" decimals="3" id="ixv-27995" unitRef="pure">0.206</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock contextRef="c0" id="ixv-27996">The table below
summarizes the fair value of the intangible asset:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Purchase date September 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueOfTheIntangibleAssetTextBlock>
    <sprcy:PurchaseofAssets contextRef="c6" decimals="-3" id="ixv-27997" unitRef="usd">4861000</sprcy:PurchaseofAssets>
    <ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost contextRef="c5" decimals="-3" id="ixv-27998" unitRef="usd">144000</ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c5" decimals="-3" id="ixv-27999" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-28000" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost contextRef="c4" decimals="-3" id="ixv-28001" unitRef="usd">486000</ifrs-full:IntangibleAssetFairValueUsedAsDeemedCost>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-28002" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-28003" unitRef="usd">486000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c6" decimals="-3" id="ixv-28004" unitRef="usd">144000</ifrs-full:ReversalOfImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-22368">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 12:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRADE PAYABLES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;802&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,199&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <sprcy:DisclosureOfTradePayables contextRef="c0" id="ixv-22378">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;802&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,199&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfTradePayables>
    <sprcy:AccruedExpenses contextRef="c4" decimals="-3" id="ixv-28005" unitRef="usd">538000</sprcy:AccruedExpenses>
    <sprcy:AccruedExpenses contextRef="c5" decimals="-3" id="ixv-28006" unitRef="usd">901000</sprcy:AccruedExpenses>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-28007" unitRef="usd">264000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-28008" unitRef="usd">298000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c4" decimals="-3" id="ixv-28009" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="-3" id="ixv-28010" unitRef="usd">1199000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <sprcy:DisclosureOfOtherAccountsPayableTextBlock contextRef="c0" id="ixv-22459">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 13:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfOtherAccountsPayableTextBlock>
    <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory contextRef="c0" id="ixv-22469">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;185&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c4" decimals="-3" id="ixv-28011" unitRef="usd">48000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c5" decimals="-3" id="ixv-28012" unitRef="usd">102000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:Accruals contextRef="c4" decimals="-3" id="ixv-28013" unitRef="usd">104000</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="c5" decimals="-3" id="ixv-28014" unitRef="usd">77000</ifrs-full:Accruals>
    <ifrs-full:OtherPayables contextRef="c4" decimals="-3" id="ixv-28015" unitRef="usd">33000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c5" decimals="-3" id="ixv-28016" unitRef="usd">14000</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c4" decimals="-3" id="ixv-28017" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="-3" id="ixv-28018" unitRef="usd">193000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-22537">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 14:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification of financial assets and financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison between the carrying amount
and fair value of the Company&#x2019;s financial instruments as of December 31, 2023, and 2022, which are presented in the financial statements
not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dekel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 19, 2020, the Company entered
into a securities purchase agreement with Dekel Pharmaceutical Ltd. (&#x201c;Dekel&#x201d;) pursuant to which Dekel agreed to invest in
the Company through a private placement transaction (the &#x201c;Private Placement&#x201d;). At the time of the Private Placement, Dekel
was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private
Placement, Dekel received convertible promissory notes (the &#x201c;Notes&#x201d;), with an aggregate original principal amount of approximately
$350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company
issued a warrant to purchase up to 12,088 ordinary shares of the Company (the &#x201c;Private Placement Warrant&#x201d;) and 1,538 ordinary
shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $5,148. The Notes are unsecured,
have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder,
into ordinary shares at an initial conversion price of $0.35 per ordinary share (the &#x201c;Fixed Conversion Price&#x201d;), subject to
adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed
Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary
shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received
by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and
on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35 per ordinary
share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The warrants&#x2019; fair value was
calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March&#160;23,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Underlying Share Price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial risk factors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#x2019;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#x2019;s
financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Foreign currency risk:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects
to settle all of its financial liabilities in less than one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Refer to Note 14a for more information.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities contextRef="c0" id="ixv-22556">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;Financial assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;The tables below are a comparison between the carrying amount
and fair value of the Company&#x2019;s financial instruments as of December 31, 2023, and 2022, which are presented in the financial statements
not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Carrying amount&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</sprcy:DisclosureOfFinancialAssetsAndFinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-28019" unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-28020" unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c4" decimals="-3" id="ixv-28021" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <sprcy:GovernmentAuthorities contextRef="c4" decimals="-3" id="ixv-28022" unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities contextRef="c5" decimals="-3" id="ixv-28023" unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables contextRef="c4" decimals="-3" id="ixv-28024" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c5" decimals="-3" id="ixv-28025" unitRef="usd">46000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets contextRef="c4" decimals="-3" id="ixv-28026" unitRef="usd">659000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets contextRef="c5" decimals="-3" id="ixv-28027" unitRef="usd">591000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c4" decimals="-3" id="ixv-28028" unitRef="usd">6065000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c5" decimals="-3" id="ixv-28029" unitRef="usd">4316000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <sprcy:CreditFromOthers contextRef="c4" decimals="-3" id="ixv-28030" unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers contextRef="c5" decimals="-3" id="ixv-28031" unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability contextRef="c4" decimals="-3" id="ixv-28032" unitRef="usd">532000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability contextRef="c5" decimals="-3" id="ixv-28033" unitRef="usd">2737000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c4" decimals="-3" id="ixv-28034" unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c5" decimals="-3" id="ixv-28035" unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c4" decimals="-3" id="ixv-28036" unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c5" decimals="-3" id="ixv-28037" unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c137"
      decimals="-3"
      id="ixv-28039"
      unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c140"
      decimals="-3"
      id="ixv-28040"
      unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c137"
      decimals="-3"
      id="ixv-28041"
      unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c140"
      decimals="-3"
      id="ixv-28042"
      unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <sprcy:GovernmentAuthorities
      contextRef="c137"
      decimals="-3"
      id="ixv-28043"
      unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities
      contextRef="c140"
      decimals="-3"
      id="ixv-28044"
      unitRef="usd">62000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables
      contextRef="c137"
      decimals="-3"
      id="ixv-28045"
      unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="c140"
      decimals="-3"
      id="ixv-28046"
      unitRef="usd">203000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c137"
      decimals="-3"
      id="ixv-28047"
      unitRef="usd">659000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c140"
      decimals="-3"
      id="ixv-28048"
      unitRef="usd">659000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c137"
      decimals="-3"
      id="ixv-28049"
      unitRef="usd">6065000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c140"
      decimals="-3"
      id="ixv-28050"
      unitRef="usd">6065000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <sprcy:CreditFromOthers
      contextRef="c137"
      decimals="-3"
      id="ixv-28051"
      unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers
      contextRef="c140"
      decimals="-3"
      id="ixv-28052"
      unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability
      contextRef="c137"
      decimals="-3"
      id="ixv-28053"
      unitRef="usd">532000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability
      contextRef="c140"
      decimals="-3"
      id="ixv-28054"
      unitRef="usd">532000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities
      contextRef="c137"
      decimals="-3"
      id="ixv-28055"
      unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c140"
      decimals="-3"
      id="ixv-28056"
      unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c137"
      decimals="-3"
      id="ixv-28057"
      unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c140"
      decimals="-3"
      id="ixv-28058"
      unitRef="usd">656000</ifrs-full:FinancialLiabilities>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c141"
      decimals="-3"
      id="ixv-28059"
      unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c144"
      decimals="-3"
      id="ixv-28060"
      unitRef="usd">3634000</ifrs-full:RestrictedCashAndCashEquivalents>
    <sprcy:GovernmentAuthorities
      contextRef="c141"
      decimals="-3"
      id="ixv-28061"
      unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <sprcy:GovernmentAuthorities
      contextRef="c144"
      decimals="-3"
      id="ixv-28062"
      unitRef="usd">45000</sprcy:GovernmentAuthorities>
    <ifrs-full:OtherReceivables
      contextRef="c141"
      decimals="-3"
      id="ixv-28063"
      unitRef="usd">46000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="c144"
      decimals="-3"
      id="ixv-28064"
      unitRef="usd">46000</ifrs-full:OtherReceivables>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c141"
      decimals="-3"
      id="ixv-28065"
      unitRef="usd">591000</sprcy:InvestmentsInFinancialAssets>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c144"
      decimals="-3"
      id="ixv-28066"
      unitRef="usd">591000</sprcy:InvestmentsInFinancialAssets>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c141"
      decimals="-3"
      id="ixv-28067"
      unitRef="usd">4316000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c144"
      decimals="-3"
      id="ixv-28068"
      unitRef="usd">4316000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <sprcy:CreditFromOthers
      contextRef="c141"
      decimals="-3"
      id="ixv-28069"
      unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers
      contextRef="c144"
      decimals="-3"
      id="ixv-28070"
      unitRef="usd">102000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability
      contextRef="c141"
      decimals="-3"
      id="ixv-28071"
      unitRef="usd">2737000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability
      contextRef="c144"
      decimals="-3"
      id="ixv-28072"
      unitRef="usd">2737000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities
      contextRef="c141"
      decimals="-3"
      id="ixv-28073"
      unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="c144"
      decimals="-3"
      id="ixv-28074"
      unitRef="usd">27000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c141"
      decimals="-3"
      id="ixv-28075"
      unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="c144"
      decimals="-3"
      id="ixv-28076"
      unitRef="usd">2866000</ifrs-full:FinancialLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="c133"
      decimals="-3"
      id="ixv-28077"
      unitRef="usd">350000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash
      contextRef="c134"
      decimals="-3"
      id="ixv-28078"
      unitRef="usd">315000</ifrs-full:PricesSpecifiedInForwardAgreementsToPurchaseFinancialAssetsForCash>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c135"
      decimals="0"
      id="ixv-28079"
      unitRef="shares">12088</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c134"
      decimals="0"
      id="ixv-28080"
      unitRef="shares">1538</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:CashOutflowForLeases
      contextRef="c136"
      decimals="-3"
      id="ixv-28081"
      unitRef="usd">220000</ifrs-full:CashOutflowForLeases>
    <sprcy:PurchasePrice
      contextRef="c136"
      decimals="-3"
      id="ixv-28082"
      unitRef="usd">5148000</sprcy:PurchasePrice>
    <sprcy:MaturityDate contextRef="c133" id="ixv-28083">2021-03-23</sprcy:MaturityDate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c134"
      decimals="2"
      id="ixv-28084"
      unitRef="pure">0.12</ifrs-full:BorrowingsInterestRate>
    <sprcy:InitialConversionPrice
      contextRef="c134"
      decimals="2"
      id="ixv-28085"
      unitRef="usdPershares">0.35</sprcy:InitialConversionPrice>
    <sprcy:ConversionPrice
      contextRef="c133"
      decimals="2"
      id="ixv-28086"
      unitRef="pure">0.70</sprcy:ConversionPrice>
    <sprcy:OrdinaryShareExercisePrice
      contextRef="c133"
      decimals="2"
      id="ixv-28087"
      unitRef="usdPershares">0.35</sprcy:OrdinaryShareExercisePrice>
    <sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock contextRef="c0" id="ixv-28088">The warrants&#x2019; fair value was
calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March&#160;23,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Underlying Share Price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfWarrantsFairValueUsingBlackscholesTableTextBlock>
    <sprcy:DividendYield contextRef="c0" decimals="2" id="ixv-28089" unitRef="pure">0</sprcy:DividendYield>
    <sprcy:DividendYield contextRef="c6" decimals="2" id="ixv-28090" unitRef="pure">0</sprcy:DividendYield>
    <sprcy:DividendYield
      contextRef="c145"
      decimals="2"
      id="ixv-28091"
      unitRef="pure">0</sprcy:DividendYield>
    <sprcy:ExpectedVolatility contextRef="c0" decimals="2" id="ixv-28092" unitRef="pure">0.72</sprcy:ExpectedVolatility>
    <sprcy:ExpectedVolatility contextRef="c6" decimals="2" id="ixv-28093" unitRef="pure">0.72</sprcy:ExpectedVolatility>
    <sprcy:ExpectedVolatility
      contextRef="c145"
      decimals="4"
      id="ixv-28094"
      unitRef="pure">1.2201</sprcy:ExpectedVolatility>
    <sprcy:RiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-28095" unitRef="pure">0.0384</sprcy:RiskFreeInterestRate>
    <sprcy:RiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-28096" unitRef="pure">0.04</sprcy:RiskFreeInterestRate>
    <sprcy:RiskFreeInterestRate
      contextRef="c145"
      decimals="4"
      id="ixv-28097"
      unitRef="pure">0.0038</sprcy:RiskFreeInterestRate>
    <sprcy:UnderlyingAdsPrice
      contextRef="c0"
      decimals="2"
      id="ixv-28098"
      unitRef="usdPershares">4.88</sprcy:UnderlyingAdsPrice>
    <sprcy:UnderlyingAdsPrice
      contextRef="c6"
      decimals="2"
      id="ixv-28099"
      unitRef="usdPershares">19.66</sprcy:UnderlyingAdsPrice>
    <sprcy:UnderlyingAdsPrice
      contextRef="c145"
      decimals="2"
      id="ixv-28100"
      unitRef="usdPershares">11.18</sprcy:UnderlyingAdsPrice>
    <sprcy:ExercisePricePerShare
      contextRef="c0"
      decimals="0"
      id="ixv-28101"
      unitRef="usdPershares">637</sprcy:ExercisePricePerShare>
    <sprcy:ExercisePricePerShare
      contextRef="c6"
      decimals="0"
      id="ixv-28102"
      unitRef="usdPershares">637</sprcy:ExercisePricePerShare>
    <sprcy:ExercisePricePerShare
      contextRef="c145"
      decimals="0"
      id="ixv-28103"
      unitRef="usdPershares">637</sprcy:ExercisePricePerShare>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c0"
      decimals="0"
      id="ixv-28104"
      unitRef="usdPershares">0</sprcy:WarrantsFairValueinDollarsPerShares>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c6"
      decimals="0"
      id="ixv-28105"
      unitRef="usdPershares">0</sprcy:WarrantsFairValueinDollarsPerShares>
    <sprcy:WarrantsFairValueinDollarsPerShares
      contextRef="c145"
      decimals="2"
      id="ixv-28106"
      unitRef="usdPershares">0.36</sprcy:WarrantsFairValueinDollarsPerShares>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c0" id="ixv-23565">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 15:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EMPLOYEE BENEFIT LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Employee benefits consist of short-term
benefits and post-employment benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Post-employment benefits:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#x201c;Severance Pay Law&#x201d;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#x2019;s liability is accounted for as a post-employment benefit. The computation of the Company&#x2019;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#x2019;s salary and employment
term which establish the entitlement to receive the compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Defined contribution plans:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 61%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses in respect of defined contribution plans&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory contextRef="c0" id="ixv-28107">These contributions and contributions for compensation represent defined contribution plans.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 61%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses in respect of defined contribution plans&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;105&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="-3" id="ixv-28108" unitRef="usd">105000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c6" decimals="-3" id="ixv-28109" unitRef="usd">115000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c7" decimals="-3" id="ixv-28110" unitRef="usd">98000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-23639">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 16:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TAXES ON INCOME&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax rates applicable to the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2023, 2022, and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The assessments of the Company are
deemed final through the 2016 tax year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carryforward tax losses and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has accumulated tax losses
since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2023, the Company&#x2019;s
net carryforward tax losses are estimated to grow to approximately $62,000.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate contextRef="c0" decimals="2" id="ixv-28111" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c6" decimals="2" id="ixv-28112" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c7" decimals="2" id="ixv-28113" unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <sprcy:OperatingLossCarryforwardsTaxAmount contextRef="c4" decimals="-3" id="ixv-28114" unitRef="usd">62000000</sprcy:OperatingLossCarryforwardsTaxAmount>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-23706">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 17:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement with Dekel Pharmaceuticals Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#x201c;Dekel License Agreement&#x201d;). The Dekel License Agreement became effective
in August 2015.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include:
(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 14, 2019, an amendment to the
Dekel License Agreement was signed (the &#x201c;Amendment&#x201d;), which encompasses the Company and Dekel&#x2019;s original intention to
exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are
sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of
activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the
foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment also prescribes for a
specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under
the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also
included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#x2019;s former Executive Chairman
of the Board and former interim Chief Executive Officer, towards the Company&#x2019;s field of activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#x201c;Yissum&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#x201c;Yissum License Agreement&#x201d;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#x2019;s share in such joint patents shall be automatically included in the Yissum License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agreement with Hannover Medical School:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#x201c;MHH&#x201d;) to conduct during 2018 a phase IIb clinical
trial titled &#x201c;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#x201d; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of
approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the
first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a
new agreement or will be paid back to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Agreement with Yale University:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 2, 2023, Capital Point Ltd. (&#x201c;Capital Point&#x201d;) filed with the Tel Aviv-Jaffa District Court (the &#x201c;Court&#x201d;) a suit against the Company, case number 2050-05-23 (the &#x201c;Suit&#x201d;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit challenges a certain warrant issued by the Company to Capital Point (the &#x201c;Capital Point Warrant&#x201d;) to purchase $340,000 of ordinary shares of the Company (the &#x201c;Warrant Shares&#x201d;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#x2019;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;As of December 31, 2023, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the Approval Date, the Company cannot
predict the likelihood of success of the Suit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <sprcy:DekelLicenseAgreementDescription contextRef="c0" id="ixv-28115">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash
in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues
of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European
Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the respective
milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization
and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would
likely be 2029.</sprcy:DekelLicenseAgreementDescription>
    <sprcy:AnnualInvestment contextRef="c0" decimals="-3" id="ixv-28116" unitRef="usd">350000</sprcy:AnnualInvestment>
    <sprcy:AdditionalMilestoneAmount
      contextRef="c146"
      decimals="-3"
      id="ixv-28117"
      unitRef="usd">75000</sprcy:AdditionalMilestoneAmount>
    <sprcy:InstallmentAmount
      contextRef="c147"
      decimals="-3"
      id="ixv-28118"
      unitRef="usd">122000</sprcy:InstallmentAmount>
    <sprcy:EstimatedAmount
      contextRef="c147"
      decimals="-3"
      id="ixv-28119"
      unitRef="usd">776000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c148"
      decimals="-3"
      id="ixv-28120"
      unitRef="usd">1385000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c149"
      decimals="-3"
      id="ixv-28121"
      unitRef="usd">370000</sprcy:EstimatedAmount>
    <ifrs-full:IssuedCapitalOrdinaryShares contextRef="c4" decimals="-3" id="ixv-28122" unitRef="usd">340000000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:CapitalCommitments contextRef="c4" decimals="-3" id="ixv-28123" unitRef="ils">10000000000</ifrs-full:CapitalCommitments>
    <ifrs-full:CapitalCommitments contextRef="c4" decimals="-4" id="ixv-28124" unitRef="usd">2750000</ifrs-full:CapitalCommitments>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-23861">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 18:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Reverse Share Splits&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#x2019;s share capital
to 75,000,000 ordinary shares with &lt;span style="-sec-ix-hidden: hidden-fact-181"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital
up to a ratio of 30:1 (the &#x201c;Third Reverse Split&#x201d;). Following the implementation of the Third Reverse Split, the Company&#x2019;s
authorized share capital was adjusted under the Company&#x2019;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, &lt;span style="-sec-ix-hidden: hidden-fact-182"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt; ordinary&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of share capital &#x2013; in respect of investment in affiliate (Note 18f)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share issued to a consultant (Note 19(a)(5))&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of shelf prospectus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of August 2023 financing round (Note 18i)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of rounding errors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issuance of share capital &#x2013; in respect of October 2023 financing round (Note 18j)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rights attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Voting rights at the shareholders meeting,
right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capital management in the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s capital management
objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating a return for the shareholders, investors
and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of
capital return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional issuance of ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 2, 2022, the Company issued
a consultant 923 ordinary shares in respect of services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 1, 2022, the Company issued
a consultant 1,423 ordinary shares in respect of services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 22, 2023, the Company issued
13,858 ordinary shares in respect of the stock purchase&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;agreement entered into
by and among Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo&#x201d;) (see also note 25a)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2021 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 4, 2021, the Company completed
a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an
aggregate of 44,332 units, as follows: (a) 35,243 units at a price of $183.82 per unit, consisting of (i) one ordinary share of the Company,
and (ii) a Series A Warrant to purchase an equal number of units purchased (the &#x201c;2021 Series A Warrants&#x201d;) and a Series B Warrant
(the &#x201c;2021 Series B Warrants&#x201d; and, collectively with the 2021 Series A Warrants, the March 2021 Warrants) to purchase half
the number of units, and (b) 9,089 pre-funded units at a price of $183.79 per unit, consisting of (i) one pre-funded warrant to purchase
one ordinary share and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The 2021 Series A Warrants have an
exercise price of&#160;$183.82&#160;per ordinary share and the 2021 Series B Warrants have an exercise price of&#160;$275.60&#160;per
ordinary share). Both were exercisable upon issuance and will expire five years from the date of issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2021, the Company issued 4,929 ordinary shares in respect of the exercise of 385 2021 Series A Warrants and the exercise of 4,544 of pre-funded
warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2022, the Company issued 3,846 ordinary shares in respect of the exercise of 3,846 pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June 2022 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210(the &#x201c;June 2022 Financing Round&#x201d;), providing for the issuance
of an aggregate of 136,388 units and pre-funded units, as follows: (a) 12,885 units at a price of $74.88 per unit, each consisting of
(i) one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 123,504 pre-funded units at a price of $73.29 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants have an exercise
price of&#160;$68.38&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven years from the
date of issuance.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2022, the Company issued 123,504 ordinary shares in respect of the exercise of 123,504 pre-funded warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;August 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 14, 2023, the Company closed
an underwritten public offering (the &#x201c;2023 Public Offering&#x201d;) of 212,500 ordinary shares, at a purchase price of $5.20 per
ordinary share and pre-funded warrants to purchase up to 37,500 ordinary shares at a purchase price of $5.174 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#x201c;Aegis&#x201d;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 37,500 ordinary shares solely to
cover over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;October 2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the private placement,
the Company issued an aggregate of 1,930,108 units, each unit consisting of two pre-funded warrants, or Pre-Funded Warrants. The Pre-Funded
Warrants have an exercise price of $0.001, are immediately exercisable upon issuance and have a term of five years from the date of issuance.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-23877">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December&#160;31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c4"
      decimals="INF"
      id="ixv-28125"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-28126"
      unitRef="shares">706683</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c5"
      decimals="INF"
      id="ixv-28127"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-28128"
      unitRef="shares">261494</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c150"
      decimals="0"
      id="ixv-28129"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:DescriptionOfReverseShareSplit contextRef="c152" id="ixv-28130">the Company convened
a general meeting of its shareholders, whereby the shareholders approved, inter alia, a reverse split of the Company&#x2019;s share capital
up to a ratio of 30:1 (the &#x201c;Third Reverse Split&#x201d;).</sprcy:DescriptionOfReverseShareSplit>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c152"
      decimals="0"
      id="ixv-28131"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c0" id="ixv-23996">&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt; ordinary&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-indent: -9pt; padding-left: 9pt"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;261,494&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issuance of share capital &#x2013; in respect of investment in affiliate (Note 18f)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share issued to a consultant (Note 19(a)(5))&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of shelf prospectus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of August 2023 financing round (Note 18i)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of share capital &#x2013; in respect of rounding errors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issuance of share capital &#x2013; in respect of October 2023 financing round (Note 18j)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;706,683&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-28132"
      unitRef="shares">261494</ifrs-full:NumberOfSharesIssued>
    <sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate
      contextRef="c0"
      decimals="INF"
      id="ixv-28133"
      unitRef="shares">13858</sprcy:IssuanceOfShareCapitalInRespectOfInvestmentInAffiliate>
    <sprcy:ShareIssuedToAConsultant
      contextRef="c0"
      decimals="INF"
      id="ixv-28134"
      unitRef="shares">7942</sprcy:ShareIssuedToAConsultant>
    <sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus
      contextRef="c0"
      decimals="INF"
      id="ixv-28135"
      unitRef="shares">296</sprcy:IssuanceOfShareCapitalInRespectOfShelfProspectus>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-28136"
      unitRef="shares">237500</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors
      contextRef="c0"
      decimals="INF"
      id="ixv-28137"
      unitRef="shares">2688</sprcy:IssuanceOfShareCapitalInRespectOfRoundingErrors>
    <sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound
      contextRef="c0"
      decimals="INF"
      id="ixv-28138"
      unitRef="shares">182905</sprcy:IssuanceOfShareCapitalInRespectOfOctober2023FinancingRound>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-28139"
      unitRef="shares">706683</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c154"
      decimals="0"
      id="ixv-28140"
      unitRef="shares">923</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c155"
      decimals="0"
      id="ixv-28141"
      unitRef="shares">1423</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c156"
      decimals="0"
      id="ixv-28142"
      unitRef="shares">13858</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:GrossProceeds
      contextRef="c157"
      decimals="-3"
      id="ixv-28143"
      unitRef="usd">8150000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c158"
      decimals="0"
      id="ixv-28144"
      unitRef="shares">44332</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c158"
      decimals="0"
      id="ixv-28145"
      unitRef="shares">35243</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c158"
      decimals="2"
      id="ixv-28146"
      unitRef="usdPershares">183.82</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c159"
      decimals="0"
      id="ixv-28147"
      unitRef="shares">9089</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c159"
      decimals="2"
      id="ixv-28148"
      unitRef="usdPershares">183.79</sprcy:AggregateUnitsPerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c160"
      decimals="2"
      id="ixv-28149"
      unitRef="usdPershares">183.82</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c161"
      decimals="2"
      id="ixv-28150"
      unitRef="usdPershares">275.6</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:DateOfIssuance contextRef="c158" id="ixv-28151">P5Y</sprcy:DateOfIssuance>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c162"
      decimals="0"
      id="ixv-28152"
      unitRef="shares">4929</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c7"
      decimals="0"
      id="ixv-28153"
      unitRef="shares">385</sprcy:WarrantsAndExercise>
    <sprcy:WarrantsAndExercise
      contextRef="c163"
      decimals="0"
      id="ixv-28154"
      unitRef="shares">4544</sprcy:WarrantsAndExercise>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c164"
      decimals="0"
      id="ixv-28155"
      unitRef="shares">3846</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c165"
      decimals="0"
      id="ixv-28156"
      unitRef="shares">3846</sprcy:WarrantsAndExercise>
    <sprcy:GrossProceeds
      contextRef="c166"
      decimals="-3"
      id="ixv-28157"
      unitRef="usd">10210000</sprcy:GrossProceeds>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c167"
      decimals="0"
      id="ixv-28158"
      unitRef="shares">136388</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c167"
      decimals="0"
      id="ixv-28159"
      unitRef="shares">12885</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c167"
      decimals="2"
      id="ixv-28160"
      unitRef="usdPershares">74.88</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c168"
      decimals="0"
      id="ixv-28161"
      unitRef="shares">123504</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c168"
      decimals="2"
      id="ixv-28162"
      unitRef="usdPershares">73.29</sprcy:AggregateUnitsPerShare>
    <sprcy:WarrantsExercisePrice
      contextRef="c169"
      decimals="2"
      id="ixv-28163"
      unitRef="pure">68.38</sprcy:WarrantsExercisePrice>
    <sprcy:DateOfIssuance contextRef="c167" id="ixv-28164">P7Y</sprcy:DateOfIssuance>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory contextRef="c0" id="ixv-28165">The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Underlying share price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c0" decimals="2" id="ixv-28166" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c6" decimals="2" id="ixv-28167" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c0" decimals="2" id="ixv-28168" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c6" decimals="2" id="ixv-28169" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c0" decimals="5" id="ixv-28170" unitRef="pure">0.03872</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c6" decimals="4" id="ixv-28171" unitRef="pure">0.0397</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-28172"
      unitRef="usdPershares">4.88</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c6"
      decimals="3"
      id="ixv-28173"
      unitRef="usdPershares">19.656</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-28174"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c6"
      decimals="2"
      id="ixv-28175"
      unitRef="usdPershares">68.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c4" decimals="-3" id="ixv-28176" unitRef="usd">192000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c5" decimals="-3" id="ixv-28177" unitRef="usd">2396000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c170"
      decimals="0"
      id="ixv-28178"
      unitRef="shares">123504</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c171"
      decimals="0"
      id="ixv-28179"
      unitRef="shares">123504</sprcy:WarrantsAndExercise>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c172"
      decimals="0"
      id="ixv-28180"
      unitRef="shares">212500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c172"
      decimals="2"
      id="ixv-28181"
      unitRef="usdPershares">5.2</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c173"
      decimals="0"
      id="ixv-28182"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c173"
      decimals="3"
      id="ixv-28183"
      unitRef="usdPershares">5.174</sprcy:PurchasePricePerShare>
    <sprcy:AggregateGrossProceeds
      contextRef="c172"
      decimals="-3"
      id="ixv-28184"
      unitRef="usd">1300000</sprcy:AggregateGrossProceeds>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c174"
      decimals="0"
      id="ixv-28185"
      unitRef="shares">37500</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c175"
      decimals="-3"
      id="ixv-28186"
      unitRef="usd">5026000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c176"
      decimals="0"
      id="ixv-28187"
      unitRef="shares">1930108</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c177"
      decimals="3"
      id="ixv-28188"
      unitRef="usdPershares">0.001</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-24422">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 19:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SHARE-BASED PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The cost of share-based payment recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The 2005 and 2015 ESOP and 2023 Plan of the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#x201c;2023 Plan&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span&gt;The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. &lt;/span&gt;Under the 2023 Plan, the Company may grant its employees and other
service providers equity based incentive awards (&#x201c;Share Options&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board approved
to reserve for &lt;span&gt;issuance under the 2023 Plan &lt;span style="-sec-ix-hidden: hidden-fact-183"&gt;1,000,0000&lt;/span&gt; Ordinary Shares. As &lt;/span&gt;of the date of
this report, no shares were issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 12, 2019, the Board approved and granted 45 ordinary shares under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $10,920.00 per share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of share options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
was set at $5,824 per Share Option.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 10, 2019 (the &#x201c;2019 Grant Date&#x201d;), the Board approved the grant of 3 Share Options under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2019 General Meeting&#x201d;), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 1 Share Options was not granted. Out of the 2 Share Options that were granted, 1 Share Options didn&#x2019;t require the general meeting&#x2019;s approval. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2019 Grant Date. The exercise price was set at $5,460.00 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;According to IFRS 2, &#x201c;&lt;i&gt;Share-based
Payment&lt;/i&gt;&#x201d;, the fair value of the Share Options was estimated using the Black-Scholes OPM, in which the fair value estimation
for the Share Options which required the 2019 General Meeting&#x2019;s approval was calculated based on parameters as of December 31, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;10,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,031.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,004&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
approved on October 10, 2019 by the Board, and on January 15, 2020 at the 2019 General Meeting (valuated as of December 31, 2019) was
set at $2,966.6 and $1,328.6, per Share Option, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 3, 2022 (the &#x201c;2022 Grant Date&#x201d;), the Board approved the grant of 6,851 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2022 General Meeting&#x201d;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $169 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February&#160;10,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 3,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;174.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of the Share Options
granted on January 3, 2022, was set at $158.34 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $114.66 per Share Option. The Share Options&#x2019; vesting period was set to commence retroactively from April 21, 2021, and
end at April 21, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2023, the Company issued to consultants 7,942 ordinary shares in respect of services rendered. The ordinary shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $94. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options cancelled during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;2022:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;76.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,851&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,141&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;163.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No Share Options were granted during 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life of the Share Options outstanding was 4.03 years and 5.03 years as of December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The range of exercise prices of Share Options outstanding at the end of the year was $169 - $21,944 (inclusive) as of December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock contextRef="c0" id="ixv-28189">The expenses due to share-based compensation
for the years ended December 31, 2023, 2022 and 2021, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;633&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock>
    <sprcy:ResearchAndDevelopmentsExpenses contextRef="c0" decimals="-3" id="ixv-28190" unitRef="usd">34000</sprcy:ResearchAndDevelopmentsExpenses>
    <sprcy:ResearchAndDevelopmentsExpenses contextRef="c6" decimals="-3" id="ixv-28191" unitRef="usd">264000</sprcy:ResearchAndDevelopmentsExpenses>
    <sprcy:ResearchAndDevelopmentsExpenses contextRef="c7" decimals="-3" id="ixv-28192" unitRef="usd">27000</sprcy:ResearchAndDevelopmentsExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c0" decimals="-3" id="ixv-28193" unitRef="usd">68000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c6" decimals="-3" id="ixv-28194" unitRef="usd">633000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:GeneralAndAdministrativeExpenses contextRef="c7" decimals="-3" id="ixv-28195" unitRef="usd">16000</sprcy:GeneralAndAdministrativeExpenses>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c0" decimals="-3" id="ixv-28196" unitRef="usd">102000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c6" decimals="-3" id="ixv-28197" unitRef="usd">897000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:ExpensesDueToSharebasedCompensation contextRef="c7" decimals="-3" id="ixv-28198" unitRef="usd">43000</sprcy:ExpensesDueToSharebasedCompensation>
    <sprcy:OrdinarySharesGranted
      contextRef="c179"
      decimals="0"
      id="ixv-28199"
      unitRef="shares">45</sprcy:OrdinarySharesGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c179"
      decimals="2"
      id="ixv-28200"
      unitRef="usdPershares">10920</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock contextRef="c0" id="ixv-24590">&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of share options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;i&gt;Based on the above-mentioned, hereinafter
are the parameters used in order to estimate the fair value of the Share Options using the Black-Scholes OPM:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;October&#160;10,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,031.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,004&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;February&#160;10,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;January 3,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Underlying ordinary share price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;174.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life of Share Options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed contextRef="c0" decimals="2" id="ixv-28201" unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate contextRef="c0" decimals="2" id="ixv-28202" unitRef="pure">0.76</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-28203" unitRef="pure">0.0261</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c0" id="ixv-28204">P10Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOfShareOption
      contextRef="c0"
      decimals="-3"
      id="ixv-28205"
      unitRef="usdPershares">5824000</sprcy:FairValueOfShareOption>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c180"
      decimals="2"
      id="ixv-28206"
      unitRef="usdPershares">5460</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c185"
      decimals="2"
      id="ixv-28207"
      unitRef="usdPershares">2031.12</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c181"
      decimals="0"
      id="ixv-28208"
      unitRef="usdPershares">4004</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c185"
      decimals="2"
      id="ixv-28209"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c181"
      decimals="2"
      id="ixv-28210"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c185"
      decimals="2"
      id="ixv-28211"
      unitRef="pure">0.73</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c181"
      decimals="2"
      id="ixv-28212"
      unitRef="pure">0.70</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c185"
      decimals="4"
      id="ixv-28213"
      unitRef="pure">0.0191</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c181"
      decimals="4"
      id="ixv-28214"
      unitRef="pure">0.0167</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c185" id="ixv-28215">P9Y9M10D</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c181" id="ixv-28216">P10Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOfShareOption
      contextRef="c181"
      decimals="1"
      id="ixv-28217"
      unitRef="usdPershares">2966.6</sprcy:FairValueOfShareOption>
    <sprcy:FairValueOfShareOption
      contextRef="c182"
      decimals="1"
      id="ixv-28218"
      unitRef="usdPershares">1328.6</sprcy:FairValueOfShareOption>
    <sprcy:ShareOptionsGranted
      contextRef="c183"
      decimals="0"
      id="ixv-28219"
      unitRef="shares">6851</sprcy:ShareOptionsGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c183"
      decimals="0"
      id="ixv-28220"
      unitRef="usdPershares">169</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c186"
      decimals="2"
      id="ixv-28221"
      unitRef="usdPershares">129.74</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:UnderlyingOrdinarySharePrices
      contextRef="c187"
      decimals="2"
      id="ixv-28222"
      unitRef="usdPershares">174.98</sprcy:UnderlyingOrdinarySharePrices>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c186"
      decimals="2"
      id="ixv-28223"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed
      contextRef="c187"
      decimals="2"
      id="ixv-28224"
      unitRef="pure">0</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRangeOfDividendUsed>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c186"
      decimals="2"
      id="ixv-28225"
      unitRef="pure">1.33</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate
      contextRef="c187"
      decimals="2"
      id="ixv-28226"
      unitRef="pure">1.34</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c186"
      decimals="4"
      id="ixv-28227"
      unitRef="pure">0.02</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate
      contextRef="c187"
      decimals="4"
      id="ixv-28228"
      unitRef="pure">0.0146</sprcy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestRate>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c186" id="ixv-28229">P6Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="c187" id="ixv-28230">P6Y</sprcy:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c183"
      decimals="2"
      id="ixv-28231"
      unitRef="usdPershares">158.34</sprcy:FairValueOfShareOptionsGranted>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c184"
      decimals="2"
      id="ixv-28232"
      unitRef="usdPershares">114.66</sprcy:FairValueOfShareOptionsGranted>
    <sprcy:OrdinarySharesIssued
      contextRef="c0"
      decimals="0"
      id="ixv-28233"
      unitRef="shares">7942</sprcy:OrdinarySharesIssued>
    <sprcy:OrdinarySharesGrantedDiscountRate contextRef="c0" decimals="2" id="ixv-28234" unitRef="pure">0.25</sprcy:OrdinarySharesGrantedDiscountRate>
    <sprcy:FairValueOfOrdinarySharesGranted contextRef="c0" decimals="0" id="ixv-28235" unitRef="usd">94</sprcy:FairValueOfOrdinarySharesGranted>
    <sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock contextRef="c0" id="ixv-24889">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of share options and changes in directors (and former directors), officers, employees and consultants share options during the years ended on December 31, 2023, and 2022:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;2023:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options cancelled during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;2022:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;209&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;76.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options granted during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,851&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,060&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Share Options exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,141&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;163.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfShareOptionsAndWeightedAverageExercisePricesExplanatoryTableTextBlock>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c5"
      decimals="0"
      id="ixv-28236"
      unitRef="shares">7060</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c5"
      decimals="2"
      id="ixv-28237"
      unitRef="usdPershares">166.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionsCancelledInSharebasedPaymentArrangement
      contextRef="c0"
      decimals="0"
      id="ixv-28238"
      unitRef="shares">-47</sprcy:NumberOfShareOptionsCancelledInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c0"
      decimals="2"
      id="ixv-28239"
      unitRef="usdPershares">144.55</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c4"
      decimals="0"
      id="ixv-28240"
      unitRef="shares">7013</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-28241"
      unitRef="usdPershares">166.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement
      contextRef="c0"
      decimals="0"
      id="ixv-28242"
      unitRef="shares">5869</sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-28243"
      unitRef="usdPershares">165.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c33"
      decimals="0"
      id="ixv-28244"
      unitRef="shares">209</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c33"
      decimals="2"
      id="ixv-28245"
      unitRef="usdPershares">76.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionGrantedInSharebasedPaymentArrangement
      contextRef="c6"
      decimals="0"
      id="ixv-28246"
      unitRef="shares">6851</sprcy:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c6"
      decimals="0"
      id="ixv-28247"
      unitRef="usdPershares">169</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfOutstandingShareOption
      contextRef="c5"
      decimals="0"
      id="ixv-28248"
      unitRef="shares">7060</sprcy:NumberOfOutstandingShareOption>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c5"
      decimals="2"
      id="ixv-28249"
      unitRef="usdPershares">166.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement
      contextRef="c6"
      decimals="0"
      id="ixv-28250"
      unitRef="shares">4141</sprcy:NumberOfShareOptionExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c5"
      decimals="2"
      id="ixv-28251"
      unitRef="usdPershares">163.8</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption contextRef="c0" id="ixv-28252">P4Y10D</sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption>
    <sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption contextRef="c6" id="ixv-28253">P5Y10D</sprcy:WeightedAverageRemainingContractualLifesOfOutstandingShareOption>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c4"
      decimals="0"
      id="ixv-28254"
      unitRef="usdPershares">169</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c5"
      decimals="0"
      id="ixv-28255"
      unitRef="usdPershares">21944</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c0" id="ixv-25093">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;20:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;REVENUES AND COST OF REVENUES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company sells products directly
to customers mainly through its online Amazon stores.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the Company&#x2019;s standard
contract terms, customers have a right of return within 30 until 90 days. For contracts with rights of return, the Company recognizes
revenue based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a
significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable
if it expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its
estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31,
2023, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right
of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In certain contracts, the Company evaluates
the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining the nature
of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis based upon
its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible for fulfillment
of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other factors. Based on
its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore, sales are recorded
on a gross basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022(*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amazon fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchased goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Storage&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Freight&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice in industry
and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock contextRef="c0" id="ixv-28256">The following table discloses the breakdown
of our revenues, cost of sales and gross profit for the periods set forth below:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022(*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amazon fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchased goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Storage&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Freight&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice in industry
and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock>
    <sprcy:CostOfGoodsSold
      contextRef="c191"
      decimals="-3"
      id="ixv-28257"
      unitRef="usd">672000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold
      contextRef="c192"
      decimals="-3"
      id="ix_6_fact"
      unitRef="usd">301000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold
      contextRef="c197"
      decimals="-3"
      id="ixv-28259"
      unitRef="usd">11000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold
      contextRef="c198"
      decimals="-3"
      id="ix_7_fact"
      unitRef="usd">21000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold contextRef="c0" decimals="-3" id="ixv-28261" unitRef="usd">683000</sprcy:CostOfGoodsSold>
    <sprcy:CostOfGoodsSold contextRef="c6" decimals="-3" id="ix_8_fact" unitRef="usd">322000</sprcy:CostOfGoodsSold>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c0" id="ixv-25266">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;21:- &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;392&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;436&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;357&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory, professional and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;719&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;750&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;934&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and preclinical studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;703&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;254&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chemistry and formulations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;141&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;281&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;335&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,641&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,803&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,990&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;General and administrative expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;415&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;437&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;256&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amazon fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,042&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;424&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Storage&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;145&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt; width: 58%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional and directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,594&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,417&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;161&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office maintenance, rent and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;135&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor relations and business expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,486&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;784&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,972&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,778&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Other expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;210&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Finance income:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net change in fair value of financial liabilities designated at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,205&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,219&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Finance expenses:&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance expenses related to warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,204&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Losses from remeasurement of investment in financial assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,046&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;770&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance expense in respect of leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance expenses from interest and commissions&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-202; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,014&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice in industry
and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss contextRef="c0" id="ixv-25276">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: center; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;392&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;436&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;357&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;27&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory, professional and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;719&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;750&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;934&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and preclinical studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;703&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical studies&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;254&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chemistry and formulations&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;141&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;281&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;335&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,641&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,803&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,990&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;General and administrative expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages and related expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;415&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;437&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;256&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amazon fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,042&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;424&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Storage&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;145&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt; width: 58%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional and directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 10%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,594&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,499&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,417&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;161&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office maintenance, rent and other expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;135&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investor relations and business expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,486&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;784&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,972&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,778&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Other expenses:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;210&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Finance income:&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net change in fair value of financial liabilities designated at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,205&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,219&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7,832&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Finance expenses:&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance expenses related to warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,204&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange rate differences, net&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Losses from remeasurement of investment in financial assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,046&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;770&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance expense in respect of leases&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance expenses from interest and commissions&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-202; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,055&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,014&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reclassified to correlate with common practice in industry
and better reflect profit and loss.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</sprcy:DisclosureOfInformationToTheItemsOfProfitOrLoss>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c200"
      decimals="-3"
      id="ixv-28264"
      unitRef="usd">392000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c201"
      decimals="-3"
      id="ixv-28265"
      unitRef="usd">436000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c202"
      decimals="-3"
      id="ixv-28266"
      unitRef="usd">357000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c203"
      decimals="-3"
      id="ixv-28267"
      unitRef="usd">34000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c204"
      decimals="-3"
      id="ixv-28268"
      unitRef="usd">264000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c205"
      decimals="-3"
      id="ixv-28269"
      unitRef="usd">27000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c206"
      decimals="-3"
      id="ixv-28270"
      unitRef="usd">719000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c207"
      decimals="-3"
      id="ixv-28271"
      unitRef="usd">750000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c208"
      decimals="-3"
      id="ixv-28272"
      unitRef="usd">934000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c209"
      decimals="-3"
      id="ixv-28273"
      unitRef="usd">101000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c210"
      decimals="-3"
      id="ixv-28274"
      unitRef="usd">703000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c211"
      decimals="-3"
      id="ixv-28275"
      unitRef="usd">165000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c212"
      decimals="-3"
      id="ixv-28276"
      unitRef="usd">254000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c213"
      decimals="-3"
      id="ixv-28277"
      unitRef="usd">369000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c214"
      decimals="-3"
      id="ixv-28278"
      unitRef="usd">172000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c215"
      decimals="-3"
      id="ixv-28279"
      unitRef="usd">141000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c216"
      decimals="-3"
      id="ixv-28280"
      unitRef="usd">281000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1
      contextRef="c217"
      decimals="-3"
      id="ixv-28281"
      unitRef="usd">335000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c0" decimals="-3" id="ixv-28282" unitRef="usd">1641000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c6" decimals="-3" id="ixv-28283" unitRef="usd">2803000</sprcy:ResearchAndDevelopmentExpenses1>
    <sprcy:ResearchAndDevelopmentExpenses1 contextRef="c7" decimals="-3" id="ixv-28284" unitRef="usd">1990000</sprcy:ResearchAndDevelopmentExpenses1>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c200"
      decimals="-3"
      id="ixv-28285"
      unitRef="usd">415000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c201"
      decimals="-3"
      id="ixv-28286"
      unitRef="usd">437000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c202"
      decimals="-3"
      id="ixv-28287"
      unitRef="usd">256000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c203"
      decimals="-3"
      id="ixv-28288"
      unitRef="usd">68000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c204"
      decimals="-3"
      id="ixv-28289"
      unitRef="usd">633000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c205"
      decimals="-3"
      id="ixv-28290"
      unitRef="usd">16000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c218"
      decimals="-3"
      id="ixv-28291"
      unitRef="usd">1042000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c219"
      decimals="-3"
      id="ixv-28292"
      unitRef="usd">424000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-28293"
      unitRef="usd">145000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c222"
      decimals="-3"
      id="ixv-28294"
      unitRef="usd">90000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-28295"
      unitRef="usd">2594000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-28296"
      unitRef="usd">2499000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-28297"
      unitRef="usd">2417000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c226"
      decimals="-3"
      id="ixv-28298"
      unitRef="usd">86000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c227"
      decimals="-3"
      id="ixv-28299"
      unitRef="usd">161000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c228"
      decimals="-3"
      id="ixv-28300"
      unitRef="usd">5000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c229"
      decimals="-3"
      id="ixv-28301"
      unitRef="usd">202000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c230"
      decimals="-3"
      id="ixv-28302"
      unitRef="usd">162000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c231"
      decimals="-3"
      id="ixv-28303"
      unitRef="usd">165000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c232"
      decimals="-3"
      id="ixv-28304"
      unitRef="usd">110000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c233"
      decimals="-3"
      id="ix_9_fact"
      unitRef="usd">80000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-28306"
      unitRef="usd">135000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c235"
      decimals="-3"
      id="ixv-28307"
      unitRef="usd">369000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c236"
      decimals="-3"
      id="ixv-28308"
      unitRef="usd">1486000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-28309"
      unitRef="usd">784000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-28310" unitRef="usd">5031000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-28311" unitRef="usd">5972000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-28312" unitRef="usd">3778000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c0" decimals="-3" id="ixv-28313" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c6" decimals="-3" id="ixv-28314" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:FinanceIncome
      contextRef="c238"
      decimals="-3"
      id="ixv-28315"
      unitRef="usd">2205000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c239"
      decimals="-3"
      id="ixv-28316"
      unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c241"
      decimals="-3"
      id="ixv-28317"
      unitRef="usd">14000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-28318" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c6" decimals="-3" id="ixv-28319" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="c245"
      decimals="-3"
      id="ixv-28320"
      unitRef="usd">1204000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c246"
      decimals="-3"
      id="ixv-28321"
      unitRef="usd">6000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c242"
      decimals="-3"
      id="ixv-28322"
      unitRef="usd">4000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c243"
      decimals="-3"
      id="ixv-28323"
      unitRef="usd">3000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c247"
      decimals="-3"
      id="ixv-28324"
      unitRef="usd">1046000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c248"
      decimals="-3"
      id="ixv-28325"
      unitRef="usd">770000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c250"
      decimals="-3"
      id="ixv-28326"
      unitRef="usd">9000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c251"
      decimals="-3"
      id="ixv-28327"
      unitRef="usd">15000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c252"
      decimals="-3"
      id="ixv-28328"
      unitRef="usd">4000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c254"
      decimals="-3"
      id="ixv-28329"
      unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c255"
      decimals="-3"
      id="ixv-28330"
      unitRef="usd">8000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-28331" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c6" decimals="-3" id="ixv-28332" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c7" decimals="-3" id="ixv-28333" unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0" id="ixv-26135">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 22:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LOSS PER SHARE/ADS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;In&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Continuing operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Basic loss per share&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;408&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of potential dilutive ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see note 18a).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share Options to employees, officers, directors and consultants; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable warrants to investors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c0" id="ixv-26151">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;In&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;In&lt;br/&gt; thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Continuing operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Basic loss per share&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;408&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;79&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of potential dilutive ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see note 18a).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-28334"
      unitRef="shares">408000</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c0" decimals="-3" id="ixv-28335" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c6"
      decimals="INF"
      id="ix_10_fact"
      unitRef="shares">176000</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c6" decimals="-3" id="ixv-28337" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c7"
      decimals="INF"
      id="ix_11_fact"
      unitRef="shares">79000</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c7" decimals="-3" id="ixv-28339" unitRef="usd">-5789000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-28340"
      unitRef="shares">408000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c0" decimals="-3" id="ixv-28341" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c6"
      decimals="INF"
      id="ix_12_fact"
      unitRef="shares">176000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c6" decimals="-3" id="ixv-28343" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c7"
      decimals="INF"
      id="ix_13_fact"
      unitRef="shares">79000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c7" decimals="-3" id="ixv-28345" unitRef="usd">-5789000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0" id="ixv-26451">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;23:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OPERATING SEGMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies the principles
of IFRS 8,&#160;&#x201c;&lt;i&gt;Operating Segments&lt;/i&gt;&#x201d;&lt;i&gt;&#160;&lt;/i&gt;(&#x201c;IFRS 8&#x201d;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#x2019;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#x201c;CODM&#x201d;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#x2019;s management determined that it has two reportable segments &#x2013; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#x2019;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The review of the CODM is carried out
according to the results of the segment&#x2019;s activity. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,773&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,818&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,595&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c0" id="ixv-28347">The Group&#x2019;s CODM is the CEO
of the Company.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Segment loss (gain)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,773&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Company&#x2019;s share of losses of company accounted for at equity, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,818&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;External&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; font-style: italic; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline; width: 64%; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,595&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Drug&lt;br/&gt; Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Online&lt;br/&gt; Sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Segment Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,664&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,605&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Segment Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <sprcy:ExternalRevenues
      contextRef="c257"
      decimals="-3"
      id="ixv-28348"
      unitRef="usd">2879000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c0" decimals="-3" id="ixv-28349" unitRef="usd">2879000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c257"
      decimals="-3"
      id="ixv-28350"
      unitRef="usd">2879000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c0" decimals="-3" id="ixv-28351" unitRef="usd">2879000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c256"
      decimals="-3"
      id="ixv-28352"
      unitRef="usd">5359000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c257"
      decimals="-3"
      id="ixv-28353"
      unitRef="usd">414000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-28354" unitRef="usd">5773000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c0" decimals="-3" id="ixv-28355" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-28356" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:InterestRevenueExpense contextRef="c0" decimals="-3" id="ixv-28357" unitRef="usd">-1164000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c0" decimals="-3" id="ixv-28358" unitRef="usd">22000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-28359" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <sprcy:ExternalRevenues
      contextRef="c259"
      decimals="-3"
      id="ixv-28360"
      unitRef="usd">1347000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c6" decimals="-3" id="ixv-28361" unitRef="usd">1347000</sprcy:ExternalRevenues>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c259"
      decimals="-3"
      id="ixv-28362"
      unitRef="usd">1347000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c6" decimals="-3" id="ixv-28363" unitRef="usd">1347000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c258"
      decimals="-3"
      id="ixv-28364"
      unitRef="usd">8405000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c259"
      decimals="-3"
      id="ixv-28365"
      unitRef="usd">-118000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c6" decimals="-3" id="ixv-28366" unitRef="usd">8287000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c6" decimals="-3" id="ixv-28367" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c6" decimals="-3" id="ixv-28368" unitRef="usd">-5818000</ifrs-full:InterestRevenueExpense>
    <sprcy:TaxExpense contextRef="c6" decimals="-3" id="ixv-28369" unitRef="usd">14000</sprcy:TaxExpense>
    <ifrs-full:ProfitLoss contextRef="c6" decimals="-3" id="ixv-28370" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c260"
      decimals="-3"
      id="ixv-28371"
      unitRef="usd">5768000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c7" decimals="-3" id="ixv-28372" unitRef="usd">5768000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:InterestRevenueExpense contextRef="c7" decimals="-3" id="ixv-28373" unitRef="usd">21000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:ProfitLoss contextRef="c7" decimals="-3" id="ixv-28374" unitRef="usd">-5789000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherAssets
      contextRef="c262"
      decimals="-3"
      id="ixv-28375"
      unitRef="usd">7069000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c263"
      decimals="-3"
      id="ixv-28376"
      unitRef="usd">4113000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c4" decimals="-3" id="ixv-28377" unitRef="usd">11182000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c262"
      decimals="-3"
      id="ixv-28378"
      unitRef="usd">1441000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c263"
      decimals="-3"
      id="ixv-28379"
      unitRef="usd">154000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c4" decimals="-3" id="ixv-28380" unitRef="usd">1595000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c264"
      decimals="-3"
      id="ixv-28381"
      unitRef="usd">9664000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c265"
      decimals="-3"
      id="ixv-28382"
      unitRef="usd">941000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c5" decimals="-3" id="ixv-28383" unitRef="usd">10605000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c264"
      decimals="-3"
      id="ixv-28384"
      unitRef="usd">4021000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c265"
      decimals="-3"
      id="ixv-28385"
      unitRef="usd">135000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c5" decimals="-3" id="ixv-28386" unitRef="usd">4156000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0" id="ixv-27125">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;24:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRANSACTIONS AND BALANCES WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;962&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees (see also note 25a)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo Inc.&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands. Mr. Oz Adler, our Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands (see also note 25a).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2022, we entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, our Chief Technologies Officer, Mr. Weiss, our President, and Mr. Adler, our Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#x201c;Cooperation Agreement&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $40 and $208, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, we invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also note 8).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Amitai Weiss, our chairman of the board of directors, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory contextRef="c0" id="ixv-27141">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Key&lt;br/&gt; management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;br/&gt; related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutBalanceWithRelatePartiesExplanatory>
    <ifrs-full:CurrentAssets
      contextRef="c269"
      decimals="-3"
      id="ixv-28387"
      unitRef="usd">121000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c269"
      decimals="-3"
      id="ixv-28388"
      unitRef="usd">108000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentLiabilities
      contextRef="c268"
      decimals="-3"
      id="ixv-28389"
      unitRef="usd">95000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c270"
      decimals="-3"
      id="ixv-28390"
      unitRef="usd">70000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c271"
      decimals="-3"
      id="ixv-28391"
      unitRef="usd">55000</ifrs-full:CurrentLiabilities>
    <sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory contextRef="c0" id="ixv-27246">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale of minority interest in subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutTransactionsWithRelatePartiesExplanatory>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c0" decimals="-3" id="ixv-28392" unitRef="usd">40000</sprcy:ResearchAndDevelopmentExpenses>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c6" decimals="-3" id="ixv-28393" unitRef="usd">208000</sprcy:ResearchAndDevelopmentExpenses>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-28394" unitRef="usd">2985000</ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-27305">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term benefits&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;962&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Management fees (see also note 25a)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost of share-based payment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;779&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c0" decimals="-3" id="ixv-28395" unitRef="usd">1204000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c6" decimals="-3" id="ixv-28396" unitRef="usd">1940000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c7" decimals="-3" id="ixv-28397" unitRef="usd">962000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c0" decimals="-3" id="ixv-28398" unitRef="usd">220000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c0" decimals="-3" id="ixv-28399" unitRef="usd">84000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c6" decimals="-3" id="ixv-28400" unitRef="usd">779000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c7" decimals="-3" id="ixv-28401" unitRef="usd">43000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c0" decimals="-3" id="ixv-28402" unitRef="usd">40000</sprcy:ResearchAndDevelopmentExpenses>
    <sprcy:ResearchAndDevelopmentExpenses contextRef="c6" decimals="-3" id="ixv-28403" unitRef="usd">208000</sprcy:ResearchAndDevelopmentExpenses>
    <ifrs-full:CurrentInvestments
      contextRef="c266"
      decimals="-5"
      id="ixv-28404"
      unitRef="usd">1500000</ifrs-full:CurrentInvestments>
    <sprcy:ExchangeOfCommonShares
      contextRef="c267"
      decimals="0"
      id="ixv-28405"
      unitRef="shares">7692</sprcy:ExchangeOfCommonShares>
    <sprcy:OutstandingShareCapital
      contextRef="c267"
      decimals="4"
      id="ixv-28406"
      unitRef="pure">0.0933</sprcy:OutstandingShareCapital>
    <sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock contextRef="c0" id="ixv-27455">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px; text-align: left"&gt;&lt;b&gt;NOTE 25:- &lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;SIGNIFICANT EVENTS DURING THE REPORTING PERIOD&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo Inc.&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#x2019;s wholly owned subsidiary, SciSparc US which owns Wellution&lt;sup&gt;TM&lt;/sup&gt;, for $2,500 in cash, and additional deferred cash payments of approximately $489,330 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#x201c;Price Adjustment&#x201d;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#x201c;Holdback Shares&#x201d;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#x2019; Brands, the Company holds approximately 51% of the share capital of SciSparc US.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Pursuant to the agreement, at the closing
of the transaction, Jeffs&#x2019; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#x2019; Brands provides
management services to SciSparc US for the Wellution&lt;sup&gt;TM &lt;/sup&gt;brand for a monthly fee of $20 and Jeffs&#x2019; Brands received a one-time
signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party
with 30 days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31, 2023, the Company
has recorded management services expenses in the amount of $220.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, in connection with the closing
of the transaction, the Company and Jeffs&#x2019; Brands, engaged in a mutual share exchange in the amount of $288,238 of ordinary shares
from each of the Company and Jeffs&#x2019; Brands. The number of shares in the share exchange was calculated based on the average closing
price of the relevant company&#x2019;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the
closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#x2019; Brands and Jeffs&#x2019; Brands acquired 13,858 ordinary
shares of the Company having an aggregate value of $288,238, which was adjusted from $300,000 according to the 4.99% ownership limit included
in the definitive agreements. As of December 31, 2023, the listed share price of Jeff&#x2019;s Brands on the NASDAQ was $ 3.05, and the
Company has recorded a loss in its statements of comprehensive loss of $180 on its investment.&lt;/p&gt;</sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock>
    <sprcy:InterestPercentgae
      contextRef="c272"
      decimals="2"
      id="ixv-28407"
      unitRef="pure">0.49</sprcy:InterestPercentgae>
    <ifrs-full:Cash
      contextRef="c273"
      decimals="-3"
      id="ixv-28408"
      unitRef="usd">2500000</ifrs-full:Cash>
    <sprcy:DeferredCashPayments
      contextRef="c272"
      decimals="-3"
      id="ixv-28409"
      unitRef="usd">489330000</sprcy:DeferredCashPayments>
    <sprcy:ShareCapitalPercentage
      contextRef="c274"
      decimals="2"
      id="ixv-28410"
      unitRef="pure">0.51</sprcy:ShareCapitalPercentage>
    <sprcy:FeeExpenses contextRef="c0" decimals="-3" id="ixv-28411" unitRef="usd">20000</sprcy:FeeExpenses>
    <sprcy:BonusAmountReceived contextRef="c0" decimals="-3" id="ixv-28412" unitRef="usd">51000</sprcy:BonusAmountReceived>
    <sprcy:FeeExpenses
      contextRef="c275"
      decimals="-3"
      id="ixv-28413"
      unitRef="usd">10000</sprcy:FeeExpenses>
    <ifrs-full:ServicesExpense contextRef="c0" decimals="-3" id="ixv-28414" unitRef="usd">220000</ifrs-full:ServicesExpense>
    <sprcy:MutualShareExchangeAmount contextRef="c0" decimals="-3" id="ixv-28415" unitRef="usd">288238000</sprcy:MutualShareExchangeAmount>
    <sprcy:OrdinarySharesAcquired
      contextRef="c0"
      decimals="0"
      id="ixv-28416"
      unitRef="shares">35345</sprcy:OrdinarySharesAcquired>
    <sprcy:OrdinarySharesAcquired
      contextRef="c276"
      decimals="0"
      id="ixv-28417"
      unitRef="shares">13858</sprcy:OrdinarySharesAcquired>
    <sprcy:AggregateValue contextRef="c0" decimals="-3" id="ixv-28418" unitRef="usd">288238000</sprcy:AggregateValue>
    <sprcy:AdjustedAmountOfAggregateValue
      contextRef="c276"
      decimals="-3"
      id="ixv-28419"
      unitRef="usd">300000000</sprcy:AdjustedAmountOfAggregateValue>
    <sprcy:OwnershipPercentage contextRef="c0" decimals="4" id="ixv-28420" unitRef="pure">0.0499</sprcy:OwnershipPercentage>
    <sprcy:ListedSharePrice
      contextRef="c4"
      decimals="2"
      id="ixv-28421"
      unitRef="usdPershares">3.05</sprcy:ListedSharePrice>
    <sprcy:ComprehensiveLossOnInvestment contextRef="c4" decimals="-3" id="ixv-28422" unitRef="usd">180000</sprcy:ComprehensiveLossOnInvestment>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-27504">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;26:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EVENTS AFTER THE REPORTING DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On January 21, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;), as amended on February 26, 2024, with YA II PN, LTD (&#x201c;YA&#x201d;),
which provided for the sale of up to $20,000 of the Company&#x2019;s Ordinary Shares (the &#x201c;Advance Shares&#x201d;). Of the $20,000
eligible to be sold pursuant to the SEPA, or the Commitment Amount, Company has sold 925,159 ordinary shares as of the issuance date of
these financial statements. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of 97% of
the market price, which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000, each a Pre-Paid Advance. Each Pre-Paid Advance will
be evidenced by a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 24-months following its issuance and
shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to 18% per annum upon an Event
of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note, the Company shall pay to YA
a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued interest, payable in cash or
by submitting an advance notice, where YA will offset the amount due to be paid to us under such notice against an equal amount of the
monthly installment amount, at the Company&#x2019;s option. If the Company elects to pay in cash, the installment amount shall also include
a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains the Company&#x2019;s
customary representations and warranties and Events of Default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, pursuant to the SEPA, the
Company issued to YA an aggregate of 55,293 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $200.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;YA will pay all brokerage fees and commissions
and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA The Company will pay the expenses
(except brokerage fees and commissions and similar expenses) incurred to register under the Securities Act the offer and sale of the Ordinary
Shares pursuant to the SEPA by YA.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="c277"
      decimals="-3"
      id="ixv-28423"
      unitRef="usd">20000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="c277"
      decimals="-3"
      id="ixv-28424"
      unitRef="usd">20000000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c278"
      decimals="0"
      id="ixv-28425"
      unitRef="shares">925159</ifrs-full:NumberOfSharesIssued>
    <sprcy:SharePricePercentage
      contextRef="c277"
      decimals="2"
      id="ixv-28426"
      unitRef="pure">0.97</sprcy:SharePricePercentage>
    <sprcy:PrepaidAdvance contextRef="c0" decimals="-3" id="ixv-28427" unitRef="usd">5000000</sprcy:PrepaidAdvance>
    <sprcy:AccruedInterestPercentage contextRef="c0" decimals="2" id="ixv-28428" unitRef="pure">0.05</sprcy:AccruedInterestPercentage>
    <sprcy:CommitmentPercentage contextRef="c0" decimals="2" id="ixv-28429" unitRef="pure">0.18</sprcy:CommitmentPercentage>
    <sprcy:InstallmentPaymentPercentage contextRef="c0" decimals="2" id="ixv-28430" unitRef="pure">0.10</sprcy:InstallmentPaymentPercentage>
    <sprcy:PaymentPremiumPercentage contextRef="c0" decimals="2" id="ixv-28431" unitRef="pure">0.05</sprcy:PaymentPremiumPercentage>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c279"
      decimals="0"
      id="ixv-28432"
      unitRef="shares">55293</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-28433" unitRef="usd">200000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:NoncontrollingInterests
      contextRef="c5"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c7"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c7"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c7"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9
      contextRef="c6"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9
      contextRef="c7"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="c7"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c7"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c7"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c6"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c7"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c15"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c19"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c20"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c21"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c24"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c20"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c21"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c22"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c24"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c21"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c22"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c24"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c19"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c20"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c21"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c22"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c23"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c24"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c7"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c17"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c19"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c20"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c21"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c22"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c24"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c32"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c34"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c35"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c36"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c37"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c38"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c41"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c35"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c36"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c37"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c38"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c39"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExerciseOfWarrants
      contextRef="c41"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c36"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c37"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c38"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c39"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c41"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c49"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c50"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c51"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c52"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c53"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c54"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c50"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c51"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c52"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c54"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c55"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c51"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c52"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c53"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c54"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c55"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c57"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c51"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c52"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c53"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c54"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c55"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c57"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c52"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c53"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c54"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c55"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c57"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c6"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="c7"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="c6"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="c7"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c7"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c7"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="c7"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c6"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c7"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c6"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c7"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c0"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PurchaseOfFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c7"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c7"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c0"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c7"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="c7"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ReceiptofShortTermCreditFromOthers
      contextRef="c0"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ReceiptofShortTermCreditFromOthers
      contextRef="c6"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c6"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RegistrationOfWarrants
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RegistrationOfWarrants
      contextRef="c6"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentInFinancialAsset
      contextRef="c6"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentInFinancialAsset
      contextRef="c7"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnpaidIssueExpenses
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:UnpaidIssueExpenses
      contextRef="c6"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:LeaseholdImprovements
      contextRef="c76"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="c33"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:FairValueOfInvestment
      contextRef="c0"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c116"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c71"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c119"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c120"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c122"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c116"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c119"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c122"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c122"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c125"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c129"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c131"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets
      contextRef="c116"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c125"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c129"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="c116"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipmentGrossCarryingAmountFullyDepreciated
      contextRef="c116"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="c33"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c5"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c138"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c139"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c138"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c139"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c138"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c139"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c138"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c139"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c138"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c139"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c138"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c139"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c138"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c139"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c138"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c139"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c138"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c139"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c138"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c142"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="c143"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c141"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c142"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c143"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c144"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c142"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:GovernmentAuthorities
      contextRef="c143"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c142"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherReceivables
      contextRef="c143"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c142"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:InvestmentsInFinancialAssets
      contextRef="c143"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c142"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="c143"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c142"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CreditFromOthers
      contextRef="c143"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c142"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c143"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c142"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="c143"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c142"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c151"
      id="hidden-fact-181"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c153"
      id="hidden-fact-182"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c178"
      decimals="0"
      id="hidden-fact-183"
      unitRef="shares">10000000</ifrs-full:NumberOfSharesIssued>
    <sprcy:CostOfGoodsSold
      contextRef="c188"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c189"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c190"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c193"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c194"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c195"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c196"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c199"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CostOfGoodsSold
      contextRef="c7"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="c220"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet
      contextRef="c7"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c240"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c242"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c243"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c7"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c244"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c241"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c249"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c253"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c0"
      id="hidden-fact-203"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c6"
      id="hidden-fact-204"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c7"
      id="hidden-fact-205"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c256"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c256"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c258"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c258"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c260"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c261"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c7"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c260"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c261"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="c7"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c261"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c268"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c270"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c271"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c268"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c270"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c271"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="c269"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ResearchAndDevelopmentExpenses
      contextRef="c7"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c6"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities
      contextRef="c7"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:KeyManagementPersonnelCompensationManagementFees
      contextRef="c6"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:KeyManagementPersonnelCompensationManagementFees
      contextRef="c7"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-28665">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-28666">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-28667">0001611746</dei:EntityCentralIndexKey>
    <dei:NoTradingSymbolFlag contextRef="c3" id="ixv-28668">true</dei:NoTradingSymbolFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see note 18a).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-185"
          xlink:label="hidden-fact-185"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-189"
          xlink:label="hidden-fact-189"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified to correlate with common practice in industry
and better reflect profit and loss.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-185"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-189"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-204"
          xlink:label="hidden-fact-204"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-205"
          xlink:label="hidden-fact-205"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Loss per share retroactively adjusted in these consolidated
statements of comprehensive loss to reflect &#x201c;Reverse Split&#x201d; (see note 18a).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-204"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-205"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
